Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary proxy statement.
Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)).
Definitive Proxy Statement.
Definitive Additional Materials.
Soliciting Material Pursuant to § 240.14a-12.
Microchip Technology Incorporated
(Name of Registrant as Specified In Its Charter)
____________________________________________________________________
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
(2)
(3)
(4)
(5)
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed to Exchange Act Rule 0-11 (set forth the
amount on which the fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for
which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the
Form or Schedule and the date of its filing.
Table of Contents
(1)
(2)
(3)
(4)
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
Filing Party:
Date Filed:
Table of Contents
TIME:
PLACE:
ITEMS OF
BUSINESS:
RECORD DATE:
ANNUAL REPORT:
PROXY:
MICROCHIP TECHNOLOGY INCORPORATED
2355 West Chandler Boulevard, Chandler, Arizona 85224-6199
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
August 20, 2019
9:00 a.m. Mountain Standard Time
Microchip Technology Incorporated
2355 W. Chandler Boulevard
Chandler, Arizona 85224-6199
(1) The election of each of Steve Sanghi, Matthew W. Chapman, L.B. Day, Esther L.
Johnson and Wade F. Meyercord to our Board of Directors to serve for the ensuing year
and until their successors are elected and qualified.
(2) To approve a French sub-plan under our 2004 Equity Plan.
(3) To ratify the appointment of Ernst & Young LLP as the independent registered public
accounting firm of Microchip for the fiscal year ending March 31, 2020.
(4) To hold an advisory (non-binding) vote regarding the compensation of our named
executives.
(5) To consider a stockholder proposal requesting our Board to report on our processes for
identifying and analyzing human rights risks to workers in our operations and supply
chain.
(6) To transact such other business as may properly come before the annual meeting or any
adjournment(s) thereof.
The Microchip Board of Directors recommends that you vote FOR each of the foregoing
items (1) through (4), and AGAINST the foregoing item (5).
Holders of Microchip common stock of record at the close of business on June 25, 2019 are
entitled to vote at the annual meeting.
Microchip's fiscal 2019 Annual Report, which is not a part of the proxy soliciting material, is
enclosed.
It is important that your shares be represented and voted at the annual meeting. You can vote
your shares by completing and returning the proxy card sent to you. Stockholders may have a
choice of voting their shares over the internet or by telephone. If internet or telephone voting
is available to you, voting instructions are printed on the proxy card sent to you. You can
revoke your proxy at any time prior to its exercise at the annual meeting by following the
instructions in the accompanying proxy statement.
/s/ Kim van Herk
Kim van Herk
Secretary
Table of Contents
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting
of Stockholders to be Held on August 20, 2019
The Microchip Notice of Annual Meeting, Proxy Statement and Annual Report on Form 10-K for the fiscal year
ended March 31, 2019 are available at www.microchip.com/annual_reports.
Chandler, Arizona
July 15, 2019
Table of Contents
TABLE OF CONTENTS
Page
PROXY STATEMENT
THE BOARD OF DIRECTORS
CERTAIN TRANSACTIONS
DELINQUENT SECTION 16(A) REPORTS
PROPOSAL ONE - ELECTION OF DIRECTORS
PROPOSAL TWO - APPROVAL OF FRENCH SUB-PLAN UNDER THE 2004 EQUITY INCENTIVE
PLAN
PROPOSAL THREE - RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
PROPOSAL FOUR - APPROVAL OF EXECUTIVE COMPENSATION
PROPOSAL FIVE - STOCKHOLDER PROPOSAL FOR OUR BOARD TO REPORT ON
RECRUITMENT AND FORCED LABOR RISK TO WORKERS
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND EXECUTIVE
OFFICERS
EXECUTIVE COMPENSATION - COMPENSATION DISCUSSION AND ANALYSIS
COMPENSATION OF NAMED EXECUTIVE OFFICERS
EQUITY COMPENSATION PLAN INFORMATION
CODE OF BUSINESS CONDUCT AND ETHICS
OTHER MATTERS
1
4
9
9
10
13
22
24
25
28
30
43
56
58
58
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED
2355 West Chandler Boulevard
Chandler, Arizona 85224-6199
PROXY STATEMENT
You are cordially invited to attend our annual meeting on Tuesday, August 20, 2019, beginning at 9:00 a.m., Mountain
Standard Time. The annual meeting will be held at our Chandler facility located at 2355 W. Chandler Blvd., Chandler, AZ
85224-6199.
We are providing these proxy materials in connection with the solicitation by the Board of Directors (the "Board") of
Microchip Technology Incorporated ("Microchip") of proxies to be voted at Microchip's 2019 annual meeting of stockholders
and at any adjournment(s) thereof.
Our fiscal year begins on April 1 and ends on March 31. References in this proxy statement to fiscal 2019 refer to the
12-month period from April 1, 2018 through March 31, 2019; references to fiscal 2018 refer to the 12-month period from
April 1, 2017 through March 31, 2018; and references to fiscal 2017 refer to the 12-month period from April 1, 2016 through
March 31, 2017.
We anticipate first mailing this proxy statement and accompanying form of proxy on July 15, 2019 to holders of record
of Microchip's common stock on June 25, 2019 (the "Record Date").
PROXIES AND VOTING PROCEDURES
YOUR VOTE IS IMPORTANT. Because many stockholders cannot attend the annual meeting in person, it is
necessary that a large number of stockholders be represented by proxy. Stockholders may have a choice of voting over the
internet, by using a toll-free telephone number or by completing a proxy card and mailing it in the postage-paid envelope
provided. Please refer to your proxy card or the information forwarded by your bank, broker or other holder of record to see
which options are available to you. Under Delaware law, stockholders may submit proxies electronically. Please be aware that
if you vote over the internet, you may incur costs such as telephone and internet access charges for which you will be
responsible.
You can revoke your proxy at any time before it is exercised by timely delivery of a properly executed, later-dated
proxy (including an internet or telephone vote if these options are available to you) or by voting by ballot at the annual meeting.
The method by which you vote will in no way limit your right to vote at the annual meeting if you later decide to
attend in person. If your shares are held in the name of a bank, broker or other holder of record, you must obtain a proxy,
executed in your favor, from the holder of record, to be able to vote at the annual meeting.
All shares entitled to vote and represented by properly completed proxies received prior to the annual meeting and not
revoked will be voted at the annual meeting in accordance with the instructions on such proxies. IF YOU DO NOT
INDICATE HOW YOUR SHARES SHOULD BE VOTED ON A MATTER, THE SHARES REPRESENTED BY
YOUR PROPERLY COMPLETED PROXY WILL BE VOTED AS OUR BOARD OF DIRECTORS RECOMMENDS.
1
Table of Contents
If any other matters are properly presented at the annual meeting for consideration, including, among other things,
consideration of a motion to adjourn the annual meeting to another time or place, the persons named as proxies and acting
thereunder will have discretion to vote on those matters according to their best judgment to the same extent as the person
delivering the proxy would be entitled to vote. At the date this proxy statement went to press, we did not anticipate that any
other matters would be raised at the annual meeting.
Stockholders Entitled to Vote
Stockholders of record at the close of business on the Record Date, June 25, 2019, are entitled to notice of and to vote
at the annual meeting. Each share is entitled to one vote on each of the five director nominees and one vote on each other
matter properly brought before the annual meeting. On the Record Date, there were 238,034,746 shares of our common stock
issued and outstanding.
In accordance with Delaware law, a list of stockholders entitled to vote at the annual meeting will be available at the
annual meeting on August 20, 2019, and for 10 days prior to the annual meeting at 2355 West Chandler Boulevard, Chandler,
Arizona, between the hours of 9:00 a.m. and 4:30 p.m., Mountain Standard Time.
Required Vote
Quorum, Abstentions and Broker Non-Votes
The presence, in person or by proxy, of the holders of a majority of the shares entitled to vote at the annual meeting is
necessary to constitute a quorum at the annual meeting. Abstentions and broker "non-votes" are counted as present and entitled
to vote for purposes of determining a quorum. A broker "non-vote" occurs when a nominee holding shares for a beneficial
owner (i.e., in "street name") does not vote on a particular proposal because the nominee does not have discretionary voting
power with respect to that item and has not received instructions from the beneficial owner. Under the rules of the New York
Stock Exchange (NYSE), which apply to NYSE member brokers trading in non-NYSE stock, brokers have discretionary
authority to vote shares on certain routine matters if customer instructions are not provided. Proposal Three to be considered at
the annual meeting may be treated as a routine matter. Consequently, if you do not return a proxy card, your broker may have
discretion to vote your shares on such matter.
Election of Directors (Proposal One)
A nominee for director shall be elected to the board of directors if the votes cast for such nominee's election exceed the
votes cast against such nominee's election. For this purpose, votes cast shall exclude abstentions, withheld votes or broker non-
votes with respect to that director's election. Notwithstanding the immediately preceding sentence, in the event of a contested
election of directors, directors shall be elected by the vote of a plurality of the votes cast. A contested election shall mean any
election of directors in which the number of candidates for election as director exceeds the number of directors to be elected. If
directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
Approval of French Sub-Plan Under the 2004 Equity Inventive Plan (Proposal Two)
The affirmative vote of the holders of a majority of the shares of common stock present in person or represented by
proxy and entitled to vote at the annual meeting is required for approval of the French sub-plan under our 2004 Equity Incentive
Plan. Abstentions will have the same effect as voting against this proposal. Broker "non-votes" are not counted for purposes of
approving this matter, and thus will not affect the outcome of the voting on such proposal.
Ratification of Independent Registered Public Accounting Firm (Proposal Three)
The affirmative vote of the holders of a majority of the shares of common stock present in person or represented by
proxy and entitled to vote at the annual meeting is required for ratification of the appointment of Ernst & Young LLP as the
independent registered public accounting firm of Microchip for the fiscal year ending March 31, 2020. Abstentions will have
the same effect as voting against this proposal.
2
Table of Contents
Advisory Vote Regarding the Compensation of our Named Executives (Proposal Four)
The affirmative vote of the holders of a majority of the shares of common stock present in person or represented by
proxy and entitled to vote at the annual meeting is required to approve, on an advisory (non-binding) basis, the compensation of
our named executive officers as disclosed in this proxy statement in accordance with the rules of the Securities and Exchange
Commission (the "SEC"). Abstentions will have the same effect as voting against this proposal. Broker "non-votes" are not
counted for purposes of approving this matter, and thus will not affect the outcome of the voting on such proposal.
Stockholder Proposal for our Board to Report on Recruitment and Forced Labor Risk to Workers (Proposal Five)
The affirmative vote of the holders of a majority of the shares of common stock present in person or represented by
proxy and entitled to vote at the annual meeting is required for approval of the stockholder proposal for our Board of Directors
to report on recruitment and forced labor risk to workers. Abstentions will have the same effect as voting against this proposal.
Broker "non-votes" are not counted for purposes of approving this matter, and thus will not affect the outcome of the voting on
such proposal.
Electronic Access to Proxy Statement and Annual Report
This proxy statement and our fiscal 2019 Annual Report are available at www.microchip.com/annual_reports.
We will post our future proxy statements and annual reports on Form 10-K on our website as soon as reasonably
practicable after they are electronically filed with the SEC. All such filings on our website are available free of charge. The
information on our website is not incorporated into this proxy statement. Our internet address is www.microchip.com.
Cost of Proxy Solicitation
Microchip will pay its costs of soliciting proxies including the cost of any proxy solicitor if a proxy solicitor is
engaged. Proxies may be solicited on behalf of Microchip by its directors, officers or employees in person or by telephone,
facsimile or other electronic means. We may also reimburse brokerage firms and other custodians, nominees and fiduciaries for
their expenses incurred in sending proxies and proxy materials to beneficial owners of Microchip common stock.
3
Table of Contents
THE BOARD OF DIRECTORS
Meetings of the Board of Directors
Our Board of Directors met 5 times in fiscal 2019. Each director attended 100% of the aggregate of (i) the total
number of the meetings of the Board of Directors held during fiscal 2019 during such time as such person was a director, and
(ii) the total number of meetings held by all of the committees of the Board of Directors on which he or she served during fiscal
2019 during such time as such person was a director. The Board of Directors has a practice of meeting in executive session on
a periodic basis without management or management directors (i.e., Mr. Sanghi) present. The Board of Directors has
determined that each of Mr. Chapman, Mr. Day, Ms. Johnson and Mr. Meyercord is an independent director as defined by
applicable SEC rules and NASDAQ listing standards.
Board Leadership Structure
The Board of Directors believes that Microchip's Chief Executive Officer, Steve Sanghi, is best situated to serve as
Chairman because he is the director most familiar with Microchip's business and industry, and most capable of effectively
identifying strategic priorities and leading the discussion and execution of strategy. The Board's independent directors have
different perspectives and roles in strategic development. In particular, Microchip's independent directors bring experience,
oversight and expertise from outside the company and the industry, while the Chief Executive Officer brings company-specific
experience and industry expertise. The Board of Directors believes that the combined role of Chairman and Chief Executive
Officer promotes strategy development and execution, and facilitates information flow between management and the Board of
Directors, which are essential to effective governance. Microchip does not have a lead independent director.
Board Oversight of Risk Management
The Board of Directors and the Board committees oversee risk management in a number of ways. The Audit
Committee oversees the management of financial and accounting related risks as an integral part of its duties. Similarly, the
Compensation Committee considers risk management when setting the compensation policies and programs for Microchip's
executive officers. As part of this process, our Compensation Committee concluded that our compensation policies and
practices do not create risks that are reasonably likely to have a material adverse effect on Microchip.
The Board of Directors and the Audit Committee regularly receive reports on various risk-related items including risks
related to manufacturing operations, intellectual property, taxes, cybersecurity, IT system continuity, products and employees.
The Board and the Audit Committee also receive periodic reports on Microchip's efforts to manage such risks through safety
measures, system improvements, insurance or self-insurance. The Board of Directors believes that the leadership structure
described above facilitates the Board's oversight of risk management because it allows the Board, working through its
committees, to participate actively in the oversight of management's actions.
Communications from Stockholders
Stockholders may communicate with the Board of Directors or individual members of the Board of Directors,
provided that all such communication is submitted in writing to the attention of the Secretary at Microchip Technology
Incorporated, 2355 West Chandler Boulevard, Chandler, Arizona 85224-6199, who will then forward such communication to
the appropriate director or directors.
Committees of the Board of Directors
The following table lists our three Board committees, the directors who served on them and the number of committee
meetings held in fiscal 2019:
4
Table of Contents
Mr. Chapman
Mr. Day
Ms. Johnson
Mr. Meyercord
Mr. Sanghi
MEMBERSHIP ON BOARD COMMITTEES IN FISCAL 2019
Name
Audit
C
Compensation
Nominating
and Governance
C
1
C
9
Meetings held in fiscal 2019
13
C = Chair
= Member
Audit Committee
The responsibilities of our Audit Committee are to appoint, compensate, retain and oversee Microchip's independent
registered public accounting firm, oversee the accounting and financial reporting processes of Microchip and audits of its
financial statements, and provide the Board of Directors with the results of such monitoring. These responsibilities are further
described in the committee charter which was amended and restated as of May 15, 2015. A copy of the Audit Committee
charter is available at the About/Investor Relations section under Mission Statement/Corporate Governance on
www.microchip.com.
Our Board of Directors has determined that all members of the Audit Committee are independent directors as defined
by applicable SEC rules and NASDAQ listing standards. The Board of Directors has also determined that each of
Mr. Chapman and Mr. Meyercord meet the requirements for being an "audit committee financial expert" as defined by
applicable SEC rules.
In fiscal 2005, our Board and our Audit Committee adopted a policy with respect to (i) the receipt, retention and
treatment of complaints received by us regarding questionable accounting, internal accounting controls or auditing matters;
(ii) the confidential, anonymous submission by our employees of concerns regarding questionable accounting, internal
accounting controls or auditing matters; and (iii) the prohibition of harassment, discrimination or retaliation arising from
submitting concerns regarding questionable accounting, internal accounting controls or auditing matters or participating in an
investigation regarding questionable accounting, internal accounting controls or auditing matters. In fiscal 2012, our Board and
our Audit Committee approved an amended policy to include matters regarding violations of federal or state securities laws, or
the commission of bribery. This policy, called "Reporting Legal Non-Compliance," was created in accordance with applicable
SEC rules and NASDAQ listing requirements. A copy of this policy is available at the About/Investor Relations section under
Mission Statement/Corporate Governance on www.microchip.com.
Compensation Committee
Our Compensation Committee has oversight responsibility for the compensation and benefit programs for our
executive officers and other employees, and for administering our equity incentive and employee stock purchase plans adopted
by our Board of Directors. The responsibilities of our Compensation Committee are further described in the committee charter
which was amended and restated as of May 21, 2019. The committee charter is available at the About/Investor Relations
section under Mission Statement/Corporate Governance on www.microchip.com.
The Board of Directors has determined that all members of our Compensation Committee are independent directors as
defined by applicable SEC rules, NASDAQ listing standards and other requirements. For more information on our
Compensation Committee, please refer to the "Compensation Discussion and Analysis" at page 30.
5
Table of Contents
Nominating and Governance Committee
Our Nominating and Governance Committee has the responsibility to help ensure that our Board is properly
constituted to meet its fiduciary obligations to our stockholders and Microchip and that we have and follow appropriate
governance standards. In so doing, the Nominating and Governance Committee identifies and recommends director candidates,
develops and recommends governance principles, and recommends director nominees to serve on committees of the Board of
Directors. The responsibilities of our Nominating and Governance Committee are further described in the committee charter, as
amended and restated as of May 19, 2014, which is available at the About/Investor Relations section under Mission Statement/
Corporate Governance on www.microchip.com. The Board of Directors has determined that all members of the Nominating and
Governance Committee are independent directors as defined by applicable SEC rules and NASDAQ listing standards.
When considering a candidate for a director position, the Nominating and Governance Committee looks for
demonstrated character, judgment, relevant business, functional and industry experience, and a high degree of skill. The
Nominating and Governance Committee believes it is important that the members of the Board of Directors represent diverse
viewpoints. Accordingly, the Nominating and Governance Committee considers issues of diversity in identifying and
evaluating director nominees, including differences in education, professional experience, viewpoints, technical skills,
individual expertise, ethnicity and gender. The Nominating and Governance Committee evaluates director nominees
recommended by a stockholder in the same manner as it would any other nominee. The Nominating and Governance
Committee will consider nominees recommended by stockholders provided such recommendations are made in accordance
with procedures described in this proxy statement under "Requirements, Including Deadlines, for Receipt of Stockholder
Proposals for the 2020 Annual Meeting of Stockholders; Discretionary Authority to Vote on Stockholder Proposals" at page 58.
We do not pay any third party to identify or assist in identifying or evaluating potential nominees for director.
Attendance at the Annual Meeting of Stockholders
All directors are encouraged, but not required, to attend our annual meeting of stockholders. All directors attended our
fiscal 2018 annual meeting of stockholders on August 14, 2018.
REPORT OF THE AUDIT COMMITTEE (*)
Our Board of Directors has adopted a written charter setting out the purposes and responsibilities of the Audit
Committee. The Board of Directors and the Audit Committee review and assess the adequacy of the charter on an annual basis.
A copy of the Audit Committee Charter is available at the About/Investor Relations section under Mission Statement/Corporate
Governance on www.microchip.com.
Each of the directors who serves on the Audit Committee meets the independence and experience requirements of the
SEC rules and NASDAQ listing standards. This means that the Microchip Board of Directors has determined that no member
of the Audit Committee has a relationship with Microchip that may interfere with such member's independence from Microchip
and its management, and that all members have the required knowledge and experience to perform their duties as committee
members.
We have received from Ernst & Young LLP the written disclosure and the letter required by Rule 3526 of the Public
Company Accounting Oversight Board (Communication with Audit Committees Concerning Independence) and have discussed
with Ernst & Young LLP their independence from Microchip. We also discussed with Ernst & Young LLP all matters required
to be discussed by Public Company Accounting Oversight Board (PCAOB) standards. We have considered whether and
determined that the provision of the non-audit services rendered to us by Ernst & Young LLP during fiscal 2019 was compatible
with maintaining the independence of Ernst & Young LLP.
6
Table of Contents
We have reviewed and discussed with management the audited annual financial statements included in Microchip's
Annual Report on Form 10-K for the fiscal year ended March 31, 2019 and filed with the SEC, as well as the unaudited
financial statements filed with Microchip's quarterly reports on Form 10-Q. We also met with both management and Ernst &
Young LLP to discuss those financial statements.
Based on these reviews and discussions, we recommended to the Board of Directors that Microchip's audited financial
statements be included in Microchip's Annual Report on Form 10-K for the fiscal year ended March 31, 2019 for filing with the
SEC.
By the Audit Committee of the Board of Directors:
Matthew W. Chapman (Chairman)
Esther L. Johnson
Wade F. Meyercord
________________________
(*) The Report of the Audit Committee is not "soliciting" material and is not deemed "filed" with the SEC, and is not
incorporated by reference into any filings of Microchip under the Securities Act of 1933 or the Securities Exchange Act of
1934, whether made before or after the date of this proxy statement and irrespective of any general incorporation language
contained in such filings.
Director Compensation
Procedures Regarding Director Compensation
The Board of Directors sets non-employee director compensation. Microchip does not pay employee directors for
services provided as a member of the Board of Directors. Our program of cash and equity compensation for non-employee
directors is designed to achieve the following goals: compensation should fairly pay directors for work required for a company
of Microchip's size and scope; compensation should align directors' interests with the long-term interests of stockholders;
compensation should be competitive so as to attract and retain qualified non-employee directors; and the structure of the
compensation should be simple, transparent and easy for stockholders to understand. Non-employee director compensation is
typically reviewed once per year to assess whether any adjustment is needed to further such goals. The Board of Directors has
not used outside consultants in setting non-employee director compensation.
Director Fees
Effective November 14, 2016, non-employee directors received an annual retainer of $71,500, paid in quarterly
installments, and $3,000 for each meeting attended in person. Effective May 21, 2019, the Board approved an increase in the
annual retainer from $71,500 to $75,000. Directors do not receive any additional compensation for telephonic meetings of the
Board of Directors, for meetings of committees of the Board, or for serving as a committee chair.
Equity Compensation
Under the terms of our 2004 Equity Incentive Plan, each non-employee director is automatically granted:
•
•
upon the date that the individual is first appointed or elected to the Board of Directors as a non-employee
director, that number of restricted stock units ("RSUs") equal to $160,000 (based on the fair market value of
our common stock on the grant date) which shall vest in equal 25% annual installments on each of the four
anniversaries of the tenth business day of the second month of our fiscal quarter in which the grant is made;
and
upon the date of our annual meeting, provided that the individual has served as a non-employee director for at
least three months on that date and has been elected by the stockholders to serve as a member of the Board of
Directors at that annual meeting, that number of RSUs equal to $84,000 (or $123,000 for grants occurring
after May 21, 2019), based on the fair market value of our common stock on the grant date which shall vest in
7
Table of Contents
equal 50% annual installments on each of the two anniversaries of the tenth day of the second month of our
fiscal quarter in which the grant is made.
All vesting of the above grants is contingent upon the non-employee director maintaining his or her continued status as
a non-employee director through the applicable vesting date.
In accordance with the foregoing, on August 14, 2018, each of Mr. Chapman, Mr. Day, Ms. Johnson and
Mr. Meyercord was granted 999 RSUs.
The following table details the total compensation for Microchip's non-employee directors for fiscal 2019:
DIRECTOR COMPENSATION
Name
Steve Sanghi (2)
Matthew W. Chapman
L.B. Day
Esther L. Johnson
Wade F. Meyercord
Fees Earned
or Paid in
Cash
Stock
Awards(1)
Option
Awards
Non-Equity
Incentive Plan
Compensation
All Other
Compensation
Total
$
— $
— $
— $
— $
— $
—
83,500
83,500
83,500
83,500
81,139
81,139
81,139
81,139
—
—
—
—
—
—
—
—
—
—
—
—
164,639
164,639
164,639
164,639
(1) The stock award of 999 RSUs to each of the directors on August 14, 2018 had a fair value on the grant date of $81.22 per
share and a market value on the grant date of $84.08 per share with an aggregate market value of each award of
approximately $84,000.
(2) Mr. Sanghi, our Chief Executive Officer and Chairman of the Board, does not receive any additional compensation for
his service as a member of the Board of Directors.
Compensation Committee Interlocks and Insider Participation
The Compensation Committee is currently comprised of Mr. Meyercord (Chair) and Mr. Day. Each such person is an
independent director. Neither Mr. Day nor Mr. Meyercord had any related-party transaction with Microchip during fiscal 2019
other than compensation for service as a director. In addition, neither of such directors has a relationship that would constitute a
compensation committee interlock under applicable SEC rules. During fiscal 2019, no Microchip executive officer served on
the compensation committee (or equivalent) or the board of directors of another entity whose executive officer(s) served either
on Microchip's Compensation Committee or Board of Directors.
8
Table of Contents
CERTAIN TRANSACTIONS
During fiscal 2019, Microchip had no related-party transactions within the meaning of applicable SEC rules.
Pursuant to its charter, the Audit Committee reviews issues involving potential conflicts of interest and reviews and
approves all related-party transactions as contemplated by NASDAQ and SEC rules and regulations. The Audit Committee
may consult with the Board of Directors regarding certain conflict of interest matters that do not involve a member of the
Board.
DELINQUENT SECTION 16(A) REPORTS
Section 16(a) and related rules under the Securities Exchange Act of 1934 require our directors, executive officers and
stockholders holding more than 10% of our common stock to file reports of holdings and transactions in Microchip stock with
the SEC and to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of the copies of such
forms received by us during fiscal 2019, and written representations from our directors and executive officers that no other
reports were required, we believe that all Section 16(a) filing requirements applicable to our directors, executive officers and
stockholders holding more than 10% of our common stock were met for fiscal 2019, except that Mr. Meyercord filed one late
Form 4 on June 28, 2019 reporting one transaction.
9
Table of Contents
PROPOSAL ONE
ELECTION OF DIRECTORS
The Board currently consists of five directors: Steve Sanghi, Matthew W. Chapman, L.B. Day, Esther L. Johnson and
Wade F. Meyercord. Unless proxy cards are otherwise marked, the persons named in the proxy card will vote such proxy for
the election of the nominees named below. Each of the nominees is currently serving as a director and has agreed to continue
serving if re-elected. If any of the nominees becomes unable or declines to serve as a director at the time of the annual meeting,
the persons named in the proxy card will vote such proxy for any nominee designated by the current Board of Directors to fill
the vacancy. We do not expect that any of the nominees will be unable or will decline to serve as a director.
Our Board of Directors has determined that each of the following nominees for director is an independent director as
defined by applicable SEC rules and NASDAQ listing standards: Mr. Chapman, Mr. Day, Ms. Johnson and Mr. Meyercord.
The term of office of each person who is elected as a director at the annual meeting will continue until the 2020 annual
meeting of stockholders and until a successor has been elected and qualified.
Vote Required; Board Recommendation
A nominee for director in an uncontested election shall be elected to the Board of Directors if the votes cast for such
nominee's election exceed the votes cast against such nominee's election (with votes cast excluding abstentions, withheld notes
or broker non-votes).
The Board of Directors unanimously recommends that stockholders vote FOR the nominees listed below.
Information on Nominees for Director (as of June 30, 2019)
Name
Steve Sanghi
Matthew W. Chapman
L.B. Day
Esther L. Johnson
Wade F. Meyercord
Age
63
68
74
67
78
Position(s) Held
Chief Executive Officer and
Chairman of the Board
Director
Director
Director
Director
Steve Sanghi has served as Chief Executive Officer since October 1991, and as Chairman of the Board since October
1993. He served as President from August 1990 to February 2016 and has served as a director since August 1990. In
November 2016, Mr. Sanghi joined the Board of Directors of Myomo, Inc., a publicly traded commercial stage medical robotics
company that offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. In February
2018, Mr.Sanghi joined the Board of Directors of Mellanox Technologies Ltd., a publicly traded supplier of end-to-end Ethernet
and InfiniBand intelligent interconnect solutions and services for servers, storage, and hyper-converged infrastructure.
The Board of Directors concluded that Mr. Sanghi should be nominated to serve as a director since he has served as
CEO of Microchip for over 25 years and has provided very strong leadership to Microchip over this period. The Board of
Directors believes that Mr. Sanghi's management skills have been instrumental to Microchip's extraordinary growth and
profitability over the past 25 years and to the strong position Microchip has attained in its key markets.
10
Table of Contents
Matthew W. Chapman has served as a director of Microchip since May 1997. After serving for over 11 years,
Mr. Chapman retired in February 2018 from his position as Chief Executive Officer of Northwest Evaluation Association, a
not-for-profit education services organization providing computer adaptive testing for millions of students throughout the
United States and in 140 other countries. In his career, Mr. Chapman has served as CEO and Chairman of Concentrex
Incorporated, a publicly held company specializing in supplying software solutions and service to U.S. financial institutions.
Mr. Chapman served as a member of the Board of Directors of the Oregon Business Association and Knowledge Alliance. He
is currently serving on the Board of Regents of the University of Portland and the board of two not-for-profit organizations.
The Board of Directors concluded that Mr. Chapman should be nominated to serve as a director due to his significant
CEO level experience at several corporations. The Board of Directors also recognizes Mr. Chapman's experience in financial
matters and that his background establishes him as an audit committee financial expert under applicable rules and makes him
well suited to serve on the Board of Directors’ nominating and governance committee.
L.B. Day has served as a director of Microchip since December 1994. Mr. Day serves as President of L.B. Day &
Company, Inc., which provides strategic planning, strategic marketing and organization design services to the elite of the
technology world. He has written on strategic planning and is involved with competitive factor assessment in the
semiconductor and other technology market segments, geared to helping client organizations incorporate competitive factor
assessment findings into their strategic plans. He has served as a board member or as an advisor to many public and private
boards.
The Board of Directors concluded that Mr. Day should be nominated to serve as a director due to his significant
experience in corporate management and strategic matters. In particular, through his consulting practice, Mr. Day has been a
key strategic advisor to a number of large public corporations. The Board of Directors also recognizes Mr. Day's experience in
financial matters. The Board of Directors believes that Mr. Day's background makes him well suited to serve on the Board of
Directors' nominating and governance committee and compensation committee.
Esther L. Johnson has served as a director of Microchip since October 2013. From April 2007 until her April 2012
retirement, Ms. Johnson served as the Vice President and General Manager of Carrier Electronics, a provider of high
technology heating, air-conditioning and refrigeration solutions, and a part of United Technology Corporation, a publicly held
company that provides high technology products and services to the aerospace and building systems industries. Prior to her
position as Vice President and General Manager, since 1983, Ms. Johnson held a variety of other management positions with
Carrier Electronics, including Director of Operations and Global Supply Chain Manager. Ms. Johnson was instrumental in
Carrier being recognized by Industry Week as one of the "Top 10 Factories in North America." She has served as a board
member on multiple private company boards.
The Board of Directors concluded that Ms. Johnson should be nominated to serve as a director due to her significant
executive level experience in the technology industry. The Board of Directors also recognizes the knowledge and experience
Ms. Johnson has gained through her service on the boards of various private companies. The Board of Directors also
recognizes Ms. Johnson's experience in financial matters. The Board of Directors believes that Ms. Johnson's background
makes her well suited to serve on the Board of Directors' audit committee and nominating and governance committee.
Wade F. Meyercord has served as a director of Microchip since June 1999. Since October 2002, he has served as
President of Meyercord & Associates, Inc., a privately held management consulting firm specializing in executive
compensation matters and stock plan consulting for technology companies, a position he previously held part time beginning in
1987. Mr. Meyercord served as a member of the Board of Directors of Endwave Corporation, a publicly held company, from
March 2004 until it was acquired in 2011. Mr. Meyercord served as a member of the Board of Directors of California Micro
Devices Corporation, a publicly held company, from January 1993 to October 2009 and Magma Design Automation, Inc., a
publicly held company, from January 2004 to June 2005.
11
Table of Contents
The Board of Directors concluded that Mr. Meyercord should be nominated to serve as a director due to his significant
experience as a senior executive and board member of a number of companies in the technology industry. Mr. Meyercord
gained further industry experience through his consulting practice. The Board of Directors believes that Mr. Meyercord's
background makes him well suited to serve on the Board of Directors' nominating and governance committee and
compensation committee. The Board of Directors also recognizes his experience in financial matters and that his background
establishes him as an audit committee financial expert under applicable rules.
12
Table of Contents
PROPOSAL TWO
APPROVAL OF FRENCH SUB-PLAN UNDER
THE 2004 EQUITY INCENTIVE PLAN
Recent changes to the income tax and social tax treatment of French tax-qualified RSUs ("French-Qualified RSUs")
were implemented into French law. Pursuant to the French law, U.S. companies are permitted, but not required, to grant
French-Qualified RSUs, which provide for more favorable tax treatment for both French employers and their employees than
the current non-qualified RSU awards granted under our 2004 Equity Incentive Plan (the "Plan").
The Plan, as most recently amended by our Board on May 21, 2019 and most recently approved by our stockholders at
our 2017 annual meeting of stockholders, currently provides that the administrator of the Plan has the authority to prescribe
rules and regulations relating to local country sub-plans to the Plan for the purpose of qualifying for preferred tax treatment
under foreign tax laws. Accordingly, our Board of Directors has approved the French-Qualified Restricted Stock Unit Sub-Plan
(the "French Sub-Plan"), a sub-plan under the Plan, subject to stockholder approval, to permit the grant of French-Qualified
RSUs. In addition to the approval of our Board of Directors or our Compensation Committee, French law requires that
stockholders approve the French Sub-Plan.
Therefore, we are seeking stockholder approval of the French Sub-Plan, which is intended to realize potential tax
benefits to our French employees by permitting the grant of French-Qualified RSUs that qualify for more favorable tax
treatment. We are neither seeking approval for an increase in the number of shares available for issuance under the
Plan, nor are we seeking approval of any revisions to the Plan. Instead, we are asking stockholders to approve the
French Sub-Plan solely to comply with the stockholder authorization requirement under French tax law to permit the
granting of tax-favored French-Qualified RSUs.
We believe that it is in our best interests and the best interests of our stockholders to give us the discretion to grant
awards under the French Sub-Plan that would qualify for the income and social tax treatment authorized under French law. If
the French Sub-Plan is approved by our stockholders at the Annual Meeting, the French Sub-Plan will become effective on
August 20, 2019 (the "Effective Date"). Any shares issued with respect to the French-Qualified RSUs will be satisfied under
the existing share reserve of the Plan and will have terms consistent with the existing Plan.
French Sub-Plan Key Terms
In addition to stockholder approval of the French Sub-Plan, other key requirements for French-Qualified RSUs
granted under the French law include that: (i) the French-Qualified RSUs must provide for a minimum vesting period of one
year from the grant date, (ii) the sale of shares acquired upon vesting of French-Qualified RSUs must be restricted for a
minimum of two years from the grant date, (iii) the French-Qualified RSUs cannot be granted to any employee or managing
director who (1) owns more than 10% of the company’s share capital or (2) will due to the grant, own more than 10% of the
company’s share capital and (iv) shares acquired upon vesting may not be sold during “closed periods” which include ten
quotation days preceding and three quotation days following the financial statement disclosures/filings or blackout periods.
The full text of the French Sub-Plan is attached as Appendix A to this Proxy Statement.
French Tax Consequences of French-Qualified RSUs
Upon stockholder approval of the French Sub-Plan, stock awards that are granted to French-resident employees and
that qualify as French-Qualified RSUs under French law will not be subject to tax until shares acquired under the Plan are sold,
at which time the taxable amount is divided into the gain at vesting and any additional gain at sale. The vesting gain (i.e., the
value of the shares issued upon vesting) not exceeding €300,000 is subject to tax as salary at the employee’ s marginal income
tax rate after a 50% rebate, which under the law, applies regardless of how long the shares are held before sale. Employee
social security also applies at a rate of 17.2% (of which 6.8% is deductible), plus surtax for income over €250,000 or €500,000
for single or married taxpayers, respectively. The portion of the vesting gain exceeding €300,000 is subject to tax as salary at
the employee’s marginal income tax rate without any rebate, and to employee social security at a rate of 9.7% (of which 6.8%
13
Table of Contents
is deductible), plus employee specific social security of 10% and surtax (as described above). Any additional gain at sale (i.e.,
sale price less fair market value of shares at vesting) is subject to income and social taxes at a combined flat 30% rate (or at the
election of the employee, the employee’s marginal income tax rate) plus surtax (as described above). In addition, the
employing company may receive certain tax benefits, including being subject to a 20% social insurance contribution upon
vesting of French-Qualified RSUs instead of the 30% social insurance contribution imposed prior to the new French law
depending on the applicable French-qualified regime. The tax consequences of participating in the French Sub-Plan may vary
by individual situations and circumstances. Income tax laws, regulations and interpretations with respect to the French Sub-
Plan may also change frequently. Participants in the French Sub-Plan should rely upon their own tax advisors for advice
concerning the specific tax consequences and treatment applicable to them.
General Information About the Plan
The Plan was initially approved by our stockholders in August 2004, and was most recently amended in May 2019.
The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards (which may be granted in the
form of restricted stock or RSUs), performance shares, performance units, and deferred stock units to our employees and
consultants as well as for automatic grants of RSUs to the non-employee members of our Board.
The Plan Includes Compensation and Governance Best Practices
The Plan includes provisions that are considered best practices for compensation and corporate governance purposes.
These provisions protect our stockholders' interest, as follows:
•
•
•
•
No Annual Evergreen. The Plan does not contain an annual "evergreen" provision that automatically
increases the number of shares available for issuance each year. As a result, any increases to the number of
shares reserved for issuance under the Plan will require approval from our stockholders.
Administration. The Plan is administered by the Compensation Committee, which consists entirely of
independent non-employee directors.
Annual Limits on Awards. The Plan sets reasonable, annual limits as to the awards that individuals may
receive during each fiscal year.
Repricing or Exchange Programs are Not Allowed. The Plan does not permit outstanding options or stock
appreciation rights to be repriced or exchanged for other awards.
• Minimum Vesting Requirements. In general, awards vesting on the basis of an individual's continuous
service with us will vest in full no earlier than the one-year anniversary of the grant date although up to 5%
of the shares reserved in the Plan may be granted without this minimum vesting requirement.
•
•
•
•
No Single-Trigger Vesting Acceleration upon a Change of Control. The Plan provides that only in the
event an award is not assumed or replaced will vesting accelerate on a Change of Control.
Limited Transferability. Awards under the Plan generally may not be sold, assigned, transferred, pledged,
or otherwise encumbered, unless otherwise approved by the administrator.
No Tax Gross-ups. The Plan does not provide for any tax gross-ups.
No Dividends on Unvested Restricted Stock. The Plan provides that a participant has no right to receive
dividends on restricted stock until the restrictions on shares of restricted stock lapse.
Our executive officers and directors have an interest in the Plan because they are eligible to receive equity awards
under the Plan. However, none of our current executive officers or directors is expected to receive an award under the French
Sub-Plan.
Please see the summary of the Plan below. However, this summary is not a complete description of all of the
provisions of the Plan and is qualified in its entirety by reference to the Plan which was filed as an exhibit to our Annual Report
on Form 10-K filed with the SEC on May 30, 2019.
14
Table of Contents
Vote Required and Recommendation
An affirmative vote of a majority of the shares of our common stock present in person or represented by proxy and
entitled to vote at our Annual Meeting is required to approve the French Sub-Plan under the Plan. Abstentions will have the
same effect as voting against this proposal. Broker "non-votes" are not counted for purposes of approving the French Sub-Plan
under the Plan and thus will not affect the outcome of the voting on such proposal.
Our Board of Directors unanimously recommends a vote "FOR" Proposal Two, the approval of the French
Sub-Plan under our 2004 Equity Incentive Plan.
Summary Description of the 2004 Equity Incentive Plan
As noted above, this proposal does not amend the Plan and is limited to approving the French Sub-Plan as required by
French law for the grant of French-Qualified RSUs to eligible employees in France. Please note that the Plan is not a part of
our proxy solicitation materials. Capitalized terms used herein and not defined shall have the meanings set forth in the Plan.
General. The purposes of the Plan are to attract and retain the best available personnel, provide additional incentive to
our employees, consultants and non-employee directors and promote the success of our business.
Shares Available for Issuance. Subject to adjustment for changes in our capitalization, the maximum aggregate
number of shares of common stock which may be issued under the Plan is 36,387,887.
If an award expires or becomes unexercisable without having been exercised in full, or with respect to restricted stock,
RSUs, performance shares, performance units or deferred stock units, is forfeited to or repurchased by us, the unpurchased
shares (or for awards other than stock options and stock appreciation rights, the forfeited or repurchased shares) which were
subject thereto shall become available for future grant or sale under the Plan (unless the Plan has terminated). With respect to
stock appreciation rights, the gross shares issued (i.e., shares actually issued pursuant to a stock appreciation right, as well as
the shares that represent payment of the exercise price and any applicable tax withholdings pursuant to a stock appreciation
right) shall cease to be available under the Plan. Shares that have actually been issued under the Plan under any award shall not
be returned to the Plan and shall not become available for future distribution under the Plan; provided, however, that if shares
of restricted stock, performance shares, performance units or deferred stock units are repurchased by us at their original
purchase price or are forfeited to us, such shares shall become available for future grant under the Plan. Shares used to pay the
exercise price or purchase price, if applicable, of an award shall become available for future grant or sale under the Plan. To the
extent an award under the Plan is paid out in cash rather than stock, such cash payment shall not result in reducing the number
of shares available for issuance under the Plan.
Administration. The Plan may be administered by our Board of Directors or a committee or committees, which may
be appointed by our Board of Directors (the "Administrator").
Subject to the provisions of the Plan, the Administrator has the authority to: (i) construe and interpret the plan and
awards; (ii) prescribe, amend or rescind rules and regulations relating to the Plan; (iii) select the service providers to whom
awards are to be granted (apart from the non-employee director automatic grant provisions); (iv) subject to the limits set forth
in the Plan, determine the number of shares or equivalent units to be granted subject to each award; (v) determine whether and
to what extent awards are to be granted; (vi) determine the terms and conditions, not inconsistent with the terms of the Plan,
applicable to awards granted under the Plan; (vii) modify or amend any outstanding award subject to applicable legal
restrictions and the restrictions set forth in the Plan; (viii) authorize any person to execute, on our behalf, any instrument
required to effect the grant of an award; (ix) approve forms of agreement for use under the Plan; (x) allow participants to satisfy
tax withholding obligations by electing to have Microchip withhold from the shares or cash to be issued upon exercise, vesting
of an award (or distribution of a deferred stock unit) that number of shares or cash having a fair market value equal to the
minimum amount required to be withheld; (xi) determine the fair market value of the shares of our common stock and (xii)
subject to certain limitations, take any other actions deemed necessary or advisable for the administration of the Plan. All
decisions, interpretations and other actions of the Administrator shall be final and binding on all holders of options or rights and
on all persons deriving their rights therefrom.
15
Table of Contents
Plan Term. Unless previously terminated by the Board of Directors, the Plan shall terminate on May 21, 2022.
Discount Award Limitations. No stock options or stock appreciation rights may be granted with an exercise price that
is less than 100% of fair market value on the date of grant.
No Repricing. The Plan prohibits option or stock appreciation right repricing, including by way of an exchange for
another award or for cash.
Eligibility. The Plan provides that awards may be granted to our employees, consultants and non-employee directors.
Minimum Vesting Requirements. Except with respect to 5% of the maximum number of shares issuable under the
Plan, no award that vests on the basis of an individual's continuous service with us will vest earlier than one year following the
date of grant; provided, however, that vesting of an award may be accelerated upon the death, disability, or involuntary
termination of the service of the grantee, or in connection with a corporate transaction, as defined in the Plan.
Performance Goals. The Administrator may make performance goals applicable to awards made to participants. Any
applicable performance goals will be determined at the Administrator's discretion, and may differ from participant to participant
and from award to award.
Terms and Conditions of Options. Each option granted under the Plan is evidenced by a written stock option
agreement between the participant and Microchip and is subject to the following terms and conditions:
(a) Exercise Price. The Administrator determines the exercise price of options at the time the options are
granted. However, the exercise price of a stock option may not be less than 100% of the fair market value of the common stock
on the date the option is granted. For purposes of the Plan, "fair market value" is generally the closing sale price for the
common stock (or the closing bid if no sales were reported) on the date the option is granted.
(b) Form of Consideration. The means of payment for shares issued upon exercise of an option is specified in
each option agreement and generally may be made by cash, check, other shares of our common stock owned by the participant,
delivery of an exercise notice together with irrevocable instructions to a broker to deliver to us the exercise price from sale
proceeds, by a combination thereof, or by such other consideration and method of payment to the extent permitted by
applicable laws.
(c) Exercise of the Option. Each stock option agreement will specify the term of the option and the date when
the option is to become exercisable. However, in no event shall an option granted under the Plan be exercised more than ten
years after the date of grant. Until the shares are issued, no right to vote or receive dividends or any other rights as a
stockholder shall exist with respect to the underlying shares.
(d) Termination of Employment. If a participant's employment terminates for any reason (other than death or
permanent disability), all options held by such participant under the Plan expire upon the earlier of (i) such period of time as is
set forth in his or her option agreement or (ii) the expiration date of the option. In the absence of a specified time in the option
agreement, the option will remain exercisable for three months following the participant's termination. The participant may
exercise all or part of his or her option at any time before such expiration to the extent that such option was exercisable at the
time of termination of employment.
(e) Permanent Disability. If an employee is unable to continue employment with us as a result of permanent
and total disability (as defined in the Code), all options held by such participant under the Plan shall expire upon the earlier of
(i) such period of time as is set forth in his or her option agreement or (ii) the expiration date of the option. In the absence of a
specified time in the option agreement, the option will remain exercisable for six months following the participant's
termination. The participant may exercise all or part of his or her option at any time before such expiration to the extent that
such option was exercisable at the time of termination of employment.
(f) Death. If a participant dies while employed by us, 100% of his or her awards shall immediately vest, and his
or her option shall expire upon the earlier of (i) such period of time as is set forth in his or her option agreement or (ii) the
expiration date of the option. In the absence of a specified time in the option agreement, the option will remain exercisable for
16
Table of Contents
12 months following the participant's termination. The executors or other legal representatives or the participant may exercise
all or part of the participant's option at any time before such expiration with respect to all shares subject to such option.
(g) Other Provisions. The stock option agreement may contain terms, provisions and conditions that are
consistent with the Plan as determined by the Administrator.
Share Limits. No participant may be granted stock options and stock appreciation rights to purchase more than
1,500,000 shares of common stock in any fiscal year, except that up to 4,000,000 shares may be granted in the participant's first
fiscal year of service.
Terms and Conditions of Stock Appreciation Rights. The Administrator determines the exercise price of stock
appreciation rights (or "SARs") at the time they are granted. However, the exercise price of a SAR may not be less than 100%
of the fair market value of the common stock on the date the SAR is granted. Otherwise, the Administrator, subject to the
provisions of the Plan (including the share limit referred to above and the minimum vesting requirements), shall have complete
discretion to determine the terms and conditions of SARs granted under the Plan. However, in no event shall a SAR granted
under the Plan be exercised more than ten years after the date of grant. Until the shares are issued, no right to vote or receive
dividends or any other rights as a stockholder shall exist with respect to the underlying shares.
Payment of Stock Appreciation Right Amount. Upon exercise of an SAR, the holder of the SAR shall be entitled to
receive payment in an amount equal to the product of (i) the difference between the fair market value of a share on the date of
exercise and the exercise price and (ii) the number of shares for which the SAR is exercised.
Payment upon Exercise of Stock Appreciation Right. At the discretion of the Administrator, payment to the holder of
an SAR may be in cash, shares of our common stock or a combination thereof. To the extent that an SAR is settled in cash, the
shares available for issuance under the Plan shall not be diminished as a result of the settlement.
Stock Appreciation Right Agreement. Each SAR grant shall be evidenced by an agreement that specifies the exercise
price, the term of the SAR, the conditions of exercise, and such other terms and conditions as the committee, in its sole
discretion, shall determine.
Expiration of Stock Appreciation Rights. SARs granted under the Plan expire as determined by the Administrator, but
in no event later than ten years from date of grant. No SAR may be exercised by any person after its expiration. The same
provisions regarding termination of service that apply to options apply to SARs.
Terms and Conditions of Restricted Stock. Subject to the terms and conditions of the Plan, restricted stock may be
granted to our employees and consultants at any time and from time to time at the discretion of the Administrator. Subject to
the minimum vesting requirements, the Administrator has complete discretion to determine (i) the number of shares subject to a
restricted stock award granted to any participant and (ii) the conditions for grant or for vesting that must be satisfied, which
typically will be based principally or solely on continued provision of services but may include a performance-based
component. However, no participant shall be granted a restricted stock award covering more than 300,000 shares in any of our
fiscal years, except that up to 750,000 shares may be granted in the participant's first fiscal year of service. Until the shares are
issued, no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the underlying
shares. Restricted stock may also be granted in the form of RSUs. Each RSU granted is a bookkeeping entry representing an
amount equal to the fair market value of a share of our common stock.
Restricted Stock Award Agreement. Each restricted stock grant shall be evidenced by an agreement that specifies the
purchase price (if any) and such other terms and conditions as the Administrator shall determine; provided, however, that if the
restricted stock grant has a purchase price, the purchase price must be paid no more than ten years following the date of grant.
17
Table of Contents
Terms and Conditions of Performance Shares. Subject to the terms and conditions of the Plan, performance shares
may be granted to our employees and consultants at any time and from time to time as determined at the discretion of the
Administrator. The Administrator has complete discretion to determine (i) the number of shares of our common stock subject
to a performance share award granted to any participant and (ii) the conditions that must be satisfied for grant or for vesting,
which typically will be based principally or solely on achievement of performance milestones but may include a service-based
component. However, no participant shall be granted a performance share award covering more than 300,000 shares in any of
our fiscal years, except that up to 750,000 shares may be granted on the participant's first fiscal year of service.
Performance Share Award Agreement. Each performance share grant shall be evidenced by an agreement that
specifies such other terms and conditions as the Administrator, in its sole discretion, shall determine.
Terms and Conditions of Performance Units. Performance units are similar to performance shares, except that they
are settled in cash equivalent to the fair market value of the underlying shares of our common stock, determined as of the
vesting date. The shares available for issuance under the Plan shall not be diminished as a result of the settlement of a
performance unit. No participant shall be granted a performance unit award covering more than $1,500,000 in any of
Microchip's fiscal years, except that a newly hired participant may receive a performance unit award covering up to $4,000,000
in the participant's first fiscal year of service.
Performance Unit Award Agreement. Each performance unit grant shall be evidenced by an agreement that shall
specify such terms and conditions as shall be determined at the discretion of the Administrator.
Terms and Conditions of Deferred Stock Units. Deferred stock units consist of restricted stock, performance share or
performance unit awards that the Administrator, in its sole discretion, permits to be paid out in installments or on a deferred
basis, in accordance with rules and procedures established by the Administrator. Deferred stock units are subject to the
individual annual limits that apply to each type of award.
Dividend Equivalent Right Restrictions. The Plan does not permit the granting of dividend equivalent rights, including
but not limited to, on options or SARs. Accordingly, in no event will dividend equivalent rights be paid out on unearned
performance-based vesting awards under the Plan.
Awards to Non-Employee Directors. The Plan provides for initial and annual awards to non-employee directors within
prescribed parameters. Specifically, each non-employee director is entitled to receive the following automatic grants: (i) for
new non-employee directors, a grant of that number of RSUs equal to $160,000 divided by the fair market value of a share on
the date of grant, rounded down to the nearest whole share (the "Initial RSU Grant"), and (ii) for continuing non-employee
directors who have served at least three months on the date of the annual meeting, a grant of that number of RSUs equal to
$84,000 (or $123,000 for grants occurring after May 21, 2019) divided by the fair market value of a share on the date of grant,
rounded down to the nearest whole share (the "Annual RSU Grant"), provided that such non-employee director has been
elected by the stockholders to serve as a member of the Board at that annual meeting. The Initial RSU Grant vests in equal
25% annual installments on each of the four anniversaries of the tenth business day of the second month of our fiscal quarter in
which the grant is made. The Annual RSU Grant vests in equal 50% annual installments on each of the two anniversaries of the
tenth day of the second month of our fiscal quarter in which the grant is made. Vesting of the Initial RSU Grant and the Annual
RSU Grant is contingent upon the applicable non-employee director maintaining continued status as a non-employee director
through the applicable vesting date.
Non-Transferability of Awards. Unless determined otherwise by the Administrator, an award granted under the Plan
may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the recipient, only by the recipient. In no event may an
award granted under the Plan be exchanged for consideration. If the Administrator makes an award granted under the Plan
transferable, such award shall contain such additional terms and conditions as the Administrator deems appropriate.
Acceleration upon Death. In the event that a participant dies while a service provider, 100% of his or her awards shall
immediately vest.
18
Table of Contents
Leave of Absence. In the event that a participant goes on an unpaid leave of absence, award vesting will cease until he
or she returns to work, except as required by law or as determined by the Administrator.
Forfeiture on Misconduct. Should (i) a participant's service be terminated for misconduct (including, but not limited
to, any act of dishonesty, willful misconduct, fraud or embezzlement), or (ii) a participant makes any unauthorized use or
disclosure of confidential information or trade secrets of Microchip or its parent or subsidiary, then all outstanding awards held
by the participant will terminate immediately and cease to be outstanding, including both vested and unvested awards.
Adjustment Upon Changes in Capitalization. In the event that our capital stock is changed by reason of any stock
split, reverse stock split, stock dividend, combination or reclassification of our common stock or any other increase or decrease
in the number of issued shares of common stock effected without receipt of consideration by us, appropriate proportional
adjustments shall be made in the number and class of shares of stock subject to the Plan, the individual fiscal year limits
applicable to restricted stock, RSUs, performance share awards, SARs and options, the number and class of shares of stock
subject to any award outstanding under the Plan, and the exercise price of any such outstanding option or SAR or other award,
provided that such automatic adjustments will not be made to the number of shares to be granted to our non-employee directors
under the Plan. Any such adjustment shall be made by the Compensation Committee of our Board of Directors, whose
determination shall be conclusive.
Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of Microchip, the Administrator
will notify each participant as soon as practicable prior to the effective date of such proposed transaction. The Administrator in
its discretion may provide for a participant to have the right to exercise his or her option or SAR until ten days prior to such
transaction as to all the shares covered by the award, including shares as to which the award would not otherwise be
exercisable. The Administrator may provide that any repurchase option or forfeiture rights held by Microchip will lapse 100%
and vesting will accelerate 100%, provided that the proposed dissolution or liquidation takes place at the time and in the
manner contemplated. To the extent that it has not been exercised (with respect to options or SARs) or vested (with respect to
other awards), an award will terminate immediately prior to the consummation of the proposed action.
Change of Control. In the event of a change of control of Microchip, the successor corporation (or its parent or
subsidiary) will assume or substitute each outstanding award. If the successor corporation refuses to assume the awards or to
substitute equivalent awards, such awards shall become 100% vested. In such event, the Administrator shall notify the
participant that each award subject to exercise is fully exercisable for 30 days from the date of such notice and that the award
terminates upon expiration of such period.
Amendment, Suspensions and Termination of the Plan. Our Board of Directors may amend, suspend or terminate the
Plan at any time; provided, however, that stockholder approval is required for any amendment to the extent necessary to comply
with Rule 16b-3 promulgated under the Securities Exchange Act of 1934 ("Rule 16b-3") or Section 422 of the Code, or any
similar rule or statute. The Plan will terminate on May 21, 2022 unless earlier terminated by the Board of Directors.
Federal Tax Information
The following paragraphs are a summary of the general federal income tax consequences to U.S. taxpayers and us of
awards granted under the Plan. Tax consequences for any particular individual may be different.
Options. Options granted under the Plan are nonstatutory options that do not qualify as incentive stock options under
Section 422 of the Code.
A participant will not recognize any taxable income at the time the participant is granted a nonstatutory option.
However, upon its exercise, the participant will recognize taxable income generally measured as the excess of the then-fair
market value of the shares purchased over the exercise price of the option. Any taxable income recognized in connection with
an option exercise by a participant who is also our employee will be subject to tax withholding by us. Upon resale of such
shares by the participant, any difference between the sale price and the participant's exercise price, to the extent not recognized
as taxable income as described above, will be treated as short-term or long-term capital gain or loss, depending on the holding
period.
19
Table of Contents
Stock Appreciation Rights. No taxable income is reportable when an SAR is granted to a participant. Upon exercise,
the participant will recognize ordinary income in an amount equal to the fair market value of any shares of our common stock
received and/or the amount of cash received. Any taxable income recognized in connection with exercise of an SAR by a
participant who is also our employee will be subject to tax withholding by us. Any additional gain or loss recognized upon any
later disposition of the shares of our common stock would be a capital gain or loss.
Restricted Stock, Performance Units and Performance Shares. A participant will not have taxable income upon grant
(unless, with respect to restricted stock that is not in the form of RSUs, he or she elects to be taxed at that time). Instead, he or
she will recognize ordinary income at the time of vesting/delivery equal to the fair market value (on the vesting date) of the
vested shares or cash received minus any amount paid for the shares of our vested common stock. Any taxable income
recognized in connection with an award of restricted stock, performance units, and performance shares by a participant who is
also our employee will be subject to tax withholding by us.
Deferred Stock Units. Typically, a participant will recognize employment taxes upon the vesting of a deferred stock
unit and income upon its delivery. The participant may be subject to additional taxation, interest and penalties if the deferred
stock unit does not comply with Section 409A of the Code.
Tax Effect for Microchip. We generally will be entitled to a tax deduction in connection with an award under the Plan
in an amount equal to the ordinary income realized by a participant at the time the participant recognizes such income (for
example, the exercise of a non-qualified stock option) except that we will not be entitled to a deduction for compensation paid
to our covered employees.
Section 409A of the Code. Section 409A of the Code imposes certain requirements on non-qualified deferred
compensation arrangements. These include requirements with respect to an individual's election to defer compensation and the
individual's selection of the timing and form of distribution of the deferred compensation. Section 409A of the Code also
generally provides that distributions must be made on or following the occurrence of certain events (e.g., the individual's
separation from service, a predetermined date, or the individual's death). Section 409A of the Code imposes restrictions on an
individual's ability to change his or her distribution timing or form after the compensation has been deferred. For certain
individuals who are officers, Section 409A of the Code requires that such individual's distribution commence no earlier than six
months after such officer's separation from service.
Awards granted under the Plan with a deferral feature will be subject to the requirements of Section 409A of the Code.
If an award is subject to and fails to satisfy the requirements of Section 409A of the Code, the recipient of that award will
recognize ordinary income on the amounts deferred under the award, to the extent vested, which may be prior to when the
compensation is actually or constructively received. Also, if an award that is subject to Section 409A of the Code fails to
comply with the provisions of Section 409A of the Code, Section 409A of the Code imposes an additional 20% federal income
tax on compensation recognized as ordinary income, as well as possible interest charges and penalties. Certain states have
enacted laws similar to Section 409A of the Code which impose additional taxes, interest and penalties on non-qualified
deferred compensation arrangements. We will also have reporting requirements with respect to such amounts, and will have
certain withholding requirements.
THE FOREGOING IS ONLY A SUMMARY OF THE EFFECT OF U.S. FEDERAL INCOME TAXATION
UPON PARTICIPANTS AND MICROCHIP UNDER THE PLAN. IT DOES NOT PURPORT TO BE COMPLETE,
AND DOES NOT DISCUSS THE TAX CONSEQUENCES OF A SERVICE PROVIDER'S DEATH OR THE
PROVISIONS OF THE INCOME TAX LAWS OF ANY MUNICIPALITY, STATE OR FOREIGN COUNTRY IN
WHICH A SERVICE PROVIDER MAY RESIDE.
Accounting Treatment. Under current accounting rules mandating expensing for all compensatory equity awards,
including stock options and RSUs, we recognize compensation expense for all awards granted under the Plan. This will result
in a direct charge to our reported earnings.
20
Table of Contents
Number of Awards Granted to Employees, Consultants, and Directors
The amount, timing, and value of discretionary awards under the Plan, including grants to our CEO and our four other
most highly compensated executive officers, is at the discretion of the Administrator and therefore not determinable in advance.
The future award of RSUs to non-employee directors is subject to the election of such individuals as directors and the fair
market value of the common stock on the date the RSUs are granted. No options were granted under the Plan during fiscal
2019. The following table sets forth the aggregate number of RSUs granted under the Plan during fiscal 2019 to each of our
named executive officers; executive officers as a group; directors who are not executive officers as a group; and all employees
who are not executive officers as a group:
EQUITY GRANTS IN FISCAL 2019 UNDER THE PLAN1
Name of Individual or Identity of Group and Position
Steve Sanghi, CEO and Chairman of the Board
Ganesh Moorthy, President and Chief Operating Officer
Stephen V. Drehobl, Senior VP, MCU8 and Technology Development Division
Mitchell R. Little, Senior VP, Worldwide Sales and Applications
J. Eric Bjornholt, Senior VP and CFO
All current executive officers as a group (6 people)
All current directors who are not executive officers as a group (4 people)
All other employees as a group
Number of
Shares Subject
to RSUs
Granted
Weighted
Average Fair
Value (2)
146,367 $
67,172
30,681
25,534
19,497
310,538
3,996
1,636,874
77.79
77.69
77.63
77.73
77.64
77.73
81.22
77.84
(1) This table includes grants under the Plan in fiscal 2019. There were no grants under the French Sub-Plan in fiscal 2019. It
is not expected that any of our current executive officers or directors will receive awards under the French Sub-Plan.
(2) Represents the weighted average fair value per share as of the grant date.
21
Table of Contents
PROPOSAL THREE
RATIFICATION OF APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee of our Board of Directors has appointed Ernst & Young LLP, independent registered public
accounting firm, to audit our consolidated financial statements for the fiscal year ending March 31, 2020. Ernst & Young LLP
has audited our financial statements since the fiscal year ended March 31, 2002 and has served as our independent registered
public accounting firm since June 2001. The partner in charge of our audit is rotated every five years. Other partners and non-
partner personnel are rotated on a periodic basis as required.
We anticipate that a representative of Ernst & Young LLP will be present at the annual meeting, will have the
opportunity to make a statement if he or she desires and will be available to respond to appropriate questions. Stockholder
ratification of the appointment of Ernst & Young LLP is not required by our Bylaws or applicable law. However, our Board of
Directors chose to submit such appointment to our stockholders for ratification. In the event of a negative vote on such
ratification, the Audit Committee will reconsider its selection.
Fees Paid to Independent Registered Public Accounting Firm
Audit Fees
This category includes fees associated with our annual audit, the reviews of our quarterly reports on Form 10-Q, and
statutory audits required internationally. This category also includes advice on audit and accounting matters that arose during,
or as a result of, the audit or the review of our interim financial statements, statutory audits and the assistance with review of
our SEC registration statements. This category also included fees associated with the audit of our internal control over
financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. The aggregate fees billed or to be billed by
Ernst & Young LLP in each of the last two fiscal years for such services were approximately $7,683,067 for fiscal 2019 and
$4,255,816 for fiscal 2018. Audit fees in fiscal 2019 were significantly higher than those in fiscal 2018 due to our acquisition
of Microsemi Corporation.
Audit-Related Fees
This category includes fees associated with employee benefit plan audits, internal control reviews, accounting
consultations and attestation services that are not required by statute or regulation. The aggregate fees billed or to be billed by
Ernst & Young LLP for such services were approximately $37,290 for fiscal 2019 and no fees for fiscal 2018.
Tax Fees
This category includes fees associated with tax return preparation, tax advice and tax planning. The aggregate fees
billed or to be billed by Ernst & Young LLP in the last two fiscal years for such services were approximately $1,414,294 for
fiscal 2019 and $186,994 for fiscal 2018. Tax fees in fiscal 2019 were significantly higher than those in fiscal 2018 due to our
acquisition and integration of Microsemi Corporation, and due to projects related to the Tax Cuts and Jobs Act of 2017.
All Other Fees
This category includes fees for support and advisory services not related to audit services or tax services. There were
no such fees in fiscal 2019 or fiscal 2018.
Our Audit Committee pre-approves all audit and permissible non-audit services provided by our independent
registered public accounting firm. These services may include audit services, audit-related services, tax services and other
services. The Audit Committee has adopted a policy for the pre-approval of services provided by our independent registered
public accounting firm. Under the policy, pre-approval is generally provided for up to one year, and any pre-approval is
detailed as to the particular service or category of services and is subject to a specific budget or limit. The Audit Committee
may also pre-approve particular services on a case-by-case basis. The Chairman of the Audit Committee has the delegated
22
Table of Contents
authority from the Audit Committee to pre-approve a specified level of services, and such pre-approvals are then
communicated to the full Audit Committee at its next scheduled meeting. During fiscal 2019, all audit and non-audit services
rendered by Ernst & Young LLP were approved in accordance with our pre-approval policy.
Our Audit Committee has determined that the non-audit services rendered by Ernst & Young LLP during fiscal 2019
and fiscal 2018 were compatible with maintaining the independence of Ernst & Young LLP.
Vote Required; Board Recommendation
The affirmative vote of a majority of the votes cast on the proposal at the annual meeting is required to approve the
ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of Microchip for the
fiscal year ending March 31, 2020. Abstentions will have the same effect as a vote against this proposal.
Upon the recommendation of our Audit Committee, our Board of Directors unanimously recommends that
stockholders vote "FOR" Proposal Three, the ratification of our independent registered public accounting firm, as
described in this Proxy Statement.
23
Table of Contents
PROPOSAL FOUR
APPROVAL OF EXECUTIVE COMPENSATION
As contemplated in the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank
Act"), Section 14A of the Securities Exchange Act of 1934 enables our stockholders to vote to approve, on an advisory (non-
binding) basis, the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with the
SEC's rules (commonly referred to as a "Say-on-Pay").
As described under the heading "Executive Compensation — Compensation Discussion and Analysis," our
executive compensation program is a comprehensive package designed to motivate our executive officers to achieve our
corporate objectives and is intended to be competitive and allow us to attract and retain highly qualified executive officers. We
believe that the various elements of our executive compensation program work together to promote our goal of ensuring that
total compensation should be related to both our performance and individual performance.
Stockholders are urged to read the "Compensation Discussion and Analysis" section of this Proxy Statement,
beginning on page 30, which discusses how our executive compensation policies implement our compensation philosophy, and
the "Compensation of Named Executive Officers" section of this Proxy Statement, which contains tabular information and
narrative discussion about the compensation of our named executive officers. These sections provide additional details about
our executive compensation programs, including information about the fiscal 2019 compensation of our named executive
officers. The Compensation Committee and our Board of Directors believe that these policies are effective in implementing
our compensation philosophy and in achieving our goals.
We are asking our stockholders to indicate their support for our executive compensation as described in this Proxy
Statement. This Say-on-Pay proposal gives our stockholders the opportunity to express their views on our named executive
officers' compensation. This vote is not intended to address any specific item of compensation, but rather the overall
compensation of our named executive officers and the philosophy, policies and practices described in this Proxy Statement.
Accordingly, we are asking our stockholders to approve, on an advisory basis, the compensation of the named executive
officers, as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the SEC, including the
Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosures.
The Say-on-Pay vote is advisory, and therefore not binding on us, the Compensation Committee or our Board of
Directors. However, our Board of Directors and our Compensation Committee value the opinions of our stockholders and to
the extent there is any significant vote against the named executive officer compensation as disclosed in this Proxy Statement,
we will consider our stockholders' concerns and the Compensation Committee will evaluate whether any actions are necessary
to address those concerns. Our current policy is to provide stockholders with an opportunity to approve the compensation of
our named executive officers each year at our annual meeting of stockholders. Thus, it is expected that the next such vote will
occur at our 2020 annual meeting.
Vote Required; Board Recommendation
The affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting is required to approve the
compensation of our named executive officers on an advisory (non-binding) basis. Abstentions will have the same effect as a
vote against this proposal. Broker "non-votes" are not counted for purposes of approving the compensation of our named
executive officers on an advisory (non-binding) basis and thus will not affect the outcome of the voting on such proposal.
Our Board of Directors unanimously recommends voting "FOR" Proposal Four, the approval, on an advisory
(non-binding) basis, of the compensation of our named executive officers, as described in this Proxy Statement.
24
Table of Contents
PROPOSAL FIVE
STOCKHOLDER PROPOSAL FOR OUR BOARD TO REPORT ON
RECRUITMENT AND FORCED LABOR RISK TO WORKERS
Friends Fiduciary Corporation, 1650 Arch Street, Suite 1904, Philadelphia, PA 19103, who held, as of March 7, 2019,
more than 800 shares of our common stock, is the proponent of a stockholder proposal. The proposal and supporting statement
submitted by the proponent are set forth below.
“Microchip Technology, Inc. - Recruitment and Forced Labor Proposal - 2019
“RESOLVED. Shareholders request the Board of Directors to report, at reasonable cost and omitting proprietary information,
on the Company’s process for identifying and analyzing potential and actual human rights risks to workers in its operations and
supply chain.
SUPPORTING STATEMENT. In developing the report, the Company could consider:
• Human rights principles used to frame the assessment
•
Frequency of assessment
• Methodology used to track and measure performance on forced labor risks, and
• How results of the assessment are incorporated into company policies and decision making.
WHEREAS, an estimated 16 million people are trapped (1) in conditions of forced labor in extended private sector supply
chains, generating over $150 billion in profits for illegal labor recruiters and employers through underpayment of wages.(2)
Migrant workers globally are prime targets for exploitation,(3) including discrimination, retaliation, debt bondage,
illegal wage deductions, and confiscated or restricted access to personal documents that limits workers’ freedom of movement
and leads to forced labor and human trafficking. The U.S. Department of Labor lists China and Malaysia as particularly at risk
of forced labor in the electronics sector.(4) A 2014 study by Verité found that nearly a third of migrant workers in Malaysia’s
electronics sector are in situations of forced labor.(5) Raw materials used in electronics products - including tin, tungsten,
tantalum and gold - are often produced with forced labor.(6)
According to the UN Guiding Principles on Business and Human Rights, companies have the responsibility to respect
human rights within their operations and supply chains. Any company directly or indirectly employing migrant workers must
carry out human rights due diligence to assess, identify, prevent and mitigate the risk to workers and to remediate resulting
negative impacts. The OECD Guidelines for Multinational Enterprises similarly state that companies should respect human
rights by adopting internal policies, carrying out due diligence, and seeking to prevent, mitigate, and remediate human rights
impacts linked to their business operations.(7) The State of California and the United Kingdom passed laws requiring
companies to report on their actions to eradicate human trafficking and slavery.
KnowTheChain’s 2018 Benchmarking Report on Forced Labor in the ICT Sector gave the Company an overall score
of only 7 out of 100.(8)
Given the company’s lack of risk mitigation and disclosure, investors have insufficient information to gauge if the
Company is sufficiently addressing this serious risk to the company and to workers.”
(1) https://www.ilo.org/wcmsp5/groups/public/---dgreports/---dcomm/documents/publication/wcms_575479.pdf
(2) https://www.ilo.org/wcmsp5/groups/public/---ed_norm/---declaration/documents/publication/wcms_243391.pdf
(3) https://www.ilo.org/global/topics/fair-recruitment/lang--en/index.htm
(4) https://www.dol.gov/sites/default/files/documents/ilab/listofgoods.pdf
(5) https://www.verite.org/research/electronicsmalaysia
(6) https://www.dol.gov/sites/default/files/documents/ilab/listofgoods.pdf
(7) http://www.oecd.org/daf/inv/mne/48004323.pdf
(8) https://knowthechain.org/companies/83/
25
Table of Contents
Board of Directors' Statement in Opposition to Stockholder Proposal
Our Board of Directors carefully considered this proposal and concluded that its adoption is not necessary because we
have corporate policies and practices addressing human rights risks in both our operations and in our supply chain that we
disclose on our website. In addition to being unnecessary, our Board of Directors believes that the proposal for a report is
vague and that the development of the scope of a report that would satisfy the proponent, as well as production of the report
itself, would not be a productive use of management or corporate resources or in the best interests of Microchip or its
stockholders.
At Microchip, we support regulatory and industry-driven efforts to ensure our global staff and suppliers are treated
ethically. We agree with the principles on which this proposal is based and have already taken steps that address the concerns
expressed. For example, our Code of Business Conduct and Ethics requires compliance with laws and ethical behavior by our
employees, agents, contractors and consultants. The code includes reporting and accountability provisions that may include
immediate termination of employment or business relationships as permitted by law. We have policies and procedures to
identify, analyze and mitigate human rights risks of operations and in our supply chain. In addition to our Code of Business
Conduct and Ethics, our corporate policies and practices addressing human rights include, among others:
• We are a member of the Responsible Minerals Initiative (RMI), working toward the goal of assuring our products, and
all of the products that are supplied to us by our supply chain, are not irresponsibly sourced. Pursuant to our policy,
which is posted on our website, all smelters in our integrated circuits’ supply chain were listed on the RMI’s
Compliant smelter list.
• Microchip is a participant in, and promotes adherence to, the United Nations Global Compact. The UN Global
Compact supports companies to conduct business responsibly by aligning their strategies and operations with ten
principles on human rights, labor, environment and anti-corruption, among other things.
• Microchip's supplier agreements and purchase order terms and conditions obligate our suppliers to a broad spectrum
of social and environmental compliance requirements, including prohibitions on the use of forced labor and child
labor. Such agreements require adherence to applicable laws.
• Microchip conducts quarterly business reviews with its significant contractors and reviews topics that comprise our
Corporate Social Responsibility Program.
• Microchip typically uses direct material suppliers that are either ISO9001 or IATF16949 certified. Capabilities and
quality standards are surveyed and reviewed at the time of supplier selection. Microchip may request and review third-
party audit results as part of the selection process. Absent other concerns arising during the supplier relationship,
audits are primarily to review quality and supporting documentation. Microchip's wafer foundry suppliers are audited
with site visits on a periodic basis, some annually.
• Microchip provides ethics training to employees, which includes an obligation to comply with laws and report
violations of laws. Microchip has policies and training programs prohibiting discrimination, sexual harassment and
work-place violence.
• Microchip's two main assembly facilities located outside of the United States have each been subject to third party
customer managed audits in the past 12 months. Neither of these audits resulted in any finding of non-compliance
with respect to recruitment or forced labor practices.
Microchip’s human rights policies are described in our corporate sustainability report available on our website.
Microchip also issues disclosure statements under the California Transparency in Supply Chains Act and the United Kingdom
Modern Slavery Act to emphasize those actions we have taken to eradicate slavery and human trafficking from our direct
supply chain for tangible goods offered for sale. Our latest disclosure statement is also available on our website.
26
Table of Contents
Our Board of Directors believes our corporate policies clearly describe our process for identifying and analyzing
human rights risks of operations and in our supply chain, and include the items indicated in the proposal that the company
could consider in developing the report, rendering the proposal duplicative and unnecessary. In addition, the proposal for a
report is vague and the cost to scope and produce such a report would not be a productive use of management or corporate
resources or in the best interests of Microchip or its stockholders.
Vote Required; Board Recommendation
The affirmative vote of a majority of the votes cast on the proposal at the Annual Meeting is required to approve the
stockholder proposal. Abstentions will have the same effect as a vote against this proposal. Broker “non-votes” are not counted
for purposes of approving the stockholder proposal and thus will not affect the outcome of the voting on such proposal.
Our Board of Directors unanimously recommends voting "AGAINST" Proposal Five, the adoption of the
Stockholder Proposal for our Board to Report on Recruitment and Forced Labor Risk to Workers.
27
Table of Contents
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS,
DIRECTORS AND EXECUTIVE OFFICERS
The following table sets forth information concerning the beneficial ownership of our common stock as of June 20,
2019 for: (a) each director, (b) our CEO, our CFO and the three other most highly compensated executive officers named in the
Summary Compensation Table, (c) all directors and executive officers as a group, and (d) each person who is known to us to
own beneficially more than 5% of our common stock. Except as otherwise indicated in the footnotes to this table, and subject
to applicable community property laws and joint tenancies, the persons named in this table have sole voting and investment
power with respect to all shares of common stock held by such person:
Name and Address of Beneficial Owner
Number of Shares
Beneficially Owned (1)
Percent of
Common Stock (1)
T. Rowe Price Associates, Inc. (2)
The Vanguard Group, Inc. (3)
Dodge & Cox (4)
BlackRock, Inc. (5)
Janus Henderson Group PLC (6)
Steve Sanghi (7)
Matthew W. Chapman (8)
Wade F. Meyercord (9)
Esther L. Johnson (10)
L.B. Day (11)
Ganesh Moorthy (12)
J. Eric Bjornholt (13)
Stephen V. Drehobl (14)
Mitchell R. Little (15)
31,284,609
26,971,567
18,879,583
16,492,576
11,946,532
4,781,567
20,665
22,836
8,201
10,823
299,049
29,591
26,092
16,152
13.14
11.33
7.93
6.93
5.02
2.01
*
*
*
*
*
*
*
*
All directors and executive officers as a group (10 people) (16)
5,271,574
2.21
* Represented less than 1% of the outstanding shares of common stock as of June 20, 2019. Our shares of common stock
outstanding at June 20, 2019 were 238,034,702.
(1) For each individual and group included in the table, the number of shares beneficially owned includes shares of common
stock issuable to the identified individual or group pursuant to RSUs that will vest and stock options that are exercisable
within 60 days of June 20, 2019. With respect to RSUs that will vest within 60 days of June 20, 2019, the full vesting
amount of shares has been included in the table, however, the actual shares issued is expected to be lower as the shares
actually issued will be net of taxes. In calculating the percentage of ownership of each individual or group, share amounts
that are attributable to options and RSUs that vest within 60 days of June 20, 2019 are deemed to be outstanding for the
purpose of calculating the percentage of shares of common stock owned by such individual or group, but are not deemed to
be outstanding for the purpose of calculating the percentage of shares of common stock owned by any other individual or
group.
(2) Address is 100 E. Pratt Street, Baltimore, MD 21202. All information is based solely on the Schedule 13G/A filed by T.
Rowe Price Associates, Inc. on February 14, 2019, with the exception of the percentage of common stock held which is
based on shares outstanding at June 20, 2019. Such Schedule 13G/A indicates that T. Rowe Price Associates, Inc. (i) has
28
Table of Contents
sole power to dispose of or direct the disposition of 31,277,809 shares of common stock; and (ii) has sole power to vote or
direct the vote of 12,526,268 shares of common stock.
(3) Address is 100 Vanguard Boulevard, Malvern, PA 19355. All information is based solely on the Schedule 13G/A filed by
The Vanguard Group, Inc. on February 11, 2019, with the exception of the percentage of common stock held which is
based on shares outstanding at June 20, 2019. Such Schedule 13G/A indicates that The Vanguard Group, Inc. (i) has sole
power to dispose of or direct the disposition of 26,642,052 shares of common stock and shared power to dispose of or
direct the disposition of 329,515 shares of common stock; and (ii) has sole power to vote or direct the vote of 288,651
shares of common stock and shared power to vote or direct the vote of 49,330 shares of common stock.
(4) Address is 555 California Street, 40th Floor, San Francisco, CA 94104. All information is based solely on the Schedule
13G filed by Dodge & Cox on February 14, 2019 with the exception of the percentage of common stock held which is
based on shares outstanding at June 20, 2019. Such Schedule 13G indicates that Dodge & Cox (i) has sole power to
dispose of or direct the disposition of 18,879,583 shares of common stock; and (ii) has sole power to vote or direct the vote
of 18,051,858 shares of common stock.
(5) Address is 55 East 52nd Street, New York, NY 10055. All information is based solely on the Schedule 13G/A filed by
BlackRock, Inc. on February 8, 2019 with the exception of the percentage of common stock held which is based on shares
outstanding at June 20, 2019. Such Schedule 13G/A indicates that BlackRock, Inc. (i) has sole power to dispose of or
direct the disposition of 16,492,576 shares of common stock; and (ii) has sole power to vote or direct the vote of
14,574,359 shares of common stock.
(7)
(6) Address is 201 Bishopsgate EC2M 3AE, United Kingdom. All information is based solely on the Schedule 13G filed by
Janus Henderson Group PLC on February 12, 2019 with the exception of the percentage of common stock held which is
based on shares outstanding at June 20, 2019. Such Schedule 13G indicates that Janus Henderson Group PLC (i) has
shared power to dispose of or direct the disposition of 11,946,532 shares of common stock; and (ii) has shared power to
vote or direct the vote of 11,946,532 shares of common stock.
Includes 1,788,208 shares held of record by The Sanghi Trust (the "Sanghi Trust") 2,952,936 shares held of record by The
Sanghi Family Limited Partnership (the "Family Limited Partnership"), and includes an aggregate of 40,423 shares subject
to RSUs that vest within 60 days of June 20, 2019. Steve Sanghi and Maria T. Sanghi are the sole trustees of the Sanghi
Trust. The Sanghi Trust is the sole member of the Sanghi LLC which is the sole general partner of the Family Limited
Partnership.
Includes an aggregate of 1,585 shares subject to RSUs that vest within 60 days of June 20, 2019.
Includes 18,251 shares held of record by Wade F. Meyercord and Phyllis Meyercord as trustees, 1,585 shares subject to RSUs
that vest within 60 days of June 20, 2019, and 3,000 shares issuable upon exercise of options that are exercisable within 60
days of June 20, 2019.
(8)
(9)
(10) Includes an aggregate of 1,007 shares subject to RSUs that vest within 60 days of June 20, 2019.
(11) Includes an aggregate of 1,585 shares subject to RSUs that vest within 60 days of June 20, 2019.
(12) Includes 282,090 shares held of record by Ganesh Moorthy and Hema Moorthy as trustees, and includes an aggregate of
16,959 shares subject to RSUs that vest within 60 days of June 20, 2019.
(13) Includes 24,320 shares held of record by J. Eric Bjornholt and Lynn Bjornholt as trustees, and includes an aggregate of 5,271
shares subject to RSUs that vest within 60 days of June 20, 2019.
(14) Includes an aggregate of 8,283 shares subject to RSUs that vest within 60 days of June 20, 2019.
(15) Includes an aggregate of 7,343 shares subject to RSUs that vest within 60 days of June 20, 2019.
(16) Includes an aggregate of 3,000 shares issuable upon exercise of options that are exercisable within 60 days of June 20, 2019,
and 90,134 RSUs that vest within 60 days of June 20, 2019.
29
Table of Contents
EXECUTIVE COMPENSATION
COMPENSATION DISCUSSION AND ANALYSIS
Overview of the Compensation Program
The Compensation Committee of our Board of Directors, presently comprised of Mr. Day and Mr. Meyercord, reviews
the performance of our executive officers and makes compensation decisions regarding our executive officers. Our policies for
setting compensation for each of our named executive officers (i.e., our CEO, CFO, and our three other most highly paid
executive officers) are the same as those for the rest of our executive officers. Our compensation program is a comprehensive
package designed to motivate the executive officers to achieve our corporate objectives and is intended to be competitive and
allow us to attract and retain highly qualified executive officers. In general, the types of compensation and benefits provided to
our executive officers are similar to those provided to a broad base of Microchip employees, and include salary, cash bonuses,
RSUs, and other benefits described below.
Our Executive Compensation Policy and Objectives
Our compensation policy for executive officers, including our named executive officers, and key employees is based
on a "pay-for-performance" philosophy. This "pay-for-performance" philosophy emphasizes variable compensation, primarily
by placing a large portion of pay at risk. We believe that this philosophy meets the following objectives:
•
•
•
•
•
•
rewards performance that may contribute to increased stockholder value,
attracts, retains, motivates and rewards individuals with competitive compensation opportunities,
aligns an executive officer's total compensation with our business objectives,
fosters a team environment among our management that focuses their energy on achieving our financial and
business objectives consistent with Microchip's "guiding values,"
balances short-term and long-term strategic goals, and
builds and encourages ownership of our common stock.
Decisions regarding cash and equity compensation also include subjective determinations and consideration of various
factors with the weight given to a particular factor varying from time to time and in various individual cases, such as an
executive officer's experience in the industry and the perceived value of the executive officer's position to Microchip as a
whole.
We believe that the overall compensation levels for our executive officers, including our named executive officers, in
fiscal 2019 were consistent with our "pay-for-performance" philosophy and were commensurate with our fiscal 2019
performance.
Executive Compensation Process
The Compensation Committee evaluates and establishes the compensation of our executive officers, including the
named executive officers. The Compensation Committee seeks input from Mr. Sanghi when discussing the performance of,
and compensation levels for, the executive officers other than himself. Mr. Sanghi does not participate in deliberations relating
to his own compensation.
The Compensation Committee designs our executive compensation program to be competitive with those of other
companies in the semiconductor or related industries in our market. The Compensation Committee determines appropriate
levels of compensation for each executive officer based on their level of responsibility within the organization, performance,
and overall contribution. After such determination, the Compensation Committee makes allocations between long-term and
short-term as well as the cash and non-cash elements of compensation. Microchip's financial and business objectives, the
30
Table of Contents
salaries of executive officers in similar positions with comparable companies and individual performance are considered in
making these determinations. To the extent compensation information is reviewed for other companies, it is obtained from
published materials such as proxy statements, and information gathered from such companies directly. We do not engage
consultants to conduct such review process for us or utilize a specific peer group.
The executive officer compensation process begins with consideration of Microchip's overall budget for employee
compensation. The Compensation Committee considers the budgeted salary data and individual executive officer salary
increases are determined with the goal of keeping the executive officer salary increases within the budgeted range for other
employees. In setting salaries for executive officers, the Compensation Committee may consider relevant industry data but
does not target any overall industry percentage level or peer group average.
Microchip's compensation budget is created as part of its annual and quarterly operating plan processes under which
business and financial objectives are initially developed by our executive officers, in conjunction with their respective business
units, and then discussed with and approved by our CEO. These objectives are then reviewed by our Board of Directors and are
the overall financial and business objectives on which incentive compensation is based.
The Compensation Committee sets the compensation of our Chairman and CEO, Mr. Sanghi, in the same manner as
each of our other executive officers. In particular, the Compensation Committee considers Mr. Sanghi's level of responsibility,
performance, and overall contribution to the results of the organization. The Compensation Committee also considers the
compensation of CEOs of other companies in the semiconductor or related industries in our market. Mr. Sanghi participates in
the same cash incentive, equity incentive and benefit programs as our other executive officers. For example, his compensation
is subject to the same performance metrics as our other executive officers under our Executive Management Incentive
Compensation Plan ("EMICP"). The Compensation Committee recognizes that Mr. Sanghi's total compensation package is
significantly higher than that of our other executive officers and the Compensation Committee believes this is appropriate in
consideration of Mr. Sanghi's superior leadership of Microchip over a long period of time. In particular, the Compensation
Committee believes that Mr. Sanghi's leadership has been key to the substantial revenue and profitability growth, strong market
position and substantial increase in the market value of Microchip since taking Microchip public in 1993, and to leading
Microchip's strong performance relative to others in the industry over a number of years.
For fiscal 2019, the Compensation Committee reviewed and approved the total compensation package of all of our
executive officers, including the elements of compensation discussed below, and determined the amounts to be reasonable and
competitive.
At our last annual meeting of stockholders held in August 2018, our stockholders approved an advisory (non-binding)
proposal concerning our executive compensation program with approximately 95% of the votes cast in favor of the proposal.
The Compensation Committee considered the results of this vote in establishing the compensation program for fiscal 2019.
Elements of Compensation
Our executive compensation program is currently comprised of four major elements:
•
•
•
•
annual base salary,
incentive cash bonuses,
equity compensation, and
compensation and employee benefits generally available to all of our employees.
The retirement benefits and other benefits offered to our executive officers are largely the same as those we provide to
a broad base of employees. While our executive officers' level of participation in our management incentive compensation
plans and equity incentive plans is typically higher than for our non-executive employees, based on the officers' level of
responsibility and industry experience, the plans in which our executive officers are eligible to participate are very similar to
31
Table of Contents
those for many of our other employees. The Compensation Committee reviews each element of compensation separately and
total compensation as a whole, other than those benefits which are available to all employees. The Compensation Committee
determines the appropriate mix of elements to meet our compensation objectives and to help ensure that we remain competitive
with the compensation practices in our industry and market.
Although our executive officers are entitled to certain severance and change of control benefits (as described below),
the Compensation Committee does not consider such benefits to be elements of compensation for purposes of annual
compensation reviews because such benefits may never be paid.
Base Salaries. Salary reviews for executive employees were conducted annually in fiscal 2019. A budget for salary
increases was established with any increases in salary determined on a discretionary basis based on the performance reviews of
the executives. When setting base salaries, we review the business and financial objectives for Microchip as a whole, as well as
the objectives for each of the individual executive officers relative to their respective areas of responsibility. In particular, we
consider our overall growth in-end-market demand and growth in-end-market demand in our strategic business units, non-
GAAP gross margins, non-GAAP operating expenses, non-GAAP net income per diluted share, cash generation, expected
capital expenditures and other financial considerations in setting our budgets for salaries. We also consider the individual
performance of our named executive officers including the officer's level of responsibility, performance, overall contribution to
the results of the organization, the officer's base salary relative to the salaries of our other officers, salary relative to comparable
positions in the industry and market, the officer's overall compensation including incentive cash bonuses and equity
compensation and the officer's performance relative to expectations. We do not assign any specific weight to any such factor
but consider such factors as a whole for each executive. This review encompasses the objectives for both the immediately
preceding fiscal year and the upcoming fiscal year. There were no increases to the base salaries paid to our named executive
officers during fiscal 2019.
Incentive Cash Bonuses. The Compensation Committee sets performance goals which, if met, result in quarterly
payments to our executive officers under the EMICP. Executive officers may also receive quarterly payments under the
Discretionary Management Incentive Compensation Plan ("DMICP"). The Compensation Committee establishes performance
goals which it believes are challenging, require a high level of performance and motivate participants to drive stockholder
value, but which goals are expected to be achievable in the context of business conditions anticipated at the time the goals are
set. When setting the performance goals, the Compensation Committee places more emphasis on the overall expected financial
performance of Microchip rather than on the achievement of any one individual goal. The Compensation Committee believes
that this focus on the overall payout incentivizes outstanding performance across the corporation and drives the overall
financial success of the corporation. The Compensation Committee uses the DMICP to help achieve the overall objectives of
the performance bonus program.
The performance metrics under the EMICP are determined by the Compensation Committee at the beginning of each
quarter and may be based on GAAP financial results, non-GAAP financial results or end-market demand for our products at the
discretion of the Compensation Committee. The Compensation Committee typically uses the end-market demand metric when
setting the targets because it believes such metric is more useful in understanding our operating results. End-market demand is
the net dollar amount of our products, licensing revenue, and services delivered to our direct (non-distributor) customers and by
our distributors to their customers. We believe that our end-market demand metric reflects true end-market demand based on
when product is sold to direct customers or by our distributors to an end customer. Our non-GAAP adjustments, where
applicable, include the effect of share-based compensation, expenses related to our acquisition activities (including intangible
asset amortization, inventory valuation costs, excess capacity charges to normalize acquired inventory levels, severance and
other restructuring costs, and legal and other general and administrative expenses associated with acquisitions), non-cash
interest expenses on our convertible debentures, adjustments for a manufacturing excursion issue with one of our suppliers,
losses on the settlement of debt and losses on available-for-sale investments. The earnings per share metric changes each
quarter.
Each of the other performance metrics is reviewed each quarter but may be the same for multiple quarters. For the
first quarter of fiscal 2019, there were no cash bonuses paid to the employees under the EMICP, the DMICP or the ECBP due to
32
Table of Contents
the Board's decision to conserve cash and focus on paying down the debt that was incurred in order to acquire Microsemi. The
tables below sets forth the performance metrics under the EMICP for the second, third and fourth quarters of fiscal 2019.
Q2 FY19 Performance Metrics
Target Quarterly Measurement
Actual Results
Q2 FY19 % (1)
Target % of
Bonus
Q2 FY19 Perf.
%
Q2 FY19
Bonus Payout
%
Performance
Metric
Total sequential revenue growth
Gross margin percentage (non-GAAP)
Operating expenses as a percentage of sales (non-GAAP)
Operating income as a percentage of sales (non-GAAP)
Earnings per share (quarterly) (non-GAAP)
EMICP Total
DMICP Total
25.00
57.50
27.80
28.70
20.00
15.00
15.00
15.00
24.37
15.80
61.70
30.75
23.42
36.90
38.28
38.95
$1.45
15.00
180.52
39.50
N/A
(3)
80.00
20.00
N/A
161.90(2)
N/A
(20.75)(2)
(1) The goals include the combined results of Microchip and Microsemi Corporation, which Microchip acquired on May 29,
2018. For the second quarter of fiscal 2019, the performance metrics were based on non-GAAP financial results.
(2) 50% of the combined amount under the EMICP and the DMICP for the second quarter of fiscal 2019 was paid in cash, and
the other 50% was paid in RSUs that will vest on November 15, 2019 subject to continued service.
(3) Each quarter, the Target Quarterly Measurement under the DMICP is discretionary.
33
Table of Contents
Target Quarterly Measurement
Actual Results
Q3 and Q4 FY19 Performance Metrics (1)
Performance
Metric
Q3 FY19 % Q4 FY19 %
Target % of
Bonus
Q3 FY19
Perf. %
Q3 FY19
Bonus Payout
%
Q4 FY19
Perf. %
Q4 FY19
Bonus Payout
%
Total sequential revenue growth
High performance micro-
controller sequential revenue
growth
Analog sequential revenue growth
Field-programmable gate array
(FPGA) sequential revenue
growth
1.50
1.50
1.50
1.50
1.50
11.00
(6.43)
(18.08)
(5.36)
(14.15)
1.50
1.50
1.50
4.00
3.00
2.00
(7.66)
(8.21)
(7.25)
(7.67)
(6.15)
(4.65)
(5.77)
(4.27)
8.71
6.81
(4.97)
(2.31)
Gross margin percentage
57.50
58.50
15.00
62.23
32.74
62.51
30.04
Operating expenses as a
percentage of sales
Operating income as a percentage
of sales
27.80
27.50
15.00
24.80
30.00
25.58
24.60
28.70
30.00
15.00
37.43
36.83
36.93
32.33
Earnings per share (quarterly)
$1.44
$1.30
15.00
165.86
30.18
151.88
31.83
EMICP Total
DMICP Total
N/A
N/A
80.00
N/A
105.61(2)
(4)
(4)
20.00
N/A
(9.20)(2)
N/A
N/A
90.39(3)
(7.96)(3)
(1) These goals include the impact of Microchip's acquisition of Microsemi Corporation. For the third quarter of fiscal 2019, the
performance metrics were based on non-GAAP financial results. For the fourth quarter of fiscal 2019, the performance metrics
were based on end-market demand financial results.
(2) 65% of the combined amount under the EMICP and DMICP for the third quarter of fiscal 2019 was paid in cash, and the other
35% was paid in RSUs that will vest on February 15, 2020 subject to continued service.
(3) 65% of the combined amount under the EMICP and DMICP for the fourth quarter of fiscal 2019 was paid in cash, and the
other 35% was paid in RSUs that will vest in full on May 15, 2020 subject to continued service.
(4) Each quarter, the Target Quarterly Measurement under the DMICP is discretionary.
34
Table of Contents
The total amount payable to each executive under the EMICP and the DMICP is based on a percentage of the
executive's base salary at the beginning of the quarter. The participation percentage for each executive is determined at the
beginning of the fiscal year based on the executive's base salary at that time and typically stays at the same level for each
quarter of the fiscal year. However, the Compensation Committee may change the participation level of an executive each
quarter to reflect changes in the performance or responsibilities of the executive or other factors. The dollar amount of the
target bonus for each executive is based on assumed achievement of all performance metrics under the EMICP (as disclosed in
the tables above) and payment of 20% as a discretionary award under the DMICP (as disclosed in the tables above). The
aggregate budgeted bonus pool under the various management incentive compensation plans is calculated by multiplying each
eligible executive officer's bonus target percentage by the executive's base salary. In fiscal 2019, the quarterly payments under
the EMICP for our named executive officers were targeted at an aggregate of approximately $438,598 for all such officers as a
group. In fiscal 2019, the quarterly payments under the DMICP for our named executive officers were targeted at an aggregate
of approximately $109,650 for all such officers as a group. Bonuses under the EMICP are subject to a maximum award of
$2,500,000 per individual per performance period (which can be a fiscal quarter, a fiscal year or a longer period not exceeding
five fiscal years); however, all awards to date have been substantially less than such maximum amount.
The actual awards under the EMICP are based on our actual quarterly financial performance compared to the
performance metrics and the actual awards under the DMICP are determined in the discretion of our Compensation Committee
and can be significantly higher or lower than the 20% target. The actual awards are calculated by multiplying the overall award
percentage payout for the quarter by the applicable percentage of the executive's salary at the end of the fiscal quarter that the
award relates to. Thus, if an executive's salary or participation percentage changes during the year, up or down, this would
affect the executive's actual bonus payment during the fiscal year. For fiscal 2019, the specific total bonus percentages under
both the EMICP and DMICP for each of our named executive officers were as follows: for Mr. Sanghi it was 200% of his
salary for the associated quarter; for Mr. Moorthy it was 80% of his salary; for Mr. Little it was 46% of his salary; for
Mr. Drehobl it was 45% of his salary; and for Mr. Bjornholt it was 32% of his salary. These bonus percentages did not change
from the percentages used for fiscal 2018.
As indicated in the above table, for the third quarter of fiscal 2019, 2.0% of the quarterly EMICP payment was based
on Microchip's FPGA business unit achieving total sequential revenue growth of 1.5%. Accordingly, if Microchip's FPGA
business unit's sequential revenue growth for the third quarter was 1.5%, then each executive would be paid the corresponding
2.0% of the EMICP target bonus amount for that quarter. If Microchip's FPGA business unit's revenue growth for the third
quarter was 0.75%, then each executive would be paid a corresponding 1.0% of his target bonus amount for that quarter (i.e.,
1/2 of the 2.0%) and if Microchip's FPGA business unit's revenue growth for the third quarter was 3.0%, then each executive
would be paid a corresponding 4.0% of the target bonus amount for that quarter (i.e., 3.0/1.5 of the 2.0%). A similar
methodology is applied each quarter to each of the performance metrics listed in the above table.
As set forth in the above tables, during fiscal 2019, our CEO and other executive officers received bonuses under the
EMICP for each quarter of fiscal 2019 other than the first quarter. Such EMICP bonus amounts were paid in a combination of
cash and awards of RSUs vesting in full one year after the date of the grant, subject to continued service. There were no
payments made under the DMICP for fiscal 2019. Applying the award percentages to each named executive officer's
participation level in the plans, for fiscal 2019, the total bonus payments made in cash under the EMICP and the DMICP for our
named executive officers, other than our CEO, ranged from $38,759 to $158,539. In fiscal 2019, Mr. Sanghi earned an
aggregate EMICP bonus payment made in cash of $700,389. Please see footnote 4 to the Summary Compensation Table on
page 44 of this Proxy Statement which sets forth the actual amount of the EMICP and DMICP awards for each named
executive officer for fiscal 2019. In fiscal 2019, the portion of the earned EMICP and DMICP awards that were paid in RSUs
for our named executive officers, other than our CEO, ranged from 348 shares to 1,423 shares and our CEO earned RSUs for
6,282 shares. The differences in the levels of compensation under these programs for the various executive officers are based
upon their relative contribution, performance, experience, and responsibility level within the organization.
35
Table of Contents
Equity Compensation. Equity compensation, such as RSUs, constitutes a significant portion of our incentive
compensation program because we believe that executive officers and key employees should hold a long-term equity stake in
Microchip to align their collective interests with the interests of our stockholders. Accordingly, in fiscal 2019, equity grants in
the form of RSUs were a significant portion of our executive officers' total compensation package.
We typically make equity compensation grants to executive officers and key employees in connection with their initial
employment, and we also typically make quarterly evergreen grants of equity to incentivize employees on a continuing basis as
their initial equity awards vest. In setting the amount of the equity compensation grants, the estimated value of the grants is
considered, as well as the intrinsic value of the outstanding equity compensation held by the executive officer. In setting these
amounts and any performance goals, the Compensation Committee uses its judgment after considering the effect of the overall
RSU amounts and the percentage of RSUs granted to executive officers in connection with the overall financial results and
performance of Microchip.
The evergreen grants of RSUs for the second, third and fourth quarters of fiscal 2019 were awarded with vesting
subject to meeting specified performance goals related to achieving certain levels of operating expenses over a specified time
frame. Specifically, with respect to the RSU awards made in July 2018, the performance goal was related to achieving non-
GAAP operating expenses for the three months ended September 30, 2018 of less than $435 million; with an achievement of
$395 million of non-GAAP operating expenses necessary for full vesting of the award. With respect to the awards made in
October 2018, the performance goal was related to achieving non-GAAP operating expenses for the three months ended
December 31, 2018 of less than $435 million; with an achievement of $395 million of non-GAAP operating expenses necessary
for full vesting of the award. With respect to the awards made in January 2019, the performance goal was related to achieving
non-GAAP operating expenses for the three months ended March 31, 2019 of less than $415 million, with an achievement of
$375 million of non-GAAP operating expenses necessary for full vesting of the award. With respect to each of the performance
goals for the RSU grants, the goals exclude the impact of any acquisitions completed by Microchip during the performance
period. Based on the actual results compared to the performance goals for each such period, all of the quarterly evergreen
awards will vest at 100%; however, in addition to the performance-based vesting requirements, the vesting of each of the
foregoing RSU awards is subject to the continued service of the officer on the vesting date which is approximately four years
from the grant date.
Grants of RSUs in fiscal 2019 typically were scheduled to vest approximately four years from the grant date. RSUs do
not have a purchase price and therefore have immediate value to recipients upon vesting. On March 31, 2019, approximately
61.6% of our employees worldwide were eligible to receive RSUs under our 2004 Equity Incentive Plan. For more than ten
years, RSUs have been the principal equity compensation vehicle for Microchip executive officers and key employees.
Grants of RSUs may also be made in connection with promotions, other changes in responsibilities or in recognition of
other individual or Microchip developments or achievements. In this regard, on September 4, 2018, the Compensation
Committee approved RSU awards to key employees, including executive officers, under a leadership grant program. Under
this program, Microchip conducted its succession planning process and merit based RSU grants were made to key employees
based on the results of such process. Under this program, RSUs for an aggregate of approximately 415,751 shares were granted
to key executive and non-executive employees of Microchip with RSUs for an aggregate of 160,065 shares granted to
executives. The vesting of such RSUs was subject to a performance goal related to achieving non-GAAP operating expenses
for the three months ended December 31, 2018 of less than $435 million, with an achievement of $395 million of non-GAAP
operating expense necessary for full vesting of the award. The performance goal for the leadership grant was achieved and the
RSUs will vest over 12 quarters with the first vesting on August 15, 2020, subject to the continued service of the officer. In
addition, in August 2018, the Compensation Committee approved RSU grants (vesting in full after one year) to our executives
ranging from 333 shares to 6,019 shares as an additional retention mechanism since there were no payments made under the
EMICP, DMICP or ECBP for the first quarter of fiscal 2019.
In granting equity compensation awards to executive officers, we consider numerous factors, including:
•
•
the individual's position, experience, and responsibilities,
the individual's future potential to influence our mid- and long-term growth,
36
Table of Contents
•
•
the vesting schedule of the awards, and
the number and value of awards previously granted.
We do not separately target the equity element of our executive officer compensation programs at a specific percentage
of overall compensation. However, overall total compensation is structured to be competitive so that we can attract and retain
executive officers. In setting equity award levels, we also take into consideration the impact of the equity-based awards on the
dilution of our stockholders' ownership interests in our common stock.
The Compensation Committee grants RSUs to executive officers and current employees on a quarterly basis in an
attempt to more evenly record stock-based compensation expense. Grants of RSUs to new employees (other than executives)
are made once per month by the Employee Committee at a meeting of such committee. Grants of RSUs to any new executive
officer would be made at the first meeting of the Compensation Committee following the election of such officer. Microchip
does not have any program, plan or practice to time grants of RSUs in coordination with the release of material non-public
information. Microchip does not time, nor do we plan to time, the release of material non-public information for the purposes
of affecting the value of executive compensation.
See the table under "Grants of Plan-Based Awards for Fiscal Year Ended March 31, 2019" at page 45 for information
regarding RSUs granted during fiscal 2019 to our named executive officers.
Stock Ownership Guidelines for Key Employees and Directors. To help ensure alignment of the interests of our
management and Board of Directors with those of our stockholders, we have put in place a stock holding policy that applies to
each member of our management and Board of Directors. This policy was proposed by our Nominating and Governance
Committee and ratified by our Board of Directors in October 2003. Under this policy, each of our directors, executive officers,
vice presidents and internal director-level employees must maintain a specified minimum level of ownership of our stock
during their tenure in their respective office or position. During fiscal 2019, all of our executive officers and directors were in
compliance with the terms of such policy.
Microchip's insider trading policy prohibits executive officers from speculating in Microchip stock, which includes a
prohibition on short selling, buying and selling options (including writing covered calls) or hedging or any type of arrangement
that has a similar economic effect.
Other Compensation and Employee Benefits Generally Available to All Employees. We maintain compensation and
employee benefits that are generally available to all Microchip employees, including:
our employee stock purchase plans,
•
• medical, dental, vision, employee assistance program, flexible spending, and disability insurance,
•
•
•
•
life insurance benefits,
a 401(k) retirement savings plan,
an employee cash bonus plan, and
vacation and paid time off.
Since these programs are generally available to all employees, these forms of compensation are not independently
evaluated by the Compensation Committee in connection with the determination of executive officer compensation.
Employee Stock Purchase Plans. Our 2001 Employee Stock Purchase Plan is a Section 423 qualified employee stock
purchase plan that allows all U.S. employees the opportunity to purchase our common stock through payroll deductions at 85%
of the fair market value at the lower of the price as of the opening of the two-year offering period or at the end of any six-month
purchase period. A significant portion of our international employees have the ability to participate in our 1994 International
Employee Stock Purchase Plan that allows them the opportunity to purchase our common stock through payroll deductions at
85% of the fair market value at the lower of the price as of the opening or the end of any six-month offering period.
Medical, Dental, Vision, Employee Assistance Program, Flexible Spending, Disability Insurance and Accidental Death
and Dismemberment. We make medical, dental, vision, employee assistance program, flexible spending, and disability
insurance generally available to all of our employees through our active benefit plans. Under these generally available plans,
37
Table of Contents
our named executive officers are eligible to receive between $1,000 and $7,500 per month in long-term disability coverage
depending on which plan they elect. Short-term disability coverage is provided which allows for 100% of base salary to be
paid for six months in the event of disability. Accidental death and dismemberment insurance, which is generally available to
our U.S. employees, is provided by Microchip to our executives with a benefit of one times the executive's annual salary. Since
all of our U.S. employees participate in these plans on a non-discriminatory basis, the value of these benefits to our named
executive officers is not required to be included in the Summary Compensation Table on page 43 pursuant to SEC rules and
regulations.
Life Insurance. In fiscal 2019, we provided life insurance coverage to our named executive officers in the amount up
to one and a half times the executive's annual salary (up to a maximum of $500,000). The named executive officers may
purchase supplemental life insurance at their own expense.
401(k). We maintain a 401(k) plan for the benefit of all of our U.S. employees to allow our employees to save for
retirement. We contribute to our 401(k) plan each year based on our profitability during the year, subject to maximum
contributions and other rules prescribed by federal law governing such plans. Our named executive officers are permitted to
participate in the plans to the same extent as our other U.S. employees. Our Compensation Committee approved discretionary
matching contributions for the first, second and third quarters of fiscal 2019 equal to $0.50 for each dollar contributed by the
employee for the first 4% of their salary contributions. For the fourth quarter of fiscal 2019, our Compensation Committee
approved discretionary matching contributions equal to $0.40 for each dollar contributed by the employee for the first 4% of
their salary contribution. There are no required matching contributions under the plan.
Employee Cash Bonus Plan. All of our employees worldwide participate in our Employee Cash Bonus Plan
("ECBP"). The ECBP is a discretionary bonus plan designed to allow our full-time employees, not just our executive officers,
to share in the success of the company. The target bonus under the ECBP is 2.5 days of base salary per quarter, or on an annual
basis, two weeks of annual base salary which may be granted by the Compensation Committee if certain Microchip operating
profitability objectives are achieved. Under the ECBP, the Compensation Committee can set the eligibility requirements and
targets and has discretion to pay more or less than the stated target. Other eligibility terms also apply, such as an attendance
requirement and a performance requirement.
The payout under the ECBP is approved by the Compensation Committee based on our actual quarterly operating
results. For the second, third and fourth quarters of fiscal 2019, bonus awards were paid out to executives at 100%, 90%, and
75% of target, respectively. There was no payout under the ECBP for the first quarter of fiscal 2019. For each quarter (other
than the first quarter), an additional award was paid out to selected employees on a discretionary basis based on performance
achievements by such employees during the quarter. Under the ECBP, for fiscal 2019, our named executive officers other than
our CEO received total payments ranging from $6,611 to $12,240, and our CEO received $21,626.
Vacation and Paid Time-Off Benefits. We provide vacation and other paid holidays to all of our employees, including
our named executive officers. We believe our vacation and holidays are comparable to others in the industry.
Non-Qualified Deferred Compensation Plan. We maintain a non-qualified deferred compensation plan for certain
employees, including our named executive officers, who receive compensation in excess of the 401(k) contribution limits
imposed under the Internal Revenue Code and desire to defer more compensation than they would otherwise be permitted
under a tax-qualified retirement plan, such as our 401(k) plan. Microchip does not make contributions to this non-qualified
deferred compensation plan. This plan allows our executive officers to make pre-tax contributions to this plan which would be
fully taxed to the executive officers after the executive officer's termination of employment with Microchip.
We do not have pension plans or other retirement plans for our named executive officers or our other U.S. employees.
Employment Contracts, Termination of Employment and Change of Control Arrangements. We do not have
employment contracts with our CEO, CFO or any of our executive officers, nor agreements to pay severance on involuntary
termination (other than as stated in the change of control agreements described below) or upon retirement. Our CEO, CFO, and
our executive officers have entered into change of control agreements with us.
38
Table of Contents
The change of control agreements were designed to help ensure the continued services of our key executive officers in
the event that a change of control of the company is effected, and to assist our key executive officers in transitioning from
Microchip if, as a result of a change of control, they lose their positions. We believe that the benefits provided by these
agreements help to ensure that our management team will be incentivized to remain employed with Microchip during a change
of control. Capitalized terms used herein and not defined shall have the meanings set forth in the change of control agreements.
Additionally, our 2004 Equity Incentive Plan has a change of control provision which provides that any successor company
shall assume each outstanding award or provide an equivalent substitute award; however, if the successor fails to do so, vesting
of awards shall accelerate. The Compensation Committee considered prevalent market practices in determining the severance
amounts and the basis for selecting the events triggering payment in the agreements.
With respect to our CEO, CFO and VP of Worldwide Sales, if the executive officer's employment terminates for
reasons other than Cause within the Change of Control Period, the executive officer will be entitled to receive severance
benefits consisting of the following primary components:
•
•
•
•
a one-time payment of the executive's base salary in effect immediately prior to the Change of Control or
termination date, whichever is greater, for the following periods: (1) in the case of the CEO, two years; (2) in
the case of the CFO and the VP Worldwide Sales, one year;
a one-time payment of the executive's bonuses for which the executive was or would have been eligible in the
year in which the Change of Control occurred or for the year in which termination occurred, whichever is
greater, for the following periods: (1) in the case of the CEO, two years; (2) in the case of the CFO and the
VP of Worldwide Sales, one year;
a continuation of medical and dental benefits (subject to any required employee contributions) for the
following periods: (1) in the case of the CEO, two years; (2) in the case of the CFO and VP of Worldwide
Sales, one year; provided in each case that such benefits would cease sooner if and when the executive officer
becomes covered by the plans of another employer; and
a payment to cover any excise tax that may be due under Section 4999 of the Code, if the payments provided
for in the change of control agreement constitute "parachute payments" under Section 280G of the Code and
the value of such payments is more than three times the executive officer's "base amount" as defined by
Section 280G(b)(3) of the Code.
With respect to our CEO, the CFO and the VP of Worldwide Sales, immediately prior to a Change of Control
(regardless of whether the executive officer's employment terminates), all equity compensation held by the executive officer
shall become fully vested.
With respect to our executive officers other than the CEO, the CFO and the VP of Worldwide Sales, if the executive
officer terminates his employment for Good Reason, or the executive's employment is terminated for reasons other than Cause
within the Change of Control Period, the executive officer will be entitled to receive severance benefits consisting of the
following primary components:
•
•
•
•
a one-time payment of his base salary in effect immediately prior to the Change of Control or termination
date, whichever is greater, for one year;
a one-time payment of his bonuses for which he was or would have been eligible in the year in which the
Change of Control occurred or for the year in which termination occurred, whichever is greater, for one year;
a continuation of medical and dental benefits (subject to any required employee contributions) for one year
(provided in each case that such benefits would cease sooner if and when the executive officer becomes
covered by the plans of another employer); and
a payment to cover any excise tax that may be due under Section 4999 of the Code, if the payments provided
for in the change of control agreement constitute "parachute payments" under Section 280G of the Code and
the value of such payments is more than three times the executive officer's "base amount" as defined by
Section 280G(b)(3) of the Code.
39
Table of Contents
With respect to our executive officers other than the CEO, the CFO and the VP of Worldwide Sales, immediately upon
termination during the Change of Control Period other than for Cause, all equity compensation held by the executive officer
shall become fully vested.
The following table sets forth the aggregate dollar value of payments, to the extent calculable, in the event of a
termination of a named executive officer on March 31, 2019, the last business day of our last completed fiscal year.
Salary
Bonus
Equity
Compensation
Due to
Accelerated
Vesting (1)
Tax Gross-up
on Change of
Control (2)
Continuation
of Certain
Benefits (3)
$
1,499,400 $
3,056,469 $
36,795,000 $
424,360
278,136
317,217
259,437
355,810
135,859
158,120
92,998
16,910,898
8,121,369
6,960,759
5,156,047
—
—
—
—
—
2 years
1 year
1 year
1 year
1 year
Name
Steve Sanghi (4)
Ganesh Moorthy (5)
Stephen V. Drehobl (5)
Mitchell R. Little (5)
J. Eric Bjornholt (5)
(1) Value represents the gain that our named executive officers would receive, calculated as the amount of unvested RSUs
multiplied by our stock price on March 31, 2019.
(2) This payment covers any excise tax that may be payable under Section 4999 of the Code if the payments provided for
under the change of control agreement constitute "parachute payments" under Section 280G of the Code and the value of
the payments is more than three times the executive officer's "base amount" as defined by Section 280G(b)(3) of the
Code.
(3) Benefits continued under the change of control agreements are limited to company-paid medical, dental, vision and life
insurance coverage at the same level of coverage the executive was provided immediately prior to termination of
employment with Microchip. Amounts are not determinable at this time and are dependent on each executive officer's
individual circumstances.
(4) The change of control payment includes an amount equal to twice the annual salary of the executive plus a bonus equal
to two times the targeted annual amount payable to such executive under our management incentive compensation plans
(EMICP and DMICP) and our ECBP.
(5) The change of control payment includes an amount equal to one times the annual salary of the executive plus a bonus
equal to the targeted annual amounts payable to such executive under our management incentive compensation plans
(EMICP and DMICP) and our ECBP.
Performance-Based Compensation and Financial Restatement
To date, Microchip has not experienced a financial restatement and has not considered or implemented a policy
regarding retroactive adjustments to any cash or equity-based incentive compensation paid to its executive officers and other
employees where such payments were predicated upon the achievement of certain financial results that would subsequently be
the subject of a restatement.
40
Table of Contents
No Tax Deductibility
As a result of the enactment of the Tax Cuts and Jobs Act in December 2017, the Code disallows a corporate income
tax deduction for executive compensation paid to certain of our named executive officers. To maintain flexibility in
compensating Microchip's executive officers in a manner designed to promote varying corporate goals, it is not the policy of
the Compensation Committee that executive compensation must be tax deductible. We intend to review the deductibility of
executive officer compensation from time to time to determine whether any actions are advisable to obtain deductibility.
Conclusion
We believe that our executive team provided outstanding service to Microchip in fiscal 2019. We will work to assure
that the executive compensation programs continue to meet Microchip's strategic goals as well as the overall objectives of the
compensation program.
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION (*)
The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis section of this
proxy statement required by Item 402(b) of Regulation S-K with management and, based on such review and discussion, the
Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included
in this proxy statement.
By the Compensation Committee of the Board of Directors:
Wade F. Meyercord (Chair)
_________________________
L.B. Day
(*) The Compensation Committee Report on executive compensation is not "soliciting" material and is not deemed "filed" with
the SEC, and is not incorporated by reference into any filings of Microchip under the Securities Act of 1933 or the Securities
Exchange Act of 1934 whether made before or after the date hereof and irrespective of any general incorporation language
contained in such filings.
41
Table of Contents
CEO PAY RATIO DISCLOSURE
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u)
of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of our
"median employee" and that of our CEO, Mr. Steve Sanghi. We believe the pay ratio information provided below is a
reasonable estimate calculated in a manner consistent with the pay ratio disclosure rules.
For fiscal 2019, our last completed fiscal year:
• The estimated median of the annual total compensation of all our employees, excluding our CEO, was
$41,125.
• The annual total compensation of our CEO, as reported in the Summary Compensation Table presented
elsewhere in this proxy statement, was $12,864,939.
• The ratio of the annual total compensation of our CEO to the median of the annual total compensation of
employees was 313 to 1.
To identify the median of the annual total compensation of all of our employees, as well as to determine the annual
total compensation of the "median employee," the methodology and the material assumptions, adjustments, and estimates that
we used were as follows:
• We selected January 1, 2019 as the date upon which we identified the median employee. We compiled a list
of all full-time, part-time, temporary and seasonal employees who were employed on that date, including
employees working both within and outside of the United States.
• We identified the "median employee" by taking all employees on this list (including international employees,
but excluding the CEO), and ranking them based on a consistently applied compensation measure that
incorporated the adjusted gross wages paid over the twelve-month period preceding the determination date
(including the grant date value of equity, as opposed to realized equity values). We converted pay for
international employees to United States Dollars using the exchange rates on January 1, 2019, and we
annualized the pay for full and part time employees who were hired during the period.
• After identifying a representative "median employee," we identified and calculated the elements of such
employee's compensation for fiscal 2019 in accordance with the requirements of Item 402(c)(2)(x) of
Regulation S-K, resulting in annual total compensation of $41,125.
• With respect to the annual total compensation for the CEO, we used the amount reported in the "Total"
column of our 2019 Summary Compensation Table.
42
Table of Contents
COMPENSATION OF NAMED EXECUTIVE OFFICERS
SUMMARY COMPENSATION TABLE
The following table lists the annual compensation for our CEO, our CFO and our three other most highly compensated
executive officers (referred to as the "named executive officers") earned in the last three fiscal years:
Name and
Principal Position
Year
Salary (1)
Bonus (2)
Stock
Awards (3)
Non-Equity
Incentive Plan
Compensation (4)
All Other
Compensation (5)
Total
2019
$
749,700 $
21,626 $ 11,386,308 $
700,389 $
6,916 $
12,864,939
Steve Sanghi,
CEO and Chairman of the Board
Ganesh Moorthy,
President and COO
Stephen V. Drehobl,
Senior VP, MCU8 and
Technology Development
Division
Mitchell R. Little,
Senior VP, Worldwide Sales and
Applications
J. Eric Bjornholt,
Senior VP and CFO
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
740,042
48,012
4,464,406
618,982
51,071
4,229,482
424,360
12,240
5,218,861
412,713
28,523
2,252,329
356,077
27,692
2,546,515
278,136
7,087
2,381,844
274,553
17,811
1,009,789
260,121
17,704
938,749
317,217
8,083
1,984,654
313,794
20,384
877,120
305,999
19,901
815,010
259,437
6,611
1,513,668
256,094
17,341
640,938
241,263
15,671
597,516
2,632,141
2,395,351
8,859
7,893,460
10,465
7,305,351
158,539
589,160
556,000
58,438
219,716
202,296
68,151
256,917
243,218
38,759
145,739
133,192
7,602
9,583
9,531
7,211
9,328
9,452
10,671
12,859
11,490
5,963
8,006
8,026
5,821,602
3,292,308
3,495,815
2,732,716
1,531,197
1,428,322
2,388,776
1,481,074
1,395,618
1,824,438
1,068,118
995,668
(1) Represents the base salary earned by each executive officer in the specified fiscal year.
(2) Represents bonuses earned by each executive officer in the specified fiscal year under our ECBP.
(3) Represents the aggregate grant date fair value of awards of RSUs made in the specified fiscal year computed in accordance
with ASC 718 Compensation - Stock Compensation. For information on the valuation assumptions made with respect to
the grants of RSUs in fiscal 2019, please refer to Note 16, "Share-Based Compensation" to Microchip's audited financial
statements for the fiscal year ended March 31, 2019 included in our Annual Report on Form 10-K filed with the SEC on
May 30, 2019.
43
Table of Contents
(4) Represents the aggregate amount of cash bonuses earned by each executive officer in the specified fiscal year under our
EMICP and DMICP. In fiscal 2019, a portion of the amounts earned under the EMICP were paid in RSUs not in cash.
Such RSUs are not included in the Non-Equity Incentive Plan Compensation column in the above table; however, all of
such RSU grants made during fiscal 2019 are included in the Stock Awards column in the above table and such outstanding
RSUs are also included in the Outstanding Equity Awards at 2019 Fiscal Year End table. Each executive officer received
the following cash payments under each of such plans in the specified fiscal year:
Named Executive Officer
Steve Sanghi
Ganesh Moorthy
Stephen V. Drehobl
Mitchell R. Little
J. Eric Bjornholt
Year
2019
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
EMICP
DMICP
$
700,389 $
2,270,065
1,979,664
158,539
507,691
461,160
58,438
189,492
167,321
68,151
221,545
201,671
38,759
125,691
110,227
—
362,076
415,687
—
81,469
94,840
—
30,224
34,975
—
35,372
41,547
—
20,048
22,965
(5) Consists of company-matching contributions under our 401(k) retirement savings plan and the full dollar value of
premiums paid by Microchip for life insurance for the benefit of the named executive officer in the amounts shown below:
Named Executive Officer
Steve Sanghi
Ganesh Moorthy
Stephen V. Drehobl
Mitchell R. Little
J. Eric Bjornholt
401(k)
Life Insurance
$
3,870 $
5,835
7,438
5,245
7,455
7,511
5,061
7,200
7,339
5,245
7,455
7,914
4,905
6,970
7,037
3,046
3,024
3,027
2,357
2,128
2,020
2,150
2,128
2,113
5,426
5,404
3,576
1,058
1,036
989
Year
2019
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
2019
2018
2017
44
Table of Contents
Grants of Plan-Based Awards During Fiscal 2019
The following table sets forth information with respect to our EMICP, our DMICP, and our ECBP, as well as RSUs
granted to our named executive officers under our 2004 Equity Incentive Plan, including the grant date fair value of the RSUs.
Amounts listed in the "Estimated Future Payouts Under Non-Equity Incentive Plan Awards" column are annual targets based on
the salaries of the named executive officers at the end of fiscal 2019. Actual payments for our bonus plans in fiscal 2019 are
reflected in the Summary Compensation Table above. Equity awards in the table below were granted in fiscal 2019.
Name
Steve Sanghi
Ganesh Moorthy
Stephen V. Drehobl
GRANTS OF PLAN-BASED AWARDS
For Fiscal Year Ended March 31, 2019
Estimated Future Payouts Under Non-
Equity Incentive Plan Awards
Grant
Date
4/2/2018
7/2/2018
8/14/2018
9/4/2018
10/1/2018
11/8/2018
1/2/2019
2/6/2019
—
—
—
4/2/2018
7/2/2018
8/14/2018
9/4/2018
10/1/2018
11/8/2018
1/2/2019
2/6/2019
—
—
—
4/2/2018
7/2/2018
8/14/2018
9/4/2018
10/1/2018
11/8/2018
1/2/2019
2/6/2019
—
—
—
Threshold
($) (1)
Target
($)
Maximum
($) (1)
All Other
Stock Awards:
Number of
Shares of
Stock or Units
(#) (2)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1,199,522 (4)
299,880 (5)
28,835 (6)
—
—
—
—
—
—
—
—
271,590 (4)
67,898 (5)
16,322 (6)
—
—
—
—
—
—
—
—
100,129 (4)
25,032 (5)
10,698 (6)
45
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
12,419
12,493
6,019
79,642
14,810
3,553
16,016
1,415
—
—
—
5,934
5,969
1,363
38,053
7,076
805
7,652
320
—
—
—
2,809
2,826
502
17,156
3,350
297
3,623
118
—
—
—
Grant Date
Fair Value of
Stock
and Option
Awards
($) (3)
1,018,482
1,072,399
497,410
6,301,275
1,059,804
259,405
1,053,212
124,322
—
—
—
486,647
512,379
112,638
3,010,753
506,359
58,773
503,196
28,115
—
—
—
230,366
242,584
41,485
1,357,383
239,726
21,684
238,248
10,367
—
—
—
Table of Contents
Name
Mitchell R. Little
J. Eric Bjornholt
Estimated Future Payouts Under Non-
Equity Incentive Plan Awards
Threshold
($) (1)
Target
($)
Maximum
($) (1)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
116,736 (4)
29,184 (5)
12,201 (6)
—
—
—
—
—
—
—
—
66,416 (4)
16,604 (5)
9,978 (6)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
All Other
Stock Awards:
Number of
Shares of
Stock or Units
(#) (2)
Grant Date
Fair Value of
Stock
and Option
Awards
($) (3)
2,346
2,247
586
192,395
192,882
48,427
14,326
1,133,473
2,664
346
2,881
138
—
—
—
1,783
1,793
333
10,888
2,126
197
2,299
78
—
—
—
190,636
25,261
189,455
12,125
—
—
—
146,224
153,911
27,519
861,459
152,137
14,383
151,182
6,853
—
—
—
Grant
Date
4/2/2018
7/2/2018
8/14/2018
9/4/2018
10/1/2018
11/8/2018
1/2/2019
2/6/2019
—
—
—
4/2/2018
7/2/2018
8/14/2018
9/4/2018
10/1/2018
11/8/2018
1/2/2019
2/6/2019
—
—
—
(1)
Individual awards under our EMICP, DMICP and ECBP are made quarterly and are not stated in terms of a threshold or
maximum amount for an award period. The EMICP does provide that the maximum amount payable to any participant is
$2.5 million for any performance period (which can be a fiscal quarter, a fiscal year or a longer period not exceeding five
fiscal years).
(2) Represents RSUs granted under Microchip's 2004 Equity Incentive Plan.
(3) This column shows the full grant date fair value of RSU awards to the named executives in fiscal 2019. Generally, the full
grant date fair value is the amount that Microchip would expense in its financial statements over the award's vesting
schedule.
(4) This annual target represents the amount targeted for estimated future payout in fiscal 2020 under Microchip's EMICP
based on the executive officer's base salary at the end of fiscal 2019.
(5) This annual target represents the amount targeted for estimated future payout in fiscal 2020 under Microchip's DMICP
based on the executive officer's base salary at the end of fiscal 2019.
(6) This annual target represents the amount targeted for future payout in fiscal 2020 under Microchip's ECBP based on the
executive officer's base salary at the end of fiscal 2019.
Summary Compensation Table and Grants of Awards Table Discussion
Based on the data in the Summary Compensation Table, the level of salary, bonus, non-equity incentive plan
compensation, and other compensation in proportion to total compensation ranged from approximately 10.4% to 17.0% for our
named executive officers in fiscal 2019. See the "Compensation Discussion and Analysis" section of this proxy statement for
further discussion of overall compensation and how compensation is determined.
46
Table of Contents
We do not have employment contracts with our named executive officers, nor agreements to pay severance on
involuntary termination (other than as stated in the change of control agreements discussed above under the heading
"Employment Contracts, Termination of Employment and Change of Control Arrangements") or retirement.
For a discussion of the material terms of the awards listed in the Grants of Awards Table, see our discussion of the
equity awards and incentive cash bonuses in the "Compensation Discussion and Analysis" section of this proxy statement under
the headings "Incentive Cash Bonuses," "Equity Compensation," and "Employee Cash Bonus Plan."
Microchip has not repriced any stock options or made any material modifications to any equity-based awards during
the last fiscal year.
47
Table of Contents
OUTSTANDING EQUITY AWARDS AT FISCAL 2019 YEAR END
Name
Number of Shares or Units of Stock That
Have Not
Vested (#)
Market Value of Shares or
Units of Stock That Have Not
Vested $ (18)
Stock Awards
Steve Sanghi
1,711,465
48,780
10,619
1,772,689
46,706
9,955
499,336
1,959,681
37,913
8,628
294,757
1,798,158
36,834
8,628
117,388
1,798,158
154,306
6,148,829
1,721,835
144,931
1,397,046
125,850
1,359,631
124,938
1,185,830
1,113,821
966,982
960,179
1,030,280
1,036,419
1,228,638
1,328,687
6,607,100
20,630 (1)
588 (1)
128 (1)
21,368 (2)
563 (2)
120 (2)
6,019 (2)
23,622 (3)
457 (3)
104 (3)
3,553 (3)
21,675 (4)
444 (4)
104 (4)
1,415 (4)
21,675 (5)
1,860 (5)
74,118 (6)
20,755 (6)
1,747 (6)
16,840 (7)
1,517 (7)
16,389 (8)
1,506 (8)
14,294 (9)
13,426 (10)
11,656 (11)
11,574 (12)
12,419 (13)
12,493 (14)
14,810 (15)
16,016 (16)
79,642 (17)
48
Table of Contents
OUTSTANDING EQUITY AWARDS AT FISCAL 2019 YEAR END
Name
Number of Shares or Units of Stock That
Have Not
Vested (#)
Market Value of Shares or
Units of Stock That Have Not
Vested $ (18)
Stock Awards
Ganesh Moorthy
716,608
105,442
22,980
742,243
100,962
21,570
113,074
820,557
81,882
18,749
66,783
752,862
79,725
18,583
26,547
859,134
73,751
2,574,664
822,714
69,272
584,951
82,545
60,146
649,660
59,731
566,617
532,188
462,004
458,769
492,285
495,188
587,025
634,810
3,156,877
8,638
1,271
277
8,947
1,217
260
1,363
9,891
987
226
805
9,075
961
224
320
10,356
889
31,035
9,917
835
7,051
995
725
7,831
720
6,830
6,415
5,569
5,530
5,934
5,969
7,076
7,652
38,053
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(3)
(3)
(3)
(3)
(4)
(4)
(4)
(4)
(5)
(5)
(6)
(6)
(6)
(7)
(7)
(7)
(8)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
49
Table of Contents
OUTSTANDING EQUITY AWARDS AT FISCAL 2019 YEAR END
Name
Number of Shares or Units of Stock That
Have Not
Vested (#)
Market Value of Shares or
Units of Stock That Have Not
Vested $ (18)
Stock Awards
Stephen V. Drehobl
387,091
11,034
2,406
400,946
10,536
2,240
41,646
443,255
8,545
1,991
24,639
406,753
8,379
1,908
9,789
406,753
34,926
1,390,741
389,497
32,769
315,995
28,455
307,533
28,289
268,210
251,950
218,683
217,189
233,035
234,445
277,916
300,564
1,423,262
4,666 (1)
133 (1)
29 (1)
4,833 (2)
127 (2)
27 (2)
502 (2)
5,343 (3)
103 (3)
24 (3)
297 (3)
4,903 (4)
101 (4)
23 (4)
118 (4)
4,903 (5)
421 (5)
16,764 (6)
4,695 (6)
395 (6)
3,809 (7)
343 (7)
3,707 (8)
341 (8)
3,233 (9)
3,037 (10)
2,636 (11)
2,618 (12)
2,809 (13)
2,826 (14)
3,350 (15)
3,623 (16)
17,156 (17)
50
Table of Contents
OUTSTANDING EQUITY AWARDS AT FISCAL 2019 YEAR END
Name
Number of Shares or Units of Stock That
Have Not
Vested (#)
Market Value of Shares or
Units of Stock That Have Not
Vested $ (18)
Stock Awards
Mitchell R. Little
336,154
9,540
2,074
348,183
9,126
1,991
48,615
384,934
7,383
1,742
28,704
353,244
7,218
1,742
11,448
353,244
30,280
1,207,815
338,228
28,455
274,432
24,722
267,048
24,556
232,952
218,766
189,978
188,651
194,624
186,411
221,005
239,008
1,188,485
4,052 (1)
115 (1)
25 (1)
4,197 (2)
110 (2)
24 (2)
586 (2)
4,640 (3)
89 (3)
21 (3)
346 (3)
4,258 (4)
87 (4)
21 (4)
138 (4)
4,258 (5)
365 (5)
14,559 (6)
4,077 (6)
343 (6)
3,308 (7)
298 (7)
3,219 (8)
296 (8)
2,808 (9)
2,637 (10)
2,290 (11)
2,274 (12)
2,346 (13)
2,247 (14)
2,664 (15)
2,881 (16)
14,326 (17)
51
Table of Contents
OUTSTANDING EQUITY AWARDS AT FISCAL 2019 YEAR END
Name
Number of Shares or Units of Stock That
Have Not
Vested (#)
Market Value of Shares or
Units of Stock That Have Not
Vested $ (18)
Stock Awards
J. Eric Bjornholt
2,961 (1)
84 (1)
19 (1)
3,068 (2)
80 (2)
17 (2)
333 (2)
3,391 (3)
65 (3)
15 (3)
197 (3)
3,112 (4)
63 (4)
15 (4)
78 (4)
3,111 (5)
267 (5)
2,979 (6)
10,638 (6)
251 (6)
2,417 (7)
218 (7)
2,353 (8)
216 (8)
2,052 (9)
1,927 (10)
1,673 (11)
1,662 (12)
1,783 (13)
1,793 (14)
2,126 (15)
2,299 (16)
10,888 (17)
245,645
6,969
1,576
254,521
6,637
1,410
27,626
281,317
5,392
1,244
16,343
258,172
5,226
1,244
6,471
258,089
22,150
247,138
882,528
20,823
200,514
18,085
195,205
17,919
170,234
159,864
138,792
137,880
147,918
148,747
176,373
190,725
903,268
(1) The award vested in full on May 15, 2019.
(2) The award vests in full on August 15, 2019 subject to continued service on such date.
(3) The award vests in full on November 15, 2019, subject to continued service on such date.
(4) The award vests in full on February 15, 2020, subject to continued service on such date.
(5) The award vests in full on May 15, 2020, subject to continued service on such date.
(6) The award vests over six quarters through August 15, 2020, subject to continued service on such date.
(7) The award vests in full on November 15, 2020, subject to continued service on such date.
(8) The award vests in full on February 15, 2021, subject to continued service on such date.
(9) The award vests in full on May 15, 2021, subject to continued service on such date.
(10) The award vests in full on August 15, 2021, subject to continued service on such date.
(11) The award vests in full on November 15, 2021, subject to continued service on such date.
(12) The award vests in full on February 15, 2022, subject to continued service on such date.
(13) The award vests in full on May 15, 2022, subject to continued service on such date.
(14) The award vests in full on August 15, 2022, subject to continued service on such date.
(15) The award vests in full on November 15, 2022, subject to continued service on such date.
52
Table of Contents
(16) The award vests in full on February 15, 2023, subject to continued service on such date.
(17) The award vests quarterly over a three-year period through May 15, 2023, subject to continued service on such date.
(18) Represents the number of RSUs multiplied by $82.96, the closing price of our common stock on March 31, 2019.
53
Table of Contents
STOCK VESTED
For Fiscal Year Ended March 31, 2019
The following table provides information, on an aggregate basis, about stock awards that vested during the fiscal year
ended March 31, 2019 for each of the named executive officers.
Microchip has not granted stock options, other than options assumed in acquisitions, since 2008. No named executive
officer held any Microchip stock options during fiscal 2019.
Name
Stock Awards
Number of Shares
Acquired on Vesting (#)
Value Realized
on Vesting ($)(1)
Steve Sanghi, CEO and Chairman of the Board
139,998
11,977,800
Ganesh Moorthy, President and COO
62,991
5,390,508
Stephen V. Drehobl, Senior VP, MCU8 and Technology Development
Division
31,665
2,709,143
Mitchell R. Little, Senior VP, Worldwide Sales and Applications
27,494
2,352,296
J. Eric Bjornholt, Senior VP and CFO
20,120
1,721,398
(1) The values realized upon vesting for RSUs are based on the closing price of our common stock on the vesting dates.
Non-Qualified Deferred Compensation for Fiscal Year 2019
All of our U.S. employees in director-level and above positions, including our executive officers, are eligible to defer a
portion of their salary and cash bonuses into our Non-Qualified Deferred Compensation Plan (the "Deferred Compensation
Plan"). Pursuant to the Deferred Compensation Plan, eligible employees can defer up to 50% of their base salary and/or cash
bonuses. In general, deferral elections are made prior to January of each year for amounts to be earned in the upcoming year.
Participants may invest amounts in various funds available under the Deferred Compensation Plan (in general, any of those
funds traded on a nationally recognized exchange). Plan earnings are calculated by reference to actual earnings of mutual funds
or other securities chosen by individual participants.
Except for a change in control or certain unforeseeable emergencies (as defined under the Deferred Compensation
Plan), benefits under the plan will not be distributed until a "distribution event" has occurred. The distribution event occurs
upon termination of employment.
We incur incidental expenses for administration of the Deferred Compensation Plan, and the receipt of any tax benefit
we might obtain based on payment of a participant's compensation is delayed until funds (including earnings or losses on the
amounts invested pursuant to the plan) are eventually distributed. We do not pay any additional compensation or guarantee
minimum returns to any participant in the Deferred Compensation Plan.
54
Table of Contents
The following table shows the non-qualified deferred compensation activity for each named executive officer for the
fiscal year ended March 31, 2019.
NON-QUALIFIED DEFERRED COMPENSATION
Name
Steve Sanghi
$
Ganesh Moorthy
Stephen V. Drehobl
Mitchell R. Little
J. Eric Bjornholt
Executive
Contributions
in Last FY (1)
Company
Contributions
in Last FY
Aggregate
Earnings
in Last FY (1)
Aggregate
Withdrawals/
Distributions
Aggregate
Balance at
Last FYE (1)
— $
—
59,050
76,844
23,397
— $
— $
— $
—
—
—
—
12,747
125,305
9,822
13,312
—
—
—
—
—
271,136
1,154,318
255,943
337,992
(1) The executive contribution amounts shown in the table were previously reported in the "Summary Compensation Table" as
salary and/or bonus for fiscal 2019 or prior fiscal years. The earnings amounts shown in the table were not previously
reported for fiscal 2019 or prior years under applicable SEC rules as such earnings were not under a defined benefit or
actuarial pension plan and there were no above-market or preferential earnings on such amounts made or provided by
Microchip.
55
Table of Contents
EQUITY COMPENSATION PLAN INFORMATION
The table below provides information about our common stock that, as of March 31, 2019, may be issued upon the
vesting of RSUs and the exercise of options and rights under the following equity compensation plans (which are all of our
equity compensation plans; provided, however, that new equity awards or stock purchase rights may only be issued under the
Microchip 2004 Equity Incentive Plan, the Microchip 1994 International Employee Stock Purchase Plan and the Microchip
2001 Employee Stock Purchase Plan):
SMSC 2009 Long Term Incentive Plan (the "LTIP"),
Supertex 2009 Equity Plan,
• Microchip 1994 International Employee Stock Purchase Plan (the "IESPP"),
• Microchip 2001 Employee Stock Purchase Plan (the "ESPP"),
• Microchip 2004 Equity Incentive Plan,
•
•
• Micrel 2003 Incentive Award Plan,
• Micrel 2012 Equity Incentive Award Plan,
• Microchip 2012 Inducement Award Plan (the "2012 Inducement Plan"),
• Atmel Corporation 2005 Stock Plan,
• Vitesse Semiconductor Corporation Amended and Restated 2001 Stock Incentive Plan,
• Vitesse 2010 Incentive Plan,
• Vitesse 2013 Incentive Plan,
•
• Microsemi 2008 Performance Incentive Plan,
•
Symmetricom 2006 Incentive Award Plan,
• Actel 1986 Equity Incentive Plan, and
• Asic Advantage, Inc. Series B Common Stock 2010 Stock Option Plan
PMC-Sierra 2008 Equity Plan,
Plan Category
(a) Number of
securities to be
issued upon
exercise of
outstanding
options and vesting
of RSUs
(b) Weighted
average
exercise price
of outstanding
options (1)
(c) Number of
securities remaining
available for future
issuance under equity
compensation plans
(excluding securities
reflected in column
(a))
Equity Compensation Plans Approved by Stockholders(2)
5,587,778
Equity Compensation Plans Not Approved by Stockholders
986,066
(3)
(5)
$42.88
$29.42
17,427,801
(4)
—
Total
6,573,844
$30.16
(6)
17,427,801
(1) The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding RSUs,
which have no exercise price.
(2) Beginning January 1, 2005, the shares authorized for issuance under our ESPP are subject to an annual automatic
increase equal to the lesser of (i) 1,500,000 shares, (ii) one-half of one percent (0.5%) of the then outstanding shares of
our common stock, or (iii) such lesser amount as is approved by our Board of Directors. Upon the approval of our
Board of Directors, 1,184,815 additional shares of common stock were reserved under the ESPP on January 1, 2019
based on the automatic increase provision. Beginning January 1, 2007, the shares authorized for issuance under our
IESPP are subject to an annual automatic increase of equal to one-tenth of one percent (0.10%) of the then outstanding
56
Table of Contents
shares of our common stock. Upon the approval of our Board of Directors, 236,963 additional shares of common stock
were reserved under the IESPP on January 1, 2019 based on the automatic increase provision.
(3) As of March 31, 2019, includes 5,572,205 shares issuable upon the vesting of RSUs granted under our 2004 Equity
Incentive Plan, and 15,573 shares issuable upon the exercise of outstanding options granted under our 2004 Equity
Incentive Plan.
(4) As of March 31, 2019, includes 10,532,795 shares remaining available for future issuance under our 2004 Equity
Incentive Plan. The remaining balance represents shares available for purchase under the IESPP and the ESPP.
(5) As of March 31, 2019, includes 11,894 shares subject to outstanding SARs under the 2012 Inducement Plan; 14,129
shares subject to outstanding options under the 2009 LTIP; 85,548 shares subject to outstanding options under the 2009
Equity Plan that Supertex adopted prior to our acquisition of Supertex in April 2014; 17,765 shares issuable upon the
exercise of outstanding options granted under the Micrel 2003 Incentive Award Plan; 5,519 shares issuable upon the
vesting of RSUs granted under the Micrel 2012 Equity Incentive Award Plan; 51,762 shares issuable upon the exercise
of outstanding options granted under the Micrel 2012 Equity Incentive Award Plan; 29,713 shares issuable upon the
vesting of RSUs granted under the Atmel Corporation 2005 Stock Plan; 32,134 shares issuable upon the exercise of
outstanding options granted under the Actel 1986 Equity Incentive Plan; 147 shares issuable upon the exercise of
outstanding options granted under the Asic Advantage, Inc. Series B Common Stock 2010 Stock Option Plan; 587,535
shares issuable upon the vesting of RSUs granted under the Microsemi 2008 Performance Incentive Plan; 96,990 shares
issuable upon the vesting of RSUs granted under the PMC-Sierra 2008 Equity Plan; 41,010 shares issuable upon the
exercise of outstanding options granted under the Symmetricom 2006 Incentive Award Plan; 1,964 shares issuable upon
the exercise of outstanding options granted under the Vitesse Semiconductor Corporation Amended and Restated 2001
Stock Incentive Plan; 4,031 shares subject to outstanding options under the Vitesse 2010 Incentive Plan; and 5,925
shares subject to outstanding options under the Vitesse 2013 Incentive Plan.
(6) As of March 31, 2019, there were a total of 281,882 shares subject to outstanding options, with a weighted average
exercise price of $30.16 per share and a weighted average term of 2.87 years.
Equity Compensation Plans Not Approved by Stockholders
Microchip 2012 Inducement Award Plan
In August 2012, our Board of Directors approved the 2012 Inducement Plan. Under our 2012 Inducement Plan, SARs
were granted to certain employees of SMSC as an inducement for them to enter employment with Microchip. The 2012
Inducement Plan was not submitted to our stockholders for approval because doing so was not required under applicable rules
and regulations in effect at the time the plan was adopted. The expiration date and other provisions of awards granted under the
2012 Inducement Plan, including vesting provisions, were established at the time of grant by the Compensation Committee. No
SAR may have a term of more than ten years. If Microchip is acquired by merger, consolidation or asset sale, or there is a
nomination and election of 50% or more of all members of the Board within a 36-month period whose election is without
recommendation of the Board, then each outstanding SAR may be terminated at the discretion of any committee appointed by
the Board upon notice to the award holder. Our Board of Directors may amend or terminate the 2012 Inducement Plan without
stockholder approval, but no amendment of the 2012 Inducement Plan may adversely affect any award previously granted
under the 2012 Inducement Plan without the written consent of the SAR holder.
57
Table of Contents
CODE OF BUSINESS CONDUCT AND ETHICS
In May 2004, our Board of Directors adopted a Code of Business Conduct and Ethics for our directors, officers
(including our chief executive officer and chief financial officer), and employees. A copy of the Code of Business Conduct and
Ethics, as amended to date, is available on our website at the About/Investor Relations section under Mission Statement/
Corporate Governance on www.microchip.com.
We intend to post on our website any amendment to, or waiver from, a provision of our code of ethics within four
business days following the date of such amendment or waiver or such other time period required by SEC rules.
OTHER MATTERS
Other Matters to be Presented at the Annual Meeting
At the date this proxy statement went to press, we did not anticipate that any other matters would be raised at the
annual meeting.
Requirements, Including Deadlines, for Receipt of Stockholder Proposals for the 2020 Annual Meeting of Stockholders;
Discretionary Authority to Vote on Stockholder Proposals
Under SEC rules, if a stockholder wants us to include a proposal in our proxy statement and form of proxy for our
2020 annual meeting, our Secretary must receive the proposal at our principal executive offices by March 17, 2020.
Stockholders interested in submitting such a proposal are advised to contact knowledgeable counsel with regard to the detailed
requirements of applicable securities laws. The submission of a stockholder proposal does not guarantee that it will be included
in our proxy statement.
Under our Bylaws, stockholders must follow certain procedures to nominate a person for election as a director or to
introduce an item of business at our annual meeting. Under these procedures, stockholders must submit the proposed nominee
or item of business by delivering a notice addressed to our Secretary at our principal executive offices. We must receive notice
as follows:
• Normally we must receive notice of a stockholder's intention to introduce a nomination or proposed item of
business for an annual meeting not less than 90 days before the first anniversary of the date on which we first
mailed our proxy statement to stockholders in connection with the previous year's annual meeting of
stockholders. Accordingly, a stockholder who intends to submit a nomination or proposal for our 2020 annual
meeting must do so no later than April 16, 2020.
• However, if we hold our 2020 annual meeting on a date that is not within 30 days before or after the
anniversary date of our 2019 annual meeting, we must receive the notice no later than the close of business on
the later of the 90th day prior to our 2020 annual meeting or the 10th day following the day on which public
announcement of the date of such annual meeting is first made.
• A stockholder's submission must include certain specified information concerning the proposal or nominee, as
the case may be, and information as to the stockholder's ownership of our common stock. Proposals or
nominations not meeting these requirements will not be considered at our 2020 annual meeting.
•
If a stockholder does not comply with the requirements of this advance notice provision, the proxies may
exercise discretionary voting authority under proxies it solicits to vote in accordance with its best judgment
on any such proposal or nomination submitted by a stockholder.
58
Table of Contents
Proxy Access
Under our amended Bylaws, a stockholder (or a group of not more than 20 stockholders) that has held at least 3% of
our outstanding common stock continuously for at least three years may nominate and include in our proxy materials for our
2020 annual meeting (i) one director nominee if the number of directors to be elected at the annual meeting is seven or less, and
(ii) if the number of directors to be elected at the annual meeting is greater than seven, director nominees constituting up to the
greater of 20% of the Board or two directors, provided in each case that the requirements set forth in the Bylaws are satisfied.
To utilize such “proxy access” nomination process, among other things, the electing stockholder(s) and proposed nominee(s)
must comply with the detailed requirements set forth in our Bylaws, including the provision of the proposing stockholder
information, various other required information, representations, undertakings, agreements and other requirements as set forth
in the Bylaws and as required by law. One such requirement is that the nomination(s) must be received in a timely manner
between 120 days and 150 days prior to the anniversary of the date our proxy statement was first sent to stockholders in
connection with the last annual meeting, which for our proxy materials for the 2020 annual meeting would be no earlier than
February 16, 2020 and no later than March 17, 2020.
The description of certain provisions of the Bylaws above is intended as a summary and is qualified in its entirety by
reference to the relevant Bylaw provisions regarding the requirements for making stockholder proposals and nominating
director candidates. To make any submission or to obtain additional information as to the proper form and content of
submissions, stockholders should contact our Secretary in writing at 2355 West Chandler Boulevard, Chandler, Arizona
85224-6199.
Householding of Annual Meeting Materials
Some brokers and other nominee record holders may be participating in the practice of "householding" proxy
statements and annual reports. This means that only one copy of our proxy statement and annual report may have been sent to
multiple stockholders in a stockholder's household. Additionally, you may have notified us that multiple stockholders share an
address and thus you requested to receive only one copy of our proxy statement and annual report. While our proxy statement
and 2019 Annual Report are available online (see "Electronic Access to Proxy Statement and Annual Report" on page 3), we
will promptly deliver a separate copy of either document to any stockholder who contacts our investor relations department at
480-792-7761 or by mail addressed to Investor Relations, Microchip Technology Incorporated, 2355 West Chandler Boulevard,
Chandler, Arizona 85224-6199, requesting such copies. If a stockholder is receiving multiple copies of our proxy statement and
annual report at the stockholder's household and would like to receive a single copy of the proxy statement and annual report
for a stockholder's household in the future, stockholders should contact their broker, or other nominee record holder to request
mailing of a single copy of the proxy statement and annual report. Stockholders receiving multiple copies of these documents
directly from us, and who would like to receive single copies in the future, should contact our investor relations department to
make such a request.
Date of Proxy Statement
The date of this proxy statement is July 15, 2019.
59
Table of Contents
APPENDIX A
RULES OF THE
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
FOR GRANTS OF RESTRICTED STOCK UNIT AWARDS
IN FRANCE
1.
Introduction.
(a)
The Board of Directors (the “Board”) of Microchip Technology Incorporated (the “Company”) has established
the 2004 Equity Incentive Plan (as amended and restated on May 21, 2019) (the “Plan”), as set forth in Appendix 1, for the benefit
of certain employees of the Company and its affiliates, including its French affiliates (each a “French Entity” and collectively
the “French Entities”), of which the Company holds directly or indirectly at least 10% of the outstanding share capital.
(b)
Section 4 of the Plan authorizes Board or a committee appointed by the Board (the "Committee") administering
the Plan to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-
plans.
(c)
The Committee has determined that it is advisable to establish specific rules for the purpose of permitting
Restricted Stock Units (“RSUs”) granted to employees of a French Entity to qualify for the specific tax and social security treatment
available for such grants in France. The Committee, therefore, intends to establish a sub-plan of the Plan (the “French Sub-Plan”)
for the purpose of granting RSUs that qualify for the specific tax and social security treatment in France applicable to shares
granted for no consideration under Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended (the
“French-Qualified Restricted Stock Units” or "Qualified Units"), to qualifying employees of a French Entity who are residents
in France for French tax purposes and/or subject to the French social security regime (the “French Participants”).
Under the French Sub-Plan, French Participants will be granted RSUs only as defined in Section 2(d) hereunder. The provisions
of the Plan permitting the grant of Nonstatutory Stock Options, Stock Appreciation Rights, Deferred Stock Units, Restricted Stock,
Performance Shares and Performance Units are not applicable to grants made under the French Sub-Plan.
2.
Definitions.
Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan. In addition, the terms set forth below
shall have the following meanings for purposes of grants made under the French Sub-Plan:
(a)
The term “Award Agreement” shall mean the written or electronic agreement, contract or other instrument or
document evidencing the Qualified Units and setting forth the applicable terms and conditions. In connection with the foregoing,
the Award Agreement may, but need not, be executed or acknowledged by the Company and/or the French Participant.
(b)
The term “Closed Period” shall be as provided for by Section L. 225-197-1 of the French Commercial Code,
as amended, and as interpreted by the French administrative guidelines, and shall mean:
(i)
ten quotation days preceding and three quotation days following the disclosure to the public of the
consolidated financial statements or the annual statements of the Company; or
(ii)
any period during which the corporate management of the Company possesses confidential information
which could, if disclosed to the public, significantly impact the quotation of the shares of Common Stock, until ten quotation days
after the day such information is disclosed to the public.
If the French Commercial Code is amended after adoption of this French Sub-Plan to modify the definition and/or the applicability
of the Closed Periods to Qualified Units, such amendments shall become applicable to any Qualified Units granted under the
French Sub-Plan, to the extent required or permitted by French law.
A-1
Table of Contents
(c)
The term “Disability” means disability as defined under categories 2 and 3 of Section L. 341-4 of the French
Social Security Code, as amended.
(d)
The term “Restricted Stock Unit” or “RSU” shall mean a promise by the Company to issue, in the future, one
share of Common Stock for each RSU granted to a French Participant, subject to specific terms and conditions, restrictions and
vesting requirements. RSUs granted under the French Sub-Plan will not give rise to dividends.
(e)
The term “Vesting Date” shall mean the date on which the French Participants are entitled to receive the shares
of Common Stock underlying the Qualified Units. The Committee may provide in the applicable award agreement that shares of
Common Stock underlying the Qualified Units will be issued only on a date occurring after the Vesting Date.
3.
Eligibility to Participate.
(a)
Subject to Section 3(c) below, any French Participant who, on the date of grant and to the extent required under
French law, is either employed under the terms and conditions of an employment contract (“contrat de travail”) with a French
Entity or who is a corporate officer of a French Entity (subject to Section 3(b) below), shall be eligible to receive, at the discretion
of the Committee, Qualified Units under the French Sub-Plan provided he or she also satisfies the eligibility conditions of Section
5 of the Plan.
(b)
Qualified Units may not be issued to corporate officers of a French Entity, other than the managing directors
(i.e., Président du Conseil d’Administration, Directeur Général, Directeur Général Délégué, Membre du Directoire, Gérant de
Sociétés par actions), unless the corporate officer is employed by a French Entity, as defined by French law and is otherwise
eligible to receive RSUs under Section 5 of the Plan.
(c)
Qualified Units may not be issued under the French Sub Plan to employees or corporate officers owning more
than ten percent (10%) of the Company’s share capital or to individuals other than employees and corporate officers of a French
Entity. Grants of Qualified Units under the French Sub-Plan shall not result in any French Participant owning more than ten percent
(10%) of the Company’s share capital.
(d)
The aggregate number of shares of Common Stock underlying Qualified Units shall not exceed 10% of the
Company’s share capital.
4.
Conditions of the Qualified Units.
(a)
Vesting of Qualified Units. The first Vesting Date of RSUs shall not occur prior to the expiration of the minimum
mandatory vesting period applicable to Qualified Units under Section L. 225-197-1 of the French Commercial Code, as amended,
the relevant sections of the French Tax Code or the French Social Security Code, as amended. However, notwithstanding the
above, in the event of the death or disability of a French Participant, all of his or her outstanding Qualified Units shall vest and
the shares of Common Stock underlying the Qualified Units shall become issuable as set forth in Section 5 of the French Sub-
Plan.
(b)
Holding of Shares of Common Stock. The shares of Common Stock issued upon vesting of the Qualified Units
granted to French Participants may be subject to a minimum mandatory holding period pursuant to Section L. 225-197-1 of the
French Commercial Code, as amended, or the relevant sections of the French Tax Code and French Social Security Code, as
amended, to benefit from the specific French tax and social security regime, even if the French Participant is no longer an employee
or corporate officer of a French Entity, the Company or any other affiliate.
In addition to this restriction upon the sale or transfer of shares of Common Stock issued to French Participants, the shares of
Common Stock may not be sold or transferred during a Closed Period, so long as Closed Periods are applicable to shares of
Common Stock underlying Qualified Units.
(c)
Managing Director. To the extent required for Qualified Units granted by the Company, specific holding periods
for the shares of Common Stock issued pursuant to the Qualified Units shall be imposed in the relevant Award Agreement for
French Participants who qualify as a managing director of the French Entity under French law (as defined in Section 3(b) above)
if such individual is receiving the Qualified Units in this capacity.
A-2
Table of Contents
(d)
French Participant’s Account. The shares of Common Stock issued to a French Participant pursuant to Qualified
Units shall be recorded in the name of the French Participant in an account with the Company, a broker, or in such other manner
as the Company may otherwise determine to ensure compliance with applicable law, including any required holding periods.
5.
Death and Disability.
In the event of termination of a French Participant’s status as a French Participant due to death, all Qualified Units held by the
French Participant at the time of his or her death (whether vested or unvested at the time of death) shall immediately become
transferable to the French Participant’s heirs. The Company shall issue the underlying shares of Common Stock to the French
Participant’s heirs only if the heirs request such issuance within six months following the death of the French Participant. If shares
are not requested by the heirs within such six-month period, any outstanding Qualified Units will be forfeited. The French
Participant’s heirs shall not be subject to the minimum mandatory holding period set forth in Section 4(b) of this French Sub-Plan,
if any.
If a French Participant ceases to be employed by the Company or a French entity by reason of his or her disability, Qualified Units
then outstanding but not previously vested, will vest and become non-forfeitable immediately, and such Qualified Units, together
with any then outstanding Qualified Units that previously vested, will be settled as promptly as practicable. The French Participant
shall not be subject to the minimum mandatory holding period set forth in Section 4(b) above, if any.
6.
Adjustments upon certain Changes affecting the Company.
In the event of a corporate transaction as set forth in Section 2(g) or 19 of the Plan, adjustments to the terms and conditions of the
Qualified Units or underlying shares of Common Stock may be made only in accordance with the Plan and pursuant to applicable
French legal and tax rules. Nevertheless, the Committee, at its discretion, may determine to make adjustments in the case of a
transaction for which adjustments are not authorized under French law, in which case, the RSUs may no longer qualify as Qualified
Units.
Assumption or substitution of the RSUs in the case of a corporate transaction as well as an acceleration of vesting or the holding
period, if any, or any other mechanism implemented upon a corporate transaction, or in any other event, may result in the RSUs
no longer being eligible for the specific French tax and social security treatment.
7.
Disqualification of Qualified Units.
If the terms and conditions of the outstanding Qualified Units are modified or adjusted due to any requirements under the applicable
laws of incorporation of the Company, or by decision of the Company’s shareholders, the Board or the Committee, the RSUs may
no longer qualify as Qualified Units. If the RSUs no longer qualify as Qualified Units, the Board or Committee may, in its sole
discretion, determine to lift, shorten or terminate certain restrictions applicable to the vesting or to the transfer of the shares of
Common Stock underlying the RSUs which had been imposed under the French Sub-Plan and/or in the Award Agreement delivered
to the French Participant in order to achieve the specific tax treatment for Qualified Units.
In the event that any RSUs or underlying shares of Common Stock no longer qualify for the specific tax treatment pursuant to
Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended, the holder of such RSUs shall be ultimately
responsible for all taxes and/or social security contributions that he or she is required to pay in connection with such RSUs or
underlying shares of Common Stock.
8.
Employment Rights.
The adoption of this French Sub-Plan shall not confer upon the French Participants or any employee of a French Entity, any
employment rights and shall not be construed as a part of any employment contracts that a French Entity has with its employees
or create any employment relationship with the Company.
9.
Non-Transferability.
Except in the case of death and disability, the Qualified Units shall not be assigned or transferred to any third party. In addition,
the Qualified Units may vest only for the benefit of the French Participant during his or her lifetime.
A-3
Table of Contents
10.
Interpretations.
It is intended that RSUs granted under the French Sub-Plan shall qualify for the specific tax and social security treatment applicable
to RSUs granted under Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended, and in accordance
with the relevant provisions set forth by French tax and social security laws. The terms of the French Sub-Plan shall be interpreted
accordingly and in accordance with the relevant guidelines published by French tax and social security administrations and subject
to the fulfillment of legal, tax and reporting obligations, if applicable. However, certain corporate transactions, certain modifications
or changes may impact the qualification of the RSUs and underlying shares of Common Stock for the specific regime in France.
11.
Amendments.
Subject to the terms of the Plan, the Committee reserves the right to amend or terminate the French Sub-Plan at any time in
accordance with applicable French law.
12.
Effective Date and Term of the French Sub-Plan.
The French Sub-Plan is adopted and effective for grants made on or after September 2, 2019 pursuant to authorization by the
Company’s shareholders.
A-4
Table of Contents
Appendix 1
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
As Amended and Restated on May 21, 2019
1.
Purposes of the Plan. The purposes of this 2004 Equity Incentive Plan are:
•
•
•
to attract and retain the best available personnel,
to provide additional incentive to Service Providers, and
to promote the success of the Company’s business.
Awards granted under the Plan may be Nonstatutory Stock Options, Restricted Stock, Stock Appreciation Rights,
Performance Shares, Performance Units or Deferred Stock Units, as determined by the Administrator at the time of grant.
2.
Definitions. As used herein, the following definitions shall apply:
(a)
accordance with Section 4 of the Plan.
“Administrator” means the Board or any of its Committees as shall be administering the Plan, in
(b)
“Applicable Laws” means the legal requirements relating to the administration of equity compensation
plans under state and federal corporate and securities laws and the Code.
(c)
“Award” means, individually or collectively, a grant under the Plan of Options, Restricted Stock, Stock
Appreciation Rights, Performance Shares, Performance Units or Deferred Stock Units.
(d)
“Award Agreement” means the written agreement setting forth the terms and provisions applicable to
each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.
(e)
“Awarded Stock” means the Common Stock subject to an Award.
(f)
“Board” means the Board of Directors of the Company.
(g)
“Change of Control” means the occurrence of any of the following events, in one or a series of related
transactions:
(1)
any “person,” as such term is used in Sections 13(d) and 14(d) of the Exchange Act, other
than the Company, a subsidiary of the Company or a Company employee benefit plan, including any trustee of such plan acting
as trustee, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company’s then
outstanding securities entitled to vote generally in the election of directors? or
(2)
a merger or consolidation of the Company or any direct or indirect subsidiary of the Company
with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting
securities of the Company or such surviving entity outstanding immediately after such merger or consolidation; or
(3)
the sale or disposition by the Company of all or substantially all of the Company’s assets; or
(4)
a change in the composition of the Board, as a result of which fewer than a majority of the
directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are Directors as of the date this
Plan is approved by the Board, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a
A-1-1
Table of Contents
majority of the Incumbent Directors and whose election or nomination was not in connection with any transaction described in
(1) or (2) above or in connection with an actual or threatened proxy contest relating to the election of directors of the Company.
(h)
“Code” means the Internal Revenue Code of 1986, as amended.
(i)
(j)
“Committee” means a committee appointed by the Board in accordance with Section 4 of the Plan.
“Common Stock” means the common stock of the Company.
(k)
“Company” means Microchip Technology Incorporated.
(l)
“Consultant” means any person, including an advisor, engaged by the Company or a Parent or
Subsidiary to render services and who is compensated for such services. The term Consultant shall not include Directors who
are compensated by the Company only for their service as Directors.
(m)
“Deferred Stock Unit” means a deferred stock unit Award granted to a Participant pursuant to
Section 13.
(n)
“Director” means a member of the Board.
(o)
“Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code.
(p)
“Employee” means any person, including Officers and Directors, employed by the Company or any
Parent or Subsidiary of the Company. A Service Provider shall not cease to be an Employee in the case of (i) any leave of
absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, any
Subsidiary, or any successor. Neither service as a Director nor payment of a director’s fee by the Company shall be sufficient
to constitute “employment” by the Company.
(q)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
(r)
“Fair Market Value” means, as of any date, the value of Common Stock determined as follows:
(1)
If the Common Stock is listed on any established stock exchange or a national market system,
including without limitation the Nasdaq National Market of the National Association of Securities Dealers, Inc. Automated
Quotation (“Nasdaq”) System, the Fair Market Value of a Share of Common Stock shall be the closing sales price for such
stock (or the closing bid, if no sales were reported) as quoted on such system or exchange (or the exchange with the greatest
volume of trading in Common Stock) on the day of determination, as reported in The Wall Street Journal or such other source
as the Administrator deems reliable;
(2)
If the Common Stock is quoted on the Nasdaq System (but not on the Nasdaq National
Market thereof) or is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market
Value of a Share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the
last market trading day prior to the day of determination, as reported in The Wall Street Journal or such other source as the
Administrator deems reliable; or
determined in good faith by the Administrator.
(3)
In the absence of an established market for the Common Stock, the Fair Market Value shall be
(s)
“Fiscal Year” means a fiscal year of the Company.
(t)
“Fiscal Quarter” means a fiscal quarter of the Company.
(u)
“Non-Employee Director” means a member of the Board who is not an Employee.
(v)
“Nonstatutory Stock Option” means an Option not intended to qualify as an incentive stock option
under Section 422 of the Code and regulations promulgated thereunder.
(w)
“Notice of Grant” means a written or electronic notice evidencing certain terms and conditions of an
individual Award. The Notice of Grant is part of the Option Agreement.
A-1-2
Table of Contents
(x)
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the
Exchange Act and the rules and regulations promulgated thereunder.
(y)
“Option” means a stock option granted pursuant to the Plan.
(z)
“Option Agreement” means a written or electronic agreement between the Company and a Participant
evidencing the terms and conditions of an individual Option grant. The Option Agreement is subject to the terms and
conditions of the Plan.
(aa)
“Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Section 424(e)
of the Code.
Section 11.
(bb) “Participant” means the holder of an outstanding Award granted under the Plan.
(cc)
“Performance Share” means a performance share Award granted to a Participant pursuant to
(dd) “Performance Unit” means a performance unit Award granted to a Participant pursuant to Section 12.
(ee)
“Plan” means this 2004 Equity Incentive Plan, as amended and restated.
(ff)
“Restricted Stock” means Shares granted pursuant to Section 10 of the Plan.
(gg) “Rule 16b-3” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when
discretion is being exercised with respect to the Plan.
(hh) “Section 16(b)” means Section 16(b) of the Exchange Act, as amended.
(ii)
“Service Provider” means an Employee, Consultant or Non-Employee Director.
(jj)
“Share” means a share of the Common Stock, as adjusted in accordance with Section 19 of the Plan.
(kk) “Stock Appreciation Right” or “SAR” means an Award granted pursuant to Section 9 of the Plan.
(ll)
“Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing, as defined in
Section 424(f) of the Code.
3.
Stock Subject to the Plan. Subject to the provisions of Section 19 of the Plan, the maximum aggregate
number of Shares which may be issued under the Plan is 36,300,000 Shares plus any Shares subject to any outstanding options
under the Company’s 1993 or 1997 Nonstatutory Stock Option Plans that expire unexercised, up to a maximum of an additional
5,000,000 Shares.
The Shares may be authorized, but unissued, or reacquired Common Stock.
If an Award expires or becomes unexercisable without having been exercised in full, or with respect to Restricted
Stock, Performance Shares, Performance Units or Deferred Stock Units, is forfeited to or repurchased by the Company, the
unpurchased Shares (or for Awards other than Options and SARs, the forfeited or repurchased Shares) which were subject
thereto shall become available for future grant or sale under the Plan (unless the Plan has terminated). With respect to SARs,
the gross Shares issued (i.e., Shares actually issued pursuant to a Stock Appreciation Right, as well as the Shares that represent
payment of the exercise price and any applicable tax withholdings) pursuant to a SAR will cease to be available under the Plan.
Shares that have actually been issued under the Plan under any Award shall not be returned to the Plan and shall not become
available for future distribution under the Plan; provided, however, that if Shares of Restricted Stock, Performance Shares,
Performance Units or Deferred Stock Units are repurchased by the Company at their original purchase price or are forfeited to
the Company, such Shares shall become available for future grant under the Plan. Shares used to pay the exercise price or
purchase price, if applicable, of an Award shall become available for future grant or sale under the Plan. To the extent an
Award under the Plan is paid out in cash rather than stock, such cash payment shall not result in reducing the number of Shares
available for issuance under the Plan.
A-1-3
Table of Contents
4.
Administration of the Plan.
(a)
Procedure.
(1) Multiple Administrative Bodies. The Plan may be administered by different Committees with
respect to different groups of Service Providers.
(2) Reserved.
(3) Rule 16b-3. To the extent desirable to qualify transactions hereunder as exempt under
Rule 16b-3, the transactions contemplated hereunder shall be structured to satisfy the requirements for exemption under
Rule 16b-3.
(A) the Board or (B) a Committee, which committee shall be constituted to satisfy Applicable Laws.
(4) Other Administration. Other than as provided above, the Plan shall be administered by
(b)
Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee,
subject to the specific duties delegated by the Board to such Committee, the Administrator shall have the authority, in its
discretion:
the Plan;
(1)
to determine the Fair Market Value of the Common Stock, in accordance with Section 2(u) of
automatic grants to Non-Employee Directors provided for in Section 17 of the Plan);
(2)
to select the Service Providers to whom Awards may be granted hereunder (other than the
(3)
to determine whether and to what extent Awards or any combination thereof, are granted
under the Plan;
(4)
to determine the number of shares of Common Stock or equivalent units to be covered by
each Award granted under the Plan;
(5)
to approve forms of agreement for use under the Plan;
(6)
to determine the terms and conditions, not inconsistent with the terms of the Plan, of any
award granted under the Plan. Such terms and conditions include, but are not limited to, the exercise price, the time or times
when Options or SARs may be exercised or other Awards vest (which may be based on performance criteria), any vesting
acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the shares of Common
Stock relating thereto, based in each case on such factors as the Administrator, in its sole discretion, shall determine;
(7)
to construe and interpret the terms of the Plan and Awards;
regulations relating to sub-plans established for the purpose of qualifying for preferred tax treatment under foreign tax laws;
(8)
to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and
(9)
to modify or amend each Award (subject to Sections 8(c), 9(b) and 21(c) of the Plan),
including the discretionary authority to extend the post-termination exercisability period of Options and SARs longer than is
otherwise provided for in the Plan;
effect the grant of an Award previously granted by the Administrator;
(10)
to authorize any person to execute on behalf of the Company any instrument required to
(11)
to allow Participants to satisfy withholding tax obligations by electing to have the Company
withhold from the Shares or cash to be issued upon exercise or vesting of an Award (or distribution of a Deferred Stock Unit)
that number of Shares or cash having a Fair Market Value equal to the minimum amount required to be withheld (but no more).
The Fair Market Value of any Shares to be withheld shall be determined on the date that the amount of tax to be withheld is to
be determined. All elections by a Participant to have Shares or cash withheld for this purpose shall be made in such form and
under such conditions as the Administrator may deem necessary or advisable;
A-1-4
Table of Contents
(12)
to determine the terms and restrictions applicable to Awards; and
(13)
to make all other determinations deemed necessary or advisable for administering the Plan.
(c)
Effect of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations
shall be final and binding on all Participants and any other holders of Awards.
5.
Eligibility. Restricted Stock, Performance Shares, Performance Units, Stock Appreciation Rights, Deferred
Stock Units and Nonstatutory Stock Options may be granted to Service Providers. Non-Employee Directors shall only receive
Awards pursuant to Section 17 of the Plan.
6.
Limitations.
(a) Nonstatutory Stock Option. Each Option shall be designated in the Notice of Grant as a Nonstatutory
Stock Option.
(b) No Employment Rights. Neither the Plan nor any Award shall confer upon a Participant any right with
respect to continuing the Participant’s employment with the Company or its Subsidiaries, nor shall they interfere in any way
with the Participant’s right or the Company’s or Subsidiary’s right, as the case may be, to terminate such employment at any
time, with or without cause or notice.
(c) Annual Limitations. The following limitations shall apply to grants of Options and Stock Appreciation
Rights to Participants:
(1) No Participant shall be granted, in any Fiscal Year, Options and Stock Appreciation Rights to
purchase more than 1,500,000 Shares; provided, however, that such limit shall be 4,000,000 Shares in the Participant’s first
Fiscal Year of Company service.
(2)
the Company’s capitalization as described in Section 19(a).
The foregoing limitations shall be adjusted proportionately in connection with any change in
(d) Minimum Vesting Requirements.
(1) General. Except as specified in Section 6(d)(2), Awards will vest no earlier than the one (1)-
year anniversary of such Award’s grant date (except if accelerated pursuant to a Change of Control or a termination of the
Participant’s status as a Service Provider due to a Participant’s death, or a Participant’s Disability) (each, an “Acceleration
Event”).
(2)
Exception. Awards may be granted to any Service Provider without regard to the minimum
vesting requirements set forth in Section 6(d)(1) if the Shares subject to such Awards would not result in more than five percent
(5%) of the maximum aggregate number of Shares reserved for issuance pursuant to all outstanding Awards granted under the
Plan (the “5% Limit”). Any Awards that have their vesting discretionarily accelerated (except if accelerated pursuant to an
Acceleration Event) are subject to the 5% Limit. For purposes of clarification, the Administrator may accelerate the vesting of
any Awards pursuant to an Acceleration Event without such vesting acceleration counting toward the 5% Limit. The 5% Limit
applies in the aggregate to Awards that do not satisfy the minimum vesting requirements as set forth in Section 6(d)(1) and to
the discretionary vesting acceleration of Awards specified in this Section 6(d)(2).
7.
Term of Plan. The Plan is effective as of October 1, 2004 (the “Effective Date”). It shall continue in effect
until May 22, 2022, unless sooner terminated under Section 21 of the Plan.
8.
Stock Options.
(a)
Term. The term of each Option shall be stated in the Notice of Grant; provided, however, that the term
shall be ten (10) years from the date of grant or such shorter term as may be provided in the Notice of Grant.
A-1-5
Table of Contents
(b) Option Exercise Price. The per share exercise price for the Shares to be issued pursuant to exercise of
an Option shall be determined by the Administrator and shall be no less than 100% of the Fair Market Value per share on the
date of grant.
(c) No Repricing. The exercise price for an Option may not be reduced. This shall include, without
limitation, a repricing of the Option as well as an Option exchange program whereby the Participant agrees to cancel an
existing Option in exchange for an Option, SAR, other Award or cash.
(d) Waiting Period and Exercise Dates. At the time an Option is granted, the Administrator shall fix the
period within which the Option may be exercised and shall determine any conditions which must be satisfied before the Option
may be exercised. In so doing, the Administrator may specify that an Option may not be exercised until the completion of a
service period.
(e)
Form of Consideration. The Administrator shall determine the acceptable form of consideration for
exercising an Option, including the method of payment. Subject to Applicable Laws, such consideration may consist entirely
of:
(1)
cash;
(2)
check;
(3)
other Shares which (A) in the case of Shares acquired upon exercise of an option have been
owned by the Participant for more than six months on the date of surrender, and (B) have a Fair Market Value on the date of
surrender equal to the aggregate exercise price of the Shares as to which said Option shall be exercised;
delivery of a properly executed exercise notice together with such other documentation as the
Administrator and the broker, if applicable, shall require to effect an exercise of the Option and delivery to the Company of the
sale proceeds required to pay the exercise price?
(4)
(5)
any combination of the foregoing methods of payment? or
(6)
permitted by Applicable Laws.
such other consideration and method of payment for the issuance of Shares to the extent
(f)
Exercise of Option.
Any Option granted hereunder shall be exercisable according to the terms of the Plan and at such times and under such
conditions as determined by the Administrator and set forth in the Option Agreement.
An Option may not be exercised for a fraction of a Share.
An Option shall be deemed exercised when the Company receives: (i) written or electronic notice of exercise (in
accordance with the Option Agreement) from the person entitled to exercise the Option, and (ii) full payment for the Shares
with respect to which the Option is exercised. Full payment may consist of any consideration and method of payment
authorized by the Administrator and permitted by the Option Agreement and the Plan. Shares issued upon exercise of an
Option shall be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or
her spouse. Until the stock certificate evidencing such Shares is issued (as evidenced by the appropriate entry on the books of
the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as
a stockholder shall exist with respect to the optioned stock, notwithstanding the exercise of the Option. The Company shall
issue (or cause to be issued) such stock certificate promptly after the Option is exercised. No adjustment will be made for a
dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in
Section 19 of the Plan.
Exercising an Option in any manner shall decrease the number of Shares thereafter available for sale under the Option,
by the number of Shares as to which the Option is exercised.
A-1-6
Table of Contents
(g)
Termination of Relationship as a Service Provider. If a Participant ceases to be a Service Provider,
other than upon the Participant’s misconduct, death or Disability, the Participant may exercise his or her Option within such
period of time as is specified in the Option Agreement to the extent that the Option is vested on the date of termination (but in
no event later than the expiration of the term of such Option as set forth in the Option Agreement). In the absence of a
specified time in the Option Agreement, the Option shall remain exercisable for three (3) months following the Participant’s
termination. If, on the date of termination, the Participant is not vested as to his or her entire Option, the Shares covered by the
unvested portion of the Option shall revert to the Plan. If, after termination, the Participant does not exercise his or her Option
within the time specified by the Administrator, the Option shall terminate, and the Shares covered by such Option shall revert to
the Plan.
(h) Disability. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability, the
Participant may exercise his or her Option within such period of time as is specified in the Option Agreement to the extent the
Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in
the Option Agreement). In the absence of a specified time in the Option Agreement, the Option shall remain exercisable for six
(6) months following the Participant’s termination. If, on the date of termination, the Participant is not vested as to his or her
entire Option, the Shares covered by the unvested portion of the Option shall revert to the Plan. If, after termination, the
Participant does not exercise his or her Option within the time specified herein, the Option shall terminate, and the Shares
covered by such Option shall revert to the Plan.
(i)
Death of Participant. If a Participant dies while a Service Provider, the Option may be exercised
following the Participant’s death within such period of time as is specified in the Option Agreement (but in no event may the
option be exercised later than the expiration of the term of such Option as set forth in the Option Agreement), by the personal
representative of the Participant’s estate, provided such representative has been designated prior to Participant’s death in a form
acceptable to the Administrator. If no such representative has been designated by the Participant, then such Option may be
exercised by the person(s) to whom the Option is transferred pursuant to the Participant’s will or in accordance with the laws of
descent and distribution. In the absence of a specified time in the Option Agreement, the Option shall remain exercisable for
twelve (12) months following Participant’s death. If the Option is not so exercised within the time specified herein, the Option
shall terminate, and the Shares covered by such Option shall revert to the Plan.
9.
Stock Appreciation Rights.
(a) Grant of SARs. Subject to the terms and conditions of the Plan, SARs may be granted to Participants
at any time and from time to time as shall be determined by the Administrator, in its sole discretion. The Administrator shall
have complete discretion to determine the number of SARs granted to any Participant.
(b)
Exercise Price and Other Terms. Subject to Section 4(c) of the Plan, the Administrator, subject to the
provisions of the Plan, shall have complete discretion to determine the terms and conditions of SARs granted under the Plan;
provided, however, that no SAR may have a term of more than ten (10) years from the date of grant. The per share exercise
price for the Shares or cash to be issued pursuant to exercise of an SAR shall be determined by the Administrator and shall be
no less than 100% of the Fair Market Value per share on the date of grant. The exercise price may not be reduced. This shall
include, without limitation, a repricing of the SAR as well as an SAR exchange program whereby the Participant agrees to
cancel an existing SAR in exchange for an Option, SAR, other Award or cash.
(c)
Payment of SAR Amount. Upon exercise of an SAR, a Participant shall be entitled to receive payment
from the Company in an amount determined by multiplying:
(1)
the difference between the Fair Market Value of a Share on the date of exercise over the
exercise price; times
(2)
the number of Shares with respect to which the SAR is exercised.
evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no
With respect to SARs settled in Shares, until the stock certificate evidencing such Shares is issued (as
A-1-7
Table of Contents
right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the SAR, notwithstanding the
exercise of the SAR.
(d)
in cash, Shares or a combination thereof.
Payment Upon Exercise of SAR. At the discretion of the Administrator, payment for an SAR may be
(e)
SAR Agreement. Each SAR grant shall be evidenced by an Award Agreement that shall specify the
exercise price, the term of the SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its
sole discretion, shall determine.
(f)
Expiration of SARs. An SAR granted under the Plan shall expire upon the date determined by the
Administrator, in its sole discretion, and set forth in the Award Agreement.
(g)
Termination of Relationship as a Service Provider. If a Participant ceases to be a Service Provider,
other than upon the Participant’s death or Disability termination, the Participant may exercise his or her SAR within such
period of time as is specified in the SAR Agreement to the extent that the SAR is vested on the date of termination (but in no
event later than the expiration of the term of such SAR as set forth in the SAR Agreement). In the absence of a specified time
in the SAR Agreement, the SAR shall remain exercisable for three (3) months following the Participant’s termination. If, on
the date of termination, the Participant is not vested as to his or her entire SAR, the Shares covered by the unvested portion of
the SAR shall revert to the Plan. If, after termination, the Participant does not exercise his or her SAR within the time specified
by the Administrator, the SAR shall terminate, and the Shares covered by such SAR shall revert to the Plan.
(h) Disability. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability, the
Participant may exercise his or her SAR within such period of time as is specified in the SAR Agreement to the extent the SAR
is vested on the date of termination (but in no event later than the expiration of the term of such SAR as set forth in the SAR
Agreement). In the absence of a specified time in the SAR Agreement, the SAR shall remain exercisable for six (6) months
following the Participant’s termination. If, on the date of termination, the Participant is not vested as to his or her entire SAR,
the Shares covered by the unvested portion of the SAR shall revert to the Plan. If, after termination, the Participant does not
exercise his or her SAR within the time specified herein, the SAR shall terminate, and the Shares covered by such SAR shall
revert to the Plan.
(i)
Death of Participant. If a Participant dies while a Service Provider, the SAR may be exercised
following the Participant’s death within such period of time as is specified in the SAR Agreement (but in no event may the
SAR be exercised later than the expiration of the term of such SAR as set forth in the SAR Agreement), by the personal
representative of the Participant’s estate, provided such representative has been designated prior to Participant’s death in a form
acceptable to the Administrator. If no such representative has been designated by the Participant, then such SAR may be
exercised by the person(s) to whom the SAR is transferred pursuant to the Participant’s will or in accordance with the laws of
descent and distribution. In the absence of a specified time in the SAR Agreement, the SAR shall remain exercisable for twelve
(12) months following Participant’s death. If the SAR is not so exercised within the time specified herein, the SAR shall
terminate, and the Shares covered by such SAR shall revert to the Plan.
10.
Restricted Stock.
(a) Grant of Restricted Stock. Subject to the terms and conditions of the Plan, Restricted Stock may be
granted to Participants at any time as shall be determined by the Administrator, in its sole discretion. The Administrator shall
have complete discretion to determine (i) the number of Shares subject to a Restricted Stock award granted to any Participant
(provided that during any Fiscal Year, no Participant shall be granted more than 300,000 Shares of Restricted Stock)? provided,
however, that such limit shall be 750,000 Shares in the Participant’s first Fiscal Year of Company service, and (ii) the
conditions that must be satisfied, which typically will be based principally or solely on continued provision of services but may
include a performance-based component, upon which is conditioned the grant or vesting of Restricted Stock.
(b) Restricted Stock Units. Restricted Stock may be granted in the form of Restricted Stock or units to
acquire Shares. Each such unit shall be the equivalent of one Share for purposes of determining the number of Shares subject
A-1-8
Table of Contents
to an Award. With respect to the units to acquire Shares, until the Shares are issued, no right to vote or receive dividends or any
other rights as a stockholder shall exist.
(c) Other Terms. The Administrator, subject to the provisions of the Plan, shall have complete discretion
to determine the terms and conditions of Restricted Stock granted under the Plan. Restricted Stock grants shall be subject to
the terms, conditions, and restrictions determined by the Administrator at the time the stock is awarded. The Administrator may
require the recipient to sign a Restricted Stock Award agreement as a condition of the award. Any certificates representing the
Shares of stock awarded shall bear such legends as shall be determined by the Administrator.
(d) Restricted Stock Award Agreement. Each Restricted Stock grant shall be evidenced by an agreement
that shall specify the purchase price (if any) and such other terms and conditions as the Administrator, in its sole discretion,
shall determine; provided, however, that if the Restricted Stock grant has a purchase price, such purchase price must be paid no
more than ten (10) years following the date of grant.
(e) Dividends and Other Distributions. Until the restrictions set forth in the Restricted Stock Award
agreement have lapsed, Service Providers holding Shares of Restricted Stock will not be entitled to receive dividends and other
distributions paid with respect to such Shares. However, to the extent the restrictions in the Restricted Stock Award have
lapsed, Service Providers holding Shares of Restricted Stock will be entitled to receive dividends, even if there are other
restrictions on the Shares of Restricted Stock (e.g., a lock up period due to a public offering or a restriction due to possession of
material nonpublic information).
11.
Performance Shares.
(a) Grant of Performance Shares. Subject to the terms and conditions of the Plan, Performance Shares
may be granted to Participants at any time as shall be determined by the Administrator, in its sole discretion. The Administrator
shall have complete discretion to determine (i) the number of Shares subject to a Performance Share award granted to any
Participant (provided that during any Fiscal Year, no Participant shall be granted more than 300,000 units of Performance
Shares); provided, however, that such limit shall be 750,000 Shares in the Participant’s first Fiscal Year of Company service,
and (ii) the conditions that must be satisfied, which typically will be based principally or solely on achievement of performance
milestones but may include a service-based component, upon which is conditioned the grant or vesting of Performance Shares.
Performance Shares shall be granted in the form of units to acquire Shares. Each such unit shall be the equivalent of one Share
for purposes of determining the number of Shares subject to an Award. Until the Shares are issued, no right to vote or receive
dividends or any other rights as a stockholder shall exist with respect to the units to acquire Shares.
(b) Other Terms. The Administrator, subject to the provisions of the Plan, shall have complete discretion
to determine the terms and conditions of Performance Shares granted under the Plan. Performance Share grants shall be
subject to the terms, conditions, and restrictions determined by the Administrator at the time the stock is awarded, which may
include such performance-based milestones as are determined appropriate by the Administrator. The Administrator may require
the recipient to sign a Performance Shares agreement as a condition of the award. Any certificates representing the Shares of
stock awarded shall bear such legends as shall be determined by the Administrator.
Performance Share Award Agreement. Each Performance Share grant shall be evidenced by an
agreement that shall specify such other terms and conditions as the Administrator, in its sole discretion, shall determine.
(c)
12.
Performance Units.
(a) Grant of Performance Units. Performance Units are similar to Performance Shares, except that they
shall be settled in a cash equivalent to the Fair Market Value of the underlying Shares, determined as of the vesting date.
Subject to the terms and conditions of the Plan, Performance Units may be granted to Participants at any time and from time to
time as shall be determined by the Administrator, in its sole discretion. The Administrator shall have complete discretion to
determine the conditions that must be satisfied, which typically will be based principally or solely on achievement of
performance milestones but may include a service-based component, upon which is conditioned the grant or vesting of
Performance Units. Performance Units shall be granted in the form of units to acquire Shares. Each such unit shall be the cash
A-1-9
Table of Contents
equivalent of one Share of Common Stock. No right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to Performance Units or the cash payable thereunder.
(b) Number of Performance Units. The Administrator will have complete discretion in determining the
number of Performance Units granted to any Participant, provided that during any Fiscal Year, no Participant shall receive
Performance Units having an initial value greater than $1,500,000, provided, however, that such limit shall be $4,000,000 in the
Participant’s first Fiscal Year of Company service.
(c) Other Terms. The Administrator, subject to the provisions of the Plan, shall have complete discretion
to determine the terms and conditions of Performance Units granted under the Plan. Performance Unit grants shall be subject
to the terms, conditions, and restrictions determined by the Administrator at the time the stock is awarded, which may include
such performance-based milestones as are determined appropriate by the Administrator. The Administrator may require the
recipient to sign a Performance Unit agreement as a condition of the award. Any certificates representing the Shares awarded
shall bear such legends as shall be determined by the Administrator.
(d)
Performance Unit Award Agreement. Each Performance Unit grant shall be evidenced by an
agreement that shall specify such terms and conditions as the Administrator, in its sole discretion, shall determine.
13.
Deferred Stock Units.
(a) Description. Deferred Stock Units shall consist of a Restricted Stock, Performance Share or
Performance Unit Award that the Administrator, in its sole discretion permits to be paid out in installments or on a deferred
basis, in accordance with rules and procedures established by the Administrator. Deferred Stock Units shall remain subject to
the claims of the Company’s general creditors until distributed to the Participant.
(b) Annual Limits. Deferred Stock Units shall be subject to the annual limits applicable to the underlying
Restricted Stock, Performance Share or Performance Unit Award.
14.
Death of Participant. In the event that a Participant dies while a Service Provider, then 100% of his or her
Awards shall immediately vest.
15.
Leaves of Absence. Unless the Administrator provides otherwise or as otherwise required by Applicable
Laws, vesting of Awards granted hereunder shall cease commencing on the first day of any unpaid leave of absence and shall
only recommence upon return to active service.
16.
Misconduct. Should (i) the Participant’s service be terminated for misconduct (including, but not limited to,
any act of dishonesty, willful misconduct, fraud or embezzlement), or (ii) the Participant makes any unauthorized use or
disclosure of confidential information or trade secrets of the Company or any Parent or Subsidiary, then in any such event all
outstanding Awards held by the Participant under the Plan shall terminate immediately and cease to be outstanding, including
as to both vested and unvested Awards.
17.
Non-Employee Director Options.
(a)
Initial Grants. Each Non-Employee Director who first becomes a Non-Employee Director on or after
May 5, 2010 (excluding any Non-Employee Director who previously served on the Board), shall be automatically granted that
number of Restricted Stock Units equal to $160,000 divided by the Fair Market Value, rounded down to the nearest whole
Share (the “Initial RSU Grant”), as of the date that the individual first is appointed or elected as a Non-Employee Director. The
Initial RSU Grant will vest in equal 25% annual installments on each of the four anniversaries of the tenth business day of the
second month of the Fiscal Quarter in which the grant is made. All vesting of the Initial RSU Grant is contingent upon the
Non-Employee Director maintaining continued status as a Non-Employee Director through the applicable vesting date.
(b) Annual Grants. On the date of the Company’s annual stockholders’ meeting, each Non-Employee
Director who has served as a Non-Employee Director for at least three months on that date shall be automatically granted that
number of Restricted Stock Units equal to $84,000 (or $123,000 for grants occurring after the Amendment Date) divided by the
Fair Market Value, rounded down to the nearest whole Share (the “Annual RSU Grant”), provided that such Non-Employee
A-1-10
Table of Contents
Director has been elected by the stockholders to serve as a member of the Board at that annual stockholders’ meeting. The
Annual RSU Grant will vest in equal 50% annual installments on each of the two anniversaries of the tenth day of the second
month of the Fiscal Quarter in which the grant is made. All vesting of the Annual RSU Grant is contingent upon the Non-
Employee Director maintaining continued status as a Non-Employee Director through the applicable vesting date.
18.
Non-Transferability of Awards. Unless determined otherwise by the Administrator, an Award may not be
sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or
distribution and may be exercised, during the lifetime of the recipient, only by the recipient. In no event may an Award be
transferred in exchange for consideration. If the Administrator makes an Award transferable, such Award shall contain such
additional terms and conditions as the Administrator deems appropriate.
19.
Adjustments Upon Changes in Capitalization, Dissolution or Liquidation or Change of Control.
(a)
Changes in Capitalization. Subject to any required action by the stockholders of the Company, the
number of shares of Common Stock covered by each outstanding Award, the number of shares of Common Stock which have
been authorized for issuance under the Plan but as to which no Awards have yet been granted or which have been returned to
the Plan upon cancellation or expiration of an Award, as well as the price per share of Common Stock covered by each such
outstanding Award and the Fiscal Year annual share issuance limits under Sections 6(c), 10(a) and 11(a) shall be proportionately
adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse
stock split, stock dividend, combination or reclassification of the Common Stock, or any other increase or decrease in the
number of issued shares of Common Stock effected without receipt of consideration by the Company; provided, however, that
any such change in capitalization shall not affect the number of shares awarded under the automatic grants to Non-Employee
Directors described in Sections 17(a) and (b), and provided that conversion of any convertible securities of the Company shall
not be deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Committee,
whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance by
the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no
adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock subject to an
Award.
(b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the
Administrator shall notify each Participant as soon as practicable prior to the effective date of such proposed transaction. The
Administrator in its discretion may provide for a Participant to have the right to exercise his or her Option or SAR until ten (10)
days prior to such transaction as to all of the Awarded Stock covered thereby, including Shares as to which the Award would not
otherwise be exercisable. In addition, the Administrator may provide that any Company repurchase option or forfeiture rights
applicable to any Award shall lapse 100%, and that any Award vesting shall accelerate 100%, provided the proposed dissolution
or liquidation takes place at the time and in the manner contemplated. To the extent it has not been previously exercised (with
respect to Options and SARs) or vested (with respect to other Awards), an Award will terminate immediately prior to the
consummation of such proposed action.
(c)
Change of Control.
(1)
Stock Options and SARs. In the event of a Change of Control, each outstanding Option and
SAR shall be assumed or an equivalent option or SAR substituted by the successor corporation or a Parent or Subsidiary of the
successor corporation. In the event that the successor corporation refuses to assume or substitute for the Option or SAR, the
Participant shall fully vest in and have the right to exercise the Option or SAR as to all of the Awarded Stock, including Shares
as to which it would not otherwise be vested or exercisable. If an Option or SAR becomes fully vested and exercisable in lieu
of assumption or substitution in the event of a Change of Control, the Administrator shall notify the Participant in writing or
electronically that the Option or SAR shall be fully vested and exercisable for a period of thirty (30) days from the date of such
notice, and the Option or SAR shall terminate upon the expiration of such period. For the purposes of this paragraph, the
Option or SAR shall be considered assumed if, following the Change of Control, the option or stock appreciation right confers
the right to purchase or receive, for each Share of Awarded Stock subject to the Option or SAR immediately prior to the Change
of Control, the consideration (whether stock, cash, or other securities or property) received in the Change of Control by holders
A-1-11
Table of Contents
of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of
consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that
if such consideration received in the Change of Control is not solely common stock of the successor corporation or its Parent,
the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the
exercise of the Option or SAR, for each Share of Awarded Stock subject to the Option or SAR, to be solely common stock of
the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common
Stock in the Change of Control.
(2) Restricted Stock, Performance Shares, Performance Units and Deferred Stock Units. In the
event of a Change of Control, each outstanding Restricted Stock, Performance Share, Performance Unit and Deferred Stock
Unit award shall be assumed or an equivalent Restricted Stock, Performance Share, Performance Unit and Deferred Stock Unit
award substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the
successor corporation refuses to assume or substitute for the Restricted Stock, Performance Share, Performance Unit or
Deferred Stock Unit award, the Participant shall fully vest in the Restricted Stock, Performance Share, Performance Unit or
Deferred Stock Unit including as to Shares (or with respect to Performance Units, the cash equivalent thereof) which would not
otherwise be vested. For the purposes of this paragraph, a Restricted Stock, Performance Share, Performance Unit and
Deferred Stock Unit award shall be considered assumed if, following the Change of Control, the award confers the right to
purchase or receive, for each Share (or with respect to Performance Units, the cash equivalent thereof) subject to the Award
immediately prior to the Change of Control, the consideration (whether stock, cash, or other securities or property) received in
the Change of Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders
were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares);
provided, however, that if such consideration received in the Change of Control is not solely common stock of the successor
corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to
be received, for each Share and each unit/right to acquire a Share subject to the Award, to be solely common stock of the
successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common
Stock in the Change of Control.
20.
Date of Grant. The date of grant of an Award shall be, for all purposes, the date on which the Administrator
makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the
determination shall be provided to each Participant within a reasonable time after the date of such grant.
21.
Amendment and Termination of the Plan.
(a) Amendment and Termination. The Board may at any time amend, alter, suspend or terminate the Plan.
(b)
Stockholder Approval. The Company shall obtain stockholder approval of any Plan amendment to the
extent necessary and desirable to comply with Section 422 of the Code (or any successor rule or statute or other applicable law,
rule or regulation, including the requirements of any exchange or quotation system on which the Common Stock is listed or
quoted). Such stockholder approval, if required, shall be obtained in such a manner and to such a degree as is required by the
applicable law, rule or regulation.
(c)
Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the
Plan shall impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator,
which agreement must be in writing and signed by the Participant and the Company.
22.
Conditions Upon Issuance of Shares.
(a)
Legal Compliance. Shares shall not be issued pursuant to the exercise of an Award unless the exercise
of the Award or the issuance and delivery of such Shares (or with respect to Performance Units, the cash equivalent thereof)
shall comply with Applicable Laws and shall be further subject to the approval of counsel for the Company with respect to such
compliance.
(b)
Investment Representations. As a condition to the exercise or receipt of an Award, the Company may
require the person exercising or receiving such Award to represent and warrant at the time of any such exercise or receipt that
A-1-12
Table of Contents
the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the
opinion of counsel for the Company, such a representation is required.
23.
Liability of Company.
(a)
Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory
body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale
of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to
which such requisite authority shall not have been obtained.
(b) Grants Exceeding Allotted Shares. If the Awarded Stock covered by an Award exceeds, as of the date
of grant, the number of Shares which may be issued under the Plan without additional stockholder approval, such Award shall
be void with respect to such excess Awarded Stock, unless stockholder approval of an amendment sufficiently increasing the
number of Shares subject to the Plan is timely obtained in accordance with Section 21(b) of the Plan.
24.
Reservation of Shares. The Company, during the term of this Plan, will at all times reserve and keep
available such number of Shares as shall be sufficient to satisfy the requirements of the Plan.
A-1-13
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED
2019 ANNUAL MEETING OF STOCKHOLDERS
Tuesday, August 20, 2019
9:00 a.m. Mountain Standard Time
2355 W. Chandler Blvd.
Chandler, Arizona 85224-6199
This Proxy is solicited on behalf of the Board of Directors
2019 ANNUAL MEETING OF STOCKHOLDERS
I (whether one or more of us) appoint Steve Sanghi and J. Eric Bjornholt, and each of them, each with full power of substitution,
to be my Proxies. The Proxies may vote on my behalf, in accordance with my instructions, all of my shares entitled to vote at the
2019 Annual Meeting of Stockholders of Microchip Technology Incorporated and any adjournment(s) of that meeting. The meeting
is scheduled for August 20, 2019, at 9:00 a.m., Mountain Standard Time, at Microchip's Chandler, Arizona facility at 2355 W.
Chandler Blvd., Chandler, Arizona 85224-6199. The Proxies may vote on my behalf as if I were personally present at the meeting.
This Proxy will be voted as directed or, if no contrary direction is indicated, will be voted (1) FOR the election of each of
the director nominees; (2) FOR the approval of a French sub-plan under our 2004 Equity Incentive Plan; (3) FOR the
ratification of Ernst & Young LLP as Microchip's independent registered public accounting firm for the fiscal year ending
March 31, 2020; (4) FOR the approval, on an advisory (non-binding) basis, of the compensation of our named executives;
and (5) AGAINST approval of a stockholder proposal requesting our Board to report on our processes for identifying and
analyzing human rights risks to workers in our operations and supply chain; and as my Proxies deem advisable on such
other matters as may properly come before the meeting or any adjournment(s) thereof. The proposals described in the
accompanying proxy statement have been proposed by the Board of Directors.
IF VOTING BY MAIL, PLEASE COMPLETE, DATE AND SIGN ON REVERSE SIDE AND RETURN THIS PROXY
CARD PROMPTLY USING THE ENCLOSED ENVELOPE.
YOUR VOTE IS IMPORTANT!
Thank you in advance for participating in our 2019 Annual Meeting
Vote by Internet, Telephone or Mail
24 Hours a Day, 7 Days a Week
Your phone or internet vote authorizes the named proxies to vote your shares
in the same manner as if you marked, signed and returned your proxy card.
INTERNET/MOBILE
www.proxypush.com/mchp
PHONE
1-866-883-3382
MAIL
Use the internet to vote your proxy
until 11:59 p.m. (CT) on
August 19, 2019.
Use a touch-tone telephone to vote
your proxy until 11:59 p.m. (CT)
on August 19, 2019.
Mark, sign and date your proxy
card and return it in the
postage-paid envelope provided.
If you vote your proxy by internet or by telephone, you do NOT need to mail back your Proxy Card.
Table of Contents
TO VOTE BY MAIL AS THE BOARD OF DIRECTORS RECOMMENDS ON ALL ITEMS BELOW,
SIMPLY SIGN, DATE, AND RETURN THIS PROXY CARD.
The Board of Directors recommends you vote FOR the following:
1.
Election of Directors:
01 Steve Sanghi
02 Matthew W. Chapman
03 L.B. Day
04 Esther L. Johnson
05 Wade F. Meyercord
For
For
For
For
For
Against
Against
Against
Against
Against
Abstain
Abstain
Abstain
Abstain
Abstain
The Board of Directors recommends you vote FOR proposals 2, 3 and 4.
2.
3.
4.
Proposal to approve a French sub-plan under our 2004 Equity
Incentive Plan.
Proposal to ratify the appointment of Ernst & Young LLP as the
independent registered public accounting firm of Microchip for the
fiscal year ending March 31, 2020.
Proposal to approve, on an advisory (non-binding) basis, the
compensation of our named executives.
For
For
For
Against
Abstain
Against
Abstain
Against
Abstain
The Board of Directors recommends you vote AGAINST proposal 5.
5.
Stockholder proposal requesting our Board to report on our
processes for identifying and analyzing human rights risks to
workers in our operations and supply chain.
For
Against
Abstain
Date _________________________________
Signature(s) in Box
Please sign exactly as your name(s) appears on the Proxy. If held in joint
tenancy, all persons should sign. Trustees, administrators, etc., should
include title and authority. Corporations must provide full name of
corporation and title of authorized officer signing the Proxy.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
FORM 10-K
Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended March 31, 2019
OR
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _________ to __________
Commission File Number: 0-21184
MICROCHIP TECHNOLOGY INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
Delaware
86-0629024
(State or Other Jurisdiction of Incorporation or Organization)
(IRS Employer Identification No.)
2355 W. Chandler Blvd., Chandler, AZ 85224-6199
(Address of Principal Executive Offices, Including Zip Code)
(480) 792-7200
(Registrant's Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
Common Stock, $0.001 Par Value Per Share
MCHP
NASDAQ® Global Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes
Yes
No
No
Indicate by checkmark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or
an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth
company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
Aggregate market value of the voting and non-voting common equity held by non-affiliates as of September 30, 2018 based upon the closing price
of the common stock as reported by the NASDAQ Global Market on such date was approximately $18,239,644,611.
Number of shares of Common Stock, $0.001 par value, outstanding as of May 28, 2019: 237,926,508 shares
Document
Proxy Statement for the 2019 Annual Meeting of Stockholders
Part of Form 10-K
III
Documents Incorporated by Reference
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
FORM 10-K
TABLE OF CONTENTS
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.
Item 16.
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
PART I
PART II
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases
of Equity Securities
Selected Financial Data
Management's Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
PART III
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accountant Fees and Services
PART IV
Exhibits and Financial Statement Schedules
Form 10-K Summary
Signatures
Power of Attorney
Page
3
12
27
28
29
29
30
32
33
54
55
55
55
57
58
58
58
59
59
60
61
62
63
2
Table of Contents
PART I
This Form 10-K contains certain forward-looking statements that involve risks and uncertainties, including statements
regarding our strategy and future financial performance and those statements identified under "Item 7 – Management's
Discussion and Analysis of Financial Condition and Results of Operations – Note Regarding Forward-looking
Statements." Our actual results could differ materially from the results described in these forward-looking statements as a
result of certain factors including those set forth under "Item 1A – Risk Factors," beginning below at page 12, and elsewhere in
this Form 10-K. Although we believe that the matters reflected in the forward-looking statements are reasonable, we cannot
guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on these
forward-looking statements. We disclaim any obligation to update information contained in any forward-looking statement. In
this Form 10-K, "we," "us," "our," and "Microchip" each refers to Microchip Technology Incorporated and its subsidiaries.
Item 1. BUSINESS
We develop, manufacture and sell specialized semiconductor products used by our customers for a wide variety of
embedded control applications. Our product portfolio comprises general purpose and specialized 8-bit, 16-bit, and 32-bit
microcontrollers, 32-bit microprocessors, field-programmable gate array (FPGA) products, a broad spectrum of high-
performance linear, mixed-signal, power management, thermal management, discrete diodes and Metal Oxide Semiconductor
Field Effect Transistors (MOSFETS), radio frequency (RF), timing, timing systems, safety, security, wired connectivity and
wireless connectivity devices, as well as Serial Electrically Erasable Programmable Read Only Memory (EEPROM), Serial
Flash memories, Parallel Flash memories, Serial Electrically Erasable Random Access Memory (EERAM) and Serial Static
Random Access Memory (SRAM). We also license Flash-IP solutions that are incorporated in a broad range of products. Our
synergistic product portfolio targets thousands of applications worldwide and a growing demand for high-performance designs
in the automotive, aerospace, defense, space, communications, computing, consumer and industrial control markets. We
comply with several quality systems, including: ISO9001 (2015 version), IATF16949 (2016 version), AS9100 (2016 version),
and TL9000.
Microchip Technology Incorporated was incorporated in Delaware in 1989. Our executive offices are located at 2355 West
Chandler Boulevard, Chandler, Arizona 85224-6199 and our telephone number is (480) 792-7200.
Our Internet address is www.microchip.com. We post the following filings on our website as soon as reasonably
practicable after they are electronically filed with or furnished to the Securities and Exchange Commission:
•
•
•
•
•
our annual report on Form 10-K
our quarterly reports on Form 10-Q
our current reports on Form 8-K
our proxy statement
any amendments to the above-listed reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Securities
Exchange Act of 1934
All of our SEC filings on our website are available free of charge. The information on our website is not incorporated into
this Form 10-K.
Acquisition of Microsemi
On May 29, 2018, we completed our acquisition of Microsemi Corporation (Microsemi), a publicly traded company
headquartered in Aliso Viejo, California. We paid an aggregate of approximately $8.19 billion in cash to the stockholders of
Microsemi. The total consideration transferred in the acquisition, including approximately $53.9 million of non-cash
consideration for the exchange of certain share-based payment awards of Microsemi for stock awards of Microchip, was
approximately $8.24 billion. In addition to the consideration transferred, we recognized in our consolidated financial
statements $3.23 billion in liabilities of Microsemi consisting of debt, taxes payable and deferred, pension obligations,
restructuring, and contingent and other liabilities of which $2.06 billion of existing debt was paid off. We financed the
purchase price using approximately $8.10 billion of borrowings consisting of $3.10 billion of loans under our revolving line of
credit (the "Revolving Credit Facility"), $3.00 billion of term loans ("Term Loan Facility") provided under our amended and
restated Credit Agreement, and $2.00 billion in newly issued senior secured notes. We incurred $22.0 million in costs related to
the acquisition. As a result of the acquisition, Microsemi became a wholly owned subsidiary of Microchip. Microsemi offers a
comprehensive portfolio of semiconductor and system solutions for aerospace and defense, communications, data center and
industrial markets. Our primary reason for this acquisition was to expand our range of solutions, products and capabilities by
extending our served available market.
3
Table of Contents
Industry Background
Competitive pressures require original equipment manufacturers (OEM) of a wide variety of products to expand product
functionality and provide differentiation while maintaining or reducing cost. To address these requirements, manufacturers
often use integrated circuit-based embedded control systems that enable them to:
differentiate their products
replace less efficient electromechanical control devices
reduce the number of components in their system
add product functionality
reduce the system level energy consumption
•
•
•
•
•
• make systems safer to operate
•
•
decrease time to market for their products
significantly reduce product cost
Embedded control systems have been incorporated into thousands of products and subassemblies in a wide variety of
applications and markets worldwide, including:
automotive comfort, safety, information and entertainment applications
•
remote control devices
•
handheld tools
•
large and small home appliances
•
portable computers and accessories
•
robotics
•
energy monitoring
•
•
thermostats
• motor controls
•
•
•
•
•
• medical devices
•
•
•
•
•
•
avionics
actuators
satellite power systems
routers and video surveillance systems
storage and server systems
communication infrastructure systems
security systems
smoke and carbon monoxide detectors
consumer electronics
power supplies
applications needing touch buttons, touch screens and graphical user interfaces
Embedded control systems typically incorporate a microcontroller as the principal active, and sometimes sole,
component. A microcontroller is a self-contained computer-on-a-chip consisting of a central processing unit, often with on-
board non-volatile program memory for program storage, random access memory for data storage and various analog and
digital input/output peripheral capabilities. In addition to the microcontroller, a complete embedded control system often
incorporates application-specific software, various analog, mixed-signal, timing, connectivity, security and non-volatile
memory components such as EEPROMs and Flash memory.
The increasing demand for embedded control has made the market for microcontrollers a significant segment of the
semiconductor market at $19 billion in calendar year 2018. Microcontrollers are primarily available in 8-bit through 32-bit
architectures. 8-bit microcontrollers remain very cost-effective for a wide range of high-volume embedded control applications
and, as a result, continue to represent a significant portion of the overall microcontroller market. 16-bit and 32-bit
microcontrollers provide higher performance and functionality, and are generally found in more complex embedded control
applications. FPGAs are programmable integrated circuits that are used to implement complex logic functions and can be re-
programmed at any time, allowing for multiple implementations and revisions during or after the end customer system is
manufactured. Some versions of FPGAs also include a microcontroller or microprocessor core to provide additional system on
chip functionality for compute intensive tasks. The analog and mixed-signal segment of the semiconductor market is very large
at $56 billion in calendar year 2018, and this market is fragmented into a large number of sub segments.
4
Table of Contents
Our Products
Our strategic focus is on embedded control solutions, including:
general purpose and specialized microcontrollers and 32-bit microprocessors
•
• wired and wireless connectivity products
•
•
•
•
• memory products
•
technology licensing
development tools and related software
FPGA products
analog, interface, mixed signal, timing, timing systems and security products
discrete diodes and MOSFETS
We provide cost-effective embedded control solutions that also offer the advantages of small size, high performance,
extreme low power usage, wide voltage range operation, mixed signal integration, and ease of development, thus enabling
timely and cost-effective integration of our solutions by our customers in their end products.
Microcontrollers
We offer a broad family of proprietary general purpose microcontroller products marketed under multiple brand
names. We believe that our microcontroller product families provide leading function and performance characteristics in the
worldwide microcontroller market. With over 3,700 microcontrollers in our product portfolio, we target the 8-bit, 16-bit, and
32-bit microcontroller and 32-bit embedded microprocessor markets. We have shipped more than 25 billion microcontrollers
to customers worldwide since 1990. We also offer specialized microcontrollers for automotive, industrial, computing,
communications, lighting, power supplies, motor control, human machine interface, security, wired connectivity and wireless
connectivity.
We leverage our circuit design, process technologies, development tools, applications knowledge, and manufacturing
experiences to enable our customers to implement various embedded control functions in their end systems with our
microcontrollers.
Development Tools
We offer a comprehensive set of low-cost and easy-to-learn application development tools. These tools enable system
designers to quickly and easily program our microcontroller products for specific applications and, we believe, they are an
important factor for facilitating design wins.
Our family of development tools for our microcontroller products range from entry-level systems, which include an
assembler and programmer or in-circuit debugging hardware, to fully configured systems that provide in-circuit emulation
capability. We also offer a complete suite of compilers, software code configurators and simulators. Customers moving from
entry-level designs to those requiring real-time emulation are able to preserve their investment in learning and tools as they
migrate to future microcontroller devices in our portfolio.
Many independent companies also develop and market application development tools that support our microcontroller
product architectures, including an extensive amount of third-party tool suppliers whose products support our microcontroller
architectures.
We believe that familiarity with and adoption of development tools from Microchip as well as third-party development tool
partners by an increasing number of product designers will be an important factor in the future selection of our embedded
control products. These development tools allow design engineers to develop thousands of application-specific products from
our standard microcontrollers.
Field-Programmable Gate Array (FPGA) Products
Our FPGA product line was primarily acquired as a part of our acquisition of Microsemi. Our portfolio of non-volatile FPGAs
range in densities from 100 to 481,000 logic elements and are recognized for their low power, high security and extended reliability.
We market and sell our FPGA products and related solutions into a broad range of applications with the industrial, defense, aviation,
space and communication markets.
5
Table of Contents
We offer a comprehensive set of development tools for our FPGA products. These tools enable system designers to visualize,
implement, simulate and program complex logic functions in the FPGA. Our development tool suite manages the entire design
flow from design entry, simulation, synthesis, through place-and-route, timing, and power analysis. We also provide C/C++
development and debugging environment to support our FPGAs that implement embedded microcontrollers or microprocessor
cores.
Analog, Power, Interface, Mixed Signal and Timing Products
Our analog, power, interface, mixed signal and timing products consist of several families with over 7,850 power
management, linear, mixed-signal, high voltage, thermal management, discrete diodes and MOSFETS, radio frequency (RF),
drivers, safety, security, timing, USB, ethernet, wireless and other interface products.
We market and sell our analog, power, interface, mixed signal and timing products into our microcontroller,
microprocessor and FPGA customer base, and to customers who use microcontrollers and FPGA products from other suppliers
and to customers who use other products that may not fit our traditional microcontroller, FPGA and memory products customer
base.
Memory Products
Our memory products consist of EEPROMs, Serial Flash memories, Parallel Flash memories, Serial SRAM memories and
EERAM. Serial EEPROMs, Serial Flash memories, Serial SRAMs and EERAM have a very low I/O pin requirement,
permitting production of very small footprint devices. We sell our memory products primarily into the embedded control
market, complementing our microcontroller offerings.
Technology Licensing
Our technology licensing business generates license fees and royalties associated with technology licenses for the use of
our SuperFlash® embedded flash and Smartbits® one time programmable NVM technologies. We also generate fees for
engineering services related to these technologies. We license our NVM technologies to foundries, integrated device
manufacturers and design partners throughout the world for use in the manufacture of their advanced microcontroller products,
gate array, RF, analog and neuromorphic compute products that require embedded non-volatile memory.
Multi-Market and Other
Our multi-market and other business offers manufacturing services (wafer foundry and assembly and test subcontracting),
legacy application specific integrated circuits, complex programmable logic devices, products for aerospace applications and
timing systems.
Manufacturing
Our manufacturing operations include wafer fabrication, wafer probe, assembly and test. The ownership of a substantial
portion of our manufacturing resources is an important component of our business strategy, enabling us to maintain a high level
of manufacturing control, resulting in us being one of the lowest cost producers in the embedded control industry. By owning
wafer fabrication facilities and our assembly and test operations, and by employing statistical techniques (statistical process
control, designed experiments and wafer level monitoring), we have been able to achieve and maintain high production
yields. Direct control over manufacturing resources allows us to shorten our design and production cycles. This control also
allows us to capture a portion of the wafer manufacturing and assembly and testing profit margin. We do outsource a
significant portion of our manufacturing requirements to third parties and the amount of our outsourced manufacturing has
increased in recent years due to our acquisitions of Microsemi and other companies that outsource all or substantial portions of
their manufacturing.
Our manufacturing facilities are located in:
• United States
Chandler, Arizona (wafer probe)
Tempe, Arizona (Fab 2)
Gresham, Oregon (Fab 4)
Colorado Springs, Colorado (Fab 5)
Garden Grove, California (manufacturing, R&D and administrative)
6
Table of Contents
San Jose, California (design, R&D, and administrative)
Simsbury, Connecticut (manufacturing, R&D and administrative)
Beverly, Massachusetts (manufacturing)
Lawrence, Massachusetts (manufacturing and administrative)
Lowell, Massachusetts (wafer fabrication, assembly and test, R&D, warehousing and administrative)
Mt. Holly Springs, Pennsylvania (manufacturing, R&D and administrative)
• Thailand
•
•
•
Chacherngsao (wafer probe, assembly and test)
Philippines
Calamba, Laguna (wafer probe and test)
France
Nantes, Loire-Atlantique (design, engineering, test, probe, administrative and warehousing)
Ireland
Ennis, County Clare (manufacturing)
• Germany
Neckarbischofsheim, Baden-Württemberg (manufacturing and administrative)
Teltow, Brandenburg (wafer fabrication, assembly and test, wafer probe, R&D, warehousing and
administrative)
Wafer Fabrication
Fab 2 currently produces 8-inch wafers and supports various manufacturing process technologies, but predominantly
utilizes our 0.5 microns to 1.0 microns processes. During fiscal 2019, we increased Fab 2's capacity to support more advanced
technologies by making process improvements, upgrading existing equipment, and adding equipment.
Fab 4 currently produces 8-inch wafers using predominantly 0.13 microns to 0.5 microns manufacturing
processes. During fiscal 2019, we increased Fab 4's capacity to support more advanced technologies by making process
improvements, upgrading existing equipment, and adding equipment. A significant amount of additional clean room capacity
in Fab 4 can be brought on line in the future to support incremental wafer fabrication capacity needs.
Fab 5 is a 6-inch wafer fabrication facility that currently utilizes processes from 0.25 microns to 1.0 microns. During fiscal
2019, we made use of the existing capacity of Fab 5 to support demand.
We believe the combined capacity of Fab 2, Fab 4, and Fab 5 will provide sufficient capacity to allow us to respond to
increases in future demand over the next several years with modest incremental capital expenditures.
We continue to transition products to more advanced process technologies to reduce future manufacturing costs. We
believe that our ability to successfully transition to more advanced process technologies is important for us to remain
competitive.
We augment our internal manufacturing capabilities by outsourcing a portion of our wafer production requirements to
third-party wafer foundries. As a result of our acquisitions in recent years, we have become more reliant on outside wafer
foundries for our wafer fabrication requirements. In fiscal 2019, approximately 57% of our sales came from products that were
produced at outside wafer foundries.
As a result of our acquisition of Microsemi, we acquired several smaller wafer fabrication facilities, which utilize older
technologies that are appropriate for the discrete products they manufacture. We plan to operate these fabrication facilities with
modest investment to keep them operational with the exception of the facility in Bend, Oregon, which discontinued production
in March 2019.
Assembly and Test
We perform product assembly and test at various facilities located around the world. During fiscal 2019, we increased
capacity at our Thailand and Philippines facilities to support more technologies by making process improvements, upgrading
existing equipment, and adding equipment. During fiscal 2019, approximately 38% of our assembly requirements were being
performed in our internal facilities and approximately 49% of our test requirements were performed in internal facilities. We
use third-party assembly and test contractors for the balance of our assembly and test requirements. Over time, we intend to
continue to migrate a portion of the outsourced assembly and test activities to our internal facilities.
7
Table of Contents
General Matters Impacting Our Manufacturing Operations
Due to the high fixed costs inherent in semiconductor manufacturing, consistently high manufacturing yields have
significant positive effects on our gross profit and overall operating results. Our continuous focus on manufacturing
productivity has allowed us to maintain excellent manufacturing yields at our facilities. Our manufacturing yields are primarily
driven by a comprehensive implementation of statistical process control, extensive employee training and effective use of our
manufacturing facilities and equipment. Maintenance of manufacturing productivity and yields are important factors in the
achievement of our operating results. The manufacture of integrated circuits, particularly non-volatile, erasable complementary
metal-oxide semiconductor (CMOS) memory and logic devices, such as those that we produce, are complex processes. These
processes are sensitive to a wide variety of factors, including the level of contaminants in the manufacturing environment,
impurities in the materials used and the performance of our manufacturing personnel and equipment. As is typical in the
semiconductor industry, we have from time to time experienced lower than anticipated manufacturing yields. Our operating
results will suffer if we are unable to maintain yields at or above approximately the current levels.
Historically, we have relied on our ability to respond quickly to customer orders as part of our competitive strategy,
resulting in customers placing orders with relatively short delivery schedules. In order to respond to such requirements, we
have historically maintained a significant work-in-process and finished goods inventory.
The following table summarizes our long-lived assets (consisting of property, plant and equipment) by geography at the
end of fiscal 2019, fiscal 2018 and fiscal 2017 (in millions).
United States
Thailand
Various other countries
Total long-lived assets
2019
March 31,
2018
2017
$
$
521.1
209.3
266.3
996.7
$
$
393.3
215.5
159.1
767.9
$
$
388.5
178.0
116.8
683.3
We have many suppliers of raw materials and subcontractors which provide our various materials and service needs. We
generally seek to have multiple sources of supply for our raw materials and services, but, in some cases, we may rely on a
single or limited number of suppliers.
Sales and Distribution
General
We market and sell our products worldwide primarily through a network of direct sales personnel and distributors.
Our direct sales force focuses on a wide variety of strategic accounts in three geographical markets: the Americas, Europe
and Asia. We currently maintain sales and technical support centers in major metropolitan areas in all three geographic
markets. We believe that a strong technical service presence is essential to the continued development of the embedded control
market. Many of our client engagement managers, embedded system engineers (ESEs), and sales management have technical
degrees or backgrounds and have been previously employed in high technology environments. We believe that the technical
knowledge of our sales force is a key competitive advantage in the sale of our products. The primary mission of our ESE team
is to provide technical assistance to customers and to conduct periodic training sessions for the balance of our sales team. ESEs
also frequently conduct technical seminars and workshops in major cities around the world.
Our licensing division has dedicated sales, technology, design, product, test and reliability personnel that support the
requirements of our licensees.
For information regarding our revenue, results of operations, and total assets for each of our last three fiscal years, refer to
our financial statements included in this Form 10-K.
Distribution
Our distributors focus primarily on servicing the product requirements of a broad base of diverse customers. We believe
that distributors provide an effective means of reaching this broad and diverse customer base. We believe that customers
recognize us for our products and brand name and use distributors as an effective supply channel.
8
Table of Contents
In fiscal 2019, we derived 51% of our net sales through distributors and 49% of our net sales from customers serviced
directly by us. In fiscal 2018, we derived 54% of our net sales through distributors and 46% of our net sales from customers
serviced directly by us. In fiscal 2017, we derived 55% of our net sales through distributors and 45% of our net sales from
customers serviced directly by us. With the exception of Arrow Electronics, our largest distributor, which made up 10% of our
net sales, no other distributor or end customer accounted for more than 10% of our net sales in fiscal 2019. In fiscal 2018 and
fiscal 2017, no distributor or end customer accounted for more than 10% of our net sales.
We do not have long-term agreements with our distributors and we, or our distributors, may each terminate our relationship
with little or no advanced notice. The loss of, or the disruption in the operations of, one or more of our distributors could
reduce our future net sales in a given quarter and could result in an increase in inventory returns.
Backlog
As of April 30, 2019, our backlog was approximately $2,378.9 million, compared to $1,833.9 million as of April 30,
2018. Our backlog includes all purchase orders scheduled for delivery within the subsequent 12 months.
We primarily produce standard products that can be shipped from inventory within a relatively short time after we receive
an order. Our business and, to a large extent, that of the entire semiconductor industry, is characterized by short-term orders
and shipment schedules. Orders constituting our current backlog are subject to changes in delivery schedules, or to
cancellation at the customer's option without significant penalty. Thus, while backlog is useful for scheduling production,
backlog as of any particular date may not be a reliable measure of our sales for any future period.
Competition
The semiconductor industry is intensely competitive and has been characterized by price erosion and rapid technological
change. We compete with major domestic and international semiconductor companies, some of which have greater market
recognition and greater financial, technical, marketing, distribution and other resources than we have with which to pursue
engineering, manufacturing, marketing and distribution of their products. We also compete with a number of companies that
we believe have copied, cloned, pirated or reverse engineered our proprietary product lines in such countries as China and
Taiwan. We are continuing to take actions to vigorously and aggressively defend and protect our intellectual property on a
worldwide basis.
We currently compete principally on the basis of the technical innovation and performance of our embedded control
products, including the following product characteristics:
performance
analog, digital and mixed signal functionality and level of functional integration
field programmability
•
•
•
• memory density
•
•
•
•
•
low power consumption
extended voltage ranges
reliability
packaging alternatives
completeness of development tool line
We believe that other important competitive factors in the embedded control market include:
•
•
•
•
•
•
ease of use
functionality of application development systems
dependable delivery, quality and availability
technical and innovative service and support
time to market
price
We believe that we compete favorably with other companies on all of these factors, but we may be unable to compete
successfully in the future, which could harm our business.
9
Table of Contents
Patents, Licenses and Trademarks
We maintain a portfolio of U.S. and foreign patents, expiring on various dates through 2038. We also have numerous
additional U.S. and foreign patent applications pending. We do not expect that the expiration of any particular patent will have
a material impact on our business. While our intention is to continue to patent our technology and manufacturing processes, we
believe that our continued success depends primarily on the technological skills and innovative capabilities of our personnel
and our ability to rapidly commercialize new and enhanced products. As with any operating company, the scope and strength
of our intellectual property assets, including our pending and existing patents, trademarks, copyrights, and other intellectual
property rights may be insufficient to provide meaningful protection or commercial advantage. Moreover, pursuing violations
of intellectual property rights on a worldwide basis is a complex challenge involving multinational patent, trademark, copyright
and trade secret laws. Further, the laws of particular foreign countries often fail to protect our intellectual property rights to the
same extent as the laws of the U.S.
We have also entered into certain intellectual property licenses and cross-licenses with other companies and those licenses
relate to semiconductor products and manufacturing processes. As is typical in the semiconductor industry, we and our
customers from time to time receive, and may continue to receive, demand letters from third parties asserting infringement of
patent and other intellectual property rights. We diligently investigate all such notices and respond as we believe
appropriate. In most cases we believe that we can obtain necessary licenses on commercially reasonable terms, however, we
cannot be certain that this would be the case, or that litigation or damages for any past infringement could be avoided.
Litigation, which could result in substantial costs and require significant attention from management, may be necessary to
enforce our intellectual property rights, or to defend against claimed infringement of the rights of others. The failure to obtain
necessary licenses, or the necessity of engaging in defensive litigation, could harm our business.
Environmental Regulation
We must comply with many different federal, state, local and foreign governmental regulations related to the use, storage,
discharge and disposal of certain chemicals and gases used in our manufacturing processes. Our facilities have been designed
to comply with these regulations and we believe that our activities are conducted in material compliance with such regulations.
Any changes in such regulations or in their enforcement could require us to acquire costly equipment or to incur other
significant expenses to comply with environmental regulations. Any failure by us to adequately control the storage, use,
discharge and disposal of regulated substances could result in significant future liabilities.
Increasing public attention has been focused on the environmental impact of electronic manufacturing operations. While
we have not experienced any materially adverse effects on our operations from recently adopted environmental regulations, our
business and results of operations could suffer if for any reason we fail to control the storage or use of, or to adequately restrict
the discharge or disposal of, hazardous substances under present or future environmental regulations.
Employees
As of March 31, 2019, we had 18,286 employees. We have never had a work stoppage and believe that our employee
relations are good.
Executive Officers of the Registrant
The following sets forth certain information regarding our executive officers as of April 30, 2019:
Name
Steve Sanghi
Ganesh Moorthy
J. Eric Bjornholt
Stephen V. Drehobl
Mitchell R. Little
Richard J. Simoncic
Age
63
59
48
57
67
55
Position
Chief Executive Officer and Chairman of the Board
President and Chief Operating Officer
Senior Vice President, Chief Financial Officer
Senior Vice President, MCU8 and MCU16 Business Units
Senior Vice President, Worldwide Client Engagement
Senior Vice President, Analog Power and Interface Business Units
10
Table of Contents
Mr. Sanghi has served as Chief Executive Officer since October 1991, and as Chairman of the Board since October 1993.
He served as President from August 1990 to February 2016 and has served as a director since August 1990. Mr. Sanghi holds
an M.S. degree in Electrical and Computer Engineering from the University of Massachusetts and a B.S. degree in Electronics
and Communication from Punjab University. In November 2016, Mr. Sanghi joined the Board of Directors of Myomo, Inc., a
publicly traded commercial stage medical robotics company that offers expanded mobility for those suffering from neurological
disorders and upper-limb paralysis. In February 2018, Mr. Sanghi joined the board of Mellanox Technologies Ltd., a publicly
traded supplier of end-to-end Ethernet and InfiniBand intelligent interconnect solutions and services for servers, storage, and
hyper-converged infrastructure.
Mr. Moorthy has served as President since February 2016 and as Chief Operating Officer since June 2009. He also served
as Executive Vice President from October 2006 to August 2012 and as a Vice President in various roles since he joined
Microchip in 2001. Prior to this time, he served in various executive capacities with other semiconductor companies. Mr.
Moorthy holds an M.B.A. in Marketing from National University, a B.S. degree in Electrical Engineering from the University
of Washington and a B.S. degree in Physics from the University of Mumbai, India. Mr. Moorthy was elected to the Board of
Directors of Rogers Corporation in July 2013.
Mr. Bjornholt was promoted to Senior Vice President in 2019 and has served as Vice President of Finance since 2008 and
as Chief Financial Officer since January 2009. He has served in various financial management capacities since he joined
Microchip in 1995. Mr. Bjornholt holds a Master's degree in Taxation from Arizona State University and a B.S. degree in
Accounting from the University of Arizona.
Mr. Drehobl was promoted to Senior Vice President in 2019 and has served as Vice President of the MCU8 business unit
and various other divisions and business units since July 2001. He has been employed by Microchip since August 1989 and has
served as a Vice President in various roles since February 1997. Mr. Drehobl holds a Bachelor of Technology degree from the
University of Dayton.
Mr. Little was promoted to Senior Vice President in 2019 and has served as Vice President of Worldwide Sales since July
2000. He has been employed by Microchip since 1989 and has served as a Vice President in various roles since September
1993. Mr. Little holds a B.S. degree in Engineering Technology from United Electronics Institute.
Mr. Simoncic was promoted to Senior Vice President in 2019 and has served as Vice President, Analog Power and Interface
Business Units since September 1999. From October 1995 to September 1999, he served as Vice President in various
roles. Since joining Microchip in 1990, Mr. Simoncic held various roles in Design, Device/Yield Engineering and Quality
Systems. Mr. Simoncic holds a B.S. degree in Electrical Engineering Technology from DeVry Institute of Technology.
11
Table of Contents
Item 1A. Risk Factors
When evaluating Microchip and its business, you should give careful consideration to the factors listed below, in addition
to the information provided elsewhere in this Form 10-K and in other documents that we file with the Securities and Exchange
Commission.
Our operating results are impacted by global economic conditions and may fluctuate in the future due to a number of
factors that could reduce our net sales and profitability.
Our operating results are affected by a wide variety of factors that could reduce our net sales and profitability, many of
which are beyond our control. Some of the factors that may affect our operating results include:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
general economic, industry or political conditions in the U.S. or internationally;
changes in demand or market acceptance of our products and products of our customers, and market fluctuations
in the industries into which such products are sold;
changes in tax regulations and policies in the U.S. and other countries in which we do business including the
impact of the Tax Cuts and Jobs Act of 2017 (the "Act");
new accounting pronouncements or changes in existing accounting standards and practices;
our ability to continue to realize the expected benefits of our acquisitions including our acquisition of Microsemi;
our ability to ramp our factory capacity to meet customer demand;
our ability to secure sufficient wafer foundry, assembly and testing capacity;
changes or fluctuations in customer order patterns and seasonality;
changes in utilization of our manufacturing capacity and fluctuations in manufacturing yields;
the mix of inventory we hold and our ability to satisfy orders from our inventory;
levels of inventories held by our customers;
risk of excess and obsolete inventories;
competitive developments including pricing pressures;
unauthorized copying of our products resulting in pricing pressure and loss of sales;
availability of raw materials and equipment;
our ability to successfully transition products to more advanced process technologies to reduce manufacturing
costs;
the level of orders that are received and can be shipped in a quarter, including the impact of product lead times;
the level of sell-through of our products through distribution;
fluctuations in our mix of product sales;
trade restrictions and changes in tariffs, including those impacting China;
announcements of other significant acquisitions by us or our competitors;
disruptions in our business or our customers' businesses due to cybersecurity incidents, terrorist activity, armed
conflict, war, worldwide oil prices and supply, public health concerns, fires, natural disasters or disruptions in the
transportation system;
constrained availability from other electronic suppliers impacting our customers' ability to ship their products,
which in turn may adversely impact our sales to those customers;
costs and outcomes of any current or future tax audits or any litigation or claims involving intellectual property,
our Microsemi acquisition, customers or other issues;
fluctuations in commodity or energy prices; and
property damage or other losses, whether or not covered by insurance.
We believe that period-to-period comparisons of our operating results are not necessarily meaningful and that you should
not rely upon any such comparisons as indications of our future performance. In future periods, our operating results may fall
below our public guidance or the expectations of public market analysts and investors, which would likely have a negative
effect on the price of our common stock. Uncertain global economic conditions, the ongoing economic recovery and
uncertainty surrounding the strength and duration of such recovery have caused our operating results to fluctuate significantly
and make comparability between periods less meaningful.
We may not fully realize the anticipated benefits of our completed or future acquisitions or divestitures including our
acquisition of Microsemi.
We have acquired, and expect in the future to acquire, additional businesses that we believe will complement or augment
our existing businesses. On May 29, 2018, we completed our acquisition of Microsemi, which was our largest and most
complex acquisition ever. In addition, in April 2016, we completed our acquisition of Atmel; and in August 2015, we
12
Table of Contents
completed our acquisition of Micrel. The integration process for our acquisitions is complex and may be costly and time
consuming and include unanticipated issues, expenses and liabilities. We may not be able to successfully or profitably
integrate, operate, maintain and manage any newly acquired operations or employees. We may not be able to maintain uniform
standards, procedures and policies and we may be unable to realize the expected synergies and cost savings from the
integration. There may be increased risk due to integrating financial reporting and internal control systems. We may have
difficulty in developing, manufacturing and marketing the products of a newly acquired company, or in growing the business at
the rate we anticipate. Following an acquisition, we may not achieve the revenue or net income levels that justify the
acquisition. We may suffer loss of key employees, customers and strategic partners of acquired companies and it may be
difficult to implement our corporate culture at acquired companies. We have been and may in the future be subject to claims
from terminated employees, shareholders of Microchip or the acquired companies and other third parties related to the
transaction. In particular, in connection with our Microsemi and Atmel acquisitions, we became involved with third-party
claims, litigation and disputes related to such businesses and transactions. See Note 13 to our consolidated financial statements
for information regarding pending litigation. Acquisitions may also result in charges (such as acquisition-related expenses,
write-offs, restructuring charges, or future impairment of goodwill), contingent liabilities, adverse tax consequences, additional
share-based compensation expense and other charges that adversely affect our operating results. To fund our acquisition of
Microsemi, we used a significant portion of our cash balances and incurred approximately $8.10 billion of additional debt. We
may fund future acquisitions of new businesses or strategic alliances by utilizing cash, borrowings under our Revolving Credit
Facility, raising debt, issuing shares of our common stock, or other mechanisms.
Further, if we decide to divest assets or a business, we may encounter difficulty in finding or completing divestiture
opportunities or alternative exit strategies on acceptable terms or in a timely manner. These circumstances could delay the
achievement of our strategic objectives or cause us to incur additional expenses with respect to assets or a business that we want
to dispose of, or we may dispose of assets or a business at a price or on terms that are less favorable than we had anticipated.
Even following a divestiture, we may be contractually obligated with respect to certain continuing obligations to customers,
vendors, landlords or other third parties. We may also have continuing obligations for pre-existing liabilities related to the
assets or businesses. Such obligations may have a material adverse impact on our results of operations and financial condition.
In addition to acquisitions, we have in the past, and expect in the future, to enter into joint development agreements or
other business or strategic relationships with other companies. These transactions are subject to a number of risks similar to
those we face with our acquisitions including our ability to realize the expected benefits of any such transaction, to successfully
market and sell any products resulting from such transactions or to successfully integrate any technology developed through
such transactions.
Our financial condition and results of operations could be adversely affected if we do not effectively manage our current or
future debt.
As of March 31, 2019, the principal amount of our outstanding indebtedness was $11.66 billion. In connection with our
acquisition of Microsemi, which closed on May 29, 2018, we incurred debt consisting of $3.10 billion under our revolving line
of credit, $3.00 billion under our new term loan facility, and $2.00 billion in newly issued senior secured notes. At March 31,
2019, we had $3.27 billion in outstanding borrowings under our revolving line of credit which provides $3.60 billion of
revolving loan commitments that terminate in 2023. At March 31, 2019, we had $1.91 billion of outstanding borrowings under
the term loan facility. In February 2017, we issued $2.65 billion of aggregate principal value of senior and junior convertible
debt.
As a result of such transactions, we have a substantially greater amount of debt than we had maintained in the past. Our
maintenance of substantial levels of debt could adversely affect our ability to take advantage of corporate opportunities and
could adversely affect our financial condition and results of operations. We may need or desire to refinance our convertible
debt, senior debt, term loan debt or any other future indebtedness and there can be no assurance that we will be able to refinance
any of our indebtedness on commercially reasonable terms, if at all.
13
Table of Contents
Servicing our current debt will require a significant amount of cash, and we may not have sufficient cash flow from our
business to fund future payments.
Our ability to make scheduled payments of principal, to pay interest on or to refinance our indebtedness, including our
outstanding convertible debt and debt incurred to finance our acquisition of Microsemi, depends on our future performance,
which is subject to economic, financial, competitive and other factors. Our business may not continue to generate cash flow
from operations in the future sufficient to service our debt and to fund capital expenditures, dividend payments, share
repurchases or acquisitions. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives,
such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive.
Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.
We are dependent on orders that are received and shipped in the same quarter and therefore have limited visibility to future
product shipments.
Our net sales in any given quarter depend upon a combination of shipments from backlog and customer orders that are both
received and shipped in that same quarter, which we refer to as turns orders. We measure turns orders at the beginning of a
quarter based on the orders needed to meet the shipment targets that we set entering the quarter. Historically, we have relied on
our ability to respond quickly to customer orders as part of our competitive strategy, resulting in customers placing orders with
relatively short delivery schedules. Shorter lead times generally mean that turns orders as a percentage of our business are
relatively high in any particular quarter and reduce our backlog visibility on future product shipments. Turns orders correlate to
overall semiconductor industry conditions and product lead times. Because turns orders are difficult to predict, varying levels
of turns orders make it more difficult to forecast net sales. As a significant portion of our products are manufactured at
foundries, foundry lead times may affect our ability to satisfy certain turns orders. If we do not achieve a sufficient level of
turns orders in a particular quarter relative to our revenue targets, our revenue and operating results will likely suffer.
Intense competition in the markets we serve may lead to pricing pressures, reduced sales of our products or reduced market
share.
The semiconductor industry is intensely competitive and has been characterized by price erosion and rapid technological
change. We compete with major domestic and international semiconductor companies, many of which have greater market
recognition and substantially greater financial, technical, marketing, distribution and other resources than we do. The
semiconductor industry has experienced significant merger and acquisition activity and consolidation in recent years which has
resulted in several of our competitors becoming much larger in terms of revenue, product offerings and scale. We may be
unable to compete successfully in the future, which could harm our business. Our ability to compete successfully depends on a
number of factors both within and outside our control, including, but not limited to:
•
•
•
•
•
•
•
•
•
•
•
•
•
the quality, performance, reliability, features, ease of use, pricing and diversity of our products;
our success in designing and manufacturing new products including those implementing new technologies;
our ability to ramp production and increase capacity, as needed, at our wafer fabrication and assembly and test
facilities;
the rate at which customers incorporate our products into their own applications and the success of such
applications;
the rate at which the markets that we serve redesign and change their own products;
our ability to obtain adequate foundry and assembly and test capacity and supplies of raw materials and other
supplies at acceptable prices;
changes in demand in the markets that we serve and the overall rate of growth or contraction of such markets,
including but not limited to the automotive, personal computing and consumer electronics markets;
product introductions by our competitors;
the number, nature and success of our competitors in a given market;
our ability to protect our products and processes by effective utilization of intellectual property rights;
our ability to remain price competitive against companies that have copied our proprietary product lines,
especially in countries where intellectual property rights protection is difficult to achieve and maintain;
our ability to address the needs of our customers; and
general market and economic conditions.
14
Table of Contents
Historically, average selling prices in the semiconductor industry decrease over the life of any particular product. The
average selling prices of our microcontroller and proprietary analog, interface, mixed signal and timing products have remained
relatively constant, while average selling prices of our memory and non-proprietary analog, interface, mixed signal and timing
products have declined over time. The overall average selling price of our products is affected by these trends; however,
variations in our product and geographic mix of sales can cause wider fluctuations in our overall average selling price in any
given period.
We have experienced, and expect to continue to experience, modest pricing declines in certain of our more mature
proprietary product lines, primarily due to competitive conditions. We have been able to moderate average selling price
declines in many of our proprietary product lines by continuing to introduce new products with more features and higher prices.
However, there can be no assurance that we will be able to do so in the future. We have experienced in the past, and expect to
continue to experience in the future, varying degrees of competitive pricing pressures in our memory and non-proprietary
analog, interface, mixed signal and timing products. We may be unable to maintain average selling prices for our products as a
result of increased pricing pressure in the future, which could adversely impact our operating results.
We are dependent on wafer foundries and other contractors to perform key manufacturing functions for us, and our
licensees of our SuperFlash and other technologies also rely on foundries and other contractors.
We rely on outside wafer foundries for a significant portion of our wafer fabrication needs. Specifically, during fiscal 2019
and fiscal 2018, approximately 57% and 42%, respectively, of our net sales came from products that were produced at outside
wafer foundries. We also use several contractors located primarily in Asia for a portion of the assembly and testing of our
products. Specifically, during fiscal 2019, approximately 62% of our assembly requirements and 51% of our test requirements
were performed by third party contractors compared to approximately 58% of our assembly requirements and 36% of our test
requirements during fiscal 2018. Our reliance on third party contractors and foundries increased as a result of our acquisitions
of Microsemi, Atmel, Micrel, SMSC, Supertex and ISSC. The disruption or termination of any of our contractors could harm
our business and operating results.
Our use of third parties somewhat reduces our control over the subcontracted portions of our business. Our future
operating results could suffer if any contractor were to experience financial, operational or production difficulties or situations
when demand exceeds capacity, or if they were unable to maintain manufacturing yields, assembly and test yields and costs at
approximately their current levels, or if the countries in which such contractors are located were to experience political
upheaval or infrastructure disruption. If these third parties are unable or unwilling to timely deliver products or services
conforming to our quality standards, we may not be able to qualify additional manufacturing sources for our products in a
timely manner on terms favorable to us, or at all. Additionally, these subcontractors could abandon fabrication processes that
are important to us, or fail to adopt advanced manufacturing technologies that we desire to control costs. In any such event, we
could experience an interruption in production, an increase in manufacturing and production costs or a decline in product
reliability, and our business and operating results could be adversely affected. Further, our use of subcontractors increases the
risks of potential misappropriation of our intellectual property.
Certain of our SuperFlash and other technology licensees also rely on outside wafer foundries for wafer fabrication
services. If our licensees were to experience any disruption in supply from outside wafer foundries, this would reduce the
revenue we receive in our technology licensing business and would harm our operating results.
Our operating results will suffer if we ineffectively utilize our manufacturing capacity or fail to maintain manufacturing
yields.
The manufacture and assembly of integrated circuits, particularly non-volatile, erasable CMOS memory and logic devices
such as those that we produce, are complex processes. These processes are sensitive to a wide variety of factors, including the
level of contaminants in the manufacturing environment, impurities in the materials used, the performance of our wafer
fabrication and assembly and test personnel and equipment, and other quality issues. As is typical in the semiconductor
industry, we have from time to time experienced lower than anticipated manufacturing yields. Our operating results will suffer
if we are unable to maintain yields at or above approximately the current levels. This could include delays in the recognition of
revenue, loss of revenue or future orders, and customer-imposed penalties for our failure to meet contractual shipment
deadlines. Our operating results are also adversely affected when we operate at less than optimal capacity. In fiscal 2019, we
operated at below normal capacity levels resulting in an unabsorbed capacity charge of $19.0 million. We operated at normal
capacity levels during fiscal 2018.
15
Table of Contents
Our operating results are impacted by both seasonality and the wide fluctuations of supply and demand in the
semiconductor industry.
The semiconductor industry is characterized by seasonality and wide fluctuations of supply and demand. Historically,
since a significant portion of our revenue is from consumer markets and international sales, our business tends to generate
stronger revenues in the first and second quarters and comparatively weaker revenues in the third and fourth quarters of our
fiscal year. Broad fluctuations in our overall business, changes in semiconductor industry and global economic conditions, and
our acquisition activity (including our acquisition of Microsemi) have had and can have a more significant impact on our results
than seasonality. As a result, in periods when these broad fluctuations, changes in business conditions or acquisitions occur, it
is difficult to assess the impact of seasonal factors on our business. The semiconductor industry has also experienced
significant economic downturns, characterized by diminished product demand and production over-capacity. We have sought
to reduce our exposure to this industry cyclically by selling proprietary products, that cannot be easily or quickly replaced, to a
geographically diverse customer base across a broad range of market segments. However, we have experienced substantial
period-to-period fluctuations in operating results and expect, in the future, to experience period-to-period fluctuations in
operating results due to general industry or economic conditions.
Our business is dependent on distributors to service our end customers.
Sales to distributors accounted for approximately 51% of our net sales in fiscal 2019 and approximately 54% of our net
sales in fiscal 2018. We do not have long-term agreements with our distributors, and we and our distributors may each
terminate our relationship with little or no advance notice.
Any future adverse conditions in the U.S. or global economies or in the U.S. or global credit markets could materially
impact the operations of our distributors. Any deterioration in the financial condition of our distributors or any disruption in the
operations of our distributors could adversely impact the flow of our products to our end customers and adversely impact our
results of operation. In addition, during an industry or economic downturn, it is possible there will be an oversupply of
products and a decrease in demand for our products from our distributors, which could reduce our net sales in a given period
and result in an increase in inventory returns. Violations of the Foreign Corrupt Practices Act, or similar laws, by our
distributors or other channel partners could have a material adverse impact on our business.
Our success depends on our ability to introduce new products on a timely basis.
Our future operating results depend on our ability to develop and timely introduce new products that compete effectively
on the basis of price and performance and which address customer requirements. The success of our new product introductions
depends on various factors, including, but not limited to:
•
•
•
•
•
effective new product selection;
timely completion and introduction of new product designs;
procurement of licenses for intellectual property rights from third parties under commercially reasonable terms;
timely filing and protection of intellectual property rights for new product designs;
availability of development and support tools and collateral literature that make complex new products easy for
engineers to understand and use; and
• market acceptance of our customers' end products.
Because our products are complex, we have experienced delays from time to time in completing new product development.
In addition, our new products may not receive or maintain substantial market acceptance. We may be unable to timely design,
develop and introduce competitive products, which could adversely impact our future operating results.
Our success also depends upon our ability to develop and implement new design and process technologies. Semiconductor
design and process technologies are subject to rapid technological change and require significant R&D expenditures. We and
other companies in the industry have, from time to time, experienced difficulties in effecting transitions to advanced process
technologies and, consequently, have suffered reduced manufacturing yields or delays in product deliveries. Our future
operating results could be adversely affected if any transition to future process technologies is substantially delayed or
inefficiently implemented.
16
Table of Contents
We may lose sales if suppliers of raw materials, components or equipment fail to meet our or our customers' needs or
increase costs due to increased tariffs or other factors.
Our semiconductor manufacturing operations require raw and processed materials and equipment that must meet exacting
standards. We generally have more than one source for these supplies, but there are only a limited number of suppliers capable
of delivering various materials and equipment that meet our standards. The materials and equipment necessary for our business
could become more difficult to obtain as worldwide use of semiconductors in product applications increases. Additionally,
consolidation in our supply chain due to mergers and acquisitions may reduce the number of suppliers or change the
relationships that we have with our suppliers. Also, the application of trade restrictions or tariffs by the U.S. or other countries
may adversely impact the industry supply chain. For example, the U.S. government has recently increased tariffs on products
that have China as their country of origin and which are imported into the U.S. Likewise, the China government has increased
tariffs on products that have the U.S. as their country of origin and which are imported into China. We have taken steps to
mitigate the costs of these tariffs on our business. Although these increases in tariffs did not result in significant increases to the
operating costs of our business, they did, however, adversely impact demand for our products during fiscal 2019. The recent
additional tariffs imposed on components or equipment that we or our suppliers source from China will increase our costs and
could have a material adverse impact on our operating results in the three months ending June 30, 2019 or future periods. We
may also incur increases in manufacturing costs in mitigating the impact of tariffs on our operations. This could also impair
sourcing flexibility. We have experienced supply shortages from time to time in the past, and on occasion our suppliers have
told us they need more time than expected to fill our orders or that they will no longer support certain equipment with updates
or spare and replacement parts. In particular, we have recently experienced longer lead times for equipment which we need for
capacity expansion at certain of our manufacturing facilities. An interruption of any materials or equipment sources, or the lack
of supplier support for a particular piece of equipment, could harm our business.
Our customers may also be adversely affected by these same issues. The materials, components and equipment necessary
for their businesses could become more difficult to obtain for various reasons not limited to business interruptions of suppliers,
consolidation in their supply chain due to mergers and acquisitions, or application of trade restrictions or tariffs that impair
sourcing flexibility or increase costs. If our customers are not able to produce their products, then their need for our products
will decrease. Such interruptions of our customers’ businesses could harm our business.
Interruptions in our IT systems, unauthorized access to our IT systems or improper handling of data, could adversely affect
our business.
We rely on the efficient and uninterrupted operation of complex IT systems and networks to operate our business. Any
significant disruption to our systems or networks, including, but not limited to, new system implementations, computer viruses,
security breaches, facility issues, natural disasters, terrorism, war, telecommunication failures or energy blackouts could have a
material adverse impact on our operations, sales and operating results. Such disruption could result in a loss of our intellectual
property or the release of sensitive competitive information or supplier, customer or employee personal data. Any loss of such
information could harm our competitive position, result in a loss of customer confidence, and cause us to incur significant costs
to remedy the damages caused by any such disruptions or security breaches. Additionally, any failure to properly manage the
collection, handling, transfer or disposal of personal data of employees and customers may result in regulatory penalties,
enforcement actions, remediation obligations, litigation, fines and other sanctions.
From time to time, we have experienced verifiable attacks on our data, attempts to breach our security and attempts to
introduce malicious software into our IT systems. For example, we have learned of an ongoing compromise of our computer
networks by what is believed to be sophisticated hackers. We have engaged experienced legal counsel and a leading forensic
investigatory firm with experience in such matters. We have taken steps to identify malicious activity on our network including
a compromise of our network and, as of the date of this filing, we are implementing a containment plan. We are continuing to
evaluate the effectiveness of the containment plan and the amount and content of the information that was compromised and to
implement additional remedial actions. At this time, we do not believe that this IT system compromise has had a material
adverse effect on our business or resulted in any material damage to us. However, we are still evaluating the amount and type
of data that was compromised and there can be no assurance as to what the impact of this IT system compromise will be. As a
result of the IT system compromise, our management, including our chief executive officer and our chief financial officer, has
concluded that our internal controls related to IT system access were not effective as of March 31, 2019 resulting in a material
weakness in our internal controls. For additional information, refer to Item 9A "Controls and Procedures."
Were any future attacks to be successful, we may be unaware of the incident, its magnitude, or its effects until significant
harm is done. In recent years, we have implemented improvements to our protective measures which include, but are not
limited to, the following: firewalls, antivirus measures, patches, log monitors, event correlation tools, routine backups with
offsite retention of storage media, system audits, data partitioning and routine password modifications. As a result of the
17
Table of Contents
material weakness in our internal controls resulting from the IT systems compromise, we have taken remediation actions and
implemented additional controls. There can be no assurance that such system improvements will be sufficient to prevent or
limit the damage from any future cyber attacks or disruptions. Any such attack or disruption could result in additional costs
related to rebuilding of our internal systems, defending litigation, responding to regulatory actions, or paying damages. Such
attacks or disruptions could have a material adverse impact on our business, operations and financial results.
Third-party service providers, such as wafer foundries, assembly and test contractors, distributors, credit card processors
and other vendors have access to certain portions of our and our customers' sensitive data. In the event that these service
providers do not properly safeguard the data that they hold, security breaches and loss of data could result. Any such loss of
data by our third-party service providers could negatively impact our business, operations and financial results, as well as our
relationship with our customers.
If we fail to remediate our recently identified material weaknesses and achieve and maintain proper and effective internal
control and remediate current or future deficiencies, our ability to produce accurate and timely financial statements could
be impaired, which could harm our operating results, our ability to operate our business and investors' views of us.
As discussed in Item 9A “Controls and Procedures” in this report on Form 10-K, in the fourth quarter of fiscal 2019,
we identified a material weakness in our internal controls related to accounting for income taxes and we also identified a
material weakness in our internal controls related to IT system access. Internal controls related to such matters are important to
accurately reflect our financial position and results of operations in our financial reports. We are in the process of remediating
the material weaknesses, but our efforts may not be successful. If we are unable to remediate the material weaknesses in an
appropriate and timely manner, or if we identify additional control deficiencies that individually or together constitute
significant deficiencies or material weaknesses, our ability to accurately record, process, and report financial information and
consequently, our ability to prepare financial statements within required time periods, could be adversely affected. Failure to
maintain effective internal controls could result in violations of applicable securities laws, stock exchange listing requirements,
and the covenants under our debt agreements, subject us to litigation and investigations, negatively affect investor confidence in
our financial statements, and adversely impact our stock price and ability to access capital markets.
Ensuring that we have adequate internal financial and accounting controls and procedures so that we can produce accurate
financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our
internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements in accordance with United States generally accepted accounting
principles. We are required to comply with Section 404 of the Sarbanes-Oxley Act of 2002 which requires an annual
management assessment of the effectiveness of our internal control over financial reporting and a report by our independent
auditors. In addition to the recently identified material weaknesses related to accounting for income taxes and to IT system
access, we have from time to time identified significant deficiencies related to other matters. If we fail to remediate our
material weaknesses or significant deficiencies or to maintain proper and effective internal control over financial reporting in
the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating
results, harm our ability to operate our business and reduce the trading price of our stock.
Our reported financial results may be adversely affected by new accounting pronouncements or changes in existing
accounting standards and practices.
We prepare our financial statements in conformity with accounting principles generally accepted in the U.S. These
accounting principles are subject to interpretation or changes by the Financial Accounting Standards Board (FASB) and the
SEC. New accounting pronouncements and varying interpretations of accounting standards and practices have occurred in the
past and are expected to occur in the future. New accounting pronouncements or a change in the interpretation of existing
accounting standards or practices may have a significant effect on our reported financial results and may even affect our
reporting of transactions completed before the change is announced or effective.
Business interruptions to our operations or the operations of our key vendors, subcontractors, licensees or customers,
whether due to natural disasters, cybersecurity incidents, or other events, could harm our business.
Operations at any of our facilities, at the facilities of any of our wafer fabrication or assembly and test subcontractors, or at
any of our significant vendors or customers may be disrupted for reasons beyond our control. These reasons may include work
stoppages, power loss, cyber attacks, incidents of terrorism or security risk, political instability, public health issues,
telecommunications, transportation or other infrastructure failure, radioactive contamination, fire, earthquake, floods, volcanic
eruptions or other natural disasters. We have taken steps to mitigate the impact of some of these events should they occur;
18
Table of Contents
however, we cannot be certain that our actions will be effective to avoid a significant impact on our business in the event of a
disaster or other business interruption.
In particular, Thailand has experienced periods of severe flooding in recent years. While our facilities in Thailand have
continued to operate normally, there can be no assurance that any future flooding in Thailand would not have a material adverse
impact on our operations. If operations at any of our facilities, or our subcontractors' facilities are interrupted, we may not be
able to shift production to other facilities on a timely basis, and we may need to spend significant amounts to repair or replace
our facilities and equipment. If we experienced business interruptions, we would likely experience delays in shipments of
products to our customers and alternate sources for production may be unavailable on acceptable terms. This could result in
reduced revenues and profits and the cancellation of orders or loss of customers. Although we maintain business interruption
insurance, such insurance will likely not be enough to compensate us for any losses that may occur and any losses or damages
incurred by us as a result of business interruptions could significantly harm our business.
Additionally, operations at our customers and licensees may be disrupted for a number of reasons. In the event of customer
disruptions, sales of our products may decline and our revenue, profitability and financial condition could suffer. Likewise, if
our licensees are unable to manufacture and ship products incorporating our technology, or if there is a decrease in product
demand due to a business disruption, our royalty revenue may decline.
Our technology licensing business exposes us to various risks.
Our technology licensing business is based on our SuperFlash and other technologies. The success of our licensing
business depends on the continued market acceptance of these technologies and on our ability to further develop and enhance
such technologies and to introduce new technologies in the future. To be successful, any such technology must be able to be
repeatably implemented by licensees, provide satisfactory yield rates, address licensee and customer requirements, and perform
competitively. The success of our technology licensing business depends on various other factors, including, but not limited to:
•
•
•
•
•
proper identification of licensee requirements;
timely development and introduction of new or enhanced technology;
our ability to protect and enforce our intellectual property rights for our licensed technology;
our ability to limit our liability and indemnification obligations to licensees;
availability of sufficient development and support services to assist licensees in their design and manufacture of
products integrating our technology;
availability of foundry licensees with sufficient capacity to support OEM production; and
•
• market acceptance of our customers' end products.
Because our licensed technologies are complex, there may be delays from time to time in developing and enhancing such
technologies. There can be no assurance that our existing or any enhanced or new technology will achieve or maintain
substantial market acceptance. Our licensees may experience disruptions in production or lower than expected production
levels which would adversely affect the revenue that we receive from them. Our technology license agreements generally
include an indemnification clause that indemnifies the licensee against liability and damages (including legal defense costs)
arising from intellectual property matters. We could be exposed to substantial liability for claims or damages related to
intellectual property matters or indemnification claims. Any claim, with or without merit, could result in significant legal fees
and require significant attention from our management. Any of the foregoing issues may adversely impact the success of our
licensing business and adversely affect our future operating results.
We are exposed to various risks related to legal proceedings or claims.
We are currently, and in the future may be, involved in legal proceedings or claims regarding patent infringement, other
intellectual property rights, product failures, our Microsemi acquisition, contracts and other matters. As is typical in the
semiconductor industry, we receive notifications from third parties from time to time who believe that we owe them
indemnification or other obligations related to claims made against us, our direct or indirect customers or our licensees. These
legal proceedings and claims, even if meritless, could result in substantial costs to us and divert our resources. If we are not
able to resolve a claim, settle a matter, obtain necessary licenses on commercially reasonable terms, reengineer our products or
processes to avoid infringement, provide a cost-effective remedy, or successfully prosecute or defend our position, we could
incur uninsured liability in any of them, be required to take an appropriate charge to operations, be enjoined from selling a
material portion of our products or using certain processes, suffer a reduction or elimination in the value of our inventories, and
our business, financial condition or results of operations could be harmed.
19
Table of Contents
It is also possible that from time to time we may be subject to claims related to the manufacture, performance or use of our
products. These claims may be due to injuries, economic damage or environmental exposures related to manufacturing, a
product's nonconformance to our specifications or specifications agreed upon with the customer, changes in our manufacturing
processes, or unexpected customer system issues due to the integration of our products or insufficient design or testing by our
customers. We could incur significant expenses related to such matters, including, but not limited to:
•
•
•
•
•
•
•
costs related to writing off the value of our inventory of nonconforming products;
recalling nonconforming products;
providing support services, product replacements, or modifications to products and the defense of such claims;
diversion of resources from other projects;
lost revenue or a delay in the recognition of revenue due to cancellation of orders or unpaid receivables;
customer imposed fines or penalties for failure to meet contractual requirements; and
a requirement to pay damages or penalties.
Because the systems into which our products are integrated have a higher cost of goods than the products we sell, the
expenses and damages we are asked to pay may be significantly higher than the sales and profits we received from the products
involved. While we specifically exclude consequential damages in our standard terms and conditions, certain of our contracts
may not exclude such liabilities. Further, our ability to avoid such liabilities may be limited by applicable law. We do have
liability insurance which covers certain damages arising out of product defects, but we do not expect that insurance will cover
all claims or be of a sufficient amount to fully protect against such claims. Costs or payments we may make in connection with
these customer claims may adversely affect the results of our operations.
Further, we sell to customers in industries such as automotive, aerospace, defense, safety, security, and medical, where
failure of the systems in which our products are integrated could cause damage to property or persons. We may be subject to
claims if our products, or the integration of our products, cause system failures. We will face increased exposure to claims if
there are substantial increases in either the volume of our sales into these applications or the frequency of system failures
integrating our products.
Failure to adequately protect our intellectual property could result in lost revenue or market opportunities.
Our ability to obtain patents, licenses and other intellectual property rights covering our products and manufacturing
processes is important for our success. To that end, we have acquired certain patents and patent licenses and intend to continue
to seek patents on our technology and manufacturing processes. The process of seeking patent protection can be long and
expensive, and patents may not be issued from currently pending or future applications. In addition, our existing and new
patents, trademarks and copyrights that issue may not have sufficient scope or strength to provide meaningful protection or
commercial advantage to us. We may be subject to, or may ourselves initiate, interference proceedings in the U.S. Patent and
Trademark Office, patent offices of a foreign country or U.S. or foreign courts, which can require significant financial and
management resources. In addition, the laws of certain foreign countries do not protect our intellectual property rights to the
same extent as the laws of the U.S. Infringement of our intellectual property rights by a third party could result in
uncompensated lost market and revenue opportunities for us. Although we continue to vigorously and aggressively defend and
protect our intellectual property on a worldwide basis, there can be no assurance that we will be successful in our endeavors.
Our operating results may be adversely impacted if economic conditions impact the financial viability of our licensees,
customers, distributors, or suppliers.
We regularly review the financial performance of our licensees, customers, distributors and suppliers. However, any
downturn in global economic conditions may adversely impact the financial viability of our licensees, customers, distributors or
suppliers. The financial failure of a large licensee, customer or distributor, an important supplier, or a group thereof, could have
an adverse impact on our operating results and could result in our not being able to collect our accounts receivable balances,
higher reserves for doubtful accounts, write-offs for accounts receivable, and higher operating costs as a percentage of net sales.
We are highly dependent on foreign sales and operations, which exposes us to foreign political and economic risks including
risks from recent increases in tariffs.
Sales to foreign customers account for a substantial portion of our net sales. During fiscal 2019, approximately 80% of our
net sales were made to foreign customers, including 22% in China and 13% in Taiwan. During fiscal 2018, approximately 85%
of our net sales were made to foreign customers, including 30% in China and 11% in Taiwan. In fiscal 2019, our acquisition of
Microsemi and our transition to sell-in revenue recognition contributed to the changes in net sales by country.
20
Table of Contents
A strong position in the Chinese market is a key component of our global growth strategy. The market for integrated
circuit products in China is highly competitive, and both international and domestic competitors are aggressively seeking to
increase their market share. Increased competition or economic weakness in the China market may make it difficult for us to
achieve our desired sales volumes in China. In particular, the trade relationship between the U.S. and China has worsened,
economic conditions in China remain uncertain, and we are unable to predict whether such uncertainty will continue or worsen
in future periods. The U.S. government has increased tariffs on products that have China as their country of origin and which
are imported into the U.S. Likewise, the China government has increased tariffs on products that have the U.S. as their country
of origin and which are imported into China. We have taken steps to mitigate the costs of these tariffs on our business.
Although these increases in tariffs did not result in significant increases to the operating costs of our business, they did,
however, adversely impact demand for our products during fiscal 2019. The recent additional tariffs imposed on components or
equipment that we or our suppliers source from China will increase our costs and could have a material adverse impact on our
operating results in the three months ending June 30, 2019 or future periods. Additionally, tariffs on our customers' products
could impact their sales of such end products, resulting in lower demand for our products. We may also incur increases in
manufacturing costs in mitigating the impact of tariffs on our customers.
We purchase a substantial portion of our raw materials and equipment from foreign suppliers. In addition, we own product
assembly and testing facilities near Bangkok, Thailand, which has experienced periods of political instability in the past. A
large portion of our finished goods inventory is maintained in Thailand. From time to time, Thailand has also experienced
periods of severe flooding. There can be no assurance that any future flooding or political instability in Thailand would not
have a material adverse impact on our operations. As part of our Atmel acquisition, we acquired a test facility in Calamba,
Philippines. We use various foundries and other foreign contractors for a significant portion of our assembly and testing and
wafer fabrication requirements.
Our reliance on foreign operations, foreign suppliers, maintenance of substantially all of our finished goods inventory at
foreign locations and significant foreign sales exposes us to foreign political and economic risks, including, but not limited to:
•
•
•
•
•
•
•
•
•
•
•
•
•
political, social and economic instability;
trade restrictions and changes in tariffs;
potentially adverse tax consequences;
economic uncertainty in the worldwide markets served by us;
import and export license requirements and restrictions;
changes in rules and laws related to taxes, environmental, health and safety, technical standards and consumer
protection in various jurisdictions;
currency fluctuations and foreign exchange regulations;
difficulties in staffing and managing international operations;
employment regulations;
disruptions due to cybersecurity incidents;
disruptions in international transport or delivery;
public health conditions; and
difficulties in collecting receivables and longer payment cycles.
If any of these risks materialize, or are worse than we anticipate, our sales could decrease and our operating results could
suffer, we could face an increase in the cost of components, production delays, general business interruptions, delays from
difficulties in obtaining export licenses for certain technology, tariffs and other barriers and restrictions, longer payment cycles,
increased taxes, restrictions on the repatriation of funds and the burdens of complying with a variety of foreign laws, any of
which could ultimately have a material adverse effect on our business.
Further changes in trade policy, tariffs, additional taxes, or restrictions on supplies, equipment, and raw materials including
rare earth minerals, may limit our ability to produce products, increase our selling and/or manufacturing costs, decrease
margins, reduce the competitiveness of our products, or inhibit our ability to sell products or purchase necessary equipment and
supplies, which could have a material adverse effect on our business, results of operations, or financial conditions.
Our contractual relationships with our customers expose us to risks and liabilities.
We do not typically enter into long-term contracts with our non-distributor customers, and therefore we cannot be certain
about future order levels from our customers. When we do enter into customer contracts, the contract is generally cancelable at
the convenience of the customer. Even though we had over 121,000 customers and our ten largest direct customers made up
approximately 11% of our total revenue for fiscal 2019 and six of our top ten direct customers are contract manufacturers that
21
Table of Contents
perform manufacturing services for many customers, cancellation of customer contracts could have an adverse impact on our
revenue and profits.
We have contracts with certain customers that differ from our standard terms of sale. For several of the significant markets
that we sell into, such as the automotive and personal computer markets, our current or potential customers may possess
significant leverage over us in negotiating the terms and conditions of supply as a result of their market size and position. For
example, under certain contracts we may commit to supply specific quantities of products on scheduled delivery dates, or agree
to extend our obligations for certain liabilities such as warranties or indemnification for quality issues or claims of intellectual
property infringement. If we are unable to supply the customer as required under the contract, the customer may incur
additional production costs, lost revenues due to subsequent delays in their own manufacturing schedule, or quality-related
issues. We may be liable for the customer's costs, expenses and damages associated with their claims and we may be obligated
to defend the customer against claims of intellectual property infringement and pay the associated legal fees. While we try to
minimize the number of contracts which contain such provisions, manage the risks underlying such liabilities, and set caps on
our liability exposure, sometimes we are not able to do so. In order to win important designs, avoid losing business to
competitors, maintain existing business, or be permitted to bid on new business, we have been, and may in the future be, forced
to agree to uncapped liability for such items as intellectual property infringement, product failure, or confidentiality. Such
provisions expose us to risk of liability far exceeding the purchase price of the products we sell under such contracts, the
lifetime revenues we receive from such products, or various forms of potential consequential damages. Further, where we do
not have negotiated contracts with our customers, the terms of our customer's orders may govern the transaction and contain
terms that are not favorable to us. These significant additional risks could result in a material adverse impact on our results of
operations and financial condition.
Reliance on government contracts and sales to governmental agencies could have a material adverse effect on our results of
operations.
A significant portion of the sales of Microsemi (which we acquired in May 2018) are from or are derived from government
agencies or customers whose principal sales are to U.S. government agencies. Such sales are subject to uncertainties regarding
governmental spending levels, spending priorities and policy changes. Future sales to U.S. government agencies or customers
are also subject to uncertain government appropriations and national defense policies and priorities, including the constraints of
the budgetary process, changes in the timing and potential spending priorities and the impact of any past or future government
shutdowns, contract terminations or renegotiations, or future sequestrations. Such sales are also subject to uncertainties related
to monetary, regulatory, tax and trade policies implemented by current or future administrations or by the U.S. Congress.
In the past, Microsemi has experienced delays and reductions in appropriations on programs that included its products. For
example, there were federal government shutdowns from January 20, 2018 to January 23, 2018 and from December 22, 2018
through January 25, 2019. Further delays, reductions in or terminations of government contracts or subcontracts, including
those caused by any past or future shutdown of the U.S. federal government, could materially and adversely affect our operating
results. If the U.S. government fails to complete its annual budget process or to provide for a continuing resolution to fund
government operations, another federal government shutdown may occur, during which time we may experience further delays
and reductions in appropriations or reductions in or terminations of government contracts or subcontracts, which could
materially and adversely affect our operating results. While we generally function as a subcontractor in these type of
transactions, further changes in U.S. government procurement regulations and practices, particularly surrounding initiatives to
reduce costs, may adversely impact the contracting environment and our operating results.
The U.S. government and its contractors may terminate their contracts with Microsemi or us at any time. For example, in
2014, Microsemi had a $75 million contract terminated for convenience by the U.S. government. Uncertainty with respect to
government spending and termination of contracts associated with government related projects could have a material adverse
impact on the revenue and other benefits we achieve from our Microsemi acquisition. Our business related to U.S.
governmental agencies or customers requires us to comply with applicable governmental regulations, particularly for our
facilities, systems and personnel that service such customers. Maintaining compliance with these regulations, including any
audit requirements, requires that we devote significant resources to such matters in terms of training, personnel, information
technology and facilities. Any failure to maintain compliance with these requirements may result in fines and penalties and loss
of current or future business that may materially and adversely affect our operating results.
We must attract and retain qualified personnel to be successful, and competition for qualified personnel can be intense.
Our success depends upon the efforts and abilities of our senior management, engineering, manufacturing and other
personnel. The competition for qualified engineering and management personnel can be intense. We may be unsuccessful in
retaining our existing key personnel or in attracting and retaining additional key personnel that we require. The loss of the
22
Table of Contents
services of one or more of our key personnel or the inability to add key personnel could harm our business. The loss of, or any
inability to attract personnel, even if not key personnel, if experienced in sufficient numbers could harm our business. We have
no employment agreements with any member of our senior management team.
Fluctuations in foreign currency exchange rates could adversely impact our operating results.
We use forward currency exchange contracts in an attempt to reduce the adverse earnings impact from the effect of
exchange rate fluctuations on our non-U.S. dollar net balance sheet exposures. Nevertheless, in periods when the U.S. dollar
significantly fluctuates in relation to the non-U.S. currencies in which we transact business, the value of our non-U.S. dollar
transactions can have an adverse effect on our results of operations and financial condition. In particular, in periods when a
foreign currency significantly declines in value in relation to the U.S. dollar, customers transacting in that foreign currency may
find it more difficult to fulfill their previously committed contractual obligations or to undertake new obligations to make
payments or purchase products. In periods when the U.S. dollar is significantly declining in relation to the British pound, Euro,
Thai baht, Taiwan dollar and Malaysian ringgit, the operational costs in our European and Thailand subsidiaries are adversely
affected. Although our business has not been materially adversely impacted by recent changes in the value of the U.S. dollar,
there can be no assurance as to the future impact that any weakness or strength in the U.S. dollar will have on our business or
results of operations.
The occurrence of events for which we are self-insured, or which exceed our insurance limits, may adversely affect our
profitability and liquidity.
We have insurance contracts with independent insurance companies related to many different types of risk; however, we
self-insure for some potentially significant risks and obligations. In these circumstances, we believe that it is more cost
effective for us to self-insure certain risks than to pay the high premium costs. The risks and exposures that we self-insure
include, but are not limited to certain property, product defects, cybersecurity matters, employment risks, environmental
matters, political risks, and intellectual property matters. Should there be a loss or adverse judgment or other decision in an
area for which we are self-insured, then our financial condition, results of operations and liquidity may be adversely affected.
We are subject to stringent environmental and other regulations, which may force us to incur significant expenses.
We must comply with all applicable federal, state, local and foreign governmental regulations related to the use, storage,
discharge and disposal of toxic, volatile or otherwise hazardous substances used in our products and manufacturing processes.
Our failure to comply with applicable regulations could result in fines, suspension of production, cessation of operations or
future liabilities. Such environmental regulations have required us in the past, and could require us in the future, to buy costly
equipment or to incur significant expenses to comply with such regulations. Our failure to control the use of, or adequately
restrict the discharge of, hazardous substances could impact the health of our employees and others and could impact our ability
to operate. Such failure could also restrict our ability to ship certain products to certain countries, require us to modify our
operations' logistics, or require us to incur other significant costs and expenses. There is a continuing expansion in
environmental laws with a focus on reducing or eliminating hazardous substances and substances of high concern in electronic
products and shipping materials. These and other future environmental regulations could require us to reengineer certain of our
existing products and may make it more expensive for us to manufacture, sell and ship our products. In addition, the number
and complexity of laws focused on the energy efficiency of electronic products and accessories, the recycling of electronic
products, and the reduction in the quantity and the recycling of packing materials have expanded significantly. It may be
difficult for us to timely comply with these laws and we may not have sufficient quantities of compliant products to meet
customers' needs, thereby adversely impacting our sales and profitability. We may also have to write off inventory in the event
that we hold unsaleable inventory as a result of changes to regulations or customer requirements. We expect these risks and
trends to continue. In addition, we anticipate increased customer requirements to meet voluntary criteria related to the
reduction or elimination of substances of high concern in our products, energy efficiency measures, and supplier practices
associated with sourcing and manufacturing. These requirements may increase our own costs, as well as those passed on to us
by our supply chain.
Customer demands for us to implement business practices that are more stringent than existing legal requirements may
reduce our revenue opportunities or cause us to incur higher costs.
Some of our customers and potential customers are requiring that we implement operating practices that are more stringent
than what is required by applicable laws with respect to workplace and labor requirements, the type of materials we use in our
products, environmental matters or other items. To comply with such requirements, we may have to pass these same operating
practices on to our suppliers. Our suppliers may refuse to implement these operating practices, or may charge us more for
complying with them. The cost to implement such practices may cause us to incur higher costs and reduce our profitability, and
23
Table of Contents
if we choose not to implement such practices, such customers may disqualify us as a supplier, resulting in decreased revenue
opportunities. Developing, administering, monitoring and auditing these customer-requested practices at our own sites and
those in our supply chain will increase our costs and may require that we hire more personnel.
Customer demands and regulations related to conflict-free minerals may force us to incur additional expenses.
As required by the Dodd-Frank Wall Street Reform and Consumer Protection Act, in August 2012, the SEC released
investigation, disclosure and reporting requirements regarding the use of "conflict" minerals mined from the Democratic
Republic of Congo and adjoining countries and which are necessary to the functionality or production of products. We filed a
report on Form SD with the SEC regarding such matters on May 23, 2018. Other countries are considering similar regulations.
If we cannot certify that we are using conflict-free minerals, customers may demand that we change the sourcing of minerals
and other materials used in the manufacture of our products, even if the costs for compliant minerals and materials significantly
increases and availability is limited. If we make changes to materials or suppliers, there will likely be costs associated with
qualifying new suppliers and production capacity and quality could be negatively impacted. Our relationships with customers
and suppliers may be adversely affected if we are unable to certify that our products are "conflict-free." We have incurred, and
expect in the future to incur, additional costs associated with complying with these new disclosure requirements, such as costs
related to determining the source of any conflict minerals used in our products. We may also encounter challenges to satisfy
those customers who require that all of the components of our products be certified as conflict free in a materially different
manner than advocated by the Responsible Minerals Initiative or the Dodd-Frank Wall Street Reform and Consumer Protection
Act. If we are not able to meet customer requirements, customers may choose to disqualify us as a supplier and we may have to
write off inventory in the event that it cannot be sold.
Regulatory authorities in jurisdictions into or from which we ship our products could levy fines, restrict or delay our ability
to export or transfer products, or increase costs associated with the manufacture or transfer of products.
A significant portion of our sales are made through the exporting and importing of products. In addition to local
jurisdictions' trade regulations, our U.S.-manufactured products or products based on U.S. technology are subject to U.S. laws
and regulations governing international trade, including, but not limited to the Foreign Corrupt Practices Act, Export
Administration Regulations, International Traffic in Arms Regulations and trade sanctions against embargoed countries and
denied entities administered by the U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC). Licenses or
proper license exceptions are required for the shipment of our products to certain countries. A determination by the U.S. or
foreign government that we have failed to comply with trade or export regulations or anti-bribery regulations can result in
penalties which may include denial of export privileges, fines, civil or criminal penalties, and seizure of products. Such
penalties could have a material adverse effect on our business, sales and earnings. Further, a change in these laws and
regulations could restrict our ability to transfer product to previously permitted countries, customers, distributors or other third
parties. Any one or more of these sanctions or a change in laws or regulations could have a material adverse effect on our
business, financial condition and results of operations.
For certain of our products associated with our Microsemi acquisition, we rely on U.S. export licenses to ship our products
to non-U.S. customers. In 2018, there was a federal government shutdown from January 20, 2018 to January 23, 2018 and a
second shutdown from December 22, 2018 through January 25, 2019. Due to the U.S. federal government shutdown, the
agency that approves these export licenses was temporarily closed. This resulted in a delay in certain shipments that were
scheduled to ship within the quarter. Although this delay did not result in a material adverse impact on our revenue in previous
quarters, it could have a material adverse impact on our revenue within the quarter of any future government shutdown, and in
the following quarter depending on the ability of the governmental agency to expedite processing of licenses delayed during the
shutdown.
The U.S. and other countries have levied tariffs and taxes on certain goods. Trade tensions between the U.S. and China
escalated in 2018 and 2019, including the U.S. increasing tariffs on Chinese origin goods, and China increasing tariffs on U.S.
goods. Some of our products were affected and are continuing to be affected by the increased tariffs. Higher duties on existing
tariffs and further rounds of tariffs have been recently announced or threatened by the U.S. and Chinese administrations. We
have taken steps to mitigate the costs of these tariffs on our business. Although these increases in tariffs did not result in
significant increases to the operating costs of our business, they did, however, adversely impact demand for our products during
fiscal 2019. The recent additional tariffs imposed on components or equipment that we or our suppliers source from China will
increase our costs and could have a material adverse impact on our operating results in the three months ending June 30, 2019
or future periods. Increased tariffs on our customers' products could impact their sales of their products, and increased tariffs on
our products in comparison to those of our competitors, could each result in lower demand for our products. Further changes in
trade policy, tariffs, additional taxes, restrictions on exports or other trade barriers, may limit our ability to produce products,
24
Table of Contents
increase our selling and/or manufacturing costs, decrease margins, reduce the competitiveness of our products, or inhibit our
ability to sell products, which could have a material adverse effect on our business, results of operations or financial conditions.
The outcome of future examinations of our income tax returns could have an adverse effect on our results of operations.
We are subject to examination of our income tax returns by the IRS and other tax authorities for fiscal 2007 and later. We
are subject to certain income tax examinations in foreign jurisdictions for fiscal 2007 and later.
We regularly assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our
provision for income taxes and have reserved for potential adjustments that may result from the current examinations. There
can be no assurance that the final determination of any of these or any future examinations will not have an adverse effect on
our effective tax rates, financial position and results of operations.
Exposure to greater than anticipated income tax liabilities, changes in tax rules and regulations (including the Act),
changes in the interpretation of tax rules and regulations, or unfavorable assessments from tax audits could affect our
effective tax rates, financial condition and results of operations
We are a U.S.-based multinational company subject to tax in multiple U.S. and foreign tax jurisdictions. Our income tax
obligations could be affected by many factors, including but not limited to changes to our corporate operating structure,
intercompany arrangements and tax planning strategies.
Our income tax expense is computed based on tax rates at the time of the respective financial period. Our future effective
tax rates, financial condition and results from operations could be unfavorably affected by changes in the tax rates in
jurisdictions where our income is earned, by changes in the tax rules and regulations or the interpretation of tax rules and
regulations in the jurisdictions in which we do business or by changes in the valuation of our deferred tax assets.
Currently, a majority of our revenue is generated from customers located outside the U.S., and a substantial portion of our
assets, including employees, are located outside of the U.S. The adoption of the Act significantly changed the taxation of U.S.-
based multinational corporations, by, among other things, reducing the U.S. corporate income tax rate, adopting elements of a
territorial tax system, assessing a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax
deferred, and creating new taxes on certain foreign-sourced earnings. The new legislation is unclear in some respects and will
require interpretations and implementing regulations by the Internal Revenue Service, as well as state tax authorities, and the
legislation could be subject to potential amendments and technical corrections, any of which could lessen or increase certain
adverse impacts of the legislation. A significant portion of our earnings are earned by our subsidiaries outside the U.S.
Changes to the taxation of certain foreign earnings resulting from the Act, along with the state tax impact of these changes and
potential future cash distributions, will likely have an adverse effect on our effective tax rate. Furthermore, changes to the
taxation of undistributed foreign earnings could change our future intentions regarding reinvestment of such earnings. The
foregoing items could have a material adverse effect on our business, cash flow, results of operations or financial conditions.
The future trading price of our common stock could be subject to wide fluctuations in response to a variety of factors.
The market price of our common stock has fluctuated significantly in the past and is likely to fluctuate in the future. The
future trading price of our common stock could be subject to wide fluctuations in response to a variety of factors, many of
which are beyond our control, including, but not limited to:
•
•
•
•
•
•
•
•
quarterly variations in our operating results or the operating results of other technology companies;
our ability to continue to realize the expected benefits of our acquisition of Microsemi;
general conditions in the semiconductor industry;
global economic and financial conditions;
changes in our financial guidance or our failure to meet such guidance;
changes in analysts' estimates of our financial performance or buy/sell recommendations;
any other acquisitions we pursue or complete; and
actual or anticipated announcements of technical innovations or new products by us or our competitors.
In addition, the stock market has from time to time experienced significant price and volume fluctuations that have affected
the market prices for many companies and that often have been unrelated to the operating performance of such companies.
These broad market fluctuations and other factors have harmed and may harm the market price of our common stock. Some or
all of the foregoing factors could also cause the market price of our convertible debentures to decline or fluctuate substantially.
25
Table of Contents
Anti-takeover defenses in our charter documents and under Delaware law could discourage takeover attempts, which could
also reduce the market price of our common stock.
Our certificate of incorporation and bylaws contain provisions that could delay or prevent a change in control of
Microchip. These provisions could also make it difficult for stockholders to elect directors that are not nominated by the
current members of our board of directors or take other corporate actions, including effecting changes in our management.
These provisions include:
•
•
•
•
•
the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval, which could be used to
significantly dilute the ownership of a hostile acquiror;
the right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of
directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill
vacancies on our board of directors;
the requirement that a special meeting of stockholders may be called only by the holders of 50% or more of the
combined voting power of all classes of our capital stock, which could delay the ability of our stockholders to
force consideration of a proposal or to take action, including the removal of directors;
the ability of our board of directors, by majority vote, to amend the bylaws, which may allow our board of
directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquiror to
amend the bylaws to facilitate an unsolicited takeover attempt; and
advance notice procedures with which stockholders must comply to nominate candidates to our board of directors
or to propose matters to be acted upon at a stockholders' meeting, which may discourage or deter a potential
acquiror from conducting a solicitation of proxies to elect the acquiror's own slate of directors or otherwise
attempting to obtain control of us.
In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These
provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from
merging or combining with us for a certain period of time. The application of Section 203 also could have the effect of
delaying or preventing a change in control of us.
Any of these provisions could, under certain circumstances, depress the market price of our common stock.
As a result of our acquisition activity, our goodwill and intangible assets have increased significantly in recent years and we
may in the future incur impairments to goodwill or intangible assets.
When we acquire a business, a substantial portion of the purchase price of the acquisition is allocated to goodwill and other
identifiable intangible assets. The amount of the purchase price which is allocated to goodwill is determined by the excess of
the purchase price over the net identifiable assets acquired. As of March 31, 2019, we had goodwill of $6.66 billion and net
intangible assets of $6.69 billion. In connection with the completion of our acquisition of Microsemi in May 2018, our balance
of goodwill and intangible assets increased significantly. We review our indefinite-lived intangible assets, including goodwill,
for impairment annually in the fourth fiscal quarter or whenever events or changes in circumstances indicate that the carrying
amount of those assets is more likely than not impaired. Factors that may be considered in assessing whether goodwill or
intangible assets may be impaired include a decline in our stock price or market capitalization, reduced estimates of future cash
flows and slower growth rates in our industry. Our valuation methodology for assessing impairment requires management to
make judgments and assumptions based on historical experience and to rely heavily on projections of future operating
performance. Because we operate in highly competitive environments, projections of our future operating results and cash
flows may vary significantly from our actual results. No goodwill impairment charges were recorded in fiscal 2019 or fiscal
2018. In fiscal 2019, we recognized $3.1 million of intangible asset impairment charges. No material intangible asset
impairment charges were recorded in fiscal 2018. If in future periods, we determine that our goodwill or intangible assets are
impaired, we will be required to write down these assets which would have a negative effect on our consolidated financial
statements.
Our foreign pension plans are unfunded, and any requirement to fund these plans in the future could negatively affect our
cash position and operating capital.
In connection with our acquisitions of Microsemi and Atmel, we assumed defined benefit pension plans that cover certain
of our French and German employees. Plan benefits are managed in accordance with local statutory requirements. Benefits are
based on years of service and employee compensation levels. The projected benefit obligation totaled $72.7 million at
March 31, 2019. Most of these plans are unfunded in compliance with local statutory regulations, and we have no immediate
26
Table of Contents
intention of funding these plans. Benefits are paid when amounts become due, commencing when participants retire. We
expect to pay approximately $1.3 million in fiscal 2020 for benefits earned. Should legislative regulations require complete or
partial funding of these plans in the future, it could negatively affect our cash position and operating capital.
From time to time we receive grants from governments, agencies and research organizations. If we are unable to comply
with the terms of those grants, we may not be able to receive or recognize grant benefits or we may be required to repay
grant benefits previously paid to us and recognize related charges, which would adversely affect our operating results and
financial position.
From time to time, we receive economic incentive grants and allowances from European governments, agencies and
research organizations targeted at increasing employment at specific locations. The subsidy grant agreements typically contain
economic incentive, headcount, capital and research and development expenditure and other covenants that must be met to
receive and retain grant benefits, and these programs can be subjected to periodic review by the relevant governments.
Noncompliance by us with the conditions of the grants could result in our forfeiture of all or a portion of any future amounts to
be received, as well as the repayment of all or a portion of amounts received to date.
Conversion of our debentures will dilute the ownership interest of our existing stockholders.
The conversion of some or all of our outstanding debentures will dilute the ownership interest of existing stockholders to
the extent we deliver common stock upon conversion of the debentures. Upon conversion, we may satisfy our conversion
obligation by delivering cash, shares of common stock or any combination, at our option. If upon conversion we elect to
deliver cash for the lesser of the conversion value and principal amount of the debentures, we would pay the holder the cash
value of the applicable number of shares of our common stock. Upon conversion, we intend to satisfy the lesser of the principal
amount or the conversion value of the debentures in cash. If the conversion value of a debenture exceeds the principal amount
of the debenture, we may also elect to deliver cash in lieu of common stock for the conversion value in excess of the one
thousand dollars principal amount (i.e., the conversion spread). There would be no adjustment to the numerator in the net
income per common share computation for the cash settled portion of the debentures as that portion of the debt instrument will
always be settled in cash. The conversion spread will be included in the denominator for the computation of diluted net income
per common share. Any sales in the public market of any common stock issuable upon conversion of our debentures could
adversely affect prevailing market prices of our common stock. In addition, the existence of the debentures may encourage
short selling by market participants because the conversion of the debentures could be used to satisfy short positions, or
anticipated conversion of the debentures into shares of our common stock could depress the price of our common stock.
Climate change regulations and sustained adverse climate change pose regulatory and physical risks that could harm our
results of operations or affect the way we conduct business.
Climate change regulations at the federal, state or local level or in international jurisdictions could require us to limit
emissions, change our manufacturing processes, obtain substitute materials which may cost more or be less available, increase
our investment in control technology for greenhouse gas emissions, fund offset projects or undertake other costly activities.
These regulations could significantly increase our costs and restrict our manufacturing operations by virtue of requirements for
new equipment. New permits may be required for our current operations, or expansions thereof. Failure to timely receive
permits could result in fines, suspension of production, or cessation of operations at one or more facilities. In addition,
restrictions on carbon dioxide or other greenhouse gas emissions could result in significant costs such as higher energy costs,
and utility companies passing down carbon taxes, emission cap and trade programs and renewable portfolio standards. The cost
of complying, or of failing to comply, with these and other climate change and emissions regulations could have an adverse
effect on our operating results.
Further, any sustained adverse change in climate could have a direct adverse economic impact on us, such as water and
power shortages, and higher costs of water or energy to control the temperature of our facilities. Certain of our operations are
located in arid or tropical regions, such as Arizona, Thailand, and the Philippines. Some environmental experts predict that
these regions may become vulnerable to storms, severe floods and droughts due to climate change. While we maintain business
recovery plans that are intended to allow us to recover from natural disasters or other events that can interrupt our business, we
cannot be certain that our plans will protect us from all such disasters or events.
Item 1B.
UNRESOLVED STAFF COMMENTS
None.
27
Table of Contents
Item 2.
PROPERTIES
At March 31, 2019, we owned and used the facilities described below:
Location
Gresham, Oregon
Approximate
Total Sq. Ft.
826,500
Wafer Fabrication (Fab 4); R&D Center; Administrative Offices; and
Warehousing
Uses
Chandler, Arizona
687,000
Executive and Administrative Offices; Wafer Probe; R&D Center; Sales and
Marketing; and Computer and Service Functions
Chacherngsao, Thailand
489,000
Assembly and Test; Wafer Probe; Sample Center; Warehousing; and
Administrative Offices
Colorado Springs,
Colorado
480,000
Manufacturing, Test, Research and Development, Computer and Service
Functions, Design and Engineering
Calamba, Philippines
460,000
Wafer Probe, Test, Warehousing and Administrative Offices
Tempe, Arizona
Bangalore, India
457,000
294,000
Wafer Fabrication (Fab 2); R&D Center; Administrative Offices; and
Warehousing
Research and Development; Sales and Marketing Support, and Administrative
Offices
Chacherngsao, Thailand
215,000
Assembly and Test; Warehousing; and Administrative Offices
Rousset, France
170,000
Design, Engineering, Test and Administrative
Lawrence, Massachusetts
160,000
Manufacturing and Administrative offices
Mount Holly Springs,
Pennsylvania
Garden Grove, California
100,000
Manufacturing, R&D and Administrative offices
98,100
Manufacturing, R&D and Administrative offices
San Jose, California
98,000
Design, Engineering, and Administrative
Chennai, India
91,000
Design and Engineering
Neckarbischofsheim,
Germany
Nantes, France
80,000
Manufacturing and Administrative offices
77,000
Design, Engineering, Test and Probe, Administrative and Warehousing
San Jose, California
71,000
Design, Engineering, and Administrative
San Jose, California
57,000
Design, Engineering, and Administrative
Beverly, Massachusetts
52,103
Manufacturing
Heilbronn, Germany
46,000
Design, Engineering and Administrative
Karlsruhe, Germany
43,000
Design, Engineering and Administrative
Ennis County, Ireland
40,000
Manufacturing
Simsbury, Connecticut
32,500
Manufacturing, R&D and Administrative offices
Shanghai, China
21,000
Research and Development; Marketing Support, and Administrative Offices
Hsinchu, Taiwan
15,000
Design, Engineering and Administrative
Our Chennai, India facility is currently under construction which will add 96,000 square feet of office space.
In addition to the facilities we own, we lease several research and development facilities and sales offices in North
America, Europe and Asia. Our aggregate monthly rental payment for our leased facilities is approximately $4.6 million.
28
Table of Contents
We currently believe that our existing facilities are suitable and will be adequate to meet our requirements for at least the
next 12 months.
See page 46 for a discussion of the capacity utilization of our manufacturing facilities.
Item 3.
LEGAL PROCEEDINGS
Refer to Note 13 to our consolidated financial statements for information regarding legal proceedings.
Item 4.
MINE SAFETY DISCLOSURES
Not applicable.
29
Table of Contents
PART II
Item 5.
MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock is traded on the NASDAQ Global Market under the symbol "MCHP."
Stock Price Performance Graph
The following graph and table show a comparison of the five-year cumulative total stockholder return, calculated on a
dividend reinvestment basis, for Microchip Technology Incorporated, the Standard & Poor's (S&P) 500 Stock Index, and the
Philadelphia Semiconductor Index.
Comparison of 5 year Cumulative Total Return*
*$100 invested on March 31, 2014 in stock or index, including reinvestment of dividends
Fiscal year ending March 31.
Copyright © 2017 S&P, a division of McGraw Hill Financial. All rights reserved.
Microchip Technology Incorporated
S&P 500 Stock Index
Philadelphia Semiconductor Index
Cumulative Total Return
March
2014
100.00
100.00
100.00
March
2015
105.55
112.73
120.57
March
2016
107.37
114.74
119.69
March
2017
168.33
134.45
182.14
March
2018
212.04
153.26
243.30
March
2019
195.92
167.81
260.60
Data acquired by Research Data Group, Inc. (www.researchdatagroup.com)
30
Table of Contents
On May 14, 2019, there were approximately 564 holders of record of our common stock. This figure does not reflect
beneficial ownership of shares held in nominee names.
Refer to "Item 12 - Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder
Matters," at page 58 below, for the information required by Item 201(d) of Regulation S-K with respect to securities authorized
for issuance under our equity compensation plans at March 31, 2019.
Issuer Purchases of Equity Securities
In May 2015, our Board of Directors authorized the repurchase of up to 20.0 million shares of our common stock in the
open market or in privately negotiated transactions. As of March 31, 2016, we had repurchased 8.6 million shares under this
authorization for approximately $363.8 million. In January 2016, our Board of Directors authorized an increase in the existing
share repurchase program to 15.0 million shares of common stock from the approximately 11.4 million shares remaining under
the prior authorization. There were no repurchases of common stock during fiscal 2019. There is no expiration date associated
with this repurchase program.
31
Table of Contents
Item 6.
SELECTED FINANCIAL DATA
You should read the following selected consolidated financial data for the five-year period ended March 31, 2019 in
conjunction with our consolidated financial statements and notes thereto and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" included in Items 7 and 8 of this Form 10-K. Our consolidated statements of
income data for each of the years in the three-year period ended March 31, 2019, and the balance sheet data as of March 31,
2019 and 2018, are derived from our audited consolidated financial statements, included in Item 8 of this Form 10-K. The
statement of income data for the years ended March 31, 2016 and 2015 and balance sheet data as of March 31, 2017, 2016 and
2015 have been derived from our audited consolidated financial statements not included herein (in the tables below all amounts
are in millions, except per share data).
Consolidated Statements of Income data:
Net sales
Special charges and other, net (2)
Loss on settlement of debt (3)
Net income from continuing operations
Basic net income per common share from continuing
operations
Diluted net income per common share from
continuing operations
Dividends declared per common share
Consolidated Balance Sheets data:
$
$
$
$
$
$
$
Total assets
Net long-term debt and capital lease obligations, less
current maturities (3)
Microchip Technology stockholders' equity
$ 18,350.0
$
$
8,956.0
5,287.5
2019 (1)
Year ended March 31,
2017 (1)
2016
2018
2015
$
5,349.5
33.7
$
(12.6) $
$
355.9
$
3,980.8
17.5
$
(16.0) $
$
255.4
$
3,407.8
98.6
$
(43.9) $
$
170.6
$
2,173.3
4.0
$
— $
$
323.9
2,147.0
2.8
(50.6)
365.3
1.51
1.42
1.457
$
$
$
$
$
$
1.10
1.03
1.449
8,257.2
1,769.1
3,279.8
$
$
$
$
$
$
0.79
0.73
1.441
7,686.9
2,912.1
3,270.7
$
$
$
$
$
$
1.59
1.49
1.433
5,537.9
2,465.8
2,150.9
$
$
$
$
$
$
1.84
1.65
1.425
4,780.7
1,840.0
2,044.7
(1) Refer to Note 2 to our consolidated financial statements for an explanation of our material business combinations during
fiscal 2019 and fiscal 2017.
(2) Refer to Note 4 to our consolidated financial statements for a discussion of the special charges and other, net.
(3) Refer to Note 12 Debt and Credit Facility for further discussion.
32
Table of Contents
Item 7.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Note Regarding Forward-looking Statements
This report, including "Item 1 – Business," "Item 1A – Risk Factors," and "Item 7 – Management's Discussion and
Analysis of Financial Condition and Results of Operations," contains certain forward-looking statements that involve risks and
uncertainties, including statements regarding our strategy, financial performance and revenue sources. We use words such as
"anticipate," "believe," "plan," "expect," "future," "continue," "intend" and similar expressions to identify forward-looking
statements. Our actual results could differ materially from the results anticipated in these forward-looking statements as a
result of certain factors including those set forth under "Risk Factors," beginning at page 12 and elsewhere in this Form 10-
K. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or achievements. You should not place undue reliance on these forward-looking
statements. We disclaim any obligation to update information contained in any forward-looking statement. These forward-
looking statements include, without limitation, statements regarding the following:
• The effects that uncertain global economic conditions and fluctuations in the global credit and equity markets may
have on our financial condition and results of operations;
• The effects and amount of competitive pricing pressure on our product lines and modest pricing declines in
certain of our more mature proprietary product lines;
• Our ability to moderate future average selling price declines;
• The effect of product mix, capacity utilization, yields, fixed cost absorption, competition and economic conditions
on gross margin;
• The amount of, and changes in, demand for our products and those of our customers;
• The impact of trade restrictions and changes in tariffs, including those impacting China;
• Our expectation that in the future we will acquire additional businesses that we believe will complement our
existing businesses;
• Our expectation that in the future we will enter into joint development agreements or other business or strategic
relationships with other companies;
• The level of orders that will be received and shipped within a quarter, including the impact of our product lead
times;
• Our expectation that our June 2019 days of inventory levels will be down 8 days to up 11 days compared to the
March 2019 levels. Our belief that our existing level of inventory will allow us to maintain competitive lead
times and provide strong delivery performance to our customers;
• The effect that distributor and customer inventory holding patterns will have on us;
• Our belief that customers recognize our products and brand name and use distributors as an effective supply
channel;
• Anticipating increased customer requirements to meet voluntary criteria related to the reduction or elimination of
substances in our products;
• Our belief that deferred cost of sales are recorded at their approximate carrying value and will have low risk of
material impairment;
• Our belief that our direct sales personnel combined with our distributors provide an effective means of reaching
our customer base;
• The accuracy of our estimates of the useful life and values of our property, assets and other liabilities;
• Our ability to increase the proprietary portion of our analog and interface product lines and the effect of such an
increase;
• Our belief that our processes afford us both cost-effective designs in existing and derivative products and greater
functionality in new product designs;
• The impact of any supply disruption we may experience;
• Our ability to effectively utilize our facilities at appropriate capacity levels and anticipated costs;
• That we adjust capacity utilization to respond to actual and anticipated business and industry-related conditions;
• That our existing facilities will provide sufficient capacity to respond to increases in demand with modest
incremental capital expenditures;
• That manufacturing costs will be reduced by transition to advanced process technologies;
• Our ability to maintain manufacturing yields;
• Continuing our investments in new and enhanced products;
• The cost effectiveness of using our own assembly and test operations;
• Our anticipated level of capital expenditures;
• Continuation and amount of quarterly cash dividends;
33
Table of Contents
• That the Atmel acquisition was structured in a manner that enabled us to utilize a substantial portion of the cash,
cash equivalents, short-term investments and long-term investments held by certain of our foreign subsidiaries in
a tax efficient manner and that our determinations with respect to the tax consequences of the acquisition are
reasonable;
• The sufficiency of our existing sources of liquidity to finance anticipated capital expenditures and otherwise meet
our anticipated cash requirements, and the effects that our contractual obligations are expected to have on them;
• The impact of seasonality on our business;
• Our belief that our IT system compromise has not had a material adverse effect on our business or resulted in any
material damage to us;
• The accuracy of our estimates used in valuing employee equity awards;
• That the resolution of legal actions will not have a material effect on our business, and the accuracy of our
assessment of the probability of loss and range of potential loss;
• The recoverability of our deferred tax assets;
• The adequacy of our tax reserves to offset any potential tax liabilities, having the appropriate support for our
income tax positions and the accuracy of our estimated tax rate;
• That we intend to pay the one-time transition tax over a period of eight years;
• Our belief that our determinations with respect to the tax consequences of the Atmel acquisition are reasonable;
• Our belief that the expiration of any tax holidays will not have a material impact on our overall tax expense or
effective tax rate;
• Our belief that the estimates used in preparing our consolidated financial statements are reasonable;
• Our actions to vigorously and aggressively defend and protect our intellectual property on a worldwide basis;
• Our ability to obtain patents and intellectual property licenses and minimize the effects of litigation;
• The level of risk we are exposed to for product liability claims or indemnification claims;
• The effect of fluctuations in market interest rates on our income and/or cash flows;
• The effect of fluctuations in currency rates;
• That we could determine to repatriate some of our offshore earnings in future periods to fund stockholder
dividends, share repurchases, acquisitions or other corporate activities;
• Our intention to satisfy the lesser of the principal amount or the conversion value of our debentures in cash;
• Our intention to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign
subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we would incur significant, additional
costs upon repatriation of such amounts.
• Changes to the taxation of undistributed foreign earnings could change our future intentions regarding
reinvestment of such earnings;
• Our belief that the effect the new tax laws will have on low-taxed income of foreign subsidiaries will have the
most significant, adverse impact;
• Our intent to maintain a high-quality investment portfolio that preserves principal, meets liquidity needs, avoids
inappropriate concentrations and delivers an appropriate yield; and
• Our ability to collect accounts receivable.
Our actual results could differ materially from the results anticipated in these forward-looking statements as a result of
certain factors including those set forth in "Item 1A – Risk Factors," and elsewhere in this Form 10-K. Although we believe
that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. You should not place undue reliance on these forward-looking statements. We disclaim
any obligation to update the information contained in any forward-looking statement.
Introduction
The following discussion should be read in conjunction with the consolidated financial statements and the related notes
that appear elsewhere in this document, as well as with other sections of this Annual Report on Form 10-K, including "Item 1 –
Business;" "Item 6 – Selected Financial Data;" and "Item 8 – Financial Statements and Supplementary Data."
We begin our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) with a
summary of our overall business strategy to give the reader an overview of the goals of our business and the overall direction of
our business and products. This is followed by a discussion of the Critical Accounting Policies and Estimates that we believe
are important to understanding the assumptions and judgments incorporated in our reported financial results. We then discuss
our Results of Operations for fiscal 2019 compared to fiscal 2018, and for fiscal 2018 compared to fiscal 2017. We then
provide an analysis of changes in our balance sheet and cash flows, and discuss our financial commitments in sections titled
"Liquidity and Capital Resources," "Contractual Obligations" and "Off-Balance Sheet Arrangements."
34
Table of Contents
Acquisition of Microsemi
On May 29, 2018, we completed our acquisition of Microsemi Corporation, a publicly traded company headquartered in
Aliso Viejo, California. We paid an aggregate of approximately $8.19 billion in cash to the stockholders of Microsemi. The
total consideration transferred in the acquisition, including approximately $53.9 million of non-cash consideration for the
exchange of certain share-based payment awards of Microsemi for stock awards of Microchip, was approximately $8.24
billion. In addition to the consideration transferred, we recognized in our consolidated financial statements $3.23 billion in
liabilities of Microsemi consisting of debt, taxes payable and deferred, pension obligations, restructuring, and contingent and
other liabilities of which $2.06 billion of existing debt was paid off. We financed the purchase price using approximately $8.10
billion of borrowings consisting of $3.10 billion of loans under our revolving line of credit (the "Revolving Credit Facility"),
$3.00 billion of term loans ("Term Loan Facility") provided under our amended and restated Credit Agreement, and $2.00
billion in newly issued senior secured notes. We incurred $22.0 million in costs related to the acquisition. As a result of the
acquisition, Microsemi became a wholly owned subsidiary of Microchip. Microsemi offers a comprehensive portfolio of
semiconductor and system solutions for aerospace and defense, communications, data center and industrial markets. Our
primary reason for this acquisition was to expand our range of solutions, products and capabilities by extending our served
available market.
For further details, see the discussion in Note 2 of our financial statements included in this report.
Material Weaknesses in Internal Controls
As discussed in Item 9A “Controls and Procedures” in this report on Form 10-K, in the fourth quarter of fiscal 2019,
we identified a material weakness in our internal controls related to accounting for income taxes and we also identified a
material weakness in our internal controls related to IT system access. Internal controls related to such matters are important to
accurately reflect our financial position and results of operations in our financial reports. We are in the process of remediating
the material weaknesses, but our efforts may not be successful. If we are unable to remediate the material weaknesses in an
appropriate and timely manner, or if we identify additional control deficiencies that individually or together constitute
significant deficiencies or material weaknesses, our ability to accurately record, process, and report financial information and
consequently, our ability to prepare financial statements within required time periods, could be adversely affected. Failure to
maintain effective internal controls could result in violations of applicable securities laws, stock exchange listing requirements,
and the covenants under our debt agreements, subject us to litigation and investigations, negatively affect investor confidence
in our financial statements, and adversely impact our stock price and ability to access capital markets. For additional
information, refer to Item 9A "Controls and Procedures."
IT System Compromise
We have learned of an ongoing compromise of our computer networks by what is believed to be sophisticated hackers.
We have engaged experienced legal counsel and a leading forensic investigatory firm with experience in such matters. We have
taken steps to identify malicious activity on our network including a compromise of our network and, as of the date of this
filing, we are implementing a containment plan. We are continuing to evaluate the effectiveness of the containment plan and
the amount and content of the information that was compromised and to implement additional remedial actions. At this time,
we do not believe that this IT system compromise has had a material adverse effect on our business or resulted in any material
damage to us. However, we are still evaluating the amount and type of data that was compromised and there can be no
assurance as to what the impact of this IT system compromise will be. As described above, in connection with the IT system
compromise, our management has concluded that we have a material weakness in our internal controls.
Strategy
Our goal is to be a worldwide leader in providing specialized semiconductor products for a wide variety of embedded
control applications. Our strategic focus is on embedded control solutions, including general purpose and specialized 8-bit, 16-
bit, and 32-bit microcontrollers, 32-bit microprocessors, field-programmable gate array (FPGA) products, a broad spectrum of
high-performance linear, mixed-signal, power management, thermal management, discrete diodes and MOSFETS, radio
frequency (RF), timing, timing systems, safety, security, wired connectivity and wireless connectivity devices, as well as Serial
Electrically Erasable Programmable Read Only Memory (EEPROM), Serial Flash memories, Parallel Flash memories, Serial
Electrically Erasable Random Access Memory (EERAM) and Serial Static Random Access Memory (SRAM). We also license
Flash-IP solutions that are incorporated in a broad range of products. We provide highly cost-effective embedded control
solutions that also offer the advantages of small size, high performance, extreme low power usage, wide voltage range
operation, mixed signal integration and ease of development, thus enabling timely and cost-effective integration of our
solutions by our customers in their end products. We license our SuperFlash technology and other technologies to wafer
35
Table of Contents
foundries, integrated device manufacturers and design partners throughout the world for use in the manufacture of advanced
microcontroller products, gate array, radio frequency (RF) and analog products that require embedded non-volatile memory.
We sell our products to a broad base of domestic and international customers across a variety of industries. The principal
markets that we serve include consumer, automotive, industrial, aerospace, office communication, and computing. Our
business is subject to fluctuations based on economic conditions within these markets.
Our manufacturing operations include wafer fabrication, wafer probe and assembly and test. The ownership of a
substantial portion of our manufacturing resources is an important component of our business strategy, enabling us to maintain
a high level of manufacturing control resulting in us being one of the lowest cost producers in the embedded control
industry. By owning wafer fabrication facilities and assembly and test operations, and by employing statistical process control
techniques, we have been able to achieve and maintain high production yields. Direct control over manufacturing resources
allows us to shorten our design and production cycles. This control also allows us to capture a portion of the wafer
manufacturing and the assembly and test profit margin. We do outsource a significant portion of our manufacturing
requirements to third parties. Our acquisition of Microsemi significantly increased the amount of our outsourced
manufacturing requirements.
We employ proprietary design and manufacturing processes in developing our embedded control products. We believe our
processes afford us both cost-effective designs in existing and derivative products and greater functionality in new product
designs. While many of our competitors develop and optimize separate processes for their logic and memory product lines, we
use a common process technology for both microcontroller and non-volatile memory products. This allows us to more fully
leverage our process research and development costs and to deliver new products to market more rapidly. Our engineers utilize
advanced computer-aided design tools and software to perform circuit design, simulation and layout, and our in-house
photomask and wafer fabrication facilities enable us to rapidly verify design techniques by processing test wafers quickly and
efficiently.
We are committed to continuing our investment in new and enhanced products, including development systems, and in our
design and manufacturing process technologies. We believe these investments are significant factors in maintaining our
competitive position. Our current research and development activities focus on the design of new microcontrollers, digital
signal controllers, memory, analog and mixed-signal products, FPGAs, timing systems, Flash-IP, development systems,
software and application-specific software libraries. We are also developing new design and process technologies to achieve
further cost reductions and performance improvements in our products.
We market and sell our products worldwide primarily through a network of direct sales personnel and distributors. Our
distributors focus primarily on servicing the product and technical support requirements of a broad base of diverse
customers. We believe that our direct sales personnel combined with our distributors provide an effective means of reaching
this broad and diverse customer base. Our direct sales force focuses primarily on major strategic accounts in three
geographical markets: the Americas, Europe and Asia. We currently maintain sales and support centers in major metropolitan
areas in North America, Europe and Asia. We believe that a strong technical service presence is essential to the continued
development of the embedded control market. Many of our client engagement managers (CEMs), embedded system engineers
(ESEs), and sales management personnel have technical degrees and have been previously employed in an engineering
environment. We believe that the technical knowledge of our sales force is a key competitive advantage in the sale of our
products. The primary mission of our ESE team is to provide technical assistance to strategic accounts and to conduct periodic
training sessions for CEMs and distributor sales teams. ESEs also frequently conduct technical seminars for our customers in
major cities around the world, and work closely with our distributors to provide technical assistance and end-user support.
See "Our operating results are impacted by both seasonality and the wide fluctuation of supply and demand in the
semiconductor industry," on page 16 for discussion of the impact of seasonality on our business.
Critical Accounting Policies and Estimates
General
Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. We review the
accounting policies we use in reporting our financial results on a regular basis. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and
related disclosure of contingent liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue
recognition, business combinations, share-based compensation, inventories, income taxes, senior and junior subordinated
36
Table of Contents
convertible debt and contingencies. We base our estimates on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Our results may differ from these estimates due
to actual outcomes being different from those on which we based our assumptions. We review these estimates and judgments
on an ongoing basis. We believe the following critical accounting policies affect our more significant judgments and estimates
used in the preparation of our consolidated financial statements.
Revenue Recognition (subsequent to our adoption of ASU 2014-09-Revenue from Contracts with Customers (ASC 606) on
April 1, 2018)
We generate revenue primarily from sales of our semiconductor products to distributors and non-distributor customers
(direct customers) and, to a lesser extent, from royalties paid by licensees of our intellectual property. We apply the following
five-step approach to determine the timing and amount of revenue recognition: (1) identify the contract with the customer, (2)
identify performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the
performance obligations in the contract, and (5) recognize revenue when the performance obligation is satisfied.
Sales to our distributors are governed by a distributor agreement, a purchase order, and an order acknowledgment. Sales to
distributors do not meet the definition of a contract, as defined by ASC 606, until the distributor has sent in a purchase order,
we have acknowledged the order, we have deemed the collectability of the consideration to be probable, and legally
enforceable rights and obligations have been created; this generally occurs 30 days prior to the estimated ship date. As is
customary in the semiconductor industry, we offer price concessions and stock rotation rights to many of our distributors. As
these are forms of variable consideration, we estimate the amount of consideration to which we will be entitled using recent
historical data and applying the expected value method. Usually, there is only a single performance obligation in the contract,
and therefore the entire transaction price is allocated to the single performance obligation. After the transaction price has been
allocated, we recognize revenue when the performance obligation is satisfied. Substantially all of the revenue generated from
contracts with distributors is recognized at the time risk and title of the inventory transfers to the distributor.
Sales to our direct customers are generally governed by a purchase order and an order acknowledgment. Sales to direct
customers usually do not meet the definition of a contract, as defined by ASC 606, until shipment of the product occurs.
Generally, the transaction price associated with contracts with direct customers is set at the standalone selling price and is not
variable. Usually, there is only a single performance obligation in the contract, and therefore the entire transaction price is
allocated to the single performance obligation. After the transaction price has been allocated, we recognize revenue when the
performance obligation is satisfied. Substantially all of the revenue generated from contracts with direct customers is
recognized at the time risk and title of the inventory transfers to the customer.
Revenue generated from our licensees is governed by licensing agreements. Our primary performance obligation related to
these agreements is to provide the licensee the right to use the intellectual property. The final transaction price is determined by
multiplying the usage of the license by the royalty, which is fixed in the licensing agreement. Revenue is recognized as usage
of the license occurs.
Revenue Recognition - Distributors (prior to our adoption of ASC 606 on April 1, 2018)
Our distributors worldwide generally had broad price protection and product return rights which prevented the sales
pricing from being fixed or determinable at the time of shipment to our distributors. Therefore, revenue recognition was
deferred until the pricing uncertainty was resolved, which generally occurred when the distributor sold the product to their
customer. At the time of shipment to these distributors, we recorded a trade receivable for the selling price as there was a
legally enforceable right to payment, relieved inventory for the carrying value of goods shipped since legal title had passed to
the distributor, and recorded the gross margin in deferred income on shipments to distributors on our consolidated balance
sheets.
Deferred income on shipments to distributors effectively represented the gross margin on the sale to the distributor;
however, the amount of gross margin that we recognized in the subsequent periods was less than the deferred margin as a result
of credits granted to distributors on specifically identified products and customers to allow the distributors to earn a competitive
gross margin on the sale of our products to their end customers and price protection concessions related to market pricing
conditions.
We sold the majority of the items in our product catalog to our distributors worldwide at a uniform list price. However,
distributors resold our products to end customers at a broad range of individually negotiated price points. The majority of our
distributors' resales required a reduction from the original list price paid. Often, under these circumstances, we remitted back to
37
Table of Contents
the distributor a portion of their original purchase price after the resale transaction was completed in the form of a credit against
the distributors' outstanding accounts receivable balance. The credits were on a per unit basis and were not given to the
distributor until they provided information to us regarding the sale to their end customer. The price reductions varied
significantly based on the customer, product, quantity ordered, geographic location and other factors. Discounts to a price less
than our cost have historically been rare. The effect of granting these credits established the net selling price to our distributors
for the product and resulted in the net revenue recognized by us when the product was sold by the distributors to their end
customers. Thus, a portion of the "deferred income on shipments to distributors" balance represented the amount of
distributors' original purchase price that was credited back to the distributors in the subsequent periods. We did not reduce
deferred income on shipments to distributors or accounts receivable by anticipated concessions; rather, price concessions were
typically recorded against deferred income on shipments to distributors and accounts receivable when incurred, which was
generally at the time the distributor sold the product. At March 31, 2018, we had approximately $479.6 million of deferred
revenue and $145.8 million in deferred cost of sales recognized as $333.8 million of deferred income on shipments to
distributors. The deferred income on shipments to distributors that was ultimately recognized in our income statement was
lower than the amount reflected on the balance sheet at March 31, 2018 due to additional price credits that were granted to the
distributors when the product was sold to their customers. These additional price credits historically have resulted in the
deferred income approximating the overall gross margins that we recognized in the distribution channel of our business.
Distributor advances, reflected as a reduction of deferred income on shipments to distributors on our consolidated balance
sheets, totaled $203.9 million at March 31, 2018. On sales to distributors, our payment terms generally require the distributor
to settle amounts owed to us for an amount in excess of their ultimate cost. The sales price to our distributors may be higher
than the amount that the distributors will ultimately owe us because distributors often negotiate price reductions after
purchasing products from us and such reductions are often significant. It is our practice to apply these negotiated price
discounts to future purchases, requiring the distributor to settle receivable balances, on a current basis, generally within 30
days, for amounts originally invoiced. This practice has an adverse impact on the working capital of our distributors. As such,
we have entered into agreements with certain distributors whereby we advance cash to the distributors to reduce the
distributors' working capital requirements. These advances are reconciled at least on a quarterly basis and are estimated based
on the amount of ending inventory as reported by the distributor multiplied by a negotiated percentage. Such advances had no
impact on our revenue recognition or our consolidated statements of income. We processed discounts taken by distributors
against our deferred income on shipments to distributors' balance and true-up the advanced amounts generally after the end of
each completed fiscal quarter. The terms of these advances are set forth in binding legal agreements and are unsecured, bear no
interest on unsettled balances and are due upon demand. The agreements governing these advances can be canceled by us at
any time.
We reduced product pricing through price protection based on market conditions, competitive considerations and other
factors. Price protection was granted to distributors on the inventory they had on hand at the date the price protection was
offered. When we reduced the price of our products, it allowed the distributor to claim a credit against its outstanding accounts
receivable balances based on the new price of the inventory it had on hand as of the date of the price reduction. There was no
immediate revenue impact from the price protection, as it was reflected as a reduction of the deferred income on shipments to
distributors' balance.
Products returned by distributors and subsequently scrapped have historically been immaterial to our consolidated results
of operations. We routinely evaluated the risk of impairment of the deferred cost of sales component of the deferred income on
shipments to distributors account. Because of the historically immaterial amounts of inventory that have been scrapped, and
historically rare instances where discounts given to a distributor resulted in a price less than our cost, we believe the deferred
costs were recorded at their approximate carrying value.
Business Combinations
All of our business combinations are accounted for at fair value under the acquisition method of accounting. Under the
acquisition method of accounting, (i) acquisition-related costs, except for those costs incurred to issue debt or equity securities,
will be expensed in the period incurred; (ii) non-controlling interests will be valued at fair value at the acquisition date; (iii) in-
process research and development will be recorded at fair value as an intangible asset at the acquisition date and amortized
once the technology reaches technological feasibility; (iv) restructuring costs associated with a business combination will be
expensed subsequent to the acquisition date; and (v) changes in deferred tax asset valuation allowances and income tax
uncertainties after the acquisition date will be recognized through income tax expense. The measurement of the fair value of
assets acquired and liabilities assumed requires significant judgment. The valuation of intangible assets, in particular, requires
that we use valuation techniques such as the income approach. The income approach includes the use of a discounted cash
flow model, which includes discounted cash flow scenarios and requires the following significant estimates: revenue,
expenses, capital spending and other costs, and discount rates based on the respective risks of the cash flows. Under the
38
Table of Contents
acquisition method of accounting, the aggregate amount of consideration we pay for a company is allocated to net tangible
assets and intangible assets based on their estimated fair values as of the acquisition date. The excess of the purchase price
over the value of the net tangible assets and intangible assets is recorded to goodwill. On an annual basis, we test goodwill for
impairment and through March 31, 2019, we have never recorded an impairment charge against our goodwill balance.
Share-based Compensation
We measure at fair value and recognize compensation expense for all share-based payment awards, including grants of
employee stock options, restricted stock units (RSUs) and employee stock purchase rights, to be recognized in our financial
statements based on their respective grant date fair values. For the past several years, we have utilized RSUs as our primary
equity incentive compensation instrument for employees. Share-based compensation cost is measured on the grant date based
on the fair market value of our common stock discounted for expected future dividends and is recognized as expense on a
straight-line basis over the requisite service periods. Total share-based compensation expense recognized in fiscal 2019 was
$166.4 million, of which $151.5 million was reflected in operating expenses and $14.9 million was reflected in cost of sales.
Total share-based compensation included in our inventory balance was $12.4 million at March 31, 2019.
During the year ended March 31, 2017, we elected to early adopt ASU 2016-09, Compensation - Stock Compensation,
Improvements to Employee Share-Based Payment Accounting (Topic 718). Under this standard, entities are permitted to make
an accounting policy election to either estimate forfeitures on share-based payment awards, as previously required, or to
recognize forfeitures as they occur. We have elected to recognize forfeitures as they occur. Prior to the adoption of ASU
2016-09, we estimated the number of share-based awards to be forfeited due to employee turnover.
If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate,
increase or cancel any remaining unearned share-based compensation expense. Future share-based compensation expense and
unearned share-based compensation will increase to the extent that we grant additional equity awards to employees or we
assume unvested equity awards in connection with acquisitions.
Inventories
Inventories are valued at the lower of cost or net realizable value using the first-in, first-out method. We write down our
inventory for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of
inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual
market conditions are less favorable than those we projected, additional inventory write-downs may be required. Inventory
impairment charges establish a new cost basis for inventory and charges are not subsequently reversed to income even if
circumstances later suggest that increased carrying amounts are recoverable. In estimating our inventory obsolescence, we
primarily evaluate estimates of demand over a 12-month period and record impairment charges for inventory on hand in excess
of the estimated 12-month demand. Estimates for projected 12-month demand are generally based on the average shipments of
the prior three-month period, which are then annualized to adjust for any potential seasonality in our business. The estimated
12-month demand is compared to our most recently developed sales forecast to further reconcile the 12-month demand
estimate. Management reviews and adjusts the estimates as appropriate based on specific situations. For example, demand can
be adjusted up for new products for which historic sales are not representative of future demand. Alternatively, demand can be
adjusted down to the extent any existing products are being replaced or discontinued.
In periods where our production levels are substantially below our normal operating capacity, the reduced production
levels of our manufacturing facilities are charged directly to cost of sales. As a result of production being below normal
operating levels in our wafer fabrication facilities, approximately $19.0 million was charged to cost of sales in fiscal 2019.
There was no charge to cost of sales for reduced production levels in fiscal 2018 or fiscal 2017.
Income Taxes
As part of the process of preparing our consolidated financial statements, we are required to estimate our income taxes in
each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure together with
assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences
result in deferred tax assets and liabilities, which are included within our consolidated balance sheets. We must then assess the
likelihood that our deferred tax assets will be recovered from future taxable income within the relevant jurisdiction and to the
extent we believe that recovery is not likely, we must establish a valuation allowance. We provided valuation allowances for
certain of our deferred tax assets, where it is more likely than not that some portion, or all of such assets, will not be realized.
39
Table of Contents
Various taxing authorities in the U.S. and other countries in which we do business scrutinize the tax structures employed
by businesses. Companies of our size and complexity are regularly audited by the taxing authorities in the jurisdictions in
which they conduct significant operations. During the year ended March 31, 2019, various foreign jurisdictions finalized their
audits. The close of these audits did not have an adverse impact on our financial statements. We are currently being audited by
the tax authorities in the United States and in various foreign jurisdictions. At this time, we do not know what the outcome of
these audits will be. We record benefits for uncertain tax positions based on an assessment of whether it is more likely than not
that the tax positions will be sustained based on their technical merits under currently enacted law. If this threshold is not met,
no tax benefit of the uncertain tax position is recognized. If the threshold is met, we recognize the largest amount of the tax
benefit that is more than 50% likely to be realized upon ultimate settlement.
The accounting model as defined in Accounting Standards Codification ("ASC") 740 related to the valuation of uncertain
tax positions requires us to presume that the tax position will be examined by the relevant taxing authority that has full
knowledge of all relevant information and that each tax position will be evaluated without consideration of the possibility of
offset or aggregation with other positions. The recognition requirement for the liability exists even if we believe the possibility
of examination by a taxing authority or discovery of the related risk matters is remote or where we have a long history of the
taxing authority not performing an exam or overlooking an issue. We will record an adjustment to a previously recorded
position if new information or facts related to the position are identified in a subsequent period. All adjustments to the
positions are recorded through the income statement. Generally, adjustments will be recorded in periods subsequent to the
initial recognition if the taxing authority has completed an audit of the period that results in the position being effectively
settled or if the statute of limitation expires. Due to the inherent uncertainty in the estimation process and in consideration of
the criteria of the accounting model, amounts recognized in the financial statements in periods subsequent to the initial
recognition may significantly differ from the estimated exposure of the position under the accounting model.
On December 22, 2017, the Act was enacted into law. The Act provides for numerous significant tax law changes and
modifications including the reduction of the U.S. federal corporate income tax rate from 35.0% to 21.0%, the requirement for
companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and the
creation of new taxes on certain foreign-sourced earnings. As a fiscal year-end taxpayer, certain provisions of the Act began to
impact us in our third quarter of fiscal 2018, while other provisions have become effective for us in fiscal 2019.
In addition to the impacts of tax reform on fiscal 2018, the Act also establishes new tax laws that are effective for fiscal
2019, including, but not limited to, (1) a new provision designed to tax low-taxed income of foreign subsidiaries ("GILTI"),
which allows for the possibility of using foreign tax credits ("FTCs") and a deduction of up to 50% to offset the income tax
liability (subject to some limitations); (2) limitations on the deductibility of certain executive compensation; (3) limitations on
the deductibility of interest expense; and (4) limitations on the use of FTCs to reduce the U.S. income tax liability. While each
of these provisions is expected to have an impact on our tax expense in future periods, the increase in tax expense for GILTI is
the most significant.
Generally accepted accounting principles in the United States of America (US GAAP) allows taxpayers to make an
accounting policy election of either (1) treating taxes due on GILTI inclusions as a current-period expense when incurred or (2)
recognizing deferred taxes for temporary basis differences that are expected to reverse as GILTI in future years. We are making
a policy choice to include taxes due on the future GILTI inclusion in taxable income when incurred.
Senior and Junior Subordinated Convertible Debt
We separately account for the liability and equity components of our senior and junior subordinated convertible debt in a
manner that reflects our nonconvertible debt (unsecured debt) borrowing rate when interest cost is recognized. This results in a
bifurcation of a component of the debt, classification of that component in equity and the accretion of the resulting discount on
the debt to be recognized as part of interest expense in our consolidated statements of income. Lastly, we include the dilutive
effect of the shares of our common stock issuable upon conversion of the outstanding senior and junior subordinated
convertible debt in our diluted income per share calculation regardless of whether the market price triggers or other contingent
conversion features have been met. We apply the treasury stock method as we have the intent and have adopted an accounting
policy to settle the principal amount of the senior and junior subordinated convertible debentures in cash. This method results
in incremental dilutive shares when the average fair value of our common stock for a reporting period exceeds the conversion
prices per share and adjusts as dividends are recorded in the future.
40
Table of Contents
Contingencies
In the ordinary course of our business, we are exposed to various liabilities as a result of contracts, product liability,
customer claims and other matters. Additionally, we are involved in a limited number of legal actions, both as plaintiff and
defendant. Consequently, we could incur uninsured liability in any of those actions. We also periodically receive notifications
from various third parties alleging infringement of patents or other intellectual property rights, or from customers requesting
reimbursement for various costs. With respect to pending legal actions to which we are a party and other claims, although the
outcomes are generally not determinable, we believe that the ultimate resolution of these matters will not have a material
adverse effect on our financial position, cash flows or results of operations. Litigation and disputes relating to the
semiconductor industry are not uncommon, and we are, from time to time, subject to such litigation and disputes. As a result,
no assurances can be given with respect to the extent or outcome of any such litigation or disputes in the future.
We accrue for claims and contingencies when losses become probable and reasonably estimable. As of the end of each
applicable reporting period, we review each of our matters and, where it is probable that a liability has been or will be incurred,
we accrue for all probable and reasonably estimable losses. Where we can reasonably estimate a range of losses we may incur
regarding such a matter, we record an accrual for the amount within the range that constitutes our best estimate. If we can
reasonably estimate a range but no amount within the range appears to be a better estimate than any other, we use the amount
that is the low end of such range. Contingencies of an acquired company that exist as of the date of the acquisition are
measured at fair value if determinable, which generally is based on a probability weighted model. If fair value is not
determinable, contingencies of an acquired company are recognized when they become probable and reasonably estimable.
Results of Continuing Operations
The following table sets forth certain operational data as a percentage of net sales for the fiscal years indicated:
Net sales
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Amortization of acquired intangible assets
Special charges and other, net
Operating income
Net Sales
Year Ended March 31,
2018
2017
2019
100.0%
45.2
54.8
15.4
12.8
12.6
0.6
13.4%
100.0%
39.2
60.8
13.3
11.4
12.2
0.4
23.5%
100.0%
48.4
51.6
16.0
14.7
9.9
2.9
8.1%
We operate in two industry segments and engage primarily in the design, development, manufacture and sale of
semiconductor products as well as the licensing of our SuperFlash and other technologies. We sell our products to distributors
and original equipment manufacturers, referred to as OEMs, in a broad range of markets, perform ongoing credit evaluations of
our customers and generally require no collateral. In certain circumstances, a customer's financial condition may require
collateral, and, in such cases, the collateral would be typically provided by letters of credit.
The following table summarizes our net sales for the periods covered by this report (dollars in millions):
Net sales
Year Ended March 31,
2019
$ 5,349.5
% Change
2018
% Change
2017
34.4% $ 3,980.8
16.8% $ 3,407.8
The increase in net sales in fiscal 2019 compared to fiscal 2018 was due primarily to our acquisition of Microsemi and was
partially offset by our adoption of ASC 606 and demand fluctuations in the markets we serve. Revenue earned from Microsemi
products accounted for a 39.4% increase in net sales in fiscal 2019 compared to fiscal 2018. This increase was partially offset
by our adoption of ASC 606 on April 1, 2018, which affected the timing of revenue recognition with our distributors as
41
Table of Contents
discussed further in the Critical Accounting Policies and Estimates section of this Form 10-K on page 36. To a lesser extent
than the adoption of ASC 606, net sales and demand were also negatively impacted by general economic conditions, trade
restrictions and changes in tariffs. We sell a large number of products to a large and diverse customer base and, excluding the
impacts of our Microsemi acquisition and the adoption of ASC 606, there was not any product, customer or market that
accounted for a material portion of the change. The overall average selling price of our products is affected by pricing declines
over the life of individual products; however, variations in our product and geographic mix of sales can cause wider fluctuations
in our overall average selling price in any given period. The overall average selling price of our products increased
significantly during fiscal 2019 compared to fiscal 2018 due to our acquisition of Microsemi, whose average selling price is
higher than the average selling price of our historical business due to the types of products they offer and the types of customers
and markets they serve.
The increase in net sales in fiscal 2018 compared to fiscal 2017 was impacted by the following two accounting factors,
which occurred in fiscal 2017:
•
•
an amount of revenue that could not be recognized under generally accepted accounting principles in the United
States relating to Atmel's inventory in the distribution channel on the acquisition date; and
the impact of the change in timing of revenue recognition for some of Atmel's distributors from shipment to the
distributor to upon sale by the distributor to their customers.
Excluding the impact of the two accounting factors described above, net sales for fiscal 2018 compared to
fiscal 2017 increased 14.0%. This increase was primarily due to growth in our business driven by favorable economic and
semiconductor industry conditions. Approximately 6% of the increase in net sales during this period was due to increases in the
overall average selling price of products sold as a result of favorable market conditions and product and geographic mix. The
remaining sales growth was primarily due to a net increase in the volume of products sold. We sell a large number of products
to a large and diverse customer base and there was not any product, customer or market that accounted for a material portion of
the increase. The overall average selling price of our products is affected by pricing declines over the life of individual
products; however, variations in our product and geographic mix of sales can cause wider fluctuations in our overall average
selling price in any given period.
As discussed in the following paragraphs, there were revenue increases across many of our product lines. Key factors
impacting the amount of net sales during the last three fiscal years include:
•
•
•
•
•
•
•
•
•
•
•
our acquisition of Microsemi, which closed on May 29, 2018;
our acquisition of Atmel, which closed on April 4, 2016;
global economic conditions in the markets we serve;
trade restrictions and changes in tariffs;
semiconductor industry conditions;
adoption of the new revenue recognition standard (ASC 606) on April 1, 2018;
our new product offerings that have increased our served available market;
customers' increasing needs for the flexibility offered by our programmable solutions;
inventory holding patterns of our customers, including distributors;
increasing semiconductor content in our customers' products; and
continued market share gains in the segments of the markets we address.
Net sales by product line for fiscal 2019, 2018 and 2017 were as follows (dollars in millions):
Microcontrollers
Analog, interface, mixed signal and timing
products
Field-programmable gate array products
Memory products
Technology licensing
Multi-market and other
Total net sales
Year Ended March 31,
2019
2,921.9
$
%
54.6
2018
2,619.1
$
%
65.9
2017
2,147.3
$
1,530.7
303.8
184.0
132.4
276.7
5,349.5
$
28.6
5.7
3.4
2.5
5.2
100.0
$
952.0
—
199.7
104.8
105.2
3,980.8
23.9
—
5.0
2.6
2.6
100.0
$
888.9
—
184.1
91.2
96.3
3,407.8
%
63.0
26.1
—
5.4
2.7
2.8
100.0
42
Table of Contents
Microcontrollers
Our microcontroller product line represents the largest component of our total net sales. Microcontrollers and associated
application development systems accounted for approximately 54.6%, 65.9% and 63.0% of our net sales in fiscal 2019, 2018
and 2017, respectively. The decrease in fiscal 2019 compared to fiscal 2018 is due to our acquisition of Microsemi, whose
microcontroller product line accounted for a relatively low percentage of its total net sales.
Net sales of our microcontroller products increased approximately 11.6% in fiscal 2019 compared to fiscal 2018, and
increased approximately 22.0% in fiscal 2018 compared to fiscal 2017. The increase in net sales in fiscal 2019 compared to
fiscal 2018 resulted primarily from our acquisition of Microsemi. The increase in net sales in fiscal 2018 compared to fiscal
2017 resulted primarily from growth in our business driven by general economic and semiconductor industry conditions and
market share gains.
Historically, average selling prices in the semiconductor industry decrease over the life of any particular product. The
overall average selling prices of our microcontroller products have remained relatively constant over time due to the proprietary
nature of these products. We have experienced, and expect to continue to experience, moderate pricing pressure in certain
microcontroller product lines, primarily due to competitive conditions. We have in the past been able to, and expect in the
future to be able to, moderate average selling price declines in our microcontroller product lines by introducing new products
with more features and higher prices. We may be unable to maintain average selling prices for our microcontroller products as
a result of increased pricing pressure in the future, which would adversely affect our operating results. The average selling
price of our microcontroller products is affected by these trends; however, variations in our product and geographic mix of sales
can cause wider fluctuations in the average selling price of our microcontroller products in any given period.
Analog, Interface, Mixed Signal and Timing Products
Sales of our analog, interface, mixed signal and timing products accounted for approximately 28.6%, 23.9% and 26.1% of
our net sales in fiscal 2019, 2018 and 2017, respectively. The increase in fiscal 2019 compared to fiscal 2018 is due to our
acquisition of Microsemi, whose analog, interface, mixed signal and timing product line accounted for a relatively high
percentage of its total net sales.
Net sales of our analog, interface, mixed signal and timing products increased approximately 60.8% in fiscal 2019
compared to fiscal 2018 and increased approximately 7.1% in fiscal 2018 compared to fiscal 2017. The increase in net sales in
fiscal 2019 compared to fiscal 2018 resulted primarily from our acquisition of Microsemi. The increase in net sales in fiscal
2018 compared to fiscal 2017 resulted primarily from growth in our business driven by general economic and semiconductor
industry conditions and market share gains. Additionally, some new analog products, which are integrated with a
microcontroller core, are classified as microcontrollers, rather than analog. This classification adversely impacted some of the
increases in net sales of analog products during fiscal 2019 compared to fiscal 2018 and during fiscal 2018 compared to fiscal
2017.
Analog, interface, mixed signal and timing products can be proprietary or non-proprietary in nature. Currently, we
consider a majority of our analog, interface, mixed signal and timing products to be proprietary in nature, where prices are
relatively stable, similar to the pricing stability experienced in our microcontroller products. The non-proprietary portion of our
analog, interface, mixed signal and timing business will experience price fluctuations, driven primarily by the current supply
and demand for those products. We may be unable to maintain the average selling prices of our analog, interface, mixed signal
and timing products as a result of increased pricing pressure in the future, which would adversely affect our operating
results. We anticipate the proprietary portion of our analog, interface, mixed signal and timing products will increase over time.
Field-Programmable Gate Array (FPGA) Products
Our FPGA product line was primarily acquired as part of our acquisition of Microsemi on May 29, 2018. Sales of our
FPGA products accounted for approximately 5.7% of our net sales in fiscal 2019.
FPGA product pricing has historically been relatively stable because they are proprietary products with significant design
in complexity and they are frequently designed into long-lived end applications.
43
Table of Contents
Memory Products
Sales of our memory products accounted for approximately 3.4%, 5.0%, and 5.4% of our net sales in fiscal 2019, 2018 and
2017, respectively. The decrease in fiscal 2019 compared to fiscal 2018 is due to our acquisition of Microsemi, whose product
portfolio did not include memory products.
Net sales of our memory products decreased approximately 7.9% in fiscal 2019 compared to fiscal 2018, and increased
approximately 8.5% in fiscal 2018 compared to fiscal 2017. The decrease in memory product net sales in fiscal 2019 compared
to fiscal 2018 resulted primarily from customer demand conditions. The increase in memory product net sales in fiscal 2018
compared to fiscal 2017 resulted primarily from growth in our business driven by general economic and semiconductor industry
conditions.
Memory product pricing has historically been cyclical in nature, with steep price declines followed by periods of relative price
stability, driven by changes in industry capacity at different stages of the business cycle. We have experienced, and expect to
continue to experience, varying degrees of competitive pricing pressures in our memory products. We may be unable to maintain
the average selling prices of our memory products as a result of increased pricing pressure in the future, which could adversely
affect our operating results.
Technology Licensing
Technology licensing revenue includes a combination of royalties associated with licenses for the use of our SuperFlash
and other technologies, sales of our intellectual property, and fees for engineering services. Technology licensing accounted for
approximately 2.5%, 2.6% and 2.7% of our net sales in fiscal 2019, 2018 and 2017, respectively.
Net sales related to our technology licensing increased approximately 26.3% in fiscal 2019 compared to fiscal 2018 and
increased approximately 14.9% in fiscal 2018 compared to fiscal 2017. Revenue from technology licensing can fluctuate over
time based on the production activities of our licensees, the sale of patents and other intellectual property, and general economic
and semiconductor industry conditions.
Multi-market and Other
Multi-market and Other (MMO) consists of manufacturing services (wafer foundry and assembly and test subcontracting),
legacy application specific integrated circuits, and products for aerospace applications. Revenue from these services and
products accounted for approximately 5.2%, 2.6% and 2.8% of our net sales in fiscal 2019, 2018 and 2017, respectively.
Net sales related to these services and products increased approximately $171.5 million in fiscal 2019 compared to fiscal
2018 and increased approximately $8.9 million in fiscal 2018 compared to fiscal 2017. The increase in MMO net sales in fiscal
2019 compared to fiscal 2018 resulted primarily from our acquisition of Microsemi, which significantly increased our portfolio
of timing systems products. The increase in MMO net sales in fiscal 2018 compared to fiscal 2017 resulted primarily from
growth in our business driven by general economic and semiconductor industry conditions. MMO net sales can fluctuate over
time based on general economic and semiconductor industry conditions as well as changes in demand for our manufacturing
services (wafer foundry and assembly and test subcontracting).
Distribution
Distributors accounted for approximately 51% of our net sales in fiscal 2019, approximately 54% of our net sales in fiscal
2018 and approximately 55% of our net sales in fiscal 2017. The decrease in this percentage in fiscal 2019 compared to fiscal
2018 is due to our acquisition of Microsemi, whose distributors accounted for a smaller portion of net sales than Microchip's
historical business. With the exception of Arrow Electronics, our largest distributor, which made up 10% of our net sales, no
other distributor or end customer accounted for more than 10% of our net sales in fiscal 2019. In fiscal 2018 and fiscal 2017,
no distributor or end customer accounted for more than 10% of our net sales. Our distributors focus primarily on servicing the
product requirements of a broad base of diverse customers. We believe that distributors provide an effective means of reaching
this broad and diverse customer base. We believe that customers recognize Microchip for its products and brand name and use
distributors as an effective supply channel.
Generally, we do not have long-term agreements with our distributors and we, or our distributors, may terminate our
relationships with each other with little or no advance notice. The loss of, or the disruption in the operations of, one or more of
our distributors could reduce our future net sales in a given quarter and could result in an increase in inventory returns.
44
Table of Contents
At March 31, 2019, our distributors maintained 35 days of inventory of our products compared to 36 days at March 31,
2018 and 33 days at March 31, 2017. Over the past ten fiscal years, the days of inventory maintained by our distributors have
fluctuated between approximately 27 days and 47 days. Prior to our adoption of ASC 606 on April 1, 2018, we did not believe
that inventory holding patterns at our distributors materially impacted our net sales due to the fact that we recognized revenue
based on when the distributor sells the product to their customer. Upon our adoption of ASC 606 commencing on April 1,
2018, we are required to recognize revenue from distributors at the time our products are sold to the distributor. As a result,
beginning April 1, 2018, inventory holding patterns at our distributors may have a material impact on our net sales.
Sales by Geography
Sales by geography for fiscal 2019, 2018 and 2017 were as follows (dollars in millions):
Americas
Europe
Asia
Total net sales
Year Ended March 31,
2019
1,353.6
1,225.2
2,770.7
5,349.5
$
$
%
25.3
22.9
51.8
100.0
2018
717.4
962.1
2,301.3
3,980.8
$
$
%
18.0
24.2
57.8
100.0
2017
641.8
808.6
1,957.4
3,407.8
$
$
%
18.8
23.7
57.5
100.0
Americas sales include sales to customers in the U.S., Canada, Central America and South America. Sales to foreign
customers accounted for approximately 80%, 85% and 84% of our total net sales in fiscal 2019, 2018 and 2017, respectively.
Substantially all of our foreign sales are U.S. dollar denominated. Sales to customers in Asia have generally increased over
time due to many of our customers transitioning their manufacturing operations to Asia and growth in demand from the
emerging Asian market; however, sales to Asia as a percentage of our total net sales decreased in fiscal 2019 compared to fiscal
2018 due to our acquisition of Microsemi, whose sales to customers in Asia accounted for a smaller portion of their total net
sales than Microchip's historical business, and to a lesser extent, trade restrictions and changes in tariffs. Sales to customers in
the Americas increased as a percentage of total sales in fiscal 2019 compared to fiscal 2018 due to our acquisition of
Microsemi, which had more concentration in the aerospace and defense industry in the Americas. Our sales force in the
Americas and Europe supports a significant portion of the design activity for products which are ultimately shipped to Asia.
Sales to customers in China accounted for approximately 22%, 30% and 32% of our net sales in fiscal 2019, 2018 and
2017, respectively. Sales to customers in Taiwan accounted for approximately 13%, 11% and 9% of our net sales in fiscal
2019, 2018 and 2017, respectively. We did not have sales into any other foreign countries that exceeded 10% of our net sales
during fiscal 2019, 2018 or 2017. In fiscal 2019, our acquisition of Microsemi and our transition to sell-in revenue recognition
contributed to the changes in net sales by country. Our transition from sell-through revenue recognition to sell-in revenue
recognition contributed to the changes in net sales by country because under sell-through revenue recognition we assigned
revenue to the country of our distributor's end customer and under sell-in revenue recognition we assigned revenue to the
country of our distributor. For additional information on our transition from sell-through to sell-in revenue recognition, refer to
Note 1 of our consolidated financial statements.
Gross Profit
Our gross profit was $2,931.3 million in fiscal 2019, $2,420.7 million in fiscal 2018 and $1,757.2 million in fiscal
2017. Gross profit as a percentage of sales was 54.8% in fiscal 2019, 60.8% in fiscal 2018 and 51.6% in fiscal 2017.
The most significant factors affecting our gross profit percentage in the periods covered by this Form 10-K were:
•
•
•
•
•
charges of approximately $365.7 million in fiscal 2019 and approximately $186.7 million in fiscal 2017 related to
the recognition of acquired inventory at fair value as a result of our acquisitions which increased the value of our
acquired inventory and subsequently increased our cost of sales and reduced our gross margins when the related
revenue was recognized;
for each of fiscal 2019 and fiscal 2017, inventory write-downs being higher than the gross margin impact of sales of
inventory that was previously written down; and
for fiscal 2018, inventory write-downs being lower than the gross margin impact of sales of inventory that was
previously written down;
unabsorbed capacity charges due to operating at below normal capacity in fiscal 2019; and
fluctuations in the product mix of microcontrollers, analog, interface, mixed signal and timing products, FPGA
products, memory products and technology licensing.
45
Table of Contents
Other factors that impacted our gross profit percentage in the periods covered by this Form 10-K include:
•
•
•
continual cost reductions in wafer fabrication and assembly and test manufacturing, such as new manufacturing
technologies and more efficient manufacturing techniques;
lower depreciation as a percentage of cost of sales; and
economic market conditions and product mix.
We adjust our wafer fabrication and assembly and test capacity utilization as required to respond to actual and anticipated
business and industry-related conditions. When production levels are below normal capacity, which we measure as a
percentage of the capacity of the installed equipment, we charge cost of sales for the unabsorbed capacity. In fiscal 2019, we
operated at below normal capacity levels resulting in an unabsorbed capacity charge of $19.0 million. During fiscal 2018 and
fiscal 2017, our wafer fabrication facilities and assembly and test facilities operated at normal capacity levels.
The process technologies utilized in our wafer fabrication facilities impact our gross margins. Our wafer fabrication
facility located in Tempe, Arizona (Fab 2) currently utilizes various manufacturing process technologies, but predominantly
utilizes our 0.5 micron to 1.0 micron processes. Our wafer fabrication facility located in Gresham, Oregon (Fab 4)
predominantly utilizes our 0.13 micron to 0.5 micron processes. We continue to transition products to more advanced process
technologies to reduce future manufacturing costs. All of our production in Fab 2 and Fab 4 has been on 8-inch wafers during
the periods covered by this report. We consider normal capacity at Fab 2 and Fab 4 to be 90% to 95%. Our wafer fabrication
facility in Colorado Springs, Colorado (Fab 5) currently utilizes processes between 0.25 micron and 1.0 micron that run on 6-
inch wafers. We consider normal capacity at Fab 5 to be 70% to 75%. As a result of our acquisition of Micrel in August 2015,
we acquired a 6-inch wafer fabrication facility in San Jose, California and have since transitioned products previously
manufactured at this facility to our Fab 2, Fab 4 and Fab 5 facilities. During the quarter ended December 31, 2016, we
decommissioned this San Jose facility and, in June 2017, we completed the sale of these assets for proceeds of $10.0 million.
Our overall inventory levels were $711.7 million at March 31, 2019, compared to $476.2 million at March 31, 2018 and
$417.2 million at March 31, 2017. Our overall inventory levels increased since March 31, 2018 because of our acquisition of
Microsemi, which had $150.8 million of inventory as of March 31, 2019. We maintained 128 days of inventory on our balance
sheet at March 31, 2019 compared to 112 days of inventory at March 31, 2018 and 103 days at March 31, 2017. We expect our
days of inventory levels in the June 2019 quarter to be down 8 days to up 11 days compared to the March 2019 levels. We
believe our existing level of inventory will allow us to maintain competitive lead times and provide strong delivery
performance to our customers.
We anticipate that our gross margins will fluctuate over time, driven primarily by capacity utilization levels, the overall
product mix of microcontroller, analog, interface, mixed signal and timing products, FPGA products, memory products and
technology licensing revenue and the percentage of net sales of each of these products in a particular quarter, as well as
manufacturing yields, fixed cost absorption, and competitive and economic conditions in the markets we serve.
We operate assembly and test facilities in Thailand, the Philippines, and other locations throughout the world. During
fiscal 2019, approximately 38% of our assembly requirements were performed in our internal assembly facilities, compared to
approximately 42% during fiscal 2018 and approximately 36% during fiscal 2017. During fiscal 2019, approximately 49% of
our test requirements were performed in our internal test facilities compared to approximately 64% during fiscal 2018 and
approximately 60% during fiscal 2017. Third-party contractors located primarily in Asia perform the balance of our assembly
and test operations. The percentage of our assembly and test operations that are performed internally fluctuates over time based
on supply and demand conditions in the semiconductor industry, our internal capacity capabilities and our acquisition activities.
The decreases in the percentages of assembly and test operations performed internally in fiscal 2019 compared to fiscal
2018 were primarily due to our acquisition of Microsemi, which outsources the majority of its assembly and test requirements.
The increases in the percentages of assembly and test operations performed internally in fiscal 2018 compared to fiscal 2017
were primarily due to investments in assembly and test equipment, which increased our internal capacity capabilities. We
believe that the assembly and test operations performed at our internal facilities provide us with significant cost savings
compared to contractor assembly and test costs, as well as increased control over these portions of the manufacturing process.
We plan to continue to transition certain outsourced assembly and test capacity to our internal facilities.
We rely on outside wafer foundries for a significant portion of our wafer fabrication requirements. During fiscal 2019,
approximately 57% of our total net sales came from products that were produced at outside wafer foundries compared to
approximately 42% during fiscal 2018 and approximately 41% during fiscal 2017. The increases were primarily due to our
acquisition of Microsemi, which outsources the majority of its wafer fabrication requirements.
46
Table of Contents
Our use of third parties involves some reduction in our level of control over the portions of our business that we
subcontract. While we review the quality, delivery and cost performance of our third-party contractors, our future operating
results could suffer if any third-party contractor is unable to maintain manufacturing yields, assembly and test yields and costs
at approximately their current levels.
Research and Development (R&D)
R&D expenses for fiscal 2019 were $826.3 million, or 15.4% of sales, compared to $529.3 million, or 13.3% of sales, for
fiscal 2018 and $545.3 million, or 16.0% of sales, for fiscal 2017. We are committed to investing in new and enhanced
products, including development systems software, and in our design and manufacturing process technologies. We believe
these investments are significant factors in maintaining our competitive position. R&D costs are expensed as incurred. Assets
purchased to support our ongoing research and development activities are capitalized when related to products which have
achieved technological feasibility or that have alternative future uses and are amortized over their expected useful lives. R&D
expenses include labor, depreciation, masks, prototype wafers, and expenses for the development of process technologies, new
packages, and software to support new products and design environments.
R&D expenses increased $297.0 million, or 56.1%, for fiscal 2019 compared to fiscal 2018 primarily due to additional
costs from our acquisition of Microsemi. R&D expenses decreased $16.0 million, or 2.9%, for fiscal 2018 compared to fiscal
2017 primarily due to reductions in personnel and associated costs in connection with synergies realized from our Atmel
acquisition and lower share-based compensation expense due to accelerated vesting of equity awards held by terminated Atmel
employees during fiscal 2017.
R&D expenses fluctuate over time, primarily due to revenue and operating expense investment levels.
Selling, General and Administrative
Selling, general and administrative expenses for fiscal 2019 were $682.9 million, or 12.8% of sales, compared to $452.1
million, or 11.4% of sales, for fiscal 2018, and $499.8 million, or 14.7% of sales, for fiscal 2017. Our goal is to continue to be
more efficient with our operating expenses as our revenue increases. Selling, general and administrative expenses include
salary expenses related to field sales, marketing and administrative personnel, advertising and promotional expenditures and
legal expenses. Selling, general and administrative expenses also include costs related to our direct sales force, CEMs and
ESEs who work in sales offices worldwide to stimulate demand by assisting customers in the selection and use of our products.
Selling, general and administrative expenses increased $230.8 million, or 51.1%, for fiscal 2019 compared to fiscal 2018
primarily due to additional costs from our acquisition of Microsemi, including approximately $41.7 million of acquisition-
related legal and professional service expenses. Selling, general and administrative expenses decreased $47.7 million, or 9.5%,
for fiscal 2018 compared to fiscal 2017 due primarily to reductions in personnel and associated costs in connection with
synergies realized from our Atmel acquisition and lower share-based compensation expense due to accelerated vesting of equity
awards held by terminated Atmel employees during fiscal 2017.
Selling, general and administrative expenses fluctuate over time, primarily due to revenue and operating expense
investment levels.
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets in fiscal 2019 was $674.1 million compared to $485.5 million in fiscal 2018 and
$337.7 million in fiscal 2017. The primary reason for the increase in acquired intangible asset amortization for fiscal 2019
compared to fiscal 2018 was our acquisition of Microsemi. The primary reason for the increase in acquired intangible asset
amortization for fiscal 2018 compared to fiscal 2017 was amortization of in-process R&D assets from our acquisition of Atmel.
Special Charges and Other, Net
During fiscal 2019, we incurred special charges and other, net of $33.7 million comprised primarily of restructuring
charges of $63.9 million, offset by $30.2 million in legal contingencies. Our restructuring expenses during the fiscal year ended
March 31, 2019 were related to our most recent business acquisitions, and resulted from workforce, property and other
operating expense rationalizations as well as combining product roadmaps and manufacturing operations. During fiscal 2018,
we incurred special charges and other, net of $17.5 million comprised primarily of a $19.5 million charge for fees associated
with transitioning from a public utility provider in Oregon to a lower cost direct access provider. During fiscal 2017, we
47
Table of Contents
incurred special charges and other, net of $98.6 million comprised primarily of restructuring charges. These restructuring
charges included employee separation costs, contract exit costs, other operating expenses and intangible asset impairment losses
recognized as a result of changes in the combined product roadmaps after our acquisition of Atmel that affected the use and life
of these assets.
Other Income (Expense)
Interest income in fiscal 2019 was $8.1 million compared to $22.0 million in fiscal 2018 and $3.1 million in fiscal
2017. The primary reason for the decrease in interest income in fiscal 2019 compared to fiscal 2018 relates to lower average
cash and investment balances as we used a substantial portion of our cash to help finance the purchase price of our acquisition
of Microsemi. The primary reason for the increase in interest income in fiscal 2018 compared to fiscal 2017 relates to higher
cash and investment balances.
Interest expense in fiscal 2019 was $502.9 million compared to $199.0 million in fiscal 2018 and $146.3 million in fiscal
2017. The primary reason for the increase in interest expense in fiscal 2019 compared to fiscal 2018 relates to our additional
borrowings to help finance our acquisition of Microsemi. The primary reasons for the increase in interest expense in fiscal
2018 compared to fiscal 2017 relates to our issuance of $2,645.0 million of convertible notes in February 2017 partially offset
by lower interest expense on amounts borrowed under our credit facility.
Loss on settlement of debt in fiscal 2019 was $12.6 million compared to $16.0 million in fiscal 2018 and $43.9 million in
fiscal 2017. In fiscal 2019, we recognized a loss of $12.6 million primarily related to the voluntary prepayment of a portion of
the outstanding balance on our Term Loan Facility. In fiscal 2018 and fiscal 2017, we settled $143.8 million and $431.3
million, respectively, in principal of our 2007 Junior Subordinated Convertible Debt (2007 Junior Debt). Total conversions for
fiscal 2018 were for a principal amount of $32.5 million for which we settled the principal amount in cash and issued 0.5
million shares of our common stock in respect of the conversion value in excess of the principal amount for the conversions
occurring prior to the call notice and $41.0 million in cash for the conversion value in excess of the principal amount for the
conversion requests received after the call notice. In June 2017, we exchanged in privately negotiated transactions $111.3
million aggregate principal amount of our 2007 Junior Debt for (i) $111.3 million principal amount of our 2017 Junior
Subordinated Convertible Debt (2017 Junior Debt) with a market value of $119.3 million plus (ii) the issuance of 3.2 million
shares of our common stock with a value of $254.6 million. In the case of the fiscal 2017 settlement, the principal value of
$431.3 million was settled in cash and we issued shares of our common stock in respect of the conversion value in excess of the
principal amount plus a cash inducement fee of $5.0 million.
Other loss, net in fiscal 2019 was $2.2 million compared to other loss, net of $5.8 million in fiscal 2018 and other income,
net of $1.3 million in fiscal 2017. The primary reasons for the change in other loss during fiscal 2019 compared to fiscal 2018
relates to lower losses on investments offset by lower net gains on foreign currency exchange rate fluctuations. The primary
reasons for the change in other income (loss) during fiscal 2018 compared to fiscal 2017 relates to impairments on available for
sale investments partially offset by gains on foreign currency exchange rate fluctuations. The impairments on the available for
sale investments were due to the anticipated liquidation of these investments in the first quarter of fiscal 2019 to fund our
acquisition of Microsemi.
Provision for Income Taxes
Our provision for income taxes reflects tax on foreign earnings and federal and state tax on U.S. earnings. Our effective
tax rates for the fiscal years ended March 31, 2019 and March 31, 2018 were not meaningful due to the amount of pre-tax
income and the tax benefits recorded during the period. Excluding certain tax events described below, our effective tax rates
were lower than statutory rates in the U.S. primarily due to our mix of earnings in foreign jurisdictions with lower tax rates.
Our effective tax rate in fiscal 2019 includes a $27.5 million tax benefit received from current year generated R&D credits,
which reduced our effective tax rate by 13.4%. Our effective tax rate in fiscal 2019 includes a $13.3 million tax benefit for
share-based compensation deductions, which reduced our effective tax rate by 6.5%. Our effective tax rate in fiscal 2019
includes a $75.1 million tax benefit related to audit closures and expirations of the statute of limitations on various tax reserves,
which reduced our effective tax rate by 36.7%. Our effective tax rate in fiscal 2019 includes $95.4 million tax expense for
GILTI, which increased our effective tax rate by 46.7%. Our effective tax rate in fiscal 2019 includes a $90.6 million tax
benefit for business realignment, which reduced our effective tax rate by 44.3%.
Our effective tax rate in fiscal 2018 includes $644.7 million of tax expense estimated on a provisional basis, calculated
under SAB 118, related to the one-time transition tax on certain foreign earnings, $136.7 million of tax benefit estimated on a
provisional basis related to the revaluation of our deferred tax assets and liabilities to the newly enacted U.S. statutory tax rate
48
Table of Contents
of 21.0%, and $20.5 million of tax benefit estimated on a provisional basis related to the release of valuation allowances against
our foreign tax credit carryforwards. These three adjustments increased (reduced) our effective tax rate by 87.4%, (18.5%), and
(2.8%), respectively. Our effective tax rate in fiscal 2018 also includes a $17.0 million tax benefit received from current year
generated R&D credits, which reduced our effective tax rate by 2.3%. Our effective tax rate in fiscal 2018 also includes a $27.2
million tax benefit for share-based compensation deductions, which reduced our effective tax rate by 3.7%. Our effective tax
rate in fiscal 2018 also includes a $11.3 million benefit related to audit closures and expirations of the statute of limitations on
various tax reserves, which reduced our effective tax rate by 1.5%.
Our effective tax rate in fiscal 2017 included $36.3 million of benefits related to audit closures and expirations of the
statute of limitations on various tax reserves and $7.9 million of expense related to intercompany prepaid tax amortization,
which reduced our effective tax rate by 40.4% and increased our effective tax rate by 8.8%, respectively. Our effective tax rate
in fiscal 2017 included a $12.8 million benefit received from current year generated R&D credits, which reduced our effective
tax rate by 14.3%. Our effective tax rate in fiscal 2017 also included a $25.0 million benefit for share-based compensation
deductions, which reduced our effective tax rate by 27.8%.
We are also subject to taxation in many other jurisdictions where we have operations. The effective tax rates that we pay in
these jurisdictions vary widely, but they are generally lower than our combined U.S. federal and state effective tax rate. Our
domestic statutory tax rate for the fiscal year ended March 31, 2019 was approximately 22% and our domestic statutory tax rate
for fiscal 2018 was approximately 33%. Our non-U.S. blended statutory tax rates for fiscal 2019 and fiscal 2018 were much
lower than this amount. The difference in rates applicable in foreign jurisdictions results from a number of factors, including
lower statutory rates, historical loss carry-forwards, financing arrangements and other factors. Our effective tax rate has been,
and will continue to be impacted by the geographical dispersion of our earnings and losses.
Our foreign tax rate differential benefit primarily relates to our operations in Thailand, Malta and Ireland. Our Thailand
manufacturing operations are currently subject to numerous tax holidays granted to us based on our investment in property,
plant and equipment in Thailand. Our tax holiday periods in Thailand expire at various times in the future; however, we
actively seek to obtain new tax holidays or we will be subject to tax at the statutory tax rate of 20%. We do not expect the
future expiration of any of our tax holiday periods in Thailand to have a material impact on our effective tax rate. Our
Microsemi operations in Malaysia are also subject to a tax holiday that effectively reduces Microsemi’s income tax rate in that
jurisdiction. Microsemi’s tax holiday in Malaysia was granted in 2009 and is effective through December 2019, subject to
continued compliance with the tax holiday’s requirements. The remaining material components of foreign income taxed at a
rate lower than the U.S. are earnings accrued in Ireland at a 12.5% statutory tax rate and earnings accrued in Malta at a 0% tax
rate.
Various taxing authorities in the U.S. and other countries in which we do business are increasing their scrutiny of the tax
structures employed by businesses. Companies of our size and complexity are regularly audited by the taxing authorities in the
jurisdictions in which they conduct significant operations. For U.S. federal, and in general for U.S. state tax returns, our fiscal
2007 and later tax returns remain effectively open for examination by the taxing authorities. We are currently being audited by
the tax authorities in the United States and in various foreign jurisdictions. At this time, we do not know what the outcome of
these audits will be. We record benefits for uncertain tax positions based on an assessment of whether it is more likely than not
that the tax positions will be sustained based on their technical merits under currently enacted law. If this threshold is not met,
no tax benefit of the uncertain tax position is recognized. If the threshold is met, we recognize the largest amount of the tax
benefit that is more than 50% likely to be realized upon ultimate settlement.
Results of Discontinued Operations
Discontinued operations represent the mobile touch operations that we acquired as part of our acquisition of Atmel. On
November 10, 2016, we completed the sale of the mobile touch assets to Solomon Systech (Limited) International, a Hong
Kong based semiconductor company. The transaction included the sale of certain semiconductor products, equipment,
customer list, backlog, patents, and a license to certain other intellectual property and patents related to Atmel's mobile touch
product line. We also agreed to provide certain transition services to Solomon Systech. For financial statement purposes, the
results of operations for this discontinued business have been segregated from those of the continuing operations and are
presented in our consolidated financial statements as discontinued operations. Net loss from discontinued operations for the
year ended March 31, 2017 was $6.0 million, consisting of a pre-tax loss from operations of $8.2 million and a pre-tax gain on
sale of $0.6 million.
49
Table of Contents
Liquidity and Capital Resources
We had $430.9 million in cash, cash equivalents and short-term investments at March 31, 2019, a decrease of $1.77 billion
from the March 31, 2018 balance. The decrease in cash, cash equivalents and short-term investments over this time period is
primarily attributable to our acquisition of Microsemi.
Net cash provided by operating activities was $1.67 billion for fiscal 2019, $1.42 billion for fiscal 2018 and $1.06 billion
for fiscal 2017. The increase in net cash provided by operating activities in fiscal 2019 compared to fiscal 2018 was primarily
due to cash provided by our acquisition of Microsemi in fiscal 2019. The increase in net cash provided by operating activities
in fiscal 2018 compared to fiscal 2017 was primarily due to higher net sales as well as operating cash flows resulting from
synergies realized from our process efficiencies and restructuring efforts related to our acquisition of Atmel.
Net cash used in investing activities was $6.81 billion for fiscal 2019 compared to $1.01 billion for fiscal 2018 and $2.84
billion in fiscal 2017. Fiscal 2019 investing cash flows included net cash and cash equivalents used to finance our acquisition
of Microsemi of $7.85 billion net of $340.0 million of cash and cash equivalents acquired, offset by net cash inflows of $1.29
billion due to the sale and maturity of available-for-sale debt securities to fund our acquisition of Microsemi, and capital
expenditures of $228.9 million. Fiscal 2018 investing cash flows primarily result from the net increase in investments of
$808.1 million due to cash from operations as well as capital purchases. Fiscal 2017 investing cash flows include net cash and
cash equivalents used to finance our acquisition of Atmel of $2.75 billion. Excluding cash flows used in acquisitions, net
investing activities resulted in net cash provided of $1.04 billion in fiscal 2019 and a use of $90.5 million in fiscal 2017, and
represented primarily the net change in our investments, capital purchases and sale of assets.
Our level of capital expenditures varies from time to time as a result of actual and anticipated business conditions. Capital
expenditures were $228.9 million, $206.8 million, and $75.3 million in fiscal 2019, 2018 and 2017, respectively. Capital
expenditures were primarily for the expansion of production capacity, the addition of research and development equipment and
new office buildings. Capital expenditures in fiscal 2017 were relatively less than we had experienced in recent years as we
delayed certain purchases until we had finalized and developed plans following our acquisition of Atmel regarding technology
platforms and other manufacturing activities. We currently intend to spend between $130 million and $150 million during the
next twelve months to invest in equipment and facilities. We believe that the capital expenditures anticipated to be incurred
over the next twelve months will provide sufficient manufacturing capacity to support the growth of our production capabilities
for our new products and technologies and to bring in-house more of the assembly and test operations that are currently
outsourced. We expect to finance our capital expenditures through our existing cash balances and cash flows from operations.
Net cash provided by financing activities was $4.66 billion for fiscal 2019 compared to net cash used in financing activities
of $415.3 million for fiscal 2018 and net cash provided by financing activities of $595.5 million for fiscal 2017. Fiscal 2018
financing cash outflows were primarily the result of dividend payments and payments on the settlement of our convertible debt.
Fiscal 2019 and fiscal 2017 cash flows were favorably impacted by the net proceeds from amounts borrowed to fund our
acquisitions of Microsemi and Atmel, respectively. Significant transactions affecting our net financing cash flows include:
•
•
•
In fiscal 2019, proceeds of $3.0 billion from term loans made under the Term Loan Facility, net proceeds of $3.27
billion from borrowings under our Revolving Credit Facility, net proceeds of $1.99 billion from the issuance of
our Senior Secured Notes, $2.06 billion of cash used to repay Microsemi's existing debt, and $1.09 billion of cash
used to pay down the principal of our Term Loan Facility,
In fiscal 2017, we issued $2.65 billion of debt, of which $2.12 billion was used to settle debt and reduce
borrowings on our credit facility, and
In fiscal 2019, fiscal 2018 and fiscal 2017, we paid cash dividends to our stockholders of $344.4 million, $337.5
million, and $315.4 million, respectively. The amount of dividends paid has increased due to an increase in the
amount of dividends declared per share and in the number of shares outstanding.
On May 29, 2018, we completed the acquisition of Microsemi Corporation, a publicly traded company headquartered in
Aliso Viejo, California. We paid an aggregate of approximately $8.19 billion in cash to the stockholders of Microsemi. The
total consideration transferred in the acquisition, including approximately $53.9 million of non-cash consideration for the
exchange of certain share-based payment awards of Microsemi for stock awards for our common stock, was
approximately $8.24 billion. In addition to the consideration transferred, we recognized $3.23 billion in liabilities in our
consolidated financial statements of Microsemi consisting of debt, taxes payable and deferred, pension obligations,
restructuring, and contingent and other liabilities of which $2.06 billion of existing debt was paid off. We financed the
purchase price using approximately $8.10 billion of borrowings consisting of $3.10 billion of loans under our Revolving Credit
Facility, $3.00 billion under the Term Loan Facility, and $2.00 billion in newly issued senior secured notes. We incurred $22.0
million in acquisition costs related to the acquisition. During fiscal 2019, we voluntarily prepaid $1.09 billion of principal
50
Table of Contents
under the Term Loan Facility, of which $500.0 million was from funds borrowed under our Revolving Credit Facility.
At March 31, 2019, we had $1.91 billion of outstanding borrowings under our Term Loan Facility.
In May 2018, we entered into an amended and restated credit agreement (the "Credit Agreement") which provides for the
Revolving Credit Facility in an aggregate principal amount of approximately $3.84 billion, which was reduced to $3.60
billion in the second quarter of fiscal 2019 through the termination of the 2020 Tranche, with a $250.0 million foreign currency
sublimit, a $50.0 million letter of credit sublimit and a $25.0 million swingline loan sublimit. The Credit Agreement also
provides for the Term Loan Facility. The Revolving Credit Facility consists of $3.60 billion of revolving loan commitments
(the "2023 Revolving Loans") that terminate on May 18, 2023 (the "2023 Maturity Date"). The 2023 Revolving Loans bear
interest, at our option, at the base rate plus a spread of 0.00% to 1.00% or an adjusted LIBOR rate plus a spread of 1.00% to
2.00%, in each case, with such spread being determined based on the consolidated senior leverage ratio for the preceding four
fiscal quarter period. At March 31, 2019, we had $3.27 billion of outstanding borrowings under the Revolving Credit Facility
and no borrowings at March 31, 2018. See Note 12 of the notes to our consolidated financial statements for more information
regarding our Credit Agreement.
In June 2017, in connection with the settlement of $111.3 million of our convertible debt, we amended our credit
agreement to (i) extend the time period during which we are permitted to repurchase, redeem or exchange our 2007 Junior
Convertible Debt and (ii) amend the maximum total leverage ratio covenant to extend the time period for permitted
refinancings or exchanges of the 2007 Junior Convertible Debt that may be excluded from the calculation of the ratio, subject
to certain conditions.
In February 2017, we amended our credit agreement to, among other things, increase certain covenant compliance ratios.
The February 2017 amendment included a new collateral agreement that secures our borrowings with all assets of our
guarantor subsidiaries with the exception of real property. Proceeds of loans made under our credit agreement may be used for
working capital and general corporate purposes.
The enactment of the Act in December 2017 imposed a tax on all previously untaxed earnings of non-U.S. subsidiaries of
U.S. corporations. Due to this change, the jurisdiction in which our cash is at any given point in time, no longer has a
significant impact on our liquidity. Future distributions of non-U.S. assets to the U.S. will no longer be subject to U.S. federal
taxation. We intend to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign
subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we would incur significant, additional costs upon
repatriation of such amounts. As a result of the Act, as of March 31, 2018, we recognized a one-time provisional transition tax
expense of $644.7 million on accumulated unrepatriated foreign earnings. As we concluded with our measurement period in
accordance with SEC Staff Accounting Bulletin ("SAB") 118, we finalized our calculations of the transition tax expense during
the period ended December 31, 2018. As such, we increased our March 31, 2018 provisional amount by $13.1 million to
$657.8 million, of which we expect cash payments of approximately $280.7 million after offsets by the utilization of various
tax attribute carryforwards in the United States. This tax is to be paid over a period of eight years, with 8% of the transition tax
paid each year for fiscal 2019 through fiscal 2023, and 15%, 20%, and 25%, respectively, to be paid during fiscal 2024, 2025
and 2026.
We enter into derivative transactions from time to time in an attempt to reduce our exposure to currency rate
fluctuations. Although none of the countries in which we conduct significant foreign operations has had a highly inflationary
economy in the last five years, there is no assurance that inflation rates or fluctuations in foreign currency rates in countries
where we conduct operations will not adversely affect our operating results in the future. At March 31, 2019, we had no
foreign currency forward contracts outstanding.
On April 4, 2016, we completed our acquisition of Atmel. Under the terms of the merger agreement executed on January
19, 2016, Atmel stockholders received $8.15 per share consisting of $7.00 per share in cash and $1.15 per share in shares of
Microchip common stock. We financed the purchase price of our Atmel acquisition using approximately $2.04 billion of cash
held by certain of our foreign subsidiaries, approximately $0.94 billion from additional borrowings under our credit agreement
and approximately $486.1 million through the issuance of an aggregate of 10.1 million shares of our common stock. The
acquisition price represented a total equity value of approximately $3.47 billion, and a total enterprise value of approximately
$3.44 billion, after excluding Atmel's cash and investments net of debt on its balance sheet of approximately $39.3 million.
The acquisition was structured in a manner that enabled us to utilize a substantial portion of the cash, cash equivalents, short-
term investments and long-term investments held by certain of our foreign subsidiaries in a tax efficient manner. Although we
believe our determinations with respect to the tax consequences of the acquisition are reasonable, we are regularly audited by
the IRS and may be audited by other taxing authorities, and there can be no assurance as to the outcome of any such audit.
51
Table of Contents
There were no repurchases of common stock during fiscal 2019, 2018, or 2017. As of March 31, 2019, we held
approximately 15.6 million shares as treasury shares.
On October 28, 2002, we announced that our Board of Directors had approved and instituted a quarterly cash dividend on
our common stock. The initial quarterly dividend of $0.02 per share was paid on December 6, 2003 in the amount of
$4.1 million. To date, our cumulative dividend payments have totaled approximately $3.8 billion. Cash dividends paid per
share were $1.457, $1.449 and $1.441 during fiscal 2019, fiscal 2018 and fiscal 2017, respectively. Total dividend payments
amounted to $344.4 million, $337.5 million, $315.4 million during fiscal 2019, fiscal 2018 and fiscal 2017, respectively. A
quarterly cash dividend of $0.3655 per share was declared on May 7, 2019 and will be paid on June 4, 2019, to stockholders of
record as of May 21, 2019. We expect the aggregate cash dividend for June 4, 2019 to be approximately $87.0 million. Our
Board is free to change our dividend practices at any time and to increase or decrease the dividend paid, or not to pay a
dividend, on our common stock on the basis of our results of operations, financial condition, cash requirements and future
prospects, and other factors deemed relevant by our Board. Our current intent is to provide for ongoing quarterly cash
dividends depending upon market conditions, our results of operations and potential changes in tax laws.
We believe that our existing sources of liquidity combined with cash generated from operations and borrowings under our
Revolving Credit Facility will be sufficient to meet our currently anticipated cash requirements for at least the next 12 months.
However, the semiconductor industry is capital intensive. In order to remain competitive, we must constantly evaluate the need
to make significant investments in capital equipment for both production and research and development. We may increase our
borrowings under our Revolving Credit Facility or seek additional equity or debt financing from time to time to maintain or
expand our wafer fabrication and product assembly and test facilities, for cash dividends, for share repurchases or for
acquisitions or other purposes. The timing and amount of any such financing requirements will depend on a number of factors,
including our level of dividend payments, changes in tax laws and regulations regarding the repatriation of offshore cash
(including the impact of the Act), demand for our products, changes in industry conditions, product mix, competitive factors
and our ability to identify suitable acquisition candidates. There can be no assurance that such financing will be available on
acceptable terms, and any additional equity financing would result in incremental ownership dilution to our existing
stockholders.
Contractual Obligations
The following table summarizes our significant contractual obligations at March 31, 2019, and the effect such
obligations are expected to have on our liquidity and cash flows in future periods (in millions):
Operating lease obligations (1)
Capital purchase obligations (2)
Other purchase obligations and commitments (3)
Term Loan Facility (4)
Revolving Credit Facility (5)
2023 and 2021 Senior Notes
2017 Senior Convertible Debt (6)
2015 Senior Convertible Debt (7)
2017 Junior Convertible Debt (8)
Pension obligations (9)
Transition tax obligation (10)
Total contractual obligations (11)
Payments Due by Period
Total
Less than
1 year
1 – 3 years
3 – 5 years
More than
5 years
$
167.1
$
18.8
205.6
2,435.4
3,879.0
2,293.0
2,339.1
1,893.2
964.0
20.7
245.7
49.0
18.8
194.9
72.5
147.0
82.5
33.6
28.0
15.4
1.3
9.9
$
68.4
$
27.1
$
22.6
—
10.5
174.7
294.0
1,145.5
67.3
56.1
30.9
3.4
44.9
—
0.2
174.4
3,438.0
1,065.0
67.3
56.1
30.9
4.1
64.6
—
—
2,013.8
—
—
2,170.9
1,753.0
886.8
11.9
126.3
$ 14,461.6
$
652.9
$
1,895.7
$
4,927.7
$
6,985.3
(1) Operating lease obligations include $18.1 million of future lease payments which is recorded as a liability on the balance
sheet as of March 31, 2019. This obligation is due under an operating lease from our acquisition of Atmel for a building
in San Jose, California.
(2) Capital purchase obligations represent commitments for construction or purchases of property, plant and
equipment. These obligations were not recorded as liabilities on our balance sheet as of March 31, 2019, as we have not
yet received the related goods or taken title to the property.
52
Table of Contents
(3) Other purchase obligations and commitments include payments due under various types of licenses and outstanding
purchase commitments with our wafer foundries.
(4) The Term Loan Facility matures on May 29, 2025.
(5) For purposes of this table, we have assumed that the principal of our 2023 revolving loans outstanding at March 31, 2019
will be paid on May 18, 2023, which is the maturity date of such borrowings.
(6) For purposes of this table, we have assumed that the principal of our 2017 senior convertible debt will be paid on
February 15, 2027, which is the maturity date of such debt.
(7) For purposes of this table, we have assumed that the principal of our 2015 Senior Convertible Debt will be paid on
February 15, 2025, which is the maturity date of such debt.
(8) For purposes of this table, we have assumed that the principal of our 2017 Junior Convertible Debt will be paid on
February 15, 2037, which is the maturity date of such debt.
(9) For purposes of this table, pension obligations due in more than 5 years represent the expected pension payments from
2025 through 2029. It excludes pension obligations subsequent to 2029.
(10) During fiscal 2018, we recognized a provisionary one-time transition tax on accumulated unrepatriated foreign
earnings, estimated at $644.7 million, as a result of the recent U.S. tax reform. As of December 31, 2018, with the
conclusion of the measurement period in accordance with SAB 118, we increased this amount by $13.1 million to $657.8
million, of which we expect cash payments of approximately $280.7 million after offsets by the utilization of various tax
attribute carryforwards in the United States. Our first payment on this obligation of $35.0 million was made in the
quarter ended September 30, 2018 and we expect future cash payments of approximately $245.7 million. This tax is to
be paid over a period of eight years, with 8% of the transition tax paid each year for fiscal 2019 through fiscal 2023, and
15%, 20%, and 25%, respectively, to be paid during fiscal 2024, 2025, and 2026.
(11) The contractual obligations do not include amounts related to uncertain tax positions because reasonable estimates
cannot be made.
Purchase orders or contracts for the purchase of raw materials and other goods and services, with the exception of
commitments to our wafer foundries, are not included in the table above. We are not able to determine the aggregate amount
of such purchase orders that represent contractual obligations, as purchase orders may represent authorizations to purchase
rather than binding agreements. For the purpose of this table, contractual obligations for the purchase of goods or services
are defined as agreements that are enforceable and legally binding on us and that specify all significant terms, including:
fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the
transaction. Our purchase orders are based on our current manufacturing needs and are fulfilled by our vendors with short
time horizons. We do not have significant agreements for the purchase of raw materials or other goods specifying minimum
quantities or set prices that exceed our expected requirements for three months. We also enter into contracts for outsourced
services; however, the obligations under these contracts were not significant and the contracts generally contain clauses
allowing for cancellation without significant penalty.
The expected timing of payment of the obligations discussed above is estimated based on current information. Timing of
payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to
agreed-upon amounts for some obligations.
Off-Balance Sheet Arrangements (Including Guarantees)
As of March 31, 2019, we are not involved in any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of
SEC Regulation S-K with the exception of various operating leases for buildings and equipment entered into in the ordinary
course of business. Additionally, we may provide standby letters of credit or other guarantee instruments to certain parties as
required for certain transactions initiated by us or our subsidiaries. We have not recorded any liability in connection with
these guarantee arrangements. Based on historical experience and information currently available, we believe we will not be
required to make any payments under these guarantee arrangements. For our operating leases, we expect to make cash
payments and incur expenses throughout the lives of the operating leases. We have not recorded any liability in connection
with these operating leases. We will record the associated lease obligations as a liability when we adopt the provisions of the
Accounting Standard Update 2016-02-Leases. Refer to Note 1 to our consolidated financial statements for additional
information regarding the adoption of this accounting standard.
Recently Issued Accounting Pronouncements
Refer to Note 1 to our consolidated financial statements regarding recently issued accounting pronouncements.
53
Table of Contents
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As of March 31, 2019, our long-term debt totaled $11.66 billion. We have no interest rate exposure to rate changes on our
fixed rate debt, which totaled $6.48 billion as of March 31, 2019. We do have interest rate exposure with respect to the $5.18
billion balance of our variable interest rate debt outstanding as of March 31, 2019. A 50 basis point increase in interest rates
would impact our expected annual interest expense for the next 12 months by approximately $26.0 million.
54
Table of Contents
Item 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements listed in the index appearing under Item 15(a)(1) hereof are filed as part of this Form
10-K. See also Index to Financial Statements below.
Item 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
Item 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Annual Report on Form 10-K, as required by paragraph (b) of Rule 13a-15 or
Rule 15d-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we evaluated under the supervision
of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as
defined in Rules 13a-15(e) or 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and our
Chief Financial Officer have concluded that because of the material weaknesses in internal control over financial reporting
described below, our disclosure controls and procedures were not effective to ensure that information we are required to
disclose in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the
time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to
our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely
decisions regarding required disclosure. Our disclosure controls and procedures are designed to provide reasonable assurance
that such information is accumulated and communicated to our management. Our disclosure controls and procedures include
components of our internal control over financial reporting. Management's assessment of the effectiveness of our internal
control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well
designed and operated, can provide only reasonable, but not absolute, assurance that the control system's objectives will be met.
Material Weaknesses in Internal Control Over Financial Reporting
A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or
interim financial statements will not be prevented or detected on a timely basis.
In reviewing the accounting for certain transactions completed in fiscal 2019 as part of the realignment of our legal
structure and other significant transactions, our management identified deficiencies in the operating effectiveness of controls
intended to properly document and review relevant facts used to determine and apply the appropriate tax accounting under
accounting standards generally accepted in the United States. Additionally, our controls did not operate to validate the
completeness and accuracy of information used in the execution of certain key tax controls. These control deficiencies
impacted the deferred tax, long-term income tax payable, and income tax benefit accounts and related disclosures and resulted
in adjustments to our annual financial statements as of and for the year ended March 31, 2019. The errors arising from the
underlying deficiencies are not material to the financial statements reported in any interim or annual period and therefore, did
not result in a revision to previously filed financial statements. However, the control deficiencies could result in a failure to
timely prevent or detect misstatements of the aforementioned accounts and disclosures that could be material to the annual or
interim consolidated financial statements. Accordingly, our management has concluded that the deficiencies, in the aggregate,
constitute a material weakness in our internal control over financial reporting.
In the fourth quarter of fiscal 2019, we also identified deficiencies in the design of our internal control over financial
reporting as our management determined that there were not sufficient controls to prevent, detect and respond to unauthorized
access to our IT systems in a timely manner. Network authentication, segmentation and monitoring were in place, but were not
sufficiently designed to address changes in the current risk environment. Our management has concluded that these
deficiencies, in the aggregate, constitute a material weakness in our internal control over financial reporting
Management Report on Internal Control Over Financial Reporting
Our management, including our principal executive officer and principal financial officer, is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
55
Table of Contents
accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of
the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have
a material effect on our financial statements.
Management assessed our internal control over financial reporting as of March 31, 2019, the end of our fiscal
year. Management based its assessment on criteria established in Internal Control – Integrated Framework (2013 framework)
issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management's assessment included an
evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process
documentation, accounting policies, and our overall control environment. This assessment is supported by testing and
monitoring performed by our finance organization.
In accordance with guidance issued by the Securities and Exchange Commission, registrants are permitted to exclude
material business combinations from their final assessment of internal control over financial reporting for the first fiscal year in
which the acquisition occurred. Our management’s evaluation of internal control over financial reporting excluded the internal
control activities of Microsemi, which we acquired on May 29, 2018 as discussed in Note 2 of the consolidated financial
statements. We have included the financial results of Microsemi in our consolidated financial statements from the date of
acquisition. Total revenues excluded from our assessment of internal control over financial reporting represented
approximately 28% of our consolidated revenues for the fiscal year ended March 31, 2019. Total Microsemi assets excluded
from our assessment of internal control over financial reporting represented approximately 4% of our consolidated total assets
as of March 31, 2019.
Based on our assessment and the existence of a material weakness related to accounting for income taxes and the existence
of a material weakness related to IT system access, management has concluded that our internal control over financial reporting
was not effective as of the end of the fiscal year to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting
principles. We reviewed the results of management's assessment with the Audit Committee of our Board of Directors.
Ernst & Young LLP, an independent registered public accounting firm, who audited our consolidated financial statements
included in this Form 10-K has issued an attestation report on our internal control over financial reporting as of March 31,
2019, which is included on page F-2.
Remediation Plans and Other Information
Our management has begun implementing a remediation plan to address the control deficiencies that led to the material
weakness related to accounting for income taxes as described above. The remediation plan includes:
•
•
strengthening our income tax control with improved documentation standards, technical oversight and training; and
hiring additional qualified accounting and/or tax professionals.
With respect to the foregoing material weakness, we currently plan to have our enhanced review procedures and
documentation standards in place in the first quarter of fiscal 2020. Our goal is to remediate this material weakness by the end
of fiscal 2020, subject to there being sufficient opportunities to conclude, through testing, that the enhanced control is operating
effectively.
Our management has also begun implementing a remediation plan to address the control deficiencies that led to the
material weakness related to IT system access as described above. The remediation plan includes:
•
•
•
•
hiring additional qualified information services professionals;
strengthening technical access controls by implementing additional multi-factor authentication mechanisms;
redesigning and implementing network structure to contain and isolate relevant systems; and
implementing additional controls related to on-going incident response and monitoring.
56
Table of Contents
With respect to the foregoing material weakness related to IT system access, we currently plan to have implemented
additional multi-factor authentication and implemented additional controls in the first quarter of fiscal 2020. Our goal is to
remediate this material weakness by the end of fiscal 2020, subject to there being sufficient opportunities to conclude, through
testing, that the enhanced controls are operating effectively.
Changes in Internal Control over Financial Reporting
On May 29, 2018, we completed our acquisition of Microsemi which operated under its own set of systems and internal
controls. During the three months ended March 31, 2019, we transitioned certain of Microsemi's processes to our internal
control processes and we expect to transition more of such processes throughout the remainder of calendar year 2019.
In connection with the identified material weaknesses related to accounting for income taxes and to IT system access, we
have taken steps to remediate the material weaknesses as described above. However, other than with respect to our transition
of Microsemi to our systems and control environment as describe above, during the three months ended March 31, 2019, there
was no change in our internal control over financial reporting identified in connection with the evaluation required by
paragraph (d) of Rule 13a-15 or Rule 15d-15 that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
Item 9B. OTHER INFORMATION
J. Eric Bjornholt, our Senior Vice President, Chief Financial Officer, Mitch Little, our Senior Vice President, Worldwide
Client Engagement, Steve Drehobl, our Senior Vice President, MCU8 and MCU16 Business Units, and Rich Simoncic, our
Senior Vice President, Analog Power and Interface Business Units, have entered into trading plans as contemplated by Rule
10b-5-1 under the Exchange Act and periodic sales of our common stock have occurred and are expected to occur under such
plans.
The foregoing disclosure is being made on a voluntary basis and not pursuant to any specific requirement under Form
10 K, Form 8 K or otherwise.
57
Table of Contents
PART III
Item 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information on the members of our Board of Directors is incorporated herein by reference to our proxy statement for our
2019 annual meeting of stockholders under the captions "The Board of Directors," and "Proposal One – Election of Directors."
Information on the composition of our audit committee and the members of our audit committee, including information on
our audit committee financial experts, is incorporated by reference to our proxy statement for our 2019 annual meeting of
stockholders under the caption "The Board of Directors – Committees of the Board of Directors – Audit Committee."
Information on our executive officers is provided in Item 1, Part I of this Form 10-K under the caption "Executive Officers
of the Registrant" at page 10, above.
Information with respect to compliance with Section 16(a) of the Exchange Act, is incorporated herein by reference to our
proxy statement for our 2019 annual meeting of stockholders under the caption "Delinquent Section 16(a) Reports."
Information with respect to our code of ethics that applies to our directors, executive officers (including our principal
executive officer and our principal financial and accounting officer) and employees is incorporated by reference to our proxy
statement for our 2019 annual meeting of stockholders under the caption "Code of Business Conduct and Ethics." A copy of
our Code of Business Conduct and Ethics is available on our website at the Investor Relations section under Mission Statement/
Corporate Governance on www.microchip.com.
Information regarding material changes, if any, to procedures by which security holders may recommend nominees to our
Board of Directors is incorporated by reference to our proxy statement for the 2019 annual meeting of stockholders under the
caption "Requirements, Including Deadlines, for Receipt of Stockholder Proposals for the 2019 Annual Meeting of
Stockholders; Discretionary Authority to Vote on Stockholder Proposals."
Item 11.
EXECUTIVE COMPENSATION
Information with respect to executive compensation is incorporated herein by reference to the information under the
caption "Executive Compensation" in our proxy statement for our 2019 annual meeting of stockholders.
Information with respect to director compensation is incorporated herein by reference to the information under the caption
"The Board of Directors – Director Compensation" in our proxy statement for our 2019 annual meeting of stockholders.
Information with respect to compensation committee interlocks and insider participation in compensation decisions is
incorporated herein by reference to the information under the caption "The Board of Directors – Compensation Committee
Interlocks and Insider Participation" in our proxy statement for our 2019 annual meeting of stockholders.
Our Board compensation committee report on executive compensation is incorporated herein by reference to the
information under the caption "Executive Compensation – Compensation Committee Report on Executive Compensation" in
our proxy statement for our 2019 annual meeting of stockholders.
Item 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
Information with respect to securities authorized for issuance under our equity compensation plans is incorporated herein
by reference to the information under the caption "Executive Compensation – Equity Compensation Plan Information" in our
proxy statement for our 2019 annual meeting of stockholders.
Information with respect to security ownership of certain beneficial owners, members of our Board of Directors and
management is incorporated herein by reference to the information under the caption "Security Ownership of Principal
Stockholders, Directors and Executive Officers" in our proxy statement for our 2019 annual meeting of stockholders.
58
Table of Contents
Item 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this Item pursuant to Item 404 of Regulation S-K is incorporated by reference to the
information under the caption "Certain Transactions" contained in our proxy statement for our 2019 annual meeting of
stockholders.
The information required by this Item pursuant to Item 407(a) of Regulation S-K regarding the independence of our
directors is incorporated by reference to the information under the caption "Meetings of the Board of Directors" contained in
our proxy statement for our 2019 annual meeting of stockholders.
Item 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item related to principal accountant fees and services as well as related pre-approval
policies is incorporated by reference to the information under the caption "Independent Registered Public Accounting Firm"
contained in our proxy statement for our 2019 annual meeting of stockholders.
59
Table of Contents
Item 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) The following documents are filed as part of this Form 10-K:
PART IV
(1)
Financial Statements:
Report of Independent Registered Public Accounting Firm
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial
Reporting
Consolidated Balance Sheets as of March 31, 2019 and 2018
Consolidated Statements of Income for each of the three years in the period ended March 31,
2019
Consolidated Statements of Comprehensive Income for each of the three years in the period
ended March 31, 2019
Consolidated Statements of Cash Flows for each of the three years in the period ended March 31,
2019
Consolidated Statements of Changes in Equity for each of the three years in the period ended
March 31, 2019
Notes to Consolidated Financial Statements
(2)
(3)
Financial Statement Schedules
The Exhibits filed with this Form 10-K or incorporated herein by reference are set forth in the
Exhibit Index beginning on page 64 hereof, which Exhibit Index is incorporated herein by this
reference.
(b) See Item 15(a)(3) above.
(c) See "Index to Financial Statements" included under Item 8 to this Form 10-K.
Page
No.
F-1
F-2
F-3
F-4
F-5
F-6
F-8
F-10
None
60
Table of Contents
Item 16.
Form 10-K Summary
Not applicable.
61
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
May 30, 2019
MICROCHIP TECHNOLOGY INCORPORATED
(Registrant)
By: /s/ Steve Sanghi
Steve Sanghi
Chief Executive Officer and Chairman of the Board
62
Table of Contents
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officer or director of Microchip Technology
Incorporated, a Delaware corporation (the "Company"), does hereby constitute and appoint each of STEVE SANGHI and
J. ERIC BJORNHOLT, with full power to each of them to act alone, as the true and lawful attorneys and agents of the
undersigned, with full power of substitution and resubstitution to each of said attorneys to execute, file or deliver any and all
instruments and to do any and all acts and things which said attorneys and agents, or any of them, deem advisable to enable the
Company to comply with the Securities Exchange Act of 1934, as amended, and any requirements of the Securities and
Exchange Commission in respect thereto relating to this annual report on Form 10-K, including specifically, but without
limitation of the general authority hereby granted, the power and authority to sign such person's name individually and on
behalf of the Company as an officer or director (as indicated below opposite such person's signature) to the Company's annual
report on Form 10-K or any amendments or supplements thereto; and each of the undersigned does hereby fully ratify and
confirm all that said attorneys and agents or any of them, shall do or cause to be done by virtue hereof. This Power of Attorney
revokes any and all previous powers of attorney granted by any of the undersigned which such power would have entitled said
attorneys and agents, or any of them, to sign such person's name, individually or on behalf of the Company, to any Form 10-K.
IN WITNESS WHEREOF, each of the undersigned has executed the foregoing power of attorney on this 30th day of May,
2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
Name and Signature
Title
Date
/s/ Steve Sanghi
Steve Sanghi
/s/ Matthew W. Chapman
Matthew W. Chapman
/s/ L.B. Day
L.B. Day
/s/ Esther L. Johnson
Esther L. Johnson
/s/ Wade F. Meyercord
Wade F. Meyercord
/s/ J. Eric Bjornholt
J. Eric Bjornholt
May 30, 2019
May 30, 2019
May 30, 2019
May 30, 2019
May 30, 2019
May 30, 2019
Chief Executive Officer and
Chairman of the Board
(Principal Executive Officer)
Director
Director
Director
Director
Senior Vice President and Chief
Financial Officer
(Principal Financial and
Accounting Officer)
63
Table of Contents
EXHIBIT LIST
Exhibit
Number
2.1
2.2
3.1
3.2
4.1
4.2
4.3
10.1
10.2
10.3
10.4
10.5
10.6
10.7
Exhibit Description
Agreement and Plan of Merger, dated as of
January 19, 2016, by and among Microchip
Technology, Atmel Corporation, and Hero
Acquisition Corporation
Agreement and Plan of Merger, dated as of
March 1, 2018, by and among Microchip
Technology Incorporated, Microsemi
Corporation, and Maple Acquisition
Corporation
Restated Certificate of Incorporation of
Registrant
Incorporated by Reference
Form
8-K
File
Number
000-21184
Exhibit
2.1
Filing
Date
1/19/2016
Included
Herewith
8-K
000-21184
2.1
3/2/2018
10-Q
000-21184
3.1
11/12/2002
Amended and Restated Bylaws of Registrant,
as amended through May 21, 2019
8-K
000-21184
8-K
000-21184
3.1
4.1
5/24/2019
2/11/2015
Indenture dated as of February 11, 2015
between Microchip Technology Incorporated
and Wells Fargo Bank, N.A.
Indenture dated as of February 15, 2017
between Microchip Technology Incorporated
and Wells Fargo Bank, National Association
Indenture dated as of February 15, 2017
between Microchip Technology Incorporated
and Wells Fargo Bank, National Association
Augmenting Lender Supplement, dated as of
November 10, 2017, among Microchip
Technology Incorporated, the lender party
thereto, and JPMorgan Chase Bank, N.A., as
Administrative Agent
Master Increasing Lender Supplement, dated
as of September 1, 2017, among Microchip
Technology Incorporated, the lenders party
thereto and JPMorgan Chase Bank, N.A., as
Administrative Agent
Master Increasing Lender Supplement dated
as of March 19, 2015, by and among
Microchip Technology Incorporated and the
Increasing Lenders thereto
Amended and Restated Credit Agreement,
dated May 18, 2018, by and among Microchip
Technology Incorporated, the lenders from
time to time party there to and JPMorgan
Chase Bank, N.A., as administrative agent
Pledge and Security Agreement, dated as of
February 8, 2017, by and among Microchip
Technology Incorporated, the other grantors
party thereto and JPMorgan Chase Bank,
N.A., as Administrative Agent
Commitment Letter dated March 1, 2018,
between Microchip Technology Incorporation
and JPMorgan Chase Bank, N.A.
Form of Indemnification Agreement between
Registrant and its directors and certain of its
officers [Paper filing not on SEC website.]
64
8-K
000-21184
4.1
2/15/2017
8-K
000-21184
4.3
2/15/2017
8-K
000-21184
10.1
11/13/2017
8-K
000-21184
10.1
9/1/2017
10-K
000-21184
10.1
5/27/2015
8-K
000-21184
10.1
5/18/2018
8-K
000-21184
10.2
2/8/2017
8-K
000-21184
10.1
3/2/2018
S-1
33-57960
10.1
2/5/1993
Table of Contents
EXHIBIT LIST
Incorporated by Reference
Exhibit
Number
10.8
10.9*
10.10*
10.11
10.12*
10.13*
10.14*
10.15
10.16*
10.17
10.18*
10.19*
Exhibit Description
Microchip Technology Incorporated 2012
Inducement Award Plan
2004 Equity Incentive Plan as amended and
restated on May 21, 2019
Form of Notice of Grant of Restricted Stock
Units (officer) for 2004 Equity Incentive Plan
Form of Notice of Grant of Restricted Stock
Units (non-officer) for 2004 Equity Incentive
Plan
Form of Notice of Grant for 2004 Equity
Incentive Plan (including Exhibit A Stock
Option Agreement)
Form of Notice of Grant of Restricted Stock
Units for 2004 Equity Incentive Plan
(including Exhibit A Restricted Stock Units
Agreement)
Restricted Stock Units Agreement (Domestic)
for 2004 Equity Incentive Plan
Restricted Stock Units Agreement (Foreign)
for 2004 Equity Incentive Plan
Form of Global RSU Agreement for 2004
Equity Incentive Plan (including Notice of
Grant of Restricted Stock Units)
Form of RSU Grant Notice and Global RSU
Agreement V-4004
Form of Notice of Stock Option Grant and
Stock Option Agreement
Form of CEO RSU Grant and RSU
Agreement
10.20*
Form of S16 RSU Grant and RSU Agreement
10.21* Microchip Technology Incorporated 2001
Employee Stock Purchase Plan as amended
through February 19, 2019
10.22
10.23*
10.24*
10.25
Microchip Technology Incorporated
International Employee Stock Purchase Plan
as amended May 69, 2019
Executive Management Incentive
Compensation Plan as amended on May 16,
2016
Discretionary Executive Management
Incentive Compensation Plan
Management Incentive Compensation Plan as
amended by the Board of Directors on May
17, 2013
10.26* Microchip Technology Incorporated
Supplemental Retirement Plan
10.27*
Adoption Agreement to the Microchip
Technology Incorporated Supplemental
Retirement Plan dated January 1, 1997
Form
S-8
File
Number
333-183074
Exhibit
4.8
Filing
Date
8/3/2012
Included
Herewith
8-K
000-21184
10.1
5/24/2019
S-8
S-8
333-192273
10.2
11/12/2013
333-192273
10.3
11/12/2013
S-8
333-119939
4.5
10/25/2004
10-K
000-21184
10.6
5/31/2006
10-Q
000-21184
10.3
11/7/2007
10-Q
000-21184
10.4
11/7/2007
8-K
000-21184
10.1
9/27/2010
X
X
X
X
X
X
8-K
000-21184
10.1
8/18/2016
8-K
000-21184
10.3
8/24/2006
10-K
000-21184
10.21
5/30/2013
S-8
S-8
333-101696
4.1.1
12/6/2002
333-101696
4.1.3
12/6/2002
65
Table of Contents
EXHIBIT LIST
Incorporated by Reference
Exhibit
Number
10.28*
10.29*
10.30*
10.31*
10.32*
10.33*
10.34
10.35
10.36
21.1
23.1
24.1
31.1
31.2
32**
101.INS
Exhibit Description
Amendment dated December 9, 1999 to the
Adoption Agreement to the Microchip
Technology Incorporated Supplemental
Retirement Plan
February 3, 2003 Amendment to the Adoption
Agreement to the Microchip Technology
Incorporated Supplemental Retirement Plan
Amendments to Supplemental Retirement
Plan
Amended and Restated Adoption Agreement
to the Microchip Technology Incorporated
Supplemental Retirement Plan dated October
8, 2008, as amended December 15, 2008
Change of Control Severance Agreement
Change of Control Severance Agreement
Development Agreement dated as of August
29, 1997 by and between Registrant and the
City of Chandler, Arizona
Addendum to Development Agreement by
and between Registrant and the City of
Tempe, Arizona, dated May 11, 2000
Development Agreement dated as of July 17,
1997 by and between Registrant and the City
of Tempe, Arizona
Subsidiaries of Registrant
Consent of Independent Registered Public
Accounting Firm
Power of Attorney included on Page 63 of this
Form 10-K
Certification of Chief Executive Officer
Pursuant to Rule 13a-14(a) of the Securities
Exchange Act of 1934, as amended (the
Exchange Act)
Certification of Chief Financial Officer
Pursuant to Rule 13a-14(a) of the Securities
Exchange Act of 1934, as amended (the
Exchange Act)
Certifications Pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
XBRL Instance Document - the instance
document does not appear in the Interactive
File because its XBRL tags are embedded
within the Inline XBRL document
101.SCH XBRL Taxonomy Extension Schema
Document
101.CAL
Taxonomy Extension Calculation Linkbase
Document
101.DEF
XBRL Taxonomy Extension Definition
Linkbase Document
66
Form
S-8
File
Number
333-101696
Exhibit
4.1.4
Filing
Date
12/6/2002
Included
Herewith
10-K
000-21184
10.28
6/5/2003
10-Q
000-21184
10.1
2/9/2006
10-K
000-21184
10.28
5/24/2016
8-K
8-K
000-21184
000-21184
10-Q
000-21184
10.1
10.2
10.1
12/18/2008
12/18/2008
2/13/1998
10-K
000-21184
10.14
5/15/2001
10-Q
000-21184
10.2
2/13/1998
X
X
X
X
X
X
X
X
X
Table of Contents
EXHIBIT LIST
Incorporated by Reference
Form
File
Number
Exhibit
Filing
Date
Included
Herewith
X
X
Exhibit
Number
101.LAB XBRL Taxonomy Extension Label Linkbase
Exhibit Description
Document
101.PRE
XBRL Taxonomy Presentation Linkbase
Document
*Compensation plans or arrangements in
which directors or executive officers are
eligible to participate
**Furnished herewith.
67
Table of Contents
Annual Report on Form 10-K
Item 8, Item 15(a)(1) and (2), (b) and (c)
_________________________________
INDEX TO FINANCIAL STATEMENTS
CONSOLIDATED FINANCIAL STATEMENTS
EXHIBITS
_________________________________
YEAR ENDED MARCH 31, 2019
MICROCHIP TECHNOLOGY INCORPORATED
AND SUBSIDIARIES
CHANDLER, ARIZONA
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
Index to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial
Reporting
Consolidated Balance Sheets as of March 31, 2019 and 2018
Consolidated Statements of Income for each of the three years in the period ended March 31, 2019
Consolidated Statements of Comprehensive Income for each of the three years in the period ended
March 31, 2019
Consolidated Statements of Cash Flows for each of the three years in the period ended March 31,
2019
Consolidated Statements of Changes in Equity for each of the three years in the period ended
March 31, 2019
Notes to Consolidated Financial Statements
Page Number
F-1
F-2
F-4
F-5
F-6
F-7
F-9
F-11
i
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of Microchip Technology Incorporated
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Microchip Technology Incorporated (the Company) as of
March 31, 2019 and 2018, the related consolidated statements of income, comprehensive income, changes in equity and cash
flows for each of the three years in the period ended March 31, 2019, and the related notes (collectively referred to as the
“consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company at March 31, 2019 and 2018, and the results of its operations and its cash flows
for each of the three years in the period ended March 31, 2019, in conformity with U.S. generally accepted accounting
principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the Company's internal control over financial reporting as of March 31, 2019, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
(2013 framework), and our report dated May 30, 2019 expressed an adverse opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2001.
Phoenix, Arizona
May 30, 2019
F-1
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL CONTROL OVER
FINANCIAL REPORTING
To the Shareholders and the Board of Directors of Microchip Technology Incorporated
Opinion on Internal Control over Financial Reporting
We have audited Microchip Technology Incorporated's internal control over financial reporting as of March 31, 2019, based on
criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In our opinion, because of the effect of the material weaknesses
described below on the achievement of the objectives of the control criteria Microchip Technology Incorporated (the Company)
has not maintained effective internal control over financial reporting as of March 31, 2019, based on the COSO criteria.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there
is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be
prevented or detected on a timely basis. The following material weaknesses have been identified and included in
management’s assessment. Management has identified a material weakness in the operating effectiveness of controls related to
the Company’s income tax process. Management has also identified a material weakness in the design effectiveness of certain
IT general controls relating to system access.
As indicated in the accompanying Management’s Report on Internal Control Over Financial Reporting, management’s
assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal
controls of Microsemi Corporation, which is included in the March 31, 2019 consolidated financial statements of Microchip
Technology Incorporated and constituted approximately four percent of consolidated total assets as of March 31, 2019, and
twenty eight percent of consolidated total revenues for the year then ended. Our audit of internal control over financial
reporting of Microchip Technology Incorporated also did not include an evaluation of the internal control over financial
reporting of Microsemi Corporation.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of March 31, 2019 and 2018, the related consolidated statements
of income, comprehensive income, changes in equity and cash flows for each of the three years in the period ended March 31,
2019, and the related notes. The material weaknesses were considered in determining the nature, timing and extent of audit
tests applied in our audit of the fiscal 2019 consolidated financial statements, and this report does not affect our report dated
May 30, 2019, which expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Report
on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control
over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a
reasonable basis for our opinion.
F-2
Table of Contents
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Phoenix, Arizona
May 30, 2019
F-3
Table of Contents
Item1. Financial Statements
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in millions, except share amounts)
ASSETS
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventories
Other current assets
Total current assets
Property, plant and equipment, net
Goodwill
Intangible assets, net
Long-term deferred tax assets
Other assets
Total assets
Accounts payable
Accrued liabilities
LIABILITIES AND STOCKHOLDERS' EQUITY
Deferred income on shipments to distributors
Current portion of long-term debt
Total current liabilities
Long-term debt
Long-term income tax payable
Long-term deferred tax liability
Other long-term liabilities
Stockholders' equity:
March 31,
2019
2018
$
428.6
$
2.3
880.6
711.7
191.6
2,214.8
996.7
6,663.9
6,685.6
1,677.2
111.8
18,350.0
226.4
787.3
—
1,360.8
2,374.5
8,946.2
756.2
706.1
279.5
$
$
$
$
901.3
1,295.3
563.7
476.2
119.8
3,356.3
767.9
2,299.0
1,662.0
100.2
71.8
8,257.2
144.1
229.6
333.8
1,309.9
2,017.4
1,758.4
754.9
205.8
240.9
Preferred stock, $0.001 par value; authorized 5,000,000 shares; no shares issued or outstanding
—
—
Common stock, $0.001 par value; authorized 450,000,000 shares; 253,232,909 shares issued and
237,589,501 shares outstanding at March 31, 2019; 253,232,909 shares issued and 235,027,767 shares
outstanding at March 31, 2018
Additional paid-in capital
Common stock held in treasury: 15,643,408 shares at March 31, 2019; 18,205,142 shares at March 31,
2018
Accumulated other comprehensive loss
Retained earnings
Total stockholders' equity
Total liabilities and stockholders' equity
See accompanying notes to consolidated financial statements
0.2
2,679.6
(582.2)
(20.7)
3,210.6
5,287.5
$
18,350.0
$
0.2
2,562.5
(662.6)
(17.6)
1,397.3
3,279.8
8,257.2
F-4
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(in millions, except per share amounts)
Year ended March 31,
2019
2018
2017
Net sales
Cost of sales (1)
Gross profit
Research and development (1)
Selling, general and administrative (1)
Amortization of acquired intangible assets
Special charges and other, net (1)
Operating expenses
Operating income
Losses on equity method investments
Other income (expense):
Interest income
Interest expense
Loss on settlement of debt
Other (loss) income, net
Income before income taxes
Income tax (benefit) provision
Net income from continuing operations
Discontinued operations:
Loss from discontinued operations
Income tax benefit
Net loss from discontinued operations
Net Income
Basic net income per common share from continuing operations
Basic net loss per common share from discontinued operations
Basic net income per common share
Diluted net income per common share from continuing operations
Diluted net loss per common share from discontinued operations
Diluted net income per common share
Dividends declared per common share
Basic common shares outstanding
Diluted common shares outstanding
(1) Includes share-based compensation expense as follows:
Cost of sales
Research and development
Selling, general and administrative
Special charges and other, net
$
$
$
$
$
$
$
$
$
$
$
$
$
$
5,349.5
2,418.2
2,931.3
826.3
682.9
674.1
33.7
2,217.0
714.3
(0.2)
8.1
(502.9)
(12.6)
(2.2)
204.5
(151.4)
355.9
$
3,980.8
1,560.1
2,420.7
529.3
452.1
485.5
17.5
1,484.4
936.3
(0.2)
22.0
(199.0)
(16.0)
(5.8)
737.3
481.9
255.4
—
—
—
355.9
$
—
—
—
255.4
$
1.51
$
— $
$
1.51
1.10
$
— $
$
1.10
1.42
$
— $
$
$
1.42
1.457
236.2
249.9
1.03
$
— $
$
$
1.03
1.449
232.9
248.9
14.9
72.0
62.3
17.2
$
$
$
$
13.8
42.5
36.9
$
$
$
— $
3,407.8
1,650.6
1,757.2
545.3
499.8
337.7
98.6
1,481.4
275.8
(0.2)
3.1
(146.3)
(43.9)
1.3
89.8
(80.8)
170.6
(7.6)
(1.6)
(6.0)
164.6
0.79
(0.03)
0.76
0.73
(0.02)
0.71
1.441
217.2
234.8
18.7
46.8
62.6
—
See accompanying notes to consolidated financial statements
F-5
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in millions)
Net income
Components of other comprehensive (loss) income:
Available-for-sale securities:
Unrealized holding losses, net of tax effect
Reclassification of realized transactions, net of tax effect
Defined benefit plans:
Actuarial gains (losses) related to defined benefit pension plans, net of tax
(provision) benefit
Reclassification of realized transactions, net of tax effect
Change in net foreign currency translation adjustment
Other comprehensive loss, net of tax effect
Comprehensive income
Year Ended March 31,
2019
2018
2017
$
355.9
$
255.4
$
164.6
(5.6)
5.6
2.9
1.0
(5.3)
(1.4)
354.5
$
(13.6)
15.2
(5.6)
0.8
—
(3.2)
252.2
$
(1.5)
1.5
(5.3)
—
(5.7)
(11.0)
153.6
$
See accompanying notes to consolidated financial statements
F-6
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Deferred income taxes
Share-based compensation expense related to equity incentive plans
Loss on settlement of debt
Amortization of debt discount
Amortization of debt issuance costs
Losses on equity method investments
Gains on sale of assets
Losses on write-down of fixed assets
Impairment of intangible assets
Losses on available-for-sale investments and marketable equity securities, net
Realized gain on equity method investment
Impairment of available-for-sale investment
Amortization of premium on available-for-sale investments
Changes in operating assets and liabilities, excluding impact of acquisitions:
Decrease (increase) in accounts receivable
Decrease (increase) in inventories
Increase in deferred income on shipments to distributors
Decrease in accounts payable and accrued liabilities
Change in other assets and liabilities
Change in income tax payable
Operating cash flows related to discontinued operations
Net cash provided by operating activities
Cash flows from investing activities:
Purchases of available-for-sale investments
Maturities of available-for-sale investments
Sales of available-for-sale investments
Sale of equity method investment
Acquisition of Atmel, net of cash acquired
Acquisition of Microsemi, net of cash acquired
Investments in other assets
Proceeds from sale of assets
Capital expenditures
Net cash used in investing activities
Cash flows from financing activities: (1)
Proceeds from issuance of 2017 Senior Convertible Debt
Proceeds from issuance of 2017 Junior Convertible Debt
Payments on settlement of convertible debt
Proceeds from issuance of 2023 and 2021 Senior Notes
Proceeds from borrowings on term loan facility
Repayments of term loan facility
Proceeds from borrowings on revolving loan under credit facility
Repayments of revolving loan under credit facility
Repayment of debt assumed in Microsemi acquisition
Deferred financing costs
Payment of cash dividends
Proceeds from sale of common stock
Tax payments related to shares withheld for vested restricted stock units
Capital lease payments
Net cash provided by (used in) financing activities
F-7
Year ended March 31,
2018
2017
2019
$
355.9
$
255.4
$
164.6
876.4
(62.2)
166.4
12.6
114.6
16.5
0.2
—
0.8
3.1
—
—
6.0
(0.2)
238.8
341.6
—
(180.7)
(24.2)
(190.8)
—
1,674.8
(167.7)
78.0
1,376.6
—
—
(7,850.6)
(18.6)
0.2
(228.9)
(6,811.0)
—
—
—
1,989.5
3,000.0
(1,088.5)
4,416.5
(1,150.0)
(2,056.9)
(72.7)
(344.4)
42.6
(71.8)
(0.8)
4,663.5
615.9
51.2
93.2
16.0
106.1
6.6
0.2
(5.9)
0.1
0.5
—
—
15.5
0.3
(85.3)
(59.2)
41.0
(13.9)
14.0
367.9
—
1,419.6
(1,594.8)
786.7
—
—
—
—
(7.1)
10.3
(206.8)
(1,011.7)
—
—
(73.4)
—
—
—
187.0
(187.0)
—
(1.2)
(337.5)
42.0
(44.4)
(0.8)
(415.3)
469.2
(126.9)
128.1
43.9
56.1
4.5
0.2
(0.1)
2.6
11.9
0.1
(0.4)
1.4
—
(46.8)
223.7
109.4
(14.8)
25.7
(2.2)
9.3
1,059.5
(500.3)
0.4
470.2
1.7
(2,747.5)
—
(10.2)
23.0
(75.3)
(2,838.0)
2,070.0
575.0
(436.2)
—
—
—
1,537.0
(2,781.0)
—
(36.9)
(315.4)
42.2
(58.4)
(0.8)
595.5
Table of Contents
Effect of foreign exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents
Cash and cash equivalents, and restricted cash at beginning of period (2)
Cash and cash equivalents, and restricted cash at end of period (2)
Schedule of significant non-cash financing activity:
Year ended March 31,
2018
2017
2019
—
(472.7)
901.3
428.6
$
—
(7.4)
908.7
901.3
$
(1.0)
(1,184.0)
2,092.7
908.7
$
(1) During the fiscal year ended March 31, 2018, the Company issued $111.3 million principal amount of 2017 Junior Convertible Notes and
3.2 million shares of common stock in exchange for $111.3 million principal amount of 2007 Junior Convertible Notes. Refer to Note 12
Debt and Credit Facility for further discussion.
Schedule of restricted cash:
(2) During the fiscal year ended March 31, 2019, the Company adopted ASU 2016-18 - Statement of Cash Flows: Restricted Cash. The
following table presents the balance of restricted cash which consists of cash denominated in a foreign currency and restricted in use due to a
foreign taxing authority requirement (in millions):
Restricted cash
2019
Year ended March 31,
2018
2017
$
38.4
$
42.1
$
—
See accompanying notes to consolidated financial statements
F-8
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(in millions)
Common Stock and
Additional Paid-in-Capital
Common Stock Held
in Treasury
Shares
Amount
Shares
Amount
Accumulated
Other
Comprehensive
Income
Retained
Earnings
Total Equity
Balance at March 31, 2016
227.4
$
1,391.9
23.4
$
(820.1) $
(3.4) $
1,582.6
$
2,151.0
—
164.6
Net income
Other comprehensive loss
Issuance of common stock -
Atmel acquisition
Non-cash consideration,
exchange of employee stock
awards - Atmel acquisition
Proceeds from sales of common
stock through employee equity
incentive plans
Restricted stock unit and stock
appreciation right withholdings
Adoption of ASU 2016-09,
cumulative adjustment
Treasury stock used for new
issuances
Share-based compensation
Shares issued to settle
convertible debt
Settlement of convertible debt
Convertible Debt - issuance of
2017 senior and junior debt
Cash dividend
—
—
—
—
10.1
486.2
—
7.5
42.2
(58.4)
2.0
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(88.2)
(3.0)
88.2
127.3
862.7
(850.8)
615.2
—
—
—
—
—
—
—
—
—
—
—
4.0
(1.0)
—
(3.0)
—
12.0
—
—
—
Net income
Other comprehensive loss
Proceeds from sales of common
stock through employee equity
incentive plans
Restricted stock unit and stock
appreciation right withholdings
Treasury stock used for new
issuances
Share-based compensation
Shares issued to settle
convertible debt
Settlement of convertible debt
Convertible Debt - exchange of
2017 junior debt
Cash dividend
—
—
2.7
(0.5)
(2.2)
—
3.7
—
—
—
—
—
42.0
(44.4)
(69.3)
93.1
298.5
(337.7)
42.9
—
Balance at March 31, 2018
253.2
2,562.7
—
—
—
—
—
—
—
—
(2.2)
69.3
—
—
—
—
—
—
—
—
—
—
18.2
F-9
164.6
(11.0)
486.2
7.5
42.2
(58.4)
49.6
—
127.3
862.7
(850.8)
615.2
—
—
—
—
—
47.6
—
—
—
—
—
(11.0)
—
—
—
—
—
—
—
—
—
—
—
(315.4)
(315.4)
—
(3.2)
—
—
—
—
—
—
—
—
255.4
255.4
—
—
—
—
—
—
—
—
(3.2)
42.0
(44.4)
—
93.1
298.5
(337.7)
42.9
(337.5)
(337.5)
Balance at March 31, 2017
249.5
2,537.6
20.4
(731.9)
(14.4)
1,479.4
3,270.7
(662.6)
(17.6)
1,397.3
3,279.8
Table of Contents
Net income
Other comprehensive loss
Adoption of ASU 2016-01,
cumulative adjustment
Adoption of ASC 606,
cumulative adjustment
Adoption of ASU 2016-16,
cumulative adjustment
Non-cash consideration,
exchange of employee stock
awards - Microsemi acquisition
Proceeds from sales of common
stock through employee equity
incentive plans
Restricted stock unit and stock
appreciation right withholdings
Treasury stock used for new
issuances
Share-based compensation
Cash dividend
Common Stock and
Additional Paid-in-Capital
Common Stock Held
in Treasury
Shares
Amount
Shares
Amount
Accumulated
Other
Comprehensive
Income
Retained
Earnings
Total Equity
—
—
—
—
—
—
3.4
(0.8)
(2.6)
—
—
—
—
—
—
—
53.9
42.6
(71.8)
(80.4)
172.8
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(2.6)
80.4
—
—
—
—
—
(1.4)
(1.7)
—
—
—
—
—
—
—
—
355.9
355.9
—
1.7
(1.4)
—
242.0
242.0
1,558.1
1,558.1
—
—
—
—
—
53.9
42.6
(71.8)
—
172.8
(344.4)
(344.4)
Balance at March 31, 2019
253.2
$
2,679.8
15.6
$
(582.2) $
(20.7) $
3,210.6
$
5,287.5
See accompanying notes to consolidated financial statements
F-10
Table of Contents
MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Significant Accounting Policies
Nature of Business
Microchip Technology Incorporated ("Microchip" or the "Company") develops, manufactures and sells specialized
semiconductor products used by its customers for a wide variety of embedded control applications. Microchip's product
portfolio comprises general purpose and specialized 8-bit, 16-bit, and 32-bit microcontrollers, 32-bit microprocessors, field-
programmable gate array (FPGA) products, a broad spectrum of high-performance linear, mixed-signal, power management,
thermal management, discrete diodes and Metal Oxide Semiconductor Field Effect Transistors (MOSFETS), radio frequency
(RF), timing, timing systems, safety, security, wired connectivity and wireless connectivity devices, as well as Serial
Electrically Erasable Programmable Read Only Memory (EEPROM), Serial Flash memories, Parallel Flash memories, Serial
Electrically Erasable Random Access Memory (EERAM), and Serial Static Random Access Memory (SRAM) memories.
Microchip also licenses Flash-IP solutions that are incorporated in a broad range of products.
Principles of Consolidation
The Company prepares its consolidated financial statements in accordance with generally accepted accounting principles in
the United States of America (US GAAP). The consolidated financial statements include the accounts of Microchip and its
majority-owned and controlled subsidiaries. As further discussed in Note 2, on May 29, 2018, the Company completed its
acquisition of Microsemi Corporation (Microsemi) and the Company's financial results include Microsemi's results beginning
as of such acquisition date. All of the Company's subsidiaries are included in the consolidated financial statements. All
significant intercompany accounts and transactions have been eliminated in consolidation. All dollar amounts in the financial
statements and tables in these notes, except per share amounts, are stated in millions of U.S. dollars unless otherwise noted.
Revenue Recognition (subsequent to the adoption of ASC 606)
The Company generates revenue primarily from sales of semiconductor products to distributors and non-distributor
customers (direct customers) and, to a lesser extent, from royalties paid by licensees of intellectual property. The Company
applies the following five-step approach to determine the timing and amount of revenue recognition: (1) identify the contract
with the customer, (2) identify performance obligations in the contract, (3) determine the transaction price, (4) allocate the
transaction price to the performance obligations in the contract, and (5) recognize revenue when the performance obligation is
satisfied.
Sales to distributors are governed by a distributor agreement, a purchase order, and an order acknowledgment. Sales to
distributors do not meet the definition of a contract, as defined by ASC 606, until the distributor has sent in a purchase order,
the Company has acknowledged the order, the Company has deemed the collectability of the consideration to be probable, and
legally enforceable rights and obligations have been created; this generally occurs 30 days prior to the estimated ship date. As
is customary in the semiconductor industry, the Company offers price concessions and stock rotation rights to many of their
distributors. As these are forms of variable consideration, the Company estimates the amount of consideration to which they
will be entitled using recent historical data and applying the expected value method. Usually, there is only a single performance
obligation in the contract, and therefore the entire transaction price is allocated to the single performance obligation. After the
transaction price has been allocated, the Company recognizes revenue when the performance obligation is satisfied.
Substantially all of the revenue generated from contracts with distributors is recognized at the time risk and title of the
inventory transfers to the distributor.
Sales to direct customers are generally governed by a purchase order and an order acknowledgment. Sales to direct
customers usually do not meet the definition of a contract, as defined by ASC 606, until shipment of the product occurs.
Generally, the transaction price associated with contracts with direct customers is set at the standalone selling price and is not
variable. Usually, there is only a single performance obligation in the contract, and therefore the entire transaction price is
allocated to the single performance obligation. After the transaction price has been allocated, the Company recognizes revenue
when the performance obligation is satisfied. Substantially all of the revenue generated from contracts with direct customers is
recognized at the time risk and title of the inventory transfers to the customer.
Revenue generated from licensees is governed by licensing agreements. The Company's primary performance obligation
related to these agreements is to provide the licensee the right to use the intellectual property. The final transaction price is
F-11
Table of Contents
determined by multiplying the usage of the license by the royalty, which is fixed in the licensing agreement. Revenue is
recognized as usage of the license occurs.
For a discussion of the financial statement impact related to the adoption of ASC 606, see “Recently Adopted Accounting
Pronouncements.”
Revenue Recognition (prior to the adoption of ASC 606)
The Company recognized revenue when the earnings process was complete, as evidenced by an agreement with the
customer, transfer of title had occurred, the pricing was fixed or determinable and collectability was reasonably assured. The
Company recognized revenue from product sales to original equipment manufacturers (OEMs) upon shipment and recorded
reserves for estimated customer returns.
Distributors worldwide generally had broad price protection and product return rights which prevented the sales pricing
from being fixed or determinable at the time of the Company's shipment to the distributors. Therefore, revenue recognition was
deferred until the pricing uncertainty was resolved, which generally occurred when the distributor sold the product to their
customer. At the time of shipment to these distributors, the Company recorded a trade receivable for the selling price as there
was a legally enforceable right to payment, relieved inventory for the carrying value of goods shipped since legal title had
passed to the distributor, and recorded the gross margin in deferred income on shipments to distributors on its consolidated
balance sheets.
In connection with its acquisition of Atmel, the Company acquired certain distributor relationships where revenue was
recognized upon shipment to the distributors based on certain contractual terms or prevailing business practices that resulted in
the price being fixed and determinable at such time. Following an acquisition, the Company undertook efforts to align the
contract terms and business practices of the acquired entity with its own. Once these efforts were complete, the related revenue
recognition was changed. With respect to such distributor relationships acquired in the Atmel acquisition, as of October 1,
2016, these business practices were conformed to those of the Company’s other distributors, which beginning in October 2016
resulted in the deferral of revenue recognition until the distributor sold the product to their customers.
Deferred income on shipments to distributors effectively represented gross margin on the sale to the distributor at the initial
shipment date; however, the amount of gross margin recognized by the Company in future periods was less than the deferred
margin as a result of credits granted to distributors on specifically identified products and customers to allow the distributors to
earn a competitive gross margin on the sale of the Company's products to their end customers and price protection concessions
related to market pricing conditions.
The Company sold the majority of the items in its product catalog to its distributors worldwide at a uniform list
price. However, distributors resold the Company's products to end customers at a broad range of individually negotiated price
points. The majority of the Company's distributors' resales required a reduction from the original list price paid. Often, under
these circumstances, the Company remitted back to the distributor a portion of their original purchase price after the resale
transaction was completed in the form of a credit against the distributors' outstanding accounts receivable balance. The credits
were on a per unit basis and were not given to the distributor until they provided information regarding the sale to their end
customer. The price reductions varied significantly based on the customer, product, quantity ordered, geographic location and
other factors and discounts to a price less than the Company's cost have historically been rare. The effect of granting these
credits established the net selling price from the Company to its distributors for the product and resulted in the net revenue
recognized by the Company when the product was sold by the distributors to their end customers. Thus, a portion of the
"deferred income on shipments to distributors" balance represented the amount of distributors' original purchase price that was
to be credited back to the distributors in the future. The Company did not reduce deferred income on shipments to distributors
or accounts receivable by anticipated future price concessions; rather, price concessions are recorded against deferred income
on shipments to distributors when incurred, which is generally at the time the distributor sold the product.
At March 31, 2018, the Company had approximately $479.6 million of deferred revenue and $145.8 million in deferred
cost of sales recognized as $333.8 million of deferred income on shipments to distributors. The deferred income on shipments
to distributors that was ultimately to be recognized in the Company's income statement was lower than the amount reflected on
the balance sheet due to price credits to be granted to the distributors when the product is sold to their customers. These price
credits historically have resulted in the deferred income approximating the overall gross margins that the Company recognizes
in the distribution channel of its business.
The Company reduced product pricing through price protection based on market conditions, competitive considerations
and other factors. Price protection was granted to distributors on the inventory they have on hand at the date the price
F-12
Table of Contents
protection was offered. When the Company reduced the price of its products, it allowed the distributor to claim a credit against
its outstanding accounts receivable balances based on the new price of the inventory it has on hand as of the date of the price
reduction. There was no immediate revenue impact from the price protection, as it was reflected as a reduction of the deferred
income on shipments to distributors' balance.
Products returned by distributors and subsequently scrapped have historically been immaterial to the Company's
consolidated results of operations. The Company routinely evaluated the risk of impairment of the deferred cost of sales
component of the deferred income on shipments to distributors' account. Because of the historically immaterial amounts of
inventory that have been scrapped, and historically rare instances where discounts given to a distributor resulted in a price less
than the Company's cost, the Company believed the deferred costs have a low risk of material impairment.
Shipping charges billed to customers were included in net sales, and the related shipping costs were included in cost of sales.
The Company collected and remitted certain sales-related taxes on a portion of its sales of inventory and reported such amounts
under the net method in its consolidated statements of income.
For licenses or other technology arrangements without an upgrade period, non-royalty revenue from the license was
recognized upon delivery of the technology if the fee was fixed or determinable and collection of the fee was reasonably
assured. Royalties were recognized when reported to the Company, which generally coincided with the receipt of payment. In
certain limited circumstances, the Company entered into license and other arrangements for technologies that the Company was
continuing to enhance and refine or under which it was obligated to provide unspecified enhancements. Under these
arrangements, non-royalty revenue is recognized over the lesser of (1) the estimated period that the Company has historically
enhanced and developed refinements to the specific technology, typically one to three years (the "upgrade period"), and (2) the
remaining portion of the upgrade period after the date of delivery of all specified technology and documentation, provided that
the fee is fixed or determinable and collection of the fee is reasonably assured. Royalties received during the upgrade period
were recognized as revenue based on an amortization calculation of the elapsed portion of the upgrade period compared to the
entire estimated upgrade period. Royalties received after the upgrade period has elapsed were recognized when reported to the
Company, which generally coincided with the receipt of payment.
Product Warranty
The Company typically warrants its products against defects in materials and workmanship and non-conformance to
specifications for 12 to 24 months. The majority of the Company's product warranty claims are settled through the return of the
defective product and the shipment of replacement product. Warranty returns are included within the Company's allowance for
returns, which is based on historical return rates. Actual future returns could differ from the allowance established. In addition,
the Company accrues a liability for specific warranty costs expected to be settled other than through product return and
replacement, if a loss is probable and can be reasonably estimated. Product warranty expenses were immaterial for the fiscal
years ended March 31, 2019, 2018, and 2017.
Advertising Costs
The Company expenses all advertising costs as incurred. Advertising costs were immaterial for the fiscal years ended
March 31, 2019, 2018 and 2017.
Research and Development
Research and development costs are expensed as incurred. Assets purchased to support the Company's ongoing research
and development activities are capitalized when related to products which have achieved technological feasibility or that have
alternative future uses and are amortized over their estimated useful lives. Renewals or extensions of these assets are expensed
as incurred. Research and development expenses include expenditures for labor, share-based payments, depreciation, masks,
prototype wafers, and expenses for development of process technologies, new packages, and software to support new products
and design environments.
Restructuring Charges
The Company recognizes a liability measured at fair value for restructuring costs when the liability is incurred.
Restructuring charges are included within special charges and other, net in the consolidated statements of income and are
primarily comprised of employee separation costs, asset impairments, contract exit costs and costs of facility consolidation and
closure, including the related gains or losses associated with the sale of owned facilities. Employee separation costs includes
one-time termination benefits that are recognized as a liability at estimated fair value, at the time of communication to
F-13
Table of Contents
employees, unless future service is required, in which case the costs are recognized ratably over the future service period.
Ongoing termination benefits are recognized as a liability at estimated fair value when the amount of such benefits are probable
and reasonably estimable. Contract exit costs includes contract termination fees and future contractual commitments for lease
payments. A liability for contract exit costs is recognized in the period in which the Company terminates the contract or on the
cease-use date for leased facilities.
Foreign Currency Translation
The Company's foreign subsidiaries are considered to be extensions of the U.S. company and any translation gains and
losses related to these subsidiaries are included in other income (expense) in the consolidated statements of income. As the
U.S. dollar is utilized as the functional currency, gains and losses resulting from foreign currency transactions (transactions
denominated in a currency other than the subsidiaries' functional currency) are also included in income. For a portion of fiscal
2019 and 2017, certain foreign subsidiaries acquired as part of the Company's acquisition activities had the local currency as the
functional currency. For subsidiaries acquired as part of the Company's acquisition of Microsemi, the U.S. dollar is expected to
become the functional currency for such entities once integrated into the Company's legal structure and intercompany
agreements are executed.
Income Taxes
As part of the process of preparing its consolidated financial statements, the Company is required to estimate its income
taxes in each of the jurisdictions in which it operates. This process involves estimating its actual current tax exposure together
with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These
differences result in deferred tax assets and liabilities, which are included within the Company's consolidated balance
sheets. The Company must then assess the likelihood that its deferred tax assets will be recovered from future taxable income
within the relevant jurisdiction and to the extent the Company believes that recovery is not likely, it must establish a valuation
allowance. The Company provided valuation allowances for certain of its deferred tax assets where it is more likely than not
that some portion, or all of such assets, will not be realized.
Various taxing authorities in the U.S. and other countries in which the Company does business scrutinize the tax structures
employed by businesses. Companies of a similar size and complexity as the Company are regularly audited by the taxing
authorities in the jurisdictions in which they conduct significant operations. During the year ended March 31, 2019, various
foreign jurisdictions finalized their audits. The close of these audits did not have an adverse impact on the financial statements.
The Company is currently being audited by the tax authorities in the United States and various foreign jurisdictions. At this
time, the Company does not know what the outcome of these audits will be. The Company records benefits for uncertain tax
positions based on an assessment of whether it is more likely than not that the tax positions will be sustained based on their
technical merits under currently enacted law. If this threshold is not met, no tax benefit of the uncertain tax position is
recognized. If the threshold is met, the Company recognizes the largest amount of the tax benefit that is more than 50% likely
to be realized upon ultimate settlement.
The accounting model as defined in Accounting Standards Codification ("ASC") 740 related to the valuation of uncertain
tax positions requires the Company to presume that the tax position will be examined by the relevant taxing authority that has
full knowledge of all relevant information and that each tax position will be evaluated without consideration of the possibility
of offset or aggregation with other positions. The recognition requirement for the liability exists even if the Company believes
the possibility of examination by a taxing authority or discovery of the related risk matters is remote or where it has a long
history of the taxing authority not performing an exam or overlooking an issue. The Company will record an adjustment to a
previously recorded position if new information or facts related to the position are identified in a subsequent period. All
adjustments to the positions are recorded through the income statement. Generally, adjustments will be recorded in periods
subsequent to the initial recognition if the taxing authority has completed an audit of the period or if the statute of limitation
expires. Due to the inherent uncertainty in the estimation process and in consideration of the criteria of the accounting model,
amounts recognized in the financial statements in periods subsequent to the initial recognition may significantly differ from the
estimated exposure of the position under the accounting model.
On December 22, 2017, the Act was enacted into law. The Act provides for numerous significant tax law changes and
modifications including the reduction of the U.S. federal corporate income tax rate from 35.0% to 21.0%, the requirement for
companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and the
creation of new taxes on certain foreign-sourced earnings. As a fiscal year-end taxpayer, certain provisions of the Act began to
impact the Company in the third quarter of fiscal 2018, while other provisions have become effective for the Company in fiscal
2019.
F-14
Table of Contents
In addition to the impacts of tax reform on fiscal 2018, the Act establishes new tax laws that are effective for fiscal 2019,
including, but not limited to, (1) a new provision designed to tax low-taxed income of foreign subsidiaries (“GILTI”), which
allows for the possibility of using foreign tax credits ("FTCs") and a deduction of up to 50% to offset the income tax liability
(subject to some limitations); (2) limitations on the deductibility of certain executive compensation; (3) limitations on the
deductibility of interest expense; and (4) limitations on the use of FTCs to reduce the U.S. income tax liability. While each of
these provisions is expected to have an impact on the Company's tax expense for future periods, the increase in tax expense for
GILTI is the most significant.
The FASB allows taxpayers to make an accounting policy election of either (1) treating taxes due on GILTI inclusions as a
current-period expense when incurred or (2) recognizing deferred taxes for temporary basis differences that are expected to
reverse as GILTI in future years. The Company is making a policy choice to include taxes due on the future GILTI inclusion in
taxable income when incurred.
Cash and Cash Equivalents
All highly liquid investments, including marketable securities with an original maturity to the Company of three months or
less when acquired are considered to be cash equivalents.
Available-for-Sale Investments
The Company classifies its investments in debt and marketable equity securities as available-for-sale based upon
management's intent with regard to the investments and the nature of the underlying securities.
The Company's available-for-sale debt securities consist of government agency bonds, municipal bonds and corporate
bonds. The Company's available-for-sale debt securities are carried at fair value with unrealized gains and losses reported in
stockholders' equity unless losses are considered to be other than temporary impairments in which case the losses are
recognized through the statement of income. Premiums and discounts are amortized or accreted over the life of the related
available-for-sale security. Dividend and interest income are recognized when earned. The cost of available-for-sale debt
securities sold is calculated using the first-in, first-out (FIFO) basis at the individual security level for sales from multiple lots.
Marketable equity securities are equity securities with a readily determinable fair value that are measured and recorded at
fair value on a recurring basis with changes in fair value, whether realized or unrealized, recorded through the statement of
income. Prior to fiscal 2019, these securities were classified as available-for-sale securities and measured and recorded at fair
value with unrealized changes in fair value reported in stockholders' equity.
The Company includes within short-term investments its income yielding available-for-sale securities that can be readily
converted to cash and includes within long-term investments those income yielding available-for-sale securities with maturities
of over one year that have unrealized losses attributable to them or those that cannot be readily liquidated. As discussed in Note
5, if the Company anticipates that investments will be liquidated in anticipation of a pending merger or otherwise, any
unrealized losses are recognized as other-than-temporary impairments. If the anticipated liquidity event is within 12 months,
the securities are classified as short-term investments. In the normal course of business, the Company intends and has the
ability to hold its long-term investments with temporary impairments until such time as these assets are no longer impaired.
Derivative Instruments
Derivative instruments are required to be recorded at fair value as either assets or liabilities in the Company's consolidated
balance sheet. The Company's accounting policies for derivative instruments depends on whether the instrument has been
designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.
The Company does not apply hedge accounting to foreign currency forward contracts. Gains and losses associated with
currency rate changes on forward contracts are recorded currently in income. These gains and losses have been immaterial to
the Company's financial statements.
The Company is exposed to fluctuations in prices for energy that it consumes, particularly electricity and natural gas. The
Company also enters into variable-priced contracts for some purchases of electricity and natural gas, on an index basis. The
Company seeks, or may seek, to partially mitigate these exposures through fixed-price contracts. These contracts meet the
characteristics of derivative instruments, but generally qualify for the “normal purchases or normal sales” exception under
authoritative guidance and require no mark-to-market adjustment.
F-15
Table of Contents
Allowance for Doubtful Accounts
The Company maintains an allowance for doubtful accounts for probable losses on uncollectible accounts receivable
resulting from the inability of its customers to make required payments, which is included in bad debt expense. The Company
determines the adequacy of this allowance by routinely analyzing the composition of accounts receivable and evaluating
customer creditworthiness, credit history, facts and circumstances specific to outstanding balances and current economic
conditions.
Inventories
Inventories are valued at the lower of cost or net realizable value using the first-in, first-out method. The Company writes
down its inventory for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost
of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If
actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be
required. Inventory impairment charges establish a new cost basis for inventory and charges are not subsequently reversed to
income even if circumstances later suggest that increased carrying amounts are recoverable. In estimating reserves for
obsolescence, the Company primarily evaluates estimates of demand over a 12-month period and provides reserves for
inventory on hand in excess of the estimated 12-month demand. Estimates for projected 12-month demand are generally based
on the average shipments of the prior three-month period, which are then annualized to adjust for any potential seasonality in
the Company's business. The estimated 12-month demand is compared to the Company's most recently developed sales
forecast to further reconcile the 12-month demand estimate. Management reviews and adjusts the estimates as appropriate
based on specific situations. For example, demand can be adjusted up for new products for which historic sales are not
representative of future demand. Alternatively, demand can be adjusted down to the extent any existing products are being
replaced or discontinued.
In periods where the Company's production levels are substantially below normal operating capacity, unabsorbed overhead
production costs associated with the reduced production levels of the Company's manufacturing facilities are charged directly to
cost of sales.
Property, Plant and Equipment
Property, plant and equipment are stated at cost. Major renewals and improvements are capitalized, while maintenance and
repairs are expensed when incurred. The Company's property and equipment accounting policies incorporate estimates,
assumptions and judgments relative to the useful lives of its property and equipment. Depreciation is provided for assets placed
in service on a straight-line basis over the estimated useful lives of the relative assets, which range from 10 to 40 years for
buildings and building improvements and 3 to 7 years for machinery and equipment. The Company evaluates the carrying
value of its property and equipment when events or changes in circumstances indicate that the carrying value of such assets
may be impaired. Asset impairment evaluations are, by nature, highly subjective.
Senior and Junior Subordinated Convertible Debt
The Company separately accounts for the liability and equity components of its senior and junior subordinated convertible
debt in a manner that reflects its nonconvertible debt (unsecured debt) borrowing rate when interest cost is recognized. This
results in a bifurcation of a component of the debt, classification of that component in equity and the accretion of the resulting
discount on the debt to be recognized as part of interest expense in its consolidated statements of income. Lastly, the Company
includes the dilutive effect of the shares of its common stock issuable upon conversion of the outstanding senior and junior
subordinated convertible debt in its diluted income per share calculation regardless of whether the market price triggers or other
contingent conversion features have been met. The Company applies the treasury stock method as it has the intent and ability
to settle the principal amounts of the senior and junior subordinated convertible debentures in cash. This method results in
incremental dilutive shares when the average market value of the Company's common stock for a reporting period exceeds the
conversion prices per share and adjust as dividends are recorded in the future.
Upon a de-recognition event such as a settlement or conversion, the Company estimates the fair value of the liability
component and compares that to the carrying amount in order to calculate the appropriate amount of gain or loss. The
remaining amounts paid or issued (in the case of non cash consideration in the form of shares of common stock) are recognized
as a reduction of additional paid-in-capital. The fair value of the liability component is estimated using the current comparable
borrowing rate for an otherwise identical non-convertible debt instrument.
F-16
Table of Contents
Defined Benefit Pension Plans
The Company maintains defined benefit pension plans, covering certain of its foreign employees. For financial reporting
purposes, net periodic pension costs and pension obligations are determined based upon a number of actuarial assumptions,
including discount rates for plan obligations, and assumed rates of compensation increases for employees participating in plans.
These assumptions are based upon management's judgment and consultation with actuaries, considering all known trends and
uncertainties.
Contingencies
In the ordinary course of business, the Company is exposed to various liabilities as a result of contracts, product liability,
customer claims and other matters. Additionally, the Company is involved in a limited number of legal actions, both as plaintiff
and defendant. Consequently, the Company could incur uninsured liability in any of those actions. The Company also
periodically receives notifications from various third parties alleging infringement of patents or other intellectual property
rights, or from customers requesting reimbursement for various costs. With respect to pending legal actions to which the
Company is a party and other claims, although the outcomes are generally not determinable, the Company believes that the
ultimate resolution of these matters will not have a material adverse effect on its financial position, cash flows or results of
operations. Litigation and disputes relating to the semiconductor industry are not uncommon, and the Company is, from time to
time, subject to such litigation and disputes. As a result, no assurances can be given with respect to the extent or outcome of
any such litigation or disputes in the future.
The Company accrues for claims and contingencies when losses become probable and reasonably estimable. As of the end
of each applicable reporting period, the Company reviews each of its matters and, where it is probable that a liability has been
or will be incurred, it accrues for all probable and reasonably estimable losses. Where the Company can reasonably estimate a
range of losses it may incur regarding such a matter, it records an accrual for the amount within the range that constitutes its
best estimate. If the Company can reasonably estimate a range but no amount within the range appears to be a better estimate
than any other, it uses the amount that is the low end of such range.
Business Combinations
All of the Company's business combinations are accounted for at fair value under the acquisition method of accounting.
Under the acquisition method of accounting, (i) acquisition-related costs, except for those costs incurred to issue debt or equity
securities, will be expensed in the period incurred; (ii) non-controlling interests will be valued at fair value at the acquisition
date; (iii) in-process research and development will be recorded at fair value as an intangible asset at the acquisition date and
amortized once the technology reaches technological feasibility; (iv) restructuring costs associated with a business combination
will be expensed subsequent to the acquisition date; and (v) changes in deferred tax asset valuation allowances and income tax
uncertainties after the acquisition date will be recognized through income tax expense. The aggregate amount of consideration
paid by the Company is allocated to net tangible assets and intangible assets based on their estimated fair values as of the
acquisition date. The excess of the purchase price over the value of the net tangible assets and intangible assets is recorded to
goodwill. The measurement of fair value of assets acquired and liabilities assumed requires significant judgment. The
valuation of intangible assets, in particular, requires that the Company use valuation techniques such as the income
approach. The income approach includes the use of a discounted cash flow model, which includes discounted cash flow
scenarios and requires the following significant estimates: revenue, expenses, capital spending and other costs, and discount
rates based on the respective risks of the cash flows.
Goodwill and Other Intangible Assets
The Company's intangible assets include goodwill and other intangible assets. Goodwill is recorded when the purchase
price paid for an acquisition exceeds the estimated fair value of the net identified tangible and intangible assets acquired. Other
intangible assets include existing technologies, core and developed technology, in-process research and development,
trademarks and trade names, distribution rights and customer-related intangibles. In-process research and development is
capitalized until such time the related projects are completed or abandoned at which time the capitalized amounts will begin to
be amortized or written off. Indefinite-lived intangible assets consist of goodwill and in-process research and development
intangible assets that have not yet been placed in service. All other intangible assets are definite-lived intangible assets,
including in-process research and development assets that have been placed in service, and are amortized over their respective
estimated lives, ranging from 1 to 15 years.
The Company is required to perform an impairment review of indefinite-lived intangible assets, including goodwill
annually, and more frequently under certain circumstances. Indefinite-lived intangible assets are subjected to this annual
F-17
Table of Contents
impairment test during the fourth quarter of the Company's fiscal year. The Company engages primarily in the development,
manufacture and sale of semiconductor products as well as technology licensing. As a result, the Company concluded there are
two reporting units, semiconductor products and technology licensing. Under the qualitative indefinite-lived intangible asset
impairment assessment standard, management evaluates whether it is more likely than not that the indefinite-lived intangible
assets are impaired. If it is determined that it is more likely than not, the Company proceeds with the next step of the
impairment test, which compares the fair value of the reporting unit or indefinite-lived intangible asset to its carrying value. If
the Company determines through the impairment process that the indefinite-lived intangible asset has been impaired, the
Company will record the impairment charge in its results of operation. Through March 31, 2019, the Company has not had
impaired goodwill. In the event that facts and circumstances indicate definite-lived intangible assets may be impaired, the
Company evaluates the recoverability and estimated useful lives of such assets. If such indicators are present, recoverability is
evaluated based on whether the sum of the estimated undiscounted cash flows attributable to the asset (group) in question is less
than their carrying value. If less, the Company measures the fair value of the asset (group) and recognizes an impairment loss if
the carrying amount of the assets exceeds their respective fair values.
Impairment of Long-Lived Assets
The Company assesses whether indicators of impairment of long-lived assets are present. If such indicators are present, the
Company determines whether the sum of the estimated undiscounted cash flows attributable to the assets in question is less than
their carrying value. If less, the Company recognizes an impairment loss based on the excess of the carrying amount of the
assets over their respective fair values. Fair value is determined by discounted future cash flows, appraisals or other
methods. If the assets determined to be impaired are to be held and used, the Company recognizes an impairment loss through
a charge to operating results to the extent the present value of anticipated net cash flows attributable to the asset are less than
the asset's carrying value. The Company would depreciate the remaining value over the remaining estimated useful life of the
asset.
Share-Based Compensation
The Company has equity incentive plans under which non-qualified stock options and restricted stock units (RSUs) have
been granted to employees and non-employee members of the Board of Directors. The Company uses RSUs as its primary
equity incentive compensation instrument for employees. The Company also has employee stock purchase plans for eligible
employees. Share-based compensation cost is measured on the grant date based on the fair market value of the Company’s
common stock discounted for expected future dividends and is recognized as expense on a straight-line basis over the requisite
service periods.
If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to
accelerate or increase any remaining unearned share-based compensation expense. Future share-based compensation expense
and unearned share-based compensation will increase to the extent that the Company grants additional equity awards to
employees or it assumes unvested equity awards in connection with acquisitions.
During fiscal 2017, the Company elected to early adopt ASU 2016-09-Compensation - Stock Compensation, Improvements
to Employee Share-Based Payment Accounting (Topic 718). See "Recently Adopted Accounting Pronouncements" for
additional information on the new guidance.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investments
in debt securities and trade receivables. Investments in debt securities with original maturities of greater than six months
consist primarily of AAA and AA rated financial instruments and counterparties. The Company's investments are primarily in
direct obligations of the U.S. government or its agencies, corporate bonds, and municipal bonds.
Concentrations of credit risk with respect to accounts receivable are generally not significant due to the diversity of the
Company's customers and geographic sales areas. The Company sells its products primarily to OEMs and distributors in the
Americas, Europe and Asia. The Company performs ongoing credit evaluations of its customers' financial condition and, as
deemed necessary, may require collateral, primarily letters of credit.
Distributor advances in the consolidated balance sheets, totaled $170.7 million and $203.9 million at March 31, 2019 and
March 31, 2018, respectively. On sales to distributors, the Company's payment terms generally require the distributor to settle
amounts owed to the Company for an amount in excess of their ultimate cost. The Company's sales price to its distributors may
be higher than the amount that the distributors will ultimately owe the Company because distributors often negotiate price
F-18
Table of Contents
reductions after purchasing the products from the Company and such reductions are often significant. It is the Company's
practice to apply these negotiated price discounts to future purchases, requiring the distributor to settle receivable balances, on a
current basis, generally within 30 days, for amounts originally invoiced. This practice has an adverse impact on the working
capital of the Company's distributors. As such, the Company has entered into agreements with certain distributors whereby it
advances cash to the distributors to reduce the distributors' working capital requirements. These advances are reconciled at
least on a quarterly basis and are estimated based on the amount of ending inventory as reported by the distributor multiplied by
a negotiated percentage. Such advances have no impact on revenue recognition or the Company's consolidated statements of
income. The Company processes discounts taken by distributors against its deferred income on shipments to distributors'
balance and trues-up the advanced amounts generally after the end of each completed fiscal quarter. The terms of these
advances are set forth in binding legal agreements and are unsecured, bear no interest on unsettled balances and are due upon
demand. The agreements governing these advances can be canceled by the Company at any time.
Use of Estimates
The Company has made a number of estimates and assumptions relating to the reporting of assets, liabilities, revenues and
expenses and the disclosure of contingent assets and liabilities to prepare its consolidated financial statements in conformity
with U.S. Generally Accepted Accounting Principles. Actual results could differ from those estimates.
Business Segments
Operating segments are components of an enterprise about which separate financial information is regularly reviewed by
the chief operating decision makers ("CODMs") to assess the performance of the component and make decisions about the
resources to be allocated to the component. The Company's Chairman and Chief Executive Officer and the Company's
President and Chief Operating Officer have been identified as the CODMs as they jointly manage the Company's worldwide
consolidated enterprise. Based on the Company's structure and manner in which the Company is managed and decisions are
made, the Company's business is made up of two operating segments, semiconductor products and technology licensing.
In the semiconductor products segment, the Company designs, develops, manufactures and markets microcontrollers,
development tools and analog, interface, mixed-signal, timing, wired and wireless connectivity devices, and memory products.
Under the leadership of the CODMs, the Company is structured and organized around standardized roles and responsibilities
based on product groups and functional activities. The Company's product groups are responsible for product research, design
and development. The Company's functional activities include sales, marketing, manufacturing, information technology,
human resources, legal and finance.
The Company's product groups have similar products, production processes, types of customers and methods for
distribution. In addition, the tools and technologies used in the design and manufacture of the Company's products are shared
among the various product groups. The Company's product group leaders, under the direction of the CODMs, define the
product roadmaps and team with sales personnel to achieve design wins and revenue and other performance targets. Product
group leaders also interact with manufacturing and operational personnel who are responsible for the production, prioritization
and planning of the Company's manufacturing capabilities to help ensure the efficiency of the Company's operations and
fulfillment of customer requirements. This centralized structure supports a global operating strategy in which the CODMs
assess performance and allocate resources based on the Company's consolidated results.
Recently Adopted Accounting Pronouncements
On April 1, 2018, the Company adopted ASU 2014-09-Revenue from Contracts with Customers (ASC 606) and all related
amendments (“New Revenue Standard”) using the modified retrospective method. The Company has applied the new revenue
standard to all contracts that were entered into after adoption and to all contracts that were open as of the initial date of
adoption. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the
opening balance of retained earnings. The comparative information has not been restated and continues to be reported under
the accounting standards in effect for those periods. The adoption of the new standard impacts the Company's net sales on an
ongoing basis depending on the relative amount of revenue sold through its distributors, the change in inventory held by its
distributors, and the changes in price concessions granted to its distributors. Previously, the Company deferred revenue and
cost of sales on shipments to distributors until the distributor sold the product to their end customer. As required by the new
revenue standard, the Company no longer defers revenue and cost of sales, but rather, estimates the effects of returns and
allowances provided to distributors and records revenue at the time of sale to the distributor. Sales to non-distributor customers,
under both the previous and new revenue standards, are generally recognized upon the Company’s shipment of the product.
The cumulative effect of the changes made to the consolidated April 1, 2018 balance sheet for the adoption of the new revenue
standard is summarized in the table of opening balance sheet adjustments below. In accordance with the new revenue standard
F-19
Table of Contents
requirements, the disclosure of the impact of adoption on the consolidated income statement and balance sheet for the period
ended March 31, 2019 was as follows (in millions):
Income Statement
As reported
For the year ended March 31, 2019
Balances without
adoption of New
Revenue Standard
Effect of Change
Higher / (Lower)
Net sales
Cost of sales
Gross profit
Income before income taxes
Income tax (benefit) provision
Net income from continuing operations
Balance Sheet
ASSETS
Accounts receivable, net
Inventories
Other current assets
Other assets
Long-term deferred tax assets
LIABILITIES
Accrued liabilities
Deferred income on shipments to distributors
Long-term deferred tax liability
STOCKHOLDERS' EQUITY
Retained Earnings
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
5,349.5
2,418.2
2,931.3
204.5
(151.4)
355.9
$
$
$
$
$
$
5,380.1
2,434.0
2,946.1
219.3
(149.0)
368.3
As of March 31, 2019
Balances without
adoption of New
Revenue Standard
As reported
880.6
711.7
191.6
111.8
1,677.2
$
$
$
$
$
787.3
$
— $
706.1
$
556.1
724.2
154.7
106.3
1,700.7
420.3
288.2
689.3
$
$
$
$
$
$
$
$
$
$
$
$
$
$
(30.6)
(15.8)
(14.8)
(14.8)
(2.4)
(12.4)
Effect of Change
Higher / (Lower)
324.5
(12.5)
36.9
5.5
(23.5)
367.0
(288.2)
16.8
3,210.6
$
2,975.3
$
235.3
The significant changes in the financial statements noted in the table above are primarily due to the transition from sell-
through revenue recognition to sell-in revenue recognition as required by the New Revenue Standard, which eliminated the
balance of deferred income on shipments to distributors, significantly reduced accounts receivable, and significantly increased
retained earnings. Prior to the acquisition of Microsemi, Microsemi already recognized revenue on a sell-in basis, so the impact
of the adoption of the New Revenue Standard was primarily driven by Microchip's historical business excluding Microsemi.
During the three months ended June 30, 2018, the Company adopted ASU 2016-01-Financial Instruments - Overall
(Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This standard requires
available-for-sale equity investments to be measured at fair value with changes in fair value recognized in net income. The
adoption of this standard did not have a material impact on the Company's financial statements.
During the three months ended June 30, 2018, the Company adopted ASU 2016-16-Intra-Entity Transfers of Assets Other
Than Inventory. This standard addresses the recognition of current and deferred income taxes resulting from an intra-entity
transfer of any asset other than inventory. This standard has been applied on a modified retrospective basis through a
cumulative-effect adjustment directly to retained earnings. The adoption of this standard resulted in a cumulative-effect
increase in the Company's deferred tax assets of approximately $1.58 billion, a decrease to the Company's deferred tax
F-20
Table of Contents
liabilities of $1.1 million, a decrease to other assets of $24.1 million, and a decrease of $1.7 million to other long-term
liabilities.
During the three months ended June 30, 2018, the Company adopted ASU 2016-18-Statement of Cash Flows:
Restricted Cash. This standard requires that the statement of cash flows explain the change during the period in total cash, cash
equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally
described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling
the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard has been applied
using a retrospective transition method to each period presented. The adoption of this standard did not have a material impact
on the Company's financial statements.
The following table summarizes the opening balance sheet adjustments related to the adoption of the New Revenue
Standard, ASU 2016-01-Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities, and ASU 2016-16-Intra-Entity Transfers of Assets Other Than Inventory (in millions):
Balance as of
March 31, 2018
ASC 606
Adjustments from
ASU
2016-01
ASU
2016-16
Balance as of
April 1, 2018
ASSETS
Accounts receivable, net
Inventories
Other current assets
Long-term deferred tax assets
Other assets
LIABILITIES
Accrued liabilities
Deferred income on shipments to distributors
Long-term deferred tax liability
Other long-term liabilities
STOCKHOLDERS' EQUITY
Accumulated other comprehensive loss
Retained earnings
$
$
$
$
$
$
$
$
$
$
$
563.7
476.2
119.8
100.2
71.8
229.6
333.8
205.8
240.9
$
$
$
$
$
$
$
$
$
340.1
$
(5.1) $
$
17.2
(23.1) $
— $
— $
— $
— $
— $
— $
— $
— $ 1,579.4
— $
$
(24.1) $
$
404.2
(333.8) $
$
16.8
— $
— $
— $
— $
— $
— $
— $
(1.1) $
(1.7) $
— $
(17.6) $
$
1,397.3
— $
241.9
$
(1.7) $
1.7
$ 1,558.1
$
903.8
471.1
137.0
1,656.5
47.7
633.8
—
221.5
239.2
(19.3)
3,199.0
Recently Issued Accounting Pronouncements Not Yet Adopted
In August 2017, the FASB issued ASU 2017-12-Derivatives and Hedging (Topic 815): Targeted Improvements to
Accounting for Hedging Activities. The update expands an entity's ability to apply hedge accounting for nonfinancial and
financial risk components and allows for a simplified approach for fair value hedging of interest rate risk. The
update eliminates the need to separately measure and report hedge ineffectiveness and generally requires the entire change in
fair value of a hedging instrument to be presented in the same income statement line as the hedged item. Additionally, the
update simplifies the hedge documentation and effectiveness assessment requirements under the previous guidance. The
effective date of this standard is for fiscal years beginning after December 15, 2018 and early adoption is permitted. Adoption
will be applied through a cumulative-effect adjustment for cash flow and net investment hedges existing at the date of adoption
and prospectively for presentation and disclosure. The Company is currently evaluating the impact the adoption of this
standard will have on its consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04-Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for
Goodwill Impairment, which simplifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill
impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by
which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The amendment is
effective for annual periods and interim periods within those annual periods, beginning after December 15, 2019, and early
adoption is permitted. The Company does not expect this standard to have an impact on its consolidated financial statements.
F-21
Table of Contents
In June 2016, the FASB issued ASU 2016-13-Financial Instruments - Credit Losses: Measurement of Credit Losses on
Financial Instruments. This standard requires entities to use a current lifetime expected credit loss methodology to measure
impairments of certain financial assets. Using this methodology will result in earlier recognition of losses than under the
current incurred loss approach, which required waiting to recognize a loss until it is probable of having been incurred. The
amendments in ASU 2016-13 broaden the information that an entity must consider in developing its expected credit loss
estimate for assets measured either collectively or individually and can include forecasted information. There are other
provisions within the standard affecting how impairments of other financial assets may be recorded and presented, as well as
expanded disclosures. ASU 2016-13 is effective for interim and annual periods beginning after December 15, 2019, and
permits early adoption, but not before December 15, 2018. The standard is to be applied using a modified retrospective
approach. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial
statements.
In February 2016, the FASB issued ASU 2016-02-Leases. This standard requires lessees to recognize a lease liability and a
right-of-use asset on the balance sheet and aligns many of the underlying principles of the new lessor model with those in
Accounting Standards Codification Topic 606, Revenue from Contracts with Customers. ASU 2016-02 is effective for annual
periods, and interim periods within those annual periods, beginning after December 15, 2018, with early adoption permitted.
The Company will adopt Topic 842 using the retrospective cumulative effect adjustment transition method and record a
cumulative effect adjustment as of the adoption date. The Company currently plans to apply the package of practical
expedients to leases that commenced before the effective date whereby the Company will elect to not reassess the following: (i)
whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii)
initial direct costs for any existing leases. The Company is continuing to assess the potential impacts of the new leasing
standard. The Company expects the adoption of this standard will result in the inclusion of a significant component of the
Company’s future minimum lease commitments, as disclosed in Note 17 on its consolidated balance sheets, as right-of-use
assets and lease liabilities with no material impact to its consolidated statements of income and comprehensive income.
Note 2. Business Acquisitions
Acquisition of Microsemi
On May 29, 2018, the Company completed its acquisition of Microsemi Corporation, a publicly traded company
headquartered in Aliso Viejo, California. The Company paid an aggregate of approximately $8.19 billion in cash to the
stockholders of Microsemi. The total consideration transferred in the acquisition, including approximately $53.9 million of
non-cash consideration for the exchange of certain share-based payment awards of Microsemi for stock awards of the
Company, was approximately $8.24 billion. In addition to the consideration transferred, the Company recognized in its
consolidated financial statements $3.23 billion in liabilities of Microsemi consisting of debt, taxes payable and deferred,
restructuring, and contingent and other liabilities of which $2.06 billion of existing debt was paid off. The Company financed
the purchase price using approximately $8.10 billion of borrowings consisting of $3.10 billion under its amended and restated
revolving line of credit (the "Revolving Credit Facility"), $3.00 billion of term loans ("Term Loan Facility") provided under the
Company's amended and restated credit agreement (the "Credit Agreement"), and $2.00 billion in newly issued senior secured
notes. The Company incurred $22.0 million in acquisition costs related to the acquisition. As a result of the acquisition,
Microsemi became a wholly owned subsidiary of the Company. Microsemi offers a comprehensive portfolio of semiconductor
and system solutions for aerospace and defense, communications, data center and industrial markets. The Company's primary
reason for this acquisition was to expand the Company's range of solutions, products and capabilities by extending its served
available market.
The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the
acquirer, and the operating results of Microsemi have been included in the Company's consolidated financial statements as of
the closing date of the acquisition. Under the acquisition method of accounting, the aggregate amount of consideration paid by
the Company was allocated to Microsemi's net tangible assets and intangible assets based on their estimated fair values as of
May 29, 2018. The excess of the purchase price over the value of the net tangible assets and intangible assets was recorded to
goodwill. The factors contributing to the recognition of goodwill were based upon the Company's conclusion that there are
strategic and synergistic benefits that are expected to be realized from the acquisition. The goodwill has been allocated to the
Company's semiconductor products reporting segment. None of the goodwill related to the Microsemi acquisition is deductible
for tax purposes. The Company retained independent third-party appraisers to assist management in its valuation of the
acquired assets and liabilities.
F-22
Table of Contents
The table below represents the allocation of the purchase price to the net assets acquired based on their estimated fair
values, as well as the associated estimated useful lives of the acquired intangible assets (in millions).
Assets acquired
Cash and cash equivalents
Accounts receivable
Inventories
Other current assets
Property, plant and equipment
Goodwill
Purchased intangible assets
Long-term deferred tax assets
Other assets
Total assets acquired
Liabilities assumed
Accounts payable
Other current liabilities
Long-term debt
Deferred tax liabilities
Long-term income tax payable
Other long-term liabilities
Total liabilities assumed
Purchase price allocated
Purchased Intangible Assets
Core and developed technology
In-process research and development
Customer-related
Backlog
Other
Total purchased intangible assets
Previously reported
December 31, 2018
Adjustments
March 31, 2019
$
$
340.0
216.1
571.5
85.2
201.9
4,483.0
5,466.9
6.0
57.2
11,427.8
(233.8)
(169.4)
(2,056.9)
(604.7)
(87.2)
(31.3)
(3,183.3)
8,244.5
$
— $
(0.5)
4.7
—
(0.4)
(118.1)
167.6
(0.1)
(3.9)
49.3
—
20.1
—
39.6
(90.5)
(18.5)
(49.3)
$
— $
Weighted Average
Useful Life
(in years)
15
—
12
1
4
$
$
340.0
215.6
576.2
85.2
201.5
4,364.9
5,634.5
5.9
53.3
11,477.1
(233.8)
(149.3)
(2,056.9)
(565.1)
(177.7)
(49.8)
(3,232.6)
8,244.5
May 29, 2018
(in millions)
4,569.1
847.1
200.2
12.3
5.8
5,634.5
Purchased intangible assets include core and developed technology, in-process research and development, customer-related
intangibles, acquisition-date backlog and other intangible assets.
The estimated fair values of the core and developed technology and in-process research and development are being
determined based on the present value of the expected cash flows to be generated by the respective existing technology or
future technology. The core and developed technology intangible assets are being amortized in a manner based on the expected
cash flows used in the initial determination of fair value.
In-process research and development is capitalized until such time as the related projects are completed or abandoned at
which time the capitalized amounts will begin to be amortized or written off.
F-23
Table of Contents
Customer-related intangible assets consist of Microsemi's contractual relationships and customer loyalty related to its
distributor and end-customer relationships. The fair values of the customer-related intangibles were determined using the
distributor method, a form of the income approach based on distributor margin and expected attrition and revenue growth for
Microsemi's existing customers as of the acquisition date. Customer relationships are being amortized in a manner based on
the estimated cash flows associated with the existing customers and anticipated retention rates.
Backlog relates to the value of orders not yet shipped by Microsemi at the acquisition date, and the fair values are being
determined based on the estimated profit associated with those orders. Backlog related assets have a one year useful life and
are being amortized on a straight-line basis over that period.
The total weighted average amortization period of intangible assets acquired as a result of the Microsemi transaction is 13
years. Amortization expense associated with acquired intangible assets is not deductible for tax purposes. Thus, approximately
$856.7 million was established as a net deferred tax liability for the future amortization of the intangible assets.
The amount of Microsemi net sales and net loss included in the Company's consolidated statements of income for the fiscal
year ended March 31, 2019 was approximately $1,568.6 million and $570.8 million, respectively.
The following unaudited pro-forma consolidated results of operations for the fiscal year ended March 31,
2019 and 2018 assume the closing of the Microsemi acquisition occurred as of April 1, 2017. The pro-forma adjustments are
mainly comprised of acquired inventory fair value costs and amortization of purchased intangible assets. The pro-forma results
of operations are presented for informational purposes only and are not indicative of the results of operations that would have
been achieved if the acquisition had taken place on April 1, 2017 or of results that may occur in the future (in millions except
per share data):
Net sales
Net income (loss)
Basic net income (loss) per common share
Diluted net income (loss) per common share
Acquisition of Atmel
Year Ended March 31,
2019
2018
$
$
$
$
5,563.7
542.0
2.29
2.17
$
$
$
$
5,875.0
(762.3)
(3.27)
(3.27)
On April 4, 2016, the Company acquired Atmel, a publicly traded company based in San Jose, California. The Company
paid an aggregate of approximately $2.98 billion in cash and issued an aggregate of 10.1 million shares of its common stock to
Atmel stockholders valued at $486.1 million based on the closing price of the Company's common stock on April 4, 2016 and
incurred transaction and other fees of approximately $14.9 million. The total consideration transferred in the acquisition,
including approximately $7.5 million of non-cash consideration for the exchange of certain share-based payment awards of
Atmel for stock awards of the Company, was approximately $3.47 billion. In addition to the consideration transferred, the
Company recognized in its consolidated financial statements $653.0 million in liabilities of Atmel consisting of debt, taxes
payable and deferred, pension obligations, restructuring, and contingent and other liabilities. The Company financed the cash
portion of the purchase price using approximately $2.04 billion of cash held by certain of its foreign subsidiaries and
approximately $0.94 billion from additional borrowings under its existing credit agreement. As a result of the acquisition,
Atmel became a wholly owned subsidiary of the Company. Atmel is a worldwide leader in the design and manufacture of
microcontrollers, capacitive touch solutions, advanced logic, mixed-signal, nonvolatile memory and radio frequency
components. The Company's primary reason for this acquisition was to expand the Company's range of solutions, products and
capabilities by extending its served available market.
The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the
acquirer, and the operating results of Atmel have been included in the Company's consolidated financial statements as of the
closing date of the acquisition. Under the acquisition method of accounting, the aggregate amount of consideration paid by the
Company was allocated to Atmel's net tangible assets and intangible assets based on their estimated fair values as of April 4,
2016. The excess of the purchase price over the value of the net tangible assets and intangible assets was recorded to goodwill.
The factors contributing to the recognition of goodwill were based upon the Company's conclusion that there are strategic and
synergistic benefits that are expected to be realized from the acquisition. The goodwill has been allocated to the Company's
F-24
Table of Contents
semiconductor products reporting segment. None of the goodwill related to the Atmel acquisition is deductible for tax
purposes. The Company retained independent third-party appraisers to assist management in its valuation.
The table below represents the allocation of the final purchase price to the net assets acquired based on their estimated fair
values, as well as the associated estimated useful lives of the acquired intangible assets (amounts in millions).
Assets acquired
Cash and cash equivalents
Accounts receivable
Inventories
Prepaid expenses and other current assets
Assets held for sale
Property, plant and equipment
Goodwill
Purchased intangible assets
Long-term deferred tax assets
Other assets
Total assets acquired
Liabilities assumed
Accounts payable
Other current liabilities
Long-term line of credit
Deferred tax liabilities
Long-term income tax payable
Other long-term liabilities
Total liabilities assumed
Purchase price allocated
Purchased Intangible Assets
Core and developed technology
In-process research and development
Customer-related
Backlog
Other
Total purchased intangible assets
$
$
$
$
230.2
141.4
335.1
28.4
32.0
129.9
1,286.4
1,888.4
46.7
7.5
4,126.0
(55.7)
(121.0)
(192.0)
(27.5)
(115.1)
(141.7)
(653.0)
3,473.0
April 4, 2016
(in millions)
1,075.0
140.7
630.6
40.3
1.8
1,888.4
Weighted Average
Useful Life
(in years)
11
—
6
1
5
Purchased intangible assets include core and developed technology, in-process research and development, customer-related
intangibles, acquisition-date backlog and other intangible assets. The estimated fair values of the core and developed
technology and in-process research and development were determined based on the present value of the expected cash flows to
be generated by the respective existing technology or future technology. The core and developed technology intangible assets
are being amortized in a manner based on the expected cash flows used in the initial determination of fair value. In-process
research and development is capitalized until such time as the related projects are completed or abandoned at which time the
capitalized amounts will begin to be amortized or written off. Customer-related intangible assets consist of Atmel's contractual
relationships and customer loyalty related to its distributor and end-customer relationships, and the fair values of the customer-
related intangibles were determined based on Atmel's projected revenues. An analysis of expected attrition and revenue growth
for existing customers was prepared from Atmel's historical customer information. Customer relationships are being amortized
in a manner based on the estimated cash flows associated with the existing customers and anticipated retention rates. Backlog
relates to the value of orders not yet shipped by Atmel at the acquisition date, and the fair values were based on the estimated
profit associated with those orders. Backlog related assets had a one year useful life and were being amortized on a straight-
F-25
Table of Contents
line basis over that period. The total weighted average amortization period of intangible assets acquired as a result of the Atmel
transaction is 9 years. Amortization expense associated with acquired intangible assets is not deductible for tax purposes.
Thus, approximately $178.1 million was established as a net deferred tax liability for the future amortization of the intangible
assets.
Note 3. Net Sales
The following table represents the Company's net sales by product line (in millions):
Microcontrollers
Analog, interface, mixed signal and timing products
Field-programmable gate array products
Memory products
Technology licensing
Multi-market and other
Total net sales
Year Ended
March 31, 2019
$
$
2,921.9
1,530.7
303.8
184.0
132.4
276.7
5,349.5
All of the product lines listed above are included in the Company's Semiconductor Product segment with the exception of
Technology Licensing, which belongs to the Technology Licensing segment.
The following table represents the Company's net sales by contract type (in millions).
Distributors
Direct customers
Licensees
Total net sales
Year Ended
March 31, 2019
$
$
2,719.1
2,498.0
132.4
5,349.5
Distributors are customers that buy products with the intention of reselling them. Distributors generally have a distributor
agreement with the Company to govern the terms of the relationship. Direct customers are non-distributor customers, which
generally do not have a master sales agreement with the Company. The Company's direct customers primarily consist of
original equipment manufacturers (OEMs) and, to a lesser extent, contract manufacturers. Licensees are customers of the
Company's Technology Licensing segment, which include purchasers of intellectual property and customers that have licensing
agreements to use the Company's SuperFlash® embedded flash and Smartbits® one time programmable NVM technologies.
All of the contract types listed in the table above are included in the Company's Semiconductor Product segment with the
exception of Licensees, which belong to the Technology Licensing segment.
Substantially all of the Company's net sales are recognized from contracts with customers, and therefore, subject to the
new revenue recognition standard.
Semiconductor Product Segment
For contracts related to the purchase of semiconductor products, the Company satisfies its performance obligation when
control of the ordered product transfers to the customer. The timing of the transfer of control depends on the agreed upon
shipping terms with the customer, but generally occurs upon shipment, which is when physical possession of the product has
been transferred and legal title of the product transfers to the customer. Payment is generally due within 30 days of the ship
date. Payment is generally collected after the Company satisfies its performance obligation, therefore contract liabilities are
uncommon. Also, the Company usually does not record contract assets because the Company has an unconditional right to
payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a
F-26
Table of Contents
contract asset. Refer to Note 8 for the opening and closing balances of the Company's receivables. As contracts with
customers generally have an expected duration of one year or less, the balance of open performance obligations as of period
end that will be recognized as revenue subsequent to March 31, 2020 is immaterial.
Generally, there is only a single performance obligation in the Company's contracts with customers for semiconductor
products; as such, the entire transaction price is allocated to the single performance obligation and allocation of the transaction
price to individual performance obligations is not necessary. The consideration received from customers is fixed, with the
exception of consideration from certain distributors. Certain of the Company's distributors are granted price concessions and
return rights, which result in variable consideration. The amount of revenue recognized for sales to these certain distributors is
adjusted for estimates of the price concessions and return rights that are expected to be claimed. These estimates are based on
the recent history of price concessions and stock rotations.
Technology Licensing Segment
The technology licensing segment includes sales and licensing of the Company's intellectual property. For contracts
related to the sale of the Company's intellectual property, the Company satisfies its performance obligation and recognizes
revenue when control of the intellectual property transfers to the customer. For contracts related to the licensing of the
Company's technology, the Company satisfies its performance obligation and recognizes revenue as usage of the license occurs.
The transaction price is fixed by the license agreement. Payment is collected after the Company satisfies its performance
obligation, and therefore no contract liabilities are recorded. The Company does not record contract assets due to the fact that
the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, the
Company recognizes a receivable instead of a contract asset. Refer to Note 8 for the opening and closing balances of the
Company's receivables.
Note 4. Special Charges and Other, Net
The following table summarizes activity included in the "special charges and other, net" caption on the Company's
consolidated statements of income (in millions):
Restructuring
Employee separation costs
Gain on sale of assets
Impairment charges
Contract exit costs
Other
Legal contingencies
Non-restructuring contract exit costs and other
Total
For The Years Ended March 31,
2019
2018
2017
$
65.3
$
—
3.6
(4.7)
(0.3)
(30.2)
—
$
33.7
$
1.2
(4.4)
—
0.7
—
—
20.0
17.5
$
$
39.1
—
12.6
44.1
2.8
—
—
98.6
The Company continuously evaluates its existing operations in an attempt to identify and realize cost savings opportunities
and operational efficiencies. This same approach is applied to businesses that are acquired by the Company and often the
operating models of acquired companies are not as efficient as the Company's operating model which enables the Company to
realize significant savings and efficiencies. As a result, following an acquisition, the Company will from time to time incur
restructuring expenses; however, the Company is often not able to estimate the timing or amount of such costs in advance of
the period in which they occur. The primary reason for this is that the Company regularly reviews and evaluates each position,
contract and expense against the Company's strategic objectives, long-term operating targets and other operational priorities.
Decisions related to restructuring activities are made on a "rolling basis" during the course of the integration of an acquisition
whereby department managers, executives and other leaders work together to evaluate each of these expenses and make
recommendations. As a result of this approach, at the time of an acquisition, the Company is not able to estimate the future
amount of expected employee separation or exit costs that it will incur in connection with its restructuring activities.
F-27
Table of Contents
The Company's restructuring expenses during the fiscal year ended March 31, 2019 were related to the Company's most
recent business acquisitions, and resulted from workforce, property and other operating expense rationalizations as well as
combining product roadmaps and manufacturing operations. These expenses were for employee separation costs and intangible
asset impairment charges. The impairment charges in the fiscal year ended March 31, 2019 were primarily recognized as a
result of writing off intangible assets purchased from Microsemi prior to the close of the acquisition and other intangible assets
that were impaired as a result of changes in the combined product roadmaps after the acquisition that affected the use and life
of the assets. Additional costs will be incurred in the future as additional synergies or operational efficiencies are identified in
connection with the Microsemi transaction and other previous acquisitions. The Company is not able to estimate the amount of
such future expenses at this time.
During fiscal 2018, the Company incurred expenses including non-restructuring contract exit costs of $19.5 million for
fees associated with transitioning from the public utility provider in Oregon to a lower cost direct access provider. The fee is
paid monthly and will depend on the amount of actual energy consumed by the Company's wafer fabrication facility in Oregon
over the next five years. In connection with the transition to a direct access provider, the Company signed a ten-year supply
agreement to purchase monthly amounts of energy that are less than the current average usage and priced on a per mega watt
hour published index rate in effect at those future dates. Also during fiscal 2018, the Company incurred $1.2 million of
employee separation costs in connection with the acquisition of Atmel.
The Company's restructuring expenses during fiscal 2017 were related to the Company's acquisitions of Atmel and Micrel,
and resulted from workforce, property and other operating expense rationalizations as well as combining product roadmaps and
manufacturing operations. These expenses were for employee separation costs, contract exit costs, other operating expenses
and intangible asset impairment losses. The impairment charges in fiscal 2017 were recognized as a result of changes in the
combined product roadmaps after the acquisition of Atmel that affected the use and life of these assets. At March 31, 2017,
these activities were substantially complete.
All of the Company's restructuring activities occurred in its semiconductor products segment. The Company incurred
$115.2 million in costs since the start of fiscal 2016 in connection with employee separation activities, of which $65.3 million,
$1.2 million and $39.1 million was incurred during the fiscal years ended March 31, 2019, 2018 and 2017, respectively. The
Company could incur future expenses as additional synergies or operational efficiencies are identified. The Company is not
able to estimate future expenses, if any, to be incurred in employee separation costs. The Company has incurred $40.8 million
in costs in connection with contract exit activities since the start of fiscal 2016 which includes $4.7 million of income incurred
for the year ended March 31, 2019 and $0.7 million and $44.1 million of costs incurred for the years ended March 31, 2018 and
2017, respectively. The amounts recognized during the fiscal year ended March 31, 2019 were primarily related to vacated
lease liabilities. While the Company expects to incur further acquisition-related contract exit expenses, it is not able to estimate
the amount at this time.
In the three months ended June 30, 2017, the Company completed the sale of an asset it acquired as part of its acquisition
of Micrel for proceeds of $10.0 million and the gain of $4.4 million is included in the gain on sale of assets in the above table.
F-28
Table of Contents
The following is a roll forward of accrued restructuring charges for fiscal 2019 and fiscal 2018 (in millions):
Restructuring
Non-
Restructuring
Employee
Separation
Costs
Exit Costs
Exit Costs
Total
Balance at March 31, 2017
$
5.4
$
34.8
$
— $
Charges
Payments
Non-cash - Other
Changes in foreign exchange rates
Balance at March 31, 2018
Additions due to Microsemi acquisition
Charges
Payments
Non-cash - Other
Changes in foreign exchange rates
Balance at March 31, 2019
$
1.2
(5.9)
(0.2)
0.3
0.8
10.4
48.9
(47.1)
—
(0.1)
12.9
0.7
(9.2)
1.0
—
27.3
9.0
(4.7)
(13.1)
0.7
—
$
19.2
$
Current
Non-current
Total
20.0
(0.9)
—
—
19.1
—
—
(4.1)
0.7
—
15.7
$
$
$
40.2
21.9
(16.0)
0.8
0.3
47.2
19.4
44.2
(64.3)
1.4
(0.1)
47.8
26.9
20.9
47.8
The liability for restructuring and other exit costs of $47.8 million is included in accrued liabilities and other long-term
liabilities, on the Company's consolidated balance sheets as of March 31, 2019.
Note 5. Investments
The Company's investments are intended to establish a high-quality portfolio that preserves principal, meets liquidity
needs, avoids inappropriate concentrations, and delivers an appropriate yield in relationship to the Company's investment
guidelines and market conditions.
At March 31, 2019, the company had short-term investments of $2.3 million consisting of marketable equity securities.
At March 31, 2018, short-term investments of $1.30 billion included available-for-sale debt securities of $1.29 billion and
marketable equity securities of $2.8 million. The following is a summary of available-for-sale debt securities at March 31,
2018 (in millions):
Available-for-sale debt securities:
Government agency bonds
Municipal bonds - taxable
Time deposits
Corporate bonds and debt
Total
Available-for-sale Debt Securities
Adjusted
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
$
$
723.2
14.9
11.5
542.9
1,292.5
$
$
— $
—
—
—
— $
— $
—
—
—
— $
723.2
14.9
11.5
542.9
1,292.5
The Company sold available-for-sale debt securities for proceeds of $1.38 billion during the year ended March 31, 2019 to
help finance its acquisition of Microsemi. There were no sales of available-for-sale debt securities during the year ended
March 31, 2018. The Company sold available-for-sale debt securities for proceeds of $470.2 million during the year ended
March 31, 2017. The Company recognized losses of $5.6 million on available-for-sale debt securities during the year ended
F-29
Table of Contents
March 31, 2019. The Company had no material net realized gains from sales of available-for-sale debt securities during fiscal
years ended March 31, 2018 and March 31, 2017. During the year ended March 31, 2018, the Company recognized an
impairment of $15.5 million on available-for-sale debt securities based on its evaluation of available evidence and the
Company's intent to sell these investments which were subsequently sold in the first quarter of fiscal 2019. The Company
determines the cost of available-for-sale debt securities sold on a first-in first-out (FIFO) basis at the individual security level
for sales from multiple lots. For sales of marketable equity securities, the Company uses an average cost basis at the individual
security level. Gains and losses recognized in earnings are credited or charged to other (loss) income, net on the consolidated
statements of income.
As of March 31, 2019 and 2018 , the Company had no available-for-sale debt securities in an unrealized loss position.
The Company did not have any available-for-sale debt securities at March 31, 2019. The amortized cost and estimated fair
value of the available-for-sale debt securities at March 31, 2018, by maturity are shown below (in millions). Expected
maturities can differ from contractual maturities because the issuers of the securities may have the right to prepay obligations
without prepayment penalties, and the Company views its available-for-sale debt securities as available for current operations.
Available-for-sale
Due in one year or less
Due after one year and through five years
Due after five years and through ten years
Due after ten years
Total
Note 6. Fair Value Measurements
Adjusted
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
$
246.5
$
— $
— $
1,046.0
—
—
—
—
—
—
—
—
246.5
1,046.0
—
—
$
1,292.5
$
— $
— $
1,292.5
Accounting rules for fair value clarify that fair value is an exit price, representing the amount that would be received to sell
an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-
based measurement that should be determined based on assumptions that market participants would use in pricing an asset or
liability. As a basis for considering such assumptions, the Company utilizes a three-tier fair value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:
Level 1-
Level 2-
Level 3-
Observable inputs such as quoted prices in active markets;
Inputs, other than the quoted prices in active markets, that are observable either directly or
indirectly; and
Unobservable inputs in which there is little or no market data, which require the reporting entity to
develop its own assumptions.
Marketable Debt Instruments
Marketable debt instruments include instruments such as corporate bonds and debt, government agency bonds, bank
deposits, municipal bonds, and money market mutual funds. When the Company uses observable market prices for identical
securities that are traded in less active markets, the Company classifies its marketable debt instruments as Level 2. When
observable market prices for identical securities are not available, the Company prices its marketable debt instruments using
non-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar
instruments; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated
with observable market data. Non-binding market consensus prices are based on the proprietary valuation models of pricing
providers or brokers. These valuation models incorporate a number of inputs, including non-binding and binding broker
quotes; observable market prices for identical or similar securities; and the internal assumptions of pricing providers or brokers
that use observable market inputs and, to a lesser degree, unobservable market inputs. The Company corroborates non-binding
market consensus prices with observable market data using statistical models when observable market data exists. The
discounted cash flow model uses observable market inputs, such as LIBOR-based yield curves, currency spot and forward rates,
and credit ratings.
F-30
Table of Contents
Assets Measured at Fair Value on a Recurring Basis
Assets measured at fair value on a recurring basis at March 31, 2019 are as follows (amounts in millions):
Assets
Cash and cash equivalents:
Money market mutual funds
Deposit accounts
Short-term investments:
Marketable equity securities
Total assets measured at fair value
Quoted Prices
in Active
Markets for
Identical
Instruments
(Level 1)
Significant Other
Observable
Inputs (Level 2)
Total Balance
$
$
$
8.3
—
2.3
— $
420.3
—
10.6
$
420.3
$
8.3
420.3
2.3
430.9
Assets measured at fair value on a recurring basis at March 31, 2018 are as follows (amounts in millions):
Assets
Cash and cash equivalents:
Money market mutual funds
Deposit accounts
Commercial Paper
Government agency bonds
Short-term investments:
Marketable equity securities
Corporate bonds and debt
Time deposits
Government agency bonds
Municipal bonds - taxable
Quoted Prices
in Active
Markets for
Identical
Instruments
(Level 1)
Significant Other
Observable
Inputs (Level 2)
Total Balance
$
121.0
$
— $
—
—
—
2.8
—
—
—
—
641.6
118.7
20.0
—
542.9
11.5
723.2
14.9
121.0
641.6
118.7
20.0
2.8
542.9
11.5
723.2
14.9
Total assets measured at fair value
$
123.8
$
2,072.8
$
2,196.6
There were no transfers between Level 1 or Level 2 during fiscal 2019 or fiscal 2018. There were no assets measured on a
recurring basis during fiscal 2019 or fiscal 2018 using significant unobservable inputs (Level 3).
Assets and Liabilities Measured and Recorded at Fair Value on a Non-Recurring Basis
The Company's non-marketable equity, cost method investments, certain acquired liabilities and non-financial assets, such
as intangible assets, assets held for sale and property, plant and equipment, are recorded at fair value on a non-recurring basis.
These assets are subject to fair value adjustments in certain circumstances, for example, when there is evidence of impairment.
The Company's non-marketable and cost method investments are monitored on a quarterly basis for impairment
charges. The fair values of these investments have been determined as Level 3 fair value measurements because the valuations
use unobservable inputs that require management's judgment due to the absence of quoted market prices. There were no
impairment charges recognized on these investments during the years ended March 31, 2019, 2018 and 2017. These
investments are included in other assets on the consolidated balance sheets.
F-31
Table of Contents
The fair value measurements related to the Company's non-financial assets, such as intangible assets, assets held for sale
and property, plant and equipment are based on available market prices at the measurement date based on transactions of
similar assets and third-party independent appraisals, less costs to sell where appropriate. The Company classifies these
measurements as Level 2.
Note 7. Fair Value of Financial Instruments
The carrying amount of cash equivalents approximates fair value because their maturity is less than three months.
Management believes the carrying amount of the equity and cost-method investments materially approximated fair value at
March 31, 2019 based upon unobservable inputs. The fair values of these investments have been determined as Level 3 fair
value measurements. The fair values of the Company's line of credit borrowings are estimated using discounted cash flow
analyses, based on the Company's current incremental borrowing rates for similar types of borrowing arrangements and
approximate carrying value excluding debt issuance costs. Based on the borrowing rates currently available to the Company
for bank loans with similar terms and average maturities, the fair value of the Company's line of credit borrowings at March 31,
2019 approximated the carrying value and are considered Level 2 in the fair value hierarchy described in Note 6. The carrying
amount of accounts receivable, accounts payable and accrued liabilities approximates fair value due to the short-term maturity
of the amounts and are considered Level 2 in the fair value hierarchy.
Fair Value of Subordinated Convertible Debt, Senior Secured Notes, and Term Loan Facility
The Company measures the fair value of its senior and junior subordinated convertible debt and senior secured notes for
disclosure purposes. These fair values are based on observable market prices for this debt, which is traded in less active
markets and are therefore classified as a Level 2 fair value measurement.
The following table shows the carrying amounts and fair values of the Company's senior and junior subordinated
convertible debt, senior secured notes, and term loan facility as of March 31, 2019 and 2018 (in millions).
2023 Senior Secured Notes
2021 Senior Secured Notes
Term Loan Facility
2017 Senior Convertible Debt
2015 Senior Convertible Debt
2017 Junior Convertible Debt
March 31,
2019
2018
Carrying
Amount
Fair Value
Carrying
Amount
Fair Value
$
$
$
$
$
$
985.4
987.4
1,892.1
1,493.6
1,360.8
335.9
$
$
$
$
$
$
1,020.1
1,008.1
1,911.5
2,285.4
2,810.6
740.8
$
$
$
N/A
N/A
N/A
1,437.6
1,309.9
326.7
$
$
$
N/A
N/A
N/A
2,459.2
3,079.1
876.9
(1) The carrying amounts presented are net of debt discounts and debt issuance costs (see Note 12 Debt and Credit Facility for
further information).
Note 8. Other Financial Statement Details
Accounts Receivable
Accounts receivable consists of the following (in millions):
Trade accounts receivable
Other
Total accounts receivable, gross
Less allowance for doubtful accounts
Total accounts receivable, net
F-32
March 31,
2019
2018
$
$
875.8
$
6.8
882.6
2.0
880.6
$
557.8
8.1
565.9
2.2
563.7
Table of Contents
Inventories
The components of inventories consist of the following (in millions):
Raw materials
Work in process
Finished goods
Total inventories
March 31,
2019
2018
$
$
74.5
413.0
224.2
711.7
$
$
26.0
311.8
138.4
476.2
Inventories are valued at the lower of cost and net realizable value using the first-in, first-out method. Inventory
impairment charges establish a new cost basis for inventory and charges are not subsequently reversed to income even if
circumstances later suggest that increased carrying amounts are recoverable.
Property, Plant and Equipment
Property, plant and equipment consists of the following (in millions):
Land
Building and building improvements
Machinery and equipment
Projects in process
Total property, plant and equipment, gross
Less accumulated depreciation and amortization
Total property, plant and equipment, net
March 31,
2019
2018
83.4
$
647.6
2,095.5
119.2
2,945.7
1,949.0
996.7
$
73.4
508.5
1,943.9
118.3
2,644.1
1,876.2
767.9
$
$
Depreciation expense attributed to property, plant and equipment was $180.6 million, $123.7 million and $122.9 million
for the fiscal years ending March 31, 2019, 2018 and 2017, respectively.
Accrued Liabilities
Accrued liabilities consists of the following (in millions):
Accrued compensation and benefits
Income taxes payable
Sales related reserves
Accrued expenses and other liabilities
Total accrued liabilities
March 31,
2019
2018
133.2
$
46.9
366.9
240.3
787.3
$
87.6
27.5
—
114.5
229.6
$
$
Sales related reserves represent price concessions and stock rotation rights that the Company offers to many of its
distributors. For the fiscal year ending March 31, 2018, these sales related reserves were recorded within accounts receivable,
and therefore did not exist within accrued liabilities. The Company made this change in classification as part of its adoption of
ASC 606. For additional information regarding the Company's adoption of ASC 606, refer to Note 1 of the consolidated
financial statements.
F-33
Table of Contents
Note 9. Discontinued Operations
Discontinued operations include the mobile touch operations that the Company acquired as part of its acquisition of Atmel.
The mobile touch assets had been marketed for sale since the Company's acquisition of Atmel on April 4, 2016 based on
management's decision that it was not a strategic fit for the Company's product portfolio. On November 10, 2016, the
Company completed the sale of the mobile touch assets to Solomon Systech (Limited) International, a Hong Kong based
semiconductor company. The transaction included the sale of certain semiconductor products, equipment, customer list,
backlog, patents, and a license to certain other intellectual property and patents related to the Company's mobile touch product
line. The Company also agreed to provide certain transition services to Solomon Systech, which were substantially complete as
of March 31, 2017. For financial statement purposes, the results of operations for this discontinued business have been
segregated from those of the continuing operations and are presented in the Company's consolidated financial statements as
discontinued operations.
As the Company completed the sale of the mobile touch assets on November 10, 2016, there are no discontinued
operations in the years ended March 31, 2019 or 2018. The results of discontinued operations for the year ended March 31,
2017 are as follows (in millions):
Net sales
Cost of sales
Operating expenses
Gain on Sale
Income tax benefit
Net loss from discontinued operations
Note 10. Intangible Assets and Goodwill
Intangible assets consist of the following (in millions):
Core and developed technology
Customer-related
In-process research and development
Distribution rights
Other
Total
Core and developed technology
Customer-related
In-process research and development
Distribution rights
Other
Total
$
$
Gross
Amount
7,413.0
917.1
7.7
0.3
7.3
8,345.4
$
$
March 31, 2017
18.3
15.8
10.7
0.6
(1.6)
(6.0)
March 31, 2019
Accumulated
Amortization Net Amount
6,300.1
$
373.1
(1,112.9) $
(544.0)
—
(0.2)
(2.7)
(1,659.8) $
$
7.7
0.1
4.6
6,685.6
Gross
Amount
March 31, 2018
Accumulated
Amortization Net Amount
$
1,952.3
$
716.9
12.1
0.3
1.5
2,683.1
$
$
(644.4) $
(375.9)
—
(0.1)
(0.7)
(1,021.1) $
1,307.9
341.0
12.1
0.2
0.8
1,662.0
The Company amortizes intangible assets over their expected useful lives, which range between 1 and 15 years. During
the year ended March 31, 2019, due to the acquisition of Microsemi, the Company acquired $4.57 billion of core and
developed technology which has a weighted average amortization period of 15 years, $200.2 million of customer-related
intangible assets which have a weighted average amortization period of 12 years, $12.3 million of intangible assets related to
F-34
Table of Contents
backlog with an amortization period of 1 year, $5.8 million of other intangible assets which have a weighted average
amortization period of 4 years, and $847.1 million of in-process technology. In fiscal 2019, $851.5 million of in-process
research and development intangible assets, primarily consisting of intangible assets acquired in the acquisition of Microsemi,
reached technological feasibility and was reclassified as core and developed technology and began being amortized over the
respective estimated useful lives. The following is an expected amortization schedule for the intangible assets for fiscal 2020
through fiscal 2024, absent any future acquisitions or impairment charges (in millions):
Fiscal Year Ending
March 31,
2020
2021
2022
2023
2024
Projected Amortization
Expense
$1,005.8
$944.1
$873.1
$680.0
$608.3
Amortization expense attributed to intangible assets was $695.8 million, $492.2 million and $346.3 million for fiscal years
2019, 2018 and 2017, respectively. In fiscal 2019, $9.6 million was charged to cost of sales and $686.2 million was charged to
operating expenses. In fiscal 2018, $6.1 million was charged to cost of sales and $486.1 million was charged to operating
expenses. In fiscal 2017, $4.0 million was charged to cost of sales and $342.3 million was charged to operating expenses. The
Company recognized impairment charges of $3.1 million, $0.5 million and $11.9 million in fiscal 2019, 2018 and fiscal 2017,
respectively. The impairment charges of $3.1 million in fiscal 2019 were recognized as a result of writing off intangible assets
purchased from Microsemi prior to the close of the acquisition and as a result of the changes in the combined product roadmaps
after the acquisition of Microsemi that affected the use and life of these assets. The impairment charges of $11.9 million in
fiscal 2017 were recognized primarily as a result of the acquisition of Atmel and as a result of changes in the combined product
roadmaps after the acquisition of Atmel that affected the use and life of these assets.
Goodwill activity for fiscal 2019 and fiscal 2018 was as follows (in millions):
Balance at March 31, 2017 and 2018
Additions due to the acquisition of Microsemi
Balance at March 31, 2019
Semiconductor
Products
Reporting Unit
2,279.8
$
4,364.9
Technology
Licensing
Reporting Unit
19.2
$
—
$
6,644.7
$
19.2
At March 31, 2019, the Company applied a qualitative goodwill impairment test to its two reporting units, concluding it
was not more likely than not that goodwill was impaired. Through March 31, 2019, the Company has never recorded an
impairment charge against its goodwill balance.
F-35
Table of Contents
Note 11. Income Taxes
The income tax provision consists of the following (amounts in millions):
Pretax (loss) income:
U.S.
Foreign
Current (benefit) expense:
U.S. Federal
State
Foreign
Total current (benefit) expense
Deferred expense (benefit):
U.S. Federal
State
Foreign
Total deferred (benefit) expense
Total Income tax (benefit) provision
Year Ended March 31,
2018
2017
2019
$
$
$
$
$
$
(593.4) $
797.9
204.5
$
(127.3) $
864.6
737.3
$
(279.3)
369.1
89.8
(98.0) $
(5.3)
14.1
(89.2) $
$
11.9
0.6
(74.7)
(62.2)
(151.4) $
369.4
0.5
60.8
430.7
82.5
0.1
(31.4)
51.2
481.9
$
$
$
$
21.3
1.0
23.8
46.1
(114.7)
(5.4)
(6.8)
(126.9)
(80.8)
On December 22, 2017, the Tax Cuts and Jobs Act (the "Act") was enacted into law. The Act provides for numerous
significant tax law changes and modifications including the reduction of the U.S. federal corporate income tax rate from 35.0%
to 21.0%, the requirement for companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were
previously tax deferred and the creation of new taxes on certain foreign-sourced earnings.
Accounting Standards Codification ("ASC") 740, Income Taxes, requires companies to recognize the effect of the tax law
changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin ("SAB") 118, which allowed
companies to record provisional amounts during a measurement period that is similar to the measurement period used when
accounting for business combinations. The Company recorded a reasonable estimate when measurable and with the
understanding that the provisional amount was subject to further adjustments under SAB 118. In addition, for significant items
for which the Company could not make a reasonable estimate, no provisional amounts were recorded. As of December 31,
2018, the Company completed its review of the previously recorded provisional amounts related to the Act, recorded necessary
adjustments, and the amounts are now final under SAB 118.
As of March 31, 2018, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they
were expected to reverse in the future (which was generally 21%), by recording a provisional income tax benefit of $136.7
million. Upon further analysis of certain aspects of the Act and refinement of its calculations during the period ended
December 31, 2018, the Company did not make adjustments to the provisional amount.
The one-time transition tax is based on the Company's total post-1986 earnings and profits (E&P), the tax on which the
Company previously deferred from U.S. income taxes under U.S. law. The Company recorded a provisional amount for its
one-time transition tax expense for each of its foreign subsidiaries, resulting in a transition tax expense of $644.7 million at
March 31, 2018. Upon further analyses of the Act and notices and regulations issued and proposed by the U.S. Department of
the Treasury and the Internal Revenue Service, the Company finalized its calculations of the transition tax expense during the
period ended December 31, 2018. The Company increased its March 31, 2018 provisional amount by $13.1 million to $657.8
million, which is included as a component of income tax expense from continuing operations. The measurement period
adjustment of $13.1 million decreased basic and diluted net income per common share by $0.06 and $0.05, respectively, for the
year ended March 31, 2019.
The Company intends to invest substantially all of its foreign subsidiary earnings, as well as its capital in its foreign
subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which the Company would incur significant, additional
costs upon repatriation of such amounts. It is not practical to estimate the additional tax that would be incurred, if any, if the
permanently reinvested earnings were repatriated.
F-36
Table of Contents
As of March 31, 2018, the Company removed its valuations allowance on certain foreign tax credits and recorded a
provisional income tax benefit of $36.4 million. Upon further analysis of the Act, the Company did not make adjustments to
the provisional amount.
The Act subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign
subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an
entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to
reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period
expense only. The Company has elected to account for GILTI in the year the tax is incurred.
The provision for income taxes differs from the amount computed by applying the statutory federal tax rate to income before
income taxes. The sources and tax effects of the differences in the total income tax provision are as follows (amounts in
millions):
Computed expected income tax provision
State income taxes, net of federal benefit
Foreign income taxed at lower than the federal rate
Impact of the Act - one-time transition tax, net of foreign tax credits
Impact of the Act - deferred tax effects, net of valuation allowance
Global intangible low-taxed income
Business realignment
Increases related to current year tax positions
Decreases related to prior year tax positions (1)
Share-based compensation
Research and development tax credits
Intercompany prepaid tax asset amortization
Foreign exchange
Other
Change in valuation allowance
Total income tax provision (benefit)
Year Ended March 31,
2018
2017
2019
$
$
$
43.0
(8.7)
(94.0)
13.1
—
95.4
(90.6)
9.0
(75.1)
(13.3)
(27.5)
5.2
4.6
(2.6)
(9.9)
(151.4) $
232.6
(1.3)
(208.8)
653.7
(136.7)
—
—
32.0
(11.3)
(27.2)
(17.0)
7.4
(20.5)
(0.5)
(20.5)
481.9
$
$
31.4
(4.6)
(105.0)
—
—
—
—
53.7
(36.3)
(25.0)
(12.8)
7.9
(1.7)
9.8
1.8
(80.8)
(1) The release of prior year tax positions during fiscal 2019 increased the basic and diluted net income per common share
by $0.32 and $0.30, respectively. The release of prior year tax positions during fiscal 2018 increased the basic and diluted
net income per common share by $0.05. The release of prior year tax positions during fiscal 2017 increased the basic and
diluted net income per common share by $0.17 and $0.15, respectively.
The foreign tax rate differential benefit primarily relates to the Company's operations in Thailand, Malta and Ireland. The
Company's Thailand manufacturing operations are currently subject to numerous tax holidays granted to the Company based on
its investment in property, plant and equipment in Thailand. The Company's tax holiday periods in Thailand expire between
fiscal 2022 and 2026, however, the Company actively seeks to obtain new tax holidays. The Company does not expect the
future expiration of any of its tax holiday periods in Thailand to have a material impact on its effective tax rate. The
Company’s Microsemi operations in Malaysia are subject to a tax holiday that effectively reduces the income tax rate in that
jurisdiction. Microsemi’s tax holiday in Malaysia was granted in 2009 and is effective through December 2019, subject to
continued compliance with the tax holiday’s requirements. The aggregate dollar expense derived from these tax holidays
approximated $0.1 million in fiscal 2019. The aggregate dollar benefit derived from these tax holidays approximated $6.2
million and $13.2 million in fiscal 2018 and 2017, respectively. The impact of the tax holidays during fiscal 2019 did not
impact basic and diluted net income per common share. The impact of the tax holidays during fiscal 2018 increased the basic
and diluted net income per common share by $0.03 and $0.02, respectively. The impact of the tax holidays during fiscal 2017
increased the basic and diluted net income per common share by $0.06.
F-37
Table of Contents
The tax effects of temporary differences that give rise to significant portions of the Company's deferred tax assets and deferred
tax liabilities are as follows (amounts in millions):
Deferred tax assets:
Deferred income on shipments to distributors
Inventory valuation
Net operating loss carryforward
Capital loss carryforward
Share-based compensation
Income tax credits
Property, plant and equipment
Accrued expenses and other
Intangible assets
Other
Gross deferred tax assets
Valuation allowances
Deferred tax assets, net of valuation allowances
Deferred tax liabilities:
Convertible debt
Intangible assets
Other
Deferred tax liabilities
Net deferred tax asset (liability)
Reported as:
Non-current deferred tax assets
Non-current deferred tax liability
Net deferred tax asset (liability)
March 31,
2019
2018
$
— $
45.0
94.3
9.6
42.4
376.5
23.6
91.4
1,608.1
12.6
2,303.5
(332.1)
1,971.4
(279.3)
(721.0)
—
(1,000.3)
971.1
1,677.2
(706.1)
971.1
$
$
$
$
$
$
39.1
10.7
101.1
10.6
31.4
178.4
25.7
91.2
—
—
488.2
(204.5)
283.7
(304.4)
(66.6)
(18.3)
(389.3)
(105.6)
100.2
(205.8)
(105.6)
In assessing whether it is more likely than not that deferred tax assets will be realized, the Company considers all available
evidence, both positive and negative, including its recent cumulative earnings experience and expectations of future available
taxable income of the appropriate character by taxing jurisdiction, tax attribute carryback and carryforward periods available to
them for tax reporting purposes, and prudent and feasible tax planning strategies.
The Company had federal, state and foreign NOL carryforwards with an estimated tax effect of $94.3 million available at
March 31, 2019. The federal, state and foreign NOL carryforwards expire at various times between 2020 and 2039, of which
portion of the NOL carryforwards do not expire. The Company had state tax credits of $158.5 million available at March 31,
2019. These state tax credits expire at various times between 2020 and 2039. The Company had capital loss carryforwards
with an estimated tax effect of $9.6 million available at March 31, 2019. These capital loss carryforwards begin to expire in
fiscal 2020. The Company had foreign tax credits of $18.5 million available at March 31, 2019. These foreign tax credits
begin to expire in fiscal 2022. The Company had credits for increasing research activity in the amount of $129.3 million
available at March 31, 2019. These credits begin to expire in fiscal 2020. The Company had U.S. prior year minimum tax
credits in the amount of $4.5 million available at March 31, 2019. These credits do not expire. The Company had refundable
tax credits in foreign jurisdictions of $45.8 million available at March 31, 2019. The Company had withholding tax credits in
foreign jurisdictions of $19.9 million available at March 31, 2019. These credits expire at various times between fiscal 2022
and 2024.
The Company recognizes interest and penalties related to unrecognized tax benefits through income tax expense. The
Company is subject to income taxes in the U.S. and numerous foreign jurisdictions. The Company files U.S. federal, U.S. state,
and foreign income tax returns. For U.S. federal, and in general for U.S. state tax returns, the fiscal 2007 and later tax years
remain effectively open for examination by tax authorities. For foreign tax returns, the Company is generally no longer subject
to income tax examinations for years prior to fiscal 2007.
F-38
Table of Contents
Significant judgment is required in evaluating the Company's uncertain tax positions and determining its provision for
income taxes. Although the Company believes that it has appropriately reserved for its uncertain tax positions, no assurance
can be given that the final tax outcome of these matters will not be different than expectations. The Company will adjust these
reserves in light of changing facts and circumstances, such as the closing of a tax audit, the refinement of an estimate, the
closing of a statutory audit period or changes in applicable tax law. To the extent that the final tax outcome of these matters is
different than the amounts recorded, such differences would impact the provision for income taxes in the period in which such
determination is made. The provision for income taxes includes the impact of reserve provisions and changes to the reserves
that are considered appropriate, as well as related net interest.
The Company recognizes liabilities for anticipated tax audit issues in the U.S. and other domestic and international tax
jurisdictions based on its estimate of whether, and the extent to which, the tax positions are more likely than not to be sustained
based on the technical merits. The Company believes that it has appropriate support for the income tax positions taken and to
be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many
factors including past experience and interpretations of tax laws applied to the facts of each matter.
The Company believes it maintains appropriate reserves to offset any potential income tax liabilities that may arise upon
final resolution of matters for open tax years. If such reserve amounts ultimately prove to be unnecessary, the resulting reversal
of such reserves could result in tax benefits being recorded in the period the reserves are no longer deemed necessary. If such
amounts prove to be less than an ultimate assessment, a future charge to expense would be recorded in the period in which the
assessment is determined.
The following table summarizes the activity related to the Company's gross unrecognized tax benefits from April 1, 2016 to
March 31, 2019 (amounts in millions):
Beginning balance
Increases related to acquisitions
Decreases related to settlements with tax authorities
Decreases related to statute of limitation expirations
Increases related to current year tax positions
Increases (decreases) related to prior year tax positions
Ending balance
Year Ended March 31,
2018
2017
2019
$
$
436.0
329.7
(8.3)
(16.2)
27.8
(5.6)
763.4
$
$
398.5
—
(0.1)
(10.9)
30.3
18.2
436.0
$
$
220.7
193.3
(11.7)
(7.6)
26.3
(22.5)
398.5
As of March 31, 2019 and March 31, 2018, the Company had accrued interest and penalties related to tax contingencies of
$88.1 million and $80.8 million, respectively. Interest and penalties charged to operations for the years ended March 31, 2018
and 2017 related to the Company's uncertain tax positions were $5.4 million and $5.8 million, respectively. Previously accrued
interest and penalties that were released during the year ended March 31, 2019 were $37.5 million.
The total amount of gross unrecognized tax benefits was $763.4 million and $436.0 million as of March 31, 2019
and March 31, 2018, respectively, of which $664.4 million and $436.0 million is estimated to impact the Company's effective
tax rate, if recognized. The Company estimates that it is reasonably possible unrecognized tax benefits as of March 31, 2019
could decrease by approximately $50.0 million in the next 12 months. Positions that may be resolved include various U.S. and
non-U.S. matters.
F-39
Table of Contents
Note 12. Debt and Credit Facility
Debt obligations included in the consolidated balance sheets consisted of the following (in millions):
Coupon
Interest
Rate
Effective
Interest
Rate
Fair Value of
Liability
Component at
Issuance (1)
March 31,
2019
2018
$ 3,266.5
$
1,911.5
1,000.0
1,000.0
7,178.0
—
N/A
N/A
N/A
—
Senior Secured Indebtedness
Revolving Credit Facility
Term Loan Facility
2023 Notes, maturing June 1, 2023 ("2023 Notes")
2021 Notes, maturing June 1, 2021 ("2021 Notes")
4.333%
3.922%
Total Senior Secured Indebtedness
Senior Subordinated Convertible Debt - Principal
Outstanding
2017 Senior Convertible Debt, maturing February 15, 2027
("2017 Senior Convertible Debt")
2015 Senior Convertible Debt, maturing February 15, 2025
("2015 Senior Convertible Debt")
Junior Subordinated Convertible Debt - Principal
Outstanding
2017 Junior Convertible Debt, maturing February 15, 2037
("2017 Junior Convertible Debt")
Total Convertible Debt
Gross long-term debt including current maturities
Less: Debt discount (2)
Less: Debt issuance costs (3)
Net long-term debt including current maturities
Less: Current maturities (4)
Net long-term debt
1.625%
6.0%
$1,396.3
$ 2,070.0
$ 2,070.0
1.625%
5.9%
$1,160.1
1,725.0
1,725.0
2.250%
7.4%
$321.1
686.3
686.3
4,481.3
4,481.3
11,659.3
4,481.3
(1,268.7)
(1,372.9)
(83.6)
(40.1)
10,307.0
3,068.3
(1,360.8)
(1,309.9)
$ 8,946.2
$ 1,758.4
(1) As each of the convertible instruments may be settled in cash upon conversion, for accounting purposes, they were
bifurcated into a liability component and an equity component, which are both initially recorded at fair value. The amount
allocated to the equity component is the difference between the principal value of the instrument and the fair value of the
liability component at issuance. The resulting debt discount is being amortized to interest expense at the respective
effective interest rate over the contractual term of the debt.
(2) The unamortized discount includes the following (in millions):
2023 Notes
2021 Notes
2017 Senior Convertible Debt
2015 Senior Convertible Debt
2017 Junior Convertible Debt
Total unamortized discount
F-40
March 31,
2019
2018
$
(4.4)
(3.8)
(561.9)
(351.4)
(347.2)
N/A
N/A
(616.3)
(400.3)
(356.3)
$
(1,268.7) $
(1,372.9)
Table of Contents
(3) Debt issuance costs include the following (in millions):
Revolving Credit Facility
Term Loan Facility
2023 Notes
2021 Notes
2017 Senior Convertible Debt
2015 Senior Convertible Debt
2017 Junior Convertible Debt
Total debt issuance costs
March 31,
2019
2018
(14.7) $
(19.4)
(10.2)
(8.8)
(14.5)
(12.8)
(3.2)
(83.6) $
(5.9)
N/A
N/A
N/A
(16.1)
(14.8)
(3.3)
(40.1)
$
$
(4) Current maturities include the full balance of the 2015 Senior Convertible Debt as of March 31, 2019 and 2018.
Expected maturities relating to the Company’s long-term debt as of March 31, 2019 are as follows (in millions):
Fiscal year ending March 31,
2020
2021
2022
2023
2024
Thereafter
Total
Expected Maturities
$
$
—
—
1,000.0
—
4,266.5
6,392.8
11,659.3
Ranking of Convertible Debt - The Senior Subordinated Convertible Debt and Junior Subordinated Convertible Debt
(collectively, the Convertible Debt) are unsecured obligations which are subordinated in right of payment to the amounts
outstanding under the Company's Credit Facility and Senior Secured Notes (as defined below). The Junior Subordinated
Convertible Debt is expressly subordinated in right of payment to any existing and future senior debt of the Company
(including the Credit Facility, the Senior Secured Notes, and the Senior Subordinated Convertible Debt) and is structurally
subordinated in right of payment to the liabilities of the Company's subsidiaries. The Senior Subordinated Convertible Debt is
subordinated to the Credit Facility and the Senior Secured Notes; ranks senior to the Company's indebtedness that is expressly
subordinated in right of payment to it, including the Junior Subordinated Convertible Debt; ranks equal in right of payment to
any of the Company's unsubordinated indebtedness that does not provide that it is senior to the Senior Subordinated
Convertible Debt; ranks junior in right of payment to any of the Company's secured, unsubordinated indebtedness to the extent
of the value of the assets securing such indebtedness; and is structurally subordinated to all indebtedness and other liabilities of
the Company's subsidiaries.
Summary of Conversion Features - Each series of Convertible Debt is convertible, subject to certain conditions, into cash,
shares of the Company's common stock or a combination thereof, at the Company's election, at specified Conversion Rates (see
table below), adjusted for certain events including the declaration of cash dividends. Except during the three-month period
immediately preceding the maturity date of the applicable series of Convertible Debt, each series of Convertible Debt is
convertible only upon the occurrence of (1) such time as the closing price of the Company's common stock exceeds the
Conversion Price (see table below) by 130% for 20 days (whether or not consecutive) during a period of 30 consecutive trading
days ending on the last trading day of the immediately preceding fiscal quarter or (2) during the 5 business day period after any
10 consecutive trading day period, or the measurement period, in which the trading price per $1,000 principal amount of notes
for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the
Company's common stock and the conversion rate on each such trading day or (3) upon the occurrence of certain corporate
events specified in the indenture of such series of Convertible Debt. In addition, for each series, if at the time of conversion the
applicable price of the Company's common stock exceeds the applicable Conversion Price at such time, the applicable
Conversion Rate will be increased by up to an additional maximum incremental shares rate, as determined pursuant to a
formula specified in the indenture for the applicable series of Convertible Debt, and as adjusted for cash dividends paid since
the issuance of such series of Convertible Debt. However, in no event will the applicable Conversion Rate exceed the
F-41
Table of Contents
applicable Maximum Conversion Rate specified in the indenture for the applicable series of Convertible Debt (see table below).
The following table sets forth the applicable Conversion Rates adjusted for dividends declared since issuance of such series of
Convertible Debt and the applicable Incremental Share Factors and Maximum Conversion Rates as adjusted for dividends paid
since the applicable issuance date:
2017 Senior Convertible Debt
2015 Senior Convertible Debt
2017 Junior Convertible Debt
Dividend adjusted rates as of March 31, 2019
Conversion
Rate, adjusted
Approximate
Conversion
Price,
adjusted
Incremental
Share Factor,
adjusted
Maximum
Conversion
Rate, adjusted
10.2925
16.0504
10.4763
$
$
$
97.16
62.30
95.45
5.1462
8.0252
5.2382
14.6668
22.4705
14.6668
As of March 31, 2019, the 2017 Senior Convertible Debt and the 2017 Junior Convertible Debt were not convertible. As of
March 31, 2019, the holders of the 2015 Senior Convertible Debt have the right to convert their debentures between April 1, 2019
and June 30, 2019 because the Company's common stock price has exceeded the Conversion Price by 130% for the specified
period of time during the quarter ended March 31, 2019. As of March 31, 2019, the 2015 Senior Convertible Debt had a value if
converted above par of $857.9 million.
The Company may not redeem any series of Convertible Debt prior to the relevant maturity date and no sinking fund is
provided for any series of Convertible Debt. Upon the occurrence of a fundamental change as defined in the applicable indenture
of such series of Convertible Debt, holders of such series may require the Company to purchase all or a portion of their Convertible
Debt for cash at a price equal to 100% of the principal amount plus any accrued and unpaid interest.
Interest expense includes the following (in millions):
Debt issuance amortization
Debt discount amortization
Interest expense
Total interest expense on Senior Secured Indebtedness
Debt issuance amortization
Debt discount amortization
Coupon interest expense
Total interest expense on Convertible Debt
Other interest expense
Total interest expense
Year Ended March 31,
2019
2018
2017
$
12.9
$
3.1
$
2.2
291.8
306.9
3.6
112.4
77.1
193.1
2.9
—
6.6
9.7
3.5
106.1
77.3
186.9
2.4
$
502.9
$
199.0
$
2.4
—
40.4
42.8
2.1
56.1
44.5
102.7
0.8
146.3
The remaining period over which the unamortized debt discount will be recognized as non-cash interest expense is 7.88
years, 5.88 years, and 17.88 years for the 2017 Senior Convertible Debt, 2015 Senior Convertible Debt and 2017 Junior
Convertible Debt, respectively.
In November 2017, the Company called for redemption $14.6 million in principal value of the remaining outstanding 2007
Junior Subordinated Convertible Debt (2007 Junior Convertible Debt) with an effective redemption date of December 15, 2017
for which substantially all holders submitted requests to convert. Prior to the call, conversion requests were received in both
the second and third quarters of fiscal 2018. Total conversions for fiscal 2018 were for a principal amount of $32.5 million for
which the Company settled the principal amount in cash and issued 0.5 million shares of its common stock in respect of the
conversion value in excess of the principal amount for the conversions occurring prior to the redemption notice and $41.0
F-42
Table of Contents
million in cash for the conversion value in excess of the principal amount for the conversion requests received after the notice
of redemption. A loss on total conversions was recorded for $2.2 million.
In June 2017, the Company exchanged, in privately negotiated transactions, $111.3 million aggregate principal amount of
its 2007 Junior Convertible Debt for (i) $111.3 million principal amount of 2017 Junior Convertible Debt with a market value
of $119.3 million plus (ii) the issuance of 3.2 million shares of the Company's common stock with a value of $254.6 million, of
which $56.3 million was allocated to the fair value of the liability and $321.1 million was allocated to the reacquisition of the
equity component for total consideration of $374.0 million. The transaction resulted in a loss on settlement of the 2007 Junior
Convertible Debt of approximately $13.8 million, which represented the difference between the fair value of the liability
component at time of repurchase and the sum of the carrying values of the debt component and any unamortized debt issuance
costs. The debt discount on the new 2017 Junior Convertible Debt was the difference between the par value and the fair value
of the debt resulting in a debt discount of $55.1 million which will be amortized to interest expense using the effective interest
method over the term of the debt.
In February 2017, the Company issued the 2017 Senior Convertible Debt and 2017 Junior Convertible Debt for net
proceeds of $2.04 billion and $567.7 million, respectively. In connection with the issuance of these instruments, the Company
incurred issuance costs of $33.7 million, of which $17.8 million and $3.4 million was recorded as convertible debt issuance
costs related to the 2017 Senior Convertible Debt and 2017 Junior Convertible Debt, respectively, and will be amortized using
the effective interest method over the term of the debt. The balance of $12.5 million in fees was recorded to equity. Interest on
both instruments is payable semi-annually on February 15 and August 15 of each year.
In February 2015, the Company issued the 2015 Senior Convertible Debt for net proceeds of approximately $1.69 billion.
In connection with the issuance, the Company incurred issuance costs of $30.3 million, of which $20.4 million was recorded as
debt issuance costs and will be amortized using the effective interest method over the term of the debt. The balance of $9.9
million was recorded to equity.
The Company utilized the proceeds from the issuances of the 2017 Senior Convertible Debt, 2017 Junior Convertible Debt,
and 2015 Senior Convertible Debt to reduce amounts borrowed under its Credit Facility and to settle a portion of the 2007
Junior Convertible Debt in privately negotiated transactions. In February 2017 and February 2015, the Company settled $431.3
million and $575.0 million, respectively, in aggregate principal of its 2007 Junior Convertible Debt. The February 2015
repurchase consisted solely of cash. In February 2017, the Company used cash of $431.3 million and an aggregate of 12.0
million in shares of the Company's common stock valued at $862.7 million for total consideration of $1.29 billion to repurchase
$431.3 million of the 2007 Junior Convertible Debt, of which $188.0 million was allocated to the liability component and $1.11
billion was allocated to the equity component. In addition, in February 2017, there was an inducement fee of $5.0 million
which was recorded in the consolidated statements of income in loss on settlement of debt. The consideration transferred in
February 2015 was $1.13 billion, of which $238.3 million was allocated to the liability component and $896.3 million was
allocated to the equity component. In the case of both settlements of the 2007 Junior Convertible Debt, the consideration was
allocated to the liability and equity components using the equivalent rate that reflected the borrowing rate for a similar non-
convertible debt prior to the retirement. The transactions resulted in a loss on settlement of debt of approximately $43.9 million
and $50.6 million in fiscal 2017 and fiscal 2015, respectively, which represented, in each case, the difference between the fair
value of the liability component at time of repurchase and the sum of the carrying values of the debt component and any
unamortized debt issuance costs.
Senior Secured Notes
In May 2018, the Company issued $1.00 billion aggregate principal amount of 3.922% Senior Secured Notes due 2021 (the
“2021 Notes”) and $1.00 billion aggregate principal amount of 4.333% Senior Secured Notes due 2023 (the “2023 Notes”, and
together with the 2021 Notes, the "Senior Secured Notes") to qualified institutional buyers in a Rule 144A offering. In
connection with the issuance of these instruments, the Company incurred issuance costs of $24.4 million and recorded a debt
discount of $10.5 million for fees deducted from the proceeds, which will both be amortized using the effective interest method
over the term of the debt. The 2021 Notes mature on June 1, 2021 and the 2023 Notes mature on June 1, 2023. Interest on the
2021 Notes accrues at a rate of 3.922% per annum, payable semi-annually in arrears on June 1 and December 1 of each year,
commencing on December 1, 2018. Interest on the 2023 Notes accrues at a rate of 4.333% per annum, payable semi-annually
in arrears on June 1 and December 1 of each year, commencing on December 1, 2018.
The Company may, at its option, redeem some or all of the 2021 Notes prior to June 1, 2021 at a price equal to the greater
of (a) 100% of the principal amount of the 2021 Notes redeemed or (b) the sum of the present value of all remaining scheduled
payments of principal and interest (discounted in accordance with the indenture for the 2021 Notes) that would have been due
on the redeemed 2021 Notes, in each case, plus accrued and unpaid interest to, but excluding, the redemption date. The
F-43
Table of Contents
Company may, at its option, redeem some or all of the 2023 Notes, (i) if prior to May 1, 2023 (one month prior to the maturity
date of the 2023 Notes), at a price equal to the greater of (a) 100% of the principal amount of the 2023 Notes redeemed or
(b) the sum of the present value of all remaining scheduled payments of principal and interest (discounted in accordance with
the indenture for the 2023 Notes) that would have been due on the redeemed 2023 Notes, in each case, plus accrued and unpaid
interest to, but excluding, the redemption date, and (ii) if on or after May 1, 2023 (one month prior to maturity of the 2023
Notes), at a redemption price equal to 100% of the principal amount of the notes redeemed, plus accrued and unpaid interest to,
but excluding, the redemption date.
If the Company experiences a specified change of control triggering event, the Company must offer to repurchase the
Notes at a price equal to 101% of the principal amount of the Notes repurchased, plus accrued and unpaid interest, if any, to,
but excluding, the repurchase date.
The Notes are guaranteed by certain of the Company's subsidiaries (each such guarantee, a “Note Guarantee”) that have
also guaranteed the obligations under the Company's Credit Facility and under the Term Loan Facility (the Term Loan Facility
together with the Credit Facility, the “Senior Credit Facilities”) that was entered into in connection with the Microsemi
acquisition.
The Notes and the Note Guarantees are secured, on a pari passu first lien basis with the Senior Credit Facilities, by
substantially all of the tangible and intangible assets (other than certain excluded assets) of the Company and the guarantors
that secure obligations under the Senior Credit Facilities, in each case subject to certain thresholds, exceptions and permitted
liens, as set forth in the indenture for the Senior Secured Notes and the Security Agreement, dated May 29, 2018, by and among
the Company, the subsidiary guarantors party thereto and the Collateral Agent (the "Security Agreement").
Credit Facility
In May 2018, the Company amended and restated its credit agreement to, among other things, increase the size of the
Revolving Credit Facility thereunder to $3.84 billion from $3.12 billion at March 31, 2018. In connection with the amendment
and restatement of the Credit Agreement, the Company incurred issuance costs of $13.6 million which will be amortized using
the effective interest method over the term of the debt. In the year ended March 31, 2019, the Company terminated the
commitments for the 2020 Revolving Loans which decreased the capacity of the Revolving Credit Facility to $3.60 billion.
The Credit Agreement provides for a revolving loan facility in an aggregate principal amount of approximately $3.60
billion, with a $250.0 million foreign currency sublimit, a $50.0 million letter of credit sublimit and a $25.0 million swingline
loan sublimit. The Credit Agreement consists of approximately $3.60 billion of revolving loan commitments that terminate on
May 18, 2023 (the "2023 Maturity Date"). The $244.3 million of revolving loan commitments (the "2020 Revolving Loans")
that would terminate on February 4, 2020 were canceled in the fiscal year ended March 31, 2019. The Revolving Loans bear
interest, at the Company’s option, at the base rate plus a spread of 0.00% to 1.00% or an adjusted LIBOR rate (based on one,
two, three or six-month interest periods) plus a spread of 1.00% to 2.00%, in each case with such spread being determined
based on the consolidated senior leverage ratio for the preceding four fiscal quarter period.
The Credit Agreement permits the Company to add one or more incremental term loan facilities (in addition to the loans
under the Term Loan Facility) and/or increase the commitments under the Revolving Credit Facility from time to time, subject,
in each case, to the receipt of additional commitments from existing and/or new lenders and pro forma compliance with a
consolidated senior leverage ratio set forth in the Credit Agreement.
The Company's obligations under the Credit Agreement are guaranteed by certain of its subsidiaries meeting materiality
thresholds set forth in the Credit Agreement. To secure the Company's obligations under the Credit Agreement and the
subsidiary guarantors’ obligations under the guarantees, the Company and each of the subsidiary guarantors has granted a
security interest in substantially all its assets subject to certain exceptions and limitations.
In May 2018, the Company borrowed $3.0 billion aggregate principal amount of loans under the Term Loan Facility
("Term Loans"). In connection with such borrowings, the Company incurred issuance costs of $34.7 million which will be
amortized using the effective interest method over the term of the debt. The Credit Agreement provides for quarterly
amortization payments of the Term Loans on the last business day of each March, June, September and December, commencing
with the last business day of the first full fiscal quarter to occur after the Microsemi acquisition effective date, equal to 0.25%
of the aggregate original principal amount of the Term Loans. In addition, the Credit Agreement requires mandatory
prepayments of the Term Loans from the incurrence of debt not otherwise permitted to be incurred under the Credit Agreement,
certain asset sales and certain excess cash flow. Mandatory prepayments with excess cash flow (as defined in the Credit
Agreement) are required to be made beginning with the Company’s fiscal year ending March 31, 2020 in an amount equal to
F-44
Table of Contents
50%, 25% or 0% of the excess cash flow for such fiscal year, depending on the Company’s senior leverage ratio. The Company
may prepay the Term Loans at any time without premium or penalty. Term Loans repaid or prepaid may not be reborrowed.
During fiscal 2019, the Company voluntarily prepaid $1.09 billion of principal under the Term Loan Facility of which $500.0
million was from funds borrowed under its Revolving Credit Facility. The transactions resulted in a loss on settlement of debt
of approximately $11.5 million consisting of unamortized financing fees.
Interest is due and payable in arrears quarterly for loans bearing interest at the base rate and at the end of an interest period
(or at each three-month interval in the case of loans with interest periods greater than three months) in the case of loans bearing
interest at the adjusted LIBOR rate. Principal, together with all accrued and unpaid interest, is due and payable on the 2023
Maturity Date in the case of revolving loans under the Credit Agreement and May 29, 2025 in the case of the Term Loans. The
Company pays a quarterly commitment fee on the available but unused portion of its line of credit which is calculated on the
average daily available balance during the period. The Company may prepay the loans and terminate the commitments, in
whole or in part, at any time without premium or penalty, subject to certain conditions including minimum amounts in the case
of commitment reductions and reimbursement of certain costs in the case of prepayments of LIBOR loans.
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit or restrict the
Company and its subsidiaries' ability to, among other things, incur subsidiary indebtedness, grant liens, merge or consolidate,
dispose of assets, make investments, make acquisitions, enter into certain transactions with affiliates, pay dividends or make
distributions, repurchase stock, enter into restrictive agreements and enter into sale and leaseback transactions, in each case
subject to customary exceptions for a credit facility of this size and type. The Company is also required to maintain compliance
with a senior leverage ratio, a total leverage ratio and an interest coverage ratio, all measured quarterly and calculated on a
consolidated basis. At March 31, 2019, the Company was in compliance with these financial covenants.
The financial covenants include limits on the Company's consolidated total leverage ratio and senior leverage ratio. The
maximum Total Leverage Ratio (capitalized terms not otherwise defined in this Form 10-K have the meaning of the defined
terms in the applicable agreements), measured quarterly, cannot exceed (a) 6.75 to 1.00 for any such period ended on or after
the Microsemi Acquisition Closing Date to (but excluding) the first anniversary of the Microsemi Acquisition Closing Date, (b)
6.25 to 1.00 for any such period ended on or after the first anniversary of the Microsemi Acquisition Closing Date to (but
excluding) the second anniversary of the Microsemi Acquisition Closing Date to (but excluding) the second anniversary or the
Microsemi Acquisition Closing Date and (c) 5.75 to 1.00 for any such period ended on or after the second anniversary of the
Microsemi Acquisition Closing Date. The total leverage ratio is calculated as Consolidated Total Indebtedness, excluding the
Junior Convertible Debt up to a $700 million maximum, to Consolidated EBIDTA for a period of four consecutive quarters.
The Credit Agreement also requires that the Senior Leverage Ratio, measured quarterly, not exceed (a) 4.75 to 1.00 for any
such period ended from (and including) the Microsemi Acquisition Closing Date to (but excluding) the first anniversary of the
Microsemi Acquisition Closing Date, (b) 4.25 to 1.00 for any such period ended on or after the first anniversary of the
Microsemi Acquisition Closing Date to (but excluding) the second anniversary of the Microsemi Acquisition Closing Date and
(c) 3.75 to 1.00 for any such period ended on or after the second anniversary of the Microsemi Acquisition Closing Date. The
senior leverage ratio is calculated as Consolidated Senior Indebtedness to Consolidated EBIDTA for four consecutive quarters.
The Company is also required to comply with a Minimum Interest Coverage Ratio of at least 3.25 to 1.00 for any period ended
on or after the Microsemi Acquisition Closing Date, measured quarterly.
The Credit Agreement includes customary events of default that include, among other things, non-payment defaults,
inaccuracy of representations and warranties, covenant defaults, cross default to material indebtedness, bankruptcy and
insolvency defaults, material judgment defaults, ERISA defaults and a change of control default. The occurrence of an event of
default could result in the acceleration of the obligations under the Credit Agreement. Under certain circumstances, a default
interest rate will apply on all obligations during the existence of an event of default under the Revolving Credit Facility at a per
annum rate equal to 2.00% above the applicable interest rate for any overdue principal and 2.00% above the rate applicable for
base rate loans for any other overdue amounts.
Note 13. Contingencies
In the ordinary course of the Company's business, it is exposed to various liabilities as a result of contracts, product
liability, customer claims and other matters. Additionally, the Company is involved in a limited number of legal actions, both
as plaintiff and defendant. Consequently, the Company could incur uninsured liability in any of those actions. The Company
also periodically receives notifications from various third parties alleging infringement of patents or other intellectual property
rights, or from customers requesting reimbursement for various costs. With respect to pending legal actions to which the
Company is a party and other claims, although the outcomes are generally not determinable, the Company believes that the
ultimate resolution of these matters will not have a material adverse effect on its financial position, cash flows or results of
operations. Litigation and disputes relating to the semiconductor industry are not uncommon, and the Company is, from time
F-45
Table of Contents
to time, subject to such litigation and disputes. As a result, no assurances can be given with respect to the extent or outcome of
any such litigation or disputes in the future.
In connection with its acquisition of Microsemi, which closed on May 29, 2018, the Company became involved with
the following legal matters:
Federal Shareholder Class Action Litigation. Beginning on September 14, 2018, the Company and certain of its
officers were named in two putative shareholder class action lawsuits filed in the United States District Court for the District of
Arizona, captioned Jackson v. Microchip Technology Inc., et al., Case No. 2:18-cv-02914-JJT and Maknissian v. Microchip
Technology Inc., et al., Case No. 2:18-cv-02924-JJT. On November 13, 2018, the Maknissian complaint was voluntarily
dismissed. The Jackson complaint is allegedly brought on behalf of a putative class of purchasers of Microchip common stock
between March 2, 2018 and August 9, 2018. The complaint asserts claims for alleged violations of the federal securities laws
and generally alleges that the defendants issued materially false and misleading statements and failed to disclose material
adverse facts about the Company’s business, operations, and prospects during the putative class period. The complaint seeks,
among other things, compensatory damages and attorneys’ fees and costs on behalf of the putative class. On December 11,
2018, the Court issued an order appointing the lead plaintiff. An amended complaint was filed on February 22, 2019.
Defendants filed a motion to dismiss the amended complaint on April 1, 2019.
Federal Derivative Litigation. On December 17, 2018, a shareholder derivative lawsuit was filed against certain of
the Company’s officers and directors in the United States District Court for the District of Arizona, captioned Kistenmacher v.
Sanghi, et al., Case No. 16-cv-04720. The Company is named as a nominal defendant. The complaint generally alleges that
defendants breached their fiduciary duties by, among other things, making or causing the Company to make false and
misleading statements and omissions regarding the Microsemi acquisition, the Company’s business, operations, and prospects,
and a purported failure to maintain internal controls. The complaint further alleges that certain defendants engaged in insider
trading. The complaint asserts causes of action for alleged violations of Section 14(a) of the Securities Exchange Act, breach of
fiduciary duties, and unjust enrichment and seeks unspecified monetary damages, corporate governance reforms, restitution,
and attorneys’ fees and costs.
State Derivative Litigation. On January 22, 2019, a shareholder derivative lawsuit was filed against certain of the
Company’s officers and directors in the Superior Court of Arizona for Maricopa County, captioned Reid v. Sanghi, et al., Case
No. CV2019-002389. The Company is named as a nominal defendant. The complaint generally alleges that defendants
breached their fiduciary duties by, among other things, purportedly failing to conduct adequate due diligence regarding
Microsemi prior to its acquisition, misrepresenting the Company’s business prospects and health, and engaging in improper
practices, and further alleges that certain defendants engaged in insider trading. The complaint asserts causes of action for
breach of fiduciary duty, waste, and unjust enrichment and seeks unspecified monetary damages, corporate governance
reforms, equitable and/or injunctive relief, restitution, and attorneys’ fees and costs. This case was stayed on May 23, 2019 to
allow the Federal Derivative Litigation to address certain overlapping issues.
Peterson, et al. v. Sanghi, et al. On October 9, 2018, four former officers of Microsemi Corporation filed a lawsuit in
the Superior Court of California in Orange County against us and four of our officers asserting claims for slander per se, libel
per se, trade libel, and violations of California Business and Professions Code Section 17200 ("UCL"). On November 8, 2018,
defendants removed the action to the United States District Court for the Central District of California, Case No. 18-cv-02000-
JLS. Defendants moved to dismiss, and, following the Court's ruling, Plaintiffs filed an amended complaint that dropped the
trade libel and UCL claims. The plaintiffs are seeking unspecified compensatory damages (ranging from an alleged $10
million to $100 million), as well as punitive damages, injunctive relief, and attorneys' fees and costs. Discovery has begun, and
the Court has set a Final Pretrial Conference date of May 22, 2020.
As a result of its acquisition of Atmel, which closed April 4, 2016, the Company became involved with the following legal
matters:
Continental Claim ICC Arbitration. On December 29, 2016, Continental Automotive GmbH ("Continental") filed a
Request for Arbitration with the ICC, naming as respondents the Company's subsidiaries Atmel Corporation, Atmel SARL,
Atmel Global Sales Ltd., and Atmel Automotive GmbH (collectively, "Atmel"). The Request alleges that a quality issue
affecting Continental airbag control units in certain recalled vehicles stems from allegedly defective Atmel application specific
integrated circuits ("ASICs"). Continental seeks to recover from Atmel all related costs and damages incurred as a result of the
vehicle manufacturers’ airbag control unit-related recalls, currently alleged to be $208 million. The Company's Atmel
subsidiaries intend to defend this action vigorously.
F-46
Table of Contents
Southern District of New York Action by LFoundry Rousset ("LFR") and LFR Employees. On March 4, 2014, LFR
and Jean-Yves Guerrini, individually and on behalf of a putative class of LFR employees, filed an action in the United States
District Court for the Southern District of New York (the "District Court") against the Company's Atmel subsidiary, French
subsidiary, Atmel Rousset S.A.S. ("Atmel Rousset"), and LFoundry GmbH ("LF"), LFR's German parent. The case purports to
relate to Atmel Rousset's June 2010 sale of its wafer manufacturing facility in Rousset, France to LF, and LFR's subsequent
insolvency, and later liquidation, more than three years later. The District Court dismissed the case on August 21, 2015, and the
United States Court of Appeals for the Second Circuit affirmed the dismissal on June 27, 2016. On July 25, 2016, the plaintiffs
filed a notice of appeal from the District Court's June 27, 2016 denial of their motion for relief from the dismissal judgment.
On May 19, 2017, the United States Court of Appeals for the Second Circuit affirmed the June 27, 2016 order dismissing the
case.
Individual Labor Actions by former LFR Employees. In June 2010, Atmel Rousset sold its wafer manufacturing
business in Rousset, France to LFoundry GmbH ("LF"), the German parent of LFoundry Rousset ("LFR"). LFR then leased
the Atmel Rousset facility to conduct the manufacture of wafers. More than three years later, LFR became insolvent and later
liquidated. In the wake of LFR's insolvency and liquidation, over 500 former employees of LFR have filed individual labor
actions against Atmel Rousset in a French labor court. The Company's Atmel Rousset subsidiary believes that each of these
actions is entirely devoid of merit, and, further, that any assertion by any of the Claimants of a co-employment relationship with
the Atmel Rousset subsidiary is based substantially on the same specious arguments that the Paris Commercial Court
summarily rejected in 2014 in related proceedings. The Company's Atmel Rousset subsidiary therefore intends to defend
vigorously against each of these claims. Additionally, complaints have been filed in a regional court in France on behalf of the
same group of employees against Microchip Technology Rousset, Atmel Switzerland Sarl, Atmel Corporation and Microchip
Technology Incorporated alleging that the sale of the Atmel Rousset production unit to LF was fraudulent and should be
voided. Furthermore, new claims have been filed in a regional court in France on behalf of a subset of this same group of
employees against Microchip Technology Incorporated and Atmel Corporation. These claims are specious and the defendant
entities therefore intend to defend vigorously against these claims.
The Company accrues for claims and contingencies when losses become probable and reasonably estimable. As of the
end of each applicable reporting period, the Company reviews each of its matters and, where it is probable that a liability has
been or will be incurred, the Company accrues for all probable and reasonably estimable losses. Where the Company can
reasonably estimate a range of losses it may incur regarding such a matter, the Company records an accrual for the amount
within the range that constitutes its best estimate. If the Company can reasonably estimate a range but no amount within the
range appears to be a better estimate than any other, the Company uses the amount that is the low end of such range. As of
March 31, 2019, the Company's estimate of the aggregate potential liability that is possible but not probable is approximately
$100 million in excess of amounts accrued.
The Company's technology license agreements generally include an indemnification clause that indemnifies the
licensee against liability and damages (including legal defense costs) arising from any claims of patent, copyright, trademark or
trade secret infringement by the Company's proprietary technology. The terms of these indemnification provisions approximate
the terms of the outgoing technology license agreements, which are typically perpetual unless terminated by either party for
breach. The possible amount of future payments the Company could be required to make based on agreements that specify
indemnification limits, if such indemnifications were required on all of these agreements, is approximately $164 million. There
are some licensing agreements in place that do not specify indemnification limits. As of March 31, 2019, the Company had not
recorded any liabilities related to these indemnification obligations and the Company believes that any amounts that it may be
required to pay under these agreements in the future will not have a material adverse effect on its financial position, cash flows
or results of operations.
The Company has learned of an ongoing compromise of its computer networks by what is believed to be sophisticated
hackers. The Company has engaged experienced legal counsel and a leading forensic investigatory firm with experience in
such matters. The Company has taken steps to identify malicious activity on its network including a compromise of its network
and, as of the date of this filing, the Company is implementing a containment plan. The Company is continuing to evaluate the
effectiveness of the containment plan and the amount and content of the information that was compromised and to implement
additional remedial actions. At this time, the Company does not believe that this IT system compromise has had a material
adverse effect on its business or resulted in any material damage to it. However, the Company is still evaluating the amount
and type of data that was compromised and there can be no assurance as to what the impact of this IT system compromise will
be. The Company has considered whether there may be litigation, investigations or claims related to such matter but it is too
early to know if or whether litigation, investigations or claims may be asserted or what the nature of such proceedings or
alleged damages may be.
F-47
Table of Contents
Note 14. Stock Repurchase Activity
In January 2016, the Company's Board of Directors authorized an increase to the existing share repurchase program to 15.0
million shares of common stock. There were no repurchases of common stock during fiscal 2019, 2018 and 2017. There is no
expiration date associated with this repurchase program. As of March 31, 2019, approximately 15.6 million shares remained as
treasury shares with the balance of the shares being used to fund share issuance requirements under the Company's equity
incentive plans.
Note 15. Employee Benefit Plans
Defined Benefit Plans
The Company has defined benefit pension plans that cover certain French and German employees. Most of these defined
pension plans, which were acquired in the Atmel and Microsemi acquisitions, are unfunded. Plan benefits are provided in
accordance with local statutory requirements. Benefits are based on years of service and employee compensation levels.
Pension liabilities and charges are based upon various assumptions, updated annually, including discount rates, future salary
increases, employee turnover, and mortality rates. The Company’s French pension plan provides for termination benefits paid
to covered French employees only at retirement, and consists of approximately one to five months of salary. The Company's
German pension plan provides for defined benefit payouts for covered German employees following retirement.
The aggregate net pension expense relating to these two plans is as follows (in millions):
Service costs
Interest costs
Amortization of actuarial loss
Settlements
Net pension period cost
Year Ended March 31,
2019
2018
2017
$
$
1.5
1.1
0.4
—
3.0
$
$
2.2
1.0
0.8
—
4.0
$
$
1.4
1.0
—
0.5
2.9
Interest costs and amortization of actuarial losses are recorded in the other (loss) income, net line item in the statements of
income.
The change in projected benefit obligation and the accumulated benefit obligation, were as follows (in millions):
Year Ended March 31,
2019
2018
Projected benefit obligation at the beginning of the year
$
61.0
$
Additions due to acquisition of Microsemi
Service cost
Interest cost
Actuarial losses
Benefits paid
Foreign currency exchange rate changes
Projected benefit obligation at the end of the year
Accumulated benefit obligation at the end of the year
Weighted average assumptions
Discount rate
Rate of compensation increase
9.8
1.5
1.1
6.0
(0.9)
(5.8)
72.7
66.7
$
$
$
$
50.4
—
2.2
1.0
0.7
(0.8)
7.5
61.0
55.5
1.41%
2.79%
1.73%
2.91%
The Company's pension liability represents the present value of estimated future benefits to be paid. The discount rate is
based on the quarterly average yield for Euros treasuries with a duration of 30 years, plus a supplement for corporate bonds
F-48
Table of Contents
(Euros, AA rating). Net actuarial losses, which are included in accumulated other comprehensive loss in the Company's
consolidated balance sheets, will be recognized as a component of net periodic cost over the average remaining service period.
As the defined benefit plans are unfunded, the liability recognized on the Company's consolidated balance sheet as
of March 31, 2019 was $72.7 million of which $1.3 million is included in accrued liabilities and $71.4 million is included in
other long-term liabilities. The liability recognized on the Company's consolidated balance sheet as of March 31,
2018 was $61.0 million of which $0.9 million is included in accrued liabilities and $60.1 million is included in other long-term
liabilities.
Future estimated expected benefit payments for fiscal year 2020 through 2029 are as follows (in millions):
Fiscal Year Ending March 31,
Expected Benefit Payments
2020
2021
2022
2023
2024
2025 through 2029
Total
$
$
1.3
1.5
1.9
1.8
2.3
11.9
20.7
The Company's net periodic pension cost for fiscal 2020 is expected to be approximately $3.3 million.
In connection with the acquisition of SMSC in August 2012, the Company assumed an unfunded Supplemental Executive
Retirement Plan ("SERP"), which provides former SMSC senior management with retirement, disability and death benefits.
An amendment to the SERP was executed on November 3, 2009, freezing the benefit level for existing participants as of
February 28, 2010 and closing the SERP to new participants. As of March 31, 2019, the projected benefit obligation is $3.7
million. Annual benefit payments and contributions under this plan are expected to be approximately $0.4 million in fiscal
2020 and approximately $4.1 million cumulatively in fiscal 2021 through fiscal 2029.
Defined Contribution Plans
The Company maintains a contributory profit-sharing plan for its domestic employees meeting certain eligibility and
service requirements. The plan qualifies under Section 401(k) of the Internal Revenue Code of 1986, as amended, and allows
employees to contribute up to 60% of their base salary, subject to maximum annual limitations prescribed by the IRS. The
Company has a discretionary matching contribution program. All matches are provided on a quarterly basis and require the
participant to be an active employee at the end of the applicable quarter. During fiscal 2019, 2018 and 2017, the Company's
matching contributions to the plan totaled $8.6 million, $8.8 million and $8.2 million, respectively.
The Company's 2001 Employee Stock Purchase Plan (the 2001 Purchase Plan) became effective on March 1, 2002. Under
the 2001 Purchase Plan, eligible employees of the Company may purchase shares of common stock at semi-annual intervals
through periodic payroll deductions. The purchase price in general will be 85% of the lower of the fair market value of the
common stock on the first day of the participant's entry date into the offering period or of the fair market value on the semi-
annual purchase date. Depending upon a participant's entry date into the 2001 Purchase Plan, purchase periods under the 2001
Purchase Plan consist of overlapping periods of either 24, 18, 12 or 6 months in duration. In May 2003 and August 2003, the
Company's Board and stockholders, respectively, each approved an annual automatic increase in the number of shares reserved
under the 2001 Purchase Plan. The automatic increase took effect on January 1, 2005, and on each January 1 thereafter during
the term of the plan, and is equal to the lesser of (i) 1,500,000, (ii) one half of one percent (0.5%) of the then outstanding shares
of the Company's common stock, or (iii) such lesser amount as is approved by Board of Directors. On January 1, 2019, under
the automatic increase provision, an additional 1,184,815 shares of Common Stock were reserved for sale under the 2001
Purchase Plan in future offering periods. Upon the approval of the Board of Directors, there were no shares added under the
2001 Purchase Plan on January 1, 2018 based on the automatic increase provision. On January 1, 2017, an additional
1,077,150 shares were reserved under the 2001 Purchase Plan based on the automatic increase. Since the inception of the 2001
Purchase Plan, 14,557,319 shares of common stock have been reserved for issuance and 8,293,815 shares have been issued
under this purchase plan.
F-49
Table of Contents
During fiscal 1995, a purchase plan was adopted for employees in non-U.S. locations. Such plan provided for the purchase
price per share to be 100% of the lower of the fair market value of the common stock at the beginning or end of the semi-
annual purchase plan period. Effective May 1, 2006, the Company's Board of Directors approved a purchase price per share
equal to 85% of the lower of the fair market value of the common stock at the beginning or end of the semi-annual purchase
plan period. On May 1, 2006, the Company's Board of Directors approved an annual automatic increase in the number of
shares reserved under the plan. The automatic increase took effect on January 1, 2007, and on each January 1 thereafter during
the term of the plan, and is equal to one tenth of one percent (0.1%) of the then outstanding shares of the Company's common
stock. On January 1, 2019, under the automatic increase provision, an additional 236,963 shares of Common Stock were
reserved for sale under the International Purchase Plan in future offering periods. Upon the approval of the Board of Directors,
there were no shares added under the plan on January 1, 2018 based on the automatic increase provision. On January 1, 2017,
an additional 215,430 shares were reserved under the plan based on the automatic increase. Since the inception of this
purchase plan, 2,156,176 shares of common stock have been reserved for issuance and 1,524,674 shares have been issued under
this purchase plan.
Effective January 1, 1997, the Company adopted a non-qualified deferred compensation arrangement. This plan is
unfunded and is maintained primarily for the purpose of providing deferred compensation for a select group of highly
compensated employees as defined in ERISA Sections 201, 301 and 401. There are no Company matching contributions made
under this plan.
The Company has management incentive compensation plans which provide for bonus payments, based on a percentage of
base salary, from an incentive pool created from operating profits of the Company, at the discretion of the Board of Directors. During
fiscal 2019, 2018 and 2017, $18.7 million, $48.1 million and $41.5 million were charged against operations for these plans,
respectively.
The Company also has a plan that, at the discretion of the Board of Directors, provides a cash bonus to all employees of
the Company based on the operating profits of the Company. During fiscal 2019, 2018 and 2017, $16.4 million, $36.3 million
and $28.2 million, respectively, were charged against operations for this plan.
Note 16. Share-Based Compensation
Share-Based Compensation Expense
The following table presents the details of the Company's share-based compensation expense (in millions):
Year Ended March 31,
2019
2018
2017
Cost of sales (1)
Research and development
Selling, general and administrative
Special (income) charges and other, net
Pre-tax effect of share-based compensation
Income tax benefit
$
$
14.9
72.0
62.3
17.2
166.4
35.5
$
13.8
42.5
36.9
—
93.2
28.3
Net income effect of share-based compensation
$
130.9 $
64.9 $
18.7
46.8
62.6
—
128.1
44.2
83.9
(1) During the year ended March 31, 2019, $17.2 million of share-based compensation expense was capitalized to
inventory, and $14.9 million of previously capitalized share-based compensation expense in inventory was sold. During
the year ended March 31, 2018, $11.9 million of share-based compensation expense was capitalized to inventory and $13.8
million of previously capitalized share-based compensation expense in inventory that was sold. During the year ended
March 31, 2017, $11.3 million of share-based compensation expense was capitalized to inventory. The amount of share-
based compensation included in cost of sales during fiscal 2017 included $14.5 million of previously capitalized share-
based compensation expense in inventory was sold and $4.2 million of share-based compensation expense related to the
Company's acquisition of Atmel that was not previously capitalized into inventory.
The amount of unearned share-based compensation currently estimated to be expensed in the remainder of fiscal 2020
through fiscal 2024 related to unvested share-based payment awards at March 31, 2019 is $253.4 million. The weighted
average period over which the unearned share-based compensation is expected to be recognized is approximately 1.88 years.
F-50
Table of Contents
Microsemi Acquisition-related Equity Awards
In connection with its acquisition of Microsemi on May 29, 2018, the Company assumed certain restricted stock units
(RSUs), stock appreciation rights (SARs), and stock options granted by Microsemi. The assumed awards were measured at the
acquisition date based on the estimated fair value, which was a total of $175.4 million. A portion of that fair value, $53.9
million, which represented the pre-acquisition vested service provided by employees to Microsemi, was included in the total
consideration transferred as part of the acquisition. As of the acquisition date, the remaining portion of the fair value of those
awards was $121.5 million, representing post-acquisition share-based compensation expense that will be recognized as these
employees provide service over the remaining vesting periods. During the year ended March 31, 2019, the Company
recognized $65.2 million of share-based compensation expense in connection with the acquisition of Microsemi, of which $3.5
million was capitalized into inventory and $17.2 million was due to the accelerated vesting of outstanding equity awards upon
termination of certain Microsemi employees.
Atmel Acquisition-related Equity Awards
In connection with its acquisition of Atmel on April 4, 2016, the Company assumed certain RSUs granted by Atmel. The
assumed awards were measured at the acquisition date based on the estimated fair value, which was a total of $95.9 million. A
portion of that fair value, $7.5 million, which represented the pre-acquisition vested service provided by employees to Atmel,
was included in the total consideration transferred as part of the acquisition. As of the acquisition date, the remaining portion of
the fair value of those awards was $88.4 million, representing post-acquisition share-based compensation expense that will be
recognized as these employees provide service over the remaining vesting periods.
Combined Incentive Plan Information
RSU share activity under the 2004 Plan is set forth below:
Nonvested shares at March 31, 2016
Granted
Assumed upon acquisition
Forfeited
Vested
Nonvested shares at March 31, 2017
Granted
Forfeited
Vested
Nonvested shares at March 31, 2018
Granted
Assumed upon acquisition
Forfeited
Vested
Nonvested shares at March 31, 2019
Number of
Shares
6,307,742
$
1,635,655
2,059,524
(722,212)
(2,861,253)
6,419,456
1,267,536
(279,051)
(1,735,501)
5,672,440
1,951,408
1,805,680
(408,242)
(2,729,324)
6,291,962
$
Weighted Average
Grant Date Fair
Value
36.76
51.46
46.57
43.58
38.60
42.06
77.26
49.65
38.00
50.79
77.83
91.70
73.36
61.51
64.81
The total intrinsic value of RSUs which vested during the years ended March 31, 2019, 2018 and 2017 was $229.3 million,
$146.0 million and $166.1 million, respectively. The aggregate intrinsic value of RSUs outstanding at March 31, 2019 was
$522.0 million, calculated based on the closing price of the Company's common stock of $82.96 per share on March 29,
2019. At March 31, 2019, the weighted average remaining expense recognition period was 1.91 years.
F-51
Table of Contents
Stock option and stock appreciation right (SAR) activity under the Company's stock incentive plans in the three years
ended March 31, 2019 is set forth below:
Outstanding at March 31, 2016
Exercised
Forfeited or expired
Outstanding at March 31, 2017
Exercised
Forfeited or expired
Outstanding at March 31, 2018
Assumed upon acquisition
Exercised
Forfeited or expired
Outstanding at March 31, 2019
Number of
Shares
Weighted Average
Exercise Price per
Share
913,508
(437,906)
(42,485)
433,117
(131,666)
(17,111)
284,340
141,751
(140,118)
(4,091)
281,882
$
$
33.00
34.34
34.26
31.51
31.75
34.73
31.21
25.86
27.67
39.62
30.16
The total intrinsic value of options and SARs exercised during the years ended March 31, 2019, 2018 and 2017 was $8.3
million, $7.4 million and $9.6 million, respectively. This intrinsic value represents the difference between the fair market value
of the Company's common stock on the date of exercise and the exercise price of each equity award.
The aggregate intrinsic value of options and SARs outstanding at March 31, 2019 was $14.9 million. The aggregate intrinsic
value of options and SARS exercisable at March 31, 2019 was $14.8 million. The aggregate intrinsic values were calculated based
on the closing price of the Company's common stock of $82.96 per share on March 29, 2019.
As of March 31, 2019 and March 31, 2018, the number of option and SAR shares exercisable was 278,591 and 224,022,
respectively, and the weighted average exercise price per share was $30.03 and $29.96, respectively.
There were no stock options granted in the years ended March 31, 2019, 2018 and 2017.
Note 17. Commitments
The Company leases office space and transportation and other equipment under operating leases which expire at various
dates through September 2032. The future minimum lease commitments under these operating leases at March 31, 2019 were
as follows (in millions):
Year Ending March 31,
2020
2021
2022
2023
2024
Thereafter
Total minimum payments
Amount
49.0
38.2
30.2
18.0
9.1
22.6
167.1
$
$
The terms of the leases do not contain significant restriction provisions and usually contain standard rent escalation clauses
as well as options for renewal. Rental expense under operating leases totaled $50.9 million, $30.0 million and $35.4 million for
fiscal 2019, 2018 and 2017, respectively.
Commitments for construction or purchase of property, plant and equipment totaled $18.8 million as of March 31, 2019, all
of which will be due within the next year. Other purchase obligations and commitments totaled approximately $194.9 million,
which includes outstanding purchase commitments with the Company's wafer foundries and other suppliers, for delivery in
fiscal 2020.
F-52
Table of Contents
Note 18. Geographic and Segment Information
The Company's reportable segments are semiconductor products and technology licensing. The Company does not
allocate operating expenses, interest income, interest expense, other income or expense, or provision for or benefit from income
taxes to these segments for internal reporting purposes, as the Company does not believe that allocating these expenses is
beneficial in evaluating segment performance. Additionally, the Company does not allocate assets to segments for internal
reporting purposes as it does not manage its segments by such metrics.
The following table represents net sales and gross profit for each segment (in millions):
Years ended March 31,
2019
2018
2017
Semiconductor products
Technology licensing
Total
Net Sales
Gross Profit
Net Sales
Gross Profit
Net Sales
Gross Profit
$
$
5,217.1
132.4
5,349.5
$
$
2,798.9
132.4
2,931.3
$
$
3,876.0
104.8
3,980.8
$
$
2,315.9
104.8
2,420.7
$
$
3,316.6
91.2
3,407.8
$
$
1,666.0
91.2
1,757.2
The Company sells its products to distributors and original equipment manufacturers (OEMs) in a broad range of market
segments, performs on-going credit evaluations of its customers and, as deemed necessary, may require collateral, primarily
letters of credit. The Company's operations outside the U.S. consist of product assembly and final test facilities in Thailand,
and sales and support centers and design centers in certain foreign countries. Domestic operations are responsible for the
design, development and wafer fabrication of products, as well as the coordination of production planning and shipping to meet
worldwide customer commitments. The Company's Thailand assembly and test facility is reimbursed in relation to value added
with respect to assembly and test operations and other functions performed, and certain foreign sales offices receive
compensation for sales within their territory. Accordingly, for financial statement purposes, it is not meaningful to segregate
sales or operating profits for the assembly and test and foreign sales office operations. Identifiable long-lived assets (consisting
of property, plant and equipment net of accumulated amortization) by geographic area are as follows (in millions):
United States
Thailand
Various other countries
Total long-lived assets
March 31,
2019
2018
$
$
521.1
209.3
266.3
996.7
$
$
393.3
215.5
159.1
767.9
Sales to unaffiliated customers located outside the U.S., primarily in Asia and Europe, aggregated approximately 80% of
consolidated net sales for fiscal 2019 and approximately 85% and 84% of net sales during fiscal 2018 and fiscal 2017,
respectively. Sales to customers in Europe represented approximately 23% of consolidated net sales for fiscal 2019 and
approximately 24% of consolidated net sales for each of fiscal 2018 and fiscal 2017. Sales to customers in Asia represented
approximately 52% of consolidated net sales for fiscal 2019 and approximately 58% of consolidated net sales for each of fiscal
2018 and 2017. Within Asia, sales into China represented approximately 22%, 30% and 32% of consolidated net sales for
fiscal 2019, 2018 and 2017, respectively. Sales into Taiwan represented approximately 13%, 11% and 9% of consolidated net
sales for fiscal 2019, 2018 and 2017, respectively. Sales into any other individual foreign country did not exceed 10% of the
Company's net sales for any of the three years presented.
With the exception of Arrow Electronics, the Company's largest distributor, which made up 10% of net sales, no other
distributor or end customer accounted for more than 10% of net sales in fiscal 2019. In fiscal 2018 and fiscal 2017, no
distributor or end customer accounted for more than 10% of net sales.
F-53
Table of Contents
Note 19. Derivative Instruments
Freestanding Derivative Forward Contracts
The Company has international operations and is thus subject to foreign currency rate fluctuations. Approximately 99% of
the Company's sales are U.S. Dollar denominated. However, a significant amount of the Company's expenses and liabilities are
denominated in foreign currencies and subject to foreign currency rate fluctuations. To help manage the risk of changes in
foreign currency rates, the Company periodically enters into derivative contracts comprised of foreign currency forward
contracts to hedge its asset and liability foreign currency exposure and a portion of its foreign currency operating
expenses. Foreign exchange rate fluctuations after the effects of hedging activity resulted in net gains of $1.7 million, $9.3
million and $1.0 million in fiscal 2019, 2018 and 2017, respectively. As of March 31, 2019 and 2018, the Company had no
foreign currency forward contracts outstanding. The Company recognized an immaterial amount of net losses and gains on
foreign currency forward contracts in the year ended March 31, 2019, compared to net gains of $4.2 million and net losses of
$2.3 million in the years ended March 31, 2018 and 2017, respectively. Gains and losses from changes in the fair value of
these foreign currency forward contracts and foreign currency exchange rate fluctuations are credited or charged to other (loss)
income, net. The Company does not apply hedge accounting to its foreign currency derivative instruments.
Commodity Price Risk
The Company is exposed to fluctuations in prices for energy that it consumes, particularly electricity and natural gas. The
Company also enters into variable-priced contracts for some purchases of electricity and natural gas, on an index basis. The
Company seeks, or may seek, to partially mitigate these exposures through fixed-price contracts. These contracts meet the
characteristics of derivative instruments, but generally qualify for the "normal purchases or normal sales" exception under
authoritative guidance and require no mark-to-market adjustment.
Note 20. Net Income Per Common Share From Continuing Operations
The following table sets forth the computation of basic and diluted net income per common share from continuing operations
(in millions, except per share amounts):
Net income from continuing operations
Basic weighted average common shares outstanding
Dilutive effect of stock options and RSUs
Dilutive effect of 2007 Junior Convertible Debt
Dilutive effect of 2015 Senior Convertible Debt
Dilutive effect of 2017 Senior Convertible Debt
Dilutive effect of 2017 Junior Convertible Debt
Diluted weighted average common shares outstanding
Basic net income per common share from continuing operations
Diluted net income per common share from continuing operations
Year Ended March 31,
2018
2017
2019
$
$
$
355.9
236.2
3.8
—
9.9
—
—
249.9
1.51
1.42
$
$
$
255.4
232.9
4.4
1.3
10.3
—
—
248.9
1.10
1.03
$
$
$
170.6
217.2
4.4
12.7
0.5
—
—
234.8
0.79
0.73
The Company computed basic net income per common share from continuing operations based on the weighted average
number of common shares outstanding during the period. The Company computed diluted net income per common share from
continuing operations based on the weighted average number of common shares outstanding plus potentially dilutive common
shares outstanding during the period.
Potentially dilutive common shares from employee equity incentive plans are determined by applying the treasury stock
method to the assumed exercise of outstanding stock options and the assumed vesting of outstanding RSUs. Weighted average
common shares exclude the effect of option shares which are not dilutive. There were no anti-dilutive option shares for the
years ended March 31, 2019, 2018, and 2017.
Diluted weighted average common shares outstanding for fiscal 2018 and 2017 includes 1.3 million and 12.7 million
shares, respectively, issuable upon the exchange of the Company's 2007 Junior Convertible Debt. The Company's 2007 Junior
Convertible Debt was fully settled as of December 31, 2017 (see Note 12 for details on the settlement of debt), with the
Company issuing an aggregate of 3.7 million shares of its common stock in the settlement of $143.8 million principal amount
F-54
Table of Contents
in fiscal 2018 and an aggregate of 12.0 million shares of its common stock in the settlement of $431.3 million principal amount
in fiscal 2017. The shares that were issued were included in the weighted average dilutive common shares outstanding through
the date of the issuance and were reflected in the weighted average common shares outstanding thereafter. Diluted weighted
average common shares outstanding for fiscal 2019, 2018, and 2017 includes 9.9 million shares, 10.3 million shares, and 0.5
million shares, respectively, issuable upon the exchange of the Company's 2015 Senior Convertible Debt. There were no shares
issuable upon the exchange of the Company's 2017 Junior Convertible Debt or the Company's 2017 Senior Convertible Debt.
The convertible debt has no impact on diluted net income per common share unless the average price of the Company's
common stock exceeds the conversion price because the principal amount of the debentures will be settled in cash upon
conversion. Prior to conversion, the Company will include, in the diluted net income per common share calculation, the effect
of the additional shares that may be issued when the Company's common stock price exceeds the conversion price using the
treasury stock method. The following is the weighted average conversion price per share used in calculating the dilutive effect
(See Note 12 for details on the convertible debt):
2007 Junior Convertible Debt (1)
2015 Senior Convertible Debt
2017 Senior Convertible Debt
2017 Junior Convertible Debt
(1) No longer outstanding as of December 31, 2017.
Note 21. Quarterly Results (Unaudited)
Year Ended March 31,
2019
2018
2017
$
$
$
N/A $
62.86
98.03
96.31
$
$
$
23.59
63.94
99.71
97.96
$
$
$
$
24.01
65.21
100.58
98.81
The following table presents the Company's selected unaudited quarterly operating results for the eight quarters ended
March 31, 2019. The Company believes that all adjustments of a normal recurring nature have been made to present fairly the
related quarterly results (in millions, except per share amounts). Amounts may not add to the total due to rounding:
Fiscal 2019
Net sales
Gross profit
Operating income
Net income from continuing operations
Diluted net income per common share
Fiscal 2018
Net sales
Gross profit
Operating income
Net income from continuing operations
Diluted net income per common share
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
$
$
$
$
$
$
$
$
$
$
1,212.5
642.0
132.3
35.7
0.14
First
Quarter
972.1
584.4
221.6
170.6
0.70
$
$
$
$
$
$
$
$
$
$
1,432.5
689.3
102.7
96.3
0.38
Second
Quarter
1,012.1
614.1
225.4
189.2
0.77
$
$
$
$
$
$
$
$
$
$
1,374.7
779.6
194.7
49.2
0.20
$
$
$
$
$
1,329.8
820.5
284.6
174.7
0.70
Third
Quarter
Fourth
Quarter
$
994.2
$
607.1
245.2
$
(251.1) $
(1.07) $
1,002.3
615.1
244.1
146.7
0.58
Total
5,349.5
2,931.3
714.3
355.9
1.42
Total
3,980.8
2,420.7
936.3
255.4
1.03
$
$
$
$
$
$
$
$
$
$
Refer to Note 11, Income Taxes, for an explanation of the one-time transition tax recognized in the third quarter of fiscal
2018. Refer to Note 4, Special Charges and Other, Net, for an explanation of the special charges included in operating income
in fiscal 2019 and fiscal 2018. Refer to Note 12, Debt and Credit Facility, for an explanation of the loss on settlement of debt
included in other (loss) income, net of $4.1 million during the second quarter, $0.2 million during the third quarter, and $8.3
million during the fourth quarter of fiscal 2019 and $13.8 million and $2.1 million for the first quarter and third quarter of fiscal
2018, respectively. Refer to Note 5, Investments, for an explanation of the impairment recognized on available-for-sale
securities in the fourth quarter of fiscal 2018.
F-55
Table of Contents
Note 22. Supplemental Financial Information
Cash paid for income taxes amounted to $77.6 million, $25.9 million and $48.4 million during fiscal 2019, 2018 and 2017,
respectively. Cash paid for interest on borrowings amounted to $347.9 million, $85.3 million and $82.5 million during fiscal
2019, 2018 and 2017, respectively.
A summary of additions and deductions related to the valuation allowance for deferred tax asset accounts for the years
ended March 31, 2019, 2018 and 2017 follows (amounts in millions):
Balance at
Beginning
of Year
Additions
Charged to
Costs and
Expenses
Additions
Charged to
Other
Accounts
Deductions
Balance at
End of Year
Valuation allowance for deferred tax assets:
Fiscal 2019
Fiscal 2018
Fiscal 2017
$
$
$
204.5
210.1
161.8
$
$
$
16.2
36.2
15.2
$
$
$
175.8
$
— $
37.6
$
(64.4) $
(41.8) $
(4.5) $
332.1
204.5
210.1
A summary of additions and deductions related to the allowance for doubtful accounts for the years ended March 31, 2019,
2018 and 2017 follows (amounts in millions):
Balance at
Beginning
of Year
Additions
Charged to
Costs and
Expenses
Deductions (1)
Balance at
End of Year
Allowance for doubtful accounts:
Fiscal 2019
Fiscal 2018
Fiscal 2017
$
$
$
2.2
2.1
2.5
$
$
$
— $
$
0.2
$
0.2
(0.2) $
(0.1) $
(0.6) $
2.0
2.2
2.1
(1) Deductions represent uncollectible accounts written off, net of recoveries.
Accumulated Other Comprehensive Income
The following tables present the changes in the components of accumulated other comprehensive income (AOCI) for the
years ended March 31, 2019 and 2018:
Unrealized
Holding Gains
(Losses)
Available-for-
sale Securities
Minimum
Pension
Liability
Foreign
Currency
Total
Balance at March 31, 2018
$
1.9
$
(10.1) $
(9.4) $
Impact of change in accounting principle
Opening Balance as of April 1, 2018
Other comprehensive loss before reclassifications
Amounts reclassified from accumulated other
comprehensive income (loss)
Net other comprehensive income (loss)
Balance at March 31, 2019
$
(1.7)
0.2
(5.6)
5.6
—
0.2
—
(10.1)
2.9
1.0
3.9
—
(9.4)
(5.3)
—
(5.3)
$
(6.2) $
(14.7) $
(17.6)
(1.7)
(19.3)
(8.0)
6.6
(1.4)
(20.7)
F-56
Table of Contents
Unrealized
Holding Gains
(Losses)
Available-for-
sale Securities
Minimum
Pension
Liability
Foreign
Currency
Total
Balance at March 31, 2017
Other comprehensive loss before reclassifications
Amounts reclassified from accumulated other
comprehensive income (loss)
Net other comprehensive loss
Balance at March 31, 2018
$
$
0.3
$
(5.3) $
(9.4) $
(13.6)
15.2
1.6
1.9
(5.6)
0.8
(4.8)
—
—
—
$
(10.1) $
(9.4) $
(14.4)
(19.2)
16.0
(3.2)
(17.6)
The table below details where reclassifications of realized transactions out of AOCI are recorded on the consolidated
statements of income (amounts in millions).
Description of AOCI Component
Unrealized losses on available-for-sale
securities
Amortization of actuarial loss
Reclassification of realized transactions, net of
taxes
$
$
Note 23. Dividends
Year ended March 31,
2019
2018
2017
Related Statement
of Income Line
(5.6) $
(15.2) $
(1.5) Other income, net
(1.0)
(0.8)
— Other income, net
(6.6) $
(16.0) $
(1.5) Net Income
On October 28, 2002, the Company announced that its Board of Directors had approved and instituted a quarterly cash
dividend on its common stock. The Company has continued to pay quarterly dividends and has increased the amount of such
dividends on a regular basis. Cash dividends paid per share were $1.457, $1.449 and $1.441 during fiscal 2019, 2018 and
2017, respectively. Total dividend payments amounted to $344.4 million, $337.5 million and $315.4 million during fiscal
2019, 2018 and 2017, respectively.
F-57
EXHIBIT 10.17
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
NOTICE OF GRANT OF RESTRICTED STOCK UNITS
Unless otherwise defined herein, the terms used in this Notice of Grant of Restricted Stock Units (“Grant Notice”)
shall have the same meanings as those defined in the 2004 Equity Incentive Plan (the “Plan”).
Grantee:
%%FIRST_NAME%-% %%LAST_NAME%-%
You have been granted an Award of Restricted Stock Units (“RSUs”) subject to and in accordance with the express
terms and conditions of the Plan and the Restricted Stock Unit Agreement, including the appendix for your country,
if any (“Appendix” and together with the Restricted Stock Unit Agreement, the “Agreement”) attached hereto as
Exhibit A. The Plan and Agreement are incorporated herein in their entirety. Each RSU is equivalent to the right
to receive one share of Common Stock of the Company (“Share”) for purposes of determining the number of Shares
subject to this Award. No Shares will be issued until the vesting conditions of the Award described below are
satisfied and the restrictions lapse, subject to the terms and conditions set forth in the Plan and the Agreement.
This Award does not entitle Grantee to any stockholder rights with respect to the underlying Shares until the vesting
conditions of the Award described below are satisfied, the restrictions lapse and Shares are issued to him/her.
Additional terms of this Award are as follows:
Grant Number:
Grant Date:
Vest Begin Date:
Vesting Period:
%%NUM %-%
%%OPTION_DATE,’Month DD, YYYY’%-%
%%VEST_DATE_PERIOD1,'Month DD, YYYY'%-%;
%VEST_PERIOD%
Purchase Price Per RSU
$0.00 (USD)
Total Number of RSU's Granted: %%TOTAL_SHARES_GRANTED%-%
Vesting Schedule. The RSUs vest and all restrictions lapse according to the following schedule:
%VEST_SCHEDULE%. All vesting is contingent upon the Grantee’s continual status as a Service Provider
measured from the Grant Date through the applicable Vest Date.
Termination Period. This Award automatically terminates and Grantee’s rights are forfeited with respect to any
portion of the RSUs unvested on the date Grantee ceases to be a Service Provider or in the event that Grantee has
not accepted this Grant in accordance with Company procedures 31 days or more prior to its Vest Begin Date. In
no event shall this Award vest later than the Vesting Schedule outlined above.
Binding Agreements. By signature of Company's representative below, and Grantee’s acceptance of this Grant
in accordance with Company procedures, the parties agree that this Grant Notice, the Agreement, and the Plan
constitute Grantee’s entire agreement with respect to this Award and agree to be bound by the terms therein. Grantee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon
any questions relating to the Plan, the Agreement, and/or this Award. This Award may be modified by the Company,
but in accordance with Section 21(c) of the Plan, it may not be modified adversely to Grantee’s interest except by
means of a writing signed by the Company and Grantee. The Company will administer the Plan from the United
States of America. The internal laws of the State of Arizona, United States of America, but not its choice of law
principles, will govern this Award.
GRANTEE
MICROCHIP TECHNOLOGY INCORPORATED
Acceptance: By Electronic Signature
By:
/s/ Steve Sanghi
Steve Sanghi, President and CEO
Exhibit A
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
Grant of Restricted Stock Units. Microchip Technology Incorporated (the “Company”) hereby grants
1.
to the Grantee named in the Notice of Grant of Restricted Stock Units (“Grant Notice”) an Award of Restricted
Stock Units (“RSUs”), as set forth in the Grant Notice and subject to the terms and conditions in this Restricted
Stock Unit Agreement, including any appendix for the Grantee’s country (the “Appendix” and together with
the Restricted Stock Unit Agreement, the “Agreement”) and the Company’s 2004 Equity Incentive Plan (the
“Plan”). Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings
in this Agreement.
Company's Obligation. Each RSU represents the right to receive a Share in accordance with the
2.
Vesting Period in the Grant Notice. Unless and until the RSUs vest, the Grantee will have no right to receive
Shares underlying such RSUs. Prior to actual distribution of Shares pursuant to any vested RSUs, such
RSUs will represent an unsecured obligation of the Company, payable (if at all) only from the general assets
of the Company.
Vesting Schedule. Subject to paragraph 4 of this Agreement, the RSUs awarded by this Agreement
3.
will vest and all restrictions lapse according to the vesting schedule specified in the Grant Notice.
4.
Forfeiture upon Termination as a Service Provider. Notwithstanding any contrary provision of this
Agreement or the Grant Notice, if the Grantee terminates service as a Service Provider for any or no reason
prior to vesting, the unvested RSUs awarded by this Agreement will thereupon be forfeited (as determined
in accordance with paragraph 10(j) below) at no cost to the Company.
5.
Payment after Vesting. Any RSUs that vest in accordance with paragraph 3 of this Agreement will
be paid to the Grantee (or in the event of the Grantee's death, to his or her estate) in Shares (unless otherwise
determined by the Administrator and stated in the Appendix), upon satisfaction, as determined by the
Company, of any Tax-Related Items as set forth in paragraph 9 of this Agreement. The Shares will be issued
to the Grantee as soon as practicable after the Vesting Date, but in any event, within the period ending on
the later to occur of the date that is two and a half (2 ½) months from the end of (i) the Grantee’s tax year
that includes the applicable Vesting Date, or (ii) the Company’s tax year that includes the applicable vesting
date.
Payments after Death. Any distribution or delivery to be made to the Grantee under this Agreement
6.
will, if the Grantee is then deceased, be made to the administrator or executor of the Grantee’s estate. Any
such administrator or executor must furnish the Company with (a) written notice of his or her status as
transferee, and (b) evidence satisfactory to the Company to establish the validity of the transfer and
compliance with any laws or regulations pertaining to said transfer.
7.
Grant is Not Transferable. Except to the limited extent provided in paragraph 6 of this Agreement,
RSUs may not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law
or otherwise) and will not be subject to sale under execution, attachment or similar process. Upon any
attempt to transfer, assign, pledge, hypothecate or otherwise dispose of the RSUs, or any right or privilege
conferred hereby, or upon any attempted sale under any execution, attachment or similar process, the RSUs
grant and the rights and privileges conferred hereby immediately will become null and void.
8.
Rights as Stockholder. Neither the Grantee nor any person claiming under or through the Grantee
will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable
hereunder unless and until the Grantee’s rights with respect to the RSUs have become vested and certificates
representing such Shares have been issued, recorded on the records of the Company or its transfer agents or
registrars, and delivered to the Grantee or Grantee’s broker or the Shares have been electronically transferred
to Grantee’s account.
9.
Tax Obligations. The Grantee acknowledges that regardless of any action taken by the Company
or, if different, the Grantee’s employer (the “Employer”), the ultimate liability for all income tax, social
insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the
Grantee’s participation in the Plan and legally applicable to the Grantee (“Tax-Related Items”), is and remains
the Grantee’s responsibility and may exceed the amount actually withheld by the Company or the Employer.
The Grantee further acknowledges that the Company and/or the Employer (1) make no representations or
undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs,
including, but not limited to, the grant or vesting of the RSUs, the issuance of Shares on the relevant Vesting
Date, the subsequent sale of Shares acquired at vesting of the RSUs, if any, and the receipt of any dividends;
and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the
RSUs to reduce or eliminate the Grantee’s liability for Tax-Related Items or achieve any particular tax result.
Further, if the Grantee becomes subject to Tax-Related Items in more than one jurisdiction between the Grant
Date and the date of any relevant taxable, tax and/or social security contribution withholding event, as
applicable, the Grantee acknowledges that the Company and/or the Employer (or former employer, as
applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable, tax and/or social security contribution withholding event, as applicable,
the Grantee shall pay or make appropriate arrangements satisfactory to the Company and/or the Employer
to satisfy all Tax-Related Items. In this regard, by the Grantee’s acceptance of the RSUs, the Grantee
authorizes and directs the Company and/or the Employer and any brokerage firm determined acceptable by
the Company, at their sole discretion, to satisfy any applicable withholding obligations with respect to Tax-
Related Items by one or a combination of the following: (i) withholding from the Grantee’s wages or other
cash compensation paid to the Grantee by the Company and/or the Employer; or (ii) withholding from
proceeds of the sale of Shares acquired upon vesting of the RSUs, either through a voluntary sale or through
a mandatory sale arrangement by the Company (on the Grantee’s behalf pursuant to this authorization); or
(iii) withholding in Shares to be issued upon vesting of the RSUs; or (iv) by requiring direct payment from
the Grantee in cash (or its equivalent).
Depending on the withholding method, the Company may withhold or account for Tax-Related Items
by considering applicable minimum statutory withholding amounts or other applicable withholding rates,
including maximum applicable rates, in which case the Grantee will receive a refund of any over-withheld
amount in cash and will have no entitlement to the Stock equivalent. If the Grantee’s and/or the Company’s
withholding obligations for Tax-Related Items are satisfied as described in (iii) of this paragraph, the Company
will endeavor to sell only the number of Shares required to satisfy the Grantee’s and/or the Company’s
withholding obligations for Tax-Related Items; however, the Grantee agrees that the Company may sell more
Shares than necessary to satisfy the Tax-Related Items. Further, the Grantee will be deemed to have been
issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of Shares is held
back solely for purposes of paying the Tax-Related Items due as a result of any aspect of the Grantee’s
4
participation in the Plan. The Grantee hereby consents to any action reasonably taken by the Company to
satisfy his or her obligations for Tax-Related Items.
Finally, the Grantee agrees to pay the Company or the Employer any amount of Tax-Related
Items that the Company or the Employer may be required to withhold or account for as a result of the
Grantee’s participation in the Plan that cannot be satisfied by the means previously described. The
Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares at vesting if the
Grantee fails to comply with his or her obligations in connection with the Tax-Related Items.
Nature of Grant. In accepting the RSUs, the Grantee expressly acknowledges, understands and
10.
agrees to the following:
the Plan is established voluntarily by the Company, is discretionary in nature, and may be modified,
(a)
amended, suspended or terminated by the Company at any time;
(b)
the grant of the RSUs is exceptional, voluntary, occasional and does not create any contractual or
other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in
the past;
all decisions with respect to future RSUs or other awards, if any, will be at the sole discretion of the
(c)
Company;
(d)
the Award of RSUs and the Grantee’s participation in the Plan shall not create a right to employment
or be interpreted as forming an employment or service relationship and shall not interfere with the ability
of the Company and/or the Employer to terminate the Grantee’s status as a Service Provider, if any;
(e)
the Grantee is voluntarily participating in the Plan;
the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not
(f)
intended to replace any pension rights or compensation;
the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not part
(g)
of normal or expected salary or compensation for any purposes, including, without limitation, calculating
any severance, resignation, termination, redundancy, dismissal, end-of-service payments, vacation, bonuses,
long-term service awards, indemnification, pension or retirement or welfare benefits, or any other payments,
benefits or rights of any kind, and in no event should be considered as compensation for, or relating in any
way to, past services for the Company, the Employer or any Subsidiary;
the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with
(h)
certainty;
(i)
no claim or entitlement to compensation or damages shall arise from the forfeiture of the RSUs
resulting from termination of the Grantee’s as a Service Provider (for any reason whatsoever, whether or not
later found to be invalid or in breach of employment or other laws in the jurisdiction where the Grantee is
employed or otherwise rendering services, or the terms of the Grantee’s employment or service agreement,
if any), and in consideration of the Award of the RSUs to which the Grantee is otherwise not entitled, the
Grantee agrees not to institute any claim against the Company or the Employer;
(j)
for purposes of the Award of RSUs, the Grantee’s status as a Service Provider will be considered
terminated as of the date the Grantee is no longer providing services to the Company or any Parent or
5
Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in
breach of employment laws in the jurisdiction where the Grantee is employed or rendering services or the
terms of the Grantee’s employment or service agreement, if any), and will not be extended by any notice
period (e.g., the Grantee’s period of service would not include any contractual notice period or any period
of “garden leave” or similar period mandated under employment laws in the jurisdiction where the Grantee
is employed or rendering services or the terms of the Grantee’s employment or service agreement, if any).
The Administrator shall have the exclusive discretion to determine when the Grantee is no longer actively
providing services for purposes of the RSUs (including whether the Grantee may still be considered to be
providing services while on a leave of absence).
(k)
unless otherwise agreed with the Company, the RSUs and the Shares subject to the RSUs, and the
income from and value of same, are not granted in consideration for, or in connection with the service the
Grantee may provide as a director of a Subsidiary or Affiliate of the Company; and
(l)
neither the Company, the Employer nor any Parent or Subsidiary shall be liable for any foreign
exchange rate fluctuation between the Grantee’s local currency and the U.S. Dollar that may affect the value
of the RSUs or any amounts due to the Grantee pursuant to the settlement of the RSUs or the subsequent
sale of Shares acquired upon settlement.
No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor
11.
is the Company making any recommendations regarding the Grantee’s participation in the Plan, or the
Grantee’s acquisition or sale of the underlying Shares. The Grantee understands and agrees that he or she
should advised to consult with his or her own personal tax, legal, and financial advisors regarding his or
her participation in the Plan before taking any action related to the Plan.
12.
Data Privacy. The Grantee hereby explicitly and unambiguously consents to the collection, use
and transfer, in electronic or other form, of his or her personal data as described in this Agreement and
any other grant materials, by and among, as applicable, the Company, the Employer or any other Parent
or Subsidiary for the exclusive purpose of implementing, administering and managing the Grantee’s
participation in the Plan.
The Grantee understands that the Company, Employer and any other Parent, or
(i)
Subsidiary may hold certain personal information about the Grantee, including, but not limited
to, the Grantee’s name, home address, email address and telephone number, date of birth,
Company identification number (used in the Company’s stock database), social insurance number,
passport or other identification number, salary, date of hire and employment status, nationality,
job title, any Shares or directorships held in the Company, details of all purchase rights, stock
options, RSUs or any other entitlement to Company Shares awarded, canceled, exercised, vested,
unvested or outstanding in the Grantee’s favor (“Data”), for the exclusive purpose of
implementing, administering and managing the Plan.
(ii)
The Grantee understands and agrees that Data may be transferred to E*Trade or any
other broker or stock plan service provider that may be designated by the Company and any other
third parties assisting in the implementation, administration and management of the Plan, that
these recipients may be located in the Grantee’s country or elsewhere, including in the United
States, and that that the Grantee’s country may have different data privacy laws and protections
than my country; provided however, that the Grantee’s Data is not transferred in instances where
applicable law expressly prohibits the Grantee from consenting to such transfer, or makes it
unlawful to require the Grantee’s consent to such transfer as a condition of participation. The
6
Grantee undertakes to provide any additional Data as may be required from time to time by
E*Trade or other broker as may be designated by the Company in the future in order for them to
maintain and/or modify the Grantee’s brokerage account or as otherwise may be required to
provide brokerage services to Grantee.
(iii)
The Grantee understands that he or she may request a list with the names and addresses
of any potential recipients of the Data by contacting his or her local human resources
representative. The Grantee authorizes such recipients to receive, possess, use, retain and transfer
the Data, in electronic or other form, for the purposes of implementing, administering and
managing the Grantee’s participation in the Plan, including any requisite transfer of such Data
as may be required to E*Trade or any other broker or other third party with whom the Grantee
may elect to deposit any Shares acquired upon exercise or vesting, as applicable, of purchase
rights, stock options, RSUs or other awards granted to the Grantee by the Company.
(iv)
The Grantee understands that Data will be held only as long as is necessary to implement,
administer and manage the Grantee’s participation in the Plan and that such Data will be protected
against unauthorized or unlawful processing and against accidental loss or destruction. The
Grantee understands that the Grantee may, at any time, view Data, request additional information
about the storage and processing of Data, require any necessary amendments to Data or refuse
or withdraw the consents herein, in any case without cost, by contacting the Microchip Human
Resources Department in Chandler, Arizona, U.S.A. in writing. The Grantee understands,
however, that refusing or withdrawing the Grantee’s consent may affect the Grantee’s ability to
exercise or realize benefits from purchase rights, stock options, restricted stock units or any other
awards the Grantee may receive under the Plan, to satisfy any applicable taxes due in connection
with the Grantee’s participation in the Plan or to otherwise participate in the Plan. The Grantee
further understands that by refusing or withdrawing his or her consent, the Grantee will be unable
to use his or her E*Trade account to view the status of the Grantee’s awards or to use the modeling
features. For more information on the consequences of the Grantee’s refusal to consent or
withdrawal of consent, the Grantee understands that the Grantee may contact his or her local
human resources representative.
Finally, the Grantee acknowledges and agrees that the Company may, in its sole discretion,
(v)
decide to deliver any documents related to any awards granted or Shares acquired under the Plan
or participation in the Plan or future awards that may be awarded under the Plan by electronic
means or request that the Grantee consent to participate in the Plan and agree to the collection,
use and transfer of the Grantee’s Data in connection with the Plan by electronic means, including
through the use of click-through electronic acceptance procedures. The Grantee hereby consents
to receive such documents by electronic delivery and agrees to participate in the Plan through
any on-line or electronic system established and maintained by the Company or another third
party designated by the Company. The Grantee hereby specifically acknowledges and agrees that
his or her acceptance of any documents or agreements provided under the Plan by means of a
click-through acceptance procedure will constitute a valid and legally binding acceptance on the
Grantee’s part of all terms and conditions contained in such documents or agreements.
13.
Language. If the Grantee receives this Agreement or any other document related to the Plan translated
into a language other than English and if the meaning of the translated version differs from the English
version, the English version shall control.
7
Binding Agreement. Subject to the limitation on the transferability of this grant contained herein,
14.
this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives,
successors and assigns of the parties hereto.
Additional Conditions to Issuance of Stock. If at any time the Company will determine, in its
15.
discretion, that the listing, registration or qualification of the Shares upon any securities exchange or under
any state or federal law, or the consent or approval of any governmental regulatory authority is necessary or
desirable as a condition to the issuance of Shares to the Grantee (or his or her estate), such issuance will not
occur unless and until such listing, registration, qualification, consent or approval will have been effected
or obtained free of any conditions not acceptable to the Company. The Company will make all reasonable
efforts to meet the requirements of any such state or federal law or securities exchange and to obtain any
such consent or approval of any such governmental authority.
16.
Administrator Authority. The Administrator has the power to interpret the Plan, the Grant Notice
and this Agreement and to adopt such rules for the administration, interpretation and application thereof as
are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the
determination of whether or not any RSUs have vested). All actions taken and all interpretations and
determinations made by the Administrator in good faith will be final and binding upon Grantee, the Company
and all other interested persons. No member of the Administrator will be personally liable for any action,
determination or interpretation made in good faith with respect to the Plan, the Grant Notice or this Agreement.
17.
Notice Requirement. Where there is a legal requirement for any notice or document to be sent to
any person by any other person, it shall be considered sent if an electronic transmission of the relevant
information is sent in a form previously determined as being acceptable to the Administrator. For the
avoidance of doubt, the Administrator may dispense with the requirement to tender a certificate on the
issuance of Shares under an RSU Award where the Administrator authorizes any system permitting electronic
notification.
18.
Address for Notices. Any notice to be given to the Company under the terms of this Agreement will
be addressed to the Company at 2355 West Chandler Boulevard, Chandler AZ 85224, U.S.A. Attn: Stock
Administration, or at such other address as the Company may hereafter designate in writing or electronically.
19.
Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any
documents related to current or future participation in the Plan by electronic means. The Grantee hereby
consents to receive such documents by electronic delivery and agrees to participate in the Plan through an
online or electronic system established and maintained by the Company or a third party designated by the
Company.
20.
Appendix. Notwithstanding any provisions in this Agreement, the RSUs shall be subject to any
special terms and conditions for the Grantee’s country set forth in the Appendix. Moreover, if the Grantee
relocates to one of the countries included in the Appendix, the special terms and conditions for such country
shall apply to the Grantee, to the extent that the Company determines that the application of such terms and
conditions is necessary or advisable in order to comply with local law or facilitate the administration of the
Plan. The Appendix constitutes part of this Agreement.
21.
Imposition of Other Requirements. The Company reserves the right to impose other requirements
on the Grantee’s participation in the Plan, on the RSUs and on any Shares acquired under this Award, to the
extent that the Company determines it is necessary or advisable to comply with local law or facilitate the
administration of the Plan, and to require the Grantee to sign any additional agreements or undertakings that
may be necessary to accomplish the foregoing.
8
Entire Agreement; Governing Law. The Plan and Grant Notice are incorporated herein by reference.
22.
The Plan, Grant Notice and this Agreement constitute the entire agreement of the parties with respect to the
subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company
and Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee’s
interest except by means of a writing signed by the Company and Grantee. The Company will administer
the Plan from the United States of America. This Agreement, the Grant Notice and all Awards are governed
by the internal substantive laws, but not the choice of law principles, of the State of Arizona, United States
of America.
For purposes of litigating any dispute that arises under this grant or the Agreement, the parties hereby
submit to and consent to the jurisdiction of the State of Arizona and agree that such litigation shall be
conducted in the courts of Maricopa County, Arizona, or the federal courts for the United States for the
District of Arizona, where this grant is made and/or to be performed.
23.
Severability. The provisions of this Agreement are severable, and, if any one or more provisions
are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions
nevertheless shall be binding and enforceable.
24. Waiver. The Grantee acknowledges that a waiver by the Company of breach of any provision of
this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of
any subsequent breach by the Grantee or any other grantee.
25.
Insider Trading/Market Abuse Laws. The Grantee acknowledges that, depending on his or her
country, the Grantee may be subject to insider trading restrictions and/or market abuse laws, which may
affect his or her ability to acquire or sell Shares or rights to Shares (e.g., RSUs) under the Plan during such
times as the Grantee is considered to have “inside information” regarding the Company (as defined by the
laws in the Grantee’s country). Any restrictions under these laws or regulations are separate from and in
addition to any restrictions that may be imposed under the Company’s insider trading policy. The Grantee
acknowledges that it is his or her responsibility to comply with any applicable restrictions, including those
imposed under the Company’s insider trading policy, and the Grantee is advised to consult with his or her
own personal legal and financial advisors on this matter before taking any action related to the Plan.
26.
Foreign Asset / Account Reporting Requirements, Exchange Controls. The Grantee acknowledges
that his or her country may have certain foreign asset and/or account reporting requirements and exchange
controls which may affect his or her ability to acquire or hold Shares under the Plan or cash received from
participating in the Plan (including from any dividends received or sale proceeds arising from the sale of
Shares) in a brokerage or bank account outside his or her country. The Grantee understands that he or she
may be required to report such accounts, assets or transactions to the tax or other authorities in his or her
country. The Grantee also may be required to repatriate sale proceeds or other funds received as a result of
the Grantee’s participation in the Plan to his or her country through a designated bank or broker and/or within
a certain time after receipt. In addition, the Grantee may be subject to tax payment and/or reporting obligations
in connection with any income realized under the Plan and/or from the sale of Shares. The Grantee
acknowledges that it is his or her responsibility to be compliant with all such requirements, and that the
Grantee should consult his or her personal legal and tax advisors, as applicable, to ensure the Grantee’s
compliance.
By the Grantee’s electronic acceptance of the Agreement, the Grantee agrees that this Award is granted under
and governed by the terms and conditions of the Plan, the Grant Notice and this Agreement. The Grantee
has reviewed the Plan, the Grant Notice and this Agreement in their entirety, has had an opportunity to obtain
9
the advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan, the
Grant Notice and this Agreement. The Grantee hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions relating to the Plan, the Grant Notice
and this Agreement.
GRANTEE
MICROCHIP TECHNOLOGY INCORPORATED
Acceptance: By Electronic Agreement
By:
/s/ Steve Sanghi
Steve Sanghi, Chairman and CEO
10
APPENDIX
COUNTRY-SPECIFIC TERMS AND CONDITIONS OF THE
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/
or the Agreement.
This Appendix contains additional terms and conditions that shall be applicable to the RSUs granted to the
Grantee if he or she resides and/or works in one of the countries listed below. If the Grantee is a citizen or
resident (or is considered as such for local law purposes) of a country other than the country in which the
Grantee is currently residing and/or working, or if the Grantee relocated to another country after the RSUs
are granted, the Grantee acknowledges and agrees that the Company will, in its discretion, determine the
extent to which the terms and conditions contained herein will be applicable to the Grantee.
This Appendix may also include information regarding exchange controls and certain other issues of which
the Grantee should be aware with respect to participation in the Plan. The information is based on the
securities, exchange control, and other laws in effect in the respective countries as of July, 2017. Such laws
are often complex and change frequently. As a result, the Company strongly recommends that the Grantee
not rely on the information contained herein as the only source of information relating to the consequences
of his or her participation in the Plan because the information may be out of date at the time the Grantee
vests in the RSUs or sells Shares acquired under the Plan.
In addition, the information contained herein is general in nature and may not apply to the Grantee’s particular
situation, and the Company is not in a position to assure the Grantee of a particular result. Accordingly, the
Grantee is advised to seek appropriate professional advice as to how the relevant laws in his or her country
may apply to the Grantee’s particular situation.
AUSTRALIA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be settled in
Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Australian Offer Document. The Grantee understands that the offering of the Plan in Australia is intended
to qualify for exemption from the prospectus requirements under Australian Securities & Investments
Commission ("ASIC") Class Order 14/1000 and relevant provisions of the Corporations Act 2001. Additional
details are set forth in the Offer Document for the Offer of RSUs to Australian Resident Employees.
Exchange Control Information. Exchange control reporting is required for cash transactions exceeding
AUD 10,000 and for international fund transfers. If an Australian bank is assisting with the transaction, the
bank will file the report on behalf of the Grantee.
Tax Information. The Plan is a plan to which subdivision 83A-C of the Income Tax Assessment Act
1997 (Cth) applies (subject to conditions in the Act).
AUSTRIA
Exchange Control Notification. If the Grantee holds Shares or cash (including proceeds from the sale of
Shares) obtained through the Plan outside of Austria, the Grantee may be required to submit reports to the
Austrian National Bank. An exemption applies if the value of the Shares on any given quarter does not
exceed €30,000,000 or if the value of the Shares in any given year as of December 31 does not exceed
€5,000,000.
If the former threshold is exceeded, quarterly obligations are imposed, whereas if the latter
threshold is exceeded, annual reports must be given. The deadline for filing the annual report is January 31
of the following year and the deadline for the quarterly report is the 15th of the month following the end of
the respective quarter.
A separate reporting requirement applies when the Grantee sells Shares acquired under the Plan or receives
a dividend. In that case, there may be exchange control obligations if the cash proceeds are held outside of
Austria. If the transaction volume of all accounts abroad exceed €10,000,000, the movement and balances
of all accounts must be reported monthly, on a prescribed form (Meldungen SI-Forderungen und/oder SI-
Verpflichtungen).
BELGIUM
Foreign Asset/Account Information Reporting. If the Grantee is a Belgian resident, the Grantee is required
to report any security (e.g., Shares acquired under the Plan) or bank account (including any brokerage account
held by you at E*Trade Financial or other stock plan service provider as may be selected by the Company
in the future) held outside Belgium on Grantee's annual income tax return. In a separate report, the Grantee
must provide the National Bank of Belgium with certain details regarding such foreign accounts (including
the account number, bank name and country in which such account was opened). The forms to complete
this report are available on the National Bank of Belgium website. Belgian residents should consult with
their personal tax advisors to determine their reporting obligations.
Stock Exchange Tax. From January 1, 2017, a stock exchange tax applies to transactions executed by a
Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker. The stock exchange
tax will likely apply when the Shares are sold. The Grantee should consult with his personal tax advisor for
additional details on his or her obligations with respect to the stock exchange tax.
Agreement for the Grantees in Belgium. Under Belgian tax law, if the Shares acquired at vesting of RSUs
cannot be sold for two years from the Vesting Date, the fair market value of the Shares on the Vesting Date
is deemed to be 100/120 (83 1/3%) of the actual fair market value of such shares for purposes of calculating
the taxable amount. If the Grantee would like to take advantage of this favourable tax treatment, the
Grantee must print, sign and return a copy of the Agreement Regarding a Two Year Lock Up Period
for Shares Acquired Upon Vesting of Restricted Stock Units attached as Exhibit A to this Agreement
by the deadline specified therein.
CANADA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be settled in
Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Termination of Employment. The following supplements replaces paragraph 10(j) of the Agreement:
Notwithstanding anything in the Plan or the Agreement to the contrary, for purposes of the RSUs, the
Grantee’s status as a Service Provider will be considered terminated (regardless of the reason for such
12
termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction
where the Grantee is employed or rendering services or the terms of the Grantee’s employment or service
agreement, if any), as of the date that is the earliest of (i) the date of termination as a Service Provider, (ii)
the date on which the Grantee receives a notice of termination of employment, and (iii) the date on which
the Grantee is no longer actively providing services to the Company or the Parent or Subsidiary, and shall
not include or be extended by any period following such day during which the Grantee is in receipt of or
eligible to receive any notice of termination, pay in lieu of notice of termination, severance pay or other
payments or damages, where arising under statute, contract, or at common law. The Administrator shall
have the exclusive discretion to determine when the Grantee is no longer actively providing services for
purposes of the RSUs (including whether the Grantee may still be considered to be providing services while
on a leave of absence).
Securities Law Information. The Grantee is permitted to sell Shares acquired through the Plan through
the designated broker appointed under the Plan, if any, provided that the resale of such Shares takes place
outside of Canada through the facilities of a stock exchange on which the Shares are listed (i.e., the NASDAQ
Global Select Market).
Foreign Asset / Account Reporting. Any foreign property (including Shares and RSUs acquired under the
Plan) must be reported to the Canada Revenue Agency on form T1135 (Foreign Income Verification
Statement) if the total cost of the Grantee’s foreign property exceeds C$100,000 at any time in the year.
Thus, if the C$100,000 cost threshold is exceeded by other foreign property held by the Grantee, the RSUs
must be reported (generally at nil cost). For purposes of such reporting, Shares acquired under the Plan may
be reported at their adjusted cost base (“ACB”). The ACB would normally equal the fair market value of
the Shares at time of vesting, but if the Grantee owns other Shares, this ACB may have to be averaged with
the ACB of the other Shares.
The following terms and conditions apply if the Grantee is in Quebec:
Authorization to Release and Transfer Necessary Personal Information. The following provision
supplements paragraph 12 of the Agreement:
The Grantee hereby authorizes the Company (including any Parent, Subsidiary or Affiliate) and the
Company’s representatives to discuss with and obtain all relevant information from all personnel, professional
or not, involved in the administration and operation of the Plan. The Grantee further authorizes the Company,
any Parent, Subsidiary or Affiliate and the administrator of the Plan to disclose and discuss the Plan with
their advisors. The Grantee further authorizes the Company, any Parent, Subsidiary or Affiliate to record
and keep such information in the Grantee’s employment file.
English Language Provision. The following provision supplements paragraph 13 of the Agreement:
The parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices
and legal proceedings entered into, given or instituted pursuant hereto or relating directly or directly hereto,
be drawn up in English.
Les parties reconnaissent avoir exigé la rédaction en anglais de cette convention, ainsi que de tous documents,
avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement
à, la présente convention.
13
CHINA
Deposit of Shares and Distribution of Dividends. Due to exchange control laws and regulations in the
People’s Republic of China (“PRC”), if the Grantee is a PRC national, any Shares acquired at vesting of the
RSUs will be deposited in an account established for Grantee by the Company (the “Account”) with E*Trade
Financial or any successor broker designated by Company, in its sole discretion (the “Designated Broker”).
Grantee must maintain the Shares issued to Grantee under the Plan in the Account and must not transfer the
Shares to any person, broker or other account with the Designated Broker or to a brokerage account outside
of the Designated Broker.
Any dividends related to Shares acquired under the Plan may, at the Company’s sole discretion, be deposited
into an Account with the Designated Broker, or re-invested by Company on behalf of the Grantee.
Until such time as the Shares acquired at vesting of the RSUs are sold, the Grantee must maintain the Shares
issued to Grantee under the Plan in the Account and must not transfer the Shares to another account with the
Designated Broker or to a brokerage account outside of the Designated Broker. Due to local regulatory
requirements, you agree that the Company may force the sale of the Shares within any time frame as the
Company determines to be necessary or advisable for legal or administrative reasons.
Forfeiture and Sale upon Termination as a Service Provider. The following provision replaces paragraph
4 of the Agreement:
(a)
Notwithstanding any contrary provision of this Agreement or the Grant Notice, if the Grantee
terminates service as a Service Provider for any or no reason prior to vesting, the unvested RSUs awarded
by this Agreement will thereupon be forfeited at no cost to the Company.
(b)
The Grantee must sell all Shares acquired under the Plan on or before the date of termination as a
Service Provider. Grantee hereby authorizes Company or the Designated Broker to sell such Shares on
behalf of the Grantee without notice to or consent from the Grantee if Grantee has not sold all Shares so
acquired as of the date of termination of service. The sale of Shares shall be carried out within a reasonable
time of termination of service as determined by Company. The proceeds from such sale, net any Tax-Related
Items and broker’s fees, shall be deposited in the Grantee’s bank account in China, or delivered to the Grantee
in China through such other means determined by Company, in its discretion. The Grantee hereby releases
and holds harmless Company and any Parent or Subsidiary, employees and agents (“Indemnitees”) from any
loss that the Grantee may incur due to the timing of the sale of Shares by Company and acknowledges that
the Company and the Employer are under no obligation to arrange for the sale of the Shares at any particular
price and are not liable for any fluctuations in the trading price of the Shares and/or the U.S. dollar exchange
rate.
If the Grantee does transfer Shares into an account to which Company has no visibility, then the
(c)
Grantee will sell all Shares no later than the date of termination as a Service Provider and provide written
evidence of such sale of Shares to Company within two (2) business days of the date of termination as a
Service Provider. Such evidence must be in a form acceptable to Company.
(d)
The Grantee shall defend, hold harmless and indemnify Indemnitees from any and all penalties,
damages, and costs that may be incurred by Indemnitees arising out of or in connection with the Grantee’s
failure to comply with these obligations and any requirements under local exchange control laws applicable
to him/her.
14
Exchange Control Restriction. The Grantee understands and agrees that, if he or she is a PRC national,
due to exchange control laws and regulations in the PRC, the Grantee will be required to repatriate
immediately to the PRC any cash proceeds from the sale of the Shares acquired under the Plan. The Grantee
understands further that, under applicable laws and regulations, such repatriation may need to be effected
through a special foreign exchange account established by the Company, or a Chinese Parent, Subsidiary or
Affiliate,, and the Grantee consents and agrees that the proceeds from the sale of the Shares may be transferred
to such special account before being delivered to the Grantee. Moreover, if the proceeds from the sale of
the Shares are converted to local currency, the Grantee acknowledges that the Company (including its Parent
and Subsidiary corporations) is under no obligation to secure any particular currency conversion rate and
may face delays in converting the proceeds to local currency due to exchange control restrictions in the PRC.
The Grantee agrees to bear the risk of any fluctuation in the U.S. dollar/local currency exchange rate between
the date the Grantee realizes U.S. dollar proceeds from his or her participation in the Plan and the date that
the Grantee receives cash proceeds converted to local currency. The Grantee also agrees to comply with
any other requirements that may be imposed by the Company in the future to facilitate compliance with
exchange control requirements in the PRC.
Foreign Asset/Account Reporting Information. The Grantee may be required to report to SAFE all details
of your foreign financial assets and liabilities, as well as details of any economic transactions conducted
with non-PRC residents.
DENMARK
Nature of Grant. The following provision supplements paragraph 10 of the Agreement:
In accepting the RSUs, the Grantee acknowledges that he or she understands and agrees that this grant relates
to future services to be performed and is not a bonus or compensation for past service.
Notifications
Exchange Control Information. If the Grantee establishes accounts holding Shares or cash outside
Denmark, the Grantee must report the account to the Danish Tax Administration. The form which should
be used in this respect can be obtained from a local bank. (Please note that these obligations are separate
from and in addition to the obligations described below.)
Securities/Tax Reporting Information. If the Grantee holds Shares acquired under the Plan in a brokerage
account with a broker or bank outside Denmark, the Grantee is required to inform the Danish Tax
Administration about the account. For this purpose, the Grantee must file a Form V (Erklaering V) with the
Danish Tax Administration. The Form V must be signed both by the Grantee and by the applicable broker
or bank where the account is held. By signing the Form V, the broker or bank undertakes to forward
information to the Danish Tax Administration concerning the Shares in the account without further request
each year. By signing the Form V, the Grantee authorizes the Danish Tax Administration to examine the
account. A sample of the Form V can be found at the following website: www.skat.dk/SKAT.aspx?
oId=90030&vId=0.
In addition, if the Grantee opens a brokerage account (or a deposit account with a U.S. bank) for the purpose
of holding cash outside Denmark, the Grantee is also required to inform the Danish Tax Administration about
this account. To do so, the Grantee must also file a Form K (Erklaering K) with the Danish Tax Administration.
The Form K must be signed both by the Grantee and by the applicable broker or bank where the account is
held. By signing the Form K, the broker/bank undertakes an obligation, without further request each year,
to forward information to the Danish Tax Administration concerning the content of the account. By signing
15
the Form K, Grantee authorizes the Danish Tax Administration to examine the account. A sample of Form
K can be found at the following website: www.skat.dk/SKAT.aspx?oId=73346&vId=0.
There are no country-specific provisions.
FINLAND
FRANCE
Consent to Receive Information in English. By accepting this Agreement providing for the terms and
conditions of the RSUs, the Grantee confirms that he/she has read and understood the documents relating
to this Award (i.e., the U.S. Plan and this Agreement), which were provided in English. The Grantee accepts
the terms of those documents accordingly.
En acceptant de manière électronique le présent Contrat d’Attribution décrivant les termes et conditions de
votre attribution d’Actions Gratuites, vous confirmez ainsi avoir lu et compris les documents relatifs à cette
attribution (c’est-à-dire, le Plan Américain et le présent Contrat d’Attribution) qui vous ont été communiqués
en langue anglaise. Vous en acceptez les termes en connaissance de cause.
Foreign Asset/Account Reporting Information. The Grantee may hold Shares acquired under the Plan
outside of France, provided that the Grantee declares all foreign accounts, whether open, current or closed,
on his or her annual income tax return. Failure to comply could trigger significant penalties.
Tax Information. The RSUs are not intended to qualify for the special tax and social security treatment in
France under Section L. 225-177 to L. 225-186-1.
GERMANY
Exchange Control Notification. Cross-border payments in excess of €12,500 must be reported monthly
to the German Federal Bank. In the event that Grantee makes or receives a payment in excess of this amount,
the Grantee must report the payment to Bundesbank electronically using the “General Statistics Reporting
Portal” (“Allgemeines Meldeportal Statistik”) available via Bundesbank’s website (www.bundesbank.de).
HONG KONG
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be settled in
Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Sale of Shares. In the event that the RSUs vest within six months of the Grant Date, the Grantee agrees
that he or she will not sell any Shares thus acquired prior to the six-month anniversary of the Grant Date.
Securities Law Warning. WARNING: The offer of the RSUs and the Shares subject to the RSUs do not
constitute a public offering of securities under Hong Kong law and are available only to Employees of the
Company or its Subsidiaries participating in the Plan. The Grantee should be aware that the contents of this
Agreement (including this Appendix), the Plan and any other RSU grant materials that the Grantee may
receive have not been prepared in accordance with and are not intended to constitute a “prospectus” for a
public offering of securities under the applicable securities legislation in Hong Kong. Nor have the documents
been reviewed by any regulatory authority in Hong Kong. The RSUs are intended only for the personal use
of each Grantee and may not be distributed to any other person. The Grantee is advised to exercise caution
in relation to this offer. If the Grantee is in doubt about any of the contents of this Agreement (including
16
this Appendix) or the Plan or any other RSU grant materials, the Grantee should obtain independent
professional advice.
There are no country-specific provisions.
HUNGARY
INDIA
Exchange Control Documentation. Due to Indian exchange control restrictions, Indian residents are
required to repatriate the proceeds from the sale of Shares to India within 90 days of receipt and proceeds
from any dividends within 180 days of receipt. The Grantee should receive a foreign inward remittance
certificate (“FIRC”) from the bank where the foreign currency is deposited. The Grantee should retain the
FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India, the Employer or
the Company requests proof of repatriation. It is the Grantee’s responsibility to comply with applicable
exchange control laws in India.
Foreign Asset / Account Reporting Notification. The Grantee is required to declare any foreign bank
accounts and any foreign financial assets (including Shares held outside India) in the Grantee’s annual tax
return. It is the Grantee's responsibility to comply with applicable tax laws in India.
IRELAND
Director Notification Requirement. Directors, shadow directors and secretaries of the Company’s Irish
Parent or Subsidiary corporation whose interest in the Company represents more than 1% of the Company’s
voting share capital are subject to certain notification requirements under the Irish Companies Act. Directors,
shadow directors and secretaries must notify the Irish Parent or Subsidiary corporation in writing of their
interest in the Company (e.g., RSUs, Shares, etc.) and the number and class of Shares or rights to which the
interest relates within five days of the acquisition or disposal of Shares or within five days of becoming
aware of the event giving rise to the notification. This notification requirement also applies with respect to
the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director,
shadow director or secretary).
ISRAEL
Trustee Arrangement. The Grantee understands and agrees that the RSUs offered are subject to and in
accordance with the terms of the Plan, Israeli Subplan (the “Subplan”), Agreement and the Israel Beneficiary
102 Undertaking. The Grantee understands that the RSUs shall be allocated under the provisions of the track
referred to as the “Capital Gain Route,” according to Section 102(b)(2) and 102(b)(3) of the Israeli Income
Tax Ordinance (“Section 102”) and shall be held by the trustee for the periods stated in Section 102. The
Grantee hereby confirms that he or she has: (i) read and understands the Plan, Subplan, Agreement and Israel
Beneficiary 102 Undertaking; (ii) received all the clarifications and explanations that the Grantee has
requested; and (iii) had the opportunity to consult with his or her advisers before accepting the Agreement.
In the event of any inconsistencies between the provisions of this Israeli Appendix and the Agreement, the
provisions of this Appendix shall govern the RSUs and any Shares and in no event shall any term require
shareholder approval as set out in Section 21(b) of the Plan.
17
Limited Transferability. This provision supplements Section 7 of the Agreement:
Subject to the provisions of the Plan, Section 102 and any rules or regulations or orders or procedures
promulgated thereunder, to obtain favourable tax treatment for Capital Gain Route awards, the Grantee may
not sell or transfer any RSU shares received upon vesting or received subsequently following any realization
of rights until the lapse of the holding period required is met under Section 102. Notwithstanding the above,
if any such sale or release occurs during the holding period, the sanctions under Section 102 and under any
rules or regulation or orders or procedures promulgated thereunder will apply to and will be borne by the
Grantee.
Issuance of Shares. This provision supplements paragraphs 5 and 8 of the Agreement:
If the vested RSUs are issued during the holding period, such Shares shall be restricted and held by E*Trade
Financial or any successor broker and/or trustee designated by Company and the Trustee on the Grantee’s
behalf. In the event that the vested RSUs are issued after the expiration of the holding period, the Grantee
may freely sell the shares held by E*Trade Financial, provided that the Grantee first complies with any Tax-
Related Items stipulated under this Agreement to the Trustee’s and the Company’s satisfaction, or in trust
on the Grantee’s behalf to the Trustee.
Tax Obligations. This provision supplements paragraph 9 of the Agreement:
The Grantee hereby agrees to indemnify the Company (or any Subsidiary) and/or the Trustee and hold them
harmless against and from any and all liability for any Tax-Related Items and other amounts, or interest or
penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have
withheld, any such amounts from any payment made to the Grantee. Any reference to the Company or the
Employer shall include a reference to the Trustee. The Grantee hereby undertakes to release the Trustee
from any liability in respect of any action or decisions duly taken and bona fide executed in relation to the
Plan or any RSUs or Shares acquired under the Plan. The Grantee agrees to execute any and all documents
which the Company or the Trustee may reasonably determine to be necessary in order to comply with the
Israeli Income Tax Ordinance.
The Grantee shall not be liable for the Employer’s components of payments to the national insurance institute,
unless otherwise agreed by the Grantee and allowed by applicable tax laws. Furthermore, the Grantee agrees
to indemnify the Company, the Employer and/or the Trustee and hold them harmless against and from any
and all liability for any such tax or interest or penalty thereon that Grantee has agreed to pay, including
without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from
any payment made to the Grantee for which the Grantee is responsible.
Notwithstanding anything to the contrary in the Agreement, no Tax-Related Items will be settled by
withholding Shares, unless the ITA approves otherwise in writing.
Governing Law. This section supplements paragraph 22 of the Agreement:
To the extent any covenant, condition, or other provision of the Agreement and the rights of the Grantee
hereunder are intended to be rights granted under Section 102 and therefore determined to be subject to
Israeli law, such covenant, condition, or other provision of the Agreement shall be subject to applicable
Israeli law, but shall in no way affect, impair, or invalidate any other provision of the Agreement, and the
applicability of the Plan to such covenant, condition, or other provision of the Agreement.
18
Written Acceptance. The Grantee must print, sign and deliver the signed copy of the Israel Beneficiary
102 Undertaking within 45 days of the new hire grant date to: Microchip Technology Israel Ltd., Zarchin
10, Raanana, P.O Box 4319, 43662. If the Company does not receive the signed Israel Beneficiary 102
Undertaking within 45 days, the RSUs may not qualify for preferential tax treatment.
Securities Law Information. The grant or RSUs does not constitute a public offering under the Securities
Law, 1968.
19
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
ISRAEL BENEFICIARY 102 UNDERTAKING
If the Grantee has not already executed an Israel Beneficiary 102 Undertaking in connection with
grants made under the Israeli Subplan, the Grantee must print, sign and deliver the signed copy of
this Israel Beneficiary 102 Undertaking within 45 days of the new hire grant date to: Microchip
Technology Israel Ltd., Zarchin 10, Raanana, P.O Box 4319, 43662. If the Company does not
receive the signed Israel Beneficiary 102 Undertaking within 45 days, the RSUs may not qualify for
preferential tax treatment.
1.
2.
3.
4.
5.
6.
I hereby agree that any shares (the “Shares”) (as defined by Section 102 of the
Income Tax Ordinance [New Version], 1961) (the “Tax Ordinance”) issued to me
by Microchip Technology Incorporated according to and under the terms and
conditions of the Plan and the Israeli Subplan adopted by Microchip Technology
Incorporated as of 13 December 2013 (collectively, the "Plan") are granted to me
to qualify under the capital gain tax treatment in accordance and pursuant to Section
102(b)(2) of the Tax Ordinance after 132 amendment (“Section 102”) and the
Income Tax Rules (Tax Relief upon the Allotment of Shares to Employees), 2003
(the “Rules”) unless I am otherwise notified subject to Microchip Technology
Incorporated’s absolute discretion to change such election on future grants and
subject to the Tax Authorities’ approval.
I declare and confirm that I am familiar with the terms of Section 102, the Rules,
and the implications and consequences of the chosen tax arrangement with respect
to the Shares, and consent that all the terms and conditions set forth in Section 102
and the Rules, as shall be amended from time to time, shall apply to me and bind
me.
I hereby declare and confirm that I am familiar with the provisions of the trust
agreement signed between Microchip Technology Israel Ltd. and Tamir Fishman
Trusts 2004 Ltd. (the "Trustee") (the “Trust Agreement”), including the deed of
trust, attached to the Trust Agreement and constitute an integral part thereto (“Deed
of Trust”), and I consent that the Trust Agreement and the Deed of Trust shall fully
bind me.
Without derogating from the generality of the aforesaid, I agree that the Shares will
be deposited in trust with the Trustee and be held in trust in accordance with Section
102, the Rules and the Trust Agreement.
I hereby declare and consent that any and all the rights that I shall be entitled to
with respect to the Shares, including, without limitation, dividend and shares issued
pursuant to adjustments made by Microchip Technology Incorporated and shall be
subject to Section 102, the Rules and the Trust Agreement.
Without derogating from the generality of the aforesaid, I acknowledge that during
the “Holding Period” as determined by the Tax Ordinance I am prevented from
selling the Shares, or releasing them from the Trustee, before the termination of the
20
“Holding Period” and I understand the tax implications and consequences that may
be applied as a result of breaching such obligation, as set by Section 102, which I
am familiar with.
If I will cease to be an Israeli resident or if my employment will be terminated for
any reason, the Shares shall remain subject to Section 102, the Rules and the Trust
Agreement.
I hereby agree that any tax liability whatsoever arising from the grant, vesting of
any restricted stock units, the sale of Shares, the release of Shares from the Trustee
or any other event or act with respect to the Shares granted to me, shall be borne
solely by me. I declare and consent that the Microchip Technology Incorporated,
Microchip Technology Israel Ltd. and/or the Trustee shall make any tax payment
due, out of the proceeds of any sale of Shares, to any tax authority, according to
Section 102, the Rules, the Trust Agreement or any other compulsory payments or
applicable law.
I understand that this grant of Shares under the capital gain track is conditioned
upon the receipt, inter alia, of all required approvals from the tax authorities.
Accordingly, to the extent that for whatever reason Microchip Technology Israel
Ltd. shall not be granted an approval by the Israeli Tax Authorities under Section
102, I shall bear and pay any and all taxes and any other compulsory payments
applicable to the grant, exercise, sale or other disposition of stocks; I hereby declare
and consent for the Microchip Technology Incorporated, Microchip Technology
Israel Ltd. and/or the Trustee to deduct any tax payment due, out of the proceeds
of any sale of Shares, for any payment to the tax authorities, according to the Rules,
or any other applicable compulsory payments.
I confirm that Microchip Technology Incorporated and/or the Trustee shall not be
required to release any proceeds deriving from the sale of Shares, to me, until all
required tax payments according to Section 102, the Rules and the Trust Agreement,
including any other compulsory payments, or applicable law, have been fully
assured.
I acknowledge that the Trustee is not a tax advisor and it is recommended that I
consult a tax advisor before I accept this letter, any restricted stock units vest, sell
any Shares or release them from the Trustee, or any other act.
I agree to indemnify Microchip Technology Incorporated, Microchip Technology
Israel Ltd. and/or the Trustee and to hold them harmless against and from any and
all liability for any damage and/or loss and/or expense that might occur regarding
the tax liability and/or the execution of the Trust Agreement.
I hereby agree to bear all the applicable fees and commissions involved in
establishing and maintaining trust account in the Trustee’s name, and in performing
any action in the trust account.
I hereby agree to sign any document reasonably required at the company’s and/or
the Trustee’s request.
21
7.
8.
9.
10.
11.
12.
13.
14.
15.
I hereby confirm that I read this letter thoroughly, received all the clarifications and
explanations I requested, I understand the contents of this letter and the obligations
I undertake in signing it.
Name of the Beneficiary
I.D. Number
Signature
22
ITALY
Data Privacy Notice. The following provision replaces paragraph 12 of the Agreement:
The Grantee understands that the Employer, the Company and any Parent and/or Subsidiary may hold
certain personal information about Grantee, including, without limitation, Grantee’s name, home address
and telephone number, date of birth, social insurance number or other identification number, salary,
nationality, job title, any directorships held in the Employer, the Company and any Parent and/or
Subsidiary, any Shares owned, details of all RSUs, or any other entitlement to Shares awarded, canceled,
exercised, vested, unvested or outstanding in the Grantee’s favor, for the exclusive purpose of
implementing, managing, and administering the Plan (“Data”).
The Grantee also understands that providing the Company with Data is necessary for the performance
of the Plan and that the Grantee’s refusal to provide such Data would make it impossible for the Company
to perform its contractual obligations and may affect the Grantee’s ability to participate in the Plan. The
Controller of personal data processing is Microchip Technology Incorporated at 2355 West Chandler
Boulevard, Chandler, AZ 85224, U.S.A., and, pursuant to Legislative Decree no. 196/2003, its
representative in Italy is Microchip Technology SRL with registered offices at Via Pablo Picasso 41, 20025
Legnano (MI) Italy.
The Grantee understands that Data will not be publicized, but it may be transferred to E*Trade Financial
(or one of its affiliates) or such other stock plan service provider as may be selected by the Company in
the future (any such entity, “Broker”), or other third parties involved in the management and
administration of the Plan. The Grantee understands that Data may also be transferred to the independent
registered public accounting firm engaged by the Company. The Grantee further understands that the
Company and/or any Parent and/or Subsidiary will transfer Data among themselves as necessary for the
purpose of implementing, administering, and managing the Grantee’s participation in the Plan, and that
the Company or a Subsidiary may each further transfer Data to third parties assisting the Company in
the implementation, administration, and management of the Plan, including any requisite transfer of
Data to the Broker or other third party with whom the Grantee may elect to deposit any Shares acquired
at vesting of the RSUs. Such recipients may receive, possess, use, retain, and transfer Data in electronic
or other form, for the purposes of implementing, administering, and managing the Grantee’s participation
in the Plan. The Grantee understands that these recipients may be located in or outside the European
Economic Area, such as in the United States or elsewhere. Should the Company exercise its discretion
in suspending all necessary legal obligations connected with the management and administration of the
Plan, it will delete Data as soon as it has completed all the necessary legal obligations connected with the
management and administration of the Plan.
The Grantee understands that Data processing related to the purposes specified above shall take place
under automated or non-automated conditions, anonymously when possible, that comply with the purposes
for which Data is collected and with confidentiality and security provisions, as set forth by applicable laws
and regulations, with specific reference to Legislative Decree no. 196/2003.
The processing activity, including communication, the transfer of Data abroad, including outside of the
European Economic Area, as herein specified and pursuant to applicable laws and regulations, does not
require the Grantee’s consent thereto, as the processing is necessary to performance of contractual
obligations related to implementation, administration, and management of the Plan. The Grantee
23
understands that, pursuant to paragraph 7 of the Legislative Decree no. 196/2003, the Grantee has the
right to, without limitation, access, delete, update, correct, or terminate, for legitimate reason, the Data
processing.
Furthermore, the Grantee is aware that Data will not be used for direct-marketing purposes. In addition,
Data provided can be reviewed and questions or complaints can be addressed by contacting the Grantee’s
local human resources representative.
Grant Terms Acknowledgment. By accepting the RSUs, the Grantee acknowledges having received and
reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understands and
accepts all provisions of the Plan and the Agreement, including this Appendix.
The Grantee further acknowledges having read and specifically approves the following paragraphs of the
Agreement: paragraph 9 (“Tax Obligations”), paragraph 10 (“Nature of Grant”), paragraph 13 (“Language”),
paragraph 22 (“Entire Agreement; Governing Law”), and the “Data Privacy Notice” provision set forth above
in this Appendix.
Foreign Asset / Account Reporting. Italian residents who, at any time during the fiscal year, hold foreign
financial assets (e.g., cash, Shares, etc.) which may generate income taxable in Italy are required to report
such investments or assets on their annual tax returns (Form UNICO, Schedule RW) or on a special form if
no tax return is due. The same reporting duties apply to Italian residents who are beneficial owners of the
foreign financial assets pursuant to Italian money laundering provisions, even if they do not directly hold
the foreign asset abroad.
Foreign Asset Tax Information. The value of financial assets held outside of Italy by individuals resident
of Italy is subject to a foreign asset tax, at an annual rate of 2 per thousand (0.2%). The taxable amount will
be the fair market value of the financial assets (including Shares) assessed at the end of the calendar year.
No tax payment duties arise of the amount of the foreign financial assets tax calculated on all financial assets
held abroad does not exceed €12.
24
JAPAN
Foreign Asset / Account Reporting Notification. Details of any assets held outside Japan (including Shares
acquired under the Plan) as of December 31 of each year must be reported to the tax authorities on an annual
basis, to the extent such assets have a total net fair market value exceeding ¥50 million. Such report is due
by March 15 each year. The Grantee should consult with his or her personal tax advisor as to whether the
reporting obligation applies to Grantee and whether the Grantee will be required to report details of any
outstanding RSUs or Shares held by Grantee in the report.
KOREA
Exchange Control Notification. Korean residents who realize US$500,000 or more from the sale of Shares
or the receipt of any dividends in a single transaction are required to repatriate the proceeds to Korea if the
grants were made prior to July 18, 2017. The Grantee should consult with his or her personal tax advisor
to ensure compliance with the repatriation requirements, if applicable.
Foreign Asset / Account Reporting Notification. Korean residents must declare all foreign financial
accounts (e.g., non-Korean bank accounts, brokerage accounts holding Shares) in countries that have not
entered into an "intergovernmental agreement for automatic exchange of tax information" with Korea to the
Korean tax authority and file a report with respect to such accounts if the value of such accounts exceeds
KRW 1 billion (or an equivalent amount in foreign currency). The Grantee should consult his or her personal
tax advisor regarding reporting requirements in Korea, including whether or not there is an applicable inter-
governmental agreement between Korea and any other country where the Grantee may hold any Shares or
cash acquired in connection with the Plan.
Data Privacy Acknowledgement. This provision replaces in its entirety paragraph 12 of the Agreement:
MALAYSIA
The Grantee hereby explicitly, voluntarily and
unambiguously consents to the collection, use and
transfer, in electronic or other form, of his or her
personal data as described in this Agreement and any
other Plan participation materials by and among, as
applicable, the employer, the Company and any Parent
or affiliate corporation or any third parties authorized
by same in assisting in the implementation,
administration and management of the Grantee’s
participation in the Plan.
Penerima Anugerah dengan ini secara eksplicit,
secara sukarela dan tanpa sebarang keraguan
mengizinkan pengumpulan, penggunaan dan
pemindahan, dalam bentuk elektronik atau lain-lain,
data peribadinya seperti yang dinyatakan dalam
Perjanjian ini dan apa-apa bahan penyertaan Pelan
oleh dan di antara, sebagaimana yang berkenaan,
Majikan, Syarikat dan Syarikat Sekutu atau mana-
mana pihak ketiga yang diberi kuasa oleh yang sama
untuk membantu dalam pelaksanaan, pentadbiran
dan pengurusan penyertaan Penerima Anugerah
dalam Pelan tersebut.
25
The Grantee may have previously provided the
Company and the employer with, and the Company and
the employer may hold, certain personal information
about the Grantee, including, but not limited to, his or
her name, home address and telephone number, date of
birth, social insurance number or other identification
number, salary, nationality, job title, any shares of stock
or directorships held in the Company, the fact and
conditions of the Grantee’s participation in the Plan,
details of all RSUs or any other entitlement to Shares of
stock awarded, cancelled, exercised, vested, unvested or
outstanding in the Grantee’s favor (“Data”), for the
exclusive purpose of implementing, administering and
managing the Plan.
Sebelum ini, Penerima mungkin telah membekalkan
Syarikat dan Majikan dengan, dan Syarikat dan
Majikan mungkin memegang, maklumat peribadi
tertentu tentang Penerima, termasuk, tetapi tidak
terhad kepada, namanya, alamat rumah dan nombor
telefon, tarikh lahir, nombor insurans sosial atau
nombor pengenalan lain, gaji, kewarganegaraan,
jawatan, apa-apa syer dalam saham atau jawatan
pengarah yang dipegang dalam Syarikat, fakta dan
syarat-syarat penyertaan Penerima dalam Pelan
tersebut, butir-butir semua Unit Saham Terbatas atau
apa-apa hak lain untuk syer dalam saham yang
dianugerahkan, dibatalkan, dilaksanakan, terletak
hak, tidak diletak hak ataupun bagi faedah Penerima
(“Data”), untuk tujuan yang eksklusif bagi
melaksanakan, mentadbir dan menguruskan Pelan
tersebut.
26
Penerima juga memberi kuasa untuk membuat apa-
apa pemindahan Data, sebagaimana yang
diperlukan, kepada E*Trade Corporate Financial
Services, Inc. atau pembekal perkhidmatan pelan
saham yang lain sebagaimana yang dipilih oleh
Syarikat dari semasa ke semasa, yang membantu
Syarikat dalam pelaksanaan, pentadbiran dan
pengurusan Pelan tersebut dan/atau dengan sesiapa
yang mendepositkan syer-syer Saham yang
diperolehi melalui pemberian hak dan penyelesaian
Unit-unit Saham Terbatas. Penerima mengakui
bahawa penerima-penerima ini mungkin berada di
negara Penerima atau di tempat lain, dan bahawa
negara penerima (contohnya, Amerika Syarikat)
mungkin mempunyai undang-undang privasi data
dan perlindungan yang berbeza daripada negara
Penerima, yang mungkin tidak boleh memberi tahap
perlindungan yang sama kepada Data. Penerima
faham bahawa dia boleh meminta senarai nama dan
alamat mana-mana penerima Data dengan
menghubungi wakil sumber manusia tempatannya.
Penerima memberi kuasa kepada Syarikat, pembekal
perkhidmatan pelan saham dan mana-mana
penerima lain yang mungkin membantu Syarikat
(masa sekarang atau pada masa depan) untuk
melaksanakan, mentadbir dan menguruskan
penyertaan Penerima dalam Pelan tersebut untuk
menerima, memiliki, menggunakan, mengekalkan
dan.
The Grantee also authorizes any transfer of Data, as
may be required, to E*Trade Corporate Financial
Services, Inc., or such other stock plan service provider
as may be selected by the Company in the future, which
is assisting the Company with the implementation,
administration and management of the Plan and/or
with whom any Shares acquired upon vesting and
settlement of the RSUs are deposited. The Grantee
acknowledges that these recipients may be located in
his or her country or elsewhere, and that the recipient’s
country (e.g., the United States) may have different data
privacy laws and protections to the Grantee’s country,
which may not give the same level of protection to Data.
The Grantee understands that he or she may request a
list with the names and addresses of any potential
recipients of Data by contacting his or her local human
resources representative. The Grantee authorizes the
Company, the stock plan service provider and any other
possible recipients which may assist the Company
(presently or in the future) with implementing,
administering and managing the Grantee’s
participation in the Plan to receive, possess, use, retain
and transfer Data, in electronic or other form, for the
sole purpose of implementing, administering and
managing the Grantee’s participation in the Plan. The
Grantee understands that Data will be held only as long
as is necessary to implement, administer and manage
his or her participation in the Plan. The Grantee
understands that he or she may, at any time, view Data,
request additional information about the storage and
processing of Data, require any necessary amendments
to Data or refuse or withdraw the consents herein, in
any case, without cost, by contacting in writing his or
her local human resources representative, whose
contact details Amy Choi 85229435126,
Amy.Choi@microchip.com. Further, the Grantee
understands that he or she is providing the consents
herein on a purely voluntary basis. If the Grantee does
not consent, or if the Grantee later seeks to revoke the
consent, his or her employment status or service and
career with the Employer will not be adversely affected;
the only consequence of refusing or withdrawing the
consent is that the Company would not be able to grant
future RSUs or other equity awards to the Grantee or
administer or maintain such awards. Therefore, the
Grantee understands that refusing or withdrawing his
or her consent may affect his or her ability to
participate in the Plan. For more information on the
consequences of the refusal to consent or withdrawal of
consent, the Grantee understands that he or she may
contact his or her local human resources
representative.
27
Director Notification Obligation. If the Grantee is a director of the Company’s Malaysian Parent or
Subsidiary, he or she is subject to certain notification requirements under the Malaysian Companies Act.
Among these requirements is an obligation to notify the Malaysian Parent or Subsidiary in writing when the
Grantee receives or disposes of an interest (e.g., RSUs, Shares) in the Company or any Parent or Subsidiary.
Such notifications must be made within 14 days of receiving or disposing of any interest in the Company
or any Parent or Subsidiary.
MEXICO
No Entitlement or Claims for Compensation. These provisions supplement paragraph 10 of the Agreement:
Modification. By accepting the RSUs, the Grantee understands and agrees that any modification of the
Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions
of employment.
Policy Statement. The Award of RSUs the Company is making under the Plan is unilateral and discretionary
and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without
any liability.
The Company, with registered offices at 2355 West Chandler Boulevard, Chandler, AZ 85224, U.S.A., is
solely responsible for the administration of the Plan and participation in the Plan and the acquisition of Shares
does not, in any way, establish an employment relationship between the Grantee and the Company since the
Grantee is participating in the Plan on a wholly commercial basis and the sole employer is Microchip
Technology Mexico, S.DE R.L. DE C. V. nor does it establish any rights between the Grantee and the
Employer.
Plan Document Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he/she has
received copies of the Plan, has reviewed the Plan and the Agreement in their entirety and fully understands
and accepts all provisions of the Plan and the Agreement.
In addition, by accepting the Agreement, the Grantee further acknowledges that the Grantee has read and
specifically and expressly approve the terms and conditions in paragraph 10 of the Agreement, in which the
following is clearly described and established: (i) participation in the Plan does not constitute an acquired
right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis;
(iii) participation in the Plan is voluntary; and (iv) the Company and any Parent or Subsidiary are not
responsible for any decrease in the value of the Shares underlying the RSUs.
Finally, the Grantee hereby declares that he/she does not reserve any action or right to bring any claim against
the Company for any compensation or damages as a result of the Grantee’s participation in the Plan and
therefore grant a full and broad release to the Employer, the Company and any Parent or Subsidiary with
respect to any claim that may arise under the Plan.
Spanish Translation
Reconocimiento de la Ley Laboral. Estas disposiciones complementan el apartado 10 del Acuerdo:
Modification. Al aceptar las Unidades de Acción Restringida, usted reconoce y acuerda que cualquier
modificación del Plan o su terminación no constituye un cambio o desmejora de los términos y condiciones
de empleo.
28
Declaración de Política. El Otorgamiento de Unidades de Acción Restringida de la Compañía en virtud
del Plan es unilateral y discrecional y, por lo tanto, la Compañía se reserva el derecho absoluto de modificar
y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañía, con oficinas registradas ubicadas en 2355 West Chandler Boulevard, Chandler, AZ 85224,
U.S.A., es la única responsable de la administración del Plan y de la participación en el mismo y la adquisición
de Acciones no establece de forma alguna una relación de trabajo entre usted y la Compañía, ya que su
participación en el Plan es completamente comercial y el único empleador es Microchip Technology Mexico,
S.DE R.L. DE C. V. en caso de ser aplicable, así como tampoco establece ningún derecho entre la persona
que tenga el derecho a optar y el Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de Acción
Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al igual que la totalidad
del Acuerdo y, que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y
en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leído, y que aprueba específica y expresamente los
términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por Compensación, apartado 10
del Acuerdo, en el cual se encuentra claramente descrito y establecido lo siguiente: (i) la participación en el
Plan no constituye un derecho adquirido; (ii) el Plan y la participación en el mismo es ofrecida por la Compañía
de forma enteramente discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañía, así
como su Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el
valor de las Acciones en relación a las Unidades de Acción Restringida.
Finalmente, declara que no se reserva ninguna acción o derecho para interponer una demanda en contra de
la Compañía por compensación, daño o perjuicio alguno como resultado de su participación en el Plan y, en
consecuencia, otorga el más amplio finiquito al Empleador, así como a la Compañía, a su Sociedad controlante
o Subsidiaria con respecto a cualquier demanda que pudiera originarse en virtud del Plan.
There are no country-specific provisions.
There are no country-specific provisions.
NETHERLANDS
NORWAY
PHILIPPINES
Securities Law Notice. The offer under the Plan is being made pursuant to an exemption from registration
under Section 10.2 of the Philippines Securities Regulation Code that has been approved by the Philippines
Securities and Exchange Commission.
The risks of participating in the Plan include (without limitation), the risk of fluctuation in the price of the
Shares on the NASDAQ Global Select Market and the risk of currency fluctuations between the U.S. Dollar
and the Grantee’s local currency. The value of any Shares the Grantee may acquire under the Plan may
decrease below the value of the Shares at vesting (on which the Grantee is required to pay taxes) and
fluctuations in foreign exchange rates between the Grantee’s local currency and the U.S. Dollar may affect
the value any amounts due to the Grantee pursuant to the subsequent sale of any Shares acquired upon
29
vesting. The Company is not making any representations, projections or assurances about the value of the
Shares now or in the future.
For further information on risk factors impacting the Company's business that may affect the value of the
Shares, the Grantee may refer to the risk factors discussion in the Company's Annual Report on Form 10-K
and Quarterly Reports on Form 10-Q, which are filed with the U.S. Securities and Exchange Commission
and are available online at www.sec.gov/, as well as on the Company's website at http://www.microchip.com/
doclisting/investorshome.aspx. In addition, that Grantee may receive, free of charge, a copy of the Company's
Annual Report, Quarterly Reports or any other reports, proxy statements or communications distributed to
the Company's stockholders by contacting Debbie Wussler at Microchip Technology Incorporated. The
telephone number at the executive offices is 480-792-7373.
Securities Law Information. The Grantee is permitted to sell Shares acquired under the Plan through the
designated Plan broker appointed by the Company (or such other broker to whom the Grantee may transfer
the Shares), provided that such sale takes place outside of the Philippines through the facilities of the
NASDAQ Global Select Market on which the Shares are listed.
POLAND
Exchange Control Information. If the Grantee holds foreign securities (including Shares) and maintains
accounts abroad, the Grantee may be required to file certain reports with the National Bank of Poland.
Specifically, if the value of the securities and cash held in foreign accounts exceeds PLN 7 million, the
Grantee must file reports on the transactions and balances of the accounts on a quarterly basis. Further, any
fund transfers in excess of €15,000 (or PLN 15,000 if such transfer of funds is connected with business
activity of an entrepreneur) into or out of Poland must be effected through a bank in Poland. Polish residents
are required to store all documents related to foreign exchange transactions for a period of five years.
ROMANIA
Language Consent. By accepting the grant of RSUs, the Grantee acknowledges that he or she is proficient
in reading and understanding English and fully understands the terms of the documents related to the grant,
which were provided in the English language. The Grantee accepts the terms of those documents accordingly.
Consimtamant cu privire la limba. Prin acceptarea acordarii de RSU-uri, the Granteeul confirma ca acesta
sau aceasta are un nivel adecvat de cunoastere in ce priveste cititirea si intelegerea limbii engleze, a citit si
confirma ca a inteles pe deplin termenii documentelor referitoare la acordare, care au fost furnizate in limba
engleza. the Granteeul accepta termenii acestor documente in consecinta.
Exchange Control Information. If the Grantee deposits the proceeds from the sale of Shares issued to him
or her at vesting and settlement of the Award in a bank account in Romania, the Grantee may be required to
provide the Romanian bank with appropriate documentation explaining the source of the funds. The Grantee
should consult his or her personal advisor to determine whether he or she will be required to submit such
documentation to the Romanian bank.
SINGAPORE
Securities Law Information. The RSUs are being granted pursuant to the “Qualifying Person” exemption”
under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has
not been lodged or registered as a prospectus with the Monetary Authority of Singapore. The Grantee should
note that the RSUs are subject to section 257 of the SFA and that the Grantee will not be able to make any
30
subsequent sale of the Shares in Singapore or any offers of such subsequent sale of the Shares subject to the
RSUs in Singapore, unless such sale or offer is made (i) more than six months from the Grant Date, (ii)
pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA,
or (iii) pursuant to, and in accordance with the condition of, any other applicable provisions of the SFA.
Chief Executive Officer and Director Notification Obligation. If the Grantee is the chief executive officer
(“CEO”), director, associate director or shadow director of a Singapore Parent or Subsidiary, the Grantee is
subject to certain notification requirements under the Singapore Companies Act. Among these requirements
is an obligation to notify the Singaporean Parent or Subsidiary in writing when the Grantee receives an
interest (e.g., RSUs, Shares) in the Company or any related companies. In addition, the Grantee must notify
the Singapore Parent or Subsidiary when the Grantee sells Shares of the Company or any Parent or Subsidiary
(including when the Recipient sells Shares acquired under the Plan). These notifications must be made
within two business days of acquiring or disposing of any interest in the Company or any Parent or Subsidiary.
In addition, a notification must be made of the Grantee’s interests in the Company or any Parent or Subsidiary
within two business days of becoming the CEO, director, associate director or shadow director.
SPAIN
Termination of Employment. The RSUs provide a conditional right to Shares and may be forfeited or
affected by the Grantee’s termination of employment, as set forth in the Agreement. For avoidance of doubt,
the Grantee’s rights, if any, to the RSUs upon termination of employment shall be determined as set forth
in the Agreement, including, without limitation, where (i) the Grantee is deemed to be constructively
dismissed or unfairly dismissed without good cause; (ii) the Grantee is dismissed for disciplinary or objective
reasons or due to a collective dismissal; (iii) the Grantee terminates employment due to a change of work
location, duties or any other employment or contractual condition (except as otherwise expressly set forth
in the Agreement); or (iv) the Grantee terminates employment due to the Company’s or any of its Subsidiaries’
unilateral breach of contract. Consequently, the termination of the Grantee’s employment for any of the
above reasons shall be governed by the terms of the Agreement, unless otherwise determined by the Company,
in its sole discretion.
Labor Law Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he or she understands
and agrees to the terms and conditions applicable to participation in the Plan and that he or she has received
a copy of the Plan.
The Grantee understands that the Company has unilaterally, gratuitously and discretionally decided to grant
RSUs under the Plan to individuals who may be employees of the Company or any Parent or Subsidiary of
the Company throughout the world. The decision is a limited decision that is entered into upon the express
assumption and condition that any grant will not economically or otherwise bind the Company or any Parent
or Subsidiary on an ongoing basis, other than as expressly set forth in the Plan and the Agreement.
Consequently, the Grantee understands that any grant is given on the assumption and condition that it shall
not become a part of any employment contract (either with the Company or any Parent or Subsidiary) and
shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or
any other right whatsoever. Furthermore, the Grantee understands and freely accepts that there is no guarantee
that any benefit whatsoever shall arise from any gratuitous and discretionary grant since the future value of
the RSUs and the underlying Shares is unknown and unpredictable. In addition, the Grantee understands
that this grant would not be made but for the assumptions and conditions referred to above; thus, the Grantee
understands, acknowledges and freely accepts that should any or all of the assumptions be mistaken or should
any of the conditions not be met for any reason, then the RSUs shall be null and void.
31
Exchange Control Information. It is the Grantee’s responsibility to comply with exchange control
regulations in Spain. The Grantee must declare the acquisition of Shares for statistical purposes to the Spanish
Direccion General de Comercio e Inversiones (the “DGCI”) of the Ministry of Economy and
Competitiveness. Generally, the declaration must be filed a D-6 form in January for Shares owned as of
December 31 of each year; however, if the value of the Shares or the sale proceeds exceed €1,502,530, a
declaration must be filed within one month of the acquisition or sale, as applicable.
When receiving foreign currency payments in excess of €50,000 derived from the ownership of Shares (e.g.,
as a result of the sale of the Shares or the receipt of dividends), the Grantee must inform the financial institution
receiving the payment of the basis upon which such payment is made. The Grantee will likely need to
provide the institution with the following information: (i) the Grantee’s name, address, and fiscal
identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment;
(iv) the currency used; (v) the country of origin; (vi) the reasons for the payment; and (vii) any additional
information that may be required.
Further, the Grantee is required to declare electronically to the Bank of Spain any securities accounts
(including brokerage accounts held abroad), as well as the Shares held in such accounts if the value of the
transactions during the prior tax year or the balances in such accounts as of December 31 of the prior tax
year exceed €1,000,000.
Foreign Asset/Account Reporting Information. To the extent that the Grantee holds Shares and/or has
bank accounts outside Spain with a value in excess of €50,000 (for each type of asset) as of December 31,
the Grantee will be required to report information on such assets on his or her tax return (tax form 720) for
such year. After such Shares and/or accounts are initially reported, the reporting obligation will apply for
subsequent years only if the value of any previously-reported Shares or accounts increases by more than
€20,000.
Securities Law Information. The RSUs and the Shares issued upon vesting do not qualify under Spanish
regulations as a security. No “offer of securities to the public,” as defined under Spanish law, has taken place
or will take place in the Spanish territory. The Plan and the Agreement, including this Appendix, have not
been nor will they be registered with the Comisión Nacional del Mercado de Valores (Spanish Securities
Exchange Commission), and they do not constitute a public offering prospectus.
There are no country-specific provisions.
SWEDEN
SWITZERLAND
Securities Law Notification. The grant of the RSUs and the issuance of any Shares is not intended to be a
public offering in Switzerland. Neither this document nor any other materials relating to the RSUs constitute
a prospectus as such term is understood pursuant to article 652a of the Swiss Code of Obligations, and neither
this document nor any other materials relating to the RSUs may be publicly distributed nor otherwise made
publicly available in Switzerland. Neither this document nor any other offering or marketing material relating
to the RSUs have been or will be filed with, or approved or supervised by, any Swiss regulatory authority
(in particular, the Swiss Financial Market Supervisory Authority (FINMA)).
32
TAIWAN
Data Privacy Acknowledgement. The Grantee hereby acknowledges that he or she has read and understood
the terms regarding collection, processing and transfer of Data contained in paragraph 12 of the Agreement
and by participating in the Plan, the Grantee agrees to such terms. In this regard, upon request of the Company
or the Employer, the Grantee agrees to provide an executed data privacy consent form to the Employer or
the Company (or any other agreements or consents that may be required by the Employer or the Company)
that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in the
Grantee's country, either now or in the future. The Grantee understands he or she will not be able to participate
in the Plan if the Grantee fails to execute any such consent or agreement.
Securities Law Information. The grant of the RSUs and the Shares to be issued pursuant to the Plan are
available only for eligible Service Providers. It is not a public offer of securities by a Taiwanese company;
therefore, it is exempt from registration in Taiwan.
Exchange Control Information. Taiwanese residents may acquire and remit foreign currency (including
funds to purchase or proceeds from the sale of Shares) into and out of Taiwan up to US$5 million per year
without submission of supporting documentation. If the transaction amount is TWD$500,000 or more in a
single transaction, Taiwanese residents are required to submit a foreign exchange transaction form and if the
transaction amount is US$500,000 or more in a single transaction, such residents may be required to provide
supporting documentation to the satisfaction of the remitting bank. The Grantee is personally responsible
for complying with exchange control restrictions in Taiwan.
THAILAND
Exchange Control Notification. Thai resident the Grantees realizing US$50,000 or more in a single
transaction from the sale of Shares issued to the Grantee following the vesting and settlement of RSUs must
repatriate the proceeds to Thailand and then either convert such proceeds into Thai Baht or deposit the
proceeds into a foreign currency account opened with any commercial bank in Thailand within 360 days of
repatriation. Further, for repatriated proceeds of US$50,000 or more, the Grantee must specifically report
the inward remittance to the Bank of Thailand on a Foreign Exchange Transaction Form. If the Grantee fails
to comply with these obligations, the Grantee may be subject to penalties assessed by the Bank of Thailand.
The Grantee is personally responsible for complying with exchange control restrictions in Thailand. Because
exchange control regulations change frequently and without notice, the Grantee should consult his or her
personal legal advisor to ensure compliance with applicable exchange control laws in Thailand.
UNITED KINGDOM
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be settled in
Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Tax Obligations. The following provision supplements paragraph 9 (“Tax Obligations”) of the Agreement:
Without limitation to paragraph 9 of the Agreement, the Grantee agrees that he or she is liable for all Tax-
Related Items and hereby covenants to pay all such Tax-Related Items as and when requested by the Company
or the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any
other relevant authority). The Grantee also agrees to indemnify and keep indemnified the Company and the
Employer against any Tax–Related Items that the Company or the Employer are required to pay or withhold
33
or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on the Grantee’s
behalf.
Notwithstanding the foregoing, if the Grantee is a director or executive officer of the Company (within the
meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), the Grantee
understands that he or she may not be able to indemnify the Company for the amount of any income tax not
collected from or paid by the Grantee within ninety (90) days of the end of the U.K. tax year in which the
event giving rise to the Tax-Related Items occurs, in case the indemnifications would be considered to be a
loan. In this case, the income tax not collected or paid may constitute a benefit the Grantee on which additional
income tax and National Insurance contributions (“NICs”) may be payable. The Grantee understands that
he or she will be responsible for reporting and paying any income tax due on this additional benefit directly
to HMRC under the self-assessment regime and for reimbursing the Company or the Employer, as applicable,
for the value of any NICs due on this additional benefit. If the Grantee fails to comply with his or her
obligations in connection with the income tax as described in this section, the Company may refuse to deliver
the Shares to the Grantee without any liability to the Company or the Employer.
Joint Election for Transfer of Secondary Class 1 National Insurance Contributions to the Grantee. As
a condition of vesting of the RSUs, the Grantee agrees to accept any liability for secondary Class 1 national
insurance contributions, which may be payable by the Company or the Employer in connection with the
RSUs (“Employer NICs”). To accomplish the foregoing, the Grantee agrees to enter into an election between
himself or herself and the Employer (the “Election”), by printing, signing and returning the form approved
for such Election by HMRC and attached as Exhibit B to this Agreement to the Human Resources Manager
prior to vesting of the RSUs. The Grantee further agrees to enter into any other consents or elections required
to accomplish the transfer of the Employer NICs to the Grantee, prior to vesting of the RSUs. The Grantee
further agrees to enter into such other joint elections as may be required between himself or herself and any
successor to the Company and/or the Employer. If the Grantee does not enter into an Election prior to the
vesting of the RSUs, the Grantee will permanently forfeit the RSUs without any liability to the Company
and/or the Employer and any Shares that have been issued upon vesting will be returned to the Company at
no cost to the Company.
The Grantee further agrees that the Company and/or the Employer may collect the Employer NICs by any
of the means set forth in paragraph 9 of the Agreement, as supplemented above.
*
*
*
34
EXHIBIT A
AGREEMENT
FOR PARTICIPANTS IN BELGIUM
AGREEMENT REGARDING A TWO YEAR LOCK-UP PERIOD
FOR SHARES ACQUIRED UPON VESTING OF RESTRICTED STOCK UNITS
If you have not already executed an Agreement for the Grantees in Belgium ("Agreement")
and would like to benefit from the favourable tax regime provided for in the Circular (as
defined below), please print, sign and return this Agreement to Microchip Technology
Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199 U.S.A., c/o Tricia Bajaj,
within 120 calendar days from the grant date specified in the Notice of Grant of Restricted
Stock Units. Please also retain a copy of this Agreement for your files.
BETWEEN
1) Microchip Technology Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199
U.S.A. (hereafter "Microchip"); and
2) NAME:
_________________________
ADDRESS: _________________________
(hereafter the "Grantee", and, together with Microchip, the "Parties")
WHEREAS
Microchip has granted on the grant date set forth in the applicable Notice of Grant of Restricted
Stock Units ("Grant Notice") a number of restricted stock units to the Grantee subject to the
terms and conditions in the Microchip Technology Incorporated 2004 Equity Incentive Plan (the
"Plan"), the Grant Notice and the Restricted Stock Units Agreement (the "RSU Grant");
This Agreement is also intended to cover any subsequent grant of restricted stock units that may
be made under the Plan, in the sole discretion of Microchip, on or after the Effective Date (as
defined below) ("Subsequent Grant"); and
The Grantee would like to benefit from the favourable tax regime provided for in Administrative
Circular nr. Ci.RH.241/467.450 of June 21, 1995 (the "Circular") with respect to the shares of
common stock of Microchip which he/she will acquire upon the vesting of the aforementioned
RSU Grant and any Subsequent Grant;
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 1 out of 2
PARTIES HAVE AGREED AS FOLLOWS:
The shares that will be delivered to the Grantee upon vesting of the RSU Grant and any
Subsequent Grant will be subject to a two year lock-up period, starting from the date of vesting
of the relevant grant, during which the Grantee cannot sell or otherwise transfer the respective
shares.
The Parties reserve the right to terminate this Agreement in its entirety, or as far as it relates to
any particular grant, at any time prior to the Vesting Date specified in the relevant Grant Notice.
Notice of termination must specify the grant date of the RSU Grant and/or Subsequent Grant to
which it is intended to apply. The Parties understand that termination shall disqualify the
Grantee from the favourable tax regime provided for in the Circular with respect to shares of
common stock of Microchip which he/she will acquire upon the vesting of only the particular
grant(s) specified in the notice of termination. Notice of termination shall be provided to
Microchip by email to #stockplans@microchip.com.
This Agreement shall be effective as of the date this Agreement is received by Microchip
(the "Effective Date").
COMPANY
Signature:
GRANTEE
Signature:
Printed Name:
Date:
Made in:
Steve Sanghi, Chairman of the Board & CEO
Microchip Technology Incorporated
City, Country
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 2 out of 2
EXHIBIT B
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
(UK Employees)
Important Note on the Election to Transfer Employer NICs
As a condition of participation in the Plan and the grant of RSUs over Shares granted under the
Microchip Technology Incorporated 2004 Equity Incentive Plan (the “Plan”), you are required to
enter into an Election to transfer to you any liability for employer’s National Insurance Contributions
("NICs") that may arise in connection with your participation in the Plan.
By entering into the Election:
•
•
•
you agree that any employer’s NICs liability that may arise in connection with your
participation in the Plan with respect to RSUs granted under the Plan will be transferred to
you;
you authorise your employer to recover an amount sufficient to cover this liability by such
methods including, but not limited to, deductions from your salary or other payments due or
the sale of sufficient Shares acquired pursuant to your awards; and
you acknowledge that even if you have clicked on the [“ACCEPT”] box where indicated, the
Company or your employer may still require you to sign a paper copy of this Election (or a
substantially similar form) if the Company determines such is necessary to give effect to the
Election.
Please read the Election carefully.
Please print and keep a copy of the Election for your records.
37
Election To Transfer the Employer’s National Insurance Liability to the Employee
1.
Parties
This Election is between:
(A)
Employee Name (the “Employee”), who is eligible to receive Restricted
Stock Units granted by Microchip Technology Incorporated of 2355 Chandler
Blvd., Chandler, Arizona 85224, United States (the “Company”) pursuant to
the terms and conditions of the 2004 Equity Incentive Plan (the "Plan"), and
(B) Microchip Limited (registered number 2189500) with registered office at
Microchip House, 720 Wharfedale Road, Winnersh Triangle, Wokingham,
Berkshire RG41 5TP, United Kingdom (the “Employer”), which employs the
Employee.
2.
Purpose of Election
2.1
This Election relates to the employer’s secondary Class 1 National Insurance
Contributions (the “Employer’s Liability”) which may arise on:
(i)
the acquisition of securities pursuant to the Restricted Stock Units; and/or
(ii)
(iii)
the assignment or release of the Restricted Stock Units in return for
consideration; and/or
the receipt of any other benefit in money or money’s worth in connection with
the Restricted Stock Units; and/or
(iv)
post-acquisition charges relating to the Restricted Stock Units; and/or
(v)
post-acquisition charges relating to the Restricted Stock Units,
(each, a “Taxable Event”) pursuant to section 4(4)(a) and/or paragraph 3B(1A) of the
Social Security Contributions and Benefits Act 1992.
2.2
2.3
2.4
This Election applies to all Restricted Stock Unit awards granted to the Employee
under the Plan on or after 23rd December 2005 up to the termination date of the Plan.
This Election does not apply in relation to any liability, or any part of any liability,
arising as a result of regulations being given retrospective effect by virtue of section
4B(2) of either the SSCBA, or the Social Security Contributions and Benefits
(Northern Ireland) Act 1992.
This Election does not apply in relation to any liability, or any part of any liability,
arising as a result of regulations being given retrospective effect by virtue of section
4B(2) of either the SSCBA, or the Social Security Contributions and Benefits
(Northern Ireland) Act 1992.
38
3.
The Election
This joint election does not apply with respect to any liability arising as a result of
U.K. anti-avoidance legislation. The Employee and the Employer jointly elect that
the entire liability of the Employer to pay the Employer’s Liability on the Taxable
Event is hereby transferred to the Employee. The Employee understands that by
signing this Election he or she will become personally liable for the Employer’s
Liability covered by this Election. This Election is made in accordance with
paragraph 3B(1) of Schedule 1 of the SSCBA.
4.
Payment of the Employer’s Liability
4.1
The Employee hereby authorizes the Company and/or the Employer to collect the
Employer’s Liability from the Employee at any time after the Taxable Event:
(i)
by deduction from salary or any other payment payable to the Employee at
any time on or after the date of the Taxable Event; and/or
(ii)
directly from the Employee by payment in cash or cleared funds; and/or
(iii)
by arranging, on behalf of the Employee, for the sale of some of the securities
which the Employee is entitled to receive in respect of the Restricted Stock
Units; and/or
(iii)
by any other means specified in the applicable award agreement.
4.2
4.3
The Employer hereby reserves for itself and the Company the right to withhold the
transfer of any securities to the Employee until full payment of the Employer’s
Liability is received.
The Employer agrees to remit the Employer’s Liability to HM Revenue & Customs
on behalf of the Employee within 14 days after the end of the UK tax month during
which the Chargeable Event occurs (or within 17 days after the end of the UK tax
month during which the Chargeable Event occurs if payments are made
electronically)
5.
Duration of Election
5.1
The Employee and the Employer agree to be bound by the terms of this Election
regardless of whether the Employee is transferred abroad or is not employed by the
Employer on the date on which the Employer’s Liability becomes due.
5.2
This Election will continue in effect until the earliest of the following:
(i)
(ii)
the Employee and the Employer agree in writing that it should cease to have
effect;
on the date the Employer serves written notice on the Employee terminating
its effect;
39
(iii)
on the date the HM Revenue and Customs withdraws approval of this
Election; or
(iv)
after due payment of the Employer's Liability in respect of the entirety of the
Restricted Stock Units to which this Election relates, such that the Election
ceases to have effect in accordance with its terms.
5.3
This Election will continue in force regardless of whether the Employee ceases to be
an employee of the Employer.
Schedule of Employer Companies
The employing companies to which this Election relates are:
NAME
ADDRESS
Microchip Limited
Microchip House
720 Wharfedale Road
Winnersh Trinagle
Wokingham
Berkshire
RG41 5TP
United Kingdom
40
EXHIBIT 10.18
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
NOTICE OF STOCK OPTION GRANT
Unless otherwise defined herein, the terms defined in the 2004 Equity Incentive Plan (the “Plan”) shall have the same defined
meanings in this Notice of Stock Option Grant.
Optionee
%%FIRST_NAME%-% %%LAST_NAME%-%
You have been granted an option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and the
Stock Option Agreement, as follows:
Grant Number:
Grant Date:
Date Vesting Begins:
Vesting Period:
Exercise Price per Share:
%%OPTION_NUMBER%-%
%%OPTION_DATE,’Month DD, YYYY’%-%
%%VEST_ DATE_PERIOD1, ’Month DD, YYYY’%-%
%%VEST_PERIOD%%
%%OPTION_PRICE%-%
Total Number of Options Granted:
%%TOTAL_SHARES_GRANTED%-%
Total Exercise Price:
Type of Option:
Term/Expiration Date:
%%TOTAL_OPTION_PRICE%-%
Nonstatutory Stock Option
%%EXPIRE_DATE_PERIOD1%-%
Vesting Schedule. This Option shall be exercisable, in whole or in part, in accordance with the following schedule:
%%VEST_SCHEDULE%%.
Optionee understands that the Option is granted subject to and in accordance with the express terms and conditions of the Plan.
Optionee agrees to be bound by the terms and conditions of the Plan and the terms and conditions of the Option as set forth in the
Stock Option Agreement attached hereto as Exhibit A.
Termination Period. To the extent vested, this Option may be exercised for three months after Optionee ceases to be a Service
Provider. If Optionee ceases to be a Service Provider as a result of their Disability, this Option may be exercised for six months
following their termination. If Optionee dies while a Service Provider, this Option may be exercised for twelve months after
Optionee’s death. In no event shall this Option be exercised later than the Term/Expiration Date provided above.
Binding Agreements. By signature of Company's representative below, and Grantee’s acceptance of this Grant in accordance with
Company procedures, the parties agree that this Grant Notice, the Agreement, and the Plan constitute Grantee’s entire agreement with
respect to this Award and agree to be bound by the terms therein. Grantee hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions relating to the Plan, the Agreement, and/or this Award. This
Award may be modified by the Company, but in accordance with Section 21(c) of the Plan, it may not be modified adversely to
Grantee’s interest except by means of a writing signed by the Company and Grantee. The Company will administer the Plan from the
United States of America. The internal laws of the State of Arizona, United States of America, but not its choice of law principles, will
govern this Award.
GRANTEE
MICROCHIP TECHNOLOGY INCORPORATED
Acceptance: By Electronic Signature
By:
/s/ Steve Sanghi
Steve Sanghi, President and CEO
EXHIBIT A
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
STOCK OPTION AGREEMENT
1.
Grant of Option.
The Plan Administrator of the Company hereby grants to the Optionee (the “Optionee”) named in the
Notice of Stock Option Grant to which this Agreement is attached as Exhibit A (the “Notice of Grant”) an
option (the “Option”) to purchase the number of Shares, as set forth in the Notice of Grant, at the exercise price
per share set forth in the Notice of Grant (the “Exercise Price”), subject to the terms and conditions of the Plan,
which is incorporated herein by reference. Subject to Section 21(c) of the Plan, in the event of a conflict
between the terms and conditions of the Plan and the terms and conditions of this Option Agreement, the terms
and conditions of the Plan shall prevail.
2.
Exercise of Option.
(a)
Right to Exercise. This Option is exercisable during its term in accordance with the Vesting
Schedule set out in the Notice of Grant and the applicable provisions of the Plan and this Option Agreement.
(b) Method of Exercise. This Option is exercisable by delivery of an exercise notice, in the form
attached as Exhibit A-1 (the “Exercise Notice”) or in written or electronic form as designated by the Company,
which shall state the election to exercise the Option, the number of Shares in respect of which the Option is
being exercised (the “Exercised Shares”), and such other representations and agreements as may be required by
the Company pursuant to the provisions of the Plan. The Exercise Notice shall be completed by the Optionee
and delivered to the Stock Administrator of the Company. The Exercise Notice shall be accompanied by
payment of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to be
exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by such aggregate
Exercise Price.
No Shares shall be issued pursuant to the exercise of this Option unless such issuance and exercise
complies with Applicable Laws. Assuming such compliance, for income tax purposes the Exercised Shares
shall be considered transferred to the Optionee on the date the Option is exercised with respect to such
Exercised Shares.
3.
Method of Payment.
Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at
the election of the Optionee:
(a)
cash;
(b)
check; or
(c)
to the extent permitted by the Administrator, delivery of a properly executed exercise
notice together with such other documentation as the Administrator and the broker, if applicable, shall be
required to effect an exercise of the Option and delivery to the Company of the sale proceeds required to
pay the Exercise Price.
4.
Non-Transferability of Option.
Unless determined otherwise by the Administrator, this Option may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or
distribution and may be exercised, during the lifetime of the recipient, only by the recipient. If the
Administrator makes this Option transferable, such Option shall contain this additional terms and conditions as
the Administrator deems appropriate.
5.
Term of Option.
This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised
during such term only in accordance with the Plan and the terms of this Option Agreement.
6.
Tax Obligations.
(a) Withholding Taxes. Optionee agrees to make appropriate arrangements with the
Company (or the Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all
Federal, state, local and foreign income and employment tax withholding requirements applicable to the
Option exercise. Optionee acknowledges and agrees that the Company may refuse to honor the exercise
and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise.
7.
Entire Agreement; Governing Law.
The Plan and Notice of Grant are incorporated herein by reference. The Plan, Notice of Grant and this
Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and
supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to
the subject matter hereof, and may not be modified adversely to the Optionee’s interest except by means of a
writing signed by the Company and Optionee. This agreement is governed by the internal substantive laws, but
not the choice of law rules, of Arizona.
8.
NO GUARANTEE OF CONTINUED SERVICE.
OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO
THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER
AT THE WILL OF THE COMPANY (AND NOT THROUGH THE ACT OF BEING HIRED, BEING
GRANTED AN OPTION OR PURCHASING SHARES HEREUNDER). OPTIONEE FURTHER
ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED
HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN
EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR
THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE WITH
OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE OPTIONEE’S RELATIONSHIP AS
A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
By your signature, you agree that this Option is granted under and governed by the terms and conditions
of the Plan, the Notice of Grant and this Option Agreement. Optionee has reviewed the Plan, the Notice of
Grant and this Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior
to executing this Option Agreement and fully understands all provisions of the Plan, the Notice of Grant and
Option Agreement. Optionee hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Administrator upon any questions relating to the Plan and Option Agreement. Optionee
further agrees to notify the Company upon any change in the residence address indicated below.
9.
Choice of Languages For Employees of Canadian Locations Only. The undersigned agrees that it is his
express wish that this form and all documents relating to his participation in the scheme be drawn in the English
language only. Le soussigné convient que sa volonté expresse est que ce formulaire ainsi que tous les
documents se rapportant à sa participation au régime soient rédigés en langue anglaise seulement.
By Grantee’s electronic acceptance of the Agreement, Grantee agrees that this Award is granted under
and governed by the terms and conditions of the Plan, the Grant Notice and this Agreement. Grantee has
reviewed the Plan, the Grant Notice and this Agreement in their entirety, has had an opportunity to obtain the
advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan, the Grant
Notice and this Agreement. Grantee hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Administrator upon any questions relating to the Plan, the Grant Notice and this
Agreement.
GRANTEE
MICROCHIP TECHNOLOGY INCORPORATED
Acceptance: By Electronic Signature
By: /s/ Steve Sanghi
Steve Sanghi, President and CEO
EXHIBIT 10.19
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
NOTICE OF GRANT OF RESTRICTED STOCK UNITS
Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in
this Notice of Grant.
Name:
«Name»
You have been granted «Shares» Restricted Stock Units (“RSUs”) subject to and in accordance with the express
terms and conditions of the Plan and the Restricted Stock Unit Agreement, including the appendix for your country,
if any (“Appendix” and together with the Restricted Stock Unit Agreement, the “Agreement”) attached hereto as
Exhibit A. The Plan and Agreement are incorporated herein in their entirety. Each RSU is equivalent to the right
to receive one share of Common Stock of the Company (“Share”) for purposes of determining the number of Shares
subject to this Award. No Shares will be issued until the vesting conditions of the Award described below are
satisfied and the restrictions lapse, subject to the terms and conditions set forth in the Plan and the Agreement.
This Award does not entitle Grantee to any stockholder rights with respect to the underlying Shares until the vesting
conditions of the Award described below are satisfied, the restrictions lapse and Shares are issued to him/her.
Additional terms of this Award are as follows:
Date of Grant:
«Grant_Date»
Vesting Schedule:
«Language»
Termination Period. This Award automatically terminates and Grantee’s rights are forfeited with respect to any
portion of the RSUs unvested on the date Grantee ceases to be a Service Provider or in the event that Grantee has
not accepted this Grant in accordance with Company procedures 31 days or more prior to its Vest Begin Date. In
no event shall this Award vest later than the Vesting Schedule outlined above.
Binding Agreements. By signature of Company's representative below, and Grantee’s acceptance of this Grant
in accordance with Company procedures, the parties agree that this Grant Notice, the Agreement, and the Plan
constitute Grantee’s entire agreement with respect to this Award and agree to be bound by the terms therein. Grantee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon
any questions relating to the Plan, the Agreement, and/or this Award. This Award may be modified by the Company,
but in accordance with Section 21(c) of the Plan, it may not be modified adversely to Grantee’s interest except by
means of a writing signed by the Company and Grantee. The Company will administer the Plan from the United
States of America. The internal laws of the State of Arizona, United States of America, but not its choice of law
principles, will govern this Award.
GRANTEE
Signature
Print Name
Microchip Technology Incorporated
/s/ Lauren Carr
By
Vice President of Human Resources
Title
Exhibit A
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
Grant of Restricted Stock Units. Microchip Technology Incorporated (the “Company”)
1.
hereby grants to the Grantee named in the Notice of Grant of Restricted Stock Units (“Grant Notice”)
an Award of Restricted Stock Units (“RSUs”), as set forth in the Grant Notice and subject to the
terms and conditions in this Restricted Stock Unit Agreement, including any appendix for the
Grantee’s country (the “Appendix” and together with the Restricted Stock Unit Agreement, the
“Agreement”) and the Company’s 2004 Equity Incentive Plan (the “Plan”). Unless otherwise
defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.
2.
Company's Obligation. Each RSU represents the right to receive a Share in accordance with
the Vesting Period in the Grant Notice. Unless and until the RSUs vest, the Grantee will have no
right to receive Shares underlying such RSUs. Prior to actual distribution of Shares pursuant to
any vested RSUs, such RSUs will represent an unsecured obligation of the Company, payable (if
at all) only from the general assets of the Company.
Vesting Schedule. Subject to paragraph 4 of this Agreement, the RSUs awarded by this
3.
Agreement will vest and all restrictions lapse according to the vesting schedule specified in the
Grant Notice.
Forfeiture upon Termination as a Service Provider. Notwithstanding any contrary provision
4.
of this Agreement or the Grant Notice, if the Grantee terminates service as a Service Provider for
any or no reason prior to vesting, the unvested RSUs awarded by this Agreement will thereupon be
forfeited (as determined in accordance with paragraph 10(i) below) at no cost to the Company.
5.
Payment after Vesting. Any RSUs that vest in accordance with paragraph 3 of this Agreement
will be paid to the Grantee (or in the event of the Grantee's death, to his or her estate) in Shares
(unless otherwise determined by the Administrator and stated in the Appendix), upon satisfaction,
as determined by the Company, of any Tax-Related Items as set forth in paragraph 9 of this
Agreement. The Shares will be issued to the Grantee as soon as practicable after the Vesting Date,
but in any event, within the period ending on the later to occur of the date that is two and a half (2
½) months from the end of (i) the Grantee’s tax year that includes the applicable Vesting Date, or
(ii) the Company’s tax year that includes the applicable vesting date.
Payments after Death. Any distribution or delivery to be made to the Grantee under this
6.
Agreement will, if the Grantee is then deceased, be made to the administrator or executor of the
Grantee’s estate. Any such administrator or executor must furnish the Company with (a) written
notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish
the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.
Grant is Not Transferable. Except to the limited extent provided in paragraph 6 of this
7.
Agreement, RSUs may not be transferred, assigned, pledged or hypothecated in any way (whether
by operation of law or otherwise) and will not be subject to sale under execution, attachment or
similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of
the RSUs, or any right or privilege conferred hereby, or upon any attempted sale under any execution,
attachment or similar process, the RSUs grant and the rights and privileges conferred hereby
immediately will become null and void.
8.
Rights as Stockholder. Neither the Grantee nor any person claiming under or through the
Grantee will have any of the rights or privileges of a stockholder of the Company in respect of any
Shares deliverable hereunder unless and until the Grantee’s rights with respect to the RSUs have
become vested and certificates representing such Shares have been issued, recorded on the records
of the Company or its transfer agents or registrars, and delivered to the Grantee or Grantee’s broker
or the Shares have been electronically transferred to Grantee’s account.
9.
Tax Obligations. Regardless of any action the Company or the Grantee’s employer (the
“Employer”) takes with respect to any or all income tax, social insurance, payroll tax, payment on
account or other tax-related items related to the Grantee’s participation in the Plan that are legally
applicable to the Grantee (“Tax-Related Items”), the Grantee acknowledges that the ultimate liability
for all Tax-Related Items is and remains his or her responsibility and that such liability may exceed
the amount actually withheld by the Company or the Employer. The Grantee further acknowledges
that the Company and/or the Employer (1) make no representations or undertakings regarding the
treatment of any Tax-Related Items in connection with any aspect of the RSUs, including the grant
or vesting of the RSUs, the issuance of Shares on the relevant Vesting Date, the subsequent sale of
Shares acquired at vesting of the RSUs, if any, and the receipt of any dividends; and (2) do not
commit and are under no obligation to structure the terms of the grant or any aspect of the RSUs
to reduce or eliminate the Grantee’s liability for Tax-Related Items or achieve any particular tax
result. Further, if the Grantee becomes subject to tax and/or social security contributions in more
than one jurisdiction between the Grant Date and the date of any relevant taxable, tax and/or social
security contribution withholding event, as applicable, the Grantee acknowledges that the Company
and/or the Employer (or former employer, as applicable) may be required to withhold or account
for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable, tax and/or social security contribution withholding event, the
Grantee shall pay or make appropriate arrangements satisfactory to the Company and/or the
Employer to satisfy all Tax-Related Items. In this regard, the Grantee authorizes the Company and/
or the Employer, at their sole discretion, to satisfy the obligations with respect to Tax-Related Items
by one or a combination of the following: (i) withholding from the Grantee’s wages or other cash
compensation paid to the Grantee by the Company and/or the Employer; or (ii) withholding from
proceeds of the sale of Shares acquired upon vesting of the RSUs, either through a voluntary sale
or through a mandatory sale arrangement by the Company (on the Grantee’s behalf pursuant to this
authorization); or (iii) withholding in Shares to be issued upon vesting of the RSUs; or (iv) by
requiring direct payment from the Grantee in cash (or its equivalent). To avoid negative accounting
treatment, the Company will withhold or account for Tax-Related Items by considering applicable
minimum statutory withholding amounts or other applicable withholding rates. If the Grantee’s
and/or the Company’s withholding obligations for Tax-Related Items are satisfied as described in
(iii) of this paragraph, the Company will endeavor to sell only the number of Shares required to
satisfy the Grantee’s and/or the Company’s withholding obligations for Tax-Related Items; however,
the Grantee agrees that the Company may sell more Shares than necessary to satisfy the Tax-Related
Items. Further, the Grantee will be deemed to have been issued the full number of Shares subject
to the vested RSUs, notwithstanding that a number of Shares is held back solely for purposes of
paying the Tax-Related Items due as a result of any aspect of the Grantee’s participation in the Plan.
The Grantee hereby consents to any action reasonably taken by the Company to satisfy his or her
obligations for Tax-Related Items.
Finally, the Grantee shall pay to the Company or the Employer any amount of Tax-
Related Items that the Company or the Employer may be required to withhold or account for as a
result of the Grantee’s participation in the Plan that cannot be satisfied by the means previously
described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of
Shares at vesting if the Grantee fails to comply with his or her obligations in connection with the
Tax-Related Items.
Nature of Grant. In accepting the RSUs, the Grantee expressly acknowledges, understands
10.
and agrees to the following:
(a)
The Company is granting the Award under the Plan. The Plan is established voluntarily by
the Company, is discretionary in nature, and may be modified, amended, suspended or terminated
by the Company at any time;
(b)
The grant of the Award, future grants of Awards, if any, and benefits and rights provided
under the Plan are voluntary, occasional and at the complete discretion of the Company and do not
constitute regular or periodic payments. No grant of Awards will be deemed to create any contractual
or other right to receive future RSU Awards or benefits in lieu of RSUs, whether or not such a
reservation is explicitly stated at the time of such a grant or whether such Awards have been granted
repeatedly in the past. All decisions with respect to future RSU Awards, if any, will be at the sole
discretion of the Company;
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
(c)
extraordinary items that do not constitute compensation of any kind for services of any kind rendered
to the Company or the Employer, and which are outside the scope of the Grantee’s employment
contract, if any;
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
(d)
not intended to replace any pension rights or compensation;
(e)
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
not part of Grantee’s normal or expected salary or compensation for any purposes, including, without
limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-
service payments, vacation, bonuses, long-term service awards, indemnification, pension or
retirement or welfare benefits, or any other payments, benefits or rights of any kind, and in no event
should be considered as compensation for, or relating in any way to, past services for the Company,
the Employer or any Subsidiary;
The RSUs and the Grantee’s participation in the Plan shall not be interpreted to form an
(f)
employment contract or relationship with the Company or any Subsidiary;
(g)
The future value of the underlying Shares is unknown and cannot be predicted with certainty;
No claim or entitlement to compensation or damages shall arise from forfeiture of the RSU
(h)
Awards resulting from termination of the Grantee’s employment by the Company or the Employer
(for any reason whatsoever and regardless of whether in breach of local labor laws) and, in
consideration of the RSU Awards, to which the Grantee otherwise is not entitled, the Grantee
irrevocably agrees never to institute any claim against the Company or the Employer, waives his
or her ability, if any, to bring any such claim, and releases the Company and the Employer from
any such claim that may arise; if, notwithstanding the foregoing, any such claim is allowed by a
court of competent jurisdiction, then, by participating in the Plan, the Grantee shall be deemed
irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents
necessary to request dismissal or withdrawal of such claim;
(i)
In the event the Grantee’s termination of employment (regardless of whether in breach of
local labor laws), the Grantee’s right to vest in the RSUs under the Plan, if any, will terminate
effective as of the date that the Grantee is no longer actively employed and will not be extended by
any notice period mandated under local law (e.g., active employment would not include a period
of “garden leave” or similar period pursuant to local law); the Administrator shall have the exclusive
discretion to determine when the Grantee is no longer actively employed for purposes of the RSUs;
(j)
The Company has the right, at any time to amend, suspend or terminate the Plan. The Plan
will not be deemed to constitute, and will not be construed by Grantee to constitute, part of the
terms and conditions of employment, and that the Company will not incur any liability of any kind
to Grantee as a result of any change or amendment, or any cancellation, of the Plan at any time.
(k)
The Grantee's employment with the Employer is not affected at all by any Award and shall
not create a right to further employment with the Employer. Accordingly, the terms of the Grantee's
employment with the Employer will be determined from time to time by the Company or the
Subsidiary employing the Grantee (as the case may be), and the Grantee’s participation in the Plan
shall not interfere with the ability of the Employer, which is hereby expressly reserved, to terminate
or change the terms of the employment of the Grantee at any time for any reason whatsoever, with
or without good cause or notice, except as may be expressly prohibited by the laws of the jurisdiction
in which the Grantee is employed; and
(l)
The Grantee is voluntarily participating in the Plan.
11.
No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice,
nor is the Company making any recommendations regarding the Grantee’s participation in the Plan,
or the Grantee’s acquisition or sale of the underlying Shares. The Grantee is hereby advised to
consult with his or her own personal tax, legal, and financial advisors regarding his or her
participation in the Plan before taking any action related to the Plan.
12.
Data Privacy. By entering into this Agreement, and as a condition of the vesting of the
Award, Grantee explicitly and unambiguously consents to the collection, use, and transfer of
personal data, as set forth in this Agreement and any other grant materials by and among, as
applicable, the Employer, the Company and any Parent or Subsidiary of the Company for the
exclusive purpose of implementing, administering and managing the Grantee’s participation in
the Plan.
(i)
Grantee understands that the Employer, the Company and its Subsidiaries hold
certain personal information about the Grantee, including, but not limited to, the
Grantee’s name, home address and telephone number, date of birth, social security
number or other identification number, salary, nationality, job title, any Shares or
directorships held in the Company, and details of all Awards or other entitlement to Shares
awarded, canceled, exercised, vested, unvested, or outstanding in Grantee’s favor, for the
exclusive purpose of managing and administering the Plan (“Data”).
Grantee further understands that the Employer, the Company and/or its
(ii)
Subsidiaries will transfer Data among themselves as necessary for the purposes of
implementation, administration, and management of Grantee’s participation in the Plan,
and that the Employer, the Company and/or its Subsidiaries may each further transfer
Data to any third parties assisting the Company in the implementation, administration,
and management of the Plan, including the broker or such other stock plan service
provider as may be selected by the Administrator (“Data Recipients”).
(iii) Grantee understands that the Data Recipients may be located in Grantee’s country
or elsewhere, including outside the European Economic Area, and that the Data
Recipient’s country (e.g., the United States) may have different data privacy laws and
protections. Grantee authorizes the Data Recipients to receive, possess, use, retain, and
transfer Data, in electronic or other form, for the purposes of implementing,
administering, and managing Grantee’s participation in the Plan. Grantee understands
that Data will be held only as long as is necessary to implement, administer and manage
the Grantee’s participation in the Plan.
(iv) Grantee understands that Grantee may request a list with the names and addresses
of the potential Data Recipients by contacting his/her local human resources
representative. Grantee further understands that he/she may, at any time, review the
Data, request additional information about the storage and processing of Data, request
that any necessary amendments be made to it, or withdraw Grantee’s consent herein in
writing by contacting the Company. Grantee further understands, however, that
withdrawing consent may affect Grantee’s ability to participate in the Plan. For more
information on the consequences of Grantee’s refusal to consent or withdrawal of consent,
Grantee understands that Grantee may contact his/her local human resources
representative.
Language. If the Grantee receives this Agreement or any other document related to the Plan
13.
translated into a language other than English and if the meaning of the translated version differs
from the English version, the English version shall control.
Binding Agreement. Subject to the limitation on the transferability of this grant contained
14.
herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal
representatives, successors and assigns of the parties hereto.
15.
Additional Conditions to Issuance of Stock. If at any time the Company will determine, in
its discretion, that the listing, registration or qualification of the Shares upon any securities exchange
or under any state or federal law, or the consent or approval of any governmental regulatory authority
is necessary or desirable as a condition to the issuance of Shares to the Grantee (or his or her estate),
such issuance will not occur unless and until such listing, registration, qualification, consent or
approval will have been effected or obtained free of any conditions not acceptable to the Company.
The Company will make all reasonable efforts to meet the requirements of any such state or federal
law or securities exchange and to obtain any such consent or approval of any such governmental
authority.
Administrator Authority. The Administrator has the power to interpret the Plan, the Grant
16.
Notice and this Agreement and to adopt such rules for the administration, interpretation and
application thereof as are consistent therewith and to interpret or revoke any such rules (including,
but not limited to, the determination of whether or not any RSUs have vested). All actions taken
and all interpretations and determinations made by the Administrator in good faith will be final and
binding upon Grantee, the Company and all other interested persons. No member of the
Administrator will be personally liable for any action, determination or interpretation made in good
faith with respect to the Plan, the Grant Notice or this Agreement.
17.
Notice Requirement. Where there is a legal requirement for any notice or document to be
sent to any person by any other person, it shall be considered sent if an electronic transmission of
the relevant information is sent in a form previously determined as being acceptable to the
Administrator. For the avoidance of doubt, the Administrator may dispense with the requirement
to tender a certificate on the issuance of Shares under an RSU Award where the Administrator
authorizes any system permitting electronic notification.
18.
Address for Notices. Any notice to be given to the Company under the terms of this
Agreement will be addressed to the Company at 2355 West Chandler Boulevard, Chandler AZ
85224, U.S.A. Attn: Stock Administration, or at such other address as the Company may hereafter
designate in writing or electronically.
Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to
19.
deliver any documents related to current or future participation in the Plan by electronic means.
The Grantee hereby consents to receive such documents by electronic delivery and agrees to
participate in the Plan through an online or electronic system established and maintained by the
Company or a third party designated by the Company.
Appendix. Notwithstanding any provisions in this Agreement, the RSUs shall be subject to
20.
any special terms and conditions for the Grantee’s country set forth in the Appendix. Moreover, if
the Grantee relocates to one of the countries included in the Appendix, the special terms and
conditions for such country shall apply to the Grantee, to the extent that the Company determines
that the application of such terms and conditions is necessary or advisable in order to comply with
local law or facilitate the administration of the Plan. The Appendix constitutes part of this
Agreement.
21.
Imposition of Other Requirements. The Company reserves the right to impose other
requirements on the Grantee’s participation in the Plan, on the RSUs and on any Shares acquired
under this Award, to the extent that the Company determines it is necessary or advisable to comply
with local law or facilitate the administration of the Plan, and to require the Grantee to sign any
additional agreements or undertakings that may be necessary to accomplish the foregoing.
Entire Agreement; Governing Law. The Plan and Grant Notice are incorporated herein by
22.
reference. The Plan, Grant Notice and this Agreement constitute the entire agreement of the parties
with respect to the subject matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and Grantee with respect to the subject matter hereof, and may not be
modified adversely to the Grantee’s interest except by means of a writing signed by the Company
and Grantee. The Company will administer the Plan from the United States of America. This
Agreement, the Grant Notice and all Awards are governed by the internal substantive laws, but not
the choice of law principles, of the State of Arizona, United States of America.
For purposes of litigating any dispute that arises under this grant or the Agreement, the
parties hereby submit to and consent to the jurisdiction of the State of Arizona and agree that such
litigation shall be conducted in the courts of Maricopa County, Arizona, or the federal courts for
the United States for the District of Arizona, where this grant is made and/or to be performed.
23.
Severability. The provisions of this Agreement are severable, and, if any one or more
provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining
provisions nevertheless shall be binding and enforceable.
By Grantee’s electronic acceptance of the Agreement, Grantee agrees that this Award is granted
under and governed by the terms and conditions of the Plan, the Grant Notice and this Agreement.
Grantee has reviewed the Plan, the Grant Notice and this Agreement in their entirety, has had an
opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands
all provisions of the Plan, the Grant Notice and this Agreement. Grantee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the
Administrator upon any questions relating to the Plan, the Grant Notice and this Agreement.
MICROCHIP TECHNOLOGY
By:
Vice President of Human Resources
APPENDIX
ADDITIONAL TERMS AND CONDITIONS OF THE
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
This Appendix includes additional terms and conditions that govern the RSUs granted to the Grantee
under the Plan if the Grantee resides in one of the countries listed below. All capitalized terms used,
but not defined herein shall have the meaning given to such terms in the Plan and/or the Agreement.
If the Grantee is a citizen or resident of a country other than the one in which the Grantee is currently
working or transfers employment after the RSUs are granted, the Company shall, in its discretion,
determine to what extent the terms and conditions contained herein shall be applicable to the Grantee.
AUSTRALIA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, due to securities law
considerations in Australia, the RSUs will be settled in Shares only. The RSUs do not provide any
right for the Grantee to receive a cash payment.
AUSTRIA
There are no country-specific terms and conditions.
BELGIUM
Tax Reporting. If the Grantee is a Belgian resident, the Grantee is required to report any security
(e.g., Shares acquired under the Plan) or bank account (including any brokerage account held by
you at E*Trade Financial or other stock plan service provider as may be selected by the Company
in the future) held outside Belgium on your annual income tax return.
Agreement for Participants in Belgium. Under Belgian tax law, if the Shares acquired at vesting
of RSUs cannot be sold for two years from the Vesting Date, the fair market value of the Shares on
the Vesting Date is deemed to be 100/120 (83 1/3%) of the actual fair market value of such shares
for purposes of calculating the taxable amount. If the Grantee would like to take advantage of
this favourable tax treatment, the Grantee must print, sign and return a copy of the Agreement
Regarding a Two Year Lock Up Period for Shares Acquired Upon Vesting of Restricted Stock
Units attached as Exhibit A to this Agreement by the deadline specified therein.
CANADA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, due to securities law
considerations in Canada, the RSUs will be settled in Shares only. The RSUs do not provide any
right for the Grantee to receive a cash payment.
Termination of Employment. The following provision replaces paragraph 10(i) of the Agreement:
In the event of termination of the Grantee’s employment, the Grantee’s right to vest in the RSUs
under the Plan, if any, will terminate effective as of the date that is the earlier of (i) the date on
which the Grantee receives a notice of termination of employment from the Company or the
Employer, or (ii) the date on which the Grantee is no longer employed, regardless of any notice
period or period of pay in lieu of such notice required under local law; the Administrator shall have
the exclusive discretion to determine when the Grantee is no longer employed for purposes of the
RSUs.
The following terms and conditions apply if the Grantee is in Quebec:
Authorization to Release and Transfer Necessary Personal Information. The following
provision supplements paragraph 12 of the Agreement:
The Grantee hereby authorizes the Company and the Company’s representatives to discuss with
and obtain all relevant information from all personnel, professional or not, involved in the
administration and operation of the Plan. The Grantee further authorizes the Company and/or any
Parent or Subsidiary to disclose and discuss the Plan with their advisors. The Grantee further
authorizes the Company and any Parent or Subsidiary to record and keep such information in the
Grantee’s employment file.
French Language Acknowledgment. The following provision supplements paragraph 13 of the
Agreement:
The parties acknowledge that it is their express wish that this Agreement, as well as all documents,
notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly
or directly hereto, be drawn up in English.
Les parties reconnaissent avoir exigé la rédaction en anglais de cette convention, ainsi que de tous
documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés
directement ou indirectement à, la présente convention.
CHINA
Deposit of Shares and Distribution of Dividends. Due to exchange control laws and regulations
in the People’s Republic of China (“PRC”), if the Participant is a PRC national, any Shares acquired
at vesting of the RSUs will be deposited in an account established for Grantee by the Company (the
“Account”) with E*Trade Financial or any successor broker designated by Company, in its sole
discretion (the “Designated Broker”). Grantee must maintain the Shares issued to Grantee under
the Plan in the Account and must not transfer the Shares to any person, broker or other account with
the Designated Broker or to a brokerage account outside of the Designated Broker.
Any dividends related to Shares acquired under the Plan may, at the Company’s sole discretion, be
deposited into an Account with the Designated Broker, or re-invested by Company on behalf of the
Grantee.
Until such time as the Shares acquired at vesting of the RSUs are sold, the Grantee must maintain
the Shares issued to Grantee under the Plan in the Account and must not transfer the Shares to
another account with the Designated Broker or to a brokerage account outside of the Designated
Broker.
Forfeiture and Sale upon Termination as a Service Provider. The following provision replaces
paragraph 4 of the Agreement:
(a)
Notwithstanding any contrary provision of this Agreement or the Grant Notice, if the Grantee
terminates service as a Service Provider for any or no reason prior to vesting, the unvested RSUs
awarded by this Agreement will thereupon be forfeited at no cost to the Company.
(b)
The Grantee must sell all Shares acquired under the Plan on or before the date of termination
as a Service Provider. Grantee hereby authorizes Company or the Designated Broker to sell such
Shares on behalf of the Grantee without notice to or consent from the Grantee if Grantee has not
sold all Shares so acquired as of the date of termination of service. The sale of Shares shall be
carried out within a reasonable time of termination of service as determined by Company. The
proceeds from such sale, net any Tax-Related Items and broker’s fees, shall be deposited in Grantee’s
bank account in China, or delivered to Grantee in China through such other means determined by
Company, in its discretion. Grantee hereby releases and holds harmless Company and any Parent
or Subsidiary, employees and agents (“Indemnitees”) from any loss that Grantee may incur due to
the timing of the sale of Shares by Company and acknowledges that the Company and the Employer
are under no obligation to arrange for the sale of the Shares at any particular price and are not liable
for any fluctuations in the trading price of the Shares and/or the U.S. dollar exchange rate.
If Grantee does transfer Shares into an account to which Company has no visibility, then
(c)
Grantee will sell all Shares no later than the date of termination as a Service Provider and provide
written evidence of such sale of Shares to Company within two (2) business days of the date of
termination as a Service Provider. Such evidence must be in a form acceptable to Company.
(d)
Grantee shall defend, hold harmless and indemnify Indemnitees from any and all penalties,
damages, and costs that may be incurred by Indemnitees arising out of or in connection with
Grantee’s failure to comply with these obligations and any requirements under local exchange
control laws applicable to him/her.
Exchange Control Restriction. The Grantee understands and agrees that, if he or she is a PRC
national, due to exchange control laws and regulations in the PRC, the Grantee will be required to
repatriate immediately to the PRC any cash proceeds from the sale of the Shares acquired under
the Plan. The Grantee understands further that, under applicable laws and regulations, such
repatriation may need to be effected through a special foreign exchange account established by the
Company or a Parent or Subsidiary, and the Grantee consents and agrees that the proceeds from the
sale of the Shares may be transferred to such special account before being delivered to the Grantee.
Moreover, if the proceeds from the sale of the Shares are converted to local currency, the Grantee
acknowledges that the Company (including its Parent and Subsidiary corporations) is under no
obligation to secure any particular currency conversion rate and may face delays in converting the
proceeds to local currency due to exchange control restrictions in the PRC. The Grantee agrees to
bear the risk of any fluctuation in the U.S. dollar/local currency exchange rate between the date the
Grantee realizes U.S. dollar proceeds from his or her participation in the Plan and the date that the
Grantee receives cash proceeds converted to local currency. The Grantee also agrees to comply
with any other requirements that may be imposed by the Company in the future to facilitate
compliance with exchange control requirements in the PRC.
DENMARK
There are no country-specific terms and conditions.
FRANCE
Nature of RSUs. The RSUs granted to you pursuant to this Agreement are not intended to
qualify for the favorable tax and social security treatment in France applicable to shares granted
for no consideration under Sections L. 225-197 to L. 225-197-6 of the French Commercial Code,
as amended.
Consent to Receive Information in English. By accepting this Agreement providing for the
terms and conditions of the RSUs, the Grantee confirms that he/she has read and understood the
documents relating to this Award (i.e., the U.S. Plan and this Agreement), which were provided
in English. The Grantee accepts the terms of those documents accordingly.
En acceptant de manière électronique le présent Contrat d’Attribution décrivant les termes et
conditions de votre attribution d’Actions Gratuites, vous confirmez ainsi avoir lu et compris les
documents relatifs à cette attribution (c’est-à-dire, le Plan Américain et le présent Contrat
d’Attribution) qui vous ont été communiqués en langue anglaise. Vous en acceptez les termes en
connaissance de cause.
Exchange Control Information. If the Grantee maintains a foreign bank account, he/she is
required to report such to the French tax authorities when filing his/her annual tax return.
GERMANY
There are no country-specific terms and conditions.
HONG KONG
Securities Law Warning. The offer of the RSUs and the Shares subject to the RSUs do not constitute
a public offering of securities under Hong Kong law and are available only to Employees of the
Company or its Subsidiaries participating in the Plan. The Grantee should be aware that the contents
of this Agreement have not been prepared in accordance with and are not intended to constitute a
“prospectus” for a public offering of securities under the applicable securities legislation in Hong
Kong. Nor have the documents been reviewed by any regulatory authority in Hong Kong. The
RSUs are intended only for the personal use of each Grantee and may not be distributed to any other
person. The Grantee is advised to exercise caution in relation to this offer. If the Grantee is in doubt
about any of the contents of this Agreement or the Plan, the Grantee should obtain independent
professional advice.
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be
settled in Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Sale of Shares. In the event that the RSUs vest within six months of the date of grant, the Grantee
agrees that he or she will not sell any Shares thus acquired prior to the six-month anniversary of
the date of grant.
HUNGARY
There are no country-specific terms and conditions.
INDIA
Exchange Control Documentation. The Grantee understands that he or she must repatriate the
sale proceeds upon the sale of Shares acquired under the Plan to India and convert the proceeds
into local currency within 90 days of receipt. The Grantee will receive a foreign inward remittance
certificate (“FIRC”) from the bank where the foreign currency is deposited. The Grantee should
retain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India,
the Employer or the Company requests proof of repatriation.
IRELAND
There are no country-specific terms and conditions.
ISRAEL
Terms and Conditions
The following provision applies to Grantees located in Israel on the Grant Date.
Trust Arrangement. The Grantee understands and agrees that the RSUs offered are subject to
and in accordance with the terms of the Plan, Israeli Subplan (the “Subplan”), Agreement and
the Israel Beneficiary 102 Undertaking. The Grantee understands that the RSUs shall be
allocated under the provisions of the track referred to as the “Capital Gain Route,” according to
Section 102(b)(2) and 102(b)(3) of the Israeli Income Tax Ordinance (“Section 102”) and shall
be held by the trustee for the periods stated in Section 102. The Grantee hereby confirms that he
or she has: (i) read and understands the Plan, Subplan, Agreement and Israel Beneficiary 102
Undertaking; (ii) received all the clarifications and explanations that the Grantee has requested;
and (iii) had the opportunity to consult with his or her advisers before accepting the Agreement.
In the event of any inconsistencies between the provisions of this Israeli Appendix and the
Agreement, the provisions of this Appendix shall govern the RSUs and any Shares and in no
event shall any term require shareholder approval as set out in Section 21(b) of the Plan.
Limited Transferability. This provision supplements Section 7 of the Agreement:
Subject to the provisions of the Plan, Section 102 and any rules or regulations or orders or
procedures promulgated thereunder, to obtain favourable tax treatment for Capital Gain Route
awards, the Grantee may not sell or transfer any RSU shares received upon vesting or received
subsequently following any realization of rights until the lapse of the holding period required is
met under Section 102. Notwithstanding the above, if any such sale or release occurs during the
holding period, the sanctions under Section 102 and under any rules or regulation or orders or
procedures promulgated thereunder will apply to and will be borne by the Grantee.
Issuance of Shares. This provision supplements Sections 5 and 8 of the Agreement:
If the vested RSUs are issued during the holding period, such Shares shall be restricted and held
by E*Trade Financial or any successor broker and/or trustee designated by Company and the Trustee
on the Grantee’s behalf. In the event that the vested RSUs are issued after the expiration of the
holding period, the Grantee may freely sell the shares held by E*Trade Financial, provided that the
Grantee first complies with any Tax-Related Items stipulated under this Agreement to the Trustee’s
and the Company’s satisfaction, or in trust on the Grantee’s behalf to the Trustee.
Tax Obligations. This provision supplements Section 9 of the Agreement:
The Grantee hereby agrees to indemnify the Company (or any Subsidiary) and/or the Trustee and
hold them harmless against and from any and all liability for any Tax-Related Items and other
amounts, or interest or penalty thereon, including without limitation, liabilities relating to the
necessity to withhold, or to have withheld, any such amounts from any payment made to the Grantee.
Any reference to the Company or the Employer shall include a reference to the Trustee. The Grantee
hereby undertakes to release the Trustee from any liability in respect of any action or decisions duly
taken and bona fide executed in relation to the Plan or any RSUs or Shares acquired under the Plan.
The Grantee agrees to execute any and all documents which the Company or the Trustee may
reasonably determine to be necessary in order to comply with the Israeli Income Tax Ordinance.
The Grantee shall not be liable for the Employer’s components of payments to the national insurance
institute, unless otherwise agreed by the Grantee and allowed by applicable tax laws. Furthermore,
the Grantee agrees to indemnify the Company, the Employer and/or the Trustee and hold them
harmless against and from any and all liability for any such tax or interest or penalty thereon that
Grantee has agreed to pay, including without limitation, liabilities relating to the necessity to
withhold, or to have withheld, any such tax from any payment made to the Grantee for which the
Grantee is responsible.
Notwithstanding anything to the contrary in the Agreement, no Tax-Related Items will be settled
by withholding Shares, unless the ITA approves otherwise in writing.
Governing Law. This section supplements Section 22 of the Agreement:
To the extent any covenant, condition, or other provision of the Agreement and the rights of the
Grantee hereunder are intended to be rights granted under Section 102 and therefore determined
to be subject to Israeli law, such covenant, condition, or other provision of the Agreement shall
be subject to applicable Israeli law, but shall in no way affect, impair, or invalidate any other
provision of the Agreement, and the applicability of the Plan to such covenant, condition, or
other provision of the Agreement.
Written Acceptance. The Grantee must print, sign and deliver the signed copy of the Israel
Beneficiary 102 Undertaking within 45 days of the new hire grant date to: Microchip Technology
Israel Ltd., Zarchin 10, Raanana, P.O Box 4319, 43662. If the Company does not receive the
signed Israel Beneficiary 102 Undertaking within 45 days, the RSUs may not qualify for
preferential tax treatment.
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
ISRAEL BENEFICIARY 102 UNDERTAKING
If the Grantee has not already executed an Israel Beneficiary 102 Undertaking in
connection with grants made under the Israeli Subplan, the Grantee must print, sign and
deliver the signed copy of this Israel Beneficiary 102 Undertaking within 45 days of the new
hire grant date to: Microchip Technology Israel Ltd., Zarchin 10, Raanana, P.O Box 4319,
43662. If the Company does not receive the signed Israel Beneficiary 102 Undertaking
within 45 days, the RSUs may not qualify for preferential tax treatment.
1.
2.
3.
4.
5.
I hereby agree that any shares (the “Shares”) (as defined by Section 102 of
the Income Tax Ordinance [New Version], 1961) (the “Tax Ordinance”)
issued to me by Microchip Technology Incorporated according to and under
the terms and conditions of the Plan and the Israeli Subplan adopted by
Microchip Technology Incorporated as of 13 December 2013 (collectively,
the "Plan") are granted to me to qualify under the capital gain tax treatment
in accordance and pursuant to Section 102(b)(2) of the Tax Ordinance after
132 amendment (“Section 102”) and the Income Tax Rules (Tax Relief upon
the Allotment of Shares to Employees), 2003 (the “Rules”) unless I am
otherwise notified subject to Microchip Technology Incorporated’s absolute
discretion to change such election on future grants and subject to the Tax
Authorities’ approval.
I declare and confirm that I am familiar with the terms of Section 102, the
Rules, and the implications and consequences of the chosen tax arrangement
with respect to the Shares, and consent that all the terms and conditions set
forth in Section 102 and the Rules, as shall be amended from time to time,
shall apply to me and bind me.
I hereby declare and confirm that I am familiar with the provisions of the
trust agreement signed between Microchip Technology Israel Ltd. and Tamir
Fishman Trusts 2004 Ltd. (the "Trustee") (the “Trust Agreement”), including
the deed of trust, attached to the Trust Agreement and constitute an integral
part thereto (“Deed of Trust”), and I consent that the Trust Agreement and
the Deed of Trust shall fully bind me.
Without derogating from the generality of the aforesaid, I agree that the
Shares will be deposited in trust with the Trustee and be held in trust in
accordance with Section 102, the Rules and the Trust Agreement.
I hereby declare and consent that any and all the rights that I shall be entitled
to with respect to the Shares, including, without limitation, dividend and
shares issued pursuant to adjustments made by Microchip Technology
6.
7.
8.
9.
Incorporated and shall be subject to Section 102, the Rules and the Trust
Agreement.
Without derogating from the generality of the aforesaid, I acknowledge that
during the “Holding Period” as determined by the Tax Ordinance I am
prevented from selling the Shares, or releasing them from the Trustee, before
the termination of the “Holding Period” and I understand the tax implications
and consequences that may be applied as a result of breaching such obligation,
as set by Section 102, which I am familiar with.
If I will cease to be an Israeli resident or if my employment will be terminated
for any reason, the Shares shall remain subject to section 102, the Rules and
the Trust Agreement.
I hereby agree that any tax liability whatsoever arising from the grant, vesting
of any restricted stock units, the sale of Shares, the release of Shares from
the Trustee or any other event or act with respect to the Shares granted to
me, shall be borne solely by me. I declare and consent that the Microchip
Technology Incorporated, Microchip Technology Israel Ltd. and/or the
Trustee shall make any tax payment due, out of the proceeds of any sale of
Shares, to any tax authority, according to Section 102, the Rules, the Trust
Agreement or any other compulsory payments or applicable law.
I understand that this grant of Shares under the capital gain track is
conditioned upon the receipt, inter alia, of all required approvals from the
tax authorities. Accordingly, to the extent that for whatever reason Microchip
Technology Israel Ltd. shall not be granted an approval by the Israeli Tax
Authorities under section 102, I shall bear and pay any and all taxes and any
other compulsory payments applicable to the grant, exercise, sale or other
disposition of stocks; I hereby declare and consent for the Microchip
Technology Incorporated, Microchip Technology Israel Ltd. and/or the
Trustee to deduct any tax payment due, out of the proceeds of any sale of
Shares, for any payment to the tax authorities, according to the Rules, or any
other applicable compulsory payments.
10.
I confirm that Microchip Technology Incorporated and/or the Trustee shall
not be required to release any proceeds deriving from the sale of Shares, to
me, until all required tax payments according to section 102, the Rules and
the Trust Agreement, including any other compulsory payments, or
applicable law, have been fully assured.
11.
I acknowledge that the Trustee is not a tax advisor and it is recommended
that I consult a tax advisor before I accept this letter, any restricted stock
units vest, sell any Shares or release them from the Trustee, or any other act.
12.
13.
14.
15.
I agree to indemnify Microchip Technology Incorporated, Microchip
Technology Israel Ltd. and/or the Trustee and to hold them harmless against
and from any and all liability for any damage and/or loss and/or expense that
might occur regarding the tax liability and/or the execution of the Trust
Agreement.
I hereby agree to bear all the applicable fees and commissions involved in
establishing and maintaining trust account in the Trustee’s name, and in
performing any action in the trust account.
I hereby agree to sign any document reasonably required at the company’s
and/or the Trustee’s request.
I hereby confirm that I read this letter thoroughly, received all the
clarifications and explanations I requested, I understand the contents of this
letter and the obligations I undertake in signing it.
Name of the Beneficiary
I.D. Number
Signature
ITALY
Data Privacy Notice. The following provision replaces paragraph 12 of the Agreement:
The Grantee hereby explicitly and unambiguously consents to the collection, use, processing and
transfer, in electronic or other form, of the Grantee’s personal data as described in this provision
of this Appendix by and among, as applicable, the Employer, the Company and any Parent and/
or Subsidiary for the exclusive purpose of implementing, administering, and managing the
Grantee’s participation in the Plan.
The Grantee understands that the Employer, the Company and any Parent and/or Subsidiary
may hold certain personal information about the Grantee, including, without limitation, the
Grantee’s name, home address and telephone number, date of birth, social insurance or other
identification number, salary, nationality, job title, any Shares or directorships held in the
Company or a Parent or Subsidiary, details of all RSUs, or any other entitlement to Shares
awarded, canceled, exercised, vested, unvested or outstanding in the Grantee’s favor, for the
exclusive purpose of implementing, managing, and administering the Plan (“Data”).
The Grantee also understands that providing the Company with Data is necessary for the
performance of the Plan and that the Grantee’s refusal to provide such Data would make it
impossible for the Company to perform its contractual obligations and may affect the Grantee’s
ability to participate in the Plan. The Controller of personal data processing is Microchip
Technology Incorporated at 2355 West Chandler Boulevard, Chandler, AZ 85224, U.S.A., and,
pursuant to Legislative Decree no. 196/2003, its representative in Italy is Microchip Technology
SRL with registered offices at Via Pablo Picasso 41, 20025 Legnano (MI) Italy.
The Grantee understands that Data will not be publicized, but it may be transferred to E*Trade
Financial (or one of its affiliates) or such other stock plan service provider as may be selected
by the Company in the future (any such entity, “Broker”), or other third parties involved in the
management and administration of the Plan. The Grantee understands that Data may also be
transferred to the independent registered public accounting firm engaged by the Company. The
Grantee further understands that the Company and/or any Parent and/or Subsidiary will transfer
Data among themselves as necessary for the purpose of implementing, administering, and
managing the Grantee’s participation in the Plan, and that the Company or a Subsidiary may
each further transfer Data to third parties assisting the Company in the implementation,
administration, and management of the Plan, including any requisite transfer of Data to the
Broker or other third party with whom the Grantee may elect to deposit any Shares acquired at
vesting of the RSUs. Such recipients may receive, possess, use, retain, and transfer Data in
electronic or other form, for the purposes of implementing, administering, and managing the
Grantee’s participation in the Plan. The Grantee understands that these recipients may be located
in or outside the European Economic Area, such as in the United States or elsewhere. Should
the Company exercise its discretion in suspending all necessary legal obligations connected with
the management and administration of the Plan, it will delete Data as soon as it has completed
all the necessary legal obligations connected with the management and administration of the
Plan.
The Grantee understands that Data processing related to the purposes specified above shall take
place under automated or non-automated conditions, anonymously when possible, that comply
with the purposes for which Data is collected and with confidentiality and security provisions,
as set forth by applicable laws and regulations, with specific reference to Legislative Decree no.
196/2003.
The processing activity, including communication, the transfer of Data abroad, including outside
of the European Economic Area, as herein specified and pursuant to applicable laws and
regulations, does not require the Grantee’s consent thereto, as the processing is necessary to
performance of contractual obligations related to implementation, administration, and
management of the Plan. The Grantee understands that, pursuant to paragraph 7 of the
Legislative Decree no. 196/2003, the Grantee has the right to, without limitation, access, delete,
update, correct, or terminate, for legitimate reason, the Data processing.
Furthermore, the Grantee is aware that Data will not be used for direct-marketing purposes. In
addition, Data provided can be reviewed and questions or complaints can be addressed by
contacting the Grantee’s local human resources representative.
Grant Terms Acknowledgment. By accepting the RSUs, the Grantee acknowledges having
received and reviewed the Plan and the Agreement, including this Appendix, in their entirety and
fully understands and accepts all provisions of the Plan and the Agreement, including this Appendix.
The Grantee further acknowledges having read and specifically approves the following paragraphs
of the Agreement: paragraph 9 (“Tax Obligations”), paragraph 10 (“Nature of Grant”), paragraph
13 (“Language”), paragraph 22 (“Entire Agreement; Governing Law”), and the “Data Privacy
Notice” provision set forth above in this Appendix.
JAPAN
There are no country-specific terms and conditions.
KOREA
There are no country-specific terms and conditions.
MALAYSIA
There are no country-specific terms and conditions.
MEXICO
No Entitlement or Claims for Compensation. These provisions supplement paragraph 10 of
the Agreement:
Modification. By accepting the RSUs, the Grantee understands and agrees that any
modification of the Plan or the Agreement or its termination shall not constitute a change or
impairment of the terms and conditions of employment.
Policy Statement. The Award of RSUs the Company is making under the Plan is unilateral and
discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue
it at any time without any liability.
The Company, with registered offices at 2355 West Chandler Boulevard, Chandler, AZ 85224,
U.S.A., is solely responsible for the administration of the Plan and participation in the Plan and
the acquisition of Shares does not, in any way, establish an employment relationship between the
Grantee and the Company since the Grantee is participating in the Plan on a wholly commercial
basis and the sole employer is Microchip Technology Mexico, S.DE R.L. DE C. V. nor does it
establish any rights between the Grantee and the Employer.
Plan Document Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he/
she has received copies of the Plan, has reviewed the Plan and the Agreement in their entirety
and fully understands and accepts all provisions of the Plan and the Agreement.
In addition, by accepting the Agreement, the Grantee further acknowledges that the Grantee has
read and specifically and expressly approve the terms and conditions in paragraph 10 of the
Agreement, in which the following is clearly described and established: (i) participation in the
Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by
the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv)
the Company and any Parent or Subsidiary are not responsible for any decrease in the value of
the Shares underlying the RSUs.
Finally, the Grantee hereby declares that he/she does not reserve any action or right to bring any
claim against the Company for any compensation or damages as a result of the Grantee’s
participation in the Plan and therefore grant a full and broad release to the Employer, the
Company and any Parent or Subsidiary with respect to any claim that may arise under the Plan.
Spanish Translation
Reconocimiento de la Ley Laboral. Estas disposiciones complementan el apartado 10 del
Acuerdo:
Modification. Al aceptar las Unidades de Acción Restringida, usted reconoce y acuerda que
cualquier modificación del Plan o su terminación no constituye un cambio o desmejora de los
términos y condiciones de empleo.
Declaración de Política. El Otorgamiento de Unidades de Acción Restringida de la Compañía
en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañía se reserva el derecho
absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañía, con oficinas registradas ubicadas en 2355 West Chandler Boulevard, Chandler, AZ
85224, U.S.A., es la única responsable de la administración del Plan y de la participación en el
mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre
usted y la Compañía, ya que su participación en el Plan es completamente comercial y el único
empleador es Microchip Technology Mexico, S.DE R.L. DE C. V. en caso de ser aplicable, así
como tampoco establece ningún derecho entre la persona que tenga el derecho a optar y el
Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de
Acción Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al
igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las
disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leído, y que aprueba específica y
expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por
Compensación, apartado 10 del Acuerdo, en el cual se encuentra claramente descrito y
establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el
Plan y la participación en el mismo es ofrecida por la Compañía de forma enteramente
discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañía, así como su
Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el
valor de las Acciones en relación a las Unidades de Acción Restringida.
Finalmente, declara que no se reserva ninguna acción o derecho para interponer una demanda en
contra de la Compañía por compensación, daño o perjuicio alguno como resultado de su
participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, así
como a la Compañía, a su Sociedad controlante o Subsidiaria con respecto a cualquier demanda
que pudiera originarse en virtud del Plan.
NETHERLANDS
There are no country-specific terms and conditions.
PHILIPPINES
There are no country-specific terms and conditions.
ROMANIA
There are no country-specific terms and conditions.
SINGAPORE
Securities Law Legend. The RSUs are being granted pursuant to the “Qualifying Person”
exemption” under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.)
(“SFA”). The Plan has not been lodged or registered as a prospectus with the Monetary Authority
of Singapore. The Grantee should note that the RSUs are subject to section 257 of the SFA, and
the Grantee will not be able to make (i) any subsequent sale of the Shares in Singapore or (ii) any
offer of such subsequent sale of the Shares subject to the RSUs in Singapore, unless such sale or
offer is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than
section 280) of the SFA (Chapter 289, 2006 Ed.).
SPAIN
Termination of Employment. The RSUs provide a conditional right to Shares and may be forfeited
or affected by the Grantee’s termination of employment, as set forth in the Agreement. For avoidance
of doubt, the Grantee’s rights, if any, to the RSUs upon termination of employment shall be
determined as set forth in the Agreement, including, without limitation, where (i) the Grantee is
deemed to be constructively dismissed or unfairly dismissed without good cause; (ii) the Grantee
is dismissed for disciplinary or objective reasons or due to a collective dismissal; (iii) the Grantee
terminates employment due to a change of work location, duties or any other employment or
contractual condition (except as otherwise expressly set forth in the Agreement); or (iv) the Grantee
terminates employment due to the Company’s or any of its Subsidiaries’ unilateral breach of contract.
Consequently, the termination of the Grantee’s employment for any of the above reasons shall be
governed by paragraphs 4 and 19(i) of the Agreement, unless otherwise determined by the Company,
in its sole discretion.
Labor Law Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he or she
understands and agrees to the terms and conditions applicable to participation in the Plan and that
he or she has received a copy of the Plan.
The Grantee understands that the Company has unilaterally, gratuitously and discretionally decided
to grant RSUs under the Plan to individuals who may be employees of the Company or any Parent
or Subsidiary of the Company throughout the world. The decision is a limited decision that is
entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any Parent or Subsidiary on an ongoing basis, other than as expressly
set forth in the Plan and the Agreement. Consequently, the Grantee understands that any grant is
given on the assumption and condition that it shall not become a part of any employment contract
(either with the Company or any Parent or Subsidiary) and shall not be considered a mandatory
benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
Furthermore, the Grantee understands and freely accepts that there is no guarantee that any benefit
whatsoever shall arise from any gratuitous and discretionary grant since the future value of the
RSUs and the underlying Shares is unknown and unpredictable. In addition, the Grantee understands
that this grant would not be made but for the assumptions and conditions referred to above; thus,
the Grantee understands, acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason, then the RSUs shall be null
and void.
Securities Law Legend. The RSUs and the Shares issued upon vesting are considered a private
placement outside of the scope of Spanish laws on public offerings and issuances of securities.
SWEDEN
There are no country-specific terms and conditions.
SWITZERLAND
There are no country-specific terms and conditions.
TAIWAN
There are no country-specific terms and conditions.
THAILAND
There are no country-specific terms and conditions.
UNITED KINGDOM
Tax Obligations. The following provision supplements paragraph 9 (“Tax Obligations”) of the
Agreement:
If payment or withholding of the Tax-Related Items is not made within ninety (90) days of the event
giving rise to the Tax-Related Items or such other period specified in Section 222(1)(c) of the U.K.
Income Tax (Earnings and Pensions) Act 2003 (the “Due Date”), the amount of any uncollected
Tax-Related Items shall constitute a loan owed by the Grantee to the Employer, effective as of the
Due Date. The Grantee agrees that the loan will bear interest at the then-current official rate of Her
Majesty’s Revenue & Customs (“HMRC”), it will be immediately due and repayable, and the
Company or the Employer may recover it at any time thereafter by any of the means referred to in
paragraph 9 of the Agreement.
Notwithstanding the foregoing, if the Grantee is a director or executive officer of the Company
(within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended),
the Grantee shall not be eligible for a loan from the Company to cover the Tax-Related Items. In
the event that the Grantee is a director or executive officer and any such Tax-Related Items are not
collected from or paid by the Grantee by the Due Date, the amount of any uncollected Tax-Related
Items will constitute a benefit to the Grantee on which additional income tax and National Insurance
contributions (“NICs”) will be payable. The Grantee understands that he or she will be responsible
for reporting any income tax and NICs (including the Employer NICs, as defined below) due on
this additional benefit directly to HMRC under the self-assessment regime.
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be
settled in Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Joint Election for Transfer of Secondary Class 1 National Insurance Contributions to the
Grantee. As a condition of vesting of the RSUs, the Grantee agrees to accept any liability for
secondary Class 1 national insurance contributions, which may be payable by the Company or the
Employer in connection with the RSUs (“Employer NICs”). To accomplish the foregoing, the
Grantee agrees to enter into an election between himself or herself and the Employer (the “Election”),
by printing, signing and returning the form approved for such Election by HMRC and attached as
Exhibit B to this Agreement to the Human Resources Manager prior to vesting of the RSUs. The
Grantee further agrees to enter into any other consents or elections required to accomplish the
transfer of the Employer NICs to the Grantee, prior to vesting of the RSUs. The Grantee further
agrees to enter into such other joint elections as may be required between himself or herself and
any successor to the Company and/or the Employer. If the Grantee does not enter into an Election
prior to the vesting of the RSUs, the Grantee will permanently forfeit the RSUs without any liability
to the Company and/or the Employer and any Shares that have been issued upon vesting will be
returned to the Company at no cost to the Company.
The Grantee further agrees that the Company and/or the Employer may collect the Employer NICs
by any of the means set forth in paragraph 9 of the Agreement, as supplemented above.
*
*
*
EXHIBIT A
AGREEMENT
FOR PARTICIPANTS IN BELGIUM
AGREEMENT REGARDING A TWO YEAR LOCK-UP PERIOD
FOR SHARES ACQUIRED UPON VESTING OF RESTRICTED STOCK UNITS
If you have not already executed an Agreement for Participants in Belgium ("Agreement")
and would like to benefit from the favourable tax regime provided for in the Circular (as
defined below), please print, sign and return this Agreement to Microchip Technology
Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199 U.S.A., c/o Tricia Bajaj,
within 120 calendar days from the grant date specified in the Notice of Grant of Restricted
Stock Units. Please also retain a copy of this Agreement for your files.
BETWEEN
1) Microchip Technology Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199
U.S.A. (hereafter "Microchip"); and
NAME:
_________________________
ADDRESS: _________________________
(hereafter the "Grantee", and, together with Microchip, the "Parties")
WHEREAS
Microchip has granted on the grant date set forth in the applicable Notice of Grant of Restricted
Stock Units ("Grant Notice") a number of restricted stock units to the Grantee subject to the
terms and conditions in the Microchip Technology Incorporated 2004 Equity Incentive Plan (the
"Plan"), the Grant Notice and the Restricted Stock Units Agreement (the "RSU Grant");
This Agreement is also intended to cover any subsequent grant of restricted stock units that may
be made under the Plan, in the sole discretion of Microchip, on or after the Effective Date (as
defined below) ("Subsequent Grant"); and
The Grantee would like to benefit from the favourable tax regime provided for in Administrative
Circular nr. Ci.RH.241/467.450 of June 21, 1995 (the "Circular") with respect to the shares of
common stock of Microchip which he/she will acquire upon the vesting of the aforementioned
RSU Grant and any Subsequent Grant;
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 1 out of 2
PARTIES HAVE AGREED AS FOLLOWS:
The shares that will be delivered to the Grantee upon vesting of the RSU Grant and any
Subsequent Grant will be subject to a two year lock-up period, starting from the date of vesting
of the relevant grant, during which the Grantee cannot sell or otherwise transfer the respective
shares.
The Parties reserve the right to terminate this Agreement in its entirety, or as far as it relates to
any particular grant, at any time prior to the Vesting Date specified in the relevant Grant Notice.
Notice of termination must specify the grant date of the RSU Grant and/or Subsequent Grant to
which it is intended to apply. The Parties understand that termination shall disqualify the
Grantee from the favourable tax regime provided for in the Circular with respect to shares of
common stock of Microchip which he/she will acquire upon the vesting of only the particular
grant(s) specified in the notice of termination. Notice of termination shall be provided to
Microchip by email to #stockplans@microchip.com.
This Agreement shall be effective as of the date this Agreement is received by Microchip
(the "Effective Date").
COMPANY
Signature:
/s/ Steve Sanghi
Steve Sanghi, CEO
Microchip Technology Incorporated
GRANTEE
Signature:
Printed
Name:
Date:
Made in:
City, Country
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 2 out of 2
EXHIBIT B
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
(UK Employees)
Election To Transfer the Employer’s National Insurance Liability to the Employee
1.
Parties
This Election is between:
(A)
Employee Name (the “Employee”), who is eligible to receive Restricted
Stock Units granted by Microchip Technology Incorporated of 2355 Chandler
Blvd., Chandler, Arizona 85224, United States (the “Company”) pursuant to
the terms and conditions of the 2004 Equity Incentive Plan (the "Plan"), and
(B) Microchip Limited (registered number 2189500) with registered office at
Microchip House, 720 Wharfedale Road, Winnersh Triangle, Wokingham,
Berkshire RG41 5TP, United Kingdom (the “Employer”), which employs the
Employee.
2.
Purpose of Election
2.1
This Election relates to the employer’s secondary Class 1 National Insurance
Contributions (the “Employer’s Liability”) which may arise on:
(i)
the acquisition of securities pursuant to the Restricted Stock Units; and/or
(ii)
(iii)
the assignment or release of the Restricted Stock Units in return for
consideration; and/or
the receipt of any other benefit in money or money’s worth in connection with
the Restricted Stock Units,
(each, a “Taxable Event”) pursuant to section 4(4)(a) of the Social Security
Contributions and Benefits Act 1992.
2.2
This Election applies to all Restricted Stock Unit awards granted to the Employee
under the Plan on or after 23rd December 2005 up to the termination date of the Plan.
3.
The Election
This joint election does not apply with respect to any liability arising as a result of
U.K. anti-avoidance legislation. The Employee and the Employer jointly elect that
the entire liability of the Employer to pay the Employer’s Liability on the Taxable
Event is hereby transferred to the Employee. The Employee understands that by
signing this Election he or she will become personally liable for the Employer’s
Liability covered by this Election.
4.
Payment of the Employer’s Liability
4.1
The Employee hereby authorizes the Company and/or the Employer to collect the
Employer’s Liability from the Employee at any time after the Taxable Event:
(i)
by deduction from salary or any other payment payable to the Employee at
any time on or after the date of the Taxable Event; and/or
(ii)
directly from the Employee by payment in cash or cleared funds; and/or
(iii)
by arranging, on behalf of the Employee, for the sale of some of the securities
which the Employee is entitled to receive in respect of the Restricted Stock
Units.
The Employer hereby reserves for itself and the Company the right to withhold the
transfer of any securities to the Employee until full payment of the Employer’s
Liability is received.
The Employer agrees to remit the Employer’s Liability to the HM Revenue and
Customs on behalf of the Employee within 14 days after the end of the UK tax month
during which the Taxable Event occurs.
4.2
4.3
5.
Duration of Election
5.1
The Employee and the Employer agree to be bound by the terms of this Election
regardless of whether the Employee is transferred abroad or is not employed by the
Employer on the date on which the Employer’s Liability becomes due.
5.2
This Election will continue in effect until the earliest of the following:
(i)
(ii)
the Employee and the Employer agree in writing that it should cease to have
effect;
on the date the Employer serves written notice on the Employee terminating
its effect;
(iii)
on the date the HM Revenue and Customs withdraws approval of this
Election; or
(iv)
after due payment of the Employer's Liability in respect of the entirety of the
Restricted Stock Units to which this Election relates, such that the Election
ceases to have effect in accordance with its terms.
2
GRANTEE
Signature
Print Name
Date
Microchip Technology Incorporated
By:
Vice President of Human Resources
By
Title
3
Schedule of Employer Companies
The employing companies to which this Election relates are:
NAME
ADDRESS
Microchip Limited
Microchip House
720 Wharfedale Road
Winnersh Trinagle
Wokingham
Berkshire
RG41 5TP
United Kingdom
4
EXHIBIT 10.20
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
NOTICE OF GRANT OF RESTRICTED STOCK UNITS
Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in
this Notice of Grant.
Name:
You have been granted <# of shares> Restricted Stock Units (“RSUs”) subject to and in accordance with the
express terms and conditions of the Plan and the Restricted Stock Unit Agreement, including the appendix for your
country, if any (“Appendix” and together with the Restricted Stock Unit Agreement, the “Agreement”) attached
hereto as Exhibit A. The Plan and Agreement are incorporated herein in their entirety. Each RSU is equivalent to
the right to receive one share of Common Stock of the Company (“Share”) for purposes of determining the number
of Shares subject to this Award. No Shares will be issued until the vesting conditions of the Award described below
are satisfied and the restrictions lapse, subject to the terms and conditions set forth in the Plan and the Agreement.
This Award does not entitle Grantee to any stockholder rights with respect to the underlying Shares until the vesting
conditions of the Award described below are satisfied, the restrictions lapse and Shares are issued to him/her.
Additional terms of this Award are as follows:
Date of Grant:
Vesting Schedule:
Termination Period. This Award automatically terminates and Grantee’s rights are forfeited with respect to any
portion of the RSUs unvested on the date Grantee ceases to be a Service Provider or in the event that Grantee has
not accepted this Grant in accordance with Company procedures 31 days or more prior to its Vest Begin Date. In
no event shall this Award vest later than the Vesting Schedule outlined above.
Binding Agreements. By signature of Company's representative below, and Grantee’s acceptance of this Grant
in accordance with Company procedures, the parties agree that this Grant Notice, the Agreement, and the Plan
constitute Grantee’s entire agreement with respect to this Award and agree to be bound by the terms therein. Grantee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon
any questions relating to the Plan, the Agreement, and/or this Award. This Award may be modified by the Company,
but in accordance with Section 21(c) of the Plan, it may not be modified adversely to Grantee’s interest except by
means of a writing signed by the Company and Grantee. The Company will administer the Plan from the United
States of America. The internal laws of the State of Arizona, United States of America, but not its choice of law
principles, will govern this Award.
GRANTEE:
Signature
Print Name
Microchip Technology Incorporates
/s/ Steve Sanghi
By
Chairman of the Board & CEO
Title
Exhibit A
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
Grant of Restricted Stock Units. Microchip Technology Incorporated (the “Company”)
1.
hereby grants to the Grantee named in the Notice of Grant of Restricted Stock Units (“Grant Notice”)
an Award of Restricted Stock Units (“RSUs”), as set forth in the Grant Notice and subject to the
terms and conditions in this Restricted Stock Unit Agreement, including any appendix for the
Grantee’s country (the “Appendix” and together with the Restricted Stock Unit Agreement, the
“Agreement”) and the Company’s 2004 Equity Incentive Plan (the “Plan”). Unless otherwise
defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.
2.
Company's Obligation. Each RSU represents the right to receive a Share in accordance with
the Vesting Period in the Grant Notice. Unless and until the RSUs vest, the Grantee will have no
right to receive Shares underlying such RSUs. Prior to actual distribution of Shares pursuant to
any vested RSUs, such RSUs will represent an unsecured obligation of the Company, payable (if
at all) only from the general assets of the Company.
Vesting Schedule. Subject to paragraph 4 of this Agreement, the RSUs awarded by this
3.
Agreement will vest and all restrictions lapse according to the vesting schedule specified in the
Grant Notice.
Forfeiture upon Termination as a Service Provider. Notwithstanding any contrary provision
4.
of this Agreement or the Grant Notice, if the Grantee terminates service as a Service Provider for
any or no reason prior to vesting, the unvested RSUs awarded by this Agreement will thereupon be
forfeited (as determined in accordance with paragraph 10(i) below) at no cost to the Company.
5.
Payment after Vesting. Any RSUs that vest in accordance with paragraph 3 of this Agreement
will be paid to the Grantee (or in the event of the Grantee's death, to his or her estate) in Shares
(unless otherwise determined by the Administrator and stated in the Appendix), upon satisfaction,
as determined by the Company, of any Tax-Related Items as set forth in paragraph 9 of this
Agreement. The Shares will be issued to the Grantee as soon as practicable after the Vesting Date,
but in any event, within the period ending on the later to occur of the date that is two and a half (2
½) months from the end of (i) the Grantee’s tax year that includes the applicable Vesting Date, or
(ii) the Company’s tax year that includes the applicable vesting date.
Payments after Death. Any distribution or delivery to be made to the Grantee under this
6.
Agreement will, if the Grantee is then deceased, be made to the administrator or executor of the
Grantee’s estate. Any such administrator or executor must furnish the Company with (a) written
notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish
the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.
Grant is Not Transferable. Except to the limited extent provided in paragraph 6 of this
7.
Agreement, RSUs may not be transferred, assigned, pledged or hypothecated in any way (whether
by operation of law or otherwise) and will not be subject to sale under execution, attachment or
similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of
the RSUs, or any right or privilege conferred hereby, or upon any attempted sale under any execution,
attachment or similar process, the RSUs grant and the rights and privileges conferred hereby
immediately will become null and void.
8.
Rights as Stockholder. Neither the Grantee nor any person claiming under or through the
Grantee will have any of the rights or privileges of a stockholder of the Company in respect of any
Shares deliverable hereunder unless and until the Grantee’s rights with respect to the RSUs have
become vested and certificates representing such Shares have been issued, recorded on the records
of the Company or its transfer agents or registrars, and delivered to the Grantee or Grantee’s broker
or the Shares have been electronically transferred to Grantee’s account.
9.
Tax Obligations. Regardless of any action the Company or the Grantee’s employer (the
“Employer”) takes with respect to any or all income tax, social insurance, payroll tax, payment on
account or other tax-related items related to the Grantee’s participation in the Plan that are legally
applicable to the Grantee (“Tax-Related Items”), the Grantee acknowledges that the ultimate liability
for all Tax-Related Items is and remains his or her responsibility and that such liability may exceed
the amount actually withheld by the Company or the Employer. The Grantee further acknowledges
that the Company and/or the Employer (1) make no representations or undertakings regarding the
treatment of any Tax-Related Items in connection with any aspect of the RSUs, including the grant
or vesting of the RSUs, the issuance of Shares on the relevant Vesting Date, the subsequent sale of
Shares acquired at vesting of the RSUs, if any, and the receipt of any dividends; and (2) do not
commit and are under no obligation to structure the terms of the grant or any aspect of the RSUs
to reduce or eliminate the Grantee’s liability for Tax-Related Items or achieve any particular tax
result. Further, if the Grantee becomes subject to tax and/or social security contributions in more
than one jurisdiction between the Grant Date and the date of any relevant taxable, tax and/or social
security contribution withholding event, as applicable, the Grantee acknowledges that the Company
and/or the Employer (or former employer, as applicable) may be required to withhold or account
for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable, tax and/or social security contribution withholding event, the
Grantee shall pay or make appropriate arrangements satisfactory to the Company and/or the
Employer to satisfy all Tax-Related Items. In this regard, the Grantee authorizes the Company and/
or the Employer, at their sole discretion, to satisfy the obligations with respect to Tax-Related Items
by one or a combination of the following: (i) withholding from the Grantee’s wages or other cash
compensation paid to the Grantee by the Company and/or the Employer; or (ii) withholding from
proceeds of the sale of Shares acquired upon vesting of the RSUs, either through a voluntary sale
or through a mandatory sale arrangement by the Company (on the Grantee’s behalf pursuant to this
authorization); or (iii) withholding in Shares to be issued upon vesting of the RSUs; or (iv) by
requiring direct payment from the Grantee in cash (or its equivalent). To avoid negative accounting
treatment, the Company will withhold or account for Tax-Related Items by considering applicable
minimum statutory withholding amounts or other applicable withholding rates. If the Grantee’s
and/or the Company’s withholding obligations for Tax-Related Items are satisfied as described in
(iii) of this paragraph, the Company will endeavor to sell only the number of Shares required to
satisfy the Grantee’s and/or the Company’s withholding obligations for Tax-Related Items; however,
the Grantee agrees that the Company may sell more Shares than necessary to satisfy the Tax-Related
Items. Further, the Grantee will be deemed to have been issued the full number of Shares subject
to the vested RSUs, notwithstanding that a number of Shares is held back solely for purposes of
paying the Tax-Related Items due as a result of any aspect of the Grantee’s participation in the Plan.
The Grantee hereby consents to any action reasonably taken by the Company to satisfy his or her
obligations for Tax-Related Items.
Finally, the Grantee shall pay to the Company or the Employer any amount of Tax-
Related Items that the Company or the Employer may be required to withhold or account for as a
result of the Grantee’s participation in the Plan that cannot be satisfied by the means previously
described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of
Shares at vesting if the Grantee fails to comply with his or her obligations in connection with the
Tax-Related Items.
Nature of Grant. In accepting the RSUs, the Grantee expressly acknowledges, understands
10.
and agrees to the following:
(a)
The Company is granting the Award under the Plan. The Plan is established voluntarily by
the Company, is discretionary in nature, and may be modified, amended, suspended or terminated
by the Company at any time;
(b)
The grant of the Award, future grants of Awards, if any, and benefits and rights provided
under the Plan are voluntary, occasional and at the complete discretion of the Company and do not
constitute regular or periodic payments. No grant of Awards will be deemed to create any contractual
or other right to receive future RSU Awards or benefits in lieu of RSUs, whether or not such a
reservation is explicitly stated at the time of such a grant or whether such Awards have been granted
repeatedly in the past. All decisions with respect to future RSU Awards, if any, will be at the sole
discretion of the Company;
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
(c)
extraordinary items that do not constitute compensation of any kind for services of any kind rendered
to the Company or the Employer, and which are outside the scope of the Grantee’s employment
contract, if any;
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
(d)
not intended to replace any pension rights or compensation;
(e)
For Grantee’s residing outside the U.S., the RSUs and the Shares subject to the RSUs are
not part of Grantee’s normal or expected salary or compensation for any purposes, including, without
limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-
service payments, vacation, bonuses, long-term service awards, indemnification, pension or
retirement or welfare benefits, or any other payments, benefits or rights of any kind, and in no event
should be considered as compensation for, or relating in any way to, past services for the Company,
the Employer or any Subsidiary;
The RSUs and the Grantee’s participation in the Plan shall not be interpreted to form an
(f)
employment contract or relationship with the Company or any Subsidiary;
(g)
The future value of the underlying Shares is unknown and cannot be predicted with certainty;
No claim or entitlement to compensation or damages shall arise from forfeiture of the RSU
(h)
Awards resulting from termination of the Grantee’s employment by the Company or the Employer
(for any reason whatsoever and regardless of whether in breach of local labor laws) and, in
consideration of the RSU Awards, to which the Grantee otherwise is not entitled, the Grantee
irrevocably agrees never to institute any claim against the Company or the Employer, waives his
or her ability, if any, to bring any such claim, and releases the Company and the Employer from
any such claim that may arise; if, notwithstanding the foregoing, any such claim is allowed by a
court of competent jurisdiction, then, by participating in the Plan, the Grantee shall be deemed
irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents
necessary to request dismissal or withdrawal of such claim;
(i)
In the event the Grantee’s termination of employment (regardless of whether in breach of
local labor laws), the Grantee’s right to vest in the RSUs under the Plan, if any, will terminate
effective as of the date that the Grantee is no longer actively employed and will not be extended by
any notice period mandated under local law (e.g., active employment would not include a period
of “garden leave” or similar period pursuant to local law); the Administrator shall have the exclusive
discretion to determine when the Grantee is no longer actively employed for purposes of the RSUs;
(j)
The Company has the right, at any time to amend, suspend or terminate the Plan. The Plan
will not be deemed to constitute, and will not be construed by Grantee to constitute, part of the
terms and conditions of employment, and that the Company will not incur any liability of any kind
to Grantee as a result of any change or amendment, or any cancellation, of the Plan at any time.
(k)
The Grantee's employment with the Employer is not affected at all by any Award and shall
not create a right to further employment with the Employer. Accordingly, the terms of the Grantee's
employment with the Employer will be determined from time to time by the Company or the
Subsidiary employing the Grantee (as the case may be), and the Grantee’s participation in the Plan
shall not interfere with the ability of the Employer, which is hereby expressly reserved, to terminate
or change the terms of the employment of the Grantee at any time for any reason whatsoever, with
or without good cause or notice, except as may be expressly prohibited by the laws of the jurisdiction
in which the Grantee is employed; and
(l)
The Grantee is voluntarily participating in the Plan.
11.
No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice,
nor is the Company making any recommendations regarding the Grantee’s participation in the Plan,
or the Grantee’s acquisition or sale of the underlying Shares. The Grantee is hereby advised to
consult with his or her own personal tax, legal, and financial advisors regarding his or her
participation in the Plan before taking any action related to the Plan.
12.
Data Privacy. By entering into this Agreement, and as a condition of the vesting of the
Award, Grantee explicitly and unambiguously consents to the collection, use, and transfer of
personal data, as set forth in this Agreement and any other grant materials by and among, as
applicable, the Employer, the Company and any Parent or Subsidiary of the Company for the
exclusive purpose of implementing, administering and managing the Grantee’s participation in
the Plan.
(i)
Grantee understands that the Employer, the Company and its Subsidiaries hold
certain personal information about the Grantee, including, but not limited to, the
Grantee’s name, home address and telephone number, date of birth, social security
number or other identification number, salary, nationality, job title, any Shares or
directorships held in the Company, and details of all Awards or other entitlement to Shares
awarded, canceled, exercised, vested, unvested, or outstanding in Grantee’s favor, for the
exclusive purpose of managing and administering the Plan (“Data”).
Grantee further understands that the Employer, the Company and/or its
(ii)
Subsidiaries will transfer Data among themselves as necessary for the purposes of
implementation, administration, and management of Grantee’s participation in the Plan,
and that the Employer, the Company and/or its Subsidiaries may each further transfer
Data to any third parties assisting the Company in the implementation, administration,
and management of the Plan, including the broker or such other stock plan service
provider as may be selected by the Administrator (“Data Recipients”).
(iii) Grantee understands that the Data Recipients may be located in Grantee’s country
or elsewhere, including outside the European Economic Area, and that the Data
Recipient’s country (e.g., the United States) may have different data privacy laws and
protections. Grantee authorizes the Data Recipients to receive, possess, use, retain, and
transfer Data, in electronic or other form, for the purposes of implementing,
administering, and managing Grantee’s participation in the Plan. Grantee understands
that Data will be held only as long as is necessary to implement, administer and manage
the Grantee’s participation in the Plan.
(iv) Grantee understands that Grantee may request a list with the names and addresses
of the potential Data Recipients by contacting his/her local human resources
representative. Grantee further understands that he/she may, at any time, review the
Data, request additional information about the storage and processing of Data, request
that any necessary amendments be made to it, or withdraw Grantee’s consent herein in
writing by contacting the Company. Grantee further understands, however, that
withdrawing consent may affect Grantee’s ability to participate in the Plan. For more
information on the consequences of Grantee’s refusal to consent or withdrawal of consent,
Grantee understands that Grantee may contact his/her local human resources
representative.
Language. If the Grantee receives this Agreement or any other document related to the Plan
13.
translated into a language other than English and if the meaning of the translated version differs
from the English version, the English version shall control.
Binding Agreement. Subject to the limitation on the transferability of this grant contained
14.
herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal
representatives, successors and assigns of the parties hereto.
15.
Additional Conditions to Issuance of Stock. If at any time the Company will determine, in
its discretion, that the listing, registration or qualification of the Shares upon any securities exchange
or under any state or federal law, or the consent or approval of any governmental regulatory authority
is necessary or desirable as a condition to the issuance of Shares to the Grantee (or his or her estate),
such issuance will not occur unless and until such listing, registration, qualification, consent or
approval will have been effected or obtained free of any conditions not acceptable to the Company.
The Company will make all reasonable efforts to meet the requirements of any such state or federal
law or securities exchange and to obtain any such consent or approval of any such governmental
authority.
Administrator Authority. The Administrator has the power to interpret the Plan, the Grant
16.
Notice and this Agreement and to adopt such rules for the administration, interpretation and
application thereof as are consistent therewith and to interpret or revoke any such rules (including,
but not limited to, the determination of whether or not any RSUs have vested). All actions taken
and all interpretations and determinations made by the Administrator in good faith will be final and
binding upon Grantee, the Company and all other interested persons. No member of the
Administrator will be personally liable for any action, determination or interpretation made in good
faith with respect to the Plan, the Grant Notice or this Agreement.
17.
Notice Requirement. Where there is a legal requirement for any notice or document to be
sent to any person by any other person, it shall be considered sent if an electronic transmission of
the relevant information is sent in a form previously determined as being acceptable to the
Administrator. For the avoidance of doubt, the Administrator may dispense with the requirement
to tender a certificate on the issuance of Shares under an RSU Award where the Administrator
authorizes any system permitting electronic notification.
18.
Address for Notices. Any notice to be given to the Company under the terms of this
Agreement will be addressed to the Company at 2355 West Chandler Boulevard, Chandler AZ
85224, U.S.A. Attn: Stock Administration, or at such other address as the Company may hereafter
designate in writing or electronically.
Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to
19.
deliver any documents related to current or future participation in the Plan by electronic means.
The Grantee hereby consents to receive such documents by electronic delivery and agrees to
participate in the Plan through an online or electronic system established and maintained by the
Company or a third party designated by the Company.
Appendix. Notwithstanding any provisions in this Agreement, the RSUs shall be subject to
20.
any special terms and conditions for the Grantee’s country set forth in the Appendix. Moreover, if
the Grantee relocates to one of the countries included in the Appendix, the special terms and
conditions for such country shall apply to the Grantee, to the extent that the Company determines
that the application of such terms and conditions is necessary or advisable in order to comply with
local law or facilitate the administration of the Plan. The Appendix constitutes part of this
Agreement.
21.
Imposition of Other Requirements. The Company reserves the right to impose other
requirements on the Grantee’s participation in the Plan, on the RSUs and on any Shares acquired
under this Award, to the extent that the Company determines it is necessary or advisable to comply
with local law or facilitate the administration of the Plan, and to require the Grantee to sign any
additional agreements or undertakings that may be necessary to accomplish the foregoing.
Entire Agreement; Governing Law. The Plan and Grant Notice are incorporated herein by
22.
reference. The Plan, Grant Notice and this Agreement constitute the entire agreement of the parties
with respect to the subject matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and Grantee with respect to the subject matter hereof, and may not be
modified adversely to the Grantee’s interest except by means of a writing signed by the Company
and Grantee. The Company will administer the Plan from the United States of America. This
Agreement, the Grant Notice and all Awards are governed by the internal substantive laws, but not
the choice of law principles, of the State of Arizona, United States of America.
For purposes of litigating any dispute that arises under this grant or the Agreement, the
parties hereby submit to and consent to the jurisdiction of the State of Arizona and agree that such
litigation shall be conducted in the courts of Maricopa County, Arizona, or the federal courts for
the United States for the District of Arizona, where this grant is made and/or to be performed.
23.
Severability. The provisions of this Agreement are severable, and, if any one or more
provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining
provisions nevertheless shall be binding and enforceable.
By Grantee’s electronic acceptance of the Agreement, Grantee agrees that this Award is granted
under and governed by the terms and conditions of the Plan, the Grant Notice and this Agreement.
Grantee has reviewed the Plan, the Grant Notice and this Agreement in their entirety, has had an
opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands
all provisions of the Plan, the Grant Notice and this Agreement. Grantee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the
Administrator upon any questions relating to the Plan, the Grant Notice and this Agreement.
MICROCHIP TECHNOLOGY
By: /s/ Steve Sanghi
Steve Sanghi, Chairman of the Board & CEO
APPENDIX
ADDITIONAL TERMS AND CONDITIONS OF THE
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNITS AGREEMENT
This Appendix includes additional terms and conditions that govern the RSUs granted to the Grantee
under the Plan if the Grantee resides in one of the countries listed below. All capitalized terms used,
but not defined herein shall have the meaning given to such terms in the Plan and/or the Agreement.
If the Grantee is a citizen or resident of a country other than the one in which the Grantee is currently
working or transfers employment after the RSUs are granted, the Company shall, in its discretion,
determine to what extent the terms and conditions contained herein shall be applicable to the Grantee.
AUSTRALIA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, due to securities law
considerations in Australia, the RSUs will be settled in Shares only. The RSUs do not provide any
right for the Grantee to receive a cash payment.
AUSTRIA
There are no country-specific terms and conditions.
BELGIUM
Tax Reporting. If the Grantee is a Belgian resident, the Grantee is required to report any security
(e.g., Shares acquired under the Plan) or bank account (including any brokerage account held by
you at E*Trade Financial or other stock plan service provider as may be selected by the Company
in the future) held outside Belgium on your annual income tax return.
Agreement for Participants in Belgium. Under Belgian tax law, if the Shares acquired at vesting
of RSUs cannot be sold for two years from the Vesting Date, the fair market value of the Shares on
the Vesting Date is deemed to be 100/120 (83 1/3%) of the actual fair market value of such shares
for purposes of calculating the taxable amount. If the Grantee would like to take advantage of
this favourable tax treatment, the Grantee must print, sign and return a copy of the Agreement
Regarding a Two Year Lock Up Period for Shares Acquired Upon Vesting of Restricted Stock
Units attached as Exhibit A to this Agreement by the deadline specified therein.
CANADA
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, due to securities law
considerations in Canada, the RSUs will be settled in Shares only. The RSUs do not provide any
right for the Grantee to receive a cash payment.
Termination of Employment. The following provision replaces paragraph 10(i) of the Agreement:
In the event of termination of the Grantee’s employment, the Grantee’s right to vest in the RSUs
under the Plan, if any, will terminate effective as of the date that is the earlier of (i) the date on
which the Grantee receives a notice of termination of employment from the Company or the
Employer, or (ii) the date on which the Grantee is no longer employed, regardless of any notice
period or period of pay in lieu of such notice required under local law; the Administrator shall have
the exclusive discretion to determine when the Grantee is no longer employed for purposes of the
RSUs.
The following terms and conditions apply if the Grantee is in Quebec:
Authorization to Release and Transfer Necessary Personal Information. The following
provision supplements paragraph 12 of the Agreement:
The Grantee hereby authorizes the Company and the Company’s representatives to discuss with
and obtain all relevant information from all personnel, professional or not, involved in the
administration and operation of the Plan. The Grantee further authorizes the Company and/or any
Parent or Subsidiary to disclose and discuss the Plan with their advisors. The Grantee further
authorizes the Company and any Parent or Subsidiary to record and keep such information in the
Grantee’s employment file.
French Language Acknowledgment. The following provision supplements paragraph 13 of the
Agreement:
The parties acknowledge that it is their express wish that this Agreement, as well as all documents,
notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly
or directly hereto, be drawn up in English.
Les parties reconnaissent avoir exigé la rédaction en anglais de cette convention, ainsi que de tous
documents, avis et procédures judiciaires, exécutés, donnés ou intentés en vertu de, ou liés
directement ou indirectement à, la présente convention.
CHINA
Deposit of Shares and Distribution of Dividends. Due to exchange control laws and regulations
in the People’s Republic of China (“PRC”), if the Participant is a PRC national, any Shares acquired
at vesting of the RSUs will be deposited in an account established for Grantee by the Company (the
“Account”) with E*Trade Financial or any successor broker designated by Company, in its sole
discretion (the “Designated Broker”). Grantee must maintain the Shares issued to Grantee under
the Plan in the Account and must not transfer the Shares to any person, broker or other account with
the Designated Broker or to a brokerage account outside of the Designated Broker.
Any dividends related to Shares acquired under the Plan may, at the Company’s sole discretion, be
deposited into an Account with the Designated Broker, or re-invested by Company on behalf of the
Grantee.
Until such time as the Shares acquired at vesting of the RSUs are sold, the Grantee must maintain
the Shares issued to Grantee under the Plan in the Account and must not transfer the Shares to
another account with the Designated Broker or to a brokerage account outside of the Designated
Broker.
Forfeiture and Sale upon Termination as a Service Provider. The following provision replaces
paragraph 4 of the Agreement:
(a)
Notwithstanding any contrary provision of this Agreement or the Grant Notice, if the Grantee
terminates service as a Service Provider for any or no reason prior to vesting, the unvested RSUs
awarded by this Agreement will thereupon be forfeited at no cost to the Company.
(b)
The Grantee must sell all Shares acquired under the Plan on or before the date of termination
as a Service Provider. Grantee hereby authorizes Company or the Designated Broker to sell such
Shares on behalf of the Grantee without notice to or consent from the Grantee if Grantee has not
sold all Shares so acquired as of the date of termination of service. The sale of Shares shall be
carried out within a reasonable time of termination of service as determined by Company. The
proceeds from such sale, net any Tax-Related Items and broker’s fees, shall be deposited in Grantee’s
bank account in China, or delivered to Grantee in China through such other means determined by
Company, in its discretion. Grantee hereby releases and holds harmless Company and any Parent
or Subsidiary, employees and agents (“Indemnitees”) from any loss that Grantee may incur due to
the timing of the sale of Shares by Company and acknowledges that the Company and the Employer
are under no obligation to arrange for the sale of the Shares at any particular price and are not liable
for any fluctuations in the trading price of the Shares and/or the U.S. dollar exchange rate.
If Grantee does transfer Shares into an account to which Company has no visibility, then
(c)
Grantee will sell all Shares no later than the date of termination as a Service Provider and provide
written evidence of such sale of Shares to Company within two (2) business days of the date of
termination as a Service Provider. Such evidence must be in a form acceptable to Company.
(d)
Grantee shall defend, hold harmless and indemnify Indemnitees from any and all penalties,
damages, and costs that may be incurred by Indemnitees arising out of or in connection with
Grantee’s failure to comply with these obligations and any requirements under local exchange
control laws applicable to him/her.
Exchange Control Restriction. The Grantee understands and agrees that, if he or she is a PRC
national, due to exchange control laws and regulations in the PRC, the Grantee will be required to
repatriate immediately to the PRC any cash proceeds from the sale of the Shares acquired under
the Plan. The Grantee understands further that, under applicable laws and regulations, such
repatriation may need to be effected through a special foreign exchange account established by the
Company or a Parent or Subsidiary, and the Grantee consents and agrees that the proceeds from the
sale of the Shares may be transferred to such special account before being delivered to the Grantee.
Moreover, if the proceeds from the sale of the Shares are converted to local currency, the Grantee
acknowledges that the Company (including its Parent and Subsidiary corporations) is under no
obligation to secure any particular currency conversion rate and may face delays in converting the
proceeds to local currency due to exchange control restrictions in the PRC. The Grantee agrees to
bear the risk of any fluctuation in the U.S. dollar/local currency exchange rate between the date the
Grantee realizes U.S. dollar proceeds from his or her participation in the Plan and the date that the
Grantee receives cash proceeds converted to local currency. The Grantee also agrees to comply
with any other requirements that may be imposed by the Company in the future to facilitate
compliance with exchange control requirements in the PRC.
DENMARK
There are no country-specific terms and conditions.
FRANCE
Nature of RSUs. The RSUs granted to you pursuant to this Agreement are not intended to
qualify for the favorable tax and social security treatment in France applicable to shares granted
for no consideration under Sections L. 225-197 to L. 225-197-6 of the French Commercial Code,
as amended.
Consent to Receive Information in English. By accepting this Agreement providing for the
terms and conditions of the RSUs, the Grantee confirms that he/she has read and understood the
documents relating to this Award (i.e., the U.S. Plan and this Agreement), which were provided
in English. The Grantee accepts the terms of those documents accordingly.
En acceptant de manière électronique le présent Contrat d’Attribution décrivant les termes et
conditions de votre attribution d’Actions Gratuites, vous confirmez ainsi avoir lu et compris les
documents relatifs à cette attribution (c’est-à-dire, le Plan Américain et le présent Contrat
d’Attribution) qui vous ont été communiqués en langue anglaise. Vous en acceptez les termes en
connaissance de cause.
Exchange Control Information. If the Grantee maintains a foreign bank account, he/she is
required to report such to the French tax authorities when filing his/her annual tax return.
GERMANY
There are no country-specific terms and conditions.
HONG KONG
Securities Law Warning. The offer of the RSUs and the Shares subject to the RSUs do not constitute
a public offering of securities under Hong Kong law and are available only to Employees of the
Company or its Subsidiaries participating in the Plan. The Grantee should be aware that the contents
of this Agreement have not been prepared in accordance with and are not intended to constitute a
“prospectus” for a public offering of securities under the applicable securities legislation in Hong
Kong. Nor have the documents been reviewed by any regulatory authority in Hong Kong. The
RSUs are intended only for the personal use of each Grantee and may not be distributed to any other
person. The Grantee is advised to exercise caution in relation to this offer. If the Grantee is in doubt
about any of the contents of this Agreement or the Plan, the Grantee should obtain independent
professional advice.
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be
settled in Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Sale of Shares. In the event that the RSUs vest within six months of the date of grant, the Grantee
agrees that he or she will not sell any Shares thus acquired prior to the six-month anniversary of
the date of grant.
HUNGARY
There are no country-specific terms and conditions.
INDIA
Exchange Control Documentation. The Grantee understands that he or she must repatriate the
sale proceeds upon the sale of Shares acquired under the Plan to India and convert the proceeds
into local currency within 90 days of receipt. The Grantee will receive a foreign inward remittance
certificate (“FIRC”) from the bank where the foreign currency is deposited. The Grantee should
retain the FIRC as evidence of the repatriation of funds in the event that the Reserve Bank of India,
the Employer or the Company requests proof of repatriation.
IRELAND
There are no country-specific terms and conditions.
ISRAEL
Terms and Conditions
The following provision applies to Grantees located in Israel on the Grant Date.
Trust Arrangement. The Grantee understands and agrees that the RSUs offered are subject to
and in accordance with the terms of the Plan, Israeli Subplan (the “Subplan”), Agreement and
the Israel Beneficiary 102 Undertaking. The Grantee understands that the RSUs shall be
allocated under the provisions of the track referred to as the “Capital Gain Route,” according to
Section 102(b)(2) and 102(b)(3) of the Israeli Income Tax Ordinance (“Section 102”) and shall
be held by the trustee for the periods stated in Section 102. The Grantee hereby confirms that he
or she has: (i) read and understands the Plan, Subplan, Agreement and Israel Beneficiary 102
Undertaking; (ii) received all the clarifications and explanations that the Grantee has requested;
and (iii) had the opportunity to consult with his or her advisers before accepting the Agreement.
In the event of any inconsistencies between the provisions of this Israeli Appendix and the
Agreement, the provisions of this Appendix shall govern the RSUs and any Shares and in no
event shall any term require shareholder approval as set out in Section 21(b) of the Plan.
Limited Transferability. This provision supplements Section 7 of the Agreement:
Subject to the provisions of the Plan, Section 102 and any rules or regulations or orders or
procedures promulgated thereunder, to obtain favourable tax treatment for Capital Gain Route
awards, the Grantee may not sell or transfer any RSU shares received upon vesting or received
subsequently following any realization of rights until the lapse of the holding period required is
met under Section 102. Notwithstanding the above, if any such sale or release occurs during the
holding period, the sanctions under Section 102 and under any rules or regulation or orders or
procedures promulgated thereunder will apply to and will be borne by the Grantee.
Issuance of Shares. This provision supplements Sections 5 and 8 of the Agreement:
If the vested RSUs are issued during the holding period, such Shares shall be restricted and held
by E*Trade Financial or any successor broker and/or trustee designated by Company and the Trustee
on the Grantee’s behalf. In the event that the vested RSUs are issued after the expiration of the
holding period, the Grantee may freely sell the shares held by E*Trade Financial, provided that the
Grantee first complies with any Tax-Related Items stipulated under this Agreement to the Trustee’s
and the Company’s satisfaction, or in trust on the Grantee’s behalf to the Trustee.
Tax Obligations. This provision supplements Section 9 of the Agreement:
The Grantee hereby agrees to indemnify the Company (or any Subsidiary) and/or the Trustee and
hold them harmless against and from any and all liability for any Tax-Related Items and other
amounts, or interest or penalty thereon, including without limitation, liabilities relating to the
necessity to withhold, or to have withheld, any such amounts from any payment made to the Grantee.
Any reference to the Company or the Employer shall include a reference to the Trustee. The Grantee
hereby undertakes to release the Trustee from any liability in respect of any action or decisions duly
taken and bona fide executed in relation to the Plan or any RSUs or Shares acquired under the Plan.
The Grantee agrees to execute any and all documents which the Company or the Trustee may
reasonably determine to be necessary in order to comply with the Israeli Income Tax Ordinance.
The Grantee shall not be liable for the Employer’s components of payments to the national insurance
institute, unless otherwise agreed by the Grantee and allowed by applicable tax laws. Furthermore,
the Grantee agrees to indemnify the Company, the Employer and/or the Trustee and hold them
harmless against and from any and all liability for any such tax or interest or penalty thereon that
Grantee has agreed to pay, including without limitation, liabilities relating to the necessity to
withhold, or to have withheld, any such tax from any payment made to the Grantee for which the
Grantee is responsible.
Notwithstanding anything to the contrary in the Agreement, no Tax-Related Items will be settled
by withholding Shares, unless the ITA approves otherwise in writing.
Governing Law. This section supplements Section 22 of the Agreement:
To the extent any covenant, condition, or other provision of the Agreement and the rights of the
Grantee hereunder are intended to be rights granted under Section 102 and therefore determined
to be subject to Israeli law, such covenant, condition, or other provision of the Agreement shall
be subject to applicable Israeli law, but shall in no way affect, impair, or invalidate any other
provision of the Agreement, and the applicability of the Plan to such covenant, condition, or
other provision of the Agreement.
Written Acceptance. The Grantee must print, sign and deliver the signed copy of the Israel
Beneficiary 102 Undertaking within 45 days of the new hire grant date to: Microchip Technology
Israel Ltd., Zarchin 10, Raanana, P.O Box 4319, 43662. If the Company does not receive the
signed Israel Beneficiary 102 Undertaking within 45 days, the RSUs may not qualify for
preferential tax treatment.
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
ISRAEL BENEFICIARY 102 UNDERTAKING
If the Grantee has not already executed an Israel Beneficiary 102 Undertaking in
connection with grants made under the Israeli Subplan, the Grantee must print, sign and
deliver the signed copy of this Israel Beneficiary 102 Undertaking within 45 days of the new
hire grant date to: Microchip Technology Israel Ltd., Zarchin 10, Raanana, P.O Box 4319,
43662. If the Company does not receive the signed Israel Beneficiary 102 Undertaking
within 45 days, the RSUs may not qualify for preferential tax treatment.
1.
2.
3.
4.
5.
I hereby agree that any shares (the “Shares”) (as defined by Section 102 of
the Income Tax Ordinance [New Version], 1961) (the “Tax Ordinance”)
issued to me by Microchip Technology Incorporated according to and under
the terms and conditions of the Plan and the Israeli Subplan adopted by
Microchip Technology Incorporated as of 13 December 2013 (collectively,
the "Plan") are granted to me to qualify under the capital gain tax treatment
in accordance and pursuant to Section 102(b)(2) of the Tax Ordinance after
132 amendment (“Section 102”) and the Income Tax Rules (Tax Relief upon
the Allotment of Shares to Employees), 2003 (the “Rules”) unless I am
otherwise notified subject to Microchip Technology Incorporated’s absolute
discretion to change such election on future grants and subject to the Tax
Authorities’ approval.
I declare and confirm that I am familiar with the terms of Section 102, the
Rules, and the implications and consequences of the chosen tax arrangement
with respect to the Shares, and consent that all the terms and conditions set
forth in Section 102 and the Rules, as shall be amended from time to time,
shall apply to me and bind me.
I hereby declare and confirm that I am familiar with the provisions of the
trust agreement signed between Microchip Technology Israel Ltd. and Tamir
Fishman Trusts 2004 Ltd. (the "Trustee") (the “Trust Agreement”), including
the deed of trust, attached to the Trust Agreement and constitute an integral
part thereto (“Deed of Trust”), and I consent that the Trust Agreement and
the Deed of Trust shall fully bind me.
Without derogating from the generality of the aforesaid, I agree that the
Shares will be deposited in trust with the Trustee and be held in trust in
accordance with Section 102, the Rules and the Trust Agreement.
I hereby declare and consent that any and all the rights that I shall be entitled
to with respect to the Shares, including, without limitation, dividend and
shares issued pursuant to adjustments made by Microchip Technology
6.
7.
8.
9.
Incorporated and shall be subject to Section 102, the Rules and the Trust
Agreement.
Without derogating from the generality of the aforesaid, I acknowledge that
during the “Holding Period” as determined by the Tax Ordinance I am
prevented from selling the Shares, or releasing them from the Trustee, before
the termination of the “Holding Period” and I understand the tax implications
and consequences that may be applied as a result of breaching such obligation,
as set by Section 102, which I am familiar with.
If I will cease to be an Israeli resident or if my employment will be terminated
for any reason, the Shares shall remain subject to section 102, the Rules and
the Trust Agreement.
I hereby agree that any tax liability whatsoever arising from the grant, vesting
of any restricted stock units, the sale of Shares, the release of Shares from
the Trustee or any other event or act with respect to the Shares granted to
me, shall be borne solely by me. I declare and consent that the Microchip
Technology Incorporated, Microchip Technology Israel Ltd. and/or the
Trustee shall make any tax payment due, out of the proceeds of any sale of
Shares, to any tax authority, according to Section 102, the Rules, the Trust
Agreement or any other compulsory payments or applicable law.
I understand that this grant of Shares under the capital gain track is
conditioned upon the receipt, inter alia, of all required approvals from the
tax authorities. Accordingly, to the extent that for whatever reason Microchip
Technology Israel Ltd. shall not be granted an approval by the Israeli Tax
Authorities under section 102, I shall bear and pay any and all taxes and any
other compulsory payments applicable to the grant, exercise, sale or other
disposition of stocks; I hereby declare and consent for the Microchip
Technology Incorporated, Microchip Technology Israel Ltd. and/or the
Trustee to deduct any tax payment due, out of the proceeds of any sale of
Shares, for any payment to the tax authorities, according to the Rules, or any
other applicable compulsory payments.
10.
I confirm that Microchip Technology Incorporated and/or the Trustee shall
not be required to release any proceeds deriving from the sale of Shares, to
me, until all required tax payments according to section 102, the Rules and
the Trust Agreement, including any other compulsory payments, or
applicable law, have been fully assured.
11.
I acknowledge that the Trustee is not a tax advisor and it is recommended
that I consult a tax advisor before I accept this letter, any restricted stock
units vest, sell any Shares or release them from the Trustee, or any other act.
12.
13.
14.
15.
I agree to indemnify Microchip Technology Incorporated, Microchip
Technology Israel Ltd. and/or the Trustee and to hold them harmless against
and from any and all liability for any damage and/or loss and/or expense that
might occur regarding the tax liability and/or the execution of the Trust
Agreement.
I hereby agree to bear all the applicable fees and commissions involved in
establishing and maintaining trust account in the Trustee’s name, and in
performing any action in the trust account.
I hereby agree to sign any document reasonably required at the company’s
and/or the Trustee’s request.
I hereby confirm that I read this letter thoroughly, received all the
clarifications and explanations I requested, I understand the contents of this
letter and the obligations I undertake in signing it.
Name of the Beneficiary
I.D. Number
Signature
ITALY
Data Privacy Notice. The following provision replaces paragraph 12 of the Agreement:
The Grantee hereby explicitly and unambiguously consents to the collection, use, processing and
transfer, in electronic or other form, of the Grantee’s personal data as described in this provision
of this Appendix by and among, as applicable, the Employer, the Company and any Parent and/
or Subsidiary for the exclusive purpose of implementing, administering, and managing the
Grantee’s participation in the Plan.
The Grantee understands that the Employer, the Company and any Parent and/or Subsidiary
may hold certain personal information about the Grantee, including, without limitation, the
Grantee’s name, home address and telephone number, date of birth, social insurance or other
identification number, salary, nationality, job title, any Shares or directorships held in the
Company or a Parent or Subsidiary, details of all RSUs, or any other entitlement to Shares
awarded, canceled, exercised, vested, unvested or outstanding in the Grantee’s favor, for the
exclusive purpose of implementing, managing, and administering the Plan (“Data”).
The Grantee also understands that providing the Company with Data is necessary for the
performance of the Plan and that the Grantee’s refusal to provide such Data would make it
impossible for the Company to perform its contractual obligations and may affect the Grantee’s
ability to participate in the Plan. The Controller of personal data processing is Microchip
Technology Incorporated at 2355 West Chandler Boulevard, Chandler, AZ 85224, U.S.A., and,
pursuant to Legislative Decree no. 196/2003, its representative in Italy is Microchip Technology
SRL with registered offices at Via Pablo Picasso 41, 20025 Legnano (MI) Italy.
The Grantee understands that Data will not be publicized, but it may be transferred to E*Trade
Financial (or one of its affiliates) or such other stock plan service provider as may be selected
by the Company in the future (any such entity, “Broker”), or other third parties involved in the
management and administration of the Plan. The Grantee understands that Data may also be
transferred to the independent registered public accounting firm engaged by the Company. The
Grantee further understands that the Company and/or any Parent and/or Subsidiary will transfer
Data among themselves as necessary for the purpose of implementing, administering, and
managing the Grantee’s participation in the Plan, and that the Company or a Subsidiary may
each further transfer Data to third parties assisting the Company in the implementation,
administration, and management of the Plan, including any requisite transfer of Data to the
Broker or other third party with whom the Grantee may elect to deposit any Shares acquired at
vesting of the RSUs. Such recipients may receive, possess, use, retain, and transfer Data in
electronic or other form, for the purposes of implementing, administering, and managing the
Grantee’s participation in the Plan. The Grantee understands that these recipients may be located
in or outside the European Economic Area, such as in the United States or elsewhere. Should
the Company exercise its discretion in suspending all necessary legal obligations connected with
the management and administration of the Plan, it will delete Data as soon as it has completed
all the necessary legal obligations connected with the management and administration of the
Plan.
The Grantee understands that Data processing related to the purposes specified above shall take
place under automated or non-automated conditions, anonymously when possible, that comply
with the purposes for which Data is collected and with confidentiality and security provisions,
as set forth by applicable laws and regulations, with specific reference to Legislative Decree no.
196/2003.
The processing activity, including communication, the transfer of Data abroad, including outside
of the European Economic Area, as herein specified and pursuant to applicable laws and
regulations, does not require the Grantee’s consent thereto, as the processing is necessary to
performance of contractual obligations related to implementation, administration, and
management of the Plan. The Grantee understands that, pursuant to paragraph 7 of the
Legislative Decree no. 196/2003, the Grantee has the right to, without limitation, access, delete,
update, correct, or terminate, for legitimate reason, the Data processing.
Furthermore, the Grantee is aware that Data will not be used for direct-marketing purposes. In
addition, Data provided can be reviewed and questions or complaints can be addressed by
contacting the Grantee’s local human resources representative.
Grant Terms Acknowledgment. By accepting the RSUs, the Grantee acknowledges having
received and reviewed the Plan and the Agreement, including this Appendix, in their entirety and
fully understands and accepts all provisions of the Plan and the Agreement, including this Appendix.
The Grantee further acknowledges having read and specifically approves the following paragraphs
of the Agreement: paragraph 9 (“Tax Obligations”), paragraph 10 (“Nature of Grant”), paragraph
13 (“Language”), paragraph 22 (“Entire Agreement; Governing Law”), and the “Data Privacy
Notice” provision set forth above in this Appendix.
JAPAN
There are no country-specific terms and conditions.
KOREA
There are no country-specific terms and conditions.
MALAYSIA
There are no country-specific terms and conditions.
MEXICO
No Entitlement or Claims for Compensation. These provisions supplement paragraph 10 of
the Agreement:
Modification. By accepting the RSUs, the Grantee understands and agrees that any
modification of the Plan or the Agreement or its termination shall not constitute a change or
impairment of the terms and conditions of employment.
Policy Statement. The Award of RSUs the Company is making under the Plan is unilateral and
discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue
it at any time without any liability.
The Company, with registered offices at 2355 West Chandler Boulevard, Chandler, AZ 85224,
U.S.A., is solely responsible for the administration of the Plan and participation in the Plan and
the acquisition of Shares does not, in any way, establish an employment relationship between the
Grantee and the Company since the Grantee is participating in the Plan on a wholly commercial
basis and the sole employer is Microchip Technology Mexico, S.DE R.L. DE C. V. nor does it
establish any rights between the Grantee and the Employer.
Plan Document Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he/
she has received copies of the Plan, has reviewed the Plan and the Agreement in their entirety
and fully understands and accepts all provisions of the Plan and the Agreement.
In addition, by accepting the Agreement, the Grantee further acknowledges that the Grantee has
read and specifically and expressly approve the terms and conditions in paragraph 10 of the
Agreement, in which the following is clearly described and established: (i) participation in the
Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by
the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv)
the Company and any Parent or Subsidiary are not responsible for any decrease in the value of
the Shares underlying the RSUs.
Finally, the Grantee hereby declares that he/she does not reserve any action or right to bring any
claim against the Company for any compensation or damages as a result of the Grantee’s
participation in the Plan and therefore grant a full and broad release to the Employer, the
Company and any Parent or Subsidiary with respect to any claim that may arise under the Plan.
Spanish Translation
Reconocimiento de la Ley Laboral. Estas disposiciones complementan el apartado 10 del
Acuerdo:
Modification. Al aceptar las Unidades de Acción Restringida, usted reconoce y acuerda que
cualquier modificación del Plan o su terminación no constituye un cambio o desmejora de los
términos y condiciones de empleo.
Declaración de Política. El Otorgamiento de Unidades de Acción Restringida de la Compañía
en virtud del Plan es unilateral y discrecional y, por lo tanto, la Compañía se reserva el derecho
absoluto de modificar y discontinuar el mismo en cualquier tiempo, sin responsabilidad alguna.
La Compañía, con oficinas registradas ubicadas en 2355 West Chandler Boulevard, Chandler, AZ
85224, U.S.A., es la única responsable de la administración del Plan y de la participación en el
mismo y la adquisición de Acciones no establece de forma alguna una relación de trabajo entre
usted y la Compañía, ya que su participación en el Plan es completamente comercial y el único
empleador es Microchip Technology Mexico, S.DE R.L. DE C. V. en caso de ser aplicable, así
como tampoco establece ningún derecho entre la persona que tenga el derecho a optar y el
Empleador.
Reconocimiento del Documento del Plan. Al aceptar el Otorgamiento de las Unidades de
Acción Restringida, usted reconoce que ha recibido copias del Plan, ha revisado el mismo, al
igual que la totalidad del Acuerdo y, que ha entendido y aceptado completamente todas las
disposiciones contenidas en el Plan y en el Acuerdo.
Adicionalmente, al firmar el Acuerdo, reconoce que ha leído, y que aprueba específica y
expresamente los términos y condiciones contenidos en la Renuncia de Derecho o Reclamo por
Compensación, apartado 10 del Acuerdo, en el cual se encuentra claramente descrito y
establecido lo siguiente: (i) la participación en el Plan no constituye un derecho adquirido; (ii) el
Plan y la participación en el mismo es ofrecida por la Compañía de forma enteramente
discrecional; (iii) la participación en el Plan es voluntaria; y (iv) la Compañía, así como su
Sociedad controlante, Subsidiaria o Filiales no son responsables por cualquier disminución en el
valor de las Acciones en relación a las Unidades de Acción Restringida.
Finalmente, declara que no se reserva ninguna acción o derecho para interponer una demanda en
contra de la Compañía por compensación, daño o perjuicio alguno como resultado de su
participación en el Plan y, en consecuencia, otorga el más amplio finiquito al Empleador, así
como a la Compañía, a su Sociedad controlante o Subsidiaria con respecto a cualquier demanda
que pudiera originarse en virtud del Plan.
NETHERLANDS
There are no country-specific terms and conditions.
PHILIPPINES
There are no country-specific terms and conditions.
ROMANIA
There are no country-specific terms and conditions.
SINGAPORE
Securities Law Legend. The RSUs are being granted pursuant to the “Qualifying Person”
exemption” under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.)
(“SFA”). The Plan has not been lodged or registered as a prospectus with the Monetary Authority
of Singapore. The Grantee should note that the RSUs are subject to section 257 of the SFA, and
the Grantee will not be able to make (i) any subsequent sale of the Shares in Singapore or (ii) any
offer of such subsequent sale of the Shares subject to the RSUs in Singapore, unless such sale or
offer is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than
section 280) of the SFA (Chapter 289, 2006 Ed.).
SPAIN
Termination of Employment. The RSUs provide a conditional right to Shares and may be forfeited
or affected by the Grantee’s termination of employment, as set forth in the Agreement. For avoidance
of doubt, the Grantee’s rights, if any, to the RSUs upon termination of employment shall be
determined as set forth in the Agreement, including, without limitation, where (i) the Grantee is
deemed to be constructively dismissed or unfairly dismissed without good cause; (ii) the Grantee
is dismissed for disciplinary or objective reasons or due to a collective dismissal; (iii) the Grantee
terminates employment due to a change of work location, duties or any other employment or
contractual condition (except as otherwise expressly set forth in the Agreement); or (iv) the Grantee
terminates employment due to the Company’s or any of its Subsidiaries’ unilateral breach of contract.
Consequently, the termination of the Grantee’s employment for any of the above reasons shall be
governed by paragraphs 4 and 19(i) of the Agreement, unless otherwise determined by the Company,
in its sole discretion.
Labor Law Acknowledgment. By accepting the RSUs, the Grantee acknowledges that he or she
understands and agrees to the terms and conditions applicable to participation in the Plan and that
he or she has received a copy of the Plan.
The Grantee understands that the Company has unilaterally, gratuitously and discretionally decided
to grant RSUs under the Plan to individuals who may be employees of the Company or any Parent
or Subsidiary of the Company throughout the world. The decision is a limited decision that is
entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any Parent or Subsidiary on an ongoing basis, other than as expressly
set forth in the Plan and the Agreement. Consequently, the Grantee understands that any grant is
given on the assumption and condition that it shall not become a part of any employment contract
(either with the Company or any Parent or Subsidiary) and shall not be considered a mandatory
benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
Furthermore, the Grantee understands and freely accepts that there is no guarantee that any benefit
whatsoever shall arise from any gratuitous and discretionary grant since the future value of the
RSUs and the underlying Shares is unknown and unpredictable. In addition, the Grantee understands
that this grant would not be made but for the assumptions and conditions referred to above; thus,
the Grantee understands, acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason, then the RSUs shall be null
and void.
Securities Law Legend. The RSUs and the Shares issued upon vesting are considered a private
placement outside of the scope of Spanish laws on public offerings and issuances of securities.
SWEDEN
There are no country-specific terms and conditions.
SWITZERLAND
There are no country-specific terms and conditions.
TAIWAN
There are no country-specific terms and conditions.
THAILAND
There are no country-specific terms and conditions.
UNITED KINGDOM
Tax Obligations. The following provision supplements paragraph 9 (“Tax Obligations”) of the
Agreement:
If payment or withholding of the Tax-Related Items is not made within ninety (90) days of the event
giving rise to the Tax-Related Items or such other period specified in Section 222(1)(c) of the U.K.
Income Tax (Earnings and Pensions) Act 2003 (the “Due Date”), the amount of any uncollected
Tax-Related Items shall constitute a loan owed by the Grantee to the Employer, effective as of the
Due Date. The Grantee agrees that the loan will bear interest at the then-current official rate of Her
Majesty’s Revenue & Customs (“HMRC”), it will be immediately due and repayable, and the
Company or the Employer may recover it at any time thereafter by any of the means referred to in
paragraph 9 of the Agreement.
Notwithstanding the foregoing, if the Grantee is a director or executive officer of the Company
(within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended),
the Grantee shall not be eligible for a loan from the Company to cover the Tax-Related Items. In
the event that the Grantee is a director or executive officer and any such Tax-Related Items are not
collected from or paid by the Grantee by the Due Date, the amount of any uncollected Tax-Related
Items will constitute a benefit to the Grantee on which additional income tax and National Insurance
contributions (“NICs”) will be payable. The Grantee understands that he or she will be responsible
for reporting any income tax and NICs (including the Employer NICs, as defined below) due on
this additional benefit directly to HMRC under the self-assessment regime.
RSUs Payable in Shares Only. Notwithstanding any discretion in the Plan, the RSUs will be
settled in Shares only. The RSUs do not provide any right for the Grantee to receive a cash payment.
Joint Election for Transfer of Secondary Class 1 National Insurance Contributions to the
Grantee. As a condition of vesting of the RSUs, the Grantee agrees to accept any liability for
secondary Class 1 national insurance contributions, which may be payable by the Company or the
Employer in connection with the RSUs (“Employer NICs”). To accomplish the foregoing, the
Grantee agrees to enter into an election between himself or herself and the Employer (the “Election”),
by printing, signing and returning the form approved for such Election by HMRC and attached as
Exhibit B to this Agreement to the Human Resources Manager prior to vesting of the RSUs. The
Grantee further agrees to enter into any other consents or elections required to accomplish the
transfer of the Employer NICs to the Grantee, prior to vesting of the RSUs. The Grantee further
agrees to enter into such other joint elections as may be required between himself or herself and
any successor to the Company and/or the Employer. If the Grantee does not enter into an Election
prior to the vesting of the RSUs, the Grantee will permanently forfeit the RSUs without any liability
to the Company and/or the Employer and any Shares that have been issued upon vesting will be
returned to the Company at no cost to the Company.
The Grantee further agrees that the Company and/or the Employer may collect the Employer NICs
by any of the means set forth in paragraph 9 of the Agreement, as supplemented above.
*
*
*
EXHIBIT A
AGREEMENT
FOR PARTICIPANTS IN BELGIUM
AGREEMENT REGARDING A TWO YEAR LOCK-UP PERIOD
FOR SHARES ACQUIRED UPON VESTING OF RESTRICTED STOCK UNITS
If you have not already executed an Agreement for Participants in Belgium ("Agreement")
and would like to benefit from the favourable tax regime provided for in the Circular (as
defined below), please print, sign and return this Agreement to Microchip Technology
Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199 U.S.A., c/o Tricia Bajaj,
within 120 calendar days from the grant date specified in the Notice of Grant of Restricted
Stock Units. Please also retain a copy of this Agreement for your files.
BETWEEN
1) Microchip Technology Incorporated, 2355 W. Chandler Blvd., Chandler, AZ 85224-6199
U.S.A. (hereafter "Microchip"); and
2) NAME:
_________________________
ADDRESS: _________________________
(hereafter the "Grantee", and, together with Microchip, the "Parties")
WHEREAS
Microchip has granted on the grant date set forth in the applicable Notice of Grant of Restricted
Stock Units ("Grant Notice") a number of restricted stock units to the Grantee subject to the
terms and conditions in the Microchip Technology Incorporated 2004 Equity Incentive Plan (the
"Plan"), the Grant Notice and the Restricted Stock Units Agreement (the "RSU Grant");
This Agreement is also intended to cover any subsequent grant of restricted stock units that may
be made under the Plan, in the sole discretion of Microchip, on or after the Effective Date (as
defined below) ("Subsequent Grant"); and
The Grantee would like to benefit from the favourable tax regime provided for in Administrative
Circular nr. Ci.RH.241/467.450 of June 21, 1995 (the "Circular") with respect to the shares of
common stock of Microchip which he/she will acquire upon the vesting of the aforementioned
RSU Grant and any Subsequent Grant;
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 1 out of 2
PARTIES HAVE AGREED AS FOLLOWS:
The shares that will be delivered to the Grantee upon vesting of the RSU Grant and any
Subsequent Grant will be subject to a two year lock-up period, starting from the date of vesting
of the relevant grant, during which the Grantee cannot sell or otherwise transfer the respective
shares.
The Parties reserve the right to terminate this Agreement in its entirety, or as far as it relates to
any particular grant, at any time prior to the Vesting Date specified in the relevant Grant Notice.
Notice of termination must specify the grant date of the RSU Grant and/or Subsequent Grant to
which it is intended to apply. The Parties understand that termination shall disqualify the
Grantee from the favourable tax regime provided for in the Circular with respect to shares of
common stock of Microchip which he/she will acquire upon the vesting of only the particular
grant(s) specified in the notice of termination. Notice of termination shall be provided to
Microchip by email to #stockplans@microchip.com.
This Agreement shall be effective as of the date this Agreement is received by Microchip
(the "Effective Date").
COMPANY
Signature:
By: /s/ Steve Sanghi
Steve Sanghi, Chairman of the Board & CEO
Microchip Technology Incorporated
GRANTEE
Signature:
Printed
Name:
Date:
Made in:
City, Country
Microchip Technology Incorporated
2004 Equity Incentive Plan
Page 2 out of 2
EXHIBIT B
MICROCHIP TECHNOLOGY INCORPORATED
2004 EQUITY INCENTIVE PLAN
(UK Employees)
Election To Transfer the Employer’s National Insurance Liability to the Employee
1.
Parties
This Election is between:
(A)
Employee Name (the “Employee”), who is eligible to receive Restricted
Stock Units granted by Microchip Technology Incorporated of 2355 Chandler
Blvd., Chandler, Arizona 85224, United States (the “Company”) pursuant to
the terms and conditions of the 2004 Equity Incentive Plan (the "Plan"), and
(B) Microchip Limited (registered number 2189500) with registered office at
Microchip House, 720 Wharfedale Road, Winnersh Triangle, Wokingham,
Berkshire RG41 5TP, United Kingdom (the “Employer”), which employs the
Employee.
2.
Purpose of Election
2.1
This Election relates to the employer’s secondary Class 1 National Insurance
Contributions (the “Employer’s Liability”) which may arise on:
(i)
the acquisition of securities pursuant to the Restricted Stock Units; and/or
(ii)
(iii)
the assignment or release of the Restricted Stock Units in return for
consideration; and/or
the receipt of any other benefit in money or money’s worth in connection with
the Restricted Stock Units,
(each, a “Taxable Event”) pursuant to section 4(4)(a) of the Social Security
Contributions and Benefits Act 1992.
2.2
This Election applies to all Restricted Stock Unit awards granted to the Employee
under the Plan on or after 23rd December 2005 up to the termination date of the Plan.
3.
The Election
This joint election does not apply with respect to any liability arising as a result of
U.K. anti-avoidance legislation. The Employee and the Employer jointly elect that
the entire liability of the Employer to pay the Employer’s Liability on the Taxable
Event is hereby transferred to the Employee. The Employee understands that by
signing this Election he or she will become personally liable for the Employer’s
Liability covered by this Election.
4.
Payment of the Employer’s Liability
4.1
The Employee hereby authorizes the Company and/or the Employer to collect the
Employer’s Liability from the Employee at any time after the Taxable Event:
(i)
by deduction from salary or any other payment payable to the Employee at
any time on or after the date of the Taxable Event; and/or
(ii)
directly from the Employee by payment in cash or cleared funds; and/or
(iii)
by arranging, on behalf of the Employee, for the sale of some of the securities
which the Employee is entitled to receive in respect of the Restricted Stock
Units.
The Employer hereby reserves for itself and the Company the right to withhold the
transfer of any securities to the Employee until full payment of the Employer’s
Liability is received.
The Employer agrees to remit the Employer’s Liability to the HM Revenue and
Customs on behalf of the Employee within 14 days after the end of the UK tax month
during which the Taxable Event occurs.
4.2
4.3
5.
Duration of Election
5.1
The Employee and the Employer agree to be bound by the terms of this Election
regardless of whether the Employee is transferred abroad or is not employed by the
Employer on the date on which the Employer’s Liability becomes due.
5.2
This Election will continue in effect until the earliest of the following:
(i)
(ii)
the Employee and the Employer agree in writing that it should cease to have
effect;
on the date the Employer serves written notice on the Employee terminating
its effect;
(iii)
on the date the HM Revenue and Customs withdraws approval of this
Election; or
(iv)
after due payment of the Employer's Liability in respect of the entirety of the
Restricted Stock Units to which this Election relates, such that the Election
ceases to have effect in accordance with its terms.
2
Grantee:
Signature
Print Name
Date
Microchip Technology Incorporated
By: /s/ Steve Sanghi
Steve Sanghi, Chairman of the Board & CEO
By
Title
3
Schedule of Employer Companies
The employing companies to which this Election relates are:
NAME
ADDRESS
Microchip Limited
Microchip House
720 Wharfedale Road
Winnersh Trinagle
Wokingham
Berkshire
RG41 5TP
United Kingdom
4
EXHIBIT 10.21
MICROCHIP TECHNOLOGY INCORPORATED
2001 EMPLOYEE STOCK PURCHASE PLAN
As Amended Through February 19, 2019
The following constitute the provisions of the 2001 Employee Stock Purchase Plan of Microchip
Technology Incorporated, as amended through February 19, 2019.
1.
Purpose. The purpose of the Plan is to provide employees of the Company and one or
more of its Corporate Affiliates an opportunity to purchase Common Stock of the Company through
accumulated payroll deductions. It is the intention of the Company to have the Plan have two
components: a component that is intended to qualify as an “Employee Stock Purchase Plan” under
Section 423 of the Code (the “423 Component”) and a component that is not intended to qualify as an
“employee stock purchase plan” under Section 423 of the Code (the “Non-423 Component”). The
provisions of the Plan with respect the 423 Component, accordingly, shall be construed so as to extend
and limit participation in a uniform and nondiscriminatory basis consistent with the requirements of
Section 423. An option to purchase shares of Common Stock under the Non-423 Component will be
granted pursuant to rules, procedures, or sub-plans adopted by the Administrator designed to achieve
tax, securities laws, or other objectives for Eligible Employees and the Company. Except as otherwise
provided herein, the Non-423 Component will operate and be administered in the same manner as the
423 Component.
2.
Definitions.
(a)
the Plan pursuant to Section 14.
“Administrator” shall mean the Committee designated by the Board to administer
(b)
“Board” shall mean the Board of Directors of the Company.
(c)
“Change of Control” shall mean the occurrence of any of the following events:
a merger or other reorganization in which the Company will not be the
surviving corporation (other than a reorganization effected primarily to change the State in which the
Company is incorporated); or
(i)
(ii)
the consummation of the sale or disposition by the Company of all or
substantially all of the Company’s assets; or
1
a reverse merger in which the Company is the surviving corporation but
in which more than fifty percent (50%) of the Company’s outstanding voting stock is transferred to a
person or persons different from those who held the stock immediately prior to such merger.
(iii)
(d)
“Code” shall mean the Internal Revenue Code of 1986, as amended.
(e)
accordance with Section 14 hereof.
“Committee” means a committee of the Board appointed by the Board in
(f)
“Common Stock” shall mean the common stock of the Company, par value
$0.001.
corporation.
(g)
“Company” shall mean Microchip Technology Incorporated, a Delaware
(h)
“Compensation” shall mean the following items paid to an Eligible Employee
by the Company and/ or one or more Corporate Affiliates during such individual’s period of participation
in the Plan: (i) regular base salary, and (ii) any pre-tax contributions made by the Eligible Employees
to any Code Section 401(k) plan, any Code Section 125 Plan, any unfunded non-qualified deferred
compensation plan described in Sections 201(2), 301(a)(3) or 401(a)(1) of ERISA, and (iii) all overtime
payments, bonuses, commissions, profit-sharing distributions and other incentive type payments. There
shall be excluded any contributions (except 401(k) and 125 contributions) made on the Eligible
Employee’s behalf by the Company or Corporate Affiliate.
(i)
“Corporate Affiliate” shall mean any parent or subsidiary of the Company (as
defined in Section 424 of the Code) which is incorporated in the United States, including any parent
or subsidiary corporation which becomes such after the Effective Date.
(j)
“Effective Date” shall mean March 1, 2002.
(k)
“Eligible Employee” shall mean any individual who is a common law employee
of any Participating Company and whose customary employment with the Participating Company or
group of Participating Companies is at least 20 hours per week and more than five (5) months in any
calendar year. For purposes of the Plan, the employment relationship shall be treated as continuing
intact while the individual is on sick leave or other leave of absence approved by the Company. Where
the period of leave exceeds 90 days and the individual's right to reemployment is not guaranteed either
by statute or in writing signed by a duly authorized officer of the Company, the employment relationship
shall be deemed to have terminated on the 91st day of such leave. Unless otherwise determined by the
Administrator, with respect to the Non-423 Component, any individual otherwise meeting the
2
requirements to be an “Eligible Employee” will only qualify as an Eligible Employee if such individual
is tax resident in the United States as of the first Trading Day of any Offering Period.
(l)
“Entry Date” shall mean the first Trading Day of any Offering Period. An Entry
Date occurs on the first Trading Day in March or September.
(m)
“ERISA” shall mean the Employee Retirement Income Security of 1974, as
amended.
(n)
“Exercise Date” shall mean the first Trading Day of March and September.
(o)
“Fair Market Value” shall mean the closing sales price for such stock (or the
closing bid, if no sales were reported) as quoted on such exchange or system on the date of determination,
as reported in The Wall Street Journal or such other source as the Board deems reliable; provided,
however, that if there is no closing sales price (or closing bid price, if applicable) for such date, then
the closing sales price (or closing bid price, if applicable) for the next day for which such quotation
exists.
(p)
“Offering Periods” shall mean a period of time during which an option granted
pursuant to the Plan may be exercised. The Plan shall be implemented by a series of Offering Periods
(“Series of Offering Periods”). Each Series of Offering Periods shall contain four (4) Offering Periods.
The first Offering Period in the Series shall commence on the first Trading Day on or after March 1,
2002, and shall end on the first Trading Day on or after March 1, 2004 (the “Last Day of the Series”).
The second Offering Period in the Series shall commence on the next following Entry Date, shall last
approximately 18 months and shall end on the Last Day of the Series. The third Offering Period in the
Series shall commence on the next following Entry Date, shall last approximately 12 months and shall
end on the Last Day of the Series. The fourth Offering Period in the Series shall commence on the next
following Entry Date, shall last approximately six (6) months and shall end on the Last Day of the
Series. A new Series of Offering Periods shall commence on the Last Day of the Series. The duration
and timing of Offering Periods may be changed pursuant to Section 20 of this Plan.
(q)
“Participating Company” shall mean the Company and such Corporate Affiliates
as may be designated from time to time by the Board to extend the benefits of the Plan to their Eligible
Employees. The Companies participating in the Plan are listed on the attached Schedule A.
(r)
“Plan” shall mean this Employee Stock Purchase Plan.
“Purchase Period” shall mean the approximately six (6) month period
commencing on one Exercise Date and ending with the next Exercise Date, except that the first Purchase
(s)
3
Period of any Offering Period shall commence on the first Entry Date and end with the next Exercise
Date.
(t)
“Purchase Price” shall mean 85% of the Fair Market Value of a share of Common
Stock on the Entry Date or on the Exercise Date, whichever is lower; provided, however, that the
Purchase Price may be adjusted by the Administrator pursuant to Section 20.
(u)
“Trading Day” shall mean a day on which national stock exchanges and the
Nasdaq System are open for trading.
3.
Eligibility.
(a)
Generally. Any Eligible Employee on a given Entry Date shall be eligible to
participate in the Plan.
(b)
Limitations. Any provisions of the Plan to the contrary notwithstanding, no
Eligible Employee shall be granted an option under the Plan (i) to the extent that, immediately after
the grant, such Eligible Employee (or any other person whose stock would be attributed to such Eligible
Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company and/or
hold outstanding options to purchase such stock possessing five percent (5%) or more of the total
combined voting power or value of all classes of the capital stock of the Company or of any Subsidiary,
or (ii) to the extent that his or her rights to purchase stock under all employee stock purchase plans of
the Company and its subsidiaries accrues at a rate which exceeds $25,000.00 worth of stock (determined
at the fair market value of the shares at the time such option is granted) for each calendar year in which
such option is outstanding at any time.
4.
Offering Periods. The Plan shall be implemented by a series of Offering Periods (“Series
of Offering Periods”). Each Series of Offering Periods shall contain four (4) Offering Periods. The
first Offering Period in the Series shall commence on the first Trading Day on or after March 1, 2002,
and shall end on the first Trading Day on or after March 1, 2004 (the “Last Day of the Series”). The
second Offering Period in the Series shall commence on the next following Entry Date, shall last
approximately 18 months and shall end on the Last Day of the Series. The third Offering Period in the
Series shall commence on the next following Entry Date, shall last approximately 12 months and shall
end on the Last Day of the Series. The fourth Offering Period in the Series shall commence on the next
following Entry Date, shall last approximately six (6) months and shall end on the Last Day of the
Series. A new Series of Offering Periods shall commence on the Last Day of the Series. The duration
and timing of Offering Periods may be changed pursuant to Section 20 of this Plan.
5.
Participation. An Eligible Employee may become a participant in the Plan by enrolling
via E*Trade or completing a subscription agreement authorizing payroll deductions in the form of
4
Exhibit A to this Plan and filing it with the Company's stock plan administrator, on a date determined
by such administrator, which shall be no later than five (5) Trading Days prior to the applicable Entry
Date.
6.
Payroll Deductions.
(a)
At the time a participant enrolls via E*Trade or files his or her subscription
agreement, he or she shall elect to have payroll deductions made on each pay day during the Offering
Period in any multiple of one-percent (1%), but not exceeding ten-percent (10%) of the Compensation
which he or she receives during each Purchase Period; provided, however, that should a payday occur
on an Exercise Date, a participant shall have the payroll deductions made on such day applied to his
or her account under the new Offering Period or Purchase Period, as the case may be. A participant's
elections via E*Trade enrollment or a subscription agreement shall remain in effect for successive
Offering Periods unless terminated as provided in Section 10 hereof.
(b)
Payroll deductions for a participant shall commence on the first payday following
the Entry Date and shall end on the last payday in the Offering Period to which such authorization is
applicable, unless sooner terminated by the participant as provided in Section 10 hereof. All payroll
deductions made for a participant shall be credited to his or her account under the Plan and shall be
withheld in whole percentages only. A participant may not make any additional payments into such
account.
(c)
A participant may discontinue his or her participation in the Plan as provided in
Section 10 hereof, or may decrease (but not increase) the rate of his or her payroll deductions during
the Offering Period by changing deductions via E*Trade or completing or filing with the Company a
new subscription agreement authorizing a change in payroll deduction rate. No more than one (1) such
reduction shall be allowed in any Purchase Period. A participant may only increase the rate of his or
her payroll deductions beginning with the next Offering Period which lasts 24 months. The change in
rate shall be effective as soon as administratively practicable.
(d)
Notwithstanding the foregoing, to the extent necessary to comply with Section
423(b)(8) of the Code and Section 3(b) hereof, a participant's payroll deductions may be decreased to
zero percent (0%) at any time during a Purchase Period. Payroll deductions shall recommence at the
rate provided in such participant's E*Trade elections or subscription agreement at the beginning of the
first Purchase Period which is scheduled to end in the following calendar year, unless terminated by
the participant as provided in Section 10 hereof.
At the time the option is exercised, in whole or in part, or at the time some or all
of the Company's Common Stock issued under the Plan is disposed of, the participant must make
(e)
5
adequate provision for the Company's federal, state, or other tax withholding obligations, if any, which
arise upon the exercise of the option or the disposition of the Common Stock. At any time, the Company
may, but shall not be obligated to, withhold from the participant's compensation the amount necessary
for the Company to meet applicable withholding obligations, including any withholding required to
make available to the Company any tax deductions or benefits attributable to sale or early disposition
of Common Stock by the Eligible Employee.
7.
Grant of Option. On the Entry Date of each Offering Period, each Eligible Employee
participating in such Offering Period shall be granted an option to purchase on each Exercise Date
during such Offering Period (at the applicable Purchase Price) up to a number of shares of the Company's
Common Stock determined by dividing such Eligible Employee's payroll deductions accumulated prior
to such Exercise Date and retained in the Participant's account as of the Exercise Date by the applicable
Purchase Price; provided that in no event shall an Eligible Employee be permitted to purchase during
each Purchase Period more than 7,5001 shares of the Company's Common Stock (subject to any
adjustment pursuant to Section 19), and provided further that such purchase shall be subject to the
limitations set forth in Sections 3(b) and 6 hereof. The Eligible Employee may accept the grant of such
option by enrolling via E*Trade or turning in a completed Subscription Agreement (attached hereto as
Exhibit A) to the stock plan administrator, on a date determined by such administrator, which shall be
no later than five (5) Trading Days prior to an applicable Entry Date. The Administrator may, for future
Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of the
Company's Common Stock an Eligible Employee may purchase during each Purchase Period of such
Offering Period. Exercise of the option shall occur as provided in Section 8 hereof, unless the participant
has withdrawn pursuant to Section 10 hereof. The option shall expire on the last day of the Offering
Period.
8.
Exercise of Option.
(a)
Unless a participant withdraws from the Plan as provided in Section 10 hereof,
his or her option for the purchase of shares shall be exercised automatically on the Exercise Date, and
the maximum number of full shares subject to option shall be purchased for such participant at the
applicable Purchase Price with the accumulated payroll deductions in his or her account. No fractional
shares shall be purchased; any payroll deductions accumulated in a participant's account which are not
sufficient to purchase a full share shall be retained in the participant's account for the subsequent Purchase
Period or Offering Period, subject to earlier withdrawal by the participant as provided in Section 10
________________________
1 As adjusted for a May 2002 3-for-2 stock split
6
hereof. Any other funds left over in a participant's account after the Exercise Date shall be returned to
the participant. During a participant's lifetime, a participant's option to purchase shares hereunder is
exercisable only by him or her.
(b)
If the Administrator determines that, on a given Exercise Date, the number of
shares with respect to which options are to be exercised may exceed (i) the number of shares of Common
Stock that were available for sale under the Plan on the Entry Date of the applicable Offering Period,
or (ii) the number of shares available for sale under the Plan on such Exercise Date, the Administrator
may in its sole discretion (x) provide that the Company shall make a pro rata allocation of the shares
of Common Stock available for purchase on such Entry Date or Exercise Date, as applicable, in as
uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable
among all participants exercising options to purchase Common Stock on such Exercise Date, and
continue all Offering Periods then in effect, or (y) provide that the Company shall make a pro rata
allocation of the shares available for purchase on such Entry Date or Exercise Date, as applicable, in
as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable
among all participants exercising options to purchase Common Stock on such Exercise Date, and
terminate any or all Offering Periods then in effect pursuant to Section 20 hereof. The Company may
make pro rata allocation of the shares available on the Entry Date of any applicable Offering Period
pursuant to the preceding sentence, notwithstanding any authorization of additional shares for issuance
under the Plan by the Company's shareholders subsequent to such Entry Date.
9.
Delivery. As soon as reasonably practicable after each Exercise Date on which a purchase
of shares occurs, the Company shall arrange the delivery to each participant the shares purchased upon
exercise of his or her option in a form determined by the Administrator.
10. Withdrawal.
(a)
At any time prior to the last five (5) Trading Days of a Purchase Period, a
participant may withdraw from the Plan by giving written notice to the Company in the form of Exhibit
A to this Plan. The participant shall elect to either have (i) all of the participant's payroll deductions
credited to his or her account used to purchase shares at the next Exercise Date or (ii) all payroll
deductions credited to his or her account refunded. In neither event will any further payroll deductions
for the purchase of shares be made for such Offering Period. If a participant withdraws from an Offering
Period, the participant may not re-enroll in the Plan until the next Offering Period which lasts 24 months,
and payroll deductions shall not resume at the beginning of such Offering Period unless the participant
re-enrolls in the Plan via E*Trade or delivers to the Company a new subscription agreement in a manner
provided for in Section 5.
7
(b)
A participant's withdrawal from an Offering Period shall not have any effect
upon his or her eligibility to participate in any similar plan which may hereafter be adopted by the
Company.
11.
Termination of Employment. In the event a participant ceases to be an Eligible Employee
of the Company or any Participating Company (other than as a result of death or Permanent Disability),
any payroll deductions credited to such participant's account during the Offering Period but not yet
used to purchase shares under the Plan shall be returned to such participant and such participant's option
shall be automatically terminated. In the event a participant ceases to be an Employee of the Company
or any Participating Company as a result of death or Permanent Disability, then such participant (or
personal representative of the estate of the deceased participant) may elect at any time prior to the last
five (5) Trading Days of a Purchase Period in which such termination occurs, to (i) have all of such
participant’s payroll deductions for such Purchase Period refunded to the Participant or (ii) have all
such payroll deductions used to purchase the Company’s common stock on the Exercise Date following
such termination. Further, if a Participant transfers from an offering under the 423 Component to the
Non-423 Component, the exercise of the option will be qualified under the 423 Component only to the
extent it complies with Section 423 of the Code, unless otherwise provided by the Administrator.
12.
Interest. No interest shall accrue on the payroll deductions of a participant in the Plan.
13.
Stock.
(a)
Subject to adjustment upon changes in capitalization of the Company as provided
in Section 19 hereof, the number of shares of the Company's Common Stock which shall be made
available for sale under the Plan shall be 3,275,000 shares, plus up to 150,000 remaining unissued
shares available as of the Effective Date under the Company’s previous ESPP, and plus beginning
January 1, 2005, and each January 1 thereafter during the term of the Plan, an automatic annual increase
in shares reserved of the lesser of (i) 1,500,000 shares, (ii) one half of one percent (0.5%) of the then
outstanding shares of our common stock, or (iii) such lesser amount as is approved by our Board of
Directors2; provided, however, that the shares under the Company’s previous ESPP shall not be available
__________________
2 Approved by shareholders August 15, 2003.
8
for issuance under the Plan to the extent that such reservation would, in the opinion of the Company’s
independent auditors, result in a compensation expense to the Company under either EITF 97-12 or
ASC 7183.
(b)
Until the shares are issued (as evidenced by the appropriate entry on the books
of the Company or of a duly authorized transfer agent of the Company), a participant shall only have
the rights of an unsecured creditor with respect to such shares, and no right to vote or receive dividends
or any other rights as a stockholder shall exist with respect to such shares.
(c)
Shares to be delivered to a participant under the Plan shall be held in a brokerage
account in street name.
14.
Administration. The Administrator shall administer the Plan and shall have full and
exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to determine
eligibility and to adjudicate all disputed claims filed under the Plan. Every finding, decision and
determination made by the Administrator shall, to the full extent permitted by law, be final and binding
upon all parties.
15.
Designation of Beneficiary.
(a)
A participant may file a written designation of a beneficiary who is to receive
any payroll deductions, if any, from the participant's account under the Plan in the event of such
participant's death subsequent to an Exercise Date on which the option is exercised but prior to delivery
to such participant of such payroll deductions. In addition, a participant may file a written designation
of a beneficiary who is to receive any payroll deductions from the participant's account under the Plan
in the event of such participant's death prior to exercise of the option. If a participant is married and
the designated beneficiary is not the spouse, spousal consent shall be required for such designation to
be effective.
__________________
3 All numbers in this Section 13(a) have been adjusted to reflect a May 2002 3-for-2 stock split,
the additional 500,000 shares approved by the stockholders on August 16, 2002 and the additional
975,000 shares approved by the stockholders on August 15, 2003.
9
(b)
Such designation of beneficiary may be changed by the participant at any time
by written notice. In the event of the death of a participant and in the absence of a beneficiary validly
designated under the Plan who is living at the time of such participant's death, the Company shall deliver
such payroll deductions to the executor or administrator of the estate of the participant, or if no such
(c)
All beneficiary designations shall be in such form and manner as the
Administrator may designate from time to time.
16.
Transferability. Neither payroll deductions credited to a participant's account nor any
rights with regard to the exercise of an option or to receive shares under the Plan may be assigned,
transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and
distribution or as provided in Section 15 hereof) by the participant. Any such attempt at assignment,
transfer, pledge or other disposition shall be without effect, except that the Company may treat such
act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.
17.
Use of Funds. All payroll deductions received or held by the Company under the Plan
may be used by the Company for any corporate purpose, and the Company shall not be obligated to
segregate such payroll deductions except under any offering under the Plan or for participants in the
Non-423 Component for which Applicable Laws require that Contributions to the Plan by participants
be segregated from the Company’s general corporate funds and/or deposited with an independent third
party. Until shares are issued, participants shall only have the rights of an unsecured creditor.
18.
Reports. Individual accounts shall be maintained for each participant in the Plan.
Statements of account shall be given to participating Eligible Employees at least annually, which
statements shall set forth the amounts of payroll deductions, the Purchase Price, the number of shares
purchased and the remaining cash balance, if any.
19.
Change of Control.
Adjustments Upon Changes in Capitalization, Dissolution, Liquidation, Merger or
(a)
Changes in Capitalization. Subject to any required action by the shareholders
of the Company, the maximum number of shares of the Company’s Common Stock which shall be
made available for sale under the Plan, the maximum number of shares each participant may purchase
each Purchase Period (pursuant to Section 7), as well as the price per share and the number of shares
of Common Stock covered by each option under the Plan which has not yet been exercised shall be
proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock
resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the
Common Stock, or any other change in the number of shares of Common Stock effected without receipt
of consideration by the Company; provided, however, that conversion of any convertible securities of
10
the Company shall not be deemed to have been “effected without receipt of consideration.” Such
adjustment shall be made by the Administrator, whose determination in that respect shall be final,
binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares
of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no
adjustment by reason thereof shall be made with respect to, the number or price of shares of Common
Stock subject to an option.
(b)
Change in Control. In the event of a Change of Control, each outstanding option
shall be assumed or an equivalent option substituted by the successor corporation or a Parent or
Subsidiary of the successor corporation. In the event that the successor corporation refuses to assume
or substitute for the option, any Purchase Periods then in progress shall be shortened by setting a New
Exercise Date and any Offering Periods then in progress shall end on the New Exercise Date. The New
Exercise Date shall be before the date of the Company's proposed Change of Control. The Administrator
shall notify each participant in writing, at least 10 business days prior to the New Exercise Date, that
the Exercise Date for the participant's option has been changed to the New Exercise Date and that the
participant's option shall be exercised automatically on the New Exercise Date, unless prior to such
date the participant has withdrawn from the Offering Period as provided in Section 10 hereof.
20.
Amendment or Termination.
(a)
The Administrator may at any time and for any reason terminate or amend the
Plan. Except as otherwise provided in the Plan, no such termination can affect options previously
granted, provided that an Offering Period may be terminated by the Administrator on any Exercise Date
if the Administrator determines that the termination of the Offering Period or the Plan is in the best
interests of the Company and its shareholders. Except as provided in Section 19 and this Section 20
hereof, no amendment may make any change in any option theretofore granted which adversely affects
the rights of any participant. To the extent necessary to comply with Section 423 of the Code (or any
successor rule or provision or any other applicable law, regulation or stock exchange rule), the Company
shall obtain shareholder approval in such a manner and to such a degree as required.
(b) Without shareholder consent and without regard to whether any participant rights
may be considered to have been “adversely affected,” the Administrator shall be entitled to change the
Offering Periods, limit the frequency and/or number of changes in the amount withheld during an
Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than
U.S. dollars, permit payroll withholding in excess of the amount designated by a participant in order
to adjust for delays or mistakes in the Company's processing of properly completed withholding
elections, establish reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Common Stock for each participant
properly correspond with amounts withheld from the participant's Compensation, and establish such
11
other limitations or procedures as the Administrator determines in its sole discretion advisable which
are consistent with the Plan.
(c)
In the event the Administrator determines that the ongoing operation of the Plan
may result in unfavorable financial accounting consequences, the Board may, in its discretion and, to
the extent necessary or desirable, modify or amend the Plan to reduce or eliminate such accounting
consequence including, but not limited to:
Offering Period underway at the time of the change in Purchase Price;
(i)
increasing the Purchase Price for any Offering Period including an
Exercise Date, including an Offering Period underway at the time of the Board action; and
(ii)
shortening any Offering Period so that Offering Period ends on a new
(iii)
allocating shares.
Such modifications or amendments shall not require stockholder approval or the consent of any
Plan participants.
21.
Notices. All notices or other communications by a participant to the Company under
or in connection with the Plan shall be deemed to have been duly given when received in the form and
manner specified by the Company at the location, or by the person, designated by the Company for the
receipt thereof.
22.
Conditions Upon Issuance of Shares. Shares shall not be issued with respect to an option
unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall
comply with all applicable provisions of law, domestic or foreign, including, without limitation, the
Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and
regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares
may then be listed, and shall be further subject to the approval of counsel for the Company with respect
to such compliance.
As a condition to the exercise of an option, the Company may require the person
exercising such option to represent and warrant at the time of any such exercise that the shares are being
purchased only for investment and without any present intention to sell or distribute such shares if, in
the opinion of counsel for the Company, such a representation is required by any of the aforementioned
applicable provisions of law.
23.
Term of Plan. The Plan, as amended through May 19, 2014, shall continue in effect
until August 31, 2024, unless sooner terminated under Section 20 hereof.
12
24.
Automatic Transfer to Low Price Offering Period. To the extent permitted by any
applicable laws, regulations, or stock exchange rules if the Fair Market Value of the Common Stock
on any Exercise Date in an Offering Period is lower than the Fair Market Value of the Common Stock
on the Entry Date of such Offering Period, then all participants in such Offering Period shall be
automatically withdrawn from such Offering Period immediately after the exercise of their option on
such Exercise Date and automatically re-enrolled in the immediately following Offering Period.
13
EXHIBIT A
MICROCHIP TECHNOLOGY INCORPORATED
2001 Employee Stock Purchase Plan
Subscription Agreement
Enrollment, Change and Withdrawal Form
Please print and complete all information below:
Last
First
M
Badge #:
Full Name:
Home Address:
SECTION I – PARTICIPATION ELECTION
Choose One:
I hereby decline to participate in the Employee Stock Purchase Plan for this semi-annual participation period.
I hereby authorize Microchip Technology Inc. to deduct the following amount from my salary each pay period (gross
salary).
CIRCLE ONE:
1%
2%
3%
4%
5%
6%
7%
8%
9% 10%
My participation will automatically remain in effect from one offering period to the next offering period in
accordance with my payroll deduction authorization, unless I withdraw from the ESPP, change the rate of my
payroll deduction or my employment status changes.
I can decrease my contribution percentage no more than one time during each six-month purchase period. I
can increase my contribution percentage only at the beginning of each 24-month offering period.
I can withdraw from any offering period, provided that my withdrawal is received no later than 5 business days
prior to a purchase date. See next section.
My shares will be placed in a brokerage account in street name.
SECTION II- WITHDRAWAL
I choose to stop my payroll deductions and either (select only one):
purchase Microchip Technology Inc. shares on the next purchase date.*
refund my Employee Stock Purchase Plan payroll deductions collected.*
I can withdraw from any offering period, provided that my withdrawal is received by stock plan administration
at least 5 business days prior to a purchase date.
*Note: When withdrawing from the ESPP, per the Plan you will not be eligible to re-enroll until the
beginning of the next 24-month offering period.
Signature of Employee
Date
SECTION III – BENEFICIARY (for payroll deducted, cash balance of contributions prior to a purchase)
I understand that if I am married, my spouse shall automatically be my designated beneficiary unless I elect
otherwise and my spouse consents to such election. When more than one beneficiary is designated, if the
percentage is not specified, payment will be made in equal dollars to each surviving beneficiary, or all to the last
surviving beneficiary.
Primary Beneficiary
I hereby designate the following person(s) as primary beneficiary of my payroll deduction account under the
Plan payable by reason of my death.
Name
Relationship of Beneficiary
Percentage
Contingent Beneficiary
In the event that there is no living primary beneficiary at my death, I hereby designate the following person(s)
as contingent beneficiary of my payroll deduction account.
Name
Relationship of Beneficiary
Percentage
SECTION IV- CONSENT OF SPOUSE
Note: If your spouse is not your Designated Primary Beneficiary, then this Designation of Beneficiary is
invalid without the consent of your spouse unless your spouse waived the right to consent to any change in
the beneficiary designation under a prior beneficiary designation.
I acknowledge that I am the spouse of the Participant named on the reverse side of this form. I hereby certify
that I have read this Designation of Beneficiary Form and understand that I possess a beneficial interest in my
spouse’s payroll deduction account under the Plan if I survive him/her. I hereby acknowledge and consent to
the Designation of Beneficiary on the reverse side of this form. My consent shall be irrevocable unless my
spouse subsequently changes the Designation of Beneficiary.
If my spouse changes the designation, (Choose A or B):
(A) I understand I must sign a new consent to the new designation for it to be effective.
(B) I waive my right to consent to any future change in designation. I understand I have the right to restrict
my consent only to the beneficiary designated on the reverse side of this form by checking box (A.)
I have executed this consent this
day of
, 20 .
Signature of Participant's Spouse
SCHEDULE A
LIST OF SUBSIDIARIES
PARTICIPATING IN THE
2001 EMPLOYEE STOCK PURCHASE PLAN
Amended February 19, 2019
Participation in 423 Component
Microchip Technology Inc. and its following disregarded subsidiaries, but only for so long as they remain its
disregarded subsidiaries
• Micrel, LLC
• Microchip Technology LLC
• Standard Microsystems, LLC and its following disregarded subsidiaries, but only for so long as
they remain its disregarded subsidiaries
o BridgeCo, LLC
o Standard Microsystems (Asia) LLC
• Supertex, LLC
Microsemi Corporation and its following disregarded subsidiaries, but only for so long as they remain its
disregarded subsidiaries
• Microsemi Corp. International
• Microsemi Corp (Taiwan Branch)
Microsemi Corp. – Analog Mixed Signal Group
Microsemi Corp. – Massachusetts
Microsemi Corp. – Power Management Group
Microsemi Corp. – Power Products Group
Microsemi Corp. – RFIS Diode Solutions
Microsemi Corp. – RF Power Products
Microsemi Corp. – RF Signal Processing
Microsemi Frequency and Time Corporation and its following disregarded subsidiaries, but only for so long as
they remain its disregarded subsidiaries
• Microsemi Frequency and Time Corporation (Hong Kong Branch)
• Symmetricom Puerto Rico Ltd.
Microsemi PoE, Inc.
Microsemi Semiconductor (U.S.), Inc. and its following disregarded subsidiaries, but only for so long as they
remain its disregarded subsidiaries
• Microsemi International, Inc.
Microsemi SoC Corp. and its following disregarded subsidiaries, but only for so long as they remain its disregarded
subsidiaries
• Microsemi SOC Corp (Canada Branch)
Microsemi Solutions (U.S.), Inc.
Wintegra Holding, LLC
Participation in non-423 Component
Participation of employees of these entities is subject to approval by the Administrator.
Microchip Technology Ireland Limited
EXHIBIT 10.22
MICROCHIP TECHNOLOGY INCORPORATED
1994 INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN
AS AMENDED MAY 6, 2019
I.
PURPOSE
This 1994 International Employee Stock Purchase Plan (“Plan”) is hereby established by
Microchip Technology Incorporated, a Delaware corporation ("Microchip"), in order to provide eligible
employees of foreign Microchip subsidiaries with the opportunity to acquire a proprietary interest in
Microchip through the purchase of shares of Microchip common stock at periodic intervals with their
accumulated payroll deductions. The Plan authorizes the grant of purchase rights which do not qualify
under Code Section 423 pursuant to any rules, procedures, agreements, appendices, or sub-plans adopted
by the Plan Administrator for such purpose.
II.
DEFINITIONS
For purposes of administration of the Plan, the following terms shall have the meanings
indicated:
"Common Stock" means shares of Microchip common stock, par value $0.001 per share.
"Earnings" means regular base salary plus such additional items of compensation as the Plan
Administrator may deem appropriate.
"Effective Date" means June 1, 1994. A list of the participating Foreign Subsidiaries is hereto
attached as Schedule A. For any other Foreign Subsidiary, the effective date shall be determined by the
Microchip Board of Directors or the Employee Committee of the Board of Directors prior to the time
such Foreign Subsidiary is to become a participating company in the Plan.
"Eligible Employee" means any person who is engaged, on a regularly-scheduled basis, in the
rendition of personal services outside the U.S. as an employee of a Foreign Subsidiary subject to the
control and direction of that Foreign Subsidiary as to both the work to be performed and the manner and
method of performance and has been designated as having the right to be granted purchase rights under
the Plan.
"Entry Date" shall mean the first Trading Day of any Purchase Period. An Entry Date occurs on
the first Trading Day in December or June.
"Foreign Subsidiary" means any non-U.S. Microchip subsidiary which elects, with the approval
of the Microchip Board of Directors or the Employee Committee of the Board of Directors, to extend the
benefits of this Plan to its Eligible Employees. The Foreign Subsidiaries participating in the Plan are
listed on attached Schedule A.
1
May 6, 2019
"Participant" means any Eligible Employee of a Foreign Subsidiary who is actively participating
in the Plan.
"Purchase Period" means the first U.S. business day of December to the last U.S. business day of
May and from the first U.S. business day of June to the last U.S. business day of November; provided
that Purchase Periods commencing after June, 2014 shall run from the first U.S. business day of
December to the first U.S. business day of June and from the first U.S. business day in June to the first
U.S. business day of December.
"Service" means the period during which an individual performs services as an Eligible
Employee and shall be measured from his or her hire date, whether that date is before or after the
Effective Date of the Plan.
“Trading Day” shall mean a day on which national stock exchanges and the Nasdaq System are open for
trading.
III. ADMINISTRATION
Each Foreign Subsidiary shall have responsibility for the administration of the Plan with respect
to its Eligible Employees. Accordingly, the Plan shall, as to each Foreign Subsidiary, be separately
administered by a plan administrator comprised of two or more Members of the Board of Directors, the
Employee Committee of the Board of Directors, or a designee as may be appointed by either of them
from time to time (“Plan Administrator”). The Plan Administrator shall have full authority to administer
the Plan, including the authority to designate Eligible Employees that are granted purchase rights and the
authority to interpret and construe any provision of the Plan and to adopt such rules and regulations for
administering the Plan as it may deem necessary. Decisions of the Plan Administrator shall be subject to
ratification by the Microchip Board of Directors and, when so ratified, shall be final and binding on all
parties who have an interest in the Plan.
IV.
PURCHASE PERIODS
A.
Shares of Common Stock shall be offered for purchase under the Plan through a series of
successive purchase periods until such time as (i) the maximum number of shares of Common Stock
available for issuance under the Plan shall have been purchased or (ii) the Plan shall have been sooner
terminated in accordance with Article VIII.
B.
The Plan shall be implemented in a series of successive purchase periods, each to be of a
duration of six (6) months. The initial purchase period will begin on June 1, 1994 and end on the last
U.S. business day in November 1994. Subsequent purchase periods shall run from the first U.S.
business day of December to the last U.S. business day of May and from the first U.S. business day of
June to the last U.S. business day of November; provided that purchase periods commencing after June,
2014 shall run from the first U.S. business day of December to the first U.S. business day of June and
from the first U.S. business day of June to the first U.S. business day of December.
C.
No purchase period shall commence under the Plan, nor shall any shares of Common
Stock be issued hereunder, until such time as (i) the Plan shall have been approved by the Microchip
2
May 6, 2019
Board of Directors and (ii) Microchip shall have complied with all applicable requirements of the
Securities Act of 1933 (as amended), all applicable listing requirements of any securities exchange on
which shares of the Common Stock are listed and all other applicable statutory and regulatory
requirements.
D.
The Participant shall be granted a separate purchase right for each purchase period in
which he/she participates. The purchase right shall be granted on the start date of the purchase period
and shall be automatically exercised on the last U.S. business day of that purchase period.
E.
The acquisition of Common Stock through plan participation for any purchase period
shall neither limit nor require the acquisition of Common Stock by the Participant in any subsequent
purchase period.
V.
ELIGIBILITY AND PARTICIPATION
A.
Any Eligible Employee that has been designated as having the right to be granted
purchase rights on a given Entry Date shall be eligible to participate in the Plan. Unless otherwise
determined by the Plan Administrator, all Eligible Employees meeting the conditions under this Section
V are eligible for the grant of purchase rights under the Plan.
B.
Each Eligible Employee of each Foreign Subsidiary participating in the Plan may join the
Plan in accordance with the following provisions:
-
An individual who is an Eligible Employee on a given Entry Date may enter that
purchase period on such Entry Date, provided he/she enrolls in the purchase period on or before
such Entry Date in accordance with Section V.C below. Should any such Eligible Employee not
enter the purchase period on or before the given Entry Date, then he/she may not subsequently
join that particular purchase period on any later date.
-
An individual who is an Eligible Employee but was not employed on a given
Entry Date may not participate in that purchase period but will be eligible to join the Plan on the
next Entry Date thereafter provided that he or she is then an Eligible Employee.
C.
To participate for a particular purchase period, the Eligible Employee must complete the
enrollment forms prescribed by the Plan Administrator (including a purchase agreement and a payroll
deduction authorization) and file such forms with the Plan Administrator (or its designate) at least five
U.S. business days before the start date of that purchase period.
D.
The payroll deduction authorized by the Participant shall be collected under the Plan in
the currency in which paid by the Foreign Subsidiary and may be any multiple of one percent (1%) of
the Earnings paid to the Participant during each purchase period, up to a maximum of ten percent (10%).
Any changes or fluctuations in the exchange rate at which the currency collected from the Participant
through such payroll deductions is converted into U.S. Dollars on each purchase date under the Plan
shall be borne solely by the Participant. The deduction rate so authorized shall continue in effect for the
entire purchase period and for each successive purchase period, except to the extent such rate is changed
in accordance with the following guidelines:
3
May 6, 2019
-
The Participant may, at any time during the purchase period, reduce his/her
rate of payroll deduction. Such reduction shall become effective as soon as possible after
filing of the requisite reduction form with the Plan Administrator (or its designate), but
the Participant may not effect more than one such reduction during the same purchase
period.
-
The Participant may, prior to the start date of any subsequent purchase
period, increase or decrease the rate of his/her payroll deduction by filing the appropriate
form with the Plan Administrator (or its designate). The new rate (which may not exceed
the ten percent (10%) maximum) shall become effective as of the start date of the new six
(6)-month purchase period.
Payroll deductions will automatically cease upon the termination of the Participant's
purchase right in accordance with the applicable provisions of Section VII below.
VI.
STOCK SUBJECT TO PLAN
A.
The Common Stock purchasable under the Plan shall, solely in the discretion of the
Microchip Board, be made available from authorized but unissued shares of Common Stock or from
shares of Common Stock reacquired by Microchip, including shares of Common Stock purchased on the
open market. The total number of shares reserved under the Plan prior to January 2007 is 348,593
shares, plus beginning January 1, 2007, and each January 1 thereafter during the term of the Plan, an
automatic annual increase in shares reserved of one tenth of one percent (0.1%) of the then outstanding
shares of Microchip Common Stock. The total number of shares which may be issued under the Plan
shall not exceed the number reserved.
B.
In the event any change is made to the outstanding Common Stock by reason of any stock
dividend, stock split, combination of shares or other change affecting such outstanding Common Stock
as a class without Microchip's receipt of consideration, appropriate adjustments shall be made by the
Microchip Board of Directors to (i) the class and maximum number of securities issuable over the term
of the Plan, (ii) the class and maximum number of securities purchasable per Participant during any one
purchase period and (iii) the class and number of securities and the price per share in effect under each
purchase right at the time outstanding under the Plan. Such adjustments shall be designed to preclude
the dilution or enlargement of rights and benefits under the Plan.
VII. PURCHASE RIGHTS
An Eligible Employee who participates in the Plan for a particular purchase period shall have the
right to purchase shares of Common Stock upon the terms and conditions set forth below and shall
execute a purchase agreement incorporating such terms and conditions and such other provisions (not
inconsistent with the Plan) as the Plan Administrator may deem advisable.
4
May 6, 2019
Purchase Price. Common Stock shall be issuable at the end of each purchase period at a
purchase price equal to eighty-five percent (85%) of the lower of (i) the fair market value per share on
the start date of that purchase period or (ii) the market price per share of Common Stock on the purchase
date.
Valuation. The fair market value per share of Common Stock on any relevant date under the
Plan shall be the closing selling price per share of Common Stock on that date, as officially quoted on
the Nasdaq Global Select Market. If there is no quoted selling price for such date, then the closing
selling price per share of Common Stock on the next day for which there does exist such a quotation
shall be determinative of fair market value.
Number of Purchasable Shares.
-
The number of shares purchasable per Participant during each purchase period
shall be determined as follows: first, the payroll deductions in the currency in which collected
from the Participant during that purchase period shall be converted into U.S. Dollars on the last
U.S. business day of the purchase period at the exchange rate in effect on that day; then, the
U.S. Dollar amount calculated for the Participant on the basis of such exchange rate shall be
divided by the purchase price in effect for such period to determine the number of whole shares
of Common Stock purchasable on the Participant's behalf for that purchase period.
-
However, no Participant may, during any one purchase period, purchase more
than one thousand eight hundred ninety-nine (1,899) shares of Common Stock.
-
And any provisions of the Plan to the contrary notwithstanding, no Participant
shall be granted an option under the Plan (i) to the extent that, immediately after the grant, such
Participant (or any other person whose stock would be attributed to such Participant) would own
capital stock of Microchip and/or hold outstanding options to purchase such stock possessing
five percent (5%) or more of the total combined voting power or value of all classes of the
capital stock of Microchip or of any Subsidiary, or (ii) to the extent that his or her rights to
purchase stock under all employee stock purchase plans of Microchip and its subsidiaries accrues
at a rate which exceeds $25,000.00 worth of stock (determined at the fair market value of the
shares at the time such option is granted) for each calendar year in which such option is
outstanding at any time.
Payment. Payment for the Common Stock purchased under the Plan shall be effected by means
of the Participant's authorized payroll deductions in the currency in which paid by the Foreign
Subsidiary. Such deductions shall begin with the first full payroll period beginning with or immediately
following the start date of the purchase period and shall (unless sooner terminated by the Participant)
continue through the pay day ending with or immediately prior to the last day of such purchase period.
The amounts so collected shall be credited to the Participant's book account under the Plan, but no
interest shall be paid on the balance from time to time outstanding in such account. The amounts
collected from a Participant may be commingled with the general assets of the Foreign Subsidiary or
Microchip and may be used for general corporate purposes. However, all purchases of Common Stock
5
May 6, 2019
under the Plan shall be made in U.S. Dollars on the basis of the exchange rate in effect on the last day of
each purchase period.
Termination of Purchase Right. The following provisions shall govern the termination of
outstanding purchase rights:
-
A Participant may, at any time prior to the last five (5) business days of the Foreign
Subsidiary falling within the purchase period, terminate his/her outstanding purchase right by
filing the prescribed notification form with the Plan Administrator. No further payroll
deductions shall be collected from the Participant with respect to the terminated purchase right,
and any payroll deductions collected for the purchase period in which such termination occurs
shall, at the Participant's election, be immediately refunded in the currency in which paid by the
Foreign Subsidiary or held for the purchase of shares at the end of such purchase period. If no
such election is made at the time the termination notice is filed, then the Participant's payroll
deductions shall be refunded as soon as possible after the termination date of his/her purchase
right.
-
The termination of such purchase right shall be irrevocable, and the Participant
may not subsequently rejoin the purchase period for which the terminated purchase right was
granted. In order to resume participation in any subsequent purchase period, such individual
must re-enroll in the Plan (by making a timely filing of a new purchase agreement and payroll
deduction authorization) on or before the date he/she is first eligible to join the new purchase
period.
-
If the Participant ceases to remain an Eligible Employee while his/her purchase
right is outstanding, then such purchase right shall immediately terminate, and the payroll
deductions collected from such Participant for the purchase period shall be promptly refunded
in the currency in which paid by the Foreign Subsidiary to the Participant. However, should
the Participant's cessation of Eligible Employee status occur by reason of death or permanent
disability, then such individual (or the personal representative of a deceased Participant) shall
have the following election, exercisable up until the last day of the purchase period:
-
to withdraw all of the Participant's payroll deductions for such purchase period, in
the currency in which paid by the Foreign Subsidiary, or
-
to have such funds held for the purchase of shares at the end of the purchase
period.
If no such election is made, then such funds shall be refunded as soon as possible after
the end of the purchase period. In no event, however, may any payroll deductions be made on
the Participant's behalf following his/her cessation of Eligible Employee status.
Stock Purchase. Shares of Common Stock shall automatically be purchased on behalf of each
Participant (other than Participants whose payroll deductions have previously been refunded in
accordance with the Termination of Purchase Right provisions above) on the last U.S. business day of
each purchase period. The purchase shall be effected as follows: first, each Participant's payroll
6
May 6, 2019
deductions for that purchase period (together with any carryover deductions from the preceding
purchase period) shall be converted from the currency in which paid by the Foreign Subsidiary into U.S.
Dollars at the exchange rate in effect on the purchase date, and then the amount of U.S. Dollars
calculated for each Participant on the basis of such exchange rate shall be applied to the purchase of
whole shares of Common Stock (subject to the limitation on the maximum number of purchasable
shares set forth above) at the purchase price in effect for such purchase period. Any payroll deductions
not applied to such purchase because they are not sufficient to purchase a whole share shall be held for
the purchase of Common Stock in the next purchase period. However, any payroll deductions not
applied to the purchase of Common Stock by reason of the limitation on the maximum number of shares
purchasable by the Participant during the purchase period shall be promptly refunded to the Participant
in the currency in which paid by the Foreign Subsidiary.
Proration of Purchase Rights. Should the total number of shares of Common Stock which are to
be purchased pursuant to outstanding purchase rights on any particular date exceed the number of shares
then available for issuance under the Plan, the Plan Administrator shall make a pro-rata allocation of the
available shares on a uniform and nondiscriminatory basis, and the payroll deductions of each
Participant, to the extent in excess of the aggregate purchase price payable for the Common Stock pro-
rated to such individual, shall be refunded to such Participant in the currency in which paid by the
Foreign Subsidiary.
Rights as Stockholder. A Participant shall have no stockholder rights with respect to the shares
subject to his/her outstanding purchase right until the shares are actually purchased on the Participant's
behalf in accordance with the applicable provisions of the Plan. No adjustments shall be made for
dividends, distributions or other rights for which the record date is prior to the date of such purchase.
A Participant shall be entitled to receive, as soon as practicable after the end of each
purchase period, a stock certificate (as evidenced by the appropriate entry on the books of Microchip or
of a duly authorized transfer agent of Microchip) for the number of shares purchased on the Participant's
behalf. Such certificate will be issued in "street name" for immediate deposit in a designated brokerage
account. Until the stock certificate evidencing such Shares is issued no right to vote or receive
dividends or any other rights as a stockholder shall exist. No adjustment will be made for a dividend or
other right for which the record date is prior to the date the stock certificate is issued.
Assignability. No purchase right granted under the Plan shall be assignable or transferable by the
Participant other than by will or by the laws of descent and distribution following the Participant's death,
and during the Participant's lifetime the purchase right shall be exercisable only by the Participant.
Change in Ownership. Should any of the following transactions (a "Corporate Transaction")
occur during the purchase period:
(i)
a merger or other reorganization in which Microchip will not be the surviving
corporation (other than a reorganization effected primarily to change the State in which
Microchip is incorporated), or
(ii)
of Microchip, or
a sale of all or substantially all of Microchip's assets in liquidation or dissolution
7
May 6, 2019
(iii)
a reverse merger in which Microchip is the surviving corporation but in which
more than fifty percent (50%) of Microchip's outstanding voting stock is transferred to person
or persons different from those who held the stock immediately prior to such merger, then all
outstanding purchase rights under the Plan shall automatically be exercised immediately prior to
the effective date of such Corporate Transaction by applying the payroll deductions of each
Participant for the purchase period in which such Corporate Transaction occurs to the purchase
of whole shares of Common Stock at eighty-five percent (85%) of the lower of (i) the fair
market value of the Common Stock on the start date of the purchase period in which such
Corporate Transaction occurs or (ii) the fair market value of the Common Stock immediately
prior to the effective date of such Corporate Transaction. Payroll deductions shall be converted
from the currency in which paid by the Foreign Subsidiary into U.S. Dollars on the basis of the
exchange rate in effect on the purchase date, and the applicable share limitation of Article VII
shall continue to apply to each such purchase. Should Microchip sell or otherwise dispose of its
ownership interest in any Foreign Subsidiary participating in the Plan, whether through merger
or sale of all or substantially all of the assets or outstanding capital stock of that Foreign
Subsidiary, then a similar exercise of outstanding purchase rights shall be effected immediately
prior to the effective date of such disposition, but only to the extent those purchase rights are
attributable to the employees of such Foreign Subsidiary.
Microchip shall use its best efforts to provide at least ten (10) days advance written notice of the
occurrence of any such Corporate Transaction, and the Participants shall, following the receipt of such
notice, have the right to terminate their outstanding purchase rights in accordance with the applicable
provisions of this Article VII.
VIII. AMENDMENT AND TERMINATION
The Plan has been established voluntarily by Microchip. The Microchip Board of Directors may
alter, amend, suspend or discontinue the Plan with respect to one or more Foreign Subsidiaries following
the end of any purchase period. The Microchip Board may also terminate the Plan in its entirety
immediately following the end of any purchase period. In such event, no further purchase rights shall
thereafter be granted or exercised, and no further payroll deductions shall thereafter be collected, under
the Plan.
IX. GENERAL PROVISIONS
A.
The Plan shall become effective on the designated effective date for each Foreign
Subsidiary, provided Microchip shall have complied with all applicable requirements of the Securities
Act of 1933 (as amended), all applicable listing requirements of any securities exchange on which shares
of the Common Stock are listed and all other applicable requirements established by law or regulation.
B.
The Plan shall terminate upon the earlier of (i) November 30, 2024 or (ii) the date on
which all shares available for issuance under the Plan shall have been sold pursuant to purchase rights
exercised under the Plan.
8
May 6, 2019
C.
Foreign Subsidiary.
All costs and expenses incurred in the administration of the Plan shall be paid by the
D.
Neither the action of Microchip or the Foreign Subsidiary in establishing the Plan, nor
any action taken under the Plan by the Microchip Board or the Plan Administrator, nor any provision of
the Plan itself shall constitute any form of employment contract, be construed so as to grant any person
the right to remain in the employ of the Foreign Subsidiary for any period of specific duration, and
except where expressly prohibited by applicable law such person's employment may be terminated at
any time, with or without cause.
E.
Participation in the Plan is voluntary and occasional and does not create any contractual
or other right to participate in the Plan in the future, or benefits in lieu of participation in the Plan, even
if the Participant has continually participated in the Plan in the past.
F.
Participation in the Plan does not constitute normal or expected salary or compensation
for any purposes, including but not limited to, calculating any severance, resignation, termination,
redundancy, end of service payments, bonuses, long-term service awards, pension or retirement benefits
or similar payments and in no event should be considered as compensation for, or relating in any way to
past services for Microchip or the Foreign Subsidiary.
G. Microchip, Foreign Subsidiaries and the Plan Administrator must collect, use, and
transfer personal data of Participants as described in this subsection in order to administer the Plan. By
participating in the Plan, the Participant is consenting to the collection, transfer and use of personal data
as generally described in this subsection except where requiring such consent is expressly prohibited by
local law.
(i)
Microchip and its Foreign Subsidiaries hold certain personal information about
the Participant, including, but not limited to, name, home address and telephone number, date of
birth, social insurance number, salary, nationality, job title, any Shares of Common Stock or
directorships held in Microchip, details of all participation in the Plan or other entitlement to
Shares, for the purpose of managing and administering the Plan (“Data”).
(ii) Microchip and/or its Foreign Subsidiaries will transfer Data among themselves as
necessary for the purposes of implementation, administration, and management of Participant’s
participation in the Plan, and that Microchip and/or its Foreign Subsidiaries may each further
transfer Data to identified third parties assisting them in the implementation, administration, and
management of the Plan (“Data Recipients”).
(iii)
These Data Recipients may be located in Participant’s country of residence or
elsewhere, such as the United States. By participating under this Plan, the Participant authorizes
the Data Recipients to receive, possess, use, retain, and transfer Data in electronic or other form,
for the purposes of implementing, administering, and managing Participant’s participation in the
Plan, including any transfer of such Data, as may be required for Plan administration and/or the
subsequent holding of Shares on Participant’s behalf, to a broker or third party with whom the
Shares acquired on purchase may be deposited.
9
May 6, 2019
Participant may, at any time, review the Data, request that any necessary amendments be
made to it, or withdraw Participant’s consent herein in writing by contacting Microchip.
Withdrawing consent may affect Participant’s ability to participate in the Plan.
10
May 6, 2019
SCHEDULE A
SUBSIDIARIES PARTICIPATING IN THE
INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN
Updated May 6, 2019
Foreign Subsidiaries below are approved for participation in the Plan, however participation of employees
of Foreign Subsidiaries is subject to separate approval by the Microchip Board of Directors, or the Employee
Committee of the Board of Directors.
Australia – Microchip Technology Australia PTY Ltd.
Australia – Hi-Tech Software PTY Ltd
Austria – Microchip Technology Austria GmbH
Belgium – Eqcologic NV
Canada – Microchip Technology Canada Inc.
Canada – Microsemi Semiconductor ULC
Canada – Microsemi Storage Solutions Ltd.
China – Microchip Technology Trading (Shanghai) Co., Ltd.
China – SST China Ltd.
Denmark – Microchip Technology Nordic ApS
Denmark – Microsemi Semiconductor Corporation A/S
Finland – Microchip Technology Finland OY
France – Microchip Technology Nantes
France – Microchip Technology Rousset.
France – Microchip Technology Sarl
France – Microsemi Europe SARL
France – Microsemi Power Module Products, SAS
Germany – K2L GmbH & Co. KG
Germany – Microchip Technology GmbH
Germany – Microchip Technology Germany II GmbH & Co. KG
Germany – Microchip Technology Germany GmbH
Germany – Microchip Automotive GmbH & Co. KG
Germany – Microchip Technology Munich GmbH
Germany – Microsemi Frequency and Time GmbH
Germany – Microsemi Semiconductor GmbH
A-1
Germany – Vectron International GmbH
Hong Kong – Microchip Technology Hong Kong Ltd.
Hong Kong - Microsemi (Hong Kong) Limited
Hong Kong – Supertex, Limited
Hungary – Microchip Technology Hungary Kft.
India – Microchip Technology (India) Private Limited
India – Microsemi Communications India Private Limited “Vitesse/ENT”
India – Microsemi India Private Limited
India – Microsemi Storage Solutions India Private Ltd
Ireland – Microchip Technology Ireland Limited
Ireland – Atmel Technologies Ireland Limited
Israel – Microchip Technology Israel Ltd.
Israel – Microsemi Israel Storage Solutions Ltd.
Israel – Microsemi P.O.E. Ltd
Israel – Wintegra Ltd.
Italy – Microchip Technology SRL
Italy – Microsemi Europe SRL
Italy – Microsemi Storage Solutions Europe Ltd.
Japan – Microchip Technology Japan K.K.
Japan – Microsemi Storage Solutions Japan K.K.
Korea – Microchip Technology Korea Ltd.
Korea – Microsemi (Hong Kong) Limited (Branch Office)
Korea – Microsemi Storage Solutions Korea Ltd
Macau – Microsemi Macau Commercial Offshore Limited
Malaysia – Arizona Microchip Technology (Malaysia) Sdn Bhd
Malaysia – Microchip Operations (Malaysia) Sdn. Bhd
Malaysia – Microsemi Semiconductor (Asia) Pte., Ltd. (Malaysian Branch)
Malaysia – Microsemi Solutions Sdn. Bhd.
México – Microchip Technology Mexico, S.DE R.L. DE C.V.
Netherlands – Microchip Technology (Netherlands) Europe B.V.
Netherlands – Microsemi Semiconductor XIC B.V.
Norway – Microchip Technology Norway AS
Philippines – MTI Advanced Test Development Corporation
A-2
May 6, 2019
Philippines – Microchip Technology Operations (Philippines) Corporation
Philippines – Microsemi Semiconductors – Manila (Philippines), Inc.
Poland – Microchip Technology Sp. z o.o.
Romania – Microchip Technology SRL
Romania – Microchip Sales SRL
Singapore – Microchip Technology Singapore Pte Ltd.
Singapore – Microsemi Semiconductor (Asia) Pte., Ltd.
Spain – Microchip Technology S.L.
Spain – Microchip Technology Zaragoza S.L.U.
Sweden – Microchip Technology Sweden AB
Sweden – Microsemi Europe Limited Filial
Sweden – SMSC Sweden AB
Switzerland – Microchip Technology Switzerland SA
Taiwan – Microchip Technology (Barbados) II, Inc. Taiwan Branch
Taiwan – Microsemi Storage Solutions Hong Kong Ltd (Taiwan Branch)
Taiwan – SST Taiwan Ltd.
Thailand – Arizona Microchip Technology (Thailand) Ltd.
Thailand – Microchip Technology (Thailand) Co. Ltd.
United Kingdom – Microchip Limited
United Kingdom – Microchip Touch Solutions Limited
United Kingdom – Microsemi Europe Ltd.
United Kingdom – Microsemi Semiconductor Limited
United Kingdom – Microsemi Storage Solutions Europe, Ltd
United Kingdom – Silicon Storage Technology Ltd
A-3
May 6, 2019
EXHIBIT 21.1
MICROCHIP TECHNOLOGY INCORPORATED
LIST OF SIGNIFICANT SUBSIDIARIES
Atmel Corporation
2355 W. Chandler Boulevard
Chandler, AZ 85224
Atmel Dutch Corp
Naritaweg 165 Telestone 8
Amsterdam 1043 BW
The Netherlands
EuroFranco LLC
2355 W. Chandler Boulevard
Chandler, AZ 85224
Microchip Holding Corporation
2355 W. Chandler Boulevard
Chandler, AZ 85224
Microchip Malta BMD Limited
Gort Road, Ennis Co.,
Clare Ireland
Microchip Technology (Thailand) Co., Ltd.
14 Moo 1, T. Wangtakien
A. Muang Chacherngsao
Chacherngsao 24000
Thailand
Microchip Technology (Barbados) II Incorporated
190 Elgin Avenue
George Town
Grand Cayman
Cayman Islands KY1-9005
Microchip Technology (Netherlands) Europe B.V.
Rapenburgerstraat 179 G
Amsterdam 1001 VM
The Netherlands
Microchip Technology Ireland Limited
Ground Floor, Block W
East Point Business Park
Dublin 3 Ireland
Microchip Technology Malta Limited
Ground Floor, Block W
East Point Business Park
Dublin 3 Ireland
Microchip Technology Rousset SAS
Zone Industrielle
Rousset Cedex
France 13106
Silicon Storage Technology, Ltd
720 Wharfedale Road, Winnersh Triangle,
Wokingham, Berkshire
United Kingdom RG41 5TP
Microsemi (Hong Kong) Limited
Level 12, 28 Hennessy Road,
Wanchai
Hong Kong
Microsemi Corp. – International
4th Floor, Century Yard, Cricket Square,
Elgin Avenue
Grand Cayman
Cayman Islands KY1-1209
Microsemi Corp. – Holding
4th Floor, Century Yard, Cricket Square,
Elgin Avenue
Grand Cayman
Cayman Islands KY1-1209
Microsemi Corporation
2355 W. Chandler Boulevard
Chandler, AZ 85224
Microsemi Israel, Ltd.
1 Hanagar Street,
Neve Ne-eman Industrial Zone,
Hod Hasharon 45421
Israel
Microsemi SoC Corp.
2355 W. Chandler Boulevard
Chandler, AZ 85224
Microchip Technology LLC
2355 W. Chandler Boulevard
Chandler, AZ 85224
Microsemi Storage Solutions, Inc.
2355 W. Chandler Boulevard
Chandler, AZ 85224
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Form S-3 No. 333-149999,
Form S-8 No. 33-59686,
Form S-8 No. 33-80072,
Form S-8 No. 33-81690,
Form S-8 No. 33-83196,
Form S-8 No. 333-872,
Form S-8 No. 333-40791,
Form S-8 No. 333-67215,
Form S-8 No. 333-93571,
(10)
Form S-8 No. 333-51322,
(11)
Form S-8 No. 333-73506,
(12)
Form S-8 No. 333-99655,
(13)
Form S-8 No. 333-101696,
(14)
Form S-8 No. 333-103764,
(15)
Form S-8 No. 333-109486,
(16)
Form S-8 No. 333-119939,
(17)
Form S-8 No. 333-140773,
(18)
Form S-8 No. 333-149460,
(19)
Form S-8 No. 333-177889,
(20)
Form S-8 No. 333-183074,
(21)
Form S-8 No. 333-192273,
(22)
Form S-8 No. 333-197233,
(23)
Form S-8 No. 333-201865,
(24)
Form S-8 No. 333-206210,
(25)
Form S-8 No. 333-210580,
(26)
Form S-8 No. 333-213062,
(27)
Form S-8 No. 333-221420, and
(28)
Form S-8 No. 333-225257,
of our reports dated May 30, 2019 with respect to the consolidated financial statements of Microchip Technology
Incorporated, and the effectiveness of internal control over financial reporting of Microchip Technology
Incorporated, included in this Annual Report (Form 10-K) of Microchip Technology Incorporated for the year ended
March 31, 2019.
Phoenix, Arizona
May 30, 2019
/s/ Ernst & Young LLP
CERTIFICATION
Exhibit 31.1
I, Steve Sanghi, certify that:
1.
2.
3.
4.
I have reviewed this Form 10-K of Microchip Technology Incorporated;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and l5d-l5(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
(b)
(c)
(d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred
during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control
over financial reporting.
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons
performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize
and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.
Date: May 30, 2019
/s/ Steve Sanghi
Steve Sanghi
Chief Executive Officer and Chairman of the Board
CERTIFICATION
Exhibit 31.2
I, J. Eric Bjornholt, certify that:
1.
2.
3.
4.
I have reviewed this Form 10-K of Microchip Technology Incorporated;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and l5d-l5(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
(b)
(c)
(d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred
during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control
over financial reporting.
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons
performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize
and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.
Date: May 30, 2019
/s/ J. Eric Bjornholt
J. Eric Bjornholt
Senior Vice President and Chief Financial Officer
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32
I, Steve Sanghi, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that the Annual Report of Microchip Technology Incorporated on Form 10-K for the period ended March 31, 2019 fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of
Microchip Technology Incorporated.
/s/ Steve Sanghi
By:
Name: Steve Sanghi
Title:
Date: May 30, 2019
Chief Executive Officer and Chairman of the Board
I, J. Eric Bjornholt, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that the Annual Report of Microchip Technology Incorporated on Form 10-K for the period ended March 31, 2019
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of
Microchip Technology Incorporated.
/s/ J. Eric Bjornholt
J. Eric Bjornholt
Senior Vice President and Chief Financial Officer
By:
Name:
Title:
Date: May 30, 2019